Using	VBG	O
baby	NN	O
books	NNS	O
to	TO	O
increase	VB	O
new	JJ	C
mothers	NNS	C
'	POS	O
safety	NN	O
practices	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
educational	JJ	O
baby	NN	O
books	NNS	O
are	VBP	O
an	DT	O
effective	JJ	O
method	NN	O
for	IN	O
increasing	VBG	O
low-income	JJ	O
,	,	O
first-time	JJ	O
mothers	NNS	O
'	POS	O
safety	NN	O
practices	NNS	O
during	IN	O
their	PRP$	O
child	NN	O
's	POS	O
first	JJ	O
18	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
Primiparous	JJ	C
women	NNS	SE
(	(	O
n	JJ	O
=	NNP	O
167	CD	SS
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
:	:	O
an	DT	O
educational	JJ	O
book	NN	O
group	NN	O
,	,	O
a	DT	O
noneducational	JJ	O
book	NN	O
group	NN	O
,	,	O
or	CC	O
a	DT	O
no-book	JJ	O
group	NN	O
.	.	O

Home	NNP	O
visits	NNS	O
and	CC	O
interviews	NNS	O
measured	VBN	O
safety	NN	O
practices	NNS	O
when	WRB	O
women	NNS	O
were	VBD	O
in	IN	O
their	PRP$	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
(	(	O
baseline	NN	O
)	)	O
and	CC	O
when	WRB	O
their	PRP$	O
children	NNS	O
were	VBD	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
in	IN	O
the	DT	O
educational	JJ	O
book	NN	O
group	NN	O
had	VBD	O
fewer	JJR	O
risks	NNS	O
in	IN	O
their	PRP$	O
homes	NNS	O
and	CC	O
exercised	VBD	O
more	JJR	O
safety	NN	O
practices	NNS	O
than	IN	O
the	DT	O
no-book	JJ	O
group	NN	O
(	(	O
-	:	O
20	CD	O
%	NN	O
risk	NN	O
reduction	NN	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
-.30	NNP	O
)	)	O
.	.	O

When	WRB	O
the	DT	O
safety	NN	O
practices	NNS	O
involved	VBN	O
little	JJ	O
time	NN	O
or	CC	O
expense	NN	O
(	(	O
eg	UH	O
,	,	O
putting	VBG	O
away	RB	O
sharp	JJ	O
objects	NNS	O
)	)	O
,	,	O
the	DT	O
educational	JJ	O
book	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
engage	VB	O
in	IN	O
these	DT	O
behaviors	NNS	O
than	IN	O
the	DT	O
no-book	JJ	O
group	NN	O
(	(	O
40	CD	O
%	NN	O
higher	JJR	O
practices	NNS	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
0.19	CD	O
)	)	O
or	CC	O
noneducational	JJ	O
book	NN	O
group	NN	O
(	(	O
27	CD	O
%	NN	O
higher	JJR	O
practices	NNS	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
groups	NNS	O
for	IN	O
behaviors	NNS	O
that	WDT	O
required	VBD	O
high	JJ	O
effort	NN	O
in	IN	O
time	NN	O
,	,	O
money	NN	O
,	,	O
or	CC	O
hassle	NN	O
(	(	O
eg	JJ	O
,	,	O
installing	VBG	O
latches	NNS	O
on	IN	O
cabinets	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Educational	NNP	O
baby	NN	O
books	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
an	DT	O
easy	JJ	O
and	CC	O
low-cost	JJ	O
way	NN	O
to	TO	O
increase	VB	O
the	DT	O
safety	NN	O
practices	NNS	O
of	IN	O
new	JJ	O
mothers	NNS	O
,	,	O
especially	RB	O
if	IN	O
the	DT	O
practices	NNS	O
involve	VBP	O
little	JJ	O
to	TO	O
no	DT	O
time	NN	O
,	,	O
money	NN	O
,	,	O
or	CC	O
hassle	NN	O
.	.	O

Coagulation	NNP	O
factor	NN	O
concentrate	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
haemorrhagic	JJ	C
diathesis	NN	C
of	IN	O
fulminant	JJ	C
hepatic	JJ	C
failure	NN	C
.	.	O

To	TO	O
assess	VB	O
the	DT	O
value	NN	O
of	IN	O
clotting	VBG	O
factor	NN	O
concentrate	NN	O
infusions	NNS	O
in	IN	O
fulminant	JJ	C
hepatic	JJ	C
failure	NN	C
,	,	O
a	DT	O
controlled	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
which	WDT	O
nine	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
concentrate	NN	O
alone	RB	O
or	CC	O
concentrate	VB	O
plus	CC	O
heparin	VB	O
.	.	O

The	DT	O
five	CD	O
patients	NNS	O
receiving	VBG	O
concentrate	VB	O
alone	RB	O
all	DT	O
died	VBD	O
,	,	O
with	IN	O
major	JJ	O
bleeding	VBG	O
as	IN	O
the	DT	O
direct	JJ	O
cause	NN	O
of	IN	O
death	NN	O
in	IN	O
three	CD	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
four	CD	O
receiving	VBG	O
heparin	NN	O
as	RB	O
well	RB	O
there	EX	O
was	VBD	O
only	RB	O
one	CD	O
instance	NN	O
of	IN	O
bleeding	NN	O
and	CC	O
one	CD	O
patient	NN	O
survived	VBD	O
.	.	O

Clinical	JJ	O
evidence	NN	O
of	IN	O
intravascular	JJ	O
coagulation	NN	O
appeared	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBD	O
with	IN	O
concentrate	NN	O
alone	RB	O
and	CC	O
the	DT	O
laboratory	JJ	O
evidence	NN	O
of	IN	O
this	DT	O
progressed	VBN	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
infusions	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
although	IN	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
in	IN	O
those	DT	O
receiving	VBG	O
heparin	NN	O
.	.	O

Additional	JJ	O
evidence	NN	O
for	IN	O
intravascular	JJ	O
coagulation	NN	O
came	VBD	O
from	IN	O
the	DT	O
changes	NNS	O
observed	VBN	O
in	IN	O
factor	NN	O
VIII	NNP	O
levels	NNS	O
which	WDT	O
,	,	O
although	IN	O
initially	RB	O
high	JJ	O
in	IN	O
all	DT	O
patients	NNS	O
,	,	O
fell	VBD	O
subsequently	RB	O
,	,	O
particularly	RB	O
in	IN	O
those	DT	O
given	VBN	O
concentrate	VBP	O
alone	RB	O
.	.	O

There	EX	O
was	VBD	O
some	DT	O
improvement	NN	O
in	IN	O
the	DT	O
prothrombin	NN	O
ratio	NN	O
in	IN	O
both	DT	O
groups	NNS	O
of	IN	O
patients	NNS	O
but	CC	O
not	RB	O
complete	JJ	O
correction	NN	O
,	,	O
and	CC	O
serial	JJ	O
assays	NNS	O
of	IN	O
clotting	VBG	O
factors	NNS	O
showed	VBD	O
that	IN	O
although	IN	O
factor	NN	O
II	NNP	O
rose	VBD	O
to	TO	O
high	JJ	O
levels	NNS	O
during	IN	O
treatment	NN	O
,	,	O
factors	NNS	O
IX	NNP	O
and	CC	O
X	NNP	O
showed	VBD	O
little	JJ	O
response	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
concentrate	NN	O
of	IN	O
factor	NN	O
IX	NNP	O
in	IN	O
this	DT	O
trial	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
potentiating	VBG	O
intravascular	JJ	O
coagulation	NN	O
,	,	O
was	VBD	O
inadequate	JJ	O
as	IN	O
replacement	NN	O
for	IN	O
the	DT	O
clotting	NN	O
factor	NN	O
deficiencies	NNS	O
.	.	O

Atrial	NNP	O
natriuretic	JJ	O
factor	NN	O
inhibits	NNS	O
metoclopramide	RB	O
stimulated	VBD	O
aldosterone	JJ	O
release	NN	O
in	IN	O
man	NN	SE
.	.	O

1	CD	O
.	.	O

Atrial	NNP	O
natriuretic	JJ	O
factor	NN	O
(	(	O
ANF	NNP	O
)	)	O
has	VBZ	O
an	DT	O
inhibitory	JJ	O
effect	NN	O
on	IN	O
angiotensin	NN	O
II	NNP	O
and	CC	O
ACTH	NNP	O
stimulated	VBD	O
aldosterone	CD	O
secretion	NN	O
in	IN	O
man	NN	O
.	.	O

The	DT	O
selectivity	NN	O
of	IN	O
this	DT	O
aldosterone	NN	O
suppressing	VBG	O
effect	NN	O
of	IN	O
ANF	NNP	O
is	VBZ	O
unclear	JJ	O
in	IN	O
man	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
ANF	NNP	O
on	IN	O
the	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
aldosterone	NN	O
due	JJ	O
to	TO	O
metoclopramide	VB	O
in	IN	O
man	NN	SE
.	.	O

2	CD	O
.	.	O

Eight	NNP	SS
normal	JJ	C
male	NN	SE
volunteers	NNS	O
were	VBD	O
studied	VBN	O
on	IN	O
three	CD	O
occasions	NNS	O
.	.	O

Metoclopramide	NNP	O
(	(	O
10	CD	O
mg	RB	O
slow	JJ	O
i.v	NN	O
.	.	O

)	)	O
was	VBD	O
given	VBN	O
on	IN	O
all	DT	O
study	NN	O
days	NNS	O
and	CC	O
each	DT	O
volunteer	NN	O
was	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
45	CD	O
min	JJ	O
infusion	NN	O
of	IN	O
either	DT	O
5	CD	O
%	NN	O
D-glucose	NNP	O
(	(	O
placebo	NN	O
)	)	O
or	CC	O
ANF	NNP	O
(	(	O
99-126	CD	O
)	)	O
3	CD	O
or	CC	O
15	CD	O
pmol	JJ	O
kg-1	JJ	O
min-1	NN	O
.	.	O

3	CD	O
.	.	O

Metoclopramide	NNP	O
increased	VBD	O
plasma	RB	O
aldosterone	NN	O
to	TO	O
approximately	RB	O
170	CD	O
%	NN	O
of	IN	O
baseline	NN	O
levels	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Concomitant	JJ	O
infusion	NN	O
of	IN	O
ANF	NNP	O
3	CD	O
pmol	JJ	O
kg-1	JJ	O
min-1	NN	O
and	CC	O
15	CD	O
pmol	JJ	O
kg-1	JJ	O
min-1	NN	O
significantly	RB	O
attenuated	VBD	O
this	DT	O
rise	NN	O
in	IN	O
plasma	NN	O
aldosterone	NN	O
to	TO	O
approximately	RB	O
130	CD	O
%	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
and	CC	O
110	CD	O
%	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
of	IN	O
baseline	NN	O
values	NNS	O
respectively	RB	O
.	.	O

4	CD	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
,	,	O
in	IN	O
the	DT	O
light	NN	O
of	IN	O
previous	JJ	O
findings	NNS	O
,	,	O
that	IN	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
ANF	NNP	O
represents	VBZ	O
a	DT	O
non-selective	JJ	O
action	NN	O
of	IN	O
ANF	NNP	O
on	IN	O
aldosterone	NN	O
release	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
tailored	JJ	O
skin	NN	C
cancer	NN	C
prevention	NN	O
for	IN	O
children	NNS	A
:	:	O
the	DT	O
Project	NNP	O
SCAPE	NNP	O
family	NN	O
study	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
a	DT	O
tailored	VBN	O
intervention	NN	O
to	TO	O
promote	VB	O
sun	NN	O
protection	NN	O
in	IN	O
parents	NNS	A
and	CC	O
their	PRP$	O
children	NNS	O
,	,	O
hypothesizing	VBG	O
that	IN	O
the	DT	O
tailored	VBN	O
intervention	NN	O
would	MD	O
lead	VB	O
to	TO	O
improved	JJ	O
skin	NN	O
cancer	NN	O
prevention	NN	O
behaviors	NNS	O
compared	VBN	O
to	TO	O
generic	JJ	O
materials	NNS	O
.	.	O

Families	NNS	O
were	VBD	O
recruited	VBN	O
through	IN	O
schools	NNS	O
and	CC	O
community	NN	O
centers	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
if	IN	O
there	EX	O
was	VBD	O
1	CD	O
child	NN	O
in	IN	O
Grades	NNP	O
1-3	JJ	O
at	IN	O
moderate	JJ	O
to	TO	O
high	JJ	O
risk	NN	O
for	IN	O
skin	JJ	O
cancer	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
intervention	NN	O
groups	NNS	O
:	:	O
a	DT	O
tailored	JJ	O
intervention	NN	O
,	,	O
in	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
personalized	JJ	O
skin	NN	O
cancer	NN	O
education	NN	O
through	IN	O
the	DT	O
mail	NN	O
;	:	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
received	VBD	O
generic	JJ	O
skin	NN	O
cancer	NN	O
information	NN	O
materials	NNS	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
parents	NNS	O
completed	VBD	O
questionnaires	NNS	O
about	IN	O
their	PRP$	O
and	CC	O
their	PRP$	O
children	NNS	O
's	POS	O
skin	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
prevention	NN	O
knowledge	NN	O
and	CC	O
behaviors	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
completed	VBD	O
4-day	JJ	O
sun	NN	O
exposure	NN	O
and	CC	O
protection	NN	O
diaries	NNS	O
for	IN	O
their	PRP$	O
child	NN	O
and	CC	O
themselves	PRP	O
.	.	O

Tailored	VBN	O
group	NN	O
participants	NNS	O
demonstrated	VBD	O
significantly	RB	O
greater	JJR	O
positive	JJ	O
changes	NNS	O
in	IN	O
prevention	NN	O
behavior	NN	O
after	IN	O
the	DT	O
intervention	NN	O
,	,	O
including	VBG	O
children	NNS	O
's	POS	O
use	NN	O
of	IN	O
sunscreen	NN	O
,	,	O
shirts	NNS	O
,	,	O
and	CC	O
hats	NNS	O
,	,	O
and	CC	O
parents	NNS	O
'	POS	O
use	NN	O
of	IN	O
shade	NN	O
,	,	O
and	CC	O
skin	JJ	O
examinations	NNS	O
.	.	O

Effect	JJ	O
sizes	NNS	O
were	VBD	O
small	JJ	O
and	CC	O
perceived	JJ	O
benefits	NNS	O
and	CC	O
social	JJ	O
norms	NNS	O
mediated	VBN	O
intervention	NN	O
effects	NNS	O
.	.	O

Findings	NNS	O
from	IN	O
this	DT	O
study	NN	O
support	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
focusing	VBG	O
tailored	VBN	O
communications	NNS	O
to	TO	O
families	NNS	O
in	IN	O
order	NN	O
to	TO	O
change	VB	O
skin	JJ	O
cancer	NN	O
prevention	NN	O
practices	NNS	O
in	IN	O
young	JJ	A
children	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
thiopentone/guaifenesin	NN	O
,	,	O
ketamine/guaifenesin	NN	O
and	CC	O
ketamine/midazolam	NN	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
horses	NNS	O
to	TO	O
be	VB	O
anaesthetised	VBN	C
with	IN	O
isoflurane	NN	O
.	.	O

Forty-eight	JJ	SS
horses	NNS	O
subjected	VBN	O
to	TO	O
elective	VB	C
surgery	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	SS
groups	NNS	O
of	IN	O
16	CD	SS
horses	NNS	O
.	.	O

After	IN	O
premedication	NN	O
with	IN	O
0.1	CD	O
mg/kg	NNS	O
acepromazine	VBP	O
intramuscularly	RB	O
and	CC	O
0.6	CD	O
mg/kg	NNS	O
xylazine	JJ	O
intravenously	RB	O
,	,	O
anaesthesia	NN	O
was	VBD	O
induced	VBN	O
either	RB	O
with	IN	O
2	CD	O
g	NNS	O
thiopentone	NN	O
in	IN	O
500	CD	O
ml	NN	O
of	IN	O
a	DT	O
10	CD	O
per	IN	O
cent	NN	O
guaifenesin	NN	O
solution	NN	O
,	,	O
given	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
ml/kg	NNS	O
(	(	O
group	NN	O
TG	NNP	O
)	)	O
,	,	O
or	CC	O
with	IN	O
100	CD	O
mg/kg	NNS	O
guaifenesin	NN	O
and	CC	O
2.2	CD	O
mg/kg	NN	O
ketamine	NN	O
given	VBN	O
intravenously	RB	O
(	(	O
group	NN	O
KG	NNP	O
)	)	O
,	,	O
or	CC	O
with	IN	O
0.06	CD	O
mg/kg	NNS	O
midazolam	NN	O
,	,	O
and	CC	O
2.2	CD	O
mg/kg	NN	O
ketamine	NN	O
given	VBN	O
intravenously	RB	O
(	(	O
group	NN	O
KM	NNP	O
)	)	O
.	.	O

Anaesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
sd	NN	O
)	)	O
end	NN	O
tidal	JJ	O
isoflurane	NN	O
concentration	NN	O
(	(	O
per	IN	O
cent	NN	O
)	)	O
needed	VBD	O
to	TO	O
maintain	VB	O
a	DT	O
light	JJ	O
surgical	JJ	O
anaesthesia	NN	O
(	(	O
stage	NN	O
III	NNP	O
,	,	O
plane	NN	O
2	CD	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
KM	NNP	O
(	(	O
0.91	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
than	IN	O
in	IN	O
groups	NNS	O
TG	NNP	O
(	(	O
1.11	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
and	CC	O
KG	NNP	O
(	(	O
1.14	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
sd	NN	O
)	)	O
arterial	JJ	O
pressure	NN	O
(	(	O
mmHg	NN	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
KG	NNP	O
(	(	O
67.4	CD	O
[	RB	O
2.07	CD	O
]	NN	O
)	)	O
than	IN	O
in	IN	O
groups	NNS	O
TC	NNP	O
(	(	O
75.6	CD	O
[	RB	O
2.23	CD	O
]	NN	O
)	)	O
and	CC	O
KM	NNP	O
(	(	O
81.0	CD	O
[	RB	O
2.16	CD	O
]	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
heart	NN	O
rate	NN	O
,	,	O
recovery	NN	O
time	NN	O
or	CC	O
quality	NN	O
of	IN	O
recovery	NN	O
between	IN	O
the	DT	O
three	CD	O
induction	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
pronounced	VBD	O
ataxia	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
horses	NNS	O
of	IN	O
group	NN	O
KM	NNP	O
,	,	O
especially	RB	O
after	IN	O
periods	NNS	O
of	IN	O
anaesthesia	NN	O
lasting	VBG	O
less	JJR	O
than	IN	O
75	CD	O
minutes	NNS	O
.	.	O

QT/QTc	NNP	O
study	NN	O
conducted	VBD	O
in	IN	O
Japanese	JJ	O
adult	NN	A
healthy	JJ	C
subjects	NNS	O
:	:	O
a	DT	O
novel	JJ	O
xanthine	NN	O
oxidase	NN	O
inhibitor	NN	O
topiroxostat	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
QT	NNP	O
prolongation	NN	O
.	.	O

A	DT	O
QT/QTc	NNP	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
compliance	NN	O
with	IN	O
ICH	NNP	O
E14	NNP	O
guideline	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
new	JJ	O
xanthine	JJ	O
oxidase	NN	O
inhibitor	NN	O
topiroxostat	NN	O
in	IN	O
Japanese	JJ	O
healthy	JJ	C
subjects	NNS	C
.	.	O

Forty-eight	JJ	SS
Japanese	JJ	O
healthy	JJ	C
subjects	NNS	C
(	(	O
males	NNS	SE
24	CD	SS
;	:	O
females	NNS	SE
24	CD	SS
)	)	O
received	VBD	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
topiroxostat	NN	O
(	(	O
60	CD	O
or	CC	O
180	CD	O
mg	NN	O
)	)	O
,	,	O
moxifloxacin	FW	O
(	(	O
400	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
single-center	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
four-period	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Fridericia	NNP	O
's	POS	O
formula	NN	O
(	(	O
QTcF	NNP	O
=	NNP	O
QT/RR	NNP	O
(	(	O
0.33	CD	O
)	)	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
primary	JJ	O
method	NN	O
for	IN	O
QT-interval	JJ	O
correction	NN	O
.	.	O

The	DT	O
mean	JJ	O
QTcF	NNP	O
was	VBD	O
prolonged	VBN	O
by	IN	O
moxifloxacin	NN	O
,	,	O
of	IN	O
which	WDT	O
largest	JJS	O
time-matched	JJ	O
difference	NN	O
from	IN	O
placebo	JJ	O
administration	NN	O
was	VBD	O
13.6	CD	O
milliseconds	NNS	O
with	IN	O
90	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
of	IN	O
11.2	CD	O
and	CC	O
15.9	CD	O
milliseconds	NNS	O
at	IN	O
4	CD	O
hours	NNS	O
post-dose	JJ	O
.	.	O

The	DT	O
mean	JJ	O
QTcF	NNP	O
was	VBD	O
hardly	RB	O
affected	VBN	O
by	IN	O
either	DT	O
dose	NN	O
of	IN	O
topiroxostat	NN	O
,	,	O
of	IN	O
which	WDT	O
largest	JJS	O
time-matched	JJ	O
difference	NN	O
from	IN	O
placebo	JJ	O
administration	NN	O
was	VBD	O
2.9	CD	O
milliseconds	NNS	O
with	IN	O
90	CD	O
%	NN	O
CI	NNP	O
of	IN	O
0.6	CD	O
and	CC	O
5.3	CD	O
milliseconds	NNS	O
at	IN	O
4	CD	O
hours	NNS	O
post-dose	JJ	O
for	IN	O
60	CD	O
mg	NN	O
,	,	O
and	CC	O
2.3	CD	O
milliseconds	NNS	O
with	IN	O
90	CD	O
%	NN	O
CI	NNP	O
of	IN	O
0	CD	O
and	CC	O
4.7	CD	O
milliseconds	NNS	O
at	IN	O
1	CD	O
hour	NN	O
post-dose	NN	O
for	IN	O
180	CD	O
mg	NN	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
essentially	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
sex	NN	O
subgroup	NN	O
analysis	NN	O
.	.	O

Moxifloxacin	NNP	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
positive	JJ	O
control	NN	O
for	IN	O
QT/QTc	NNP	O
studies	NNS	O
in	IN	O
Japanese	JJ	O
subjects	NNS	O
;	:	O
and	CC	O
topiroxostat	VB	O
may	MD	O
not	RB	O
cause	VB	O
QT-interval	JJ	O
prolongation	NN	O
in	IN	O
males	NNS	O
as	RB	O
well	RB	O
as	IN	O
females	NNS	O
.	.	O

Observer	NNP	O
variation	NN	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
outcome	NN	O
in	IN	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
:	:	O
experience	NN	O
from	IN	O
a	DT	O
multicenter	NN	O
,	,	O
international	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Accurate	NNP	O
and	CC	O
consistent	JJ	O
outcome	NN	O
assessment	NN	O
is	VBZ	O
essential	JJ	O
to	TO	O
randomized	VB	O
clinical	JJ	O
trials	NNS	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
explore	VB	O
observer	JJ	O
variation	NN	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
outcome	NN	O
in	IN	O
a	DT	O
recently	RB	O
completed	VBN	O
trial	NN	O
of	IN	O
dexanabinol	NN	O
in	IN	O
head	JJ	C
injury	NN	C
and	CC	O
to	TO	O
consider	VB	O
steps	NNS	O
to	TO	O
reduce	VB	O
such	JJ	O
variation	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	SS
hundred	VBD	SS
sixty-one	JJ	SS
patients	NNS	O
with	IN	O
severe	JJ	C
traumatic	JJ	C
brain	NN	C
injury	NN	C
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
86	CD	O
centers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
Phase	NNP	O
III	NNP	O
trial	NN	O
.	.	O

Outcome	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
postinjury	NN	O
using	VBG	O
the	DT	O
extended	JJ	O
Glasgow	NNP	O
Outcome	NNP	O
Scale	NNP	O
;	:	O
standardized	VBD	O
assessment	NN	O
was	VBD	O
facilitated	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
structured	JJ	O
interview	NN	O
.	.	O

Before	IN	O
initiation	NN	O
of	IN	O
trial	NN	O
centers	NNS	O
,	,	O
outcome	JJ	O
ratings	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
sample	JJ	O
cases	NNS	O
to	TO	O
establish	VB	O
initial	JJ	O
levels	NNS	O
of	IN	O
agreement	NN	O
.	.	O

Training	NN	O
sessions	NNS	O
in	IN	O
outcome	JJ	O
assessment	NN	O
were	VBD	O
held	VBN	O
,	,	O
and	CC	O
problems	NNS	O
in	IN	O
assigning	VBG	O
outcome	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

During	IN	O
the	DT	O
trial	NN	O
,	,	O
a	DT	O
process	NN	O
of	IN	O
central	JJ	O
review	NN	O
was	VBD	O
established	VBN	O
to	TO	O
monitor	VB	O
performance	NN	O
.	.	O

Interobserver	NNP	O
variation	NN	O
was	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
kappa	NN	O
statistic	JJ	O
.	.	O

RESULTS	NNP	O
Substantial	NNP	O
observer	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
rating	NN	O
of	IN	O
sample	JJ	O
cases	NNS	O
(	(	O
weighted	JJ	O
kappa	NN	O
,	,	O
0.72	CD	O
;	:	O
confidence	NN	O
interval	NN	O
,	,	O
0.68-0.75	JJ	O
)	)	O
and	CC	O
in	IN	O
assigning	VBG	O
outcome	NN	O
based	VBN	O
on	IN	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
weighted	JJ	O
kappa	NN	O
,	,	O
0.61	CD	O
;	:	O
confidence	NN	O
interval	NN	O
,	,	O
0.57-0.64	JJ	O
)	)	O
.	.	O

In	IN	O
the	DT	O
early	JJ	O
stages	NNS	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
a	DT	O
relatively	RB	O
large	JJ	O
number	NN	O
of	IN	O
discrepancies	NNS	O
(	(	O
29-37	CD	O
%	NN	O
)	)	O
were	VBD	O
identified	VBN	O
on	IN	O
central	JJ	O
review	NN	O
.	.	O

This	DT	O
number	NN	O
declined	VBD	O
as	IN	O
the	DT	O
trial	NN	O
progressed	VBD	O
and	CC	O
coincided	VBD	O
with	IN	O
investigator	NN	O
training	NN	O
and	CC	O
feedback	NN	O
from	IN	O
central	JJ	O
review	NN	O
.	.	O

Centers	NNS	O
with	IN	O
higher	JJR	O
enrollment	NN	O
rates	NNS	O
showed	VBD	O
better	JJR	O
performance	NN	O
.	.	O

CONCLUSION	NNP	O
Observer	NNP	O
variation	NN	O
in	IN	O
outcome	JJ	O
assessment	NN	O
is	VBZ	O
a	DT	O
significant	JJ	O
problem	NN	O
for	IN	O
head	NN	O
injury	NN	O
trials	NNS	O
.	.	O

Consistency	NN	O
can	MD	O
be	VB	O
improved	VBN	O
by	IN	O
standardizing	VBG	O
procedures	NNS	O
,	,	O
training	VBG	O
assessors	NNS	O
,	,	O
and	CC	O
monitoring	VBG	O
the	DT	O
quality	NN	O
of	IN	O
assessments	NNS	O
and	CC	O
providing	VBG	O
feedback	NN	O
to	TO	O
interviewers	NNS	O
.	.	O

Margarines	NNS	O
fortified	VBN	O
with	IN	O
?-linolenic	JJ	O
acid	NN	O
,	,	O
eicosapentaenoic	JJ	O
acid	NN	O
,	,	O
or	CC	O
docosahexaenoic	JJ	O
acid	NN	O
alter	IN	O
the	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
of	IN	O
erythrocytes	NNS	O
but	CC	O
do	VBP	O
not	RB	O
affect	VB	O
the	DT	O
antioxidant	JJ	O
status	NN	O
of	IN	O
healthy	JJ	O
adults	NNS	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
increased	JJ	O
intake	NN	O
of	IN	O
?-linolenic	JJ	O
acid	NN	O
(	(	O
ALA	NNP	O
)	)	O
,	,	O
EPA	NNP	O
,	,	O
or	CC	O
DHA	NNP	O
incorporated	VBN	O
into	IN	O
a	DT	O
food	NN	O
matrix	NN	O
on	IN	O
the	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
of	IN	O
erythrocytes	NNS	O
and	CC	O
on	IN	O
biomarkers	NNS	O
of	IN	O
oxidant/antioxidant	JJ	O
status	NN	O
.	.	O

To	TO	O
this	DT	O
end	NN	O
,	,	O
a	DT	O
controlled	VBN	O
dietary	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
74	CD	O
healthy	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
interventions	NNS	O
in	IN	O
which	WDT	O
margarines	NNS	O
fortified	VBD	O
with	IN	O
either	DT	O
10	CD	O
weight	NN	O
percent	NN	O
ALA	NNP	O
,	,	O
EPA	NNP	O
,	,	O
or	CC	O
DHA	NNP	O
ethyl	VBP	O
esters	NNS	O
replaced	VBD	O
their	PRP$	O
normal	JJ	O
spread	NN	O
for	IN	O
6	CD	O
wk	NN	O
.	.	O

The	DT	O
total	JJ	O
intakes	NNS	O
of	IN	O
ALA	NNP	O
,	,	O
EPA	NNP	O
,	,	O
and	CC	O
DHA	NNP	O
were	VBD	O
4.4	CD	O
,	,	O
2.2	CD	O
,	,	O
and	CC	O
2.3	CD	O
g/d	NN	O
,	,	O
respectively	RB	O
.	.	O

Consuming	VBG	O
EPA	NNP	O
increased	VBD	O
the	DT	O
erythrocyte	JJ	O
proportion	NN	O
of	IN	O
EPA	NNP	O
(	(	O
394	CD	O
%	NN	O
)	)	O
and	CC	O
the	DT	O
omega-3	JJ	O
index	NN	O
(	(	O
sum	NN	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
,	,	O
38	CD	O
%	NN	O
)	)	O
.	.	O

Consumption	NN	O
of	IN	O
DHA	NNP	O
increased	VBD	O
erythrocyte	JJ	O
DHA	NNP	O
(	(	O
91	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
omega-3	JJ	O
index	NN	O
(	(	O
98	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
EPA	NNP	O
(	(	O
137	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
omega-3	JJ	O
index	NN	O
increased	VBD	O
to	TO	O
a	DT	O
significantly	RB	O
greater	JJR	O
extent	NN	O
in	IN	O
the	DT	O
DHA	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
EPA	NNP	O
group	NN	O
.	.	O

ALA	NNP	O
did	VBD	O
not	RB	O
increase	VB	O
erythrocyte	NN	O
EPA	NNP	O
or	CC	O
the	DT	O
omega-3	JJ	O
index	NN	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
change	NN	O
in	IN	O
plasma	NN	O
uric	JJ	O
acid	NN	O
or	CC	O
antioxidant	JJ	O
capacity	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

Plasma	NNP	O
malondialdehyde	NN	O
(	(	O
MDA	NNP	O
)	)	O
increased	VBD	O
with	IN	O
the	DT	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
interventions	NNS	O
.	.	O

All	DT	O
3	CD	O
interventions	NNS	O
decreased	VBD	O
erythrocyte	JJ	O
linoleic	NN	O
acid	NN	O
hydroperoxides	NNS	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
their	PRP$	O
MDA	NNP	O
concentrations	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
intake	NN	O
of	IN	O
both	DT	O
isolated	JJ	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
incorporated	VBD	O
into	IN	O
margarine	NN	O
resulted	VBN	O
in	IN	O
an	DT	O
enhanced	JJ	O
incorporation	NN	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
into	IN	O
erythrocytes	NNS	O
.	.	O

Our	PRP$	O
findings	NNS	O
indicate	VBP	O
that	IN	O
DHA	NNP	O
is	VBZ	O
quantitatively	RB	O
superior	JJ	O
to	TO	O
EPA	NNP	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
EPA+DHA	NNP	O
tissue	NN	O
incorporation	NN	O
and	CC	O
also	RB	O
that	IN	O
4	CD	O
g/d	NN	O
ALA	NNP	O
is	VBZ	O
not	RB	O
sufficient	JJ	O
to	TO	O
increase	VB	O
the	DT	O
omega-3	JJ	O
index	NN	O
over	IN	O
a	DT	O
6-wk	JJ	O
period	NN	O
.	.	O

Immunologic	NNP	O
response	NN	O
after	IN	O
laparoscopic	NN	O
colon	NN	C
cancer	NN	C
operation	NN	O
within	IN	O
an	DT	O
enhanced	JJ	O
recovery	NN	O
program	NN	O
.	.	O

OBJECTIVE	NN	O
It	PRP	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
that	IN	O
colon	NN	O
operation	NN	O
combined	VBN	O
with	IN	O
fast-track	NN	O
(	(	O
FT	NNP	O
)	)	O
surgery	NN	O
and	CC	O
laparoscopic	NN	O
technique	NN	O
can	MD	O
shorten	VB	O
the	DT	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
accelerate	JJ	O
recovery	NN	O
of	IN	O
intestinal	JJ	O
function	NN	O
,	,	O
and	CC	O
reduce	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
post-operative	JJ	O
complications	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
regarding	VBG	O
the	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
FT	NNP	O
colon	NN	O
operation	NN	O
and	CC	O
laparoscopic	NN	O
technique	NN	O
on	IN	O
humoral	JJ	O
inflammatory	NN	O
cellular	JJ	O
immunity	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

One	CD	SS
hundred	VBD	SS
sixty-three	JJ	SS
colon	NN	C
cancer	NN	C
patients	NNS	O
underwent	VBD	O
the	DT	O
traditional	JJ	O
protocol	NN	O
and	CC	O
open	JJ	O
operation	NN	O
(	(	O
traditional	JJ	O
open	JJ	O
group	NN	O
,	,	O
n=42	RB	SS
)	)	O
,	,	O
the	DT	O
traditional	JJ	O
protocol	NN	O
and	CC	O
laparoscopic	NN	O
operation	NN	O
(	(	O
traditional	JJ	O
laparoscopic	NN	O
group	NN	O
,	,	O
n=40	RB	SS
)	)	O
,	,	O
the	DT	O
FT	NNP	O
protocol	NN	O
and	CC	O
open	JJ	O
operation	NN	O
(	(	O
FT	NNP	O
open	JJ	O
group	NN	O
,	,	O
n=41	RB	SS
)	)	O
,	,	O
or	CC	O
the	DT	O
FT	NNP	O
protocol	NN	O
and	CC	O
laparoscopic	NN	O
operation	NN	O
(	(	O
FT	NNP	O
laparoscopic	NN	O
group	NN	O
,	,	O
n=40	RB	SS
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
prior	RB	O
to	TO	O
operation	NN	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
5	CD	O
after	IN	O
operation	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
lymphocyte	JJ	O
subpopulations	NNS	O
was	VBD	O
determined	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
,	,	O
and	CC	O
serum	VB	O
interleukin-6	JJ	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Post-operative	JJ	O
hospital	NN	O
stay	NN	O
,	,	O
post-operative	JJ	O
morbidity	NN	O
,	,	O
readmission	NN	O
rate	NN	O
,	,	O
and	CC	O
in-hospital	JJ	O
mortality	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
open	JJ	O
operation	NN	O
,	,	O
laparoscopic	JJ	O
colon	NN	O
operation	NN	O
effectively	RB	O
inhibited	VBD	O
the	DT	O
release	NN	O
of	IN	O
post-operative	JJ	O
inflammatory	JJ	O
factors	NNS	O
and	CC	O
yielded	VBD	O
good	JJ	O
protection	NN	O
via	IN	O
post-operative	JJ	O
cell	NN	O
immunity	NN	O
.	.	O

FT	NNP	O
surgery	NN	O
had	VBD	O
a	DT	O
better	RBR	O
protective	JJ	O
role	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
post-operative	JJ	O
immune	NN	O
system	NN	O
compared	VBN	O
with	IN	O
traditional	JJ	O
peri-operative	JJ	O
care	NN	O
.	.	O

Inflammatory	JJ	O
reactions	NNS	O
,	,	O
based	VBN	O
on	IN	O
interleukin-6	JJ	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
levels	NNS	O
,	,	O
were	VBD	O
less	JJR	O
intense	JJ	O
following	VBG	O
FT	NNP	O
laparoscopic	NN	O
operation	NN	O
compared	VBN	O
to	TO	O
FT	NNP	O
open	JJ	O
operation	NN	O
;	:	O
however	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
specific	JJ	O
immunity	NN	O
(	(	O
CD3+	NNP	O
and	CC	O
CD4+	NNP	O
counts	NNS	O
,	,	O
and	CC	O
the	DT	O
CD4+/CD8+	NNP	O
ratio	NN	O
)	)	O
during	IN	O
these	DT	O
two	CD	O
types	NNS	O
of	IN	O
surgical	JJ	O
procedures	NNS	O
.	.	O

Post-operative	JJ	O
hospital	NN	O
stay	NN	O
in	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
FT	NNP	O
laparoscopic	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
three	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Post-operative	JJ	O
complications	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
underwent	VBP	O
FT	NNP	O
laparoscopic	NN	O
treatment	NN	O
were	VBD	O
less	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
three	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
four	CD	O
treatment	NN	O
groups	NNS	O
regarding	VBG	O
readmission	NN	O
rate	NN	O
and	CC	O
in-hospital	JJ	O
mortality	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
laparoscopic	NN	O
technique	NN	O
and	CC	O
FT	NNP	O
surgery	NN	O
rehabilitation	NN	O
program	NN	O
effectively	RB	O
inhibited	VBD	O
release	NN	O
of	IN	O
post-operative	JJ	O
inflammatory	JJ	O
factors	NNS	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
peri-operative	JJ	O
trauma	NN	O
and	CC	O
stress	NN	O
,	,	O
which	WDT	O
together	RB	O
played	VBD	O
a	DT	O
protective	JJ	O
role	NN	O
on	IN	O
the	DT	O
post-operative	JJ	O
immune	NN	O
system	NN	O
.	.	O

Combining	VBG	O
two	CD	O
treatment	NN	O
measures	NNS	O
during	IN	O
colon	NN	O
operation	NN	O
produced	VBD	O
better	RBR	O
protective	JJ	O
effects	NNS	O
via	IN	O
the	DT	O
immune	JJ	O
system	NN	O
.	.	O

The	DT	O
beneficial	JJ	O
clinical	JJ	O
effects	NNS	O
support	NN	O
that	IN	O
the	DT	O
better-preserved	JJ	O
post-operative	JJ	O
immune	NN	O
system	NN	O
may	MD	O
also	RB	O
contribute	VB	O
to	TO	O
the	DT	O
improvement	NN	O
of	IN	O
post-operative	JJ	O
results	NNS	O
in	IN	O
FT	NNP	O
laparoscopic	NN	O
patients	NNS	O
.	.	O

Learning	VBG	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
:	:	O
does	VBZ	O
comparing	VBG	O
with	IN	O
inequality	NN	O
symbols	NNS	O
help	VB	O
?	.	O
This	DT	O
study	NN	O
investigated	VBD	O
whether	IN	O
instruction	NN	O
that	WDT	O
involves	VBZ	O
comparing	VBG	O
the	DT	O
equal	JJ	O
sign	NN	O
with	IN	O
other	JJ	O
relational	JJ	O
symbols	NNS	O
is	VBZ	O
more	RBR	O
effective	JJ	O
at	IN	O
imparting	VBG	O
a	DT	O
relational	JJ	O
interpretation	NN	O
of	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
than	IN	O
instruction	NN	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
alone	RB	O
.	.	O

Third-	JJ	A
and	CC	A
fourth-grade	JJ	A
students	NNS	A
in	IN	O
a	DT	O
comparing	NN	O
symbols	NNS	O
group	NN	O
learned	VBD	O
about	IN	O
the	DT	O
greater	JJR	O
than	IN	O
,	,	O
less	JJR	O
than	IN	O
,	,	O
and	CC	O
equal	JJ	O
signs	NNS	O
and	CC	O
had	VBD	O
the	DT	O
opportunity	NN	O
to	TO	O
compare	VB	O
the	DT	O
inequality	NN	O
symbols	VBZ	O
with	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
.	.	O

Students	NNS	O
in	IN	O
an	DT	O
equal	JJ	O
sign	NN	O
group	NN	O
learned	VBD	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
only	RB	O
.	.	O

A	NNP	O
third	JJ	O
group	NN	O
of	IN	O
students	NNS	O
served	VBD	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Three	CD	O
aspects	NNS	O
of	IN	O
students	NNS	O
'	POS	O
knowledge	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
lesson	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
conceptual	JJ	O
understanding	NN	O
of	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
equation	NN	O
encoding	NN	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
problem	NN	O
solving	VBG	O
.	.	O

Students	NNS	O
in	IN	O
the	DT	O
comparing	NN	O
symbols	NNS	O
group	NN	O
showed	VBD	O
greater	JJR	O
gains	NNS	O
in	IN	O
conceptual	JJ	O
understanding	NN	O
from	IN	O
pretest	NN	O
to	TO	O
posttest	VB	O
than	IN	O
students	NNS	O
in	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
students	NNS	O
in	IN	O
the	DT	O
comparing	NN	O
symbols	NNS	O
group	NN	O
also	RB	O
scored	VBD	O
higher	JJR	O
on	IN	O
a	DT	O
posttest	NN	O
that	WDT	O
assessed	VBD	O
knowledge	NN	O
about	IN	O
inequality	NN	O
symbols	NNS	O
and	CC	O
inequality	NN	O
problem	NN	O
solving	VBG	O
.	.	O

Thus	RB	O
,	,	O
they	PRP	O
learned	VBD	O
about	IN	O
three	CD	O
symbols	NNS	O
in	IN	O
the	DT	O
same	JJ	O
amount	NN	O
of	IN	O
time	NN	O
as	IN	O
other	JJ	O
students	NNS	O
learned	VBD	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
alone	RB	O
or	CC	O
not	RB	O
at	IN	O
all	DT	O
.	.	O

Therefore	NNP	O
,	,	O
an	DT	O
instructional	JJ	O
approach	NN	O
involving	VBG	O
comparison	NN	O
can	MD	O
be	VB	O
an	DT	O
effective	JJ	O
tool	NN	O
for	IN	O
learning	VBG	O
about	IN	O
concepts	NNS	O
in	IN	O
mathematics	NNS	O
.	.	O

Enhanced	NNP	O
small	JJ	O
group	NN	O
instruction	NN	O
using	VBG	O
choral	JJ	O
responding	NN	O
and	CC	O
student	NN	O
interaction	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	C
and	CC	O
developmental	JJ	C
disabilities	NNS	C
.	.	O

The	DT	O
use	NN	O
of	IN	O
effective	JJ	O
instructional	JJ	O
strategies	NNS	O
in	IN	O
small	JJ	O
groups	NNS	O
was	VBD	O
investigated	VBN	O
to	TO	O
determine	VB	O
learning	JJ	O
effects	NNS	O
for	IN	O
24	CD	SS
elementary	JJ	A
age	NN	A
students	NNS	O
with	IN	O
autism	NN	C
and	CC	O
developmental	JJ	C
disabilities	NNS	C
.	.	O

Effective	JJ	O
strategies	NNS	O
included	VBD	O
(	(	O
a	DT	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
choral	JJ	O
responding	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
student-to-student	JJ	O
responding	NN	O
;	:	O
(	(	O
c	NN	O
)	)	O
the	DT	O
rotation	NN	O
of	IN	O
materials	NNS	O
every	DT	O
5	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
30-minute	JJ	O
group	NN	O
while	IN	O
teaching	VBG	O
2	CD	O
to	TO	O
3	CD	O
concepts	NNS	O
;	:	O
and	CC	O
(	(	O
d	NN	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
random	NN	O
,	,	O
unpredictable	JJ	O
trials	NNS	O
for	IN	O
student	NN	O
responding	VBG	O
.	.	O

Thirty-minute	JJ	O
language	NN	O
groups	NNS	O
were	VBD	O
targeted	VBN	O
to	TO	O
teach	VB	O
receptive	JJ	O
and	CC	O
expressive	JJ	O
skills	NNS	O
using	VBG	O
pictures	NNS	O
and	CC	O
common	JJ	O
objects	NNS	O
across	IN	O
five	CD	O
categories	NNS	O
(	(	O
e.g.	NN	O
,	,	O
household	NN	O
items	NNS	O
,	,	O
foods	NNS	O
)	)	O
.	.	O

Results	JJ	O
showed	VBD	O
increased	JJ	O
opportunities	NNS	O
to	TO	O
respond	VB	O
,	,	O
increased	JJ	O
levels	NNS	O
of	IN	O
responding	VBG	O
and	CC	O
academic	JJ	O
engagement	NN	O
,	,	O
higher	JJR	O
gains	NNS	O
on	IN	O
weekly	JJ	O
criterion-referenced	JJ	O
pre-	NN	O
and	CC	O
posttests	NNS	O
,	,	O
and	CC	O
decreased	VBD	O
passive	JJ	O
and	CC	O
inappropriate	JJ	O
student	NN	O
behavior	NN	O
during	IN	O
interventions	NNS	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
extended	JJ	O
duration	NN	O
peginterferon	NN	O
alfa-2a	NN	O
for	IN	O
patients	NNS	O
with	IN	O
hepatitis	NN	C
B	NNP	C
e	VBZ	C
antigen-negative	JJ	C
chronic	JJ	C
hepatitis	NN	C
B	NNP	C
.	.	O

OBJECTIVES	NNP	O
Forty-eight	JJ	O
weeks	NNS	O
of	IN	O
peginterferon	NN	O
alfa-2a	NN	O
is	VBZ	O
the	DT	O
approved	JJ	O
regimen	NNS	O
for	IN	O
chronic	JJ	C
hepatitis	NN	C
B	NNP	C
(	(	O
CHB	NNP	C
)	)	O
.	.	O

Standard	NNP	O
interferon	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
for	IN	O
hepatitis	NN	O
B	NNP	O
e	NN	O
antigen	NN	O
(	(	O
HBeAg	NNP	O
)	)	O
-negative	VBP	O
CHB	NNP	O
when	WRB	O
given	VBN	O
for	IN	O
longer	JJR	O
than	IN	O
1	CD	O
yr	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
peginterferon	JJ	O
alfa-2a	NN	O
for	IN	O
60	CD	O
wk	NN	O
,	,	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
lamivudine	NN	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	SS
patients	NNS	O
with	IN	O
HBeAg-negative	JJ	O
CHB	NNP	O
received	VBD	O
peginterferon	JJ	O
alfa-2a	JJ	O
(	(	O
180	CD	O
microg/week	NN	O
)	)	O
for	IN	O
60	CD	O
wk	NN	O
or	CC	O
peginterferon	VB	O
alfa-2a	JJ	O
(	(	O
180	CD	O
microg/week	NN	O
)	)	O
for	IN	O
12	CD	O
wk	NN	O
followed	VBN	O
by	IN	O
48	CD	O
wk	NN	O
of	IN	O
peginterferon	NN	O
alfa-2a	JJ	O
plus	CC	O
lamivudine	JJ	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
sustained	VBD	O
virologic	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
,	,	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reduction	NN	O
in	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
deoxyribonucleic	NN	O
acid	NN	O
(	(	O
HBV	NNP	O
DNA	NNP	O
)	)	O
of	IN	O
>	NNP	O
or=2	FW	O
log10	NN	O
copies/mL	NN	O
and	CC	O
HBV	NNP	O
DNA	NNP	O
<	VBD	O
20,000	CD	O
copies/mL	NN	O
at	IN	O
24	CD	O
wk	NN	O
of	IN	O
follow-up	NN	O
(	(	O
week	NN	O
84	CD	O
)	)	O
.	.	O

Hepatitis	$	O
B	NNP	O
surface	NN	O
antigen	NN	O
(	(	O
HBsAg	NNP	O
)	)	O
concentrations	NNS	O
were	VBD	O
analyzed	VBN	O
and	CC	O
compared	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
HBV	NNP	O
DNA	NNP	O
.	.	O

RESULTS	NNP	O
SVR	NNP	O
was	VBD	O
achieved	VBN	O
by	IN	O
9/13	CD	O
patients	NNS	O
(	(	O
69	CD	O
%	NN	O
)	)	O
.	.	O

At	IN	O
week	NN	O
84	CD	O
,	,	O
HBV	NNP	O
DNA	NNP	O
was	VBD	O
undetectable	JJ	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
in	IN	O
5/13	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
3	CD	O
additional	JJ	O
patients	NNS	O
had	VBD	O
a	DT	O
sustained	VBN	O
2-3	CD	O
log	NN	O
reduction	NN	O
in	IN	O
HBV	NNP	O
DNA	NNP	O
.	.	O

Five	CD	O
patients	NNS	O
demonstrated	VBD	O
a	DT	O
>	JJ	O
90	CD	O
%	NN	O
decrease	NN	O
in	IN	O
HBsAg	NNP	O
concentration	NN	O
at	IN	O
week	NN	O
60	CD	O
,	,	O
including	VBG	O
3	CD	O
with	IN	O
undetectable	JJ	O
HBV	NNP	O
DNA	NNP	O
at	IN	O
week	NN	O
84	CD	O
and	CC	O
a	DT	O
fourth	JJ	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
SVR	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Sixty	NNP	O
weeks	NNS	O
of	IN	O
peginterferon	NN	O
alfa-2a	NN	O
with	IN	O
or	CC	O
without	IN	O
lamivudine	JJ	O
resulted	VBN	O
in	IN	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
SVR	NNP	O
compared	VBN	O
to	TO	O
historical	JJ	O
controls	NNS	O
with	IN	O
HBeAg-negative	JJ	C
CHB	NNP	C
treated	VBD	O
with	IN	O
48	CD	O
wk	NN	O
of	IN	O
pegylated	JJ	O
interferon	NN	O
.	.	O

Larger	JJR	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
assess	VB	O
if	IN	O
longer	JJR	O
duration	NN	O
therapy	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
standard	JJ	O
regimen	NNS	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
greater	JJR	O
decline	NN	O
in	IN	O
HBsAg	NNP	O
concentration	NN	O
.	.	O

Olanzapine	NNP	O
versus	NN	O
haloperidol	NN	O
in	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
:	:	O
an	DT	O
open	JJ	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
Conventional	NNP	O
neuroleptics	NNS	O
ameliorate	VBP	O
symptoms	NNS	O
in	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
;	:	O
however	RB	O
,	,	O
they	PRP	O
are	VBP	O
known	VBN	O
to	TO	O
cause	VB	O
dyskinesias	NN	O
.	.	O

Atypical	JJ	O
neuroleptics	NNS	O
,	,	O
including	VBG	O
olanzapine	NN	O
,	,	O
may	MD	O
have	VB	O
less	JJR	O
risk	NN	O
for	IN	O
dyskinesia	NN	O
,	,	O
but	CC	O
their	PRP$	O
efficacy	NN	O
in	IN	O
autistic	JJ	O
disorder	NN	O
is	VBZ	O
not	RB	O
established	VBN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
open-label	JJ	O
olanzapine	NN	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
by	IN	O
using	VBG	O
haloperidol	NN	O
as	IN	O
a	DT	O
standard	JJ	O
comparator	NN	O
treatment	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
parallel	JJ	O
groups	NNS	O
design	NN	O
,	,	O
12	CD	SS
children	NNS	A
with	IN	O
DSM-IV	NNP	C
autistic	JJ	C
disorder	NN	C
(	(	O
mean	JJ	O
age	NN	O
7.8+/-2.1	CD	A
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
6	CD	O
weeks	NNS	O
of	IN	O
open	JJ	O
treatment	NN	O
with	IN	O
olanzapine	NN	O
or	CC	O
haloperidol	NN	O
.	.	O

Mean	NNP	O
final	JJ	O
dosages	NNS	O
were	VBD	O
7.9+/-2.5	JJ	O
mg/day	NN	O
for	IN	O
olanzapine	NN	O
and	CC	O
1.4+/-0.7	JJ	O
mg/day	NN	O
for	IN	O
haloperidol	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
(	(	O
CGI	NNP	O
)	)	O
and	CC	O
the	DT	O
Children	NNP	O
's	POS	O
Psychiatric	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CPRS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
had	VBD	O
symptom	VBN	O
reduction	NN	O
.	.	O

Five	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
olanzapine	NN	O
group	NN	O
and	CC	O
three	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
haloperidol	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
according	VBG	O
to	TO	O
the	DT	O
CGI	NNP	O
Improvement	NNP	O
item	NN	O
.	.	O

Subjects	NNS	O
showed	VBD	O
improvement	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
Autism	NNP	O
Factor	NNP	O
(	(	O
F1,9	NNP	O
=	NNP	O
24.4	CD	O
,	,	O
p	NN	O
=	NNP	O
.0008	NNP	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
included	VBD	O
drowsiness	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
olanzapine	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
children	NNS	A
with	IN	O
autistic	JJ	C
disorder	NN	C
.	.	O

Further	JJ	O
placebo-controlled	JJ	O
and	CC	O
long-term	JJ	O
studies	NNS	O
of	IN	O
olanzapine	NN	O
in	IN	O
autistic	JJ	O
disorder	NN	O
are	VBP	O
required	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
antihypertensives	NNS	O
after	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

Hypertension	NN	O
following	VBG	O
coronary	JJ	C
artery	JJ	C
bypass	NN	C
grafting	NN	C
is	VBZ	O
a	DT	O
common	JJ	O
problem	NN	O
that	WDT	O
may	MD	O
result	VB	O
in	IN	O
postoperative	JJ	O
myocardial	JJ	O
infraction	NN	O
or	CC	O
bleeding	NN	O
,	,	O
Hemodynamic	NNP	O
effects	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
45	CD	SS
hypertensive	JJ	C
coronary	JJ	C
bypass	NN	C
patients	NNS	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
diltiazem	NN	O
,	,	O
nitroglycerin	NN	O
,	,	O
or	CC	O
sodium	NN	O
nitroprusside	RB	O
.	.	O

Diltiazem	NNP	O
was	VBD	O
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
of	IN	O
0.3	CD	O
mg.kg-1	NN	O
within	IN	O
5	CD	O
min	NN	O
,	,	O
followed	VBN	O
by	IN	O
infusion	NN	O
of	IN	O
0.1-0.8	JJ	O
mg.kg-1.h-1	NN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

Nitroglycerin	NNP	O
was	VBD	O
infused	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
1-3	JJ	O
microg.kg.h-1	NN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
sodium	NN	O
nitroprusside	NN	O
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
1-3	JJ	O
microg.kg-1.min-1	NN	O
in	IN	O
group	NN	O
3	CD	O
.	.	O

Hemodynamic	JJ	O
measurements	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
before	IN	O
infusion	NN	O
(	(	O
T1	NNP	O
)	)	O
and	CC	O
at	IN	O
30	CD	O
min	NN	O
(	(	O
T2	NNP	O
)	)	O
,	,	O
2	CD	O
h	NN	O
(	(	O
T3	NNP	O
)	)	O
,	,	O
and	CC	O
12	CD	O
h	NN	O
(	(	O
T4	NNP	O
)	)	O
after	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
in	IN	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
decreased	VBN	O
significantly	RB	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
groups	NNS	O
at	IN	O
T1	NNP	O
and	CC	O
T2	NNP	O
.	.	O

At	IN	O
T3	NNP	O
,	,	O
heart	NN	O
rate	NN	O
in	IN	O
group	NN	O
2	CD	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
group	NN	O
1	CD	O
.	.	O

At	IN	O
T3	NNP	O
and	CC	O
T4	NNP	O
,	,	O
the	DT	O
double	JJ	O
product	NN	O
was	VBD	O
highest	JJS	O
in	IN	O
group	NN	O
3	CD	O
(	(	O
group	NN	O
1	CD	O
vs.	NN	O
3	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
3	CD	O
drugs	NNS	O
are	VBP	O
similar	JJ	O
within	IN	O
the	DT	O
first	JJ	O
30	CD	O
min	NN	O
.	.	O

However	RB	O
,	,	O
after	IN	O
30	CD	O
min	NN	O
,	,	O
diltiazem	NN	O
affords	NNS	O
better	RBR	O
myocardial	JJ	O
performance	NN	O
and	CC	O
more	RBR	O
effective	JJ	O
control	NN	O
of	IN	O
hypertension	NN	O
.	.	O

Effect	NN	O
of	IN	O
acute	NN	O
exercise	NN	O
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	A
with	IN	O
attention	NN	C
deficit	NN	C
hyperactivity	NN	C
disorder	NN	C
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
acute	NN	O
aerobic	JJ	O
exercise	NN	O
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	A
with	IN	O
attention	NN	C
deficit	NN	C
hyperactivity	NN	C
disorder	NN	C
(	(	O
ADHD	NNP	C
)	)	O
.	.	O

Forty	NNP	SS
children	NNS	A
with	IN	O
ADHD	NNP	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
exercise	NN	O
or	CC	O
control	NN	O
groups	NNS	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
a	DT	O
moderate	JJ	O
intensity	NN	O
aerobic	JJ	O
exercise	NN	O
for	IN	O
30	CD	O
min	NN	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	O
a	DT	O
running/exercise-related	JJ	O
video	NN	O
.	.	O

Neuropsychological	JJ	O
tasks	NNS	O
,	,	O
the	DT	O
Stroop	NNP	O
Test	NNP	O
and	CC	O
the	DT	O
Wisconsin	NNP	O
Card	NNP	O
Sorting	NNP	O
Test	NNP	O
(	(	O
WCST	NNP	O
)	)	O
,	,	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
acute	JJ	O
exercise	NN	O
facilitated	VBN	O
performance	NN	O
in	IN	O
the	DT	O
Stroop	NNP	O
Test	NNP	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
Stroop	NNP	O
Color-Word	NNP	O
condition	NN	O
.	.	O

Additionally	RB	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
demonstrated	VBD	O
improvement	NN	O
in	IN	O
specific	JJ	O
WCST	NNP	O
performances	NNS	O
in	IN	O
Non-perseverative	JJ	O
Errors	NNS	O
and	CC	O
Categories	NNP	O
Completed	NNP	O
,	,	O
whereas	VBZ	O
no	DT	O
influences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
those	DT	O
performances	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Tentative	JJ	O
explanations	NNS	O
for	IN	O
the	DT	O
exercise	NN	O
effect	NN	O
postulate	NN	O
that	WDT	O
exercise	NN	O
allocates	VBZ	O
attention	NN	O
resources	NNS	O
,	,	O
influences	VBZ	O
the	DT	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
,	,	O
and	CC	O
is	VBZ	O
implicated	VBN	O
in	IN	O
exercise-induced	JJ	O
dopamine	NN	O
release	NN	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
promising	VBG	O
and	CC	O
additional	JJ	O
investigations	NNS	O
to	TO	O
explore	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
exercise	NN	O
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	O
with	IN	O
ADHD	NNP	O
are	VBP	O
encouraged	VBN	O
.	.	O

Comparative	JJ	O
drug	NN	O
effects	NNS	O
and	CC	O
abuse	NN	O
liability	NN	O
of	IN	O
lorazepam	NN	O
,	,	O
buspirone	NN	O
,	,	O
and	CC	O
secobarbital	NN	O
in	IN	O
nondependent	JJ	C
subjects	NNS	O
.	.	O

The	DT	O
pharmacologic	JJ	O
effects	NNS	O
of	IN	O
lorazepam	NN	O
(	(	O
2	CD	O
mg	NN	O
)	)	O
,	,	O
buspirone	NN	O
(	(	O
20	CD	O
mg	NN	O
,	,	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
secobarbital	JJ	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
15	CD	SS
male	NN	SE
,	,	O
experienced	VBD	O
,	,	O
intermittent	JJ	O
nontherapeutic	JJ	O
drug	NN	C
users	NNS	C
.	.	O

All	DT	O
drugs	NNS	O
produced	VBD	O
a	DT	O
drug	NN	O
effect	NN	O
,	,	O
however	RB	O
,	,	O
buspirone	RB	O
20	CD	O
mg	NN	O
was	VBD	O
significantly	RB	O
less	JJR	O
liked	JJ	O
than	IN	O
were	VBD	O
lorazepam	JJ	O
,	,	O
secobarbital	JJ	O
,	,	O
or	CC	O
buspirone	RB	O
10	CD	O
mg	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
.05	NN	O
)	)	O
but	CC	O
not	RB	O
placebo	VB	O
.	.	O

Lorazepam	NNP	O
was	VBD	O
liked	VBN	O
better	RBR	O
than	IN	O
were	VBD	O
other	JJ	O
drugs	NNS	O
only	RB	O
at	IN	O
1	CD	O
hour	NN	O
and	CC	O
only	RB	O
compared	VBN	O
with	IN	O
buspirone	NN	O
20	CD	O
and	CC	O
placebo	NN	O
.	.	O

Compared	VBN	O
with	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
lorazepam	JJ	O
drug	NN	O
effects	NNS	O
were	VBD	O
greater	JJR	O
and	CC	O
resulted	VBD	O
in	IN	O
more	RBR	O
prolonged	JJ	O
impairment	NN	O
of	IN	O
a	DT	O
motor	NN	O
tracking	VBG	O
task	NN	O
,	,	O
standing	VBG	O
steadiness	NN	O
,	,	O
and	CC	O
memory	NN	O
.	.	O

Buspirone	CD	O
20	CD	O
mg	NNS	O
significantly	RB	O
impaired	JJ	O
memory	NN	O
at	IN	O
1	CD	O
hour	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
identify	VB	O
buspirone	NN	O
as	IN	O
unfamiliar	JJ	O
.	.	O

Because	IN	O
buspirone	NN	O
20	CD	O
mg	NN	O
was	VBD	O
less	JJR	O
liked	JJ	O
than	IN	O
were	VBD	O
other	JJ	O
drugs	NNS	O
,	,	O
dose	JJ	O
escalation	NN	O
as	IN	O
part	NN	O
of	IN	O
drug	NN	O
abuse	NN	O
is	VBZ	O
not	RB	O
likely	JJ	O
to	TO	O
occur	VB	O
.	.	O

Lorazepam	NNP	O
also	RB	O
was	VBD	O
not	RB	O
particularly	RB	O
liked	VBN	O
and	CC	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	O
on	IN	O
most	JJS	O
subjective	JJ	O
abuse-relevant	JJ	O
measures	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
person-centred	JJ	O
dementia	NN	O
care	NN	O
to	TO	O
prevent	VB	O
agitation	NN	O
and	CC	O
other	JJ	O
neuropsychiatric	JJ	O
symptoms	NNS	O
and	CC	O
enhance	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
nursing	NN	C
home	NN	C
patients	NNS	C
:	:	O
a	DT	O
10-month	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

AIMS	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
Dementia	NNP	O
Care	NNP	O
Mapping	NNP	O
(	(	O
DCM	NNP	O
)	)	O
or	CC	O
the	DT	O
VIPS	NNP	O
practice	NN	O
model	NN	O
(	(	O
VPM	NNP	O
)	)	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
education	NN	O
of	IN	O
the	DT	O
nursing	NN	O
home	NN	O
staff	NN	O
about	IN	O
dementia	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
in	IN	O
reducing	VBG	O
agitation	NN	O
and	CC	O
other	JJ	O
neuropsychiatric	JJ	O
symptoms	NNS	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
enhancing	VBG	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
nursing	JJ	O
home	NN	O
patients	NNS	O
.	.	O

METHODS	VB	O
A	DT	O
10-month	JJ	O
three-armed	JJ	O
cluster-randomized	JJ	O
controlled	VBN	O
trial	NN	O
compared	VBN	O
DCM	NNP	O
and	CC	O
VPM	NNP	O
with	IN	O
control	NN	O
.	.	O

Of	IN	O
624	CD	SS
nursing	NN	O
home	NN	O
patients	NNS	O
with	IN	O
dementia	NN	C
,	,	O
446	CD	SS
completed	VBD	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
change	NN	O
on	IN	O
the	DT	O
Brief	JJ	O
Agitation	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
BARS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
changes	NNS	O
on	IN	O
the	DT	O
10-item	JJ	O
version	NN	O
of	IN	O
the	DT	O
Neuropsychiatric	NNP	O
Inventory	NNP	O
Questionnaire	NNP	O
(	(	O
NPI-Q	NNP	O
)	)	O
,	,	O
the	DT	O
Cornell	NNP	O
Scale	NNP	O
for	IN	O
Depression	NNP	O
in	IN	O
Dementia	NNP	O
(	(	O
CSDD	NNP	O
)	)	O
and	CC	O
the	DT	O
Quality	NN	O
of	IN	O
Life	NNP	O
in	IN	O
Late-Stage	NNP	O
Dementia	NNP	O
(	(	O
QUALID	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Changes	NNP	O
in	IN	O
the	DT	O
BARS	NNP	O
score	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
DCM	NNP	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
or	CC	O
between	IN	O
the	DT	O
VPM	NNP	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
after	IN	O
10	CD	O
months	NNS	O
.	.	O

Positive	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
changes	NNS	O
in	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
:	:	O
the	DT	O
NPI-Q	NNP	O
sum	NN	O
score	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
subscales	NNS	O
NPI-Q	NNP	O
agitation	NN	O
and	CC	O
NPI-Q	JJ	O
psychosis	NN	O
were	VBD	O
in	IN	O
favour	NN	O
of	IN	O
both	DT	O
interventions	NNS	O
versus	VBP	O
control	NN	O
,	,	O
the	DT	O
QUALID	NNP	O
score	NN	O
was	VBD	O
in	IN	O
favour	NN	O
of	IN	O
DCM	NNP	O
versus	NN	O
control	NN	O
and	CC	O
the	DT	O
CSDD	NNP	O
score	NN	O
was	VBD	O
in	IN	O
favour	NN	O
of	IN	O
VPM	NNP	O
versus	NN	O
control	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
failed	VBD	O
to	TO	O
find	VB	O
a	DT	O
significant	JJ	O
effect	NN	O
of	IN	O
both	DT	O
interventions	NNS	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

Positive	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
methods	NNS	O
merit	VBP	O
further	JJ	O
investigation	NN	O
.	.	O

Anti-angiogenic	JJ	O
effects	NNS	O
of	IN	O
epigallocatechin-3-gallate	NN	O
in	IN	O
human	JJ	O
skin	NN	O
.	.	O

Epigallocatechin-3-gallate	NNP	O
(	(	O
EGCG	NNP	O
)	)	O
is	VBZ	O
the	DT	O
main	JJ	O
polyphenol	JJ	O
component	NN	O
of	IN	O
green	JJ	O
tea	NN	O
.	.	O

This	DT	O
compound	NN	O
exhibits	VBZ	O
antioxidant	JJ	O
,	,	O
immunomodulatory	JJ	O
,	,	O
photoprotective	JJ	O
,	,	O
anti-angiogenic	JJ	O
,	,	O
and	CC	O
anti-inflammatory	JJ	O
properties	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
small	JJ	O
randomized	NN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
split	VBD	O
face	NN	O
trial	NN	O
using	VBG	O
a	DT	O
cream	NN	O
containing	VBG	O
2.5	CD	O
%	NN	O
w/w	NN	O
of	IN	O
EGCG	NNP	O
.	.	O

Four	CD	SS
healthy	JJ	C
volunteers	NNS	O
with	IN	O
significant	JJ	O
erythema	NN	C
and	CC	O
telangiectasia	NN	C
on	IN	C
the	DT	C
face	NN	C
applied	VBD	O
EGCG	NNP	O
cream	NN	O
to	TO	O
one	CD	O
side	NN	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
vehicle	NN	O
control	NN	O
cream	NN	O
to	TO	O
the	DT	O
other	JJ	O
,	,	O
twice	JJ	O
daily	RB	O
for	IN	O
six	CD	O
weeks	NNS	O
.	.	O

After	IN	O
six	CD	O
weeks	NNS	O
,	,	O
biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
EGCG	NNP	O
and	CC	O
vehicle	NN	O
treated	VBN	O
sites	NNS	O
.	.	O

Immunohistochemistry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
VEGF	NNP	O
and	CC	O
HIF-1	NNP	O
?.	NNP	O
HIF-1	NNP	O
?	.	O
expression	NN	O
was	VBD	O
decreased	VBN	O
in	IN	O
EGCG	NNP	O
treated	VBD	O
sites	NNS	O
,	,	O
such	JJ	O
that	IN	O
28.4	CD	O
%	NN	O
of	IN	O
the	DT	O
epidermis	NN	O
showed	VBD	O
positive	JJ	O
staining	NN	O
in	IN	O
vehicle	NN	O
treated	VBD	O
vs.	FW	O
13.8	CD	O
%	NN	O
in	IN	O
EGCG	NNP	O
treated	VBD	O
sites	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
similar	JJ	O
decrease	NN	O
in	IN	O
VEGF	NNP	O
expression	NN	O
was	VBD	O
found	VBN	O
(	(	O
6.7	CD	O
%	NN	O
in	IN	O
EGCG	NNP	O
vs.	FW	O
11.0	CD	O
%	NN	O
in	IN	O
in	IN	O
vehicle-treated	JJ	O
skin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

EGCG	NNP	O
topical	JJ	O
treatments	NNS	O
influence	VB	O
HIF-1	NNP	O
?	.	O
induction	NN	O
and	CC	O
VEGF	NNP	O
expression	NN	O
and	CC	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
potential	JJ	O
agent	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
telangiectasias	NN	O
.	.	O

Role	NNP	O
of	IN	O
posterior	JJ	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
refractory	JJ	O
monosymptomatic	JJ	O
nocturnal	JJ	O
enuresis	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
evaluated	VBD	O
the	DT	O
early	JJ	O
clinical	JJ	O
and	CC	O
urodynamic	JJ	O
results	NNS	O
of	IN	O
posterior	JJ	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
refractory	JJ	C
monosymptomatic	JJ	C
nocturnal	JJ	C
enuresis	NN	C
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
28	CD	SS
patients	NNS	O
with	IN	O
refractory	JJ	O
monosymptomatic	JJ	O
nocturnal	JJ	O
enuresis	NN	O
to	TO	O
2	CD	O
equal	JJ	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
a	DT	O
weekly	JJ	O
session	NN	O
of	IN	O
posterior	JJ	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
group	NN	O
2	CD	O
was	VBD	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Evaluation	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
each	DT	O
group	NN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
posterior	JJ	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
to	TO	O
compare	VB	O
clinical	JJ	O
and	CC	O
urodynamic	JJ	O
findings	NNS	O
.	.	O

Another	DT	O
clinical	JJ	O
assessment	NN	O
was	VBD	O
done	VBN	O
3	CD	O
months	NNS	O
after	IN	O
the	DT	O
first	JJ	O
followup	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
baseline	JJ	O
clinical	JJ	O
and	CC	O
urodynamic	JJ	O
data	NNS	O
.	.	O

Overall	NNP	O
,	,	O
13	CD	O
patients	NNS	O
(	(	O
46.4	CD	O
%	NN	O
)	)	O
had	VBD	O
detrusor	VBN	O
overactivity	NN	O
and	CC	O
14	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
had	VBD	O
decreased	VBN	O
bladder	NN	O
capacity	NN	O
.	.	O

After	IN	O
treatment	NN	O
11	CD	O
group	NN	O
1	CD	O
patients	NNS	O
(	(	O
78.6	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
partial	JJ	O
or	CC	O
full	JJ	O
response	NN	O
to	TO	O
posterior	VB	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
but	CC	O
only	RB	O
2	CD	O
(	(	O
14.3	CD	O
%	NN	O
)	)	O
in	IN	O
group	NN	O
2	CD	O
had	VBD	O
a	DT	O
partial	JJ	O
response	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
average	JJ	O
number	NN	O
of	IN	O
wet	JJ	O
nights	NNS	O
in	IN	O
group	NN	O
1	CD	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
at	IN	O
baseline	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

All	DT	O
urodynamic	JJ	O
parameters	NNS	O
significantly	RB	O
improved	VBN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
wet	JJ	O
nights	NNS	O
and	CC	O
urodynamic	JJ	O
parameters	NNS	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

At	IN	O
3-month	JJ	O
followup	NN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
partial	JJ	O
or	CC	O
full	JJ	O
response	NN	O
in	IN	O
group	NN	O
1	CD	O
had	VBD	O
decreased	VBN	O
from	IN	O
11	CD	O
(	(	O
78.6	CD	O
%	NN	O
)	)	O
to	TO	O
6	CD	O
(	(	O
42.9	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
change	NN	O
was	VBD	O
evident	JJ	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

CONCLUSIONS	NNP	O
Posterior	NNP	O
tibial	JJ	O
nerve	NN	O
stimulation	NN	O
can	MD	O
be	VB	O
a	DT	O
viable	JJ	O
treatment	NN	O
option	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
refractory	JJ	O
monosymptomatic	JJ	O
nocturnal	JJ	O
enuresis	NN	O
.	.	O

However	RB	O
,	,	O
deterioration	NN	O
in	IN	O
some	DT	O
responders	NNS	O
with	IN	O
time	NN	O
suggests	VBZ	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
protocols	NNS	O
.	.	O

Clinical	JJ	O
trial	NN	O
:	:	O
exposure	NN	O
to	TO	O
ribavirin	VB	O
predicts	NNS	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
HCV	NNP	C
genotype	NN	C
1	CD	C
infection	NN	O
treated	VBN	O
with	IN	O
peginterferon	NN	O
alpha-2a	JJ	O
plus	CC	O
ribavirin	JJ	O
.	.	O

BACKGROUND	VB	O
The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	O
drug	NN	O
exposure	NN	O
on	IN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
hepatitis	NN	C
C	NNP	C
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
in	IN	O
routine	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

AIM	NNP	O
To	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
exposure	NN	O
to	TO	O
peginterferon	VB	O
alpha-2a	JJ	O
and	CC	O
ribavirin	VB	O
on	IN	O
early	JJ	O
virological	JJ	O
response	NN	O
(	(	O
EVR	NNP	O
)	)	O
and	CC	O
sustained	VBD	O
virological	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
with	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
infection	NN	O
enrolled	VBN	O
in	IN	O
a	DT	O
large	JJ	O
expanded	JJ	O
access	NN	O
programme	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	SS
hundred	VBD	SS
and	CC	SS
ninety-one	JJ	SS
patients	NNS	O
treated	VBD	O
for	IN	O
48	CD	O
weeks	NNS	O
with	IN	O
an	DT	O
initial	JJ	O
ribavirin	NN	O
dose	NN	O
of	IN	O
800	CD	O
or	CC	O
1000/1200	CD	O
mg/day	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Ribavirin	JJ	O
1000	CD	O
mg/day	NN	O
(	(	O
<	JJ	O
75	CD	O
kg	NN	O
)	)	O
or	CC	O
1200	CD	O
mg/day	NN	O
(	(	O
>	JJ	O
or=75	RB	O
kg	NN	O
)	)	O
and	CC	O
peginterferon	VB	O
alpha-2a	JJ	O
180	CD	O
microg/week	NN	O
were	VBD	O
considered	VBN	O
optimal	JJ	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	O
drug	NN	O
exposure	NN	O
(	(	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
optimal	NN	O
)	)	O
on	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	O
ribavirin	NN	O
exposure	NN	O
in	IN	O
week	NN	O
0-12	NN	O
was	VBD	O
70	CD	O
%	NN	O
and	CC	O
96	CD	O
%	NN	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
and	CC	O
1000/1200	CD	O
mg/day	NN	O
,	,	O
respectively	RB	O
.	.	O

EVR	NNP	O
and	CC	O
SVR	NNP	O
rates	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
than	IN	O
1000/1200	CD	O
mg/day	NN	O
(	(	O
EVR	NNP	O
,	,	O
75	CD	O
%	NN	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
SVR	NNP	O
,	,	O
45	CD	O
%	NN	O
vs.	FW	O
54	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

Furthermore	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
achievement	NN	O
of	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
and	CC	O
ribavirin	VB	O
dose	NN	O
over	IN	O
the	DT	O
first	JJ	O
12	CD	O
weeks	NNS	O
expressed	VBD	O
either	CC	O
as	IN	O
absolute	JJ	O
dose	NN	O
or	CC	O
proportion	NN	O
of	IN	O
optimal	JJ	O
dose	NN	O
received	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Ribavirin	NNP	O
exposure	NN	O
to	TO	O
week	NN	O
12	CD	O
is	VBZ	O
significantly	RB	O
associated	VBN	O
with	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
genotype	JJ	O
1	CD	O
patients	NNS	O
.	.	O

Maintenance	NNP	O
of	IN	O
an	DT	O
optimal	JJ	O
ribavirin	NN	O
dose	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
important	JJ	O
modifiable	JJ	O
factor	NN	O
during	IN	O
combination	NN	O
therapy	NN	O
for	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
.	.	O

1999	CD	O
WHO/ISH	NNP	O
Guidelines	NNP	O
applied	VBD	O
to	TO	O
a	DT	O
1999	CD	O
MONICA	NNP	O
sample	NN	O
from	IN	O
northern	JJ	O
Sweden	NNP	O
.	.	O

BACKGROUND	NNP	O
Treating	NNP	O
hypertension	NN	O
with	IN	O
drugs	NNS	O
is	VBZ	O
so	RB	O
far	RB	O
the	DT	O
most	RBS	O
cost-effective	JJ	O
way	NN	O
to	TO	O
reduce	VB	O
this	DT	O
important	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
important	JJ	O
to	TO	O
determine	VB	O
absolute	NN	O
risk	NN	O
,	,	O
and	CC	O
thereby	RB	O
estimate	VB	O
indication	NN	O
for	IN	O
drug	NN	O
treatment	NN	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
maintain	VB	O
a	DT	O
cost-effective	JJ	O
drug	NN	O
treatment	NN	O
.	.	O

WHO/ISH	NNP	O
Hypertension	NNP	O
Guidelines	NNP	O
from	IN	O
1999	CD	O
propose	NN	O
a	DT	O
risk	NN	O
stratification	NN	O
for	IN	O
estimating	VBG	O
absolute	NN	O
risk	NN	O
for	IN	O
CVD	NNP	O
based	VBN	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
additional	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
target	NN	O
organ	JJ	O
damage	NN	O
(	(	O
TOD	NNP	O
)	)	O
and	CC	O
CVD	NNP	O
.	.	O

OBJECTIVES	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
consequences	NNS	O
of	IN	O
applying	VBG	O
the	DT	O
recent	JJ	O
WHO/ISH	NNP	O
risk	NN	O
stratification	NN	O
scheme	NN	O
to	TO	O
a	DT	O
MONICA	NNP	O
sample	NN	O
of	IN	O
6000	CD	SS
subjects	NNS	O
from	IN	O
a	DT	O
geographically	RB	O
defined	VBN	O
population	NN	O
in	IN	O
northern	JJ	O
Sweden	NNP	O
,	,	O
regarding	VBG	O
indications	NNS	O
for	IN	O
treatment	NN	O
,	,	O
target	VB	O
blood	NN	O
pressure	NN	O
and	CC	O
risk	NN	O
distribution	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
have	VBP	O
risk-classified	JJ	O
each	DT	O
of	IN	O
these	DT	O
patients	NNS	O
using	VBG	O
a	DT	O
computer	NN	O
program	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
WHO/ISH	NNP	O
scheme	NN	O
.	.	O

Data	NNP	O
on	IN	O
TOD	NNP	O
were	VBD	O
not	RB	O
available	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
all	DT	O
,	,	O
917	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
had	VBD	O
drug-treated	JJ	C
hypertension	NN	C
.	.	O

Three-quarters	NNS	O
(	(	O
n	JJ	O
=	NNP	O
737	CD	O
)	)	O
were	VBD	O
inadequately	RB	O
treated	VBN	O
,	,	O
with	IN	O
blood	NN	O
pressure	NN	O
levels	NNS	O
at	IN	O
or	CC	O
above	VB	O
140	CD	O
or	CC	O
90	CD	O
mmHg	NN	O
.	.	O

1773	CD	O
(	(	O
30	CD	O
%	NN	O
of	IN	O
5997	CD	O
)	)	O
untreated	JJ	C
subjects	NNS	O
had	VBD	O
a	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
140/90	CD	O
or	CC	O
above	RB	O
;	:	O
16	CD	O
%	NN	O
in	IN	O
the	DT	O
low-	JJ	O
,	,	O
62	CD	O
%	NN	O
in	IN	O
the	DT	O
medium-	NN	O
,	,	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
high-	NN	O
,	,	O
and	CC	O
14	CD	O
%	NN	O
in	IN	O
the	DT	O
very-high-risk	JJ	O
group	NN	O
.	.	O

The	DT	O
corresponding	JJ	O
risk-group	JJ	O
pattern	NN	O
for	IN	O
the	DT	O
inadequately	RB	O
treated	JJ	O
hypertensives	NNS	O
(	(	O
n	JJ	O
=	NNP	O
737	CD	O
)	)	O
was	VBD	O
5.5	CD	O
,	,	O
48.3	CD	O
,	,	O
11.1	CD	O
and	CC	O
35.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

If	IN	O
we	PRP	O
shifted	VBD	O
the	DT	O
target	NN	O
blood	NN	O
pressure	NN	O
from	IN	O
below	IN	O
140/90	CD	O
to	TO	O
below	VB	O
130/85	CD	O
for	IN	O
drug-treated	JJ	O
subjects	NNS	O
under	IN	O
60	CD	O
(	(	O
n	JJ	O
=	NNP	O
278	CD	O
)	)	O
the	DT	O
number	NN	O
of	IN	O
inadequately	RB	O
treated	JJ	O
subjects	NNS	O
increased	VBN	O
by	IN	O
34	CD	O
(	(	O
12.2	CD	O
%	NN	O
of	IN	O
278	CD	O
)	)	O
;	:	O
14	CD	O
in	IN	O
the	DT	O
low-risk	JJ	O
group	NN	O
,	,	O
15	CD	O
in	IN	O
the	DT	O
medium-risk	JJ	O
group	NN	O
,	,	O
and	CC	O
only	RB	O
five	CD	O
in	IN	O
the	DT	O
high-	JJ	O
or	CC	O
very-high-risk	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Only	RB	O
one-fifth	NN	O
of	IN	O
the	DT	O
drug-treated	JJ	O
hypertensives	NNS	O
were	VBD	O
well	RB	O
controlled	VBN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
newly	RB	O
detected	VBN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
was	VBD	O
high	JJ	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
younger	JJR	O
subjects	NNS	O
with	IN	O
high	JJ	O
blood	NN	O
pressure	NN	O
had	VBD	O
low	JJ	O
risk	NN	O
,	,	O
but	CC	O
in	IN	O
those	DT	O
aged	VBN	O
45-54	CD	A
this	DT	O
had	VBD	O
already	RB	O
risen	VBN	O
to	TO	O
a	DT	O
medium	NN	O
risk	NN	O
.	.	O

Changing	VBG	O
the	DT	O
target	NN	O
blood	NN	O
pressure	NN	O
to	TO	O
below	IN	O
130/85	CD	O
,	,	O
for	IN	O
subjects	NNS	O
aged	VBN	A
below	IN	A
60	CD	A
,	,	O
as	IN	O
recommended	VBN	O
by	IN	O
WHO/ISH	NNP	O
,	,	O
affects	VBZ	O
predominantly	RB	O
low-	JJ	O
and	CC	O
medium-risk	JJ	O
groups	NNS	O
.	.	O

Effect	NN	O
of	IN	O
testosterone	NN	O
and	CC	O
a	DT	O
nutritional	JJ	O
supplement	NN	O
,	,	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
,	,	O
on	IN	O
hospital	JJ	O
admissions	NNS	O
in	IN	O
undernourished	JJ	C
older	JJR	A
men	NNS	SE
and	CC	SE
women	NNS	SE
.	.	O

BACKGROUND	NNP	O
In	IN	O
older	JJR	A
people	NNS	A
,	,	O
undernutrition	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
hospitalization	NN	O
rates	NNS	O
and	CC	O
mortality	NN	O
.	.	O

Because	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
older	JJR	O
people	NNS	O
often	RB	O
reflects	VBZ	O
a	DT	O
disproportionate	JJ	O
reduction	NN	O
of	IN	O
skeletal	JJ	O
muscle	NN	O
,	,	O
anabolic	JJ	O
treatments	NNS	O
may	MD	O
be	VB	O
beneficial	JJ	O
.	.	O

OBJECTIVE	NNP	O
Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
testosterone	NN	O
treatment	NN	O
and	CC	O
a	DT	O
nutritional	JJ	O
supplement	NN	O
have	VBP	O
additive	JJ	O
benefits	NNS	O
.	.	O

DESIGN	NNP	O
Oral	NNP	O
testosterone	NN	O
undecanoate	NN	O
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
for	IN	O
women	NNS	O
,	,	O
80	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
men	NNS	O
)	)	O
and	CC	O
an	DT	O
oral	JJ	O
nutritional	JJ	O
supplement	NN	O
(	(	O
475	CD	O
kcal/d	NN	O
)	)	O
were	VBD	O
administered	VBN	O
,	,	O
alone	RB	O
or	CC	O
combined	VBN	O
,	,	O
for	IN	O
1	CD	O
y	NNS	O
to	TO	O
49	CD	SS
community-dwelling	NN	O
,	,	O
undernourished	JJ	C
people	NNS	O
[	VBP	O
Mini	NNP	C
Nutritional	NNP	C
Assessment	NNP	C
score	VBD	C
<	JJ	C
24	CD	C
and	CC	O
low	JJ	C
body	NN	C
weight	NN	C
(	(	O
body	JJ	C
mass	NN	C
index	NN	C
,	,	C
in	IN	C
kg/m	NN	C
(	(	C
2	CD	C
)	)	C
:	:	C
<	$	C
22	CD	C
)	)	O
or	CC	O
recent	JJ	C
weight	JJ	C
loss	NN	C
(	(	O
>	JJ	O
7.5	CD	O
%	NN	O
over	IN	O
3	CD	O
mo	NNS	O
)	)	O
]	VBP	O
aged	VBN	A
>	$	A
65	CD	A
y	NN	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
77	CD	A
y	NN	O
;	:	O
26	CD	SS
women	NNS	SE
and	CC	O
23	CD	SS
men	NNS	SE
)	)	O
.	.	O

Hospital	JJ	O
admissions	NNS	O
and	CC	O
other	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
subjects	NNS	O
receiving	VBG	O
combined	VBN	O
testosterone	NN	O
and	CC	O
nutritional	JJ	O
supplements	NNS	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
hospital	NN	O
admissions	NNS	O
,	,	O
whereas	IN	O
there	EX	O
were	VBD	O
9	CD	O
admissions	NNS	O
(	(	O
2	CD	O
elective	NN	O
)	)	O
in	IN	O
13	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
no-treatment	JJ	O
group	NN	O
,	,	O
4	CD	O
in	IN	O
the	DT	O
testosterone-treated	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
,	,	O
and	CC	O
5	CD	O
in	IN	O
the	DT	O
supplement-treated	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.06	CD	O
with	IN	O
no-treatment	JJ	O
compared	VBN	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
no-treatment	JJ	O
group	NN	O
,	,	O
the	DT	O
combined-treatment	JJ	O
group	NN	O
had	VBD	O
significantly	RB	O
fewer	JJR	O
subjects	NNS	O
admitted	VBN	O
to	TO	O
hospital	VB	O
(	(	O
0	CD	O
compared	VBN	O
with	IN	O
5	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
fewer	JJR	O
days	NNS	O
in	IN	O
hospital	NN	O
(	(	O
0	CD	O
compared	VBN	O
with	IN	O
74	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.041	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
hospital	VB	O
admission	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
undernourished	JJ	C
older	JJR	A
people	NNS	O
,	,	O
combined	VBN	O
treatment	NN	O
with	IN	O
testosterone	NN	O
and	CC	O
nutritional	JJ	O
supplementation	NN	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
people	NNS	O
hospitalized	VBN	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
hospital	NN	O
admissions	NNS	O
,	,	O
which	WDT	O
are	VBP	O
important	JJ	O
endpoints	NNS	O
in	IN	O
this	DT	O
group	NN	O
.	.	O

Larger	NNP	O
,	,	O
confirmatory	NN	O
studies	NNS	O
are	VBP	O
now	RB	O
needed	VBN	O
.	.	O

This	DT	O
trial	NN	O
was	VBD	O
registered	VBN	O
before	IN	O
commencement	NN	O
at	IN	O
clinical	JJ	O
trials.gov	NN	O
as	IN	O
NCT00117000	NNP	O
.	.	O

Pedantic	JJ	O
speaking	NN	O
style	NN	O
differentiates	VBZ	O
Asperger	NNP	O
syndrome	NN	O
from	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

Asperger	NNP	O
syndrome	NN	O
(	(	O
AS	IN	O
)	)	O
is	VBZ	O
a	DT	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
recently	RB	O
introduced	VBD	O
as	IN	O
a	DT	O
new	JJ	O
diagnostic	JJ	O
category	NN	O
in	IN	O
the	DT	O
ICD-10	NNP	O
and	CC	O
the	DT	O
DSM-IV	NNP	O
.	.	O

Along	IN	O
with	IN	O
motor	NN	O
clumsiness	NN	O
,	,	O
pedantic	JJ	O
speech	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
clinical	JJ	O
feature	NN	O
of	IN	O
AS	NNP	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
define	VB	O
and	CC	O
measure	VB	O
this	DT	O
symptom	NN	O
.	.	O

We	PRP	O
studied	VBD	O
17	CD	SS
patients	NNS	O
with	IN	O
AS	NNP	C
(	(	O
ICD-10	NNP	O
;	:	O
14	CD	SS
male	NN	SE
,	,	O
3	CD	SS
female	NN	SE
;	:	O
mean	JJ	O
age	NN	O
16.4	CD	A
years	NNS	O
,	,	O
mean	JJ	O
full-scale	JJ	O
IQ	NNP	O
97	CD	O
)	)	O
and	CC	O
compared	VBN	O
them	PRP	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
13	CD	SS
patients	NNS	O
with	IN	O
normal-intelligence	JJ	C
autism	NN	C
or	CC	O
high-functioning	JJ	C
autism	NN	C
(	(	O
HFA	NNP	C
)	)	O
(	(	O
ICD-10/DSM-III-R	NNP	O
;	:	O
12	CD	SS
male	NN	SE
,	,	O
1	CD	SS
female	NN	SE
;	:	O
mean	JJ	O
age	NN	O
15.5	CD	A
years	NNS	O
,	,	O
mean	JJ	O
full-scale	JJ	O
IQ	NNP	O
81.2	CD	O
)	)	O
.	.	O

An	DT	O
operational	JJ	O
definition	NN	O
of	IN	O
pedantic	JJ	O
speech	NN	O
was	VBD	O
formulated	VBN	O
and	CC	O
a	DT	O
rating	NN	O
scale	NN	O
devised	VBD	O
.	.	O

13	CD	O
(	(	O
76	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
AS	NNP	C
patients	NNS	O
were	VBD	O
rated	VBN	O
as	IN	O
pedantic	JJ	O
compared	VBN	O
to	TO	O
4	CD	O
(	(	O
31	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
HFA	NNP	C
group	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
6.3	CD	O
;	:	O
p	NN	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
pedantic	JJ	O
speech	NN	O
is	VBZ	O
common	JJ	O
in	IN	O
AS	NNP	O
and	CC	O
may	MD	O
help	VB	O
differentiate	VB	O
AS	IN	O
from	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
standard	NN	O
wound	NN	O
care	NN	O
with	IN	O
adjunctive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
(	(	O
HBOT	NNP	O
)	)	O
to	TO	O
standard	VB	O
wound	NN	O
care	NN	O
only	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	C
,	,	O
non-healing	JJ	C
ulcers	NNS	C
of	IN	O
the	DT	O
lower	JJR	C
limb	NN	C
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	C
mellitus	NNS	C
:	:	O
a	DT	O
study	NN	O
protocol	NN	O
.	.	O

BACKGROUND	NNP	O
It	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
adjunctive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
improves	VBZ	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
,	,	O
and	CC	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
lower	JJR	O
extremity	NN	O
amputations	NNS	O
.	.	O

A	DT	O
limited	JJ	O
number	NN	O
of	IN	O
studies	NNS	O
have	VBP	O
used	VBN	O
a	DT	O
double	JJ	O
blind	NN	O
approach	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetic	JJ	C
ulcers	NNS	C
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
plus	CC	O
standard	NN	O
wound	NN	O
care	NN	O
compared	VBN	O
with	IN	O
standard	NN	O
wound	NN	O
care	NN	O
alone	RB	O
in	IN	O
preventing	VBG	O
the	DT	O
need	NN	O
for	IN	O
major	JJ	O
amputation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
and	CC	O
chronic	JJ	C
ulcers	NNS	C
of	IN	O
the	DT	O
lower	JJR	C
limb	NN	C
.	.	O

METHODS/DESIGN	NNP	O
One	CD	SS
hundred	CD	SS
and	CC	SS
eighteen	JJ	SS
(	(	O
59	CD	SS
patients	NNS	O
per	IN	O
arm	NN	O
)	)	O
patients	NNS	O
with	IN	O
non-healing	JJ	C
diabetic	JJ	C
ulcers	NNS	C
of	IN	O
the	DT	O
lower	JJR	C
limb	NN	C
,	,	O
referred	VBD	O
to	TO	O
the	DT	O
Judy	NNP	O
Dan	NNP	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
Centre	NNP	O
are	VBP	O
being	VBG	O
recruited	VBN	O
if	IN	O
they	PRP	O
are	VBP	O
at	IN	O
least	JJS	O
18	CD	A
years	NNS	O
of	IN	O
age	NN	O
,	,	O
have	VBP	O
either	DT	O
Type	NNP	C
1	CD	C
or	CC	C
2	CD	C
diabetes	NNS	C
with	IN	O
a	DT	O
Wagner	NNP	O
grading	NN	O
of	IN	O
foot	NN	O
lesions	NNS	O
2	CD	O
,	,	O
3	CD	O
or	CC	O
4	CD	O
on	IN	O
lower	JJR	O
limb	NN	O
not	RB	O
healing	VBG	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
receive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
every	DT	O
day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
during	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
and	CC	O
are	VBP	O
provided	VBN	O
ongoing	VBG	O
wound	NN	O
care	NN	O
and	CC	O
weekly	JJ	O
assessments	NNS	O
.	.	O

Patients	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
return	VB	O
to	TO	O
the	DT	O
study	NN	O
centre	NN	O
every	DT	O
week	NN	O
for	IN	O
an	DT	O
additional	JJ	O
6	CD	O
weeks	NNS	O
of	IN	O
follow-up	NN	O
for	IN	O
wound	JJ	O
evaluation	NN	O
and	CC	O
management	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
is	VBZ	O
freedom	RB	O
from	IN	O
having	VBG	O
,	,	O
or	CC	O
meeting	VBG	O
the	DT	O
criteria	NN	O
for	IN	O
,	,	O
a	DT	O
major	JJ	O
amputation	NN	O
(	(	O
below	IN	O
knee	NN	O
amputation	NN	O
,	,	O
or	CC	O
metatarsal	VB	O
level	NN	O
)	)	O
up	RB	O
to	TO	O
12	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
decision	NN	O
to	TO	O
amputate	VB	O
is	VBZ	O
made	VBN	O
by	IN	O
a	DT	O
vascular	JJ	O
surgeon	NN	O
.	.	O

Other	JJ	O
outcomes	NNS	O
include	VBP	O
wound	IN	O
healing	NN	O
,	,	O
effectiveness	NN	O
,	,	O
safety	NN	O
,	,	O
healthcare	JJ	O
resource	NN	O
utilization	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
cost-effectiveness	NN	O
.	.	O

The	DT	O
study	NN	O
will	MD	O
run	VB	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
about	IN	O
3	CD	O
years	NNS	O
.	.	O

DISCUSSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
will	MD	O
provide	VB	O
detailed	JJ	O
information	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
non-healing	JJ	O
ulcers	NNS	O
of	IN	O
the	DT	O
lower	JJR	O
limb	NN	O
.	.	O

This	DT	O
will	MD	O
be	VB	O
the	DT	O
first	JJ	O
double-blind	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
for	IN	O
this	DT	O
health	NN	O
technology	NN	O
which	WDT	O
evaluates	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
in	IN	O
prevention	NN	O
of	IN	O
amputations	NNS	O
in	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00621608	NN	O
.	.	O

Prophylactic	JJ	O
vs	NN	O
therapeutic	JJ	O
blood	NN	O
patch	NN	O
for	IN	O
obstetric	JJ	C
patients	NNS	O
with	IN	O
accidental	JJ	C
dural	JJ	C
puncture	NN	C
--	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

Epidural	JJ	O
blood	NN	O
patch	NN	O
is	VBZ	O
a	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
obstetric	JJ	C
patients	NNS	O
experiencing	VBG	O
a	DT	O
severe	JJ	C
post-dural	JJ	C
puncture	NN	C
headache	NN	C
.	.	O

Patients	NNS	O
who	WP	O
sustained	VBD	O
an	DT	O
accidental	JJ	C
dural	JJ	C
puncture	NN	C
during	IN	O
establishment	NN	O
of	IN	O
epidural	JJ	C
analgesia	NN	C
during	IN	O
labour	NN	C
or	CC	O
at	IN	O
caesarean	JJ	C
delivery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
prophylactic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
or	CC	O
conservative	JJ	O
treatment	NN	O
with	IN	O
a	DT	O
therapeutic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
if	IN	O
required	VBN	O
.	.	O

Eleven	NNP	SS
of	IN	O
60	CD	SS
(	(	O
18.3	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
prophylactic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
group	NN	O
developed	VBD	O
a	DT	O
post-dural	JJ	O
puncture	NN	O
headache	NN	O
compared	VBN	O
with	IN	O
39	CD	SS
of	IN	O
49	CD	SS
(	(	O
79.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
therapeutic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

A	DT	O
blood	NN	O
patch	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
36	CD	O
(	(	O
73.4	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
group	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
needed	VBD	O
a	DT	O
second	JJ	O
blood	NN	O
patch	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
:	:	O
6	CD	O
(	(	O
10.0	CD	O
%	NN	O
)	)	O
for	IN	O
prophylactic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
and	CC	O
4	CD	O
(	(	O
11.1	CD	O
%	NN	O
)	)	O
for	IN	O
therapeutic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
prophylactic	JJ	O
epidural	JJ	O
blood	NN	O
patch	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
method	NN	O
to	TO	O
reduce	VB	O
the	DT	O
development	NN	O
of	IN	O
post-dural	JJ	O
puncture	NN	O
headache	NN	O
in	IN	O
obstetric	JJ	C
patients	NNS	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
plus	CC	O
amantadine	NN	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
:	:	O
a	DT	O
10-week	JJ	O
randomized	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
amantadine	NN	O
to	TO	O
risperidone	VB	O
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	SS
outpatients	NNS	O
aged	VBD	O
4	CD	A
to12	NN	A
years	NNS	O
,	,	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
autism	NN	C
spectrum	NN	C
disorders	NNS	C
based	VBN	O
on	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
Text	NNP	O
Revision	NNP	O
criteria	NNS	O
,	,	O
were	VBD	O
assigned	VBN	O
to	TO	O
this	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
risperidone	JJ	O
plus	CC	O
amantadine	JJ	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
received	VBD	O
risperidone	JJ	O
plus	CC	O
placebo	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
between	IN	O
1	CD	O
and	CC	O
2.0	CD	O
mg/d	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
amantadine	NN	O
was	VBD	O
100	CD	O
or	CC	O
150	CD	O
mg/d	NNS	O
for	IN	O
patients	NNS	O
less	JJR	O
than	IN	O
30	CD	O
kg	NN	O
or	CC	O
more	JJR	O
than	IN	O
30	CD	O
kg	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Aberrant	NNP	O
Behavioral	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
and	CC	O
adverse	JJ	O
effects	NNS	O
checklist	NN	O
as	RB	O
well	RB	O
as	IN	O
clinical	JJ	O
global	JJ	O
impression-improvement	NN	O
(	(	O
CGI-I	NNP	O
)	)	O
at2	VBZ	O
checkpoints	NNS	O
of	IN	O
5-week	JJ	O
intervals	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
.	.	O

Informed	NNP	O
consentwas	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
parents	NNS	O
of	IN	O
each	DT	O
participant	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
ABC-C	NNP	O
subscales	NNS	O
,	,	O
Hyperactivity	NNP	O
and	CC	O
Irritability	NNP	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
CGI-I	JJ	O
scores	NNS	O
show	VBP	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
amantadine	NN	O
may	MD	O
be	VB	O
a	DT	O
potential	JJ	O
adjunctive	JJ	O
treatment	NN	O
strategy	NN	O
for	IN	O
autism	NN	O
and	CC	O
it	PRP	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

White	NNP	O
coat	NN	O
effect	NN	O
detected	VBD	O
using	VBG	O
self-monitoring	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
at	IN	O
home	NN	O
:	:	O
comparison	NN	O
with	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
home	NN	O
blood	NN	O
pressure	NN	O
(	(	O
HBP	NNP	O
)	)	O
is	VBZ	O
a	DT	O
reliable	JJ	O
alternative	NN	O
to	TO	O
ambulatory	VB	O
blood	NN	O
pressure	NN	O
(	(	O
ABP	NNP	O
)	)	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
the	DT	O
white	JJ	O
coat	NN	O
effect	NN	O
(	(	O
WCE	NNP	O
)	)	O
.	.	O

Hypertensive	JJ	C
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
measure	VB	O
HBP	NNP	O
for	IN	O
2	CD	O
weeks	NNS	O
or	CC	O
ABP	NNP	O
for	IN	O
24	CD	O
h.	PDT	O
The	DT	O
alternative	JJ	O
measurement	NN	O
was	VBD	O
then	RB	O
performed	VBN	O
.	.	O

Clinic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
CBP	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
a	DT	O
difference	NN	O
of	IN	O
>	NN	O
or	CC	O
=	$	O
20	CD	O
mm	NN	O
Hg	NNP	O
systolic	NN	O
or	CC	O
>	NN	O
or	CC	O
=	$	O
10	CD	O
mm	NN	O
Hg	NNP	O
diastolic	VBZ	O
BP	NNP	O
between	IN	O
CBP	NNP	O
and	CC	O
awake	VB	O
ABP	NNP	O
or	CC	O
CBP	NNP	O
and	CC	O
HBP	NNP	O
,	,	O
were	VBD	O
classified	VBN	O
as	IN	O
clinic	JJ	O
reactors	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
189	CD	SS
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
79	CD	SS
on	IN	O
stable	JJ	O
antihypertensive	JJ	O
treatment	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
WCE	NNP	O
assessed	VBD	O
using	VBG	O
the	DT	O
ABP	NNP	O
or	CC	O
the	DT	O
HBP	NNP	O
method	NN	O
(	(	O
mean	JJ	O
discrepancy	NN	O
,	,	O
systolic	JJ	O
BP	NNP	O
:	:	O
-1.5	JJ	O
+/-	JJ	O
11.7	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-3.2	NNP	O
,	,	O
0.2	CD	O
;	:	O
diastolic	JJ	O
BP	NNP	O
:	:	O
0.9	CD	O
+/-	JJ	O
7.0	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-0.1	NNP	O
,	,	O
1.9	CD	O
)	)	O
.	.	O

A	NNP	O
strong	JJ	O
association	NN	O
existed	VBD	O
between	IN	O
WCE	NNP	O
calculated	VBD	O
using	VBG	O
the	DT	O
HBP	NNP	O
or	CC	O
the	DT	O
ABP	NNP	O
method	NN	O
(	(	O
r	VB	O
=	RB	O
0.64/0.59	CD	O
systolic/diastolic	JJ	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
classified	VBN	O
as	IN	O
clinic	JJ	O
reactors	NNS	O
was	VBD	O
identical	JJ	O
using	VBG	O
the	DT	O
HBP	NNP	O
or	CC	O
the	DT	O
ABP	NNP	O
method	NN	O
(	(	O
25.9	CD	O
%	NN	O
)	)	O
.	.	O

Agreement	NN	O
between	IN	O
methods	NNS	O
in	IN	O
the	DT	O
classification	NN	O
of	IN	O
clinic	JJ	O
reactors	NNS	O
was	VBD	O
found	VBN	O
in	IN	O
147	CD	O
patients	NNS	O
(	(	O
78	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
of	IN	O
the	DT	O
HBP	NNP	O
method	NN	O
to	TO	O
classify	VB	O
correctly	RB	O
clinic	JJ	O
reactors	NNS	O
(	(	O
ABP	NNP	O
method	RB	O
used	VBD	O
as	IN	O
the	DT	O
standard	NN	O
)	)	O
were	VBD	O
57	CD	O
%	NN	O
and	CC	O
85	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
whereas	VBD	O
its	PRP$	O
positive	JJ	O
and	CC	O
negative	JJ	O
predictive	JJ	O
value	NN	O
were	VBD	O
57	CD	O
%	NN	O
and	CC	O
85	CD	O
%	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
HBP	NNP	O
is	VBZ	O
not	RB	O
appropriate	JJ	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
ABP	NNP	O
diagnostic	JJ	O
testing	NN	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
WCE	NNP	O
.	.	O

Nevertheless	NNP	O
,	,	O
HBP	NNP	O
appears	VBZ	O
useful	JJ	O
as	IN	O
a	DT	O
screening	JJ	O
test	NN	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
this	DT	O
phenomenon	NN	O
.	.	O

Three-year	JJ	O
clinical	JJ	O
outcome	NN	O
after	IN	O
primary	JJ	O
stenting	NN	O
of	IN	O
totally	RB	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
bare-metal	JJ	O
stent	JJ	O
implantation	NN	O
with	IN	O
sirolimus-eluting	JJ	O
stent	NN	O
implantation	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
total	JJ	C
coronary	JJ	C
occlusions	NNS	C
(	(	O
Primary	JJ	O
Stenting	NNP	O
of	IN	O
Totally	NNP	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
[	NNP	O
PRISON	NNP	O
]	NNP	O
II	NNP	O
study	NN	O
)	)	O
.	.	O

BACKGROUND	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
3-year	JJ	O
clinical	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Totally	NNP	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
II	NNP	O
study	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
totally	RB	C
occluded	JJ	C
coronary	JJ	C
arteries	NNS	C
randomized	VBN	O
to	TO	O
either	DT	O
sirolimus-eluting	JJ	O
Cypher	NNP	O
stents	NNS	O
(	(	O
SESs	NNP	O
)	)	O
(	(	O
Cordis	NNP	O
,	,	O
a	DT	O
Johnson	NNP	O
&	CC	O
Joshson	NNP	O
Company	NNP	O
,	,	O
Miami	NNP	O
Lakes	NNP	O
,	,	O
FL	NNP	O
)	)	O
(	(	O
100	CD	SS
patients	NNS	O
)	)	O
or	CC	O
bare-metal	JJ	O
BxVelocity	NNP	O
stents	NNS	O
(	(	O
BMSs	NNP	O
)	)	O
(	(	O
Cordis	NNP	O
)	)	O
(	(	O
100	CD	SS
patients	NNS	O
)	)	O
were	VBD	O
followed	VBN	O
clinically	RB	O
for	IN	O
3	CD	O
years	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
1	CD	O
and	CC	O
3	CD	O
years	NNS	O
,	,	O
there	EX	O
were	VBD	O
infrequent	JJ	O
additional	JJ	O
clinical	JJ	O
events	NNS	O
that	WDT	O
were	VBD	O
equally	RB	O
distributed	VBN	O
between	IN	O
the	DT	O
SES	NNP	O
and	CC	O
the	DT	O
BMS	NNP	O
group	NN	O
.	.	O

After	IN	O
3	CD	O
years	NNS	O
,	,	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
27	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
;	:	O
and	CC	O
target	VB	O
vessel	JJ	O
revascularization	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
11	CD	O
%	NN	O
in	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
30	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

Major	JJ	O
adverse	JJ	O
cardiac	NN	O
events	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
34	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
stent	JJ	O
thrombosis	NN	O
according	VBG	O
to	TO	O
the	DT	O
Academic	NNP	O
Research	NNP	O
Consortium	NNP	O
criteria	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Clinical	NNP	O
outcome	VBD	O
up	RB	O
to	TO	O
3	CD	O
years	NNS	O
after	IN	O
implantation	NN	O
of	IN	O
SESs	NNP	O
for	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
continues	VBZ	O
to	TO	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
adverse	JJ	O
clinical	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
BMSs	NNP	O
without	IN	O
the	DT	O
evidence	NN	O
for	IN	O
either	DT	O
disproportionate	NN	O
late	JJ	O
restenosis	NN	O
or	CC	O
late	JJ	O
stent	JJ	O
thrombosis	NN	O
.	.	O

Memantine	NNP	O
add-on	JJ	O
to	TO	O
risperidone	VB	O
for	IN	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	C
schizophrenia	NN	C
:	:	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
memantine	JJ	O
add-on	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
schizophrenia	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
40	CD	SS
patients	NNS	O
with	IN	O
schizophrenia	NN	C
(	(	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
)	)	O
who	WP	O
were	VBD	O
stabilized	VBN	O
on	IN	O
risperidone	NN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
memantine	NN	O
(	(	O
20	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
risperidone	VB	O
,	,	O
6	CD	O
mg/d	NN	O
,	,	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

Assessment	NNP	O
was	VBD	O
done	VBN	O
using	VBG	O
the	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
at	IN	O
baseline	NN	O
,	,	O
week	NN	O
4	CD	O
,	,	O
and	CC	O
week	NN	O
8	CD	O
.	.	O

The	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Extrapyramidal	NNP	O
Symptom	NNP	O
Rating	NNP	O
Scale	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
depression	NN	O
and	CC	O
extrapyramidal	NN	O
symptoms	NNS	O
,	,	O
respectively	RB	O
.	.	O

All	DT	O
40	CD	O
patients	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
postbaseline	NN	O
measurement	NN	O
,	,	O
and	CC	O
38	CD	SS
patients	NNS	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
memantine	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
on	IN	O
negative	JJ	O
subscale	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
at	IN	O
end	NN	O
point	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
effect	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
total	JJ	O
score	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
general	JJ	O
psychopathology	NN	O
subscale	NN	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
reduction	NN	O
of	IN	O
positive	JJ	O
symptoms	NNS	O
score	VBP	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.757	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Extrapyramidal	NNP	O
Symptom	NNP	O
Rating	NNP	O
Scale	NNP	O
scores	NNS	O
and	CC	O
frequency	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
memantine	NN	O
is	VBZ	O
a	DT	O
tolerable	JJ	O
and	CC	O
efficacious	JJ	O
add-on	JJ	O
treatment	NN	O
for	IN	O
primary	JJ	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
.	.	O

Moist	NN	O
Exposed	VBD	O
Burn	NNP	O
Ointment	NNP	O
(	(	O
MEBO	NNP	O
)	)	O
in	IN	O
partial	JJ	C
thickness	NN	C
burns	NNS	C
-	:	O
a	DT	O
randomized	JJ	O
,	,	O
comparative	JJ	O
open	JJ	O
mono-center	NN	O
study	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
dermaheal	NN	O
(	(	O
MEBO	NNP	O
)	)	O
ointment	NN	O
on	IN	O
thermal	JJ	C
2nd	CD	C
degree	NN	C
burns	NNS	C
compared	VBN	O
to	TO	O
conventional	JJ	O
therapy	NN	O
.	.	O

OBJECTIVE	NNP	O
Wound	NNP	O
healing	NN	O
in	IN	O
burn	NN	O
wounds	NNS	O
presents	VBZ	O
a	DT	O
challenge	NN	O
in	IN	O
healthcare	NN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
still	RB	O
a	DT	O
lack	NN	O
of	IN	O
alternatives	NNS	O
in	IN	O
topical	JJ	O
burn	NN	O
wound	NN	O
treatments	NNS	O
.	.	O

-	:	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
therapeutic	JJ	O
ointment	NN	O
(	(	O
MEBO	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
partial	JJ	C
thickness	NN	C
burns	NNS	C
.	.	O

METHODS	NNP	O
40	CD	SS
patients	NNS	O
received	VBD	O
either	RB	O
topical	JJ	O
treatment	NN	O
with	IN	O
Moist	NNP	O
Exposed	VBD	O
Burn	NNP	O
Ointment	NNP	O
(	(	O
MEBO	NNP	O
)	)	O
or	CC	O
standard	JJ	O
Flammazine	NNP	O
treatment	NN	O
.	.	O

All	DT	O
patients	NNS	O
suffered	VBD	O
from	IN	O
partial-thickness	JJ	O
burn	NN	O
injuries	NNS	O
(	(	O
<	VB	O
20	CD	O
%	NN	O
TBSA	NNP	O
)	)	O
.	.	O

Wounds	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
60	CD	O
up	RB	O
to	TO	O
days	NNS	O
regarding	VBG	O
wound	NN	O
healing	NN	O
,	,	O
water	NN	O
loss	NN	O
,	,	O
inflammation	NN	O
,	,	O
and	CC	O
pain	NN	O
alleviation	NN	O
.	.	O

RESULTS	NNP	O
For	IN	O
transepidermal	JJ	O
water	NN	O
loss	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
difference	NN	O
of	IN	O
2.3	CD	O
gr/m2/h	NN	O
between	IN	O
MEBO	NNP	O
,	,	O
and	CC	O
Flammazine	NNP	O
,	,	O
favoring	VBG	O
MEBO	NNP	O
.	.	O

However	RB	O
,	,	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p=0.78	NN	O
)	)	O
.	.	O

For	IN	O
all	DT	O
secondary	JJ	O
efficacy	NN	O
parameter	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

-	:	O
CONCLUSIONS	NN	O
This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
MEBO	NNP	O
ointment	NN	O
for	IN	O
topical	JJ	O
treatment	NN	O
of	IN	O
burn	NN	O
injuries	NNS	O
presents	VBZ	O
an	DT	O
attractive	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
topical	JJ	O
treatment	NN	O
of	IN	O
limited	JJ	C
partial	JJ	C
thickness	NN	C
thermal	JJ	C
burns	NNS	C
.	.	O

Lactobacillus	NNP	O
plantarum	NN	O
CECT7315	NNP	O
and	CC	O
CECT7316	NNP	O
stimulate	VBP	O
immunoglobulin	NN	O
production	NN	O
after	IN	O
influenza	JJ	C
vaccination	NN	C
in	IN	O
elderly	JJ	A
.	.	O

OBJECTIVE	IN	O
The	DT	O
effectiveness	NN	O
of	IN	O
influenza	JJ	O
vaccination	NN	O
in	IN	O
preventing	VBG	O
illness	NN	O
is	VBZ	O
lower	RBR	O
in	IN	O
the	DT	O
elderly	JJ	O
;	:	O
this	DT	O
is	VBZ	O
why	WRB	O
the	DT	O
ability	NN	O
of	IN	O
Lactobacillus	NNP	O
plantarum	NN	O
CECT	NNP	O
7315/7316	CD	O
to	TO	O
stimulate	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	C
vaccination	NN	C
in	IN	O
elderly	JJ	A
was	VBD	O
evaluated	VBN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
human	JJ	O
trial	NN	O
including	VBG	O
60	CD	SS
institutionalized	JJ	O
volunteers	NNS	O
aged	VBN	O
65-85	CD	A
years	NNS	O
was	VBD	O
performed	VBN	O
.	.	O

All	PDT	O
the	DT	O
volunteers	NNS	O
were	VBD	O
vaccinated	VBN	O
with	IN	O
a	DT	O
trivalent	JJ	O
influenza	NN	O
vaccine	NN	O
(	(	O
A/Wisconsin/67/2005	NNP	O
NYMC	NNP	O
X-161B	NNP	O
(	(	O
H3N2	NNP	O
)	)	O
,	,	O
A/Solomon	NNP	O
Islands/3/2006	NNP	O
(	(	O
H1N1	NNP	O
)	)	O
and	CC	O
B/Malaysia/2506/2004	NNP	O
)	)	O
for	IN	O
the	DT	O
Spanish	JJ	O
vaccine	NN	O
campaign	NN	O
2006/2007	CD	O
.	.	O

The	DT	O
consumption	NN	O
of	IN	O
the	DT	O
probiotic	JJ	O
began	VBD	O
between	IN	O
three	CD	O
and	CC	O
four	CD	O
months	NNS	O
after	IN	O
the	DT	O
vaccination	NN	O
.	.	O

Volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
following	VBG	O
groups	NNS	O
:	:	O
group	NN	O
A	NNP	O
(	(	O
receiving	VBG	O
5*10	CD	O
(	(	O
9	CD	O
)	)	O
cfu/day	NN	O
of	IN	O
L.	NNP	O
plantarum	NN	O
CECT	NNP	O
7315/7316	CD	O
in	IN	O
20	CD	O
g	NN	O
powdered	VBD	O
skim	JJ	O
milk	NN	O
)	)	O
,	,	O
group	NN	O
B	NNP	O
(	(	O
receiving	VBG	O
5*10	CD	O
(	(	O
8	CD	O
)	)	O
cfu/day	NN	O
of	IN	O
L.	NNP	O
plantarum	NN	O
CECT	NNP	O
7315/7316	CD	O
in	IN	O
20	CD	O
g	NN	O
powdered	VBD	O
skim	JJ	O
milk	NN	O
)	)	O
and	CC	O
group	NN	O
C	NNP	O
or	CC	O
placebo	NN	O
(	(	O
20	CD	O
g	NN	O
powered	VBN	O
skim	JJ	O
milk	NN	O
)	)	O
.	.	O

The	DT	O
participants	NNS	O
consumed	VBD	O
the	DT	O
probiotic	JJ	O
during	IN	O
3	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
consumption	NN	O
of	IN	O
L.	NNP	O
plantarum	NN	O
CECT	NNP	O
7315/7316	CD	O
during	IN	O
3	CD	O
months	NNS	O
after	IN	O
influenza	JJ	O
vaccination	NN	O
increased	VBD	O
the	DT	O
levels	NNS	O
of	IN	O
influenza-specific	JJ	O
IgA	NNP	O
and	CC	O
IgG	NNP	O
antibodies	NNS	O
.	.	O

Moreover	RB	O
,	,	O
a	DT	O
trend	NN	O
towards	IN	O
an	DT	O
increase	NN	O
in	IN	O
influenza-specific	JJ	O
IgM	NNP	O
antibodies	NNS	O
was	VBD	O
also	RB	O
observed	VBN	O
.	.	O

CONCLUSION	NNP	O
L.	NNP	O
plantarum	NN	O
CECT7315/7316	NNP	O
has	VBZ	O
an	DT	O
immunostimulating	JJ	O
effect	NN	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	O
vaccination	NN	O
in	IN	O
elderly	JJ	O
.	.	O

Enhancing	VBG	O
attitudes	NNS	O
and	CC	O
intentions	NNS	O
in	IN	O
prospective	JJ	C
blood	NN	C
donors	NNS	C
:	:	O
evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	O
donor	NN	O
recruitment	NN	O
brochure	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
little	JJ	O
empiric	JJ	O
evidence	NN	O
has	VBZ	O
been	VBN	O
published	VBN	O
concerning	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
blood	NN	O
donor	NN	O
recruitment	NN	O
materials	NNS	O
,	,	O
research	NN	O
suggests	VBZ	O
that	IN	O
simple	JJ	O
attempts	NNS	O
to	TO	O
enhance	VB	O
knowledge	NN	O
may	MD	O
not	RB	O
be	VB	O
sufficient	JJ	O
to	TO	O
motivate	VB	O
donation	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
recent	JJ	O
donor	NN	O
motivation	NN	O
studies	NNS	O
highlight	VBD	O
the	DT	O
importance	NN	O
of	IN	O
anxiety	NN	O
,	,	O
attitudes	NNS	O
,	,	O
and	CC	O
perceived	VBD	O
ability	NN	O
to	TO	O
cope	VB	O
with	IN	O
donation	NN	O
(	(	O
i.e.	JJ	O
,	,	O
self-efficacy	NN	O
)	)	O
as	IN	O
crucial	JJ	O
determinants	NNS	O
of	IN	O
donation	NN	O
intention	NN	O
.	.	O

Therefore	RB	O
,	,	O
recruitment	JJ	O
materials	NNS	O
that	WDT	O
specifically	RB	O
address	VBP	O
these	DT	O
constructs	NNS	O
have	VBP	O
the	DT	O
potential	JJ	O
to	TO	O
outperform	VB	O
traditional	JJ	O
educational	JJ	O
brochures	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
read	VB	O
one	CD	O
of	IN	O
three	CD	O
brochures	NNS	O
:	:	O
1	CD	O
)	)	O
a	DT	O
new	JJ	O
brochure	NN	O
addressing	VBG	O
common	JJ	O
donor	NN	O
concerns	NNS	O
and	CC	O
suggesting	VBG	O
specific	JJ	O
coping	VBG	O
strategies	NNS	O
,	,	O
2	CD	O
)	)	O
a	DT	O
standard	JJ	O
blood	NN	O
center	NN	O
brochure	NN	O
,	,	O
or	CC	O
3	CD	O
)	)	O
a	DT	O
control	JJ	O
brochure	NN	O
on	IN	O
healthy	JJ	O
eating	NN	O
and	CC	O
exercise	NN	O
.	.	O

Standardized	JJ	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
brochures	NNS	O
to	TO	O
assess	VB	O
change	NN	O
in	IN	O
blood	NN	O
donation	NN	O
anxiety	NN	O
,	,	O
attitude	NN	O
,	,	O
self-efficacy	NN	O
,	,	O
and	CC	O
intention	NN	O
.	.	O

RESULTS	NNP	O
Although	IN	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
noted	VBN	O
for	IN	O
the	DT	O
control	NN	O
brochure	NN	O
,	,	O
after	IN	O
reading	VBG	O
the	DT	O
new	JJ	O
brochure	NN	O
participants	NNS	O
reported	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
attitude	NN	O
,	,	O
anxiety	NN	O
,	,	O
self-efficacy	NN	O
,	,	O
and	CC	O
donation	NN	O
intention	NN	O
.	.	O

The	DT	O
standard	JJ	O
donation	NN	O
brochure	NN	O
had	VBD	O
an	DT	O
intermediate	JJ	O
effect	NN	O
.	.	O

CONCLUSION	NNP	O
Efforts	NNPS	O
to	TO	O
address	VB	O
common	JJ	O
donor	NN	O
fears	NNS	O
and	CC	O
to	TO	O
provide	VB	O
useful	JJ	O
coping	VBG	O
suggestions	NNS	O
may	MD	O
improve	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
blood	NN	O
donation	NN	O
recruitment	NN	O
materials	NNS	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
physical	JJ	O
activity	NN	O
monitoring	NN	O
and	CC	O
distance	NN	O
counselling	NN	O
in	IN	O
an	DT	O
occupational	JJ	O
health	NN	O
setting	NN	O
--	:	O
a	DT	O
research	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
(	(	O
CoAct	NNP	O
)	)	O
.	.	O

BACKGROUND	IN	O
The	DT	O
CoAct	NNP	O
(	(	O
Cocreating	NNP	O
Activity	NNP	O
)	)	O
study	NN	O
is	VBZ	O
investigating	VBG	O
a	DT	O
novel	JJ	O
lifestyle	JJ	O
intervention	NN	O
,	,	O
aimed	VBN	O
at	IN	O
the	DT	O
working	VBG	C
population	NN	C
,	,	O
with	IN	O
daily	JJ	O
activity	NN	O
monitoring	NN	O
and	CC	O
distance	NN	O
counselling	NN	O
via	IN	O
telephone	NN	O
and	CC	O
secure	NN	O
web	NN	O
messages	NNS	O
.	.	O

The	DT	O
main	JJ	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
lifestyle	JJ	O
counselling	VBG	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
physical	JJ	O
activity	NN	O
in	IN	O
an	DT	O
occupational	JJ	O
health	NN	O
setting	NN	O
.	.	O

The	DT	O
purposes	NNS	O
include	VBP	O
also	RB	O
analysing	VBG	O
the	DT	O
potential	JJ	O
effects	NNS	O
of	IN	O
changes	NNS	O
in	IN	O
physical	JJ	O
activity	NN	O
on	IN	O
productivity	NN	O
at	IN	O
work	NN	O
and	CC	O
sickness	JJ	O
absence	NN	O
,	,	O
and	CC	O
healthcare	NN	O
costs	NNS	O
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
the	DT	O
design	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
the	DT	O
participant	NN	O
flow	NN	O
until	IN	O
and	CC	O
including	VBG	O
randomization	NN	O
.	.	O

METHODS/DESIGN	NNP	O
CoAct	NNP	O
is	VBZ	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
with	IN	O
two	CD	O
arms	NNS	O
:	:	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
intervention	NN	O
group	NN	O
with	IN	O
daily	JJ	O
activity	NN	O
monitoring	NN	O
and	CC	O
distance	NN	O
counselling	NN	O
.	.	O

The	DT	O
intervention	NN	O
focuses	VBZ	O
on	IN	O
lifestyle	JJ	O
modification	NN	O
and	CC	O
takes	VBZ	O
12	CD	O
months	NNS	O
.	.	O

The	DT	O
study	NN	O
population	NN	O
consists	VBZ	O
of	IN	O
volunteers	NNS	O
from	IN	O
1100	CD	SS
eligible	JJ	O
employees	NNS	O
of	IN	O
a	DT	O
Finnish	JJ	O
insurance	NN	O
company	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
of	IN	O
this	DT	O
study	NN	O
are	VBP	O
change	NN	O
in	IN	O
physical	JJ	O
activity	NN	O
measured	VBN	O
in	IN	O
MET	NNP	O
minutes	NNS	O
per	IN	O
week	NN	O
,	,	O
work	NN	O
productivity	NN	O
and	CC	O
sickness	NN	O
absence	NN	O
,	,	O
and	CC	O
healthcare	JJ	O
utilisation	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
include	VBP	O
various	JJ	O
physiological	JJ	O
measures	NNS	O
.	.	O

Cost-effectiveness	JJ	O
analysis	NN	O
will	MD	O
also	RB	O
be	VB	O
performed	VBN	O
.	.	O

The	DT	O
outcomes	NNS	O
will	MD	O
be	VB	O
measured	VBN	O
by	IN	O
questionnaires	NNS	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
6	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
24	CD	O
months	NNS	O
,	,	O
and	CC	O
sickness	JJ	O
absence	NN	O
will	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
the	DT	O
employer	NN	O
's	POS	O
registers	NNS	O
.	.	O

DISCUSSION	NNP	O
No	NNP	O
trials	NNS	O
are	VBP	O
yet	RB	O
available	JJ	O
that	WDT	O
have	VBP	O
evaluated	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
daily	JJ	O
physical	JJ	O
activity	NN	O
monitoring	NN	O
and	CC	O
distance	NN	O
counselling	NN	O
in	IN	O
an	DT	O
occupational	JJ	O
health	NN	O
setting	NN	O
over	IN	O
a	DT	O
12	CD	O
month	NN	O
period	NN	O
and	CC	O
no	DT	O
data	NN	O
on	IN	O
cost-effectiveness	NN	O
of	IN	O
such	JJ	O
intervention	NN	O
are	VBP	O
available	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
identifier	NN	O
:	:	O
NCT00994565	NNP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
dietary	JJ	O
fibre	NN	O
source	NN	O
and	CC	O
gender	NN	O
on	IN	O
the	DT	O
postprandial	JJ	O
glucose	NN	O
and	CC	O
lipid	JJ	O
response	NN	O
in	IN	O
healthy	JJ	C
subjects	NNS	O
.	.	O

BACKGROUND	NNP	O
Consumption	NNP	O
of	IN	O
soluble	JJ	O
dietary	JJ	O
fibre	NN	O
is	VBZ	O
correlated	VBN	O
with	IN	O
decreased	JJ	O
postprandial	JJ	O
glucose	NN	O
and	CC	O
insulin	NN	O
responses	NNS	O
and	CC	O
hence	NN	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
on	IN	O
postprandial	JJ	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
triglyceride	JJ	O
concentrations	NNS	O
of	IN	O
meals	NNS	O
enriched	VBN	O
with	IN	O
soluble	JJ	O
dietary	JJ	O
fibres	NNS	O
from	IN	O
oats	NNS	O
,	,	O
rye	NN	O
bran	NN	O
,	,	O
sugar	JJ	O
beet	NN	O
fibre	NN	O
or	CC	O
a	DT	O
mixture	NN	O
of	IN	O
these	DT	O
three	CD	O
fibres	NNS	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	SS
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
(	(	O
6	CD	SE
men	NNS	SE
and	CC	SE
7	CD	SE
women	NNS	SE
,	,	O
aged	VBN	O
20-28	CD	A
years	NNS	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
came	VBD	O
to	TO	O
the	DT	O
study	NN	O
centre	NN	O
once	RB	O
a	DT	O
week	NN	O
after	IN	O
an	DT	O
overnight	JJ	O
fast	NN	O
to	TO	O
ingest	VB	O
test	NN	O
meals	NNS	O
and	CC	O
a	DT	O
control	NN	O
meal	NN	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
meals	NNS	O
contained	VBD	O
either	CC	O
oat	JJ	O
powder	NN	O
(	(	O
62	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
2.7	CD	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
rye	NN	O
bran	NN	O
(	(	O
31	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
1.7	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
sugar	JJ	O
beet	NN	O
fibre	NN	O
(	(	O
19	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
5	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
a	DT	O
mixture	NN	O
of	IN	O
these	DT	O
three	CD	O
fibres	NNS	O
(	(	O
74	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
1.7	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
from	IN	O
each	DT	O
source	NN	O
,	,	O
giving	VBG	O
5	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
or	CC	O
no	DT	O
added	JJ	O
fibre	NN	O
(	(	O
control	NN	O
)	)	O
and	CC	O
were	VBD	O
all	DT	O
adjusted	VBN	O
to	TO	O
contain	VB	O
the	DT	O
same	JJ	O
total	JJ	O
amount	NN	O
of	IN	O
available	JJ	O
carbohydrates	NNS	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
before	RB	O
and	CC	O
every	DT	O
30	CD	O
min	NN	O
up	RB	O
to	TO	O
180	CD	O
min	NN	O
after	IN	O
the	DT	O
meals	NNS	O
.	.	O

RESULTS	NNP	O
Meals	NNP	O
with	IN	O
rye	NN	O
bran	NN	O
gave	VBD	O
a	DT	O
lower	JJR	O
postprandial	JJ	O
glucose	NN	O
peak	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
meal	NN	O
,	,	O
and	CC	O
this	DT	O
effect	NN	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
women	NNS	O
compared	VBN	O
to	TO	O
men	NNS	O
.	.	O

Oat	NNP	O
powder	NN	O
,	,	O
containing	VBG	O
a	DT	O
low	JJ	O
amount	NN	O
of	IN	O
total	JJ	O
fibre	NN	O
and	CC	O
a	DT	O
high	JJ	O
amount	NN	O
of	IN	O
carbohydrates	NNS	O
in	IN	O
liquid	NN	O
matrix	NN	O
,	,	O
gave	VBD	O
a	DT	O
higher	JJR	O
incremental	JJ	O
glucose	JJ	O
peak	NN	O
concentration	NN	O
compared	VBN	O
to	TO	O
rye	VB	O
bran	NN	O
and	CC	O
sugar	NN	O
beet	NN	O
fibre	NN	O
and	CC	O
higher	JJR	O
insulin	NN	O
incremental	JJ	O
area	NN	O
under	IN	O
curve	NN	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

The	DT	O
oat	NN	O
powder	NN	O
also	RB	O
influenced	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
mixed	JJ	O
meal	NN	O
,	,	O
diminishing	VBG	O
the	DT	O
glucose-lowering	JJ	O
effects	NNS	O
.	.	O

Postprandial	NNP	O
triglyceride	NN	O
levels	NNS	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
after	IN	O
all	DT	O
fibre-rich	JJ	O
meals	NNS	O
,	,	O
but	CC	O
only	RB	O
significant	JJ	O
for	IN	O
oat	NN	O
powder	NN	O
and	CC	O
the	DT	O
mixed	JJ	O
meal	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
meal	NN	O
.	.	O

CONCLUSIONS	NNP	O
Postprandial	NNP	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
triglyceride	JJ	O
concentrations	NNS	O
are	VBP	O
influenced	VBN	O
by	IN	O
dietary	JJ	O
fibre-rich	JJ	O
meals	NNS	O
,	,	O
depending	VBG	O
on	IN	O
fibre	NN	O
source	NN	O
,	,	O
dose	NN	O
of	IN	O
soluble	JJ	O
and	CC	O
total	JJ	O
fibre	NN	O
and	CC	O
possibly	RB	O
gender	NN	O
.	.	O

Study	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
hippotherapy	NN	O
simulator	NN	O
in	IN	O
children	NNS	A
with	IN	O
cerebral	JJ	C
palsy	NN	C
:	:	O
a	DT	O
stratified	JJ	O
single-blind	NN	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
hippotherapy	NN	O
(	(	O
when	WRB	O
applied	VBN	O
by	IN	O
a	DT	O
simulator	NN	O
)	)	O
improves	VBZ	O
postural	JJ	O
control	NN	O
and	CC	O
balance	NN	O
in	IN	O
children	NNS	A
with	IN	O
cerebral	JJ	C
palsy	NN	C
.	.	O

DESIGN	NNP	O
Stratified	VBD	O
single-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
with	IN	O
an	DT	O
independent	JJ	O
assessor	NN	O
.	.	O

Stratification	NN	O
was	VBD	O
made	VBN	O
by	IN	O
gross	JJ	O
motor	NN	O
function	NN	O
classification	NN	O
system	NN	O
levels	NNS	O
,	,	O
and	CC	O
allocation	NN	O
was	VBD	O
concealed	VBN	O
.	.	O

SUBJECTS	NNP	O
Children	NNP	A
between	IN	O
4	CD	A
and	CC	A
18	CD	A
years	NNS	O
old	JJ	O
with	IN	O
cerebral	JJ	C
palsy	NN	C
.	.	O

INTERVENTIONS	JJ	O
Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
simulator	NN	O
ON	NNP	O
)	)	O
or	CC	O
control	NN	O
(	(	O
simulator	VB	O
OFF	NNP	O
)	)	O
group	NN	O
after	IN	O
getting	VBG	O
informed	JJ	O
consent	NN	O
.	.	O

Treatment	NNP	O
was	VBD	O
provided	VBN	O
once	RB	O
a	DT	O
week	NN	O
(	(	O
15	CD	O
minutes	NNS	O
)	)	O
for	IN	O
10	CD	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
(	(	O
dimension	NN	O
B	NNP	O
for	IN	O
balance	NN	O
and	CC	O
the	DT	O
Total	NNP	O
Score	NNP	O
)	)	O
and	CC	O
Sitting	VBG	O
Assessment	NNP	O
Scale	NNP	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
baseline	NN	O
(	(	O
prior	JJ	O
to	TO	O
randomization	NN	O
)	)	O
,	,	O
end	NN	O
of	IN	O
intervention	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
after	IN	O
completing	VBG	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Thirty-eight	JJ	SS
children	NNS	A
participated	VBN	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
balanced	VBN	O
at	IN	O
baseline	NN	O
.	.	O

Sitting	VBG	O
balance	NN	O
(	(	O
measured	VBN	O
by	IN	O
dimension	NN	O
B	NNP	O
of	IN	O
the	DT	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
)	)	O
improved	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
effect	NN	O
size	NN	O
=	$	O
0.36	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.71	NN	O
)	)	O
and	CC	O
the	DT	O
effect	NN	O
size	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
severely	RB	O
disabled	JJ	O
group	NN	O
(	(	O
effect	NN	O
size	NN	O
=	$	O
0.80	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.13-1.47	NN	O
)	)	O
.	.	O

The	DT	O
improvements	NNS	O
in	IN	O
sitting	VBG	O
balance	NN	O
were	VBD	O
not	RB	O
maintained	VBN	O
over	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
total	JJ	O
score	NN	O
of	IN	O
the	DT	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
and	CC	O
the	DT	O
Sitting	NNP	O
Assessment	NNP	O
Scale	NNP	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Hippotherapy	NNP	O
with	IN	O
a	DT	O
simulator	NN	O
can	MD	O
improve	VB	O
sitting	VBG	O
balance	NN	O
in	IN	O
cerebral	JJ	C
palsy	NN	C
children	NNS	A
who	WP	O
have	VBP	O
higher	JJR	O
levels	NNS	O
of	IN	O
disability	NN	O
.	.	O

However	RB	O
,	,	O
this	DT	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
overall	JJ	O
function	NN	O
of	IN	O
these	DT	O
children	NNS	O
(	(	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Classification	NNP	O
System	NNP	O
level	JJ	O
V	NNP	O
)	)	O
.	.	O

Action	NNP	O
observation	NN	O
treatment	NN	O
improves	VBZ	O
recovery	NN	O
of	IN	O
postsurgical	JJ	C
orthopedic	JJ	C
patients	NNS	C
:	:	O
evidence	NN	O
for	IN	O
a	DT	O
top-down	JJ	O
effect	NN	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
assess	VB	O
whether	IN	O
action	NN	O
observation	NN	O
treatment	NN	O
(	(	O
AOT	NNP	O
)	)	O
may	MD	O
also	RB	O
improve	VB	O
motor	NN	O
recovery	NN	O
in	IN	O
postsurgical	JJ	C
orthopedic	JJ	C
patients	NNS	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Department	NNP	O
of	IN	O
rehabilitation	NN	O
.	.	O

PARTICIPANTS	JJ	O
Patients	NNPS	O
(	(	O
N=60	NNP	SS
)	)	O
admitted	VBD	O
to	TO	O
our	PRP$	O
department	NN	O
postorthopedic	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
case	NN	O
(	(	O
n=30	NN	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=30	JJ	O
)	)	O
group	NN	O
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
age	NN	O
18	CD	A
years	NNS	A
or	CC	A
younger	JJR	A
and	CC	A
90	CD	A
years	NNS	A
or	CC	A
older	JJR	A
,	,	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
score	NN	O
of	IN	O
21	CD	O
of	IN	O
30	CD	O
or	CC	O
lower	JJR	O
,	,	O
no	DT	O
ambulating	VBG	O
order	NN	O
,	,	O
advanced	JJ	O
vision	NN	O
impairment	NN	O
,	,	O
malignancy	NN	O
,	,	O
pneumonia	NN	O
,	,	O
or	CC	O
heart	NN	O
failure	NN	O
.	.	O

INTERVENTIONS	NNP	O
All	NNP	O
participants	NNS	O
underwent	JJ	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	O
video	JJ	O
clips	NNS	O
showing	VBG	O
daily	JJ	O
actions	NNS	O
and	CC	O
to	TO	O
imitate	VB	O
them	PRP	O
afterward	RB	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	O
video	JJ	O
clips	NNS	O
with	IN	O
no	DT	O
motor	NN	O
content	NN	O
and	CC	O
to	TO	O
execute	VB	O
the	DT	O
same	JJ	O
actions	NNS	O
as	IN	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
afterward	RB	O
.	.	O

Participants	NNS	O
were	VBD	O
scored	VBN	O
on	IN	O
functional	JJ	O
scales	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
by	IN	O
a	DT	O
physician	NN	O
blinded	VBD	O
to	TO	O
group	NN	O
assignment	NN	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
MEASURES	NNP	O
Changes	NNP	O
in	IN	O
FIM	NNP	O
and	CC	O
Tinetti	NNP	O
scale	NN	O
scores	NNS	O
,	,	O
and	CC	O
dependence	NN	O
on	IN	O
walking	VBG	O
aids	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
clinical	JJ	O
and	CC	O
functional	JJ	O
scale	NN	O
scores	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
scored	VBD	O
better	JJR	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
FIM	NNP	O
total	NN	O
score	NN	O
,	,	O
P=.02	NNP	O
;	:	O
FIM	NNP	O
motor	NN	O
subscore	NN	O
,	,	O
P=.001	NNP	O
;	:	O
Tinetti	NNP	O
scale	NN	O
score	NN	O
,	,	O
P=.04	NNP	O
)	)	O
;	:	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
assigned	VBN	O
more	RBR	O
frequently	RB	O
to	TO	O
1	CD	O
crutch	NN	O
(	(	O
P=.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
,	,	O
AOT	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
present	JJ	O
results	NNS	O
strongly	RB	O
support	VB	O
top-down	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
treatment	NN	O
in	IN	O
motor	NN	O
recovery	NN	O
,	,	O
even	RB	O
in	IN	O
nonneurologic	JJ	O
patients	NNS	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
multi-faceted	JJ	O
intervention	NN	O
on	IN	O
gingival	JJ	O
health	NN	O
among	IN	O
adults	NNS	A
with	IN	O
systemic	JJ	C
sclerosis	NN	C
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
adaptive	JJ	O
oral	JJ	O
hygiene	NN	O
devices	NNS	O
and	CC	O
orofacial	JJ	O
exercise	NN	O
to	TO	O
improve	VB	O
gingival	JJ	O
health	NN	O
among	IN	O
adults	NNS	A
with	IN	O
systemic	JJ	C
sclerosis	NN	C
(	(	O
SSc	NNP	C
)	)	O
.	.	O

METHODS	NNP	O
Forty-eight	JJ	SS
patients	NNS	O
with	IN	O
SSc	NNP	C
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
the	DT	O
multifaceted	VBN	O
oral	JJ	O
health	NN	O
intervention	NN	O
or	CC	O
usual	JJ	O
dental	JJ	O
care	NN	O
control	NN	O
group	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
a	DT	O
rechargeable	JJ	O
,	,	O
powered	JJ	O
Oral-B?	NNP	O
oscillating-rotating-pulsating	NN	O
toothbrush	NN	O
and	CC	O
a	DT	O
Reach?	NNP	O
Access?	NNP	O
Flosser	NNP	O
that	WDT	O
has	VBZ	O
a	DT	O
toothbrush-like	JJ	O
handle	NN	O
.	.	O

For	IN	O
those	DT	O
with	IN	O
an	DT	O
oral	JJ	O
aperture	NN	O
of	IN	O
less	JJR	O
than	IN	O
40	CD	O
mm	NN	O
,	,	O
orofacial	JJ	O
exercises	NNS	O
were	VBD	O
taught	VBN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
each	DT	O
given	VBN	O
a	DT	O
manual	JJ	O
toothbrush	NN	O
and	CC	O
dental	JJ	O
floss	NN	O
.	.	O

Participants	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
received	VBD	O
instructions	NNS	O
and	CC	O
demonstration	NN	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
devices	NNS	O
,	,	O
and	CC	O
were	VBD	O
requested	VBN	O
to	TO	O
perform	VB	O
the	DT	O
respective	JJ	O
intervention	NN	O
twice	RB	O
a	DT	O
day	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Evaluations	NNS	O
were	VBD	O
at	IN	O
baseline	NN	O
,	,	O
3-	JJ	O
,	,	O
and	CC	O
6-months	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
gingival	JJ	O
index	NN	O
(	(	O
GI	NNP	O
)	)	O
,	,	O
an	DT	O
indicator	NN	O
of	IN	O
gingival	JJ	O
inflammation	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
reduction	NN	O
in	IN	O
GI	NNP	O
scores	NNS	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
ps	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
GI	NNP	O
scores	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
6	CD	O
months	NNS	O
was	VBD	O
20.8	CD	O
%	NN	O
which	WDT	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
clinically	RB	O
significant	JJ	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
and	CC	O
larger	JJR	O
reduction	NN	O
in	IN	O
GI	NNP	O
score	NN	O
by	IN	O
8	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
p=0.0007	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Results	NNP	O
support	NN	O
the	DT	O
use	NN	O
of	IN	O
adaptive	JJ	O
devices	NNS	O
and	CC	O
orofacial	JJ	O
exercise	NN	O
to	TO	O
improve	VB	O
gingival	NN	O
health	NN	O
in	IN	O
adults	NNS	O
with	IN	O
SSc	NNP	O
when	WRB	O
compared	VBN	O
to	TO	O
use	VB	O
of	IN	O
manual	JJ	O
toothbrushing	NN	O
and	CC	O
finger-held	JJ	O
flossing	NN	O
.	.	O

Recommending	VBG	O
and	CC	O
educating	VBG	O
patients	NNS	O
with	IN	O
SSc	NNP	O
to	TO	O
use	VB	O
adaptive	JJ	O
devices	NNS	O
to	TO	O
clean	VB	O
the	DT	O
tooth	NN	O
surfaces	NNS	O
looks	VBZ	O
promising	VBG	O
for	IN	O
long-term	JJ	O
oral	JJ	O
health	NN	O
improvement	NN	O
.	.	O

Ilioinguinal-iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
within	IN	O
travenous	JJ	O
dexketoprofen	NN	O
improves	VBZ	O
postoperative	JJ	O
analgesia	NN	O
in	IN	O
abdominal	JJ	C
hysterectomies	NNS	C
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
intravenous	JJ	O
dexketoprofen	NNS	O
trometamol	VBP	O
with	IN	O
ilioinguinal	JJ	O
and	CC	O
iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
on	IN	O
analgesic	JJ	O
quality	NN	O
and	CC	O
morphine	NN	O
consumption	NN	O
after	IN	O
total	JJ	C
abdominal	JJ	C
hysterectomy	NN	C
operations	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
clinical	JJ	O
study	NN	O
on	IN	O
61	CD	SS
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
the	DT	O
operation	NN	O
room	NN	O
,	,	O
post-anesthesia	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
inpatient	JJ	O
clinic	NN	O
.	.	O

We	PRP	O
randomly	RB	O
grouped	VBD	O
the	DT	O
61	CD	O
patients	NNS	O
into	IN	O
control	NN	O
group	NN	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
,	,	O
block	NN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
and	CC	O
dexketoprofen-block	JJ	O
group	NN	O
(	(	O
group	NN	O
DB	NNP	O
)	)	O
.	.	O

Before	IN	O
the	DT	O
skin	NN	O
incision	NN	O
performed	VBD	O
after	IN	O
anesthesia	JJ	O
induction	NN	O
,	,	O
we	PRP	O
performed	VBD	O
ilioinguinal	JJ	O
iliohypogastric	JJ	O
block	NN	O
(	(	O
group	NN	O
C	NNP	O
given	VBN	O
saline	NN	O
and	CC	O
group	NN	O
P	NNP	O
and	CC	O
DB	NNP	O
given	VBN	O
levobupivacaine	NN	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
group	NN	O
C	NNP	O
and	CC	O
B	NNP	O
,	,	O
group	NN	O
DB	NNP	O
was	VBD	O
given	VBN	O
dexketoprofen	RB	O
.	.	O

We	PRP	O
administered	VBD	O
morphine	JJ	O
analgesia	NN	O
to	TO	O
all	DT	O
patients	NNS	O
by	IN	O
patient-controlled	JJ	O
analgesia	NN	O
(	(	O
PCA	NNP	O
)	)	O
during	IN	O
the	DT	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
.	.	O

We	PRP	O
recorded	VBD	O
Visual	NNP	O
Analogue	NNP	O
Scale	NNP	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
satisfaction	NN	O
scores	NNS	O
,	,	O
morphine	NN	O
consumption	NN	O
and	CC	O
side	NN	O
effects	NNS	O
during	IN	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
the	DT	O
DB	NNP	O
group?s	NN	O
VAS	NNP	O
scores	VBZ	O
to	TO	O
be	VB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
block	NN	O
group?s	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
values	NNS	O
at	IN	O
postoperative	JJ	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
6th	CD	O
and	CC	O
12th	CD	O
hours	NNS	O
.	.	O

VAS	NNP	O
scores	NNS	O
of	IN	O
group	NN	O
C	NNP	O
were	VBD	O
higher	JJR	O
than	IN	O
of	IN	O
group	NN	O
B	NNP	O
at	IN	O
postoperative	JJ	O
fi	NN	O
rst	VBD	O
2	CD	O
hours	NNS	O
.	.	O

Time	NNP	O
to	TO	O
fi	VB	O
rst	JJ	O
PCA	NNP	O
demand	NN	O
was	VBD	O
longer	RBR	O
,	,	O
morphine	JJ	O
consumption	NN	O
values	NNS	O
were	VBD	O
lower	JJR	O
and	CC	O
satisfaction	NN	O
scores	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
DB	NNP	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Ilioinguinal-iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
with	IN	O
IV	NNP	O
dexketoprofen	NN	O
increases	NNS	O
patient	JJ	O
satisfaction	NN	O
by	IN	O
decreasing	VBG	O
opioid	JJ	O
consumption	NN	O
,	,	O
increasing	VBG	O
patient	JJ	O
satisfaction	NN	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
dexketoprofen	NN	O
trometamol	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
analgesic	NN	O
in	IN	O
postoperative	JJ	O
analgesia	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
reducing	VBG	O
postoperative	JJ	O
hip	NN	O
precautions	NNS	O
in	IN	O
total	JJ	C
hip	JJ	C
replacement	NN	C
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

Currently	NNP	O
,	,	O
many	JJ	O
rehabilitation	NN	O
protocols	NNS	O
for	IN	O
total	JJ	O
hip	NN	O
replacements	NNS	O
(	(	O
THRs	NNP	O
)	)	O
include	VBP	O
activity	NN	O
restrictions	NNS	O
to	TO	O
prevent	VB	O
postoperative	JJ	O
dislocation	NN	O
.	.	O

There	EX	O
is	VBZ	O
increasing	VBG	O
demand	NN	O
for	IN	O
more	RBR	O
efficient	JJ	O
and	CC	O
safe	JJ	O
rehabilitation	NN	O
protocols	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
evaluates	VBZ	O
the	DT	O
need	NN	O
for	IN	O
hip	NN	O
restrictions	NNS	O
following	VBG	O
a	DT	O
modified	JJ	O
anterolateral	JJ	O
procedure	NN	O
.	.	O

From	IN	O
2004	CD	O
to	TO	O
2008	CD	O
,	,	O
81	CD	SS
patients	NNS	O
seeking	VBG	O
elective	JJ	O
THRs	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
a	DT	O
standard	JJ	O
rehabilitation	NN	O
group	NN	O
or	CC	O
an	DT	O
early	JJ	O
rehabilitation	NN	O
group	NN	O
.	.	O

The	DT	O
standard	JJ	O
group	NN	O
included	VBD	O
restrictions	NNS	O
to	TO	O
avoid	VB	O
hip	NN	O
flexion	NN	O
>	VBD	O
90	CD	O
degrees	NNS	O
and	CC	O
avoidance	NN	O
of	IN	O
riding	VBG	O
in	IN	O
a	DT	O
car	NN	O
for	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
month	NN	O
.	.	O

The	DT	O
early	JJ	O
group	NN	O
had	VBD	O
no	DT	O
flexion	NN	O
or	CC	O
car	NN	O
riding	NN	O
restrictions	NNS	O
.	.	O

Forty-three	JJ	SS
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
standard	JJ	O
group	NN	O
and	CC	O
38	CD	SS
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
early	JJ	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
demographic	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
Short	JJ	O
Form	NNP	O
12-question	JJ	O
Health	NNP	O
Survey	NNP	O
and	CC	O
Harris	NNP	O
Hip	NNP	O
Score	NNP	O
preoperatively	RB	O
and	CC	O
at	IN	O
4	CD	O
weeks	NNS	O
,	,	O
1	CD	O
month	NN	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
and	CC	O
1	CD	O
year	NN	O
postoperatively	RB	O
.	.	O

The	DT	O
time-points	NNS	O
at	IN	O
which	WDT	O
the	DT	O
patient	NN	O
first	RB	O
drove	VBD	O
and	CC	O
ambulated	VBD	O
with	IN	O
a	DT	O
cane	NN	O
,	,	O
without	IN	O
a	DT	O
cane	NN	O
,	,	O
and	CC	O
without	IN	O
a	DT	O
limp	NN	O
were	VBD	O
also	RB	O
collected	VBN	O
.	.	O

No	DT	O
incidents	NNS	O
of	IN	O
dislocation	NN	O
occurred	VBD	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
group	NN	O
were	VBD	O
faster	JJR	O
to	TO	O
ambulate	VB	O
with	IN	O
only	RB	O
a	DT	O
cane	NN	O
(	(	O
P=.03	NNP	O
)	)	O
,	,	O
without	IN	O
a	DT	O
cane	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
without	IN	O
a	DT	O
limp	NN	O
(	(	O
P=.003	NNP	O
)	)	O
.	.	O

They	PRP	O
also	RB	O
drove	VBD	O
earlier	RBR	O
(	(	O
P=.02	NNP	O
)	)	O
.	.	O

Pace	NN	O
of	IN	O
recovery	NN	O
was	VBD	O
the	DT	O
only	JJ	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
early	JJ	O
rehabilitation	NN	O
protocol	NN	O
increases	VBZ	O
the	DT	O
pace	NN	O
of	IN	O
recovery	NN	O
compared	VBN	O
to	TO	O
a	DT	O
pathway	NN	O
with	IN	O
hip	NN	O
precautions	NNS	O
without	IN	O
increasing	VBG	O
complications	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
body	NN	O
positioning	VBG	O
upon	IN	O
maximal	JJ	O
oxygenation	NN	O
of	IN	O
patients	NNS	O
with	IN	O
unilateral	JJ	C
lung	NN	C
pathology	NN	C
.	.	O

A	DT	O
quasi-experimental	JJ	O
,	,	O
repeated-measures	JJ	O
cross-over	NN	O
design	NN	O
study	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
body	NN	O
position	NN	O
on	IN	O
oxygenation	NN	O
(	(	O
SaO2	NNP	O
)	)	O
blood	NN	O
pressure	NN	O
,	,	O
respiration	NN	O
and	CC	O
pulse	NN	O
in	IN	O
patients	NNS	O
with	IN	O
unilateral	JJ	C
lung	NN	C
pathology	NN	C
was	VBD	O
conducted	VBN	O
.	.	O

Previous	JJ	O
research	NN	O
strongly	RB	O
suggests	VBZ	O
that	IN	O
positioning	VBG	O
with	IN	O
the	DT	O
healthy	JJ	O
(	(	O
unaffected	JJ	O
)	)	O
lung	NN	O
in	IN	O
the	DT	O
dependent	JJ	O
lateral	NN	O
(	(	O
down	RP	O
)	)	O
position	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
improved	VBN	O
oxygenation	NN	O
,	,	O
but	CC	O
knowledge	VBP	O
about	IN	O
whether	IN	O
this	DT	O
effect	NN	O
is	VBZ	O
maintained	VBN	O
over	IN	O
time	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
determine	VB	O
:	:	O
(	(	O
1	CD	O
)	)	O
Is	VBZ	O
positioning	VBG	O
with	IN	O
the	DT	O
unaffected	JJ	O
lung	NN	O
in	IN	O
the	DT	O
dependent	JJ	O
lateral	JJ	O
position	NN	O
related	VBN	O
to	TO	O
increased	VBN	O
arterial	JJ	O
blood	NN	O
saturation	NN	O
levels	NNS	O
and	CC	O
decreased	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
pulse	NN	O
and	CC	O
respiration	NN	O
?	.	O
(	(	O
2	CD	O
)	)	O
What	WP	O
is	VBZ	O
the	DT	O
relationship	NN	O
between	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
--	:	O
oxygenation	NN	O
saturation	NN	O
levels	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
pulse	NN	O
and	CC	O
respiration	NN	O
--	:	O
and	CC	O
the	DT	O
independent	JJ	O
variables	NNS	O
--	:	O
body	NN	O
position	NN	O
and	CC	O
time	NN	O
in	IN	O
the	DT	O
position	NN	O
?	.	O
Thirty-nine	JJ	SS
patients	NNS	O
with	IN	O
unilateral	JJ	C
lung	NN	C
pathology	NN	C
were	VBD	O
positioned	VBN	O
on	IN	O
their	PRP$	O
sides	NNS	O
with	IN	O
the	DT	O
unaffected	JJ	O
lung	NN	O
down	RP	O
,	,	O
on	IN	O
their	PRP$	O
sides	NNS	O
with	IN	O
the	DT	O
affected	JJ	O
lung	NN	O
down	RB	O
,	,	O
and	CC	O
also	RB	O
in	IN	O
semi-Fowler	NN	O
's	POS	O
position	NN	O
.	.	O

Arterial	NNP	O
(	(	O
SaO2	NNP	O
)	)	O
blood	NN	O
saturation	NN	O
and	CC	O
vital	JJ	O
signs	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
0	CD	O
,	,	O
15	CD	O
and	CC	O
30	CD	O
minutes	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
relationship	NN	O
between	IN	O
oxygenation	NN	O
level	NN	O
or	CC	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Diastolic	NNP	O
blood	NN	O
pressure	NN	O
,	,	O
respiration	NN	O
and	CC	O
pulse	NN	O
did	VBD	O
vary	JJ	O
significantly	RB	O
with	IN	O
position	NN	O
.	.	O

Albendazole	JJ	O
trial	NN	O
at	IN	O
15	CD	O
or	CC	O
30	CD	O
mg/kg/day	NN	O
for	IN	O
subarachnoid	NN	C
and	CC	O
intraventricular	JJ	C
cysticercosis	NN	C
.	.	O

Thirty-six	JJ	SS
patients	NNS	O
with	IN	O
subarachnoid	JJ	C
and	CC	O
intraventricular	JJ	C
cysticercosis	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
albendazole	NN	O
at	IN	O
15	CD	O
or	CC	O
30	CD	O
mg/kg/day	JJ	O
plus	CC	O
dexamethasone	NN	O
for	IN	O
8	CD	O
days	NNS	O
.	.	O

Results	NNS	O
favored	VBD	O
a	DT	O
higher	JJR	O
dose	NN	O
,	,	O
with	IN	O
larger	JJR	O
cyst	NN	O
reduction	NN	O
on	IN	O
MRI	NNP	O
at	IN	O
90	CD	O
and	CC	O
180	CD	O
days	NNS	O
and	CC	O
higher	JJR	O
albendazole	JJ	O
sulfoxide	NN	O
levels	NNS	O
in	IN	O
plasma	NN	O
.	.	O

An	DT	O
albendazole	JJ	O
course	NN	O
at	IN	O
30	CD	O
mg/kg/day	NN	O
combined	VBN	O
with	IN	O
corticosteroids	NNS	O
is	VBZ	O
safe	JJ	O
and	CC	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
.	.	O

A	DT	O
single	JJ	O
treatment	NN	O
was	VBD	O
insufficient	JJ	O
in	IN	O
intraventricular	JJ	O
and	CC	O
giant	JJ	O
cysts	NNS	O
.	.	O

Sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
adolescent	JJ	A
and	CC	O
young	JJ	A
adult	NN	A
children	NNS	A
of	IN	O
opiate	JJ	C
addicts	NNS	C
:	:	O
outcomes	NNS	O
from	IN	O
the	DT	O
focus	NN	O
on	IN	O
families	NNS	O
prevention	VBP	O
trial	NN	O
and	CC	O
an	DT	O
examination	NN	O
of	IN	O
childhood	NN	O
and	CC	O
concurrent	JJ	O
predictors	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
.	.	O

This	DT	O
study	NN	O
reports	VBZ	O
on	IN	O
rates	NNS	O
and	CC	O
predictors	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
a	DT	O
sample	NN	O
of	IN	O
adolescent	NN	A
and	CC	O
young	JJ	A
adult	NN	A
children	NNS	A
of	IN	O
parents	NNS	O
enrolled	VBN	O
in	IN	O
methadone	NN	O
treatment	NN	O
for	IN	O
opiate	JJ	C
addiction	NN	C
.	.	O

Data	NNS	O
are	VBP	O
from	IN	O
151	CD	SS
participants	NNS	O
(	(	O
80	CD	SS
males	NNS	SE
,	,	O
71	CD	SS
females	NNS	SE
)	)	O
in	IN	O
the	DT	O
Focus	NNP	O
on	IN	O
Families	NNP	O
(	(	O
FOF	NNP	O
)	)	O
project	NN	O
,	,	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
family	NN	O
intervention	NN	O
and	CC	O
a	DT	O
study	NN	O
of	IN	O
the	DT	O
development	NN	O
of	IN	O
at-risk	JJ	O
children	NNS	O
.	.	O

The	DT	O
study	NN	O
participants	NNS	O
are	VBP	O
children	NNS	O
of	IN	O
parents	NNS	O
enrolled	VBN	O
in	IN	O
methadone	NN	O
treatment	NN	O
between	IN	O
1990	CD	O
and	CC	O
1993	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
interviewed	VBN	O
in	IN	O
2005	CD	O
when	WRB	O
they	PRP	O
ranged	VBD	O
in	IN	O
age	NN	O
from	IN	O
15	CD	A
to	TO	A
29	CD	A
years	NNS	O
.	.	O

In	IN	O
the	DT	O
year	NN	O
prior	RB	O
to	TO	O
the	DT	O
follow-up	NN	O
,	,	O
79	CD	O
%	NN	O
of	IN	O
the	DT	O
males	NNS	O
and	CC	O
83	CD	O
%	NN	O
of	IN	O
females	NNS	O
were	VBD	O
sexually	RB	O
active	JJ	O
,	,	O
26	CD	O
%	NN	O
of	IN	O
males	NNS	O
and	CC	O
10	CD	O
%	NN	O
of	IN	O
females	NNS	O
had	VBD	O
more	JJR	O
than	IN	O
one	CD	O
partner	NN	O
in	IN	O
the	DT	O
prior	JJ	O
year	NN	O
,	,	O
and	CC	O
34	CD	O
%	NN	O
of	IN	O
males	NNS	O
and	CC	O
24	CD	O
%	NN	O
of	IN	O
females	NNS	O
reported	VBN	O
having	VBG	O
sex	NN	O
outside	IN	O
of	IN	O
a	DT	O
committed	JJ	O
relationship	NN	O
.	.	O

Twenty-four	CD	O
percent	NN	O
of	IN	O
males	NNS	O
and	CC	O
17	CD	O
%	NN	O
of	IN	O
females	NNS	O
met	VBD	O
criteria	NNS	O
for	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
,	,	O
reporting	VBG	O
casual	JJ	O
or	CC	O
multiple	JJ	O
partners	NNS	O
in	IN	O
the	DT	O
prior	JJ	O
year	NN	O
and	CC	O
inconsistent	NN	O
condom	NN	O
use	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
conditions	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
terms	NNS	O
of	IN	O
any	DT	O
measure	NN	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
examined	VBN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
measures	NNS	O
of	IN	O
parent	NN	O
behavior	NN	O
and	CC	O
family	NN	O
processes	NNS	O
derived	VBN	O
from	IN	O
data	NNS	O
at	IN	O
baseline	NN	O
of	IN	O
the	DT	O
FOF	NNP	O
study	NN	O
predicted	VBD	O
whether	IN	O
participants	NNS	O
engaged	VBN	O
in	IN	O
high-risk	JJ	O
sex	NN	O
.	.	O

Among	IN	O
measures	NNS	O
derived	VBN	O
from	IN	O
data	NNS	O
collected	VBN	O
at	IN	O
long-term	JJ	O
follow-up	NN	O
,	,	O
however	RB	O
,	,	O
having	VBG	O
ever	RB	O
met	VBN	O
criteria	NNS	O
for	IN	O
substance	NN	O
abuse	NN	O
or	CC	O
dependence	NN	O
predicted	VBN	O
greater	JJR	O
likelihood	NN	O
of	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
,	,	O
and	CC	O
being	VBG	O
married	VBD	O
or	CC	O
being	VBG	O
in	IN	O
a	DT	O
romantic	JJ	O
relationship	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
likelihood	NN	O
of	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
.	.	O

The	DT	O
findings	NNS	O
point	NN	O
to	TO	O
the	DT	O
important	JJ	O
role	NN	O
of	IN	O
committed	JJ	O
relationships	NNS	O
in	IN	O
regulating	VBG	O
sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
this	DT	O
population	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
heightened	VBN	O
levels	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
associated	VBN	O
with	IN	O
substance	NN	O
abuse	NN	O
or	CC	O
dependence	NN	O
.	.	O

Allogeneic	NNP	O
marrow	NN	O
transplantation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
myeloid	NN	C
leukemia	NN	C
in	IN	O
the	DT	O
chronic	JJ	C
phase	NN	C
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
irradiation	NN	O
regimens	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
compare	VB	O
two	CD	O
regimens	NNS	O
of	IN	O
total	JJ	O
body	NN	O
irradiation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
myeloid	NN	C
leukemia	NN	C
treated	VBN	O
by	IN	O
allogeneic	JJ	C
marrow	NN	C
transplantation	NN	C
while	IN	O
in	IN	O
the	DT	O
chronic	JJ	C
phase	NN	C
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
cyclophosphamide	JJ	O
120	CD	O
mg/kg	NN	O
followed	VBN	O
by	IN	O
total	JJ	O
body	NN	O
irradiation	NN	O
and	CC	O
marrow	NN	O
from	IN	O
HLA-identical	JJ	O
siblings	NNS	O
.	.	O

Cyclosporine	NNP	O
and	CC	O
methotrexate	NN	O
were	VBD	O
used	VBN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O

Fifty-seven	JJ	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
2.0	CD	O
Gy	NNP	O
fractions	NNS	O
of	IN	O
irradiation	NN	O
daily	NN	O
for	IN	O
6	CD	O
days	NNS	O
and	CC	O
59	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
2.25	CD	O
Gy	NNP	O
fractions	NNS	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

The	DT	O
probabilities	NNS	O
of	IN	O
relapse	NN	O
at	IN	O
4	CD	O
years	NNS	O
were	VBD	O
0.25	CD	O
for	IN	O
the	DT	O
12.0	CD	O
Gy	NNP	O
group	NN	O
and	CC	O
0.00	CD	O
for	IN	O
the	DT	O
15.75	CD	O
Gy	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

The	DT	O
actuarial	JJ	O
probabilities	NNS	O
of	IN	O
survival	NN	O
and	CC	O
relapse-free	JJ	O
survival	NN	O
at	IN	O
4	CD	O
years	NNS	O
were	VBD	O
0.60	CD	O
and	CC	O
0.58	CD	O
among	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
12.0	CD	O
Gy	NNP	O
compared	VBN	O
with	IN	O
0.66	CD	O
and	CC	O
0.66	CD	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
15.75	CD	O
Gy	NNP	O
.	.	O

The	DT	O
4-year	JJ	O
probabilities	NNS	O
of	IN	O
transplant-related	JJ	O
mortality	NN	O
were	VBD	O
0.24	CD	O
and	CC	O
0.34	CD	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.13	NNP	O
)	)	O
while	IN	O
the	DT	O
probability	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
was	VBD	O
0.33	CD	O
for	IN	O
the	DT	O
12.0	CD	O
Gy	NNP	O
group	NN	O
and	CC	O
0.44	CD	O
for	IN	O
the	DT	O
15.75	CD	O
Gy	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.15	NNP	O
)	)	O
.	.	O

The	DT	O
lower	JJR	O
relapse	NN	O
probability	NN	O
in	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
the	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
total	JJ	O
body	NN	O
irradiation	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
improved	JJ	O
survival	NN	O
because	IN	O
mortality	NN	O
from	IN	O
causes	VBZ	O
other	JJ	O
than	IN	O
relapse	NN	O
was	VBD	O
increased	VBN	O
.	.	O

Behavioral	JJ	O
effects	NNS	O
of	IN	O
Org	NNP	O
2766	CD	O
,	,	O
a	DT	O
synthetic	JJ	O
analog	NN	O
of	IN	O
the	DT	O
adrenocorticotrophic	JJ	O
hormone	NN	O
(	(	O
4-9	JJ	O
)	)	O
,	,	O
in	IN	O
14	CD	SS
outpatient	JJ	O
autistic	JJ	C
children	NNS	A
.	.	O

Fourteen	NNP	SS
children	NNS	A
(	(	O
12	CD	SS
infantile	NN	C
autism	NN	C
full	JJ	O
syndrome	NN	O
present	NN	O
,	,	O
2	CD	SS
atypical	JJ	C
pervasive	JJ	C
developmental	JJ	C
disorder	NN	C
)	)	O
between	IN	O
5	CD	A
and	CC	A
13	CD	A
years	NNS	O
of	IN	O
age	NN	O
participated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
cross-over	JJ	O
trial	NN	O
.	.	O

Each	DT	O
child	NN	O
received	VBD	O
20	CD	O
mg	NNS	O
Org	JJ	O
2766	CD	O
(	(	O
synthetic	JJ	O
analog	NN	O
of	IN	O
ACTH	NNP	O
4-9	JJ	O
)	)	O
/day	NN	O
during	IN	O
4	CD	O
weeks	NNS	O
,	,	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomly	NN	O
assigned	VBN	O
sequence	NN	O
.	.	O

Drug	JJ	O
effects	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
ethological	JJ	O
playroom	NN	O
observation	NN	O
and	CC	O
by	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
ratings	NNS	O
by	IN	O
parents	NNS	O
and	CC	O
teachers	NNS	O
.	.	O

Data	NNP	O
of	IN	O
the	DT	O
playroom	NN	O
observation	NN	O
pointed	VBD	O
to	TO	O
an	DT	O
activating	VBG	O
influence	NN	O
of	IN	O
Org	NNP	O
2766	CD	O
,	,	O
as	IN	O
revealed	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
of	IN	O
stereotypic	NN	O
behavior	NN	O
and	CC	O
significant	JJ	O
increases	NNS	O
in	IN	O
change	NN	O
toys	NNS	O
,	,	O
locomote	NN	O
,	,	O
and	CC	O
talk	NN	O
.	.	O

Checklist	JJ	O
ratings	NNS	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
changes	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Human	NNP	O
recombinant	JJ	O
GM-CSF	NNP	O
in	IN	O
allogeneic	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
for	IN	O
leukaemia	NN	O
:	:	O
double-blind	JJ	O
placebo	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

A	DT	O
double-blind	NN	O
randomised	VBN	O
trial	NN	O
compared	VBN	O
20	CD	SS
patients	NNS	O
with	IN	O
leukaemia	JJ	C
receiving	VBG	O
human	JJ	O
recombinant	JJ	O
granulocyte	NN	O
macrophage	NN	O
colony	NN	O
stimulating	VBG	O
factor	NN	O
(	(	O
GM	NNP	O
CSF	NNP	O
)	)	O
,	,	O
with	IN	O
20	CD	SS
patients	NNS	O
receiving	VBG	O
placebo	NN	O
for	IN	O
14	CD	O
days	NNS	O
after	IN	O
allogeneic	JJ	O
matched	VBD	O
sibling	VBG	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
.	.	O

The	DT	O
median	JJ	O
neutrophil	NN	O
count	NN	O
at	IN	O
14	CD	O
days	NNS	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
GM	NNP	O
CSF	NNP	O
group	NN	O
(	(	O
1.90	CD	O
vs.	FW	O
0.46	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/l	NN	O
)	)	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
antibiotic	JJ	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
fever	JJ	O
days	NNS	O
was	VBD	O
the	DT	O
same	JJ	O
for	IN	O
both	DT	O
patient	JJ	O
groups	NNS	O
.	.	O

The	DT	O
lymphocyte	NN	O
count	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
GM-CSF	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
between	IN	O
days	NNS	O
10	CD	O
and	CC	O
15	CD	O
after	IN	O
transplantation	NN	O
.	.	O

The	DT	O
GM-CSF	NNP	O
group	NN	O
had	VBD	O
lower	JJR	O
haemoglobin	NN	O
concentrations	NNS	O
and	CC	O
platelets	NNS	O
counts	NNS	O
,	,	O
and	CC	O
higher	JJR	O
plasma	NN	O
urea	JJ	O
creatinine	NN	O
and	CC	O
bilirubin	NN	O
,	,	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
GM	NNP	O
CSF	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
leukaemic	JJ	O
relapse	NN	O
.	.	O

How	WRB	O
to	TO	O
establish	VB	O
equivalence	NN	O
when	WRB	O
data	NNS	O
are	VBP	O
censored	VBN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
treatments	NNS	O
for	IN	O
B	NNP	C
non-Hodgkin	JJ	C
lymphoma	NN	C
.	.	O

Interest	NN	O
in	IN	O
equivalence	NN	O
trials	NNS	O
has	VBZ	O
been	VBN	O
increasing	VBG	O
for	IN	O
many	JJ	O
years	NNS	O
,	,	O
though	IN	O
the	DT	O
methodology	NN	O
which	WDT	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
such	JJ	O
trials	NNS	O
is	VBZ	O
mainly	RB	O
for	IN	O
uncensored	JJ	O
data	NNS	O
.	.	O

In	IN	O
cancer	NN	O
research	NN	O
we	PRP	O
are	VBP	O
more	RBR	O
often	RB	O
concerned	VBN	O
with	IN	O
survival	NN	O
.	.	O

In	IN	O
an	DT	O
efficacy	NN	O
trial	NN	O
,	,	O
the	DT	O
null	JJ	O
hypothesis	NN	O
specifies	NNS	O
equality	NN	O
of	IN	O
the	DT	O
two	CD	O
survival	JJ	O
distributions	NNS	O
,	,	O
but	CC	O
in	IN	O
an	DT	O
equivalence	NN	O
trial	NN	O
,	,	O
a	DT	O
null	JJ	O
hypothesis	NN	O
of	IN	O
inequivalence	NN	O
H0	NNP	O
has	VBZ	O
to	TO	O
be	VB	O
tested	VBN	O
.	.	O

The	DT	O
usual	JJ	O
logrank	NN	O
test	NN	O
has	VBZ	O
to	TO	O
be	VB	O
modified	VBN	O
to	TO	O
test	VB	O
whether	IN	O
the	DT	O
true	JJ	O
value	NN	O
r	NN	O
of	IN	O
the	DT	O
ratio	NN	O
of	IN	O
hazard	NN	O
rates	NNS	O
in	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
is	VBZ	O
at	IN	O
least	JJS	O
equal	JJ	O
to	TO	O
a	DT	O
limit	NN	O
value	NN	O
r0	NN	O
.	.	O

If	IN	O
prognostic	JJ	O
factors	NNS	O
have	VBP	O
to	TO	O
be	VB	O
taken	VBN	O
into	IN	O
account	NN	O
,	,	O
the	DT	O
Cox	NNP	O
model	NN	O
provides	VBZ	O
tests	NNS	O
of	IN	O
Ho	NNP	O
,	,	O
and	CC	O
a	DT	O
useful	JJ	O
confidence	NN	O
interval	NN	O
for	IN	O
the	DT	O
adjusted	JJ	O
relative	JJ	O
derived	VBN	O
from	IN	O
the	DT	O
regression	NN	O
parameter	NN	O
for	IN	O
the	DT	O
treatment	NN	O
indicator	NN	O
.	.	O

An	DT	O
equivalence	NN	O
trial	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
children	NNS	A
with	IN	O
B	NNP	C
non-Hodgkin	JJ	C
lymphoma	NN	C
,	,	O
and	CC	O
serves	VBZ	O
as	IN	O
an	DT	O
illustration	NN	O
.	.	O

Long	RB	O
pediatric	JJ	O
colonoscope	NN	O
versus	NN	O
intermediate	JJ	O
length	NN	O
adult	NN	O
colonoscope	NN	O
for	IN	O
colonoscopy	NN	O
.	.	O

BACKGROUND	NNP	O
Controversy	NNP	O
exists	VBZ	O
on	IN	O
how	WRB	O
the	DT	O
length	NN	O
and	CC	O
diameter	NN	O
of	IN	O
colonoscopes	NNS	O
affect	VBP	O
the	DT	O
quality	NN	O
of	IN	O
colonoscopy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
long	JJ	O
pediatric	JJ	O
colonoscope	NN	O
with	IN	O
an	DT	O
intermediate	JJ	O
length	NN	O
adult	NN	O
colonoscope	NN	O
with	IN	O
regards	NNS	O
to	TO	O
completion	NN	O
rate	NN	O
and	CC	O
cecal	JJ	O
intubation	NN	O
time	NN	O
.	.	O

Whether	CC	O
either	DT	O
scope	NN	O
may	MD	O
be	VB	O
more	RBR	O
efficient	JJ	O
in	IN	O
any	DT	O
subgroups	NN	O
was	VBD	O
also	RB	O
investigated	VBN	O
.	.	O

METHODS	NNP	O
Asymptomatic	JJ	C
patients	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
physical	JJ	O
check-up	JJ	O
department	NN	O
of	IN	O
Buddhist	NNP	O
Dalin	NNP	O
Tzu	NNP	O
Chi	NNP	O
General	NNP	O
Hospital	NNP	O
were	VBD	O
included	VBN	O
.	.	O

A	DT	O
single	JJ	O
endoscopist	NN	O
performed	VBD	O
all	DT	O
of	IN	O
the	DT	O
colonoscopic	NN	O
examinations	NNS	O
under	IN	O
sedation	NN	O
.	.	O

Consecutive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
colonoscopy	NN	O
with	IN	O
either	DT	O
intermediate	JJ	O
length	NN	O
adult	NN	O
colonoscope	NN	O
(	(	O
CF-240I	NNP	O
)	)	O
or	CC	O
long	JJ	O
pediatric	JJ	O
colonoscope	NN	O
(	(	O
PCF-240L	NNP	O
)	)	O
.	.	O

The	DT	O
success	NN	O
rate	NN	O
and	CC	O
time	NN	O
required	VBN	O
to	TO	O
reach	VB	O
cecum	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
April	NNP	O
2005	CD	O
and	CC	O
February	NNP	O
2006	CD	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
918	CD	SS
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Incomplete	NNP	O
colonoscopy	NN	O
occurred	VBD	O
in	IN	O
21	CD	O
(	(	O
2.3	CD	O
%	NN	O
)	)	O
cases	NNS	O
(	(	O
14	CD	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
and	CC	O
seven	CD	O
in	IN	O
the	DT	O
PCF-240L	NNP	O
group	NN	O
,	,	O
P	NNP	O
>	NNP	O
0.1	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
cecal	JJ	O
mean	NN	O
insertion	NN	O
time	NN	O
was	VBD	O
6.00	CD	O
+/-	JJ	O
3.66	CD	O
min	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
CF-240I	NNP	O
and	CC	O
PCF	NNP	O
240L	CD	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
cecal	JJ	O
intubation	NN	O
rate	NN	O
(	(	O
96.9	CD	O
%	NN	O
vs	JJ	O
98.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.18	CD	O
)	)	O
,	,	O
the	DT	O
need	NN	O
for	IN	O
abdominal	JJ	O
pressure	NN	O
(	(	O
71.7	CD	O
%	NN	O
vs	JJ	O
73.4	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.55	CD	O
)	)	O
and	CC	O
change	NN	O
of	IN	O
position	NN	O
(	(	O
13.5	CD	O
%	NN	O
vs	JJ	O
11.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.37	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cecal	JJ	O
intubation	NN	O
time	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
(	(	O
5.75	CD	O
+/-	JJ	O
3.18	CD	O
vs	JJ	O
6.26	CD	O
+/-	JJ	O
3.30	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Subgroup	NNP	O
analysis	NN	O
by	IN	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
showed	VBD	O
comparable	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
except	IN	O
that	IN	O
the	DT	O
cecal	JJ	O
intubation	NN	O
times	NNS	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
when	WRB	O
only	RB	O
men	NNS	O
(	(	O
4.78	CD	O
+/-	JJ	O
2.57	CD	O
vs	JJ	O
5.50	CD	O
+/-	JJ	O
2.93	CD	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
or	CC	O
those	DT	O
younger	JJR	O
than	IN	O
50	CD	O
years	NNS	O
(	(	O
5.50	CD	O
+/-	JJ	O
2.90	CD	O
vs	JJ	O
6.25	CD	O
+/-	JJ	O
3.68	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
were	VBD	O
considered	VBN	O
.	.	O

CONCLUSION	NNP	O
Cecal	NNP	O
intubation	NN	O
time	NN	O
is	VBZ	O
shorter	RBR	O
in	IN	O
patients	NNS	O
examined	VBN	O
with	IN	O
an	DT	O
intermediate	JJ	O
length	NN	O
adult	NN	O
colonoscope	NN	O
,	,	O
mainly	RB	O
in	IN	O
the	DT	O
subgroups	NNS	O
of	IN	O
men	NNS	O
and	CC	O
those	DT	O
younger	JJR	O
than	IN	O
50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Fine	NNP	O
needle	JJ	O
aspiration	NN	O
coupled	VBN	O
with	IN	O
real-time	JJ	O
PCR	NNP	O
:	:	O
a	DT	O
painless	JJ	O
methodology	NN	O
to	TO	O
study	VB	O
adaptive	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
skeletal	JJ	O
muscle	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
In	IN	O
this	DT	O
study	NN	O
we	PRP	O
developed	VBD	O
a	DT	O
new	JJ	O
methodology	NN	O
for	IN	O
obtaining	VBG	O
human	JJ	O
skeletal	JJ	O
muscle	NN	O
samples	NNS	O
to	TO	O
evaluate	VB	O
gene	NN	O
expression	NN	O
.	.	O

This	DT	O
approach	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
a	DT	O
fine	JJ	O
needle	JJ	O
aspiration	NN	O
technique	NN	O
,	,	O
which	WDT	O
allows	VBZ	O
us	PRP	O
to	TO	O
extract	VB	O
a	DT	O
small	JJ	O
tissue	NN	O
sample	NN	O
in	IN	O
a	DT	O
significantly	RB	O
less	RBR	O
invasive	JJ	O
manner	NN	O
than	IN	O
with	IN	O
classic	JJ	O
biopsy	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Multiplex	NNP	O
tandem	VBD	O
RT-PCR	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
mRNA	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
ATP	NNP	O
production	NN	O
and	CC	O
mitochondrial	JJ	O
biogenesis	NN	O
in	IN	O
muscle	NN	O
tissue	NN	O
.	.	O

Samples	NNS	O
of	IN	O
vastus	NN	O
lateralis	NNS	O
muscle	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
21	CD	SS
healthy	JJ	C
subjects	NNS	C
with	IN	O
different	JJ	O
fitness	NN	C
levels	NNS	C
.	.	O

The	DT	O
principal	JJ	O
findings	NNS	O
in	IN	O
our	PRP$	O
study	NN	O
show	VB	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
PGC-1alpha	NNP	O
and	CC	O
COX5B	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
between	IN	O
PGC-1alpha	NNP	O
and	CC	O
MT-CO2	NNP	O
(	(	O
p=0.017	NN	O
)	)	O
expression	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
a	DT	O
significant	JJ	O
positive	JJ	O
correlation	NN	O
between	IN	O
mtDNA	NN	O
content	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
MHCI	NNP	O
present	NN	O
in	IN	O
the	DT	O
aspired	JJ	O
samples	NNS	O
were	VBD	O
found	VBN	O
(	(	O
p=0.028	NN	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
are	VBP	O
in	IN	O
agreement	NN	O
with	IN	O
current	JJ	O
knowledge	NN	O
on	IN	O
skeletal	JJ	O
muscle	NN	O
physiology	NN	O
and	CC	O
show	VB	O
the	DT	O
reliability	NN	O
of	IN	O
the	DT	O
proposed	VBN	O
method	NN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
painless	JJ	O
methodology	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
investigate	VB	O
,	,	O
in	IN	O
vivo	NN	O
,	,	O
human	JJ	O
muscle	NN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
adaptations	NNS	O
in	IN	O
response	NN	O
to	TO	O
either	DT	O
physiological	JJ	O
and/or	NN	O
pharmacological	JJ	O
stimuli	NN	O
.	.	O

This	DT	O
method	NN	O
has	VBZ	O
major	JJ	O
clinical	JJ	O
relevance	NN	O
,	,	O
such	JJ	O
as	IN	O
its	PRP$	O
application	NN	O
in	IN	O
clarifying	VBG	O
the	DT	O
mechanisms	NN	O
underling	VBG	O
metabolic	JJ	O
and	CC	O
systemic	JJ	O
disorders	NNS	O
.	.	O

Is	VBZ	O
chronic	JJ	O
sildenafil	NN	O
therapy	NN	O
safe	JJ	O
and	CC	O
clinically	RB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
systolic	JJ	C
heart	NN	C
failure	NN	C
?	.	O
Sildenafil	NNP	O
is	VBZ	O
a	DT	O
selective	JJ	O
phosphodiesterase-5	JJ	O
inhibitor	NN	O
and	CC	O
causes	VBZ	O
vasodilatation	NN	O
,	,	O
particularly	RB	O
in	IN	O
pulmonary	JJ	O
circulation	NN	O
.	.	O

Since	IN	O
left	JJ	C
heart	NN	C
failure	NN	C
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
out	IN	O
of	IN	O
proportion	NN	O
to	TO	O
left	VB	O
heart	NN	O
disease	NN	O
,	,	O
sildenafil	NN	O
may	MD	O
have	VB	O
beneficial	JJ	O
effect	NN	O
in	IN	O
such	JJ	O
patients	NNS	O
.	.	O

The	DT	O
present	JJ	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
12-week	JJ	O
,	,	O
single-center	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
sildenafil	NN	O
on	IN	O
mean	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
primary	JJ	O
endpoint	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	C
systolic	JJ	C
heart	NN	C
failure	NN	C
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
exercise	NN	O
capacity	NN	O
assessed	VBN	O
by	IN	O
6-minute	JJ	O
walk	NN	O
test	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
106	CD	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
1:1	CD	O
to	TO	O
sildenafil	VB	O
(	(	O
n=53	NN	SS
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=53	JJ	SS
)	)	O
.	.	O

Patients	NNS	O
received	VBD	O
sildenafil	JJ	O
25	CD	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
or	CC	O
matching	VBG	O
placebo	NN	O
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
and	CC	O
50	CD	O
mg	NN	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

The	DT	O
placebo-corrected	JJ	O
effect	NN	O
on	IN	O
mean	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
1.16	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-1.6	VBP	O
to	TO	O
5.1	CD	O
,	,	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
,	,	O
demonstrating	VBG	O
that	IN	O
sildenafil	NN	O
did	VBD	O
not	RB	O
decrease	VB	O
mean	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
sildenafil	NN	O
increased	VBD	O
the	DT	O
6-minute	JJ	O
walk	NN	O
test	NN	O
by	IN	O
a	DT	O
nonsignificant	JJ	O
treatment	NN	O
effect	NN	O
of	IN	O
14	CD	O
m	NN	O
(	(	O
P=.67	NNP	O
)	)	O
.	.	O

Adverse	JJ	O
effects	NNS	O
occurred	VBD	O
in	IN	O
a	DT	O
comparable	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
taking	VBG	O
sildenafil	JJ	O
and	CC	O
placebo	NN	O
,	,	O
and	CC	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
needed	VBN	O
to	TO	O
discontinue	VB	O
therapy	NN	O
.	.	O

Sildenafil	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
in	IN	O
left	JJ	O
heart	NN	O
failure	NN	O
patients	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
decrease	VB	O
blood	NN	O
pressure	NN	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
safely	RB	O
added	VBN	O
to	TO	O
standard	VB	O
heart	NN	O
failure	NN	O
therapy	NN	O
.	.	O

Rationale	NNP	O
and	CC	O
design	NN	O
of	IN	O
RE-LY	NNP	O
:	:	O
randomized	JJ	O
evaluation	NN	O
of	IN	O
long-term	JJ	O
anticoagulant	JJ	O
therapy	NN	O
,	,	O
warfarin	NN	O
,	,	O
compared	VBN	O
with	IN	O
dabigatran	NN	O
.	.	O

Vitamin	NNP	O
K	NNP	O
antagonists	NNS	O
(	(	O
VKAs	NNP	O
)	)	O
are	VBP	O
effective	JJ	O
for	IN	O
stroke	NN	O
prevention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	C
fibrillation	NN	C
(	(	O
AF	NNP	C
)	)	O
but	CC	O
are	VBP	O
difficult	JJ	O
to	TO	O
use	VB	O
.	.	O

Dabigatran	NNP	O
etexilate	NN	O
is	VBZ	O
a	DT	O
prodrug	NN	O
that	WDT	O
is	VBZ	O
rapidly	RB	O
converted	VBN	O
to	TO	O
the	DT	O
active	JJ	O
direct	JJ	O
thrombin	NN	O
inhibitor	NN	O
dabigatran	NN	O
.	.	O

It	PRP	O
is	VBZ	O
administered	VBN	O
in	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
without	IN	O
laboratory	JJ	O
monitoring	NN	O
and	CC	O
is	VBZ	O
being	VBG	O
compared	VBN	O
with	IN	O
warfarin	NN	O
(	(	O
international	JJ	O
normalized	VBN	O
ratio	JJ	O
2-3	JJ	O
)	)	O
in	IN	O
the	DT	O
RE-LY	JJ	O
trial	NN	O
.	.	O

Two	CD	O
doses	NNS	O
of	IN	O
dabigatran	NN	O
(	(	O
110	CD	O
and	CC	O
150	CD	O
mg	NNS	O
BID	NNP	O
)	)	O
are	VBP	O
being	VBG	O
evaluated	VBN	O
.	.	O

RE-LY	NNP	O
is	VBZ	O
a	DT	O
phase	NN	O
3	CD	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
multinational	NN	O
(	(	O
44	CD	O
countries	NNS	O
)	)	O
trial	NN	O
of	IN	O
patients	NNS	O
with	IN	O
nonvalvular	JJ	C
AF	NNP	C
and	CC	O
at	IN	O
least	JJS	O
1	CD	O
risk	NN	O
factor	NN	O
for	IN	O
stroke	NN	O
.	.	O

Recruitment	NNP	O
concluded	VBD	O
with	IN	O
a	DT	O
total	NN	O
of	IN	O
18,113	CD	SS
patients	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
were	VBD	O
VKA-naive	NNP	O
and	CC	O
experienced	VBN	O
are	VBP	O
included	VBN	O
in	IN	O
balanced	JJ	O
proportions	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
is	VBZ	O
stroke	VBN	O
(	(	O
including	VBG	O
hemorrhagic	NN	O
)	)	O
or	CC	O
systemic	JJ	O
embolism	NN	O
.	.	O

Safety	NNP	O
outcomes	NNS	O
are	VBP	O
bleeding	VBG	O
,	,	O
liver	JJ	O
function	NN	O
abnormalities	NNS	O
,	,	O
and	CC	O
other	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Adjudication	NN	O
of	IN	O
end	NN	O
points	NNS	O
is	VBZ	O
blinded	VBN	O
to	TO	O
drug	NN	O
assignment	NN	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
accrue	VB	O
a	DT	O
minimum	NN	O
of	IN	O
450	CD	O
events	NNS	O
with	IN	O
a	DT	O
minimum	JJ	O
1-year	JJ	O
of	IN	O
follow-up	JJ	O
.	.	O

RE-LY	NN	O
is	VBZ	O
the	DT	O
largest	JJS	O
AF	NNP	O
stroke	VBD	O
prevention	NN	O
trial	NN	O
yet	RB	O
undertaken	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
unique	JJ	O
because	IN	O
it	PRP	O
includes	VBZ	O
equal	JJ	O
numbers	NNS	O
of	IN	O
VKA-experienced	NNP	O
and	CC	O
naive	JJ	O
patients	NNS	O
and	CC	O
evaluates	VBZ	O
2	CD	O
different	JJ	O
dosages	NNS	O
of	IN	O
dabigatran	NN	O
,	,	O
which	WDT	O
may	MD	O
allow	VB	O
tailoring	NN	O
of	IN	O
dosing	VBG	O
to	TO	O
individual	JJ	O
patient	NN	O
needs	NNS	O
.	.	O

The	DT	O
worldwide	JJ	O
site	NN	O
distribution	NN	O
and	CC	O
broad	JJ	O
range	NN	O
of	IN	O
stroke	NN	O
risk	NN	O
further	RBR	O
increase	VB	O
the	DT	O
general	JJ	O
applicability	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Results	NNS	O
are	VBP	O
expected	VBN	O
in	IN	O
2009	CD	O
.	.	O

Chemotherapy	NN	O
of	IN	O
large	JJ	C
bowel	NN	C
carcinoma	NN	C
--	:	O
fluorouracil	NN	O
(	(	O
FU	NNP	O
)	)	O
+	VBP	O
hydroxyurea	NN	O
(	(	O
HU	NNP	O
)	)	O
vs.	FW	O
methyl-CCNU	NN	O
,	,	O
oncovin	NN	O
,	,	O
fluorouracil	NN	O
,	,	O
and	CC	O
streptozotocin	NN	O
(	(	O
MOF-Strep	NNP	O
)	)	O
.	.	O

An	DT	O
Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
of	IN	O
initial	JJ	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	C
measurable	JJ	C
metastatic	JJ	C
large	JJ	C
bowel	NN	C
carcinoma	NN	C
,	,	O
the	DT	O
response	NN	O
rate	NN	O
was	VBD	O
6/32	CD	O
(	(	O
19	CD	O
%	NN	O
)	)	O
for	IN	O
FU	NNP	O
+	NNP	O
HU	NNP	O
and	CC	O
5/32	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
for	IN	O
MOF-Strep	NNP	O
;	:	O
the	DT	O
estimated	JJ	O
median	JJ	O
survival	NN	O
is	VBZ	O
43	CD	O
weeks	NNS	O
for	IN	O
both	DT	O
treatments	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
MOF-Strep	NNP	O
experienced	VBD	O
substantially	RB	O
greater	JJR	O
vomiting	VBG	O
and	CC	O
hematologic	JJ	O
toxicity	NN	O
than	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
FU	NNP	O
+	NNP	O
HU	NNP	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
tonabersat	NN	O
on	IN	O
migraine	NN	C
with	IN	C
aura	NN	C
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Migraine	NNP	O
with	IN	O
aura	NN	O
is	VBZ	O
thought	VBN	O
likely	RB	O
to	TO	O
be	VB	O
caused	VBN	O
by	IN	O
cortical	JJ	O
spreading	VBG	O
depression	NN	O
(	(	O
CSD	NNP	O
)	)	O
.	.	O

Tonabersat	NNP	O
inhibits	VBZ	O
CSD	NNP	O
,	,	O
and	CC	O
we	PRP	O
therefore	RB	O
investigated	VBD	O
whether	IN	O
tonabersat	NN	O
has	VBZ	O
a	DT	O
preventive	JJ	O
effect	NN	O
in	IN	O
migraine	NN	O
with	IN	O
aura	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
,	,	O
40	CD	O
mg	NN	O
tonabersat	NN	O
once	IN	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
matched	JJ	O
placebo	NN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	C
aura	NN	C
attack	NN	C
per	IN	C
month	NN	C
during	IN	O
the	DT	O
past	JJ	O
3	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
by	IN	O
computer-generated	JJ	O
list	NN	O
.	.	O

Patients	NNS	O
kept	VBD	O
a	DT	O
detailed	JJ	O
diary	NN	O
to	TO	O
enable	VB	O
objective	JJ	O
diagnosis	NN	O
of	IN	O
each	DT	O
attack	NN	O
as	IN	O
migraine	NN	O
with	IN	O
aura	NN	O
,	,	O
migraine	NN	O
without	IN	O
aura	NN	O
,	,	O
or	CC	O
other	JJ	O
type	NN	O
of	IN	O
headache	NN	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
were	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
aura	NN	O
attacks	NNS	O
with	IN	O
or	CC	O
without	IN	O
headache	NN	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
migraine	JJ	O
headache	NN	O
days	NNS	O
with	IN	O
or	CC	O
without	IN	O
an	DT	O
aura	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
,	,	O
number	NN	O
NCT00332007	NNP	O
.	.	O

FINDINGS	NNP	O
39	CD	SS
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
of	IN	O
whom	WP	O
31	CD	SS
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
statistical	JJ	O
analysis	NN	O
of	IN	O
efficacy	NN	O
.	.	O

Median	JJ	O
(	(	O
IQR	NNP	O
)	)	O
attacks	NNS	O
of	IN	O
aura	NN	O
were	VBD	O
reduced	VBN	O
from	IN	O
3.2	CD	O
(	(	O
1.0-5.0	JJ	O
)	)	O
per	IN	O
12	CD	O
weeks	NNS	O
on	IN	O
placebo	NN	O
to	TO	O
1.0	CD	O
(	(	O
0-3.0	CD	O
)	)	O
on	IN	O
tonabersat	NN	O
(	(	O
p=0.01	NN	O
)	)	O
,	,	O
whereas	VBP	O
the	DT	O
other	JJ	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
,	,	O
median	JJ	O
migraine	NN	O
headache	NN	O
days	NNS	O
with	IN	O
or	CC	O
without	IN	O
aura	NN	O
,	,	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
placebo	NN	O
and	CC	O
tonabersat	NN	O
groups	NNS	O
(	(	O
3.0	CD	O
days	NNS	O
in	IN	O
each	DT	O
group	NN	O
;	:	O
p=0.09	NN	O
)	)	O
.	.	O

Tonabersat	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
but	CC	O
overall	JJ	O
had	VBD	O
more	RBR	O
side-effects	NNS	O
than	IN	O
placebo	NN	O
.	.	O

INTERPRETATION	NNP	O
Tonabersat	NNP	O
showed	VBD	O
a	DT	O
preventive	JJ	O
effect	NN	O
on	IN	O
attacks	NNS	O
of	IN	O
migraine	NN	O
aura	NN	O
but	CC	O
no	DT	O
efficacy	NN	O
on	IN	O
non-aura	JJ	O
attacks	NNS	O
,	,	O
in	IN	O
keeping	VBG	O
with	IN	O
its	PRP$	O
known	JJ	O
inhibitory	JJ	O
effect	NN	O
on	IN	O
CSD	NNP	O
.	.	O

The	DT	O
results	NNS	O
support	VBD	O
the	DT	O
theory	NN	O
that	IN	O
auras	NNS	O
are	VBP	O
caused	VBN	O
by	IN	O
CSD	NNP	O
and	CC	O
that	IN	O
this	DT	O
phenomenon	NN	O
is	VBZ	O
not	RB	O
involved	VBN	O
in	IN	O
attacks	NNS	O
without	IN	O
aura	NN	O
.	.	O

FUNDING	NN	O
Minster	NNP	O
Pharmaceuticals	NNP	O
;	:	O
Lundbeck	NNP	O
Foundation	NNP	O
.	.	O

Direct	JJ	O
trocar	NN	O
insertion	NN	O
vs.	FW	O
Verres	NNP	O
needle	FW	O
use	NN	O
for	IN	O
laparoscopic	JJ	C
sterilization	NN	C
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
direct	JJ	O
trocar	NN	O
insertion	NN	O
with	IN	O
prior	JJ	O
peritoneal	JJ	O
insufflation	NN	O
with	IN	O
a	DT	O
Verres	NNP	O
needle	NN	O
for	IN	O
laparoscopic	NN	C
tubal	JJ	C
sterilization	NN	C
.	.	O

Direct	JJ	O
trocar	NN	O
insertion	NN	O
resulted	VBD	O
in	IN	O
fewer	JJR	O
instrument	NN	O
insertions	NNS	O
(	(	O
21.8	CD	O
%	NN	O
vs.	FW	O
7.8	CD	O
%	NN	O
)	)	O
and	CC	O
use	NN	O
of	IN	O
smaller	JJR	O
volumes	NNS	O
of	IN	O
CO2	NNP	O
(	(	O
2.67	CD	O
vs.	FW	O
2.32	CD	O
L	NNP	O
)	)	O
.	.	O

Direct	JJ	O
trocar	NN	O
use	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
operating	NN	O
time	NN	O
from	IN	O
9	CD	O
minutes	NNS	O
,	,	O
40	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
needle	JJ	O
group	NN	O
to	TO	O
7	CD	O
minutes	NNS	O
,	,	O
30	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
trocar	NN	O
group	NN	O
.	.	O

Minor	NNP	O
omental	JJ	C
injuries	NNS	C
occurred	VBD	O
in	IN	O
a	DT	O
small	JJ	O
percentage	NN	O
of	IN	O
each	DT	O
group	NN	O
,	,	O
while	IN	O
serious	JJ	O
complications	NNS	O
occurred	VBD	O
once	RB	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Is	VBZ	O
a	DT	O
calculated	JJ	O
total	JJ	O
hip	NN	O
BMD	NNP	O
of	IN	O
clinical	JJ	O
use	NN	O
?	.	O
The	DT	O
diagnosis	NN	O
of	IN	O
osteoporosis	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
bone	NN	O
mass	NN	O
measurement	NN	O
.	.	O

To	TO	O
avoid	VB	O
the	DT	O
errors	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
measurement	NN	O
of	IN	O
spinal	JJ	O
bone	NN	O
density	NN	O
the	DT	O
total	JJ	O
hip	NN	O
has	VBZ	O
been	VBN	O
accepted	VBN	O
as	IN	O
the	DT	O
standard	JJ	O
measurement	NN	O
site	NN	O
.	.	O

This	DT	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
for	IN	O
many	JJ	O
early	JJ	O
measurements	NNS	O
.	.	O

We	PRP	O
have	VBP	O
assessed	VBN	O
whether	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
derive	VB	O
clinically	RB	O
useful	JJ	O
information	NN	O
about	IN	O
total	JJ	O
hip	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
from	IN	O
measurements	NNS	O
at	IN	O
other	JJ	O
hip	NN	O
sites	NNS	O
.	.	O

The	DT	O
bone	NN	O
mass	NN	O
measurements	NNS	O
of	IN	O
46	CD	SS
patients	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
current	JJ	O
trial	NN	O
of	IN	O
therapy	NN	O
for	IN	O
osteoporosis	NN	C
were	VBD	O
reviewed	VBN	O
.	.	O

The	DT	O
total	JJ	O
hip	NN	O
BMD	NNP	O
as	IN	O
directly	RB	O
measured	VBN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
obtained	VBN	O
from	IN	O
the	DT	O
formula	NN	O
:	:	O
Total	JJ	O
hip	NN	O
BMD	NNP	O
=	VBZ	O
0.48	CD	O
x	NN	O
Neck	NNP	O
BMD	NNP	O
+	VBD	O
0.62	CD	O
x	NNP	O
Trochanteric	NNP	O
BMD	NNP	O
+	VBD	O
0.03	CD	O
.	.	O

In	IN	O
30	CD	SS
patients	NNS	O
with	IN	O
follow-up	JJ	O
data	NNS	O
the	DT	O
rate	NN	O
of	IN	O
change	NN	O
in	IN	O
hip	NN	O
BMD	NNP	O
over	IN	O
a	DT	O
year	NN	O
was	VBD	O
also	RB	O
determined	VBN	O
by	IN	O
both	DT	O
methods	NNS	O
.	.	O

In	IN	O
the	DT	O
pretreatment	NN	O
state	NN	O
there	EX	O
was	VBD	O
good	JJ	O
agreement	NN	O
between	IN	O
the	DT	O
two	CD	O
measures	NNS	O
(	(	O
r2	VB	O
=	RB	O
0.96	CD	O
,	,	O
SEE	NNP	O
0.012	CD	O
g/cm2	NN	O
)	)	O
.	.	O

If	IN	O
the	DT	O
formula	NN	O
was	VBD	O
used	VBN	O
to	TO	O
compute	VB	O
a	DT	O
change	NN	O
in	IN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
,	,	O
the	DT	O
agreement	NN	O
between	IN	O
both	DT	O
methods	NNS	O
remained	VBD	O
good	JJ	O
.	.	O

However	RB	O
,	,	O
the	DT	O
standard	JJ	O
error	NN	O
of	IN	O
the	DT	O
estimate	NN	O
of	IN	O
the	DT	O
change	NN	O
represented	VBD	O
59	CD	O
%	NN	O
of	IN	O
the	DT	O
observed	JJ	O
change	NN	O
.	.	O

This	DT	O
indicates	VBZ	O
that	IN	O
the	DT	O
error	NN	O
associated	VBN	O
with	IN	O
this	DT	O
estimate	NN	O
is	VBZ	O
too	RB	O
great	JJ	O
to	TO	O
allow	VB	O
clinically	RB	O
meaningful	JJ	O
conclusions	NNS	O
to	TO	O
be	VB	O
drawn	VBN	O
from	IN	O
calculated	VBN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
whilst	VB	O
it	PRP	O
may	MD	O
be	VB	O
possible	JJ	O
to	TO	O
obtain	VB	O
reasonable	JJ	O
point	NN	O
estimates	NNS	O
of	IN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
from	IN	O
other	JJ	O
measures	NNS	O
in	IN	O
the	DT	O
hip	NN	O
,	,	O
these	DT	O
estimates	NNS	O
are	VBP	O
too	RB	O
imprecise	JJ	O
to	TO	O
allow	VB	O
conclusions	NNS	O
about	IN	O
change	NN	O
in	IN	O
BMD	NNP	O
to	TO	O
be	VB	O
made	VBN	O
.	.	O

Multiple	JJ	O
courses	NNS	O
of	IN	O
rituximab	NN	O
produce	NN	O
sustained	VBD	O
clinical	JJ	O
and	CC	O
radiographic	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	C
arthritis	NN	C
and	CC	O
an	DT	O
inadequate	JJ	O
response	NN	O
to	TO	O
1	CD	O
or	CC	O
more	JJR	O
tumor	JJ	O
necrosis	NN	O
factor	NN	O
inhibitors	NNS	O
:	:	O
5-year	JJ	O
data	NNS	O
from	IN	O
the	DT	O
REFLEX	NNP	O
study	NN	O
.	.	O

OBJECTIVE	VB	O
This	DT	O
5-year	JJ	O
observational	JJ	O
posthoc	NN	O
analysis	NN	O
of	IN	O
the	DT	O
REFLEX	NNP	O
study	NN	O
and	CC	O
its	PRP$	O
open-label	JJ	O
extension	NN	O
assessed	VBD	O
clinical	JJ	O
efficacy	NN	O
,	,	O
radiographic	JJ	O
response	NN	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
rituximab	NN	O
(	(	O
RTX	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	C
)	)	O
who	WP	O
had	VBD	O
an	DT	O
inadequate	JJ	O
response	NN	O
to	TO	O
tumor	VB	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF	NNP	O
)	)	O
inhibitors	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
in	IN	O
REFLEX	NNP	O
were	VBD	O
originally	RB	O
randomized	VBN	O
to	TO	O
placebo	VB	O
(	(	O
PBO	NNP	O
)	)	O
+	NN	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
;	:	O
PBO-randomized	NNP	O
)	)	O
or	CC	O
RTX	NNP	O
+	NNP	O
MTX	NNP	O
(	(	O
RTX-randomized	NNP	O
)	)	O
.	.	O

PBO-randomized	JJ	O
patients	NNS	O
were	VBD	O
rescued	VBN	O
with	IN	O
RTX	NNP	O
as	IN	O
appropriate	JJ	O
.	.	O

Patients	NNS	O
responding	VBG	O
to	TO	O
initial	JJ	O
RTX	NNP	O
treatment	NN	O
could	MD	O
receive	VB	O
further	JJ	O
RTX	NNP	O
courses	NNS	O
.	.	O

For	IN	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
analyses	NNS	O
,	,	O
PBO-randomized	JJ	O
patients	NNS	O
were	VBD	O
re-baselined	JJ	O
prior	NN	O
to	TO	O
first	JJ	O
RTX	NNP	O
treatment	NN	O
and	CC	O
the	DT	O
data	NNS	O
were	VBD	O
pooled	VBN	O
with	IN	O
RTX-randomized	JJ	O
patient	NN	O
data	NNS	O
.	.	O

Efficacy	NNP	O
outcomes	RB	O
24	CD	O
weeks	NNS	O
after	IN	O
each	DT	O
course	NN	O
were	VBD	O
calculated	VBN	O
relative	JJ	O
to	TO	O
first	JJ	O
RTX	NNP	O
pretreatment	NN	O
baseline	NN	O
.	.	O

Radiographic	JJ	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
relative	JJ	O
to	TO	O
randomization	VB	O
baseline	NN	O
for	IN	O
both	DT	O
PBO-randomized	NNP	O
and	CC	O
RTX-randomized	NNP	O
groups	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
480	CD	O
patients	NNS	O
received	VBN	O
?	.	O
1	CD	O
RTX	NNP	O
course	NN	O
.	.	O

At	IN	O
24	CD	O
weeks	NNS	O
,	,	O
American	NNP	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
20/50/70	CD	O
responses	NNS	O
were	VBD	O
62.0	CD	O
%	NN	O
,	,	O
30.8	CD	O
%	NN	O
,	,	O
and	CC	O
13.0	CD	O
%	NN	O
,	,	O
respectively	RB	O
at	IN	O
course	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
400	CD	O
)	)	O
and	CC	O
70.3	CD	O
%	NN	O
,	,	O
41.8	CD	O
%	NN	O
,	,	O
and	CC	O
22.0	CD	O
%	NN	O
at	IN	O
course	NN	O
5	CD	O
(	(	O
n	JJ	O
=	NNP	O
91	CD	O
)	)	O
.	.	O

European	JJ	O
League	NNP	O
Against	NNP	O
Rheumatism	NNP	O
good/moderate	NN	O
responses	NNS	O
were	VBD	O
77.2	CD	O
%	NN	O
and	CC	O
84.4	CD	O
%	NN	O
at	IN	O
courses	NNS	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
390	CD	O
)	)	O
and	CC	O
5	CD	O
(	(	O
n	JJ	O
=	NNP	O
90	CD	O
)	)	O
.	.	O

Rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
,	,	O
serious	JJ	O
AE	NNP	O
,	,	O
and	CC	O
infections	NNS	O
generally	RB	O
remained	VBD	O
stable	JJ	O
.	.	O

Rate	NNP	O
of	IN	O
progressive	JJ	O
joint	JJ	O
damage	NN	O
(	(	O
PJD	NNP	O
;	:	O
change	NN	O
in	IN	O
mean	JJ	O
Total	NNP	O
Sharp	NNP	O
Score	NNP	O
)	)	O
decreased	VBD	O
over	RP	O
time	NN	O
in	IN	O
both	DT	O
PBO-randomized	NNP	O
(	(	O
n	JJ	O
=	NNP	O
79	CD	O
)	)	O
and	CC	O
RTX-randomized	NNP	O
(	(	O
n	JJ	O
=	NNP	O
105	CD	O
)	)	O
groups	NNS	O
.	.	O

Mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
PJD	NNP	O
over	IN	O
5	CD	O
years	NNS	O
was	VBD	O
greater	JJR	O
in	IN	O
PBO-randomized	NNP	O
versus	NN	O
RTX-randomized	JJ	O
patients	NNS	O
(	(	O
5.51	CD	O
vs	RB	O
3.21	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
RTX	NNP	O
re-treatment	NN	O
over	IN	O
5	CD	O
years	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
maintained	VBN	O
or	CC	O
improved	VBN	O
efficacy	NN	O
,	,	O
continued	VBD	O
inhibition	NN	O
of	IN	O
PJD	NNP	O
,	,	O
and	CC	O
a	DT	O
safety	NN	O
profile	NN	O
consistent	JJ	O
with	IN	O
that	DT	O
previously	RB	O
reported	VBN	O
.	.	O

A	DT	O
delay	NN	O
in	IN	O
initiating	VBG	O
RTX	NNP	O
treatment	NN	O
may	MD	O
result	VB	O
in	IN	O
increased	JJ	O
PJD	NNP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
breast	NN	O
size	NN	O
on	IN	O
late	JJ	O
radiation	NN	O
effects	NNS	O
and	CC	O
association	NN	O
with	IN	O
radiotherapy	NN	O
dose	JJ	O
inhomogeneity	NN	O
.	.	O

A	DT	O
prospective	JJ	O
assessment	NN	O
of	IN	O
late	JJ	O
changes	NNS	O
in	IN	O
breast	NN	O
appearance	NN	O
in	IN	O
559	CD	SS
patients	NNS	O
after	IN	O
tumour	JJ	C
excision	NN	C
and	CC	O
radiotherapy	NN	C
for	IN	O
early	JJ	C
breast	NN	C
cancer	NN	C
noted	VBD	O
a	DT	O
strong	JJ	O
association	NN	O
with	IN	O
breast	NN	O
size	NN	O
.	.	O

Only	RB	O
3/48	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
small	JJ	O
breasts	NNS	O
developed	VBD	O
moderate	JJ	O
or	CC	O
severe	JJ	O
late	JJ	O
changes	NNS	O
compared	VBN	O
with	IN	O
94/423	CD	O
(	(	O
22	CD	O
%	NN	O
)	)	O
with	IN	O
medium	NN	O
sized	VBN	O
breasts	NNS	O
and	CC	O
34/88	CD	O
(	(	O
39	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

One	CD	O
possibility	NN	O
is	VBZ	O
that	IN	O
greater	JJR	O
radiation	NN	O
changes	NNS	O
are	VBP	O
related	VBN	O
to	TO	O
greater	JJR	O
dose	JJ	O
inhomogeneity	NN	O
in	IN	O
women	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
.	.	O

To	TO	O
explore	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
radiation	NN	O
dose	JJ	O
distributions	NNS	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
separate	JJ	O
group	NN	O
of	IN	O
37	CD	O
women	NNS	O
in	IN	O
whom	WP	O
three-level	JJ	O
transverse	NN	O
computer	NN	O
tomographic	JJ	O
images	NNS	O
of	IN	O
the	DT	O
breast	NN	O
in	IN	O
the	DT	O
treatment	NN	O
position	NN	O
were	VBD	O
available	JJ	O
.	.	O

A	DT	O
significant	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
breast	NN	O
size	NN	O
and	CC	O
dose	NN	O
inhomogeneity	NN	O
which	WDT	O
may	MD	O
account	VB	O
for	IN	O
the	DT	O
marked	JJ	O
changes	NNS	O
in	IN	O
breast	NN	O
appearance	NN	O
reported	VBD	O
in	IN	O
women	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	JJ	O
cortex	NN	O
on	IN	O
Stroop	NNP	O
task	NN	O
performance	NN	O
.	.	O

Several	JJ	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
rTMS	NN	O
)	)	O
can	MD	O
improve	VB	O
cognitive	JJ	O
processing	NN	O
.	.	O

Neuroimaging	VBG	O
studies	NNS	O
have	VBP	O
shown	VBN	O
the	DT	O
engagement	NN	O
of	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
(	(	O
DLPFC	NNP	O
)	)	O
in	IN	O
executive	NN	O
functioning	NN	O
,	,	O
and	CC	O
more	RBR	O
specifically	RB	O
during	IN	O
selective	JJ	O
attention	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
high-frequency	NN	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
DLPFC	NNP	O
on	IN	O
Stroop	NNP	O
task	NN	O
performance	NN	O
in	IN	O
healthy	JJ	C
female	NN	SE
volunteers	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
reaction	NN	O
time	NN	O
on	IN	O
both	CC	O
the	DT	O
incongruent	NN	O
and	CC	O
congruent	NN	O
trials	NNS	O
decreased	VBD	O
significantly	RB	O
after	IN	O
stimulation	NN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
Stroop	NNP	O
interference	NN	O
effect	NN	O
.	.	O

Mood	NNP	O
remained	VBD	O
unchanged	JJ	O
after	IN	O
rTMS	NN	O
.	.	O

Such	PDT	O
a	DT	O
pattern	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
the	DT	O
role	NN	O
of	IN	O
the	DT	O
left	NN	O
DLPFC	NNP	O
in	IN	O
implementing	VBG	O
top-down	JJ	O
attentional	JJ	O
control	NN	O
.	.	O

Propofol	NNP	O
sedation	NN	O
with	IN	O
bispectral	JJ	O
index	NN	O
monitoring	NN	O
is	VBZ	O
useful	JJ	O
for	IN	O
endoscopic	NN	O
submucosal	JJ	O
dissection	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
phase	NN	O
II	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
STUDY	NNP	O
AIMS	NNP	O
Endoscopic	NNP	O
submucosal	NN	O
dissection	NN	O
(	(	O
ESD	NNP	O
)	)	O
has	VBZ	O
become	VBN	O
a	DT	O
standard	JJ	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
treatment	NN	O
time	NN	O
tends	VBZ	O
to	TO	O
be	VB	O
relatively	RB	O
long	JJ	O
and	CC	O
insufflation	NN	O
and	CC	O
manipulation	NN	O
of	IN	O
the	DT	O
endoscope	NN	O
can	MD	O
increase	VB	O
pain	NN	O
and	CC	O
discomfort	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
find	VB	O
an	DT	O
optimal	JJ	O
method	NN	O
for	IN	O
sedation	NN	O
during	IN	O
ESD	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNP	O
scheduled	VBD	O
to	TO	O
undergo	VB	O
ESD	NNP	O
for	IN	O
early	JJ	C
gastric	JJ	C
cancer	NN	C
or	CC	C
adenoma	NN	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
sedation	NN	O
with	IN	O
midazolam	NN	O
or	CC	O
propofol	NN	O
,	,	O
and	CC	O
consciousness	JJ	O
level	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
bispectral	JJ	O
index	NN	O
(	(	O
BIS	NNP	O
)	)	O
monitoring	NN	O
.	.	O

Primary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
effectiveness	NN	O
(	(	O
three	CD	O
parameters	NNS	O
)	)	O
and	CC	O
secondary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
safety	NN	O
during	IN	O
ESD	NNP	O
and	CC	O
after	IN	O
return	NN	O
to	TO	O
the	DT	O
ward	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Study	NNP	O
registration	NN	O
was	VBD	O
in	IN	O
the	DT	O
UMIN	NNP	O
Clinical	NNP	O
Trial	NNP	O
Registry	NNP	O
(	(	O
UMIN	NNP	O
000001497	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
institutional	JJ	O
trial	NN	O
number	NN	O
was	VBD	O
KDOG	NNP	O
0801	CD	O
.	.	O

RESULTS	VBN	O
From	IN	O
June	NNP	O
2008	CD	O
through	IN	O
June	NNP	O
2009	CD	O
,	,	O
we	PRP	O
enrolled	VBD	O
178	CD	SS
patients	NNS	O
(	(	O
90	CD	O
midazolam	NN	O
,	,	O
88	CD	O
propofol	NN	O
)	)	O
.	.	O

Regarding	VBG	O
safety	NN	O
after	IN	O
ESD	NNP	O
,	,	O
recovery	NN	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
propofol	NN	O
group	NN	O
immediately	RB	O
after	IN	O
and	CC	O
at	IN	O
1	CD	O
hour	NN	O
and	CC	O
2	CD	O
hours	NNS	O
after	IN	O
return	NN	O
to	TO	O
the	DT	O
ward	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
required	VBD	O
a	DT	O
continuous	JJ	O
supply	NN	O
of	IN	O
oxygen	NN	O
2	CD	O
hours	NNS	O
after	IN	O
returning	VBG	O
to	TO	O
the	DT	O
ward	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
propofol	NN	O
group	NN	O
(	(	O
midazolam	JJ	O
18	CD	O
;	:	O
propofol	CC	O
6	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
.	.	O

Though	IN	O
propofol	NN	O
seemed	VBD	O
to	TO	O
be	VB	O
better	JJR	O
for	IN	O
effectiveness	NN	O
and	CC	O
safety	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
for	IN	O
all	DT	O
three	CD	O
primary	JJ	O
end	NN	O
points	NNS	O
and	CC	O
the	DT	O
safety	NN	O
parameters	NNS	O
(	(	O
hypotension	NN	O
,	,	O
hypoxia	NN	O
,	,	O
bradycardia	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Propofol	NNP	O
with	IN	O
BIS	NNP	O
monitoring	VBG	O
improved	JJ	O
recovery	NN	O
of	IN	O
patients	NNS	O
after	IN	O
ESD	NNP	O
,	,	O
though	IN	O
this	DT	O
study	NN	O
was	VBD	O
underpowered	VBN	O
to	TO	O
prove	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
propofol	NN	O
.	.	O

A	DT	O
description	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
of	IN	O
patients	NNS	O
recruited	VBN	O
into	IN	O
the	DT	O
Carvedilol	NNP	O
or	CC	O
Metoprolol	NNP	O
European	JJ	O
Trial	NNP	O
(	(	O
COMET	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
&	CC	O
AIMS	NNP	O
The	DT	O
COMET	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
carvedilol	NN	O
,	,	O
a	DT	O
comprehensive	JJ	O
adrenergic	NN	O
receptor	NN	O
antagonist	NN	O
,	,	O
with	IN	O
metoprolol	NN	O
,	,	O
a	DT	O
beta-1-selective	JJ	O
agent	NN	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	C
failure	NN	C
and	CC	O
left	VBD	C
ventricular	JJ	C
systolic	JJ	C
dysfunction	NN	C
.	.	O

The	DT	O
trial	NN	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
mortality	NN	O
with	IN	O
carvedilol	NN	O
that	WDT	O
was	VBD	O
consistent	JJ	O
across	IN	O
subgroups	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
report	NN	O
is	VBZ	O
to	TO	O
describe	VB	O
in	IN	O
greater	JJR	O
detail	NN	O
the	DT	O
heterogeneity	NN	O
of	IN	O
this	DT	O
population	NN	O
at	IN	O
baseline	NN	O
with	IN	O
particular	JJ	O
reference	NN	O
to	TO	O
the	DT	O
impact	NN	O
of	IN	O
symptomatic	JJ	O
severity	NN	O
,	,	O
age	NN	O
and	CC	O
gender	NN	O
on	IN	O
patient	JJ	O
characteristics	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
descriptive	JJ	O
report	NN	O
using	VBG	O
data	NNS	O
entered	VBN	O
in	IN	O
the	DT	O
COMET	NNP	O
study	NN	O
data-base	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
population	NN	O
studied	VBN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
in	IN	O
previous	JJ	O
trials	NNS	O
of	IN	O
beta-blockers	NNS	O
.	.	O

Almost	NNP	O
all	DT	O
patients	NNS	O
were	VBD	O
receiving	VBG	O
diuretics	NNS	O
and	CC	O
ACE	NNP	O
inhibitors	NNS	O
with	IN	O
few	JJ	O
patients	NNS	O
taking	VBG	O
angiotensin	JJ	O
receptor	NN	O
blockers	NNS	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
older	JJR	O
patients	NNS	O
had	VBD	O
more	RBR	O
co-morbidity	JJ	O
.	.	O

Older	JJR	O
patients	NNS	O
and	CC	O
women	NNS	O
reported	VBD	O
worse	JJR	O
symptoms	NNS	O
and	CC	O
poorer	JJR	O
well-being	JJ	O
despite	IN	O
similar	JJ	O
ventricular	JJ	O
dimensions	NNS	O
and	CC	O
systolic	JJ	O
dysfunction	NN	O
.	.	O

NT-proBNP	NNP	O
was	VBD	O
higher	RBR	O
in	IN	O
patients	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
symptoms	NNS	O
and	CC	O
older	JJR	O
patients	NNS	O
but	CC	O
not	RB	O
in	IN	O
women	NNS	O
,	,	O
although	IN	O
differences	NNS	O
in	IN	O
NT-proBNP	NNP	O
may	MD	O
have	VB	O
been	VBN	O
confounded	VBN	O
by	IN	O
differences	NNS	O
in	IN	O
renal	JJ	O
function	NN	O
.	.	O

CONCLUSION	NNP	O
Age	NNP	O
and	CC	O
gender	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
severity	NN	O
of	IN	O
cardiac	JJ	O
dysfunction	NN	O
,	,	O
appear	VBP	O
to	TO	O
have	VB	O
an	DT	O
important	JJ	O
effect	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
heart	NN	O
failure	NN	O
symptoms	NNS	O
and	CC	O
patient	JJ	O
'well-being	NN	O
'	POS	O
.	.	O

This	DT	O
could	MD	O
have	VB	O
important	JJ	O
implications	NNS	O
for	IN	O
the	DT	O
relationship	NN	O
between	IN	O
symptoms	NNS	O
and	CC	O
prognosis	NN	O
and	CC	O
therefore	RB	O
the	DT	O
way	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
are	VBP	O
selected	VBN	O
for	IN	O
clinical	JJ	O
trials	NNS	O
and	CC	O
the	DT	O
goals	NNS	O
of	IN	O
treatment	NN	O
.	.	O

This	DT	O
will	MD	O
be	VB	O
the	DT	O
subject	NN	O
of	IN	O
further	JJ	O
analyses	NNS	O
.	.	O

The	DT	O
prophylactic	JJ	O
effect	NN	O
of	IN	O
valproate	NN	O
on	IN	O
glyceryltrinitrate	NN	O
induced	VBN	O
migraine	NN	C
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
human	JJ	O
glyceryltrinitrate	NN	O
(	(	O
GTN	NNP	O
)	)	O
model	NN	O
of	IN	O
migraine	NN	O
was	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
prophylactic	JJ	O
drug	NN	O
.	.	O

We	PRP	O
chose	VBD	O
to	TO	O
test	VB	O
valproate	NN	O
due	JJ	O
to	TO	O
its	PRP$	O
well	RB	O
documented	JJ	O
effect	NN	O
as	IN	O
a	DT	O
migraine	JJ	O
prophylactic	JJ	O
drug	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
this	DT	O
compound	NN	O
would	MD	O
support	VB	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
model	NN	O
in	IN	O
prophylactic	JJ	O
antimigraine	JJ	O
drug	NN	O
development	NN	O
.	.	O

Twelve	CD	SS
patients	NNS	O
with	IN	O
migraine	NN	C
without	IN	C
aura	NN	C
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
crossover	NN	O
study	NN	O
.	.	O

Valproate	VB	O
1000	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
given	VBN	O
daily	RB	O
,	,	O
each	DT	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
13	CD	O
days	NNS	O
.	.	O

On	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
day	NN	O
of	IN	O
each	DT	O
arm	NN	O
a	DT	O
20	CD	O
min	NN	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
GTN	NNP	O
(	(	O
0.25	CD	O
microg/kg/min	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

Headache	NNP	O
was	VBD	O
registered	VBN	O
for	IN	O
12	CD	O
h	NN	O
after	IN	O
the	DT	O
infusion	NN	O
and	CC	O
headache	NN	O
intensity	NN	O
was	VBD	O
scored	VBN	O
on	IN	O
a	DT	O
scale	NN	O
from	IN	O
0	CD	O
to	TO	O
10	CD	O
.	.	O

Fulfillment	NN	O
of	IN	O
IHS	NNP	O
criteria	NNS	O
was	VBD	O
recorded	VBN	O
for	IN	O
24	CD	O
h.	PDT	O
The	DT	O
middle	JJ	O
cerebral	JJ	O
arteries	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
transcranial	JJ	O
Doppler	NNP	O
and	CC	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
and	CC	O
radial	JJ	O
arteries	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
high	JJ	O
frequency	NN	O
ultrasound	NN	O
.	.	O

GTN	NNP	O
evoked	VBD	O
migraine	JJ	O
fulfilling	NN	O
IHS	NNP	O
criteria	NNS	O
1.1	CD	O
in	IN	O
6	CD	O
patients	NNS	O
after	IN	O
placebo	NN	O
and	CC	O
in	IN	O
2	CD	O
patients	NNS	O
after	IN	O
valproate	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.125	CD	O
)	)	O
.	.	O

Including	VBG	O
additionally	RB	O
3	CD	O
patients	NNS	O
on	IN	O
placebo	NN	O
and	CC	O
1	CD	O
patient	NN	O
on	IN	O
valproate	NN	O
who	WP	O
felt	VBD	O
they	PRP	O
had	VBD	O
suffered	VBN	O
a	DT	O
migraine	JJ	O
attack	NN	O
,	,	O
but	CC	O
who	WP	O
had	VBD	O
as	IN	O
associated	VBN	O
symptoms	NNS	O
only	RB	O
photophobia	VBP	O
or	CC	O
phonophobia	VBP	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
induced	JJ	O
migraine	NN	O
after	IN	O
valproate	NN	O
was	VBD	O
seen	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
.	.	O

Median	JJ	O
peak	NN	O
headache	NN	O
intensity	NN	O
was	VBD	O
1	CD	O
(	(	O
range	VB	O
0-9	NN	O
)	)	O
after	IN	O
valproate	NN	O
compared	VBN	O
to	TO	O
4.5	CD	O
(	(	O
range	VB	O
0-8	NN	O
)	)	O
after	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
valproate	NN	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
reduced	VBN	O
the	DT	O
velocity	NN	O
in	IN	O
both	DT	O
middle	JJ	O
cerebral	NN	O
arteries	NNS	O
after	IN	O
GTN	NNP	O
(	(	O
left	VBN	O
P	NNP	O
=	NNP	O
0.021	CD	O
,	,	O
right	JJ	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
valproate	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
artery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.781	CD	O
)	)	O
or	CC	O
the	DT	O
radial	JJ	O
artery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.367	CD	O
)	)	O
before	IN	O
or	CC	O
after	IN	O
GTN	NNP	O
.	.	O

The	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
a	DT	O
prophylactic	JJ	O
effect	NN	O
of	IN	O
valproate	NN	O
may	MD	O
be	VB	O
demonstrated	VBN	O
using	VBG	O
the	DT	O
GTN	NNP	O
human	JJ	O
migraine	NN	O
model	NN	O
.	.	O

Although	IN	O
,	,	O
all	DT	O
headache	NN	O
parameters	NNS	O
were	VBD	O
reduced	VBN	O
after	IN	O
valproate	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
only	RB	O
one	CD	O
parameter	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
reduced	VBN	O
probably	RB	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
size	NN	O
of	IN	O
the	DT	O
effect	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
valproate	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

The	DT	O
GTN	NNP	O
model	NN	O
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
valid	JJ	O
tool	NN	O
for	IN	O
testing	VBG	O
new	JJ	O
prophylactic	JJ	O
antimigraine	NN	O
drugs	NNS	O
.	.	O

Transurethral	JJ	C
prostate	NN	C
resection	NN	C
and	CC	O
bleeding	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
role	NN	O
of	IN	O
finasteride	NN	O
for	IN	O
decreasing	VBG	O
operative	JJ	O
blood	NN	O
loss	NN	O
.	.	O

PURPOSE	NNP	O
Bleeding	NNP	O
associated	VBN	O
with	IN	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
can	MD	O
often	RB	O
be	VB	O
significant	JJ	O
and	CC	O
lead	JJ	O
to	TO	O
increased	VBN	O
morbidity	NN	O
and	CC	O
occasionally	RB	O
mortality	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
finasteride	NN	O
decreases	VBZ	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
hematuria	NNS	C
of	IN	O
prostatic	JJ	O
origin	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
transurethral	JJ	C
prostate	NN	C
resection	NN	C
could	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
giving	VBG	O
finasteride	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
before	RB	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	JJ	O
70	CD	SS
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
elective	JJ	C
transurethral	JJ	C
prostate	NN	C
resection	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg.	NNS	O
finasteride	JJ	O
daily	RB	O
or	CC	O
placebo	VB	O
for	IN	O
2	CD	O
weeks	NNS	O
before	RB	O
surgery	NN	O
.	.	O

Serum	NNP	O
hemoglobin	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
following	JJ	O
day	NN	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
irrigation	NN	O
fluid	NN	O
used	VBN	O
and	CC	O
its	PRP$	O
hemoglobin	JJ	O
concentration	NN	O
as	RB	O
well	RB	O
as	IN	O
resected	VBN	O
prostate	NN	O
weight	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
68	CD	SS
patients	NNS	O
who	WP	O
underwent	JJ	O
transurethral	JJ	C
prostate	NN	C
resection	NN	C
2	CD	O
were	VBD	O
withdrawn	VBN	O
before	RB	O
surgery	NN	O
,	,	O
and	CC	O
so	RB	O
32	CD	O
received	VBD	O
finasteride	NN	O
and	CC	O
36	CD	O
received	VBD	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
significantly	RB	O
less	JJR	O
mean	JJ	O
blood	NN	O
loss	NN	O
in	IN	O
irrigation	NN	O
fluid	NN	O
in	IN	O
the	DT	O
finasteride	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
43.6	CD	O
versus	NN	O
69.3	CD	O
gm	NN	O
.	.	O

hemoglobin	NN	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
difference	NN	O
was	VBD	O
more	RBR	O
significant	JJ	O
when	WRB	O
blood	NN	O
loss	NN	O
per	IN	O
gm	NN	O
.	.	O

resected	JJ	O
prostate	NN	O
was	VBD	O
calculated	VBN	O
(	(	O
2.65	CD	O
versus	NN	O
4.65	CD	O
gm	NN	O
.	.	O

hemoglobin	NN	O
per	IN	O
gm	NN	O
.	.	O

prostate	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
finasteride	NN	O
given	VBN	O
for	IN	O
2	CD	O
weeks	NNS	O
preoperatively	RB	O
decreases	VBZ	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
transurethral	JJ	C
prostate	NN	C
resection	NN	C
.	.	O

Further	NNP	O
study	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
timing	NN	O
and	CC	O
dose	JJ	O
duration	NN	O
to	TO	O
minimize	VB	O
blood	NN	O
loss	NN	O
and	CC	O
identify	VB	O
how	WRB	O
relevant	JJ	O
such	JJ	O
a	DT	O
decrease	NN	O
in	IN	O
bleeding	NN	O
is	VBZ	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Immunological	JJ	O
changes	NNS	O
after	IN	O
minimally	RB	O
invasive	JJ	O
or	CC	O
conventional	JJ	O
esophageal	JJ	O
resection	NN	O
for	IN	O
cancer	NN	C
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
a	DT	O
substudy	NN	O
analysis	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
conventional	JJ	O
open	JJ	O
esophagectomy	NN	O
[	NNP	O
open	JJ	O
surgical	JJ	O
technique	NN	O
(	(	O
OE	NNP	O
)	)	O
]	NN	O
by	IN	O
thoracotomy	NN	O
and	CC	O
laparotomy	NN	O
with	IN	O
minimally	RB	O
invasive	JJ	O
esophagectomy	NN	O
[	NNP	O
minimally	RB	O
invasive	JJ	O
procedure	NN	O
(	(	O
MIE	NNP	O
)	)	O
]	NN	O
by	IN	O
thoracoscopy	NN	O
and	CC	O
laparoscopy	NN	O
.	.	O

This	DT	O
additional	JJ	O
analysis	NN	O
focuses	VBZ	O
on	IN	O
the	DT	O
immunological	JJ	O
changes	NNS	O
and	CC	O
surgical	JJ	O
stress	NN	O
response	NN	O
in	IN	O
these	DT	O
two	CD	O
randomized	VBD	O
groups	NNS	O
of	IN	O
a	DT	O
single	JJ	O
center	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
resectable	JJ	C
esophageal	NN	C
cancer	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
OE	NNP	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	SS
)	)	O
or	CC	O
MIE	NNP	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	SS
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
neoadjuvant	JJ	O
chemoradiotherapy	NN	O
.	.	O

The	DT	O
immunological	JJ	O
response	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
means	NNS	O
of	IN	O
leukocyte	NN	O
counts	NNS	O
,	,	O
HLA-DR	NNP	O
expression	NN	O
on	IN	O
monocytes	NNS	O
,	,	O
the	DT	O
acute-phase	JJ	O
response	NN	O
by	IN	O
means	NNS	O
of	IN	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
interleukin-6	JJ	O
(	(	O
IL-6	NNP	O
)	)	O
,	,	O
and	CC	O
interleukin-8	JJ	O
(	(	O
IL-8	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
stress	NN	O
response	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
cortisol	NN	O
,	,	O
growth	NN	O
hormone	NN	O
,	,	O
and	CC	O
prolactin	NN	O
.	.	O

All	DT	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
at	IN	O
baseline	NN	O
(	(	O
preoperatively	RB	O
)	)	O
and	CC	O
24	CD	O
,	,	O
72	CD	O
,	,	O
96	CD	O
,	,	O
and	CC	O
168	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
with	IN	O
regard	NN	O
to	TO	O
leukocyte	VB	O
counts	NNS	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
prolactin	NN	O
at	IN	O
168	CD	O
h	NN	O
(	(	O
1	CD	O
week	NN	O
)	)	O
postoperatively	RB	O
.	.	O

For	IN	O
HLA-DR	NNP	O
expression	NN	O
,	,	O
IL-6	NNP	O
,	,	O
and	CC	O
CRP	NNP	O
levels	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
clear	JJ	O
rise	NN	O
in	IN	O
levels	NNS	O
upon	IN	O
operation	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
this	DT	O
substudy	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
minimally	RB	O
invasive	JJ	O
and	CC	O
conventional	JJ	O
open	JJ	O
esophagectomies	NNS	O
for	IN	O
cancer	NN	O
,	,	O
significantly	RB	O
better	RBR	O
preserved	VBN	O
leukocyte	JJ	O
counts	NNS	O
and	CC	O
IL-8	JJ	O
levels	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
open	JJ	O
group	NN	O
.	.	O

Both	DT	O
findings	NNS	O
can	MD	O
be	VB	O
related	VBN	O
to	TO	O
fewer	JJR	O
respiratory	NN	O
infections	NNS	O
found	VBD	O
postoperatively	RB	O
in	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
.	.	O

Moreover	RB	O
,	,	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
prolactin	NN	O
levels	NNS	O
at	IN	O
168	CD	O
h	NN	O
after	IN	O
surgery	NN	O
imply	NN	O
that	IN	O
the	DT	O
stress	NN	O
response	NN	O
is	VBZ	O
better	RBR	O
preserved	VBN	O
in	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
.	.	O

These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
less	JJR	O
surgical	JJ	O
trauma	NN	O
could	MD	O
lead	VB	O
to	TO	O
better	JJR	O
preserved	VBN	O
acute-phase	NN	O
and	CC	O
stress	NN	O
responses	NNS	O
and	CC	O
fewer	JJR	O
clinical	JJ	O
manifestations	NNS	O
of	IN	O
respiratory	JJ	O
infections	NNS	O
.	.	O

[	JJ	O
Usage	NN	O
of	IN	O
titanoreine	NN	O
after	IN	O
procedure	NN	C
for	IN	C
prolapse	NN	C
and	CC	C
hemorrhoids	NNS	C
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
titanoreine	NN	O
on	IN	O
early	JJ	O
postoperative	NN	O
symptoms	NNS	O
after	IN	O
procedure	NN	O
for	IN	O
prolapse	NN	O
and	CC	O
hemorrhoids	NNS	O
(	(	O
PPH	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
From	IN	O
November	NNP	O
2002	CD	O
to	TO	O
July	NNP	O
2003	CD	O
,	,	O
80	CD	SS
patients	NNS	O
who	WP	O
received	VBD	O
PPH	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
in	IN	O
to	TO	O
titanoreine	VB	O
group	NN	O
(	(	O
n=42	CC	O
)	)	O
and	CC	O
control	VB	O
group	NN	O
without	IN	O
titanoreine	NN	O
(	(	O
n=38	JJ	O
)	)	O
.	.	O

Symptom	JJ	O
relief	NN	O
was	VBD	O
recorded	VBN	O
24	CD	O
hours	NNS	O
,	,	O
6	CD	O
days	NNS	O
and	CC	O
12	CD	O
days	NNS	O
after	IN	O
PPH	NNP	O
,	,	O
urine	JJ	O
retention	NN	O
24h	CD	O
after	IN	O
PPH	NNP	O
,	,	O
first	RB	O
stool	JJ	O
time	NN	O
,	,	O
wound	IN	O
healing	VBG	O
time	NN	O
,	,	O
mean	JJ	O
hospital	NN	O
stay	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
score	NN	O
of	IN	O
symptom	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
titanoreine	NN	O
group	NN	O
(	(	O
4.4	CD	O
)	)	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
6.1	CD	O
)	)	O
24	CD	O
hours	NNS	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
symptom	NN	O
grade	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
6	CD	O
days	NNS	O
and	CC	O
12	CD	O
days	NNS	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Decrements	NNS	O
of	IN	O
symptom	NN	O
grade	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
titanoreine	NN	O
group	NN	O
than	IN	O
those	DT	O
of	IN	O
control	NN	O
group	NN	O
at	IN	O
any	DT	O
point	NN	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
urine	JJ	O
retention	NN	O
rate	NN	O
and	CC	O
mean	JJ	O
hospital	NN	O
stay	NN	O
between	IN	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Titanoreine	NNP	O
can	MD	O
effectively	RB	O
relieve	VB	O
the	DT	O
early	JJ	O
postoperative	NN	O
symptoms	NNS	O
after	IN	O
PPH	NNP	O
.	.	O

Relation	NN	O
of	IN	O
total	JJ	O
homocysteine	NN	O
and	CC	O
lipid	JJ	O
levels	NNS	O
in	IN	O
children	NNS	A
to	TO	O
premature	VB	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
male	JJ	SE
relatives	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
lipid	JJ	O
,	,	O
apo	JJ	O
B	NNP	O
,	,	O
lipoprotein	NN	O
(	(	O
a	DT	O
)	)	O
[	NN	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
]	NN	O
,	,	O
and	CC	O
total	JJ	O
homocysteine	NN	O
(	(	O
tHcy	NN	O
)	)	O
levels	NNS	O
in	IN	O
children	NNS	A
in	IN	O
relation	NN	O
to	TO	O
premature	VB	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
family	NN	O
members	NNS	O
.	.	O

Parents	NNS	O
of	IN	O
381	CD	SS
girls	NNS	SE
and	CC	O
375	CD	SS
boys	NNS	SE
age	NN	O
8-12	JJ	A
y	NN	O
completed	VBN	O
family	NN	O
history	NN	O
questionnaires	NNS	O
.	.	O

Nonfasting	VBG	O
serum	JJ	O
lipid	JJ	O
and	CC	O
lipoproteins	NNS	O
and	CC	O
plasma	NN	O
tHcy	NN	O
and	CC	O
cysteine	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
children	NNS	O
.	.	O

Serum	NNP	O
folate	NN	O
and	CC	O
vitamin	NN	O
B12	NNP	O
levels	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
a	DT	O
random	JJ	O
subsample	NN	O
of	IN	O
23	CD	O
%	NN	O
of	IN	O
the	DT	O
children	NNS	O
,	,	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
food	NN	O
frequency	NN	O
interview	NN	O
.	.	O

Children	NNP	O
whose	WP$	O
parents	NNS	O
reported	VBD	O
hypercholesterolemia	NN	O
had	VBD	O
higher	JJR	O
total	JJ	O
and	CC	O
non-HDL	JJ	O
cholesterol	NN	O
and	CC	O
apo	NN	O
B	NNP	O
levels	NNS	O
than	IN	O
the	DT	O
rest	NN	O
,	,	O
but	CC	O
these	DT	O
levels	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

tHcy	NN	O
levels	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
girls	NNS	O
and	CC	O
boys	NNS	O
.	.	O

tHcy	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
children	NNS	A
whose	WP$	O
father	NN	O
,	,	O
grandfather	NN	O
,	,	O
or	CC	O
uncle	NN	O
died	VBN	O
at	IN	O
age	NN	O
<	NN	O
or	CC	O
=	$	O
55	CD	O
y	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
than	IN	O
in	IN	O
control	NN	O
children	NNS	O
[	VBP	O
5.92	CD	O
mumol/L	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
of	IN	O
5.47-6.36	NNP	O
)	)	O
versus	NN	O
5.25	CD	O
mumol/L	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
5.16-5.34	JJ	O
)	)	O
]	NN	O
,	,	O
also	RB	O
after	IN	O
adjustment	NN	O
for	IN	O
socioeconomic	JJ	O
group	NN	O
.	.	O

Intake	NNP	O
and	CC	O
serum	NN	O
levels	NNS	O
of	IN	O
vitamin	NN	O
B12	NNP	O
and	CC	O
folate	NN	O
were	VBD	O
within	IN	O
recommended	VBN	O
or	CC	O
reference	NN	O
ranges	NNS	O
.	.	O

In	IN	O
a	DT	O
stepwise	NN	O
multiple	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
serum	NN	O
folate	NN	O
(	(	O
negative	JJ	O
correlation	NN	O
)	)	O
,	,	O
plasma	JJ	O
creatinine	NN	O
,	,	O
and	CC	O
sugar	RB	O
intake	VB	O
as	IN	O
percent	NN	O
of	IN	O
dietary	JJ	O
energy	NN	O
(	(	O
positive	JJ	O
correlations	NNS	O
)	)	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
tHcy	NN	O
(	(	O
multiple	JJ	O
r	NN	O
=	NN	O
0.44	CD	O
,	,	O
adjusted	VBN	O
r2	NN	O
=	VBZ	O
18	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
5-30	JJ	O
%	NN	O
)	)	O
.	.	O

Our	PRP$	O
data	NNS	O
show	VBP	O
that	IN	O
a	DT	O
modest	JJ	O
elevation	NN	O
in	IN	O
tHcy	NN	O
in	IN	O
children	NNS	O
was	VBD	O
related	VBN	O
to	TO	O
premature	VB	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
their	PRP$	O
male	NN	O
relatives	NNS	O
and	CC	O
may	MD	O
partly	RB	O
account	VB	O
for	IN	O
the	DT	O
contribution	NN	O
of	IN	O
family	NN	O
history	NN	O
to	TO	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

tHcy	NN	O
may	MD	O
be	VB	O
modifiable	JJ	O
through	IN	O
the	DT	O
diet	NN	O
,	,	O
even	RB	O
in	IN	O
children	NNS	O
with	IN	O
apparently	RB	O
adequate	JJ	O
vitamin	JJ	O
nutriture	NN	O
.	.	O

In	IN	O
school-aged	JJ	A
children	NNS	A
a	DT	O
combination	NN	O
of	IN	O
galacto-oligosaccharides	NNS	O
and	CC	O
Lactobacillus	NNP	O
GG	NNP	O
increases	VBZ	O
bifidobacteria	RB	O
more	JJR	O
than	IN	O
Lactobacillus	NNP	O
GG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
combination	NN	O
of	IN	O
Lactobacillus	NNP	O
GG	NNP	O
(	(	O
LGG	NNP	O
)	)	O
and	CC	O
galacto-oligosaccharides	NNS	O
(	(	O
GOS	NNP	O
)	)	O
with	IN	O
LGG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
,	,	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
intestinal	JJ	O
microbiota	NN	O
in	IN	O
school-aged	JJ	O
children	NNS	O
.	.	O

The	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
crossover	NN	O
study	NN	O
comprised	VBD	O
30	CD	SS
healthy	JJ	C
children	NNS	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
3-week	JJ	O
study	NN	O
periods	NNS	O
with	IN	O
a	DT	O
4-week	JJ	O
wash-out	JJ	O
period	NN	O
in	IN	O
between	IN	O
.	.	O

The	DT	O
children	NNS	O
ingested	VBD	O
daily	RB	O
65	CD	O
ml	NN	O
of	IN	O
milk-based	JJ	O
fruit	NN	O
juice	NN	O
containing	VBG	O
either	CC	O
LGG	NNP	O
alone	RB	O
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU	NNP	O
)	)	O
or	CC	O
LGG	NNP	O
plus	CC	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
.	.	O

Symptom	NNP	O
diaries	NNS	O
were	VBD	O
filled	VBN	O
during	IN	O
the	DT	O
study	NN	O
periods	NNS	O
.	.	O

Fecal	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
bifidobacteria	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
after	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
LGG	NNP	O
+	NNP	O
GOS	NNP	O
compared	VBN	O
with	IN	O
LGG	NNP	O
alone	RB	O
(	(	O
geometric	JJ	O
mean	VBP	O
9.33	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
vs.	FW	O
4.28	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU/g	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
lactobacilli	NN	O
or	CC	O
LGG	NNP	O
,	,	O
nor	CC	O
did	VBD	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
defecation	NN	O
frequency	NN	O
,	,	O
consistency	NN	O
of	IN	O
stools	NNS	O
or	CC	O
ease	NN	O
of	IN	O
defecation	NN	O
differ	NN	O
between	IN	O
the	DT	O
two	CD	O
study	NN	O
periods	NNS	O
.	.	O

Ingestion	NN	O
of	IN	O
LGG	NNP	O
combined	VBD	O
with	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
increased	VBD	O
the	DT	O
bifidobacteria	NN	O
more	JJR	O
than	IN	O
LGG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
and	CC	O
thus	RB	O
GOS	NNP	O
clearly	RB	O
has	VBZ	O
a	DT	O
prebiotic	JJ	O
effect	NN	O
in	IN	O
children	NNS	A
.	.	O

The	DT	O
children	NNS	O
tolerated	VBN	O
well	RB	O
a	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
self-directed	JJ	O
stress	NN	O
management	NN	O
training	NN	O
and	CC	O
home-based	JJ	O
exercise	NN	O
on	IN	O
stress	NN	O
management	NN	O
skills	NNS	O
in	IN	O
cancer	NN	C
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	C
.	.	O

Although	IN	O
exercise	NN	O
may	MD	O
be	VB	O
used	VBN	O
by	IN	O
some	DT	O
to	TO	O
decrease	VB	O
distress	NN	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
how	WRB	O
it	PRP	O
may	MD	O
contribute	VB	O
to	TO	O
stress	VB	O
management	NN	O
(	(	O
SM	NNP	O
)	)	O
among	IN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
whether	IN	O
exercise	NN	O
separately	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
SM	NNP	O
training	NN	O
is	VBZ	O
effective	JJ	O
at	IN	O
increasing	VBG	O
perceived	JJ	O
ability	NN	O
to	TO	O
manage	VB	O
stress	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
(	(	O
N	NNP	O
=	NNP	O
391	CD	SS
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
usual	JJ	O
care	NN	O
only	RB	O
(	(	O
UCO	NNP	O
)	)	O
,	,	O
SM	NNP	O
,	,	O
exercise	NN	O
(	(	O
EX	NNP	O
)	)	O
,	,	O
or	CC	O
stress	JJ	O
management	NN	O
and	CC	O
exercise	NN	O
(	(	O
SMEX	NNP	O
)	)	O
.	.	O

They	PRP	O
completed	VBD	O
the	DT	O
Measure	NN	O
of	IN	O
Current	NNP	O
Status	NNP	O
prior	RB	O
to	TO	O
receiving	VBG	O
chemotherapy	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
first	JJ	O
infusion	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
participants	NNS	O
randomized	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
condition	NN	O
would	MD	O
report	VB	O
improvements	NNS	O
in	IN	O
relaxation	NN	O
,	,	O
awareness	NN	O
of	IN	O
tension	NN	O
,	,	O
getting	VBG	O
needs	NNS	O
met	VBD	O
and	CC	O
coping	VBG	O
confidence	NN	O
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
UCO	NNP	O
.	.	O

Results	NNP	O
indicated	VBD	O
significant	JJ	O
group-by-time	JJ	O
interactions	NNS	O
for	IN	O
the	DT	O
following	NN	O
:	:	O
relaxation	NN	O
(	(	O
UCO	NNP	O
versus	NN	O
SM	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.008	CD	O
)	)	O
,	,	O
awareness	NN	O
of	IN	O
tension	NN	O
(	(	O
UCO	NNP	O
versus	NN	O
SMEX	NNP	O
,	,	O
p	NN	O
=	VBD	O
0.029	CD	O
and	CC	O
UCO	NNP	O
versus	NN	O
EX	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
getting	VBG	O
needs	NNS	O
met	VBD	O
(	(	O
UCO	NNP	O
versus	NN	O
SMEX	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.020	CD	O
)	)	O
and	CC	O
Measure	NN	O
of	IN	O
Current	NNP	O
Status	NNP	O
total	NN	O
score	NN	O
(	(	O
UCO	NNP	O
versus	NN	O
SMEX	NNP	O
,	,	O
p	NN	O
=	VBD	O
0.007	CD	O
and	CC	O
UCO	NNP	O
versus	NN	O
EX	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.016	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
group-by-time	JJ	O
interactions	NNS	O
for	IN	O
coping	VBG	O
confidence	NN	O
(	(	O
p-values	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
support	NN	O
for	IN	O
including	VBG	O
an	DT	O
exercise	NN	O
component	NN	O
in	IN	O
SM	NNP	O
interventions	NNS	O
for	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
(	(	O
clinicaltrials.gov	JJ	O
identifier	NN	O
:	:	O
NCT00740038	NNP	O
)	)	O
.	.	O

Use	NNP	O
and	CC	O
limitations	NNS	O
of	IN	O
Holter	NNP	O
electrocardiography	NN	O
in	IN	O
assessing	VBG	O
drug	NN	O
therapy	NN	O
of	IN	O
myocardial	JJ	C
ischemia	NN	C
during	IN	O
the	DT	O
peri-PTCA	JJ	C
period	NN	O
.	.	O

Incidence	NN	O
and	CC	O
pattern	NN	O
of	IN	O
myocardial	JJ	O
ischemia	NN	O
during	IN	O
the	DT	O
peri-PTCA	JJ	C
(	(	O
percutaneous	JJ	C
transluminal	JJ	C
coronary	JJ	C
angioplasty	NN	C
)	)	O
period	NN	O
and	CC	O
the	DT	O
possible	JJ	O
role	NN	O
of	IN	O
continuous	JJ	O
intravenous	JJ	O
isosorbide	NN	O
dinitrate	NN	O
in	IN	O
its	PRP$	O
prevention	NN	O
were	VBD	O
examined	VBN	O
prospectively	RB	O
in	IN	O
30	CD	SS
patients	NNS	O
.	.	O

Holter	NNP	O
electrocardiographic	JJ	O
monitoring	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
21	CD	O
+/-	JJ	O
3	CD	O
h	NN	O
before	IN	O
PTCA	NNP	O
and	CC	O
continued	VBN	O
during	IN	O
and	CC	O
for	IN	O
41	CD	O
+/-	JJ	O
8	CD	O
h	NN	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

Before	IN	O
PTCA	NNP	O
,	,	O
19	CD	O
ischemic	JJ	O
episodes	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
10	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
of	IN	O
30	CD	SS
patients	NNS	O
.	.	O

PTCA	NNP	O
produced	VBD	O
an	DT	O
abrupt	JJ	O
decrease	NN	O
in	IN	O
number	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.015	CD	O
)	)	O
and	CC	O
duration	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
of	IN	O
spontaneous	JJ	O
ischemic	JJ	O
episodes	NNS	O
.	.	O

The	DT	O
rarity	NN	O
of	IN	O
recurrent	JJ	O
myocardial	JJ	O
ischemic	JJ	O
events	NNS	O
by	IN	O
Holter	NNP	O
monitoring	NN	O
after	IN	O
PTCA	NNP	O
negated	VBD	O
any	DT	O
attempt	NN	O
at	IN	O
assessing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
intravenous	JJ	O
isosorbide	JJ	O
dinitrate	NN	O
in	IN	O
their	PRP$	O
prevention	NN	O
.	.	O

Holter	NNP	O
monitoring	NN	O
could	MD	O
not	RB	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
early	JJ	O
predictor	NN	O
of	IN	O
late	JJ	O
coronary	JJ	O
restenosis	NN	O
.	.	O

Randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
sirolimus	NN	O
for	IN	O
restenosis	NN	O
prevention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
in-stent	JJ	C
restenosis	NN	C
:	:	O
the	DT	O
Oral	NNP	O
Sirolimus	NNP	O
to	TO	O
Inhibit	NNP	O
Recurrent	NNP	O
In-stent	JJ	O
Stenosis	NNP	O
(	(	O
OSIRIS	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
recent	JJ	O
advances	NNS	O
in	IN	O
interventional	JJ	O
cardiology	NN	O
,	,	O
including	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
drug-eluting	JJ	O
stents	NNS	O
for	IN	O
de	FW	O
novo	FW	O
coronary	JJ	O
lesions	NNS	O
,	,	O
the	DT	O
treatment	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
(	(	O
ISR	NNP	O
)	)	O
remains	VBZ	O
a	DT	O
challenging	JJ	O
clinical	JJ	O
issue	NN	O
.	.	O

Given	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
systemic	JJ	O
sirolimus	JJ	O
administration	NN	O
to	TO	O
prevent	VB	O
neointimal	JJ	O
hyperplasia	NN	O
in	IN	O
animal	JJ	O
models	NNS	O
and	CC	O
to	TO	O
halt	VB	O
and	CC	O
even	RB	O
reverse	VB	O
the	DT	O
progression	NN	O
of	IN	O
allograft	NN	O
vasculopathy	NN	O
,	,	O
the	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
10-day	JJ	O
oral	JJ	O
sirolimus	NN	O
treatment	NN	O
with	IN	O
2	CD	O
different	JJ	O
loading	VBG	O
regimens	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrent	JJ	O
restenosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ISR	NNP	C
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Three	NNP	SS
hundred	VBD	SS
symptomatic	JJ	C
patients	NNS	O
with	IN	O
ISR	NNP	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
placebo	NN	O
or	CC	O
usual-dose	JJ	O
or	CC	O
high-dose	JJ	O
sirolimus	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
a	DT	O
cumulative	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
0	CD	O
,	,	O
8	CD	O
,	,	O
or	CC	O
24	CD	O
mg	NN	O
of	IN	O
sirolimus	JJ	O
2	CD	O
days	NNS	O
before	IN	O
and	CC	O
the	DT	O
day	NN	O
of	IN	O
repeat	NN	O
intervention	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
therapy	NN	O
of	IN	O
2	CD	O
mg/d	NN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

Angiographic	JJ	O
restenosis	NN	O
at	IN	O
6-month	JJ	O
angiography	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Restenosis	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
from	IN	O
42.2	CD	O
%	NN	O
to	TO	O
38.6	CD	O
%	NN	O
and	CC	O
to	TO	O
22.1	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
,	,	O
usual-dose	JJ	O
,	,	O
and	CC	O
high-dose	JJ	O
sirolimus	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.005	NNP	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
vessel	JJ	O
revascularization	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
25.5	CD	O
%	NN	O
to	TO	O
24.2	CD	O
%	NN	O
and	CC	O
to	TO	O
15.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
,	,	O
usual-dose	JJ	O
,	,	O
and	CC	O
high-dose	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.08	NNP	O
)	)	O
.	.	O

The	DT	O
sirolimus	JJ	O
blood	NN	O
concentration	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
procedure	NN	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
late	JJ	O
lumen	NNS	O
loss	NN	O
at	IN	O
follow-up	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
ISR	NNP	O
,	,	O
an	DT	O
oral	JJ	O
adjunctive	JJ	O
sirolimus	NN	O
treatment	NN	O
with	IN	O
an	DT	O
intensified	JJ	O
loading	NN	O
regimen	NNS	O
before	IN	O
coronary	JJ	O
intervention	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
angiographic	JJ	O
parameters	NNS	O
of	IN	O
restenosis	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
intravenous	JJ	O
and	CC	O
intra-arterial	JJ	O
urokinase	JJ	O
thrombolysis	NN	O
for	IN	O
acute	JJ	C
ischaemic	JJ	C
stroke	NN	C
.	.	O

Intravenous	JJ	O
fibrinolysis	NN	O
(	(	O
IVF	NNP	O
)	)	O
with	IN	O
rt-PA	NN	O
(	(	O
alteplase	NN	O
)	)	O
provides	VBZ	O
significant	JJ	O
benefits	NNS	O
in	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
three	CD	O
hours	NNS	O
following	VBG	O
stroke	NN	O
onset	VBN	O
.	.	O

Intra-arterial	JJ	O
fibrinolysis	NN	O
(	(	O
IAF	NNP	O
)	)	O
with	IN	O
pro-urokinase	NN	O
in	IN	O
PROACT	NNP	O
II	NNP	O
study	NN	O
provides	VBZ	O
quite	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
in	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
.	.	O

IVF	NNP	O
and	CC	O
IAF	NNP	O
have	VBP	O
never	RB	O
been	VBN	O
compared	VBN	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
IVF	NNP	O
and	CC	O
IAF	NNP	O
with	IN	O
urokinase	JJ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
of	IN	O
acute	JJ	C
ischaemic	JJ	C
stroke	NN	C
.	.	O

Patients	NNS	O
fulfilling	VBG	O
the	DT	O
selection	NN	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
urokinase	JJ	O
900,000	CD	O
units	NNS	O
via	IN	O
intravenous	JJ	O
or	CC	O
intra-arterial	JJ	O
routes	NNS	O
.	.	O

This	DT	O
randomised	VBD	O
monocentre	NN	O
study	NN	O
was	VBD	O
done	VBN	O
between	IN	O
December	NNP	O
1995	CD	O
and	CC	O
August	NNP	O
1997	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
modified	JJ	O
Rankin	NNP	O
score	NN	O
of	IN	O
2	CD	O
or	CC	O
less	JJR	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
mortality	NN	O
,	,	O
frequency	NN	O
of	IN	O
symptomatic	JJ	O
intracranial	JJ	O
haemorrhage	NN	O
(	(	O
SIH	NNP	O
)	)	O
,	,	O
neurological	JJ	O
and	CC	O
functional	JJ	O
scores	NNS	O
.	.	O

Fourteen	CD	SS
patients	NNS	O
were	VBD	O
given	VBN	O
IVF	NNP	O
and	CC	O
13	CD	SS
IAF	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Health	NNP	O
Authorities	NNP	O
when	WRB	O
27	CD	SS
patients	NNS	O
had	VBD	O
been	VBN	O
included	VBN	O
because	IN	O
of	IN	O
the	DT	O
mortality	NN	O
rate	NN	O
.	.	O

Seven	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
died	VBD	O
,	,	O
4	CD	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
(	(	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
3	CD	O
and	CC	O
recurrence	NN	O
in	IN	O
1	CD	O
)	)	O
,	,	O
3	CD	O
in	IN	O
the	DT	O
IA	NNP	O
group	NN	O
(	(	O
SIH	NNP	O
in	IN	O
2	CD	O
,	,	O
and	CC	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
given	VBN	O
IVF	NNP	O
were	VBD	O
treated	VBN	O
significantly	RB	O
earlier	RBR	O
(	(	O
4:16	CD	O
h	NN	O
vs	NN	O
5:24	CD	O
h	NN	O
;	:	O
p=.007	NN	O
)	)	O
.	.	O

Although	IN	O
IA	NNP	O
patients	NNS	O
showed	VBD	O
greater	JJR	O
and	CC	O
earlier	RBR	O
improvement	NN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Because	IN	O
of	IN	O
premature	NN	O
termination	NN	O
,	,	O
the	DT	O
trial	NN	O
was	VBD	O
too	RB	O
small	JJ	O
to	TO	O
provide	VB	O
any	DT	O
reliable	JJ	O
and	CC	O
conclusive	JJ	O
results	NNS	O
.	.	O

Intra-arterial	JJ	O
fibrinolysis	NN	O
began	VBD	O
significantly	RB	O
later	RBR	O
than	IN	O
IV	NNP	O
fibrinolysis	NN	O
but	CC	O
it	PRP	O
gave	VBD	O
non-significantly	RB	O
better	JJ	O
results	NNS	O
in	IN	O
this	DT	O
prematurely	RB	O
terminated	VBN	O
study	NN	O
.	.	O

Penetration	NN	O
and	CC	O
accumulation	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
uterine	JJ	O
tissue	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
moxifloxacin	NN	O
penetrates	VBZ	O
the	DT	O
uterine	JJ	O
tissue	NN	O
and	CC	O
accumulates	NNS	O
at	IN	O
levels	NNS	O
sufficient	JJ	O
to	TO	O
eradicate	VB	O
the	DT	O
major	JJ	O
pathogens	NNS	O
causing	VBG	O
pelvic	JJ	C
inflammatory	JJ	C
disease	NN	C
(	(	O
PID	NNP	C
)	)	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
multicenter	NN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
we	PRP	O
determined	VBD	O
the	DT	O
concentration	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
plasma	NN	O
and	CC	O
uterine	JJ	O
tissue	NN	O
after	IN	O
a	DT	O
single	JJ	O
,	,	O
400-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
moxifloxacin	NN	O
.	.	O

Study	NN	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
for	IN	O
time	NN	O
of	IN	O
tissue	NN	O
sampling	NN	O
,	,	O
which	WDT	O
was	VBD	O
performed	VBN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
7	CD	O
,	,	O
or	CC	O
24	CD	O
hours	NNS	O
following	VBG	O
the	DT	O
moxifloxacin	JJ	O
infusion	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
43	CD	SS
participants	NNS	O
,	,	O
40	CD	SS
were	VBD	O
randomized	VBN	O
to	TO	O
tissue	VB	O
sampling	VBG	O
.	.	O

Moxifloxacin	NNP	O
accumulated	VBD	O
in	IN	O
uterine	JJ	O
tissue	NN	O
and	CC	O
concentrations	NNS	O
were	VBD	O
highest	JJS	O
1	CD	O
hour	NN	O
after	IN	O
infusion	NN	O
in	IN	O
both	DT	O
plasma	NN	O
and	CC	O
tissue	NN	O
.	.	O

Tissue	NN	O
to	TO	O
plasma	VB	O
ratios	NNS	O
remained	VBD	O
between	IN	O
1.7	CD	O
and	CC	O
2.1	CD	O
for	IN	O
24	CD	O
hours	NNS	O
.	.	O

Moxifloxacin	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
known	VBN	O
minimum	JJ	O
inhibitory	JJ	O
concentration	NN	O
data	NNS	O
,	,	O
the	DT	O
uterine	JJ	O
tissue	NN	O
concentrations	NNS	O
of	IN	O
moxifloxacin	NN	O
achieved	VBN	O
over	IN	O
24	CD	O
hours	NNS	O
would	MD	O
be	VB	O
sufficient	JJ	O
to	TO	O
eradicate	VB	O
the	DT	O
range	NN	O
of	IN	O
bacterial	JJ	O
pathogens	NNS	O
responsible	JJ	O
for	IN	O
PID	NNP	O
.	.	O

Clinically	RB	O
relevant	JJ	O
improvement	NN	O
of	IN	O
recurrence-free	JJ	O
survival	NN	O
with	IN	O
5-aminolevulinic	JJ	O
acid	NN	O
induced	VBD	O
fluorescence	NN	O
diagnosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
superficial	JJ	C
bladder	NN	C
tumors	NNS	C
.	.	O

PURPOSES	NNP	O
Fluorescence	NNP	O
diagnosis	NN	O
induced	VBN	O
by	IN	O
5-aminolevulinic	JJ	O
acid	NN	O
enables	VBZ	O
more	RBR	O
thorough	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
superficial	JJ	C
bladder	NN	C
carcinoma	NNS	C
compared	VBN	O
with	IN	O
conventional	JJ	O
white	JJ	O
light	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
single	JJ	O
institution	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
and	CC	O
long-term	JJ	O
tumor	NN	O
recurrence	NN	O
can	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
fluorescence	NN	O
diagnosis	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
301	CD	SS
patients	NNS	O
underwent	JJ	O
transurethral	JJ	C
resection	NN	C
of	IN	O
bladder	NN	C
tumors	NNS	C
with	IN	O
white	JJ	O
light	NN	O
or	CC	O
fluorescence	NN	O
diagnosis	NN	O
.	.	O

Transurethral	JJ	O
resection	NN	O
was	VBD	O
repeated	VBN	O
5	CD	O
to	TO	O
6	CD	O
weeks	NNS	O
later	RB	O
to	TO	O
evaluate	VB	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
.	.	O

To	TO	O
determine	VB	O
recurrence-free	JJ	O
survival	JJ	O
patient	NN	O
followup	NN	O
was	VBD	O
performed	VBN	O
every	DT	O
3	CD	O
months	NNS	O
by	IN	O
white	JJ	O
light	JJ	O
cystoscopy	NN	O
and	CC	O
urine	JJ	O
cytology	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
analyzed	VBN	O
via	IN	O
Kaplan-Meier	NNP	O
methods	NNS	O
and	CC	O
multivariable	JJ	O
Cox	NNP	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
191	CD	SS
patients	NNS	O
with	IN	O
superficial	JJ	C
bladder	NN	C
carcinoma	NN	C
were	VBD	O
available	JJ	O
for	IN	O
efficacy	NN	O
analysis	NN	O
.	.	O

The	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
was	VBD	O
25.2	CD	O
%	NN	O
in	IN	O
the	DT	O
white	JJ	O
light	JJ	O
arm	NN	O
versus	NN	O
4.5	CD	O
%	NN	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
arm	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Median	JJ	O
followup	NN	O
in	IN	O
the	DT	O
white	JJ	O
light	JJ	O
arm	NN	O
in	IN	O
103	CD	O
cases	NNS	O
was	VBD	O
21.2	CD	O
months	NNS	O
(	(	O
range	VB	O
4	CD	O
to	TO	O
40	CD	O
)	)	O
compared	VBN	O
with	IN	O
20.5	CD	O
(	(	O
range	NN	O
3	CD	O
to	TO	O
40	CD	O
)	)	O
in	IN	O
the	DT	O
88	CD	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
arm	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
group	NN	O
was	VBD	O
89.6	CD	O
%	NN	O
after	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
73.8	CD	O
%	NN	O
and	CC	O
65.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
white	JJ	O
light	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

This	DT	O
superiority	NN	O
proved	VBD	O
to	TO	O
be	VB	O
independent	JJ	O
of	IN	O
risk	NN	O
group	NN	O
.	.	O

The	DT	O
adjusted	JJ	O
hazard	NN	O
ratio	NN	O
of	IN	O
fluorescence	NN	O
diagnosis	NN	O
versus	IN	O
white	JJ	O
light	JJ	O
transurethral	JJ	O
resection	NN	O
was	VBD	O
0.33	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.16	CD	O
to	TO	O
0.67	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Fluorescence	NNP	O
diagnosis	NN	O
is	VBZ	O
significantly	RB	O
superior	JJ	O
to	TO	O
conventional	JJ	O
white	JJ	O
light	JJ	O
transurethral	JJ	O
resection	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
and	CC	O
recurrence-free	JJ	O
survival	NN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
recurrence-free	JJ	O
survival	NN	O
imply	NN	O
that	WDT	O
fluorescence	NN	O
diagnosis	NN	O
is	VBZ	O
a	DT	O
clinically	RB	O
relevant	JJ	O
procedure	NN	O
for	IN	O
decreasing	VBG	O
the	DT	O
number	NN	O
of	IN	O
tumor	NN	O
recurrences	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
stable	JJ	C
angina	NN	C
of	IN	C
effort	NN	C
with	IN	O
verapamil	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
verapamil	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
26	CD	SS
patients	NNS	O
with	IN	O
stable	JJ	C
exertional	JJ	C
angina	NN	C
pectoris	NN	C
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	VBN	O
crossover	NN	O
protocol	NN	O
using	VBG	O
serial	JJ	O
treadmill	NN	O
tests	NNS	O
.	.	O

Verapamil	NNP	O
,	,	O
480	CD	O
mg/day	NN	O
,	,	O
reduced	VBD	O
anginal	JJ	O
frequency	NN	O
from	IN	O
5.6	CD	O
+/-	JJ	O
7.3	CD	O
to	TO	O
2.2	CD	O
+/-	JJ	O
3.9	CD	O
attacks	NNS	O
per	IN	O
week	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
nitroglycerin	JJ	O
consumption	NN	O
from	IN	O
3.4	CD	O
+/-	JJ	O
4.9	CD	O
to	TO	O
1.2	CD	O
+/-	JJ	O
2.5	CD	O
tablets	NNS	O
per	IN	O
week	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Treadmill	NNP	O
time	NN	O
increased	VBD	O
from	IN	O
6.4	CD	O
+/-	JJ	O
2.1	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
placebo	NN	O
phase	NN	O
to	TO	O
7.5	CD	O
+/-	JJ	O
1.8	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
verapamil	JJ	O
phase	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Verapamil	NNP	O
's	POS	O
beneficial	JJ	O
effect	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
related	VBN	O
,	,	O
in	IN	O
part	NN	O
,	,	O
to	TO	O
a	DT	O
10	CD	O
%	NN	O
reduction	NN	O
of	IN	O
the	DT	O
rate-pressure	JJ	O
product	NN	O
at	IN	O
rest	NN	O
(	(	O
p	IN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
and	CC	O
a	DT	O
12	CD	O
%	NN	O
reduction	NN	O
during	IN	O
submaximal	JJ	O
exercise	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Verapamil	NNP	O
also	RB	O
caused	VBD	O
less	JJR	O
marked	JJ	O
ST-segment	JJ	O
depressions	NNS	O
at	IN	O
peak	NN	O
exercise	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
at	IN	O
a	DT	O
similar	JJ	O
rate-pressure	NN	O
product	NN	O
,	,	O
suggesting	VBG	O
a	DT	O
favorable	JJ	O
redistribution	NN	O
of	IN	O
coronary	JJ	O
blood	NN	O
flow	NN	O
to	TO	O
the	DT	O
ischemic	JJ	O
zone	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
from	IN	O
verapamil	NN	O
were	VBD	O
minimal	JJ	O
,	,	O
consisting	VBG	O
mainly	RB	O
of	IN	O
constipation	NN	O
(	(	O
six	CD	O
patients	NNS	O
)	)	O
.	.	O

Verapamil	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
drug	NN	O
for	IN	O
treating	VBG	O
angina	NN	C
of	IN	O
effort	NN	O
.	.	O

Effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
Levitan	NNP	O
FPS	NNP	O
Scope?	NNP	O
for	IN	O
tracheal	JJ	O
intubation	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
with	IN	O
a	DT	O
simulated	JJ	O
difficult	JJ	O
airway	NN	O
.	.	O

PURPOSE	NNP	O
Studies	NNP	O
show	VBP	O
that	IN	O
the	DT	O
Levitan	NNP	O
FPS	NNP	O
(	(	O
first	JJ	O
pass	NN	O
success	NN	O
)	)	O
Scope?	NNP	O
(	(	O
LFS	NNP	O
)	)	O
is	VBZ	O
analogous	JJ	O
to	TO	O
a	DT	O
bougie	NN	O
in	IN	O
simulated	JJ	O
difficult	JJ	O
airways	NNS	O
with	IN	O
comparable	JJ	O
tracheal	JJ	O
intubation	NN	O
success	NN	O
rates	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
tracheal	JJ	O
intubation	NN	O
with	IN	O
the	DT	O
LFS	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
Macintosh	NNP	O
laryngoscope	NN	O
utilizing	VBG	O
manual	JJ	O
in-line	JJ	O
stabilization	NN	O
(	(	O
MILS	NNP	O
)	)	O
to	TO	O
simulate	VB	O
difficult	JJ	O
airways	NNS	O
.	.	O

METHODS	NNP	O
Ninety-four	JJ	O
subjects	NNS	O
successfully	RB	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Manual	JJ	O
in-line	JJ	O
stabilization	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
was	VBD	O
applied	VBN	O
and	CC	O
the	DT	O
initial	JJ	O
laryngoscopy	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
either	CC	O
the	DT	O
Macintosh	NNP	O
or	CC	O
the	DT	O
LFS	NNP	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Macintosh	NNP	O
.	.	O

Following	VBG	O
the	DT	O
initial	JJ	O
grading	NN	O
,	,	O
a	DT	O
second	JJ	O
laryngoscopy	NN	O
was	VBD	O
repeated	VBN	O
using	VBG	O
the	DT	O
second	JJ	O
randomized	JJ	O
technique	NN	O
.	.	O

Cormack-Lehane	NNP	O
grades	NNS	O
,	,	O
percentage	NN	O
of	IN	O
glottic	JJ	O
opening	NN	O
(	(	O
POGO	NNP	O
)	)	O
scores	VBZ	O
,	,	O
time	NN	O
to	TO	O
intubate	VB	O
,	,	O
number	NN	O
of	IN	O
intubation	NN	O
attempts	NNS	O
,	,	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
alternate	NN	O
techniques	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
anesthesiologist	NN	O
rated	VBD	O
the	DT	O
subjective	JJ	O
difficulty	NN	O
in	IN	O
using	VBG	O
each	DT	O
technique	NN	O
with	IN	O
a	DT	O
numeric	JJ	O
rating	NN	O
scale	NN	O
and	CC	O
a	DT	O
visual	JJ	O
rating	NN	O
scale	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
good	JJ	O
laryngoscopic	NN	O
views	NNS	O
(	(	O
Cormack-Lehane	NNP	O
grade	VBD	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
compared	VBN	O
with	IN	O
poor	JJ	O
laryngoscopic	JJ	O
views	NNS	O
(	(	O
Cormack-Lehane	NNP	O
grade	VBD	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
between	IN	O
the	DT	O
LFS	NNP	O
and	CC	O
the	DT	O
Macintosh	NNP	O
.	.	O

There	EX	O
were	VBD	O
higher	JJR	O
POGO	NNP	O
scores	NNS	O
with	IN	O
the	DT	O
LFS	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
Macintosh	NNP	O
(	(	O
80	CD	O
%	NN	O
vs	JJ	O
20	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
translate	VB	O
to	TO	O
easier	JJR	O
intubations	NNS	O
,	,	O
as	IN	O
documented	VBN	O
by	IN	O
the	DT	O
need	NN	O
for	IN	O
an	DT	O
alternate	JJ	O
intubation	NN	O
technique	NN	O
or	CC	O
time	NN	O
to	TO	O
intubate	VB	O
(	(	O
<	JJ	O
30	CD	O
and	CC	O
<	$	O
60	CD	O
sec	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
mucosal	NN	O
trauma	NN	O
,	,	O
sore	RB	O
throat	NN	O
,	,	O
and	CC	O
hemodynamic	JJ	O
responses	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
techniques	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
LFS	NNP	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Macintosh	NNP	O
laryngoscope	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
the	DT	O
efficacy	NN	O
or	CC	O
safety	NN	O
of	IN	O
tracheal	JJ	O
intubation	NN	O
in	IN	O
a	DT	O
simulated	JJ	O
difficult	JJ	O
airway	NN	O
.	.	O

Rehabilitation	NN	O
of	IN	O
therapy-related	JJ	O
cognitive	JJ	O
deficits	NNS	O
in	IN	O
patients	NNS	O
after	IN	O
hematopoietic	JJ	C
stem	NN	C
cell	NN	C
transplantation	NN	C
.	.	O

Neuropsychological	JJ	O
deficits	NNS	O
are	VBP	O
potential	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
therapy	NN	O
(	(	O
HSCT	NNP	O
)	)	O
.	.	O

Systematic	JJ	O
data	NNS	O
on	IN	O
the	DT	O
long-term	JJ	O
course	NN	O
of	IN	O
and	CC	O
therapeutic	JJ	O
options	NNS	O
for	IN	O
these	DT	O
consequences	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

One	CD	SS
hundred	VBD	SS
fifty-seven	JJ	SS
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
cognitive	JJ	C
deficits	NNS	C
following	VBG	O
HSCT	NNP	O
for	IN	O
malignant	JJ	C
diseases	NNS	C
at	IN	O
an	DT	O
in-patient	JJ	O
oncologic	NN	O
rehabilitation	NN	O
clinic	NN	O
.	.	O

Patients	NNS	O
showing	VBG	O
evidence	NN	O
of	IN	O
impairment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
training	VBG	O
groups	NNS	O
:	:	O
individualized	VBN	O
PC-supported	JJ	O
training	NN	O
or	CC	O
neuropsychological	JJ	O
group	NN	O
therapy	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
no	DT	O
specific	JJ	O
training	NN	O
.	.	O

During	IN	O
in-patient	JJ	O
rehabilitation	NN	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
comprehensive	JJ	O
neuropsychological	JJ	O
test	NN	O
battery	NN	O
improved	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
no	DT	O
specific	JJ	O
intervention	NN	O
effects	NNS	O
were	VBD	O
identified	VBN	O
.	.	O

Neuropsychological	JJ	O
deficits	NNS	O
were	VBD	O
still	RB	O
evident	JJ	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Correlation	NN	O
between	IN	O
neuropsychological	JJ	O
testing	NN	O
and	CC	O
patients	NNS	O
'	POS	O
self-evaluation	NN	O
of	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
daily	JJ	O
life	NN	O
was	VBD	O
generally	RB	O
low	JJ	O
.	.	O

Sustained	VBN	O
attention	NN	O
and	CC	O
verbal-semantic	JJ	O
memory	NN	O
played	VBD	O
the	DT	O
main	JJ	O
role	NN	O
for	IN	O
self-appraisal	JJ	O
and	CC	O
in	IN	O
the	DT	O
designation	NN	O
as	IN	O
'neuropsychologically	RB	O
impaired	VBN	O
'	''	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
a	DT	O
substantial	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
revealed	JJ	O
evidence	NN	O
of	IN	O
cognitive	JJ	O
deficits	NNS	O
a	DT	O
long	JJ	O
time	NN	O
after	IN	O
HSCT	NNP	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
need	NN	O
for	IN	O
more	JJR	O
studies	NNS	O
and	CC	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
differentiated	JJ	O
rehabilitative	JJ	O
measures	NNS	O
for	IN	O
such	JJ	O
therapeutic	JJ	O
consequences	NNS	O
.	.	O

Problem-based	JJ	O
learning	NN	O
:	:	O
is	VBZ	O
anatomy	IN	O
a	DT	O
casualty	NN	O
?	.	O
INTRODUCTION	NNP	O
The	DT	O
teaching	NN	O
of	IN	O
medical	JJ	O
anatomy	NN	O
is	VBZ	O
changing	VBG	O
.	.	O

Medical	JJ	O
schools	NNS	O
worldwide	WDT	O
are	VBP	O
moving	VBG	O
away	RB	O
from	IN	O
dissection	NN	O
and	CC	O
lectures	VBZ	O
to	TO	O
a	DT	O
more	RBR	O
integrated	JJ	O
course	NN	O
,	,	O
where	WRB	O
basic	JJ	O
science	NN	O
and	CC	O
clinical	JJ	O
skills	NNS	O
are	VBP	O
taught	JJ	O
simultaneously	RB	O
.	.	O

Medical	JJ	O
students	NNS	O
on	IN	O
these	DT	O
integrated	VBN	O
courses	NNS	O
have	VBP	O
reported	VBN	O
a	DT	O
lack	NN	O
of	IN	O
confidence	NN	O
in	IN	O
their	PRP$	O
basic	JJ	O
science	NN	O
knowledge	NN	O
,	,	O
especially	RB	O
concerning	VBG	O
anatomy	NN	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
perform	VB	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
to	TO	O
compare	VB	O
anatomical	JJ	O
knowledge	NN	O
of	IN	O
two	CD	O
groups	NNS	O
of	IN	O
second-year	JJ	O
medical	JJ	O
students	NNS	O
,	,	O
the	DT	O
first	JJ	O
group	NN	O
taught	NN	O
on	IN	O
a	DT	O
traditional	JJ	O
course	NN	O
,	,	O
the	DT	O
second	JJ	O
on	IN	O
an	DT	O
integrated	JJ	O
course	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Testing	NNP	O
was	VBD	O
done	VBN	O
using	VBG	O
a	DT	O
Questionnaire	NN	O
in	IN	O
a	DT	O
True/False	NNP	O
format	NN	O
.	.	O

There	EX	O
were	VBD	O
80	CD	SS
students	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
penalty	NN	O
for	IN	O
an	DT	O
incorrect	JJ	O
answer	NN	O
.	.	O

The	DT	O
test	NN	O
was	VBD	O
performed	VBN	O
under	IN	O
examination	NN	O
conditions	NNS	O
.	.	O

Papers	NNS	O
were	VBD	O
marked	VBN	O
under	IN	O
blind	JJ	O
conditions	NNS	O
.	.	O

Results	NNS	O
were	VBD	O
analysed	VBN	O
using	VBG	O
a	DT	O
Student	NN	O
's	POS	O
t	JJ	O
test	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Those	DT	O
students	NNS	O
taught	VBP	O
on	IN	O
a	DT	O
traditional	JJ	O
course	NN	O
exhibited	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
level	NN	O
of	IN	O
basic	JJ	O
anatomical	JJ	O
knowledge	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
than	IN	O
those	DT	O
taught	VBN	O
on	IN	O
an	DT	O
integrated	JJ	O
course	NN	O
.	.	O

The	DT	O
students	NNS	O
taught	VBD	O
on	IN	O
an	DT	O
integrated	JJ	O
course	NN	O
showed	VBD	O
a	DT	O
much	RB	O
greater	JJR	O
range	NN	O
of	IN	O
results	NNS	O
.	.	O

CONCLUSIONS	JJ	O
Students	NNS	O
taught	VBD	O
on	IN	O
a	DT	O
traditional	JJ	O
course	NN	O
have	VBP	O
a	DT	O
higher	JJR	O
level	NN	O
of	IN	O
anatomical	JJ	O
knowledge	NN	O
than	IN	O
those	DT	O
taught	VBN	O
on	IN	O
an	DT	O
integrated	JJ	O
course	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
differ	VBP	O
from	IN	O
previous	JJ	O
studies	NNS	O
done	VBN	O
in	IN	O
Europe	NNP	O
which	WDT	O
show	VBP	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
courses	NNS	O
.	.	O

Physostigmine	JJ	O
reverses	VBZ	O
propofol-induced	JJ	O
unconsciousness	NN	O
and	CC	O
attenuation	NN	O
of	IN	O
the	DT	O
auditory	NN	O
steady	JJ	O
state	NN	O
response	NN	O
and	CC	O
bispectral	JJ	O
index	NN	O
in	IN	O
human	JJ	O
volunteers	NNS	O
.	.	O

BACKGROUND	IN	O
It	PRP	O
is	VBZ	O
postulated	VBN	O
that	IN	O
alteration	NN	O
of	IN	O
central	JJ	O
cholinergic	JJ	O
transmission	NN	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
anesthetics	NNS	O
produce	VBP	O
unconsciousness	JJ	O
.	.	O

The	DT	O
authors	NNS	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
altering	VBG	O
central	JJ	O
cholinergic	JJ	O
transmission	NN	O
,	,	O
by	IN	O
physostigmine	NN	O
and	CC	O
scopolamine	NN	O
,	,	O
on	IN	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
propofol	NN	O
.	.	O

METHODS	NNP	O
Propofol	NNP	O
was	VBD	O
administered	VBN	O
to	TO	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
physical	JJ	C
status	NN	C
1	CD	C
(	(	O
n	JJ	O
=	NNP	O
17	CD	SS
)	)	O
volunteers	NNS	O
with	IN	O
use	NN	O
of	IN	O
a	DT	O
computer-controlled	JJ	O
infusion	NN	O
pump	NN	O
at	IN	O
increasing	VBG	O
concentrations	NNS	O
until	IN	O
unconsciousness	JJ	O
resulted	VBD	O
(	(	O
inability	NN	O
to	TO	O
respond	VB	O
to	TO	O
verbal	VB	O
commands	NNS	O
,	,	O
abolition	NN	O
of	IN	O
spontaneous	JJ	O
movement	NN	O
)	)	O
.	.	O

Central	NNP	O
nervous	JJ	O
system	NN	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
use	NN	O
of	IN	O
the	DT	O
Auditory	NNP	O
Steady	NNP	O
State	NNP	O
Response	NNP	O
(	(	O
ASSR	NNP	O
)	)	O
and	CC	O
Bispectral	NNP	O
Index	NNP	O
(	(	O
BIS	NNP	O
)	)	O
analysis	NN	O
of	IN	O
electrooculogram	NN	O
.	.	O

During	IN	O
continuous	JJ	O
administration	NN	O
of	IN	O
propofol	NN	O
,	,	O
reversal	NN	O
of	IN	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
physostigmine	NN	O
(	(	O
28	CD	O
microgram/kg	NN	O
)	)	O
and	CC	O
block	NN	O
of	IN	O
this	DT	O
reversal	NN	O
by	IN	O
scopolamine	NN	O
(	(	O
8.6	CD	O
microgram/kg	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Propofol	NNP	O
produced	VBD	O
unconsciousness	JJ	O
at	IN	O
a	DT	O
plasma	JJ	O
concentration	NN	O
of	IN	O
3.2	CD	O
+/-	JJ	O
0.8	CD	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
microgram/ml	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
.	.	O

Unconsciousness	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
ASSR	NNP	O
(	(	O
0.10	CD	O
+/-	JJ	O
0.08	CD	O
microV	NN	O
[	NNP	O
awake	VBP	O
baseline	JJ	O
0.32	CD	O
+/-	JJ	O
0.18	CD	O
microV	NN	O
]	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
BIS	NNP	O
(	(	O
55.7	CD	O
+/-	JJ	O
8.8	CD	O
[	JJ	O
awake	NN	O
baseline	NN	O
92.4	CD	O
+/-	JJ	O
3.9	CD	O
]	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Physostigmine	NNP	O
restored	VBD	O
consciousness	NN	O
in	IN	O
9	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
,	,	O
with	IN	O
concomitant	JJ	O
increases	NNS	O
in	IN	O
ASSR	NNP	O
(	(	O
0.38	CD	O
+/-	JJ	O
0.17	CD	O
microV	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
BIS	NNP	O
(	(	O
75.3	CD	O
+/-	JJ	O
8.3	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
all	DT	O
subjects	NNS	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
scopolamine	NN	O
blocked	VBD	O
the	DT	O
physostigmine-induced	JJ	O
reversal	NN	O
of	IN	O
unconsciousness	NN	O
and	CC	O
the	DT	O
increase	NN	O
of	IN	O
the	DT	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
(	(	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
during	IN	O
propofol-induced	JJ	O
unconsciousness	NN	O
:	:	O
0.09	CD	O
+/-	JJ	O
0.09	CD	O
microV	NN	O
and	CC	O
58.2	CD	O
+/-	JJ	O
7.5	CD	O
,	,	O
respectively	RB	O
;	:	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
after	IN	O
physostigmine	JJ	O
administration	NN	O
:	:	O
0.08	CD	O
+/-	JJ	O
0.06	CD	O
microV	NN	O
and	CC	O
56.8	CD	O
+/-	JJ	O
6.7	CD	O
,	,	O
respectively	RB	O
,	,	O
NS	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
propofol	NN	O
is	VBZ	O
mediated	VBN	O
at	IN	O
least	JJS	O
in	IN	O
part	NN	O
via	IN	O
interruption	NN	O
of	IN	O
central	JJ	O
cholinergic	NN	O
muscarinic	JJ	O
transmission	NN	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
acetylsalicylic	JJ	O
acid	NN	O
on	IN	O
B-thromboglobulin	NNP	O
and	CC	O
platelet	VB	O
factor	NN	O
4	CD	O
plasma	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
transient	JJ	C
ischaemic	JJ	C
attacks	NNS	C
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acetylsalicylic	JJ	O
acid	NN	O
(	(	O
ASA	NNP	O
)	)	O
versus	NN	O
placebo	NN	O
on	IN	O
B-thromboglobulin	NNP	O
(	(	O
B-TG	NNP	O
)	)	O
and	CC	O
platelet	JJ	O
factor	NN	O
4	CD	O
(	(	O
PF4	NNP	O
)	)	O
plasma	NN	O
levels	NNS	O
and	CC	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
in	IN	O
25	CD	SS
male	JJ	SE
patients	NNS	O
with	IN	O
transient	JJ	C
ischaemic	JJ	C
attacks	NNS	C
(	(	O
TIA	NNP	C
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
two	CD	O
groups	NNS	O
:	:	O
14	CD	O
patients	NNS	O
received	JJ	O
oral	JJ	O
treatment	NN	O
with	IN	O
ASA	NNP	O
500	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

for	IN	O
14	CD	O
days	NNS	O
,	,	O
11	CD	O
patients	NNS	O
placebo	JJ	O
b.i.d	NN	O
.	.	O

for	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

B-TG	NNP	O
and	CC	O
PF4	NNP	O
plasma	NN	O
levels	NNS	O
and	CC	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
were	VBD	O
determined	VBN	O
in	IN	O
basal	NN	O
conditions	NNS	O
,	,	O
and	CC	O
two	CD	O
hours	NNS	O
,	,	O
and	CC	O
seven	CD	O
and	CC	O
fourteen	JJ	O
days	NNS	O
after	IN	O
starting	VBG	O
with	IN	O
ASA	NNP	O
or	CC	O
placebo	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
same	JJ	O
parameters	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
20	CD	SS
healthy	JJ	C
males	NNS	SE
of	IN	O
matched	JJ	O
age	NN	O
.	.	O

Basal	NNP	O
levels	NNS	O
of	IN	O
plasma	JJ	O
B-TG	NNP	O
and	CC	O
PF4	NNP	O
and	CC	O
the	DT	O
maximal	JJ	O
amplitude	NN	O
of	IN	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
were	VBD	O
abnormally	RB	O
high	JJ	O
in	IN	O
TIA	NNP	O
patients	NNS	O
.	.	O

ASA	NNP	O
caused	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
B-TG	NNP	O
plasma	NN	O
levels	NNS	O
in	IN	O
TIA	NNP	O
patients	NNS	O
2	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
,	,	O
but	CC	O
no	DT	O
effect	NN	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
7th	CD	O
and	CC	O
14th	CD	O
day	NN	O
of	IN	O
treatment	NN	O
.	.	O

PF4	NNP	O
plasma	NN	O
levels	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
ASA	NNP	O
treatment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
ASA	NNP	O
,	,	O
at	IN	O
the	DT	O
dose	NN	O
conventionally	RB	O
used	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
release	NN	O
of	IN	O
two	CD	O
alpha-granule	JJ	O
proteins	NNS	O
.	.	O

Hyperbaric	NNP	O
oxygen	NN	O
attenuation	NN	O
of	IN	O
lipopolysaccharide-induced	JJ	C
acute	NN	C
lung	NN	C
injury	NN	C
involves	VBZ	O
heme	JJ	O
oxygenase-1	NN	O
.	.	O

BACKGROUND	NNP	O
Hyperbaric	NNP	O
oxygen	NN	O
(	(	O
HBO	NNP	O
)	)	O
attenuates	VBZ	O
lipopolysaccharide	JJ	O
(	(	O
LPS	NNP	O
)	)	O
-induced	VBD	O
acute	JJ	C
lung	NN	C
injury	NN	C
.	.	O

This	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
HBO	NNP	O
involves	VBZ	O
inhibition	NN	O
of	IN	O
inducible	JJ	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(	(	O
iNOS	NN	O
)	)	O
expression	NN	O
and	CC	O
subsequent	JJ	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
biosynthesis	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
heme	JJ	O
oxygenase-1	JJ	O
(	(	O
HO-1	NNP	O
)	)	O
on	IN	O
this	DT	O
HBO	NNP	O
inhibition	NN	O
of	IN	O
iNOS	JJ	O
induction	NN	O
and	CC	O
acute	NN	O
lung	NN	O
injury	NN	O
in	IN	O
septic	JJ	O
rat	NN	O
lungs	NNS	O
.	.	O

METHODS	NNP	O
Before	IN	O
the	DT	O
experiment	NN	O
,	,	O
72	CD	SS
rats	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
HBO	NNP	O
or	CC	O
air	NN	O
treatment	NN	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
HBO	NNP	O
pre-treatment	NN	O
,	,	O
the	DT	O
rats	NNS	O
were	VBD	O
further	RB	O
divided	VBN	O
into	IN	O
the	DT	O
following	JJ	O
subgroups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
:	:	O
(	(	O
i	NN	O
)	)	O
LPS	NNP	O
injection	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
normal	JJ	O
saline	NN	O
(	(	O
N/S	NNP	O
)	)	O
injection	NN	O
,	,	O
(	(	O
iii	NN	O
)	)	O
hemin	NN	O
(	(	O
a	DT	O
HO-1	NNP	O
inducer	NN	O
)	)	O
plus	CC	O
LPS	NNP	O
,	,	O
(	(	O
iv	NN	O
)	)	O
hemin	NN	O
alone	RB	O
,	,	O
(	(	O
v	NN	O
)	)	O
tin	NN	O
protoporphyrin	NN	O
(	(	O
SnPP	NNP	O
;	:	O
a	DT	O
HO-1	NNP	O
inhibitor	NN	O
)	)	O
plus	CC	O
LPS	NNP	O
,	,	O
and	CC	O
(	(	O
vi	NN	O
)	)	O
SnPP	NNP	O
alone	RB	O
.	.	O

All	DT	O
rats	NNS	O
were	VBD	O
maintained	VBN	O
for	IN	O
6	CD	O
h	NN	O
and	CC	O
then	RB	O
sacrificed	VBD	O
with	IN	O
a	DT	O
high-dose	JJ	O
pentobarbital	JJ	O
injection	NN	O
.	.	O

Lung	NNP	O
injuries	NNS	O
and	CC	O
relevant	JJ	O
enzymes	NNS	O
expression	NN	O
were	VBD	O
thus	RB	O
assayed	VBN	O
.	.	O

RESULTS	NNP	O
Histological	NNP	O
analysis	NN	O
,	,	O
PMNs/alveoli	NNP	O
ratio	NN	O
,	,	O
and	CC	O
wet/dry	JJ	O
weight	NN	O
ratio	NN	O
measurements	NNS	O
demonstrated	VBD	O
that	IN	O
LPS	NNP	O
caused	VBD	O
significant	JJ	O
lung	JJ	O
injury	NN	O
and	CC	O
HBO	NNP	O
and/or	VBP	O
hemin	NN	O
significantly	RB	O
attenuated	VBD	O
this	DT	O
LPS-induced	JJ	O
lung	NN	O
injury	NN	O
.	.	O

Increased	VBD	O
pulmonary	JJ	O
iNOS	NN	O
expression	NN	O
and	CC	O
NO	DT	O
production	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
lung	JJ	O
injury	NN	O
.	.	O

Induction	NN	O
of	IN	O
HO-1	NNP	O
,	,	O
by	IN	O
HBO	NNP	O
and/or	NN	O
hemin	NN	O
,	,	O
significantly	RB	O
attenuated	VBD	O
this	DT	O
LPS-induced	JJ	O
iNOS	NN	O
expression	NN	O
and	CC	O
acute	NN	O
lung	NN	O
injury	NN	O
.	.	O

SnPP	NNP	O
,	,	O
on	IN	O
the	DT	O
contrary	JJ	O
,	,	O
offset	VB	O
the	DT	O
effects	NNS	O
of	IN	O
HBO	NNP	O
and	CC	O
worsened	VBD	O
the	DT	O
LPS-induced	NNP	O
lung	NN	O
injury	NN	O
.	.	O

CONCLUSIONS	NNP	O
HBO	NNP	O
may	MD	O
act	VB	O
through	IN	O
inhibiting	VBG	O
pulmonary	JJ	O
iNOS	NN	O
expression	NN	O
to	TO	O
attenuate	VB	O
LPS-induced	NNP	O
acute	NN	O
lung	NN	O
injury	NN	O
in	IN	O
septic	JJ	C
rats	NNS	C
.	.	O

Furthermore	RB	O
,	,	O
this	DT	O
HBO	NNP	O
attenuation	NN	O
of	IN	O
iNOS	JJ	O
expression	NN	O
involves	VBZ	O
HO-1	NNP	O
induction	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
combined	VBN	O
with	IN	O
salbutamol	NN	O
and	CC	O
ipratropium	NN	O
bromide	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
chronic	JJ	C
obstructive	JJ	C
pulmonary	JJ	C
disease	NN	C
.	.	O

BACKGROUND	IN	O
The	DT	O
efficacy	NN	O
of	IN	O
nebulized	JJ	O
corticosteroids	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
exacerbation	NN	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	C
)	)	O
has	VBZ	O
been	VBN	O
poorly	RB	O
studied	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
+	VBZ	O
salbutamol/ipratropium	JJ	O
bromide	NN	O
(	(	O
1,875/375	CD	O
microg	NN	O
)	)	O
b.i.d	NN	O
.	.	O

in	IN	O
comparison	NN	O
with	IN	O
placebo	NN	O
+	NNP	O
salbutamol/ipratropium	NN	O
bromide	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
114	CD	SS
patients	NNS	O
with	IN	O
COPD	NNP	C
of	IN	O
moderate-to-severe	JJ	O
degree	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
severe	JJ	O
exacerbations	NNS	O
over	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
respiratory	NN	O
symptoms	NNS	O
,	,	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
s	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
,	,	O
shuttle	JJ	O
walking	VBG	O
test	NN	O
distance	NN	O
and	CC	O
St.	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
scores	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
number	NN	O
of	IN	O
exacerbations	NNS	O
was	VBD	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
19	CD	O
vs.	FW	O
34	CD	O
,	,	O
p	NN	O
=	NNP	O
0.054	CD	O
)	)	O
;	:	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
at	IN	O
least	JJS	O
one	CD	O
exacerbation	NN	O
during	IN	O
the	DT	O
study	NN	O
was	VBD	O
also	RB	O
decreased	VBN	O
(	(	O
16	CD	O
vs.	FW	O
26	CD	O
,	,	O
p	NN	O
=	NNP	O
0.059	CD	O
)	)	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
type	JJ	O
3	CD	O
Anthonisens	NNP	O
's	POS	O
exacerbations	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
flunisolide	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.044	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
scores	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
flunisolide	JJ	O
group	NN	O
but	CC	O
nonsignificant	NN	O
for	IN	O
dyspnea	NN	O
,	,	O
cough	NN	O
,	,	O
sputum	NN	O
amount	NN	O
and	CC	O
purulence	NN	O
.	.	O

FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
to	TO	O
baseline	VB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
-time	NN	O
curve	NN	O
during	IN	O
the	DT	O
6-month	JJ	O
period	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
(	(	O
5.2	CD	O
+/-	JJ	O
10.6	CD	O
vs.	FW	O
2.1	CD	O
+/-	JJ	O
5.0	CD	O
,	,	O
flunisolide	RB	O
vs.	FW	O
placebo	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.047	CD	O
)	)	O
.	.	O

For	IN	O
shuttle	JJ	O
walking	VBG	O
test	NN	O
distance	NN	O
and	CC	O
scores	NNS	O
of	IN	O
the	DT	O
St.	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
evaluation	NN	O
and	CC	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nebulized	NNP	O
flunisolide	NN	O
is	VBZ	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
other	JJ	O
inhaled	JJ	O
corticosteroids	NNS	O
when	WRB	O
added	VBN	O
to	TO	O
nebulized	JJ	O
salbutamol/ipratropium	NN	O
bromide	NN	O
in	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
moderate-to-severe	JJ	C
COPD	NNP	C
patients	NNS	O
.	.	O

Dissociation	NN	O
between	IN	O
cortical	JJ	O
activation	NN	O
and	CC	O
cognitive	JJ	O
performance	NN	O
under	IN	O
pharmacological	JJ	O
blood	NN	O
pressure	NN	O
elevation	NN	O
in	IN	O
chronic	JJ	O
hypotension	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
explored	VBD	O
the	DT	O
impact	NN	O
of	IN	O
pharmacological	JJ	O
blood	NN	O
pressure	NN	O
elevation	NN	O
on	IN	O
cortical	JJ	O
activation	NN	O
and	CC	O
reaction	NN	O
time	NN	O
in	IN	O
chronic	JJ	C
hypotension	NN	C
.	.	O

Effects	NNS	O
of	IN	O
the	DT	O
sympathomimetic	JJ	O
etilefrine	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
50	CD	SS
hypotensive	JJ	C
persons	NNS	O
based	VBN	O
on	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
double	JJ	O
blind	NN	O
design	NN	O
.	.	O

As	IN	O
an	DT	O
indicator	NN	O
of	IN	O
cortical	JJ	O
excitability	NN	O
,	,	O
the	DT	O
contingent	NN	O
negative	JJ	O
variation	NN	O
(	(	O
CNV	NNP	O
)	)	O
,	,	O
induced	VBN	O
by	IN	O
a	DT	O
constant	JJ	O
foreperiod	NN	O
reaction	NN	O
time	NN	O
task	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
at	IN	O
frontal	JJ	O
(	(	O
F3	NNP	O
,	,	O
Fz	NNP	O
,	,	O
F4	NNP	O
)	)	O
and	CC	O
central	JJ	O
(	(	O
C3	NNP	O
,	,	O
Cz	NNP	O
,	,	O
C4	NNP	O
)	)	O
scalp	NN	O
sites	NNS	O
.	.	O

Etilefrine	NNP	O
provoked	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
frontal	NN	O
and	CC	O
central	JJ	O
CNV	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
shorter	JJR	O
reaction	NN	O
times	NNS	O
were	VBD	O
observed	JJ	O
following	JJ	O
drug	NN	O
administration	NN	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
pharmacologically	RB	O
induced	VBN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
was	VBD	O
correlated	VBN	O
to	TO	O
CNV	NNP	O
attrition	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
performance	NN	O
enhancement	NN	O
.	.	O

Inhibitory	JJ	O
effects	NNS	O
of	IN	O
baroreceptor	NN	O
activation	NN	O
on	IN	O
cortical	JJ	O
excitability	NN	O
and	CC	O
enhanced	VBD	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
mediating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
on	IN	O
cerebral	JJ	O
functioning	NN	O
.	.	O

Implications	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hypotension	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Intra-articular	JJ	O
hyaluronic	JJ	O
acid	NN	O
compared	VBN	O
to	TO	O
exercise	VB	O
therapy	NN	O
in	IN	O
osteoarthritis	NN	C
of	IN	O
the	DT	O
ankle	NN	C
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
long-term	JJ	O
follow-up	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
hyaluronic	JJ	O
acid	NN	O
(	(	O
HA	NNP	O
)	)	O
or	CC	O
exercise	NN	O
therapy	NN	O
can	MD	O
improve	VB	O
functional	JJ	O
parameters	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	C
)	)	O
of	IN	O
the	DT	O
ankle	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
43	CD	O
ankles	NNS	O
(	(	O
30	CD	SS
patients	NNS	O
)	)	O
with	IN	O
radiographic	JJ	O
Kellgren	NNP	O
Lawrence	NNP	O
grade	VBD	O
III	NNP	O
OA	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
three	CD	O
intra-articular	JJ	O
HA	NNP	O
injections	NNS	O
,	,	O
with	IN	O
one-week	JJ	O
interval	NN	O
of	IN	O
or	CC	O
exercise	NN	O
therapy	NN	O
for	IN	O
six	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
the	DT	O
American	JJ	O
Orthopaedic	NNP	O
Foot	NNP	O
and	CC	O
Ankle	NNP	O
Society	NNP	O
(	(	O
AOFAS	NNP	O
)	)	O
Ankle-Hindfoot	NNP	O
Scale	NNP	O
and	CC	O
followed-up	NN	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Total	JJ	O
AOFAS	NNP	O
Ankle-Hindfoot	NNP	O
score	NN	O
of	IN	O
OA	NNP	O
patients	NNS	O
has	VBZ	O
improved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
varying	VBG	O
from	IN	O
61.6+/-16.8	JJ	O
to	TO	O
90.1+/-9.7	JJ	O
with	IN	O
HA	NNP	O
treatment	NN	O
and	CC	O
from	IN	O
72.1+/-16.6	JJ	O
to	TO	O
87.5+/-17.5	JJ	O
using	VBG	O
exercise	NN	O
therapy	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
This	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
confirmed	VBD	O
that	IN	O
,	,	O
both	DT	O
HA	NNP	O
injections	NNS	O
and	CC	O
exercise	NN	O
therapy	NN	O
provide	VBP	O
functional	JJ	O
improvement	NN	O
.	.	O

However	RB	O
,	,	O
larger	JJR	O
trials	NNS	O
with	IN	O
longer	JJR	O
follow-up	NN	O
are	VBP	O
necessary	JJ	O
for	IN	O
more	RBR	O
definite	JJ	O
conclusions	NNS	O
.	.	O

Gamma-hydroxybutyric	JJ	O
acid	NN	O
versus	NN	O
clomethiazole	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcohol	NN	C
withdrawal	NN	C
syndrome	NN	C
in	IN	O
a	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
:	:	O
an	DT	O
open	JJ	O
,	,	O
single-center	JJ	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Clomethiazole	NNP	O
(	(	O
CLO	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
treating	VBG	O
alcohol	NN	C
withdrawal	NN	C
syndrome	NN	C
(	(	O
AWS	NNP	C
)	)	O
.	.	O

Gamma-Hydroxybutyric	JJ	O
acid	NN	O
(	(	O
GHB	NNP	O
)	)	O
has	VBZ	O
also	RB	O
been	VBN	O
introduced	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcoholic	JJ	O
patients	NNS	O
and	CC	O
is	VBZ	O
effective	JJ	O
in	IN	O
surgical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
patients	NNS	O
in	IN	O
preventing	VBG	O
and	CC	O
treating	VBG	O
AWS	NNP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
comparative	JJ	O
studies	NNS	O
between	IN	O
CLO	NNP	O
and	CC	O
GHB	NNP	O
in	IN	O
a	DT	O
medical	JJ	O
ICU	NNP	O
setting	NN	O
.	.	O

METHODS	NNP	O
Twenty-six	NNP	SS
alcoholic	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
AWS	NNP	O
and	CC	O
concomitant	JJ	O
medical	JJ	O
diseases	NNS	O
were	VBD	O
randomally	RB	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

CLO	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
to	TO	O
12	CD	O
patients	NNS	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
250	CD	O
mg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
a	DT	O
liquid	NN	O
;	:	O
GHB	NNP	O
(	(	O
initially	RB	O
30	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
BW	NNP	O
)	)	O
followed	VBN	O
by	IN	O
15	CD	O
mg/kg	NNS	O
BW	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
to	TO	O
14	CD	O
patients	NNS	O
.	.	O

Four	CD	O
major	JJ	O
AWS	NNP	O
symptoms	NNS	O
(	(	O
tremor	NN	O
,	,	O
sweating	VBG	O
,	,	O
nausea	NN	O
,	,	O
restlessness	NN	O
)	)	O
were	VBD	O
scored	VBN	O
,	,	O
and	CC	O
the	DT	O
administration	NN	O
of	IN	O
additional	JJ	O
medication	NN	O
was	VBD	O
registered	VBN	O
.	.	O

RESULTS	NNP	O
GHB	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
treating	VBG	O
AWS	NNP	O
symptoms	NNS	O
.	.	O

In	IN	O
the	DT	O
GHB	NNP	O
group	NN	O
,	,	O
AWS	NNP	O
score	NN	O
dropped	VBD	O
from	IN	O
6.6	CD	O
+/-	JJ	O
2.6	CD	O
to	TO	O
1.8	CD	O
+/-	JJ	O
2.1	CD	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
while	IN	O
in	IN	O
the	DT	O
CLO	NNP	O
group	NN	O
,	,	O
the	DT	O
score	NN	O
dropped	VBD	O
from	IN	O
6	CD	O
+/-	JJ	O
2.5	CD	O
to	TO	O
4.1	CD	O
+/-	JJ	O
2.4	CD	O
(	(	O
n.	JJ	O
s.	NN	O
)	)	O
.	.	O

Differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=.021	NN	O
,	,	O
two-way	JJ	O
ANOVA	NNP	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
alter	VB	O
outcome	NN	O
or	CC	O
the	DT	O
duration	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
.	.	O

No	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

CONCLUSION	NNP	O
GHB	NNP	O
effectively	RB	O
controls	VBZ	O
AWS	NNP	O
symptoms	NNS	O
in	IN	O
medical	JJ	O
ICU	NNP	O
patients	NNS	O
.	.	O

The	DT	O
rapid	JJ	O
initial	JJ	O
treatment	NN	O
response	NN	O
of	IN	O
GHB	NNP	O
in	IN	O
contrast	NN	O
to	TO	O
CLO	NNP	O
has	VBZ	O
no	DT	O
influence	NN	O
on	IN	O
duration	NN	O
of	IN	O
patient	NN	O
withdrawal	NN	O
.	.	O

The	DT	O
costs	NNS	O
and	CC	O
effects	NNS	O
of	IN	O
a	DT	O
nutritional	JJ	O
education	NN	O
program	NN	O
following	VBG	O
work-site	JJ	O
cholesterol	NN	O
screening	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
costs	NNS	O
and	CC	O
impact	NN	O
of	IN	O
a	DT	O
nutrition	JJ	O
education	NN	O
program	NN	O
following	VBG	O
a	DT	O
cholesterol	NN	O
screening	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	SS
work-sites	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
educational	JJ	O
interventions	NNS	O
:	:	O
a	DT	O
usual	JJ	O
intervention	NN	O
of	IN	O
5	CD	O
minutes	NNS	O
of	IN	O
counseling	NN	O
,	,	O
or	CC	O
a	DT	O
special	JJ	O
intervention	NN	O
of	IN	O
2	CD	O
hours	NNS	O
of	IN	O
behaviorally	RB	O
based	VBN	O
education	NN	O
on	IN	O
dietary	JJ	O
changes	NNS	O
to	TO	O
lower	VB	O
serum	NN	O
cholesterol	NN	O
.	.	O

Costs	NNS	O
were	VBD	O
monitored	VBN	O
,	,	O
and	CC	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
retested	VBN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
per-person	JJ	O
cost	NN	O
for	IN	O
screening	VBG	O
and	CC	O
the	DT	O
educational	JJ	O
intervention	NN	O
was	VBD	O
about	IN	O
$	$	O
50	CD	O
.	.	O

Cholesterol	NN	O
levels	NNS	O
differed	VBD	O
little	RB	O
between	IN	O
the	DT	O
two	CD	O
intervention	NN	O
groups	NNS	O
6	CD	O
months	NNS	O
after	IN	O
screening	VBG	O
,	,	O
but	CC	O
after	IN	O
12	CD	O
months	NNS	O
those	DT	O
in	IN	O
the	DT	O
special	JJ	O
intervention	NN	O
worksites	NNS	O
showed	VBD	O
a	DT	O
6.5	CD	O
%	NN	O
drop	NN	O
in	IN	O
cholesterol	NN	O
,	,	O
whereas	IN	O
those	DT	O
at	IN	O
the	DT	O
usual	JJ	O
intervention	NN	O
worksites	NNS	O
showed	VBD	O
a	DT	O
drop	NN	O
of	IN	O
only	RB	O
3.0	CD	O
%	NN	O
.	.	O

Hence	NNP	O
a	DT	O
3.5	CD	O
%	NN	O
cholesterol	NN	O
reduction	NN	O
was	VBD	O
attributable	JJ	O
to	TO	O
the	DT	O
special	JJ	O
intervention	NN	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
behaviorally	RB	O
based	VBN	O
nutrition	JJ	O
education	NN	O
program	NN	O
following	VBG	O
cholesterol	NN	O
screening	VBG	O
can	MD	O
have	VB	O
a	DT	O
meaningful	JJ	O
impact	NN	O
on	IN	O
long-term	JJ	O
cholesterol	NN	O
levels	NNS	O
at	IN	O
a	DT	O
low	JJ	O
cost	NN	O
.	.	O

Nutrition	NNP	O
education	NN	O
in	IN	O
work-sites	NNS	O
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
useful	JJ	O
way	NN	O
to	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
heart	NN	O
disease	NN	O
in	IN	O
communities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
upper	JJ	O
arm	NN	O
brachial	NN	O
basilic	NN	O
and	CC	O
prosthetic	JJ	O
forearm	NN	O
arteriovenous	JJ	O
fistula	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
.	.	O

BACKGROUND	NNP	O
Creation	NNP	O
of	IN	O
an	DT	O
arteriovenous	JJ	O
fistula	NN	O
(	(	O
AVF	NNP	O
)	)	O
may	MD	O
increase	VB	O
left	VBD	O
ventricular	JJ	O
hypertrophy	NN	O
in	IN	O
the	DT	O
hemodialysis	NN	C
population	NN	O
.	.	O

Aim	NNP	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
brachial-basilic	JJ	O
(	(	O
BB	NNP	O
)	)	O
AVF	NNP	O
and	CC	O
the	DT	O
prosthetic	JJ	O
brachial-antecubital	JJ	O
forearm	NN	O
loop	NN	O
access	NN	O
(	(	O
PTFE	NNP	O
)	)	O
on	IN	O
cardiac	JJ	O
performance	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
BB-AVF	NNP	O
or	CC	O
prosthetic	JJ	O
brachial-antecubital	JJ	O
forearm	NN	O
loop	NN	O
access	NN	O
.	.	O

Before	IN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
AVF	NNP	O
creation	NN	O
patients	NNS	O
underwent	VBD	O
an	DT	O
echocardiographic	JJ	O
examination	NN	O
.	.	O

Mann-Whitney	JJ	O
U-test	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
relative	JJ	O
increase	NN	O
between	IN	O
the	DT	O
measured	JJ	O
cardiac	JJ	O
parameters	NNS	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Twenty-seven	JJ	SS
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
relative	JJ	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
parameters	NNS	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Only	RB	O
left	VBD	O
ventricular	JJ	O
end-diastolic	JJ	O
diameter	NN	O
tended	VBD	O
to	TO	O
be	VB	O
of	IN	O
significance	NN	O
.	.	O

Mean	NNP	O
blood	NN	O
flow	NN	O
through	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
was	VBD	O
1680+/-156	JJ	O
and	CC	O
1450+/-221	JJ	O
mL/min	NNS	O
three	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
for	IN	O
the	DT	O
PTFE	NNP	O
and	CC	O
the	DT	O
BB-AVF	NNP	O
group	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	NN	O
After	IN	O
three	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
changes	NNS	O
in	IN	O
cardiac	JJ	O
structure	NN	O
were	VBD	O
comparable	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
BB	NNP	C
and	CC	O
PTFE	NNP	C
AVFs	NNP	C
.	.	O

Also	RB	O
access	NN	O
flow	NN	O
was	VBD	O
comparable	JJ	O
at	IN	O
this	DT	O
time	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
creation	NN	O
of	IN	O
a	DT	O
fistula	NN	O
on	IN	O
LV	NNP	O
structure	NN	O
were	VBD	O
limited	VBN	O
.	.	O

Longer	RBR	O
follow	VB	O
up	RP	O
time	NN	O
may	MD	O
be	VB	O
needed	VBN	O
to	TO	O
explore	VB	O
the	DT	O
long	JJ	O
term	NN	O
effects	NNS	O
of	IN	O
different	JJ	O
vascular	JJ	O
accesses	NNS	O
on	IN	O
cardiac	JJ	O
function	NN	O
.	.	O

Optimization	NN	O
of	IN	O
acid	JJ	O
suppression	NN	O
for	IN	O
patients	NNS	O
with	IN	O
peptic	JJ	C
ulcer	NN	C
bleeding	NN	C
:	:	O
an	DT	O
intragastric	JJ	O
pH-metry	NN	O
study	NN	O
with	IN	O
omeprazole	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
whether	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
dose	NN	O
of	IN	O
omeprazole	NN	O
(	(	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
)	)	O
during	IN	O
24	CD	O
h	NNS	O
can	MD	O
be	VB	O
subsequently	RB	O
reduced	VBN	O
with	IN	O
maintained	JJ	O
effect	NN	O
.	.	O

Second	NNP	O
,	,	O
to	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
oral	JJ	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
given	VBN	O
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
up	IN	O
to	TO	O
day	NN	O
10	CD	O
,	,	O
after	IN	O
cessation	NN	O
of	IN	O
a	DT	O
3-day	JJ	O
intravenous	JJ	O
infusion	NN	O
(	(	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
partly	RB	O
blinded	VBD	O
study	NN	O
.	.	O

METHODS	NNP	O
Twelve	NNP	SS
Helicobacter	NNP	C
pylori	NN	C
(	(	C
+	NNP	C
)	)	C
patients	NNS	C
and	CC	O
12	CD	SS
H.	NNP	C
pylori	NN	C
(	(	C
-	:	C
)	)	C
subjects	NNS	O
were	VBD	O
included	VBN	O
.	.	O

In	IN	O
part	NN	O
I	PRP	O
the	DT	O
patients	NNS	O
received	VBD	O
omeprazole	JJ	O
,	,	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
,	,	O
during	IN	O
24	CD	O
h	NN	O
followed	VBN	O
by	IN	O
8	CD	O
,	,	O
4	CD	O
or	CC	O
2	CD	O
mg/h	NN	O
.	.	O

In	IN	O
part	NN	O
II	NNP	O
the	DT	O
subjects	NNS	O
received	VBD	O
80	CD	O
mg	NNS	O
+	VBD	O
8	CD	O
mg/h	NN	O
during	IN	O
3	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
20	CD	O
mg	NNS	O
omeprazole	JJ	O
orally	RB	O
,	,	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
until	IN	O
day	NN	O
10	CD	O
.	.	O

Intragastric	NNP	O
pH	NN	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
H.	NNP	O
pylori	FW	O
(	(	O
+	NN	O
)	)	O
patients	NNS	O
showed	VBD	O
a	DT	O
rapid	JJ	O
increase	NN	O
of	IN	O
intragastric	JJ	O
pH	NN	O
with	IN	O
a	DT	O
mean	JJ	O
intragastric	JJ	O
pH	NN	O
of	IN	O
6.7	CD	O
during	IN	O
the	DT	O
second	JJ	O
half	NN	O
of	IN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

After	IN	O
the	DT	O
subsequent	JJ	O
dose	NN	O
reduction	NN	O
,	,	O
the	DT	O
mean	JJ	O
pH	NN	O
decreased	VBD	O
to	TO	O
6.1-6.2	JJ	O
.	.	O

Patients	NNPS	O
continuing	VBG	O
on	IN	O
8	CD	O
mg/h	NN	O
showed	VBD	O
the	DT	O
best	JJS	O
results	NNS	O
.	.	O

Likewise	NNP	O
,	,	O
all	DT	O
H.	NNP	O
pylori	NN	O
(	(	O
-	:	O
)	)	O
subjects	VBZ	O
showed	VBD	O
a	DT	O
rapid	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	O
of	IN	O
intragastric	JJ	O
acidity	NN	O
during	IN	O
the	DT	O
infusion	NN	O
.	.	O

Subsequent	NNP	O
dose	JJ	O
reduction	NN	O
to	TO	O
20	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
led	VBN	O
to	TO	O
a	DT	O
stable	JJ	O
fraction	NN	O
of	IN	O
time	NN	O
with	IN	O
pH	JJ	O
>	JJ	O
3	CD	O
of	IN	O
72	CD	O
%	NN	O
.	.	O

CONCLUSIONS	NNP	O
Omeprazole	NNP	O
given	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
80	CD	O
mg	NNS	O
+	VBD	O
8	CD	O
mg/h	NN	O
for	IN	O
72	CD	O
h	NN	O
followed	VBN	O
by	IN	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
raised	VBD	O
the	DT	O
intragastric	JJ	O
pH	NN	O
to	TO	O
and	CC	O
above	JJ	O
levels	NNS	O
alleged	VBN	O
to	TO	O
allow	VB	O
haemostasis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
peptic	JJ	C
ulcer	NN	C
bleeding	NN	C
and	CC	O
subsequent	JJ	O
healing	NN	O
of	IN	O
the	DT	O
ulcer	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
different	JJ	O
acupuncture	NN	O
and	CC	O
moxibustion	NN	O
therapies	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
postsurgical	JJ	C
gastroparesis	NN	C
syndrome	NN	C
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
optimize	VB	O
therapy	NN	O
of	IN	O
acupuncture	NN	O
and	CC	O
moxibustion	NN	O
for	IN	O
postsurgical	JJ	O
gastroparesis	NN	O
syndrome	NN	O
(	(	O
PGS	NNP	C
)	)	O
.	.	O

METHODS	NNP	O
Forty-one	JJ	SS
cases	NNS	O
of	IN	O
PGS	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
in	IN	O
order	NN	O
of	IN	O
visiting	VBG	O
.	.	O

Group	NNP	O
A	NNP	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	SS
)	)	O
were	VBD	O
treated	VBN	O
by	IN	O
warming	VBG	O
needle	JJ	O
moxibustion	NN	O
,	,	O
group	NN	O
B	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	SS
)	)	O
by	IN	O
acupuncture	NN	O
plus	CC	O
auricular	JJ	O
point	NN	O
sticking	NN	O
,	,	O
and	CC	O
group	NN	O
C	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	SS
)	)	O
by	IN	O
routine	JJ	O
acupuncture	NN	O
.	.	O

Changes	NNS	O
of	IN	O
gastric	JJ	O
drainage	NN	O
volume	NN	O
,	,	O
therapeutic	JJ	O
times	NNS	O
and	CC	O
cured	JJ	O
rate	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
All	PDT	O
the	DT	O
3	CD	O
therapeutic	JJ	O
methods	NNS	O
could	MD	O
significantly	RB	O
decrease	VB	O
gastric	JJ	O
drainage	NN	O
volume	NN	O
.	.	O

The	DT	O
cured	JJ	O
rate	NN	O
was	VBD	O
100.0	CD	O
%	NN	O
and	CC	O
the	DT	O
therapeutic	JJ	O
times	NNS	O
was	VBD	O
(	(	O
7.24	CD	O
+/-	JJ	O
3.87	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
A	NNP	O
,	,	O
66.7	CD	O
%	NN	O
,	,	O
(	(	O
9.83	CD	O
+/-	JJ	O
4.60	CD	O
)	)	O
times	NNS	O
in	IN	O
the	DT	O
group	NN	O
B	NNP	O
and	CC	O
75.0	CD	O
%	NN	O
,	,	O
(	(	O
15.25	CD	O
+/-	JJ	O
3.81	CD	O
)	)	O
times	NNS	O
in	IN	O
the	DT	O
group	NN	O
C	NNP	O
,	,	O
with	IN	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
cured	JJ	O
rate	NN	O
and	CC	O
the	DT	O
therapeutic	JJ	O
times	NNS	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
warming	VBG	O
needle	JJ	O
moxibustion	NN	O
is	VBZ	O
the	DT	O
best	JJS	O
method	NN	O
for	IN	O
PGS	NNP	O
,	,	O
with	IN	O
less	RBR	O
therapeutic	JJ	O
times	NNS	O
,	,	O
high	JJ	O
cured	VBN	O
rate	NN	O
and	CC	O
rapid	JJ	O
effect	NN	O
.	.	O

0.1	CD	O
%	NN	O
bupivacaine	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
requirement	NN	O
for	IN	O
epidural	JJ	O
fentanyl	NN	O
infusion	NN	O
after	IN	O
major	JJ	C
abdominal	JJ	C
surgery	NN	C
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Although	IN	O
local	JJ	O
anesthesia	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
to	TO	O
potentiate	VB	O
spinal	JJ	O
morphine	NN	O
analgesia	NN	O
in	IN	O
animal	JJ	O
studies	NNS	O
,	,	O
results	NNS	O
comparing	VBG	O
epidural	JJ	O
local	JJ	O
anesthesia/opioid	NN	O
mixtures	NNS	O
with	IN	O
opioid	JJ	O
alone	NN	O
are	VBP	O
contradictory	JJ	O
in	IN	O
clinical	JJ	O
studies	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
was	VBD	O
that	IN	O
,	,	O
although	IN	O
the	DT	O
concentration	NN	O
of	IN	O
bupivacaine	NN	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
was	VBD	O
low	JJ	O
to	TO	O
minimize	VB	O
its	PRP$	O
adverse	JJ	O
effects	NNS	O
,	,	O
if	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
a	DT	O
fentanyl/bupivacaine	JJ	O
solution	NN	O
was	VBD	O
closely	RB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
need	NN	O
,	,	O
the	DT	O
presence	NN	O
bupivacaine	NN	O
would	MD	O
reduce	VB	O
the	DT	O
requirement	NN	O
for	IN	O
epidural	JJ	O
fentanyl	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
fentanyl	NN	O
(	(	O
10	CD	O
micrograms/mL	NN	O
)	)	O
or	CC	O
a	DT	O
fentanyl/bupivacaine	NN	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
mixture	NN	O
epidurally	RB	O
corresponding	VBG	O
to	TO	O
the	DT	O
dermatome	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
incision	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
for	IN	O
the	DT	O
first	JJ	O
18	CD	O
hours	NNS	O
after	IN	O
major	JJ	C
abdominal	JJ	C
surgery	NN	C
.	.	O

The	DT	O
infusion	NN	O
was	VBD	O
titrated	VBN	O
for	IN	O
each	DT	O
patient	NN	O
to	TO	O
the	DT	O
rate	NN	O
required	VBN	O
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
forced	VBN	O
inspiration	NN	O
(	(	O
pain	NN	O
score	NN	O
<	NN	O
or	CC	O
=	$	O
2	CD	O
,	,	O
maximum	JJ	O
10	CD	O
)	)	O
.	.	O

Pain	NN	O
scores	NNS	O
,	,	O
the	DT	O
fentanyl	JJ	O
doses	NNS	O
required	VBN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
fentanyl	NN	O
at	IN	O
18	CD	O
hours	NNS	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
reported	VBD	O
similar	JJ	O
median	JJ	O
pain	NN	O
scores	NNS	O
and	CC	O
were	VBD	O
equally	RB	O
satisfied	VBN	O
with	IN	O
pain	NN	O
relief	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	NN	O
required	VBN	O
post-operative	JJ	O
fentanyl	JJ	O
infusion	NN	O
rate	NN	O
(	(	O
57.7	CD	O
+/-	JJ	O
19.5	CD	O
micrograms/h	NN	O
)	)	O
and	CC	O
the	DT	O
plasma	NN	O
concentrations	NNS	O
(	(	O
0.84	CD	O
+/-	JJ	O
0.36	CD	O
ng/mL	NN	O
)	)	O
in	IN	O
the	DT	O
fentanyl	NN	O
group	NN	O
were	VBD	O
comparable	JJ	O
to	TO	O
the	DT	O
infusion	NN	O
rate	NN	O
(	(	O
54.4	CD	O
+/-	JJ	O
19.2	CD	O
micrograms/h	NN	O
)	)	O
and	CC	O
the	DT	O
plasma	NN	O
concentrations	NNS	O
(	(	O
0.86	CD	O
+/-	JJ	O
0.36	CD	O
ng/mL	NN	O
)	)	O
in	IN	O
the	DT	O
fentanyl/bupivacaine	NN	O
group	NN	O
.	.	O

Respiratory	NNP	O
and	CC	O
cardiovascular	JJ	O
functions	NNS	O
were	VBD	O
preserved	VBN	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
,	,	O
pruritus	NN	O
,	,	O
and	CC	O
periods	NNS	O
of	IN	O
drowsiness	NN	O
or	CC	O
sleep	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
low	JJ	O
concentrations	NNS	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
,	,	O
bupivacaine	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
titrated	JJ	O
dose	NN	O
of	IN	O
epidural	JJ	O
fentanyl	NN	O
required	VBN	O
for	IN	O
adequate	JJ	O
pain	NN	O
relief	NN	O
during	IN	O
forced	VBN	O
inspiration	NN	O
after	IN	O
major	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

The	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
also	RB	O
comparable	JJ	O
whether	IN	O
or	CC	O
not	RB	O
low-dose	JJ	O
bupivacaine	NN	O
infusion	NN	O
was	VBD	O
used	VBN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
Yufeining	VBG	O
on	IN	O
induced	JJ	O
sputum	JJ	O
interleukin-8	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
obstructive	JJ	C
pulmonary	JJ	C
disease	NN	C
at	IN	O
the	DT	O
stable	JJ	O
phase	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
Yufeining	NNP	O
,	,	O
a	DT	O
traditional	JJ	O
Chinese	JJ	O
medicine	NN	O
,	,	O
on	IN	O
induced	JJ	O
sputum	NN	O
interleukin-8	JJ	O
(	(	O
IL-8	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	C
)	)	O
at	IN	O
the	DT	O
stable	JJ	C
phase	NN	C
.	.	O

METHODS	NNP	O
Thirty-six	JJ	SS
patients	NNS	O
with	IN	O
COPD	NNP	C
were	VBD	O
divided	VBN	O
into	IN	O
trial	NN	O
group	NN	O
(	(	O
18	CD	O
cases	NNS	O
)	)	O
and	CC	O
control	NN	O
group	NN	O
(	(	O
18	CD	O
cases	NNS	O
)	)	O
randomly	RB	O
.	.	O

The	DT	O
trial	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
Yufeining	VBG	O
pills	NNS	O
taken	VBN	O
orally	RB	O
for	IN	O
half	PDT	O
a	DT	O
year	NN	O
;	:	O
the	DT	O
control	NN	O
group	NN	O
was	VBD	O
not	RB	O
given	VBN	O
any	DT	O
medicine	NN	O
.	.	O

Routine	NNP	O
lung	NN	O
function	NN	O
was	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Total	JJ	O
cell	NN	O
count	NN	O
(	(	O
TCC	NNP	O
)	)	O
,	,	O
differential	JJ	O
cell	NN	O
counts	NNS	O
(	(	O
DCCs	NNP	O
)	)	O
and	CC	O
IL-8	NNP	O
in	IN	O
induced	JJ	O
sputum	NN	O
were	VBD	O
determined	VBN	O
at	IN	O
the	DT	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
indices	NNS	O
of	IN	O
lung	NN	O
function	NN	O
improved	VBD	O
significantly	RB	O
after	IN	O
6	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
in	IN	O
trial	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
TCC	NNP	O
and	CC	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
decreased	VBD	O
significantly	RB	O
compared	VBN	O
with	IN	O
baseline	NN	O
in	IN	O
the	DT	O
trial	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
Sputum	NNP	O
IL-8	NNP	O
concentration	NN	O
dropped	VBD	O
significantly	RB	O
after	IN	O
6	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
,	,	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
5.216	CD	O
+/-	JJ	O
2.914	CD	O
microg/L	NN	O
to	TO	O
4.222	CD	O
+/-	JJ	O
2.140	CD	O
microg/L	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
insignificant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
parameters	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
between	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

CONCLUSION	NNP	O
Yufeining	NNP	O
could	MD	O
improve	VB	O
lung	NN	O
function	NN	O
,	,	O
decrease	NN	O
sputum	NN	O
TCC	NNP	O
,	,	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
and	CC	O
IL-8	NNP	O
concentration	NN	O
,	,	O
and	CC	O
relieve	VB	O
airway	NN	O
inflammation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
in	IN	O
the	DT	O
stable	JJ	O
phase	NN	O
.	.	O

Double-blind	NNP	O
randomized	JJ	O
evaluation	NN	O
of	IN	O
intercostal	JJ	O
nerve	NN	O
blocks	NNS	O
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
subarachnoid	VB	O
administered	JJ	O
morphine	NN	O
for	IN	O
post-thoracotomy	JJ	C
analgesia	NN	C
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Thoracotomy	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
pain	NN	O
and	CC	O
compromised	VBD	O
pulmonary	JJ	O
function	NN	O
.	.	O

Intercostal	NNP	O
nerve	NN	O
blocks	NNS	O
(	(	O
INB	NNP	O
)	)	O
and	CC	O
subarachnoid	JJ	O
morphine	NN	O
(	(	O
SM	NNP	O
)	)	O
act	NN	O
on	IN	O
different	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
pain	NN	O
pathway	RB	O
.	.	O

Each	DT	O
is	VBZ	O
effective	JJ	O
for	IN	O
post-thoracotomy	JJ	O
pain	NN	O
relief	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
these	DT	O
two	CD	O
modalities	NNS	O
in	IN	O
relieving	VBG	O
post-thoracotomy	JJ	O
pain	NN	O
and	CC	O
improving	VBG	O
postoperative	JJ	O
pulmonary	JJ	O
function	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
,	,	O
20	CD	SS
patients	NNS	O
undergoing	JJ	O
lateral	JJ	C
thoracotomy	NN	C
for	IN	O
lung	NN	C
resection	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
0.5	CD	O
mg	NN	O
SM	NNP	O
preoperatively	RB	O
and	CC	O
INB	NNP	O
with	IN	O
bupivacaine	NN	O
(	(	O
INB+	NNP	O
)	)	O
prior	RB	O
to	TO	O
wound	VB	O
closure	NN	O
or	CC	O
0.5	CD	O
mg	NNS	O
SM	NNP	O
with	IN	O
INB	NNP	O
using	VBG	O
saline	NN	O
(	(	O
INB-	NNP	O
)	)	O
.	.	O

Visual	JJ	O
analog	NN	O
scale	NN	O
pain	NN	O
scores	NNS	O
at	IN	O
rest	NN	O
,	,	O
with	IN	O
cough	NN	O
,	,	O
and	CC	O
with	IN	O
movement	NN	O
of	IN	O
the	DT	O
ipsilateral	JJ	O
arm	NN	O
,	,	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
(	(	O
FEV1	NNP	O
)	)	O
,	,	O
and	CC	O
forced	VBD	O
vital	JJ	O
capacity	NN	O
(	(	O
FVC	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
4	CD	O
,	,	O
24	CD	O
,	,	O
48	CD	O
,	,	O
and	CC	O
72	CD	O
hours	NNS	O
after	IN	O
the	DT	O
operation	NN	O
.	.	O

Opioid	NNP	O
use	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
the	DT	O
initial	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
operation	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
4	CD	O
hours	NNS	O
,	,	O
the	DT	O
INB+	NNP	O
group	NN	O
demonstrated	VBD	O
better	JJR	O
FEV1	NNP	O
(	(	O
56.6	CD	O
%	NN	O
vs.	FW	O
40.4	CD	O
%	NN	O
of	IN	O
baseline	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
FVC	NNP	O
values	NNS	O
(	(	O
54.6	CD	O
%	NN	O
vs.	FW	O
39.6	CD	O
%	NN	O
of	IN	O
baseline	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
less	RBR	O
resting	VBG	O
and	CC	O
cough	JJ	O
pain	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
FEV1	NNP	O
continued	VBD	O
to	TO	O
decline	VB	O
in	IN	O
the	DT	O
INB+	NNP	O
group	NN	O
at	IN	O
24	CD	O
hours	NNS	O
to	TO	O
lower	JJR	O
than	IN	O
the	DT	O
INB-	NNP	O
group	NN	O
although	IN	O
pain	NN	O
scores	NNS	O
were	VBD	O
similar	JJ	O
beyond	IN	O
4	CD	O
hours	NNS	O
.	.	O

Opioid	JJ	O
usage	NN	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
was	VBD	O
similar	JJ	O
(	(	O
INB-	NNP	O
,	,	O
16.7	CD	O
mg	NN	O
vs.	FW	O
INB+	NNP	O
,	,	O
13.2	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
.7	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
postoperative	JJ	O
INB	NNP	O
provided	VBD	O
modest	JJ	O
improvements	NNS	O
in	IN	O
pain	NN	O
and	CC	O
pulmonary	JJ	O
function	NN	O
when	WRB	O
used	VBN	O
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
0.5	CD	O
mg	NNS	O
SM	NNP	O
for	IN	O
post-thoracotomy	JJ	O
analgesia	NN	O
,	,	O
the	DT	O
benefits	NNS	O
were	VBD	O
transient	JJ	O
.	.	O

The	DT	O
authors	NNS	O
do	VBP	O
not	RB	O
recommend	VB	O
adding	VBG	O
INB	NNP	O
for	IN	O
patients	NNS	O
undergoing	JJ	O
lateral	JJ	O
thoracotomy	NN	O
who	WP	O
receive	VBP	O
0.5	CD	O
mg	NN	O
SM	NNP	O
.	.	O

Simvastatin	NNP	O
reduces	VBZ	O
sympathetic	JJ	O
outflow	NN	O
and	CC	O
augments	NNS	O
endothelium-independent	JJ	O
dilation	NN	O
in	IN	O
non-hyperlipidaemic	JJ	C
primary	JJ	C
hypertension	NN	C
.	.	O

OBJECTIVES	NNP	O
Previous	JJ	O
reports	NNS	O
,	,	O
involving	VBG	O
hypercholesterolaemic	JJ	O
hypertensive	JJ	O
subjects	NNS	O
,	,	O
that	IN	O
statins	VBZ	O
reduce	VB	O
muscle	NN	O
sympathetic	JJ	O
nerve	NN	O
activity	NN	O
(	(	O
MSNA	NNP	O
)	)	O
did	VBD	O
not	RB	O
investigate	VB	O
potential	JJ	O
neural	JJ	O
sites	NNS	O
of	IN	O
such	JJ	O
sympathoinhibition	NN	O
or	CC	O
determine	VB	O
its	PRP$	O
consequences	NNS	O
for	IN	O
endothelial	JJ	O
function	NN	O
or	CC	O
insulin	NN	O
resistance	NN	O
.	.	O

This	DT	O
study	NN	O
of	IN	O
hypertensive	JJ	C
subjects	NNS	C
with	IN	C
lower	JJR	C
plasma	NN	C
cholesterol	NN	C
tested	VBD	O
the	DT	O
hypotheses	NNS	O
that	WDT	O
lipophilic	JJ	O
simvastatin	NN	O
would	MD	O
attenuate	VB	O
resting	VBG	O
sympathoexcitation	NN	O
and	CC	O
augment	NN	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
MSNA	NNP	O
and	CC	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
,	,	O
flow-mediated	JJ	O
vasodilation	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomised	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

SETTING	NNP	O
Academic	NNP	O
hospital-based	JJ	O
study	NN	O
.	.	O

PATIENTS	NNP	O
Fourteen	JJ	O
non-hyperlipidaemic	JJ	O
primary	JJ	O
hypertensive	JJ	O
subjects	NNS	O
(	(	O
10	CD	O
men	NNS	O
;	:	O
overall	JJ	O
mean?SD	NN	O
age	NN	O
58?12	CD	O
years	NNS	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Four	NNP	O
weeks	NNS	O
of	IN	O
simvastatin	NN	O
(	(	O
80	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Resting	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
HR	NNP	O
,	,	O
MSNA	NNP	O
,	,	O
spontaneous	JJ	O
arterial	JJ	O
baroreflex	NN	O
MSNA	NNP	O
and	CC	O
HR	NNP	O
modulation	NN	O
,	,	O
endothelium-dependent	JJ	O
and	CC	O
endothelium-independent	JJ	O
vasodilation	NN	O
,	,	O
and	CC	O
the	DT	O
homoeostatic	JJ	O
model	NN	O
assessment	NN	O
of	IN	O
insulin	NN	O
resistance	NN	O
(	(	O
HOMA-IR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	O
lowered	VBD	O
MSNA	NNP	O
burst	JJ	O
frequency	NN	O
(	(	O
from	IN	O
32?12	CD	O
to	TO	O
25?9	CD	O
bursts/min	NN	O
)	)	O
and	CC	O
MSNA	NNP	O
burst	NN	O
incidence	NN	O
(	(	O
from	IN	O
55?23	CD	O
%	NN	O
to	TO	O
43?17	CD	O
%	NN	O
;	:	O
all	DT	O
p	VBP	O
<	$	O
0.01	CD	O
)	)	O
without	IN	O
affecting	VBG	O
BP	NNP	O
,	,	O
HR	NNP	O
,	,	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
either	DT	O
MSNA	NNP	O
or	CC	O
HR	NNP	O
,	,	O
or	CC	O
HR	NNP	O
variability	NN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
.	.	O

Plasma	NNP	O
glucose	NN	O
,	,	O
insulin	NN	O
,	,	O
HOMA-IR	NNP	O
and	CC	O
endothelium-dependent	JJ	O
vasodilation	NN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
were	VBD	O
unchanged	JJ	O
,	,	O
whereas	JJ	O
endothelium-independent	JJ	O
vasodilation	NN	O
increased	VBD	O
(	(	O
7.1?3.8	CD	O
%	NN	O
to	TO	O
9.7?3.9	CD	O
%	NN	O
,	,	O
n=13	RB	O
;	:	O
p	VB	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
fall	NN	O
in	IN	O
MSNA	NNP	O
was	VBD	O
unrelated	JJ	O
to	TO	O
the	DT	O
decrease	NN	O
in	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
r=0.41	NN	O
,	,	O
p=0.14	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
concept	NN	O
that	IN	O
,	,	O
in	IN	O
non-hyperlipidaemic	JJ	O
subjects	NNS	O
with	IN	O
primary	JJ	O
hypertension	NN	O
,	,	O
simvastatin	JJ	O
causes	VBZ	O
a	DT	O
cholesterol-independent	JJ	O
reduction	NN	O
in	IN	O
an	DT	O
elevated	JJ	O
central	JJ	O
set-point	NN	O
for	IN	O
MSNA	NNP	O
,	,	O
without	IN	O
affecting	VBG	O
arterial	JJ	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
either	DT	O
MSNA	NNP	O
or	CC	O
HR	NNP	O
.	.	O

There	EX	O
may	MD	O
be	VB	O
less	JJR	O
neurogenic	JJ	O
constraint	NN	O
on	IN	O
endothelium-independent	JJ	O
vasodilation	NN	O
as	IN	O
a	DT	O
consequence	NN	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
imitation	NN	O
effects	NNS	O
on	IN	O
children	NNS	A
with	IN	O
autism	NN	C
.	.	O

Twenty	NNP	SS
children	NNS	A
with	IN	O
autism	NN	C
(	(	O
mean	JJ	O
age	NN	O
,	,	O
5	CD	A
years	NNS	A
)	)	O
were	VBD	O
recruited	VBN	O
for	IN	O
the	DT	O
study	NN	O
from	IN	O
a	DT	O
school	NN	O
for	IN	O
children	NNS	A
with	IN	O
autism	NN	C
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
imitation	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	SS
)	)	O
or	CC	O
contingently	RB	O
responsive	JJ	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	SS
)	)	O
interaction	NN	O
group	NN	O
based	VBN	O
on	IN	O
a	DT	O
stratification	NN	O
table	NN	O
for	IN	O
gender	NN	O
and	CC	O
developmental	NN	O
and	CC	O
chronological	JJ	O
age	NN	O
.	.	O

The	DT	O
sessions	NNS	O
consisted	VBD	O
of	IN	O
four	CD	O
phases	NNS	O
,	,	O
with	IN	O
each	DT	O
phase	NN	O
lasting	VBG	O
3	CD	O
minutes	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
phase	NN	O
,	,	O
the	DT	O
child	NN	O
walked	VBD	O
into	IN	O
a	DT	O
room	NN	O
that	WDT	O
was	VBD	O
furnished	VBN	O
with	IN	O
a	DT	O
sofa	NN	O
,	,	O
a	DT	O
table	NN	O
,	,	O
chairs	NNS	O
,	,	O
and	CC	O
two	CD	O
sets	NNS	O
of	IN	O
identical	JJ	O
toys	NN	O
.	.	O

An	DT	O
adult	NN	O
was	VBD	O
in	IN	O
the	DT	O
room	NN	O
sitting	VBG	O
very	RB	O
still	RB	O
like	IN	O
a	DT	O
statue	NN	O
(	(	O
first	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
either	RB	O
imitated	VBD	O
the	DT	O
child	NN	O
or	CC	O
was	VBD	O
contingently	RB	O
responsive	JJ	O
to	TO	O
the	DT	O
child	NN	O
.	.	O

In	IN	O
the	DT	O
third	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
sat	VBD	O
still	RB	O
again	RB	O
(	(	O
second	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
fourth	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
engaged	VBN	O
in	IN	O
a	DT	O
spontaneous	JJ	O
interaction	NN	O
.	.	O

During	IN	O
the	DT	O
third	JJ	O
phase	NN	O
(	(	O
the	DT	O
second	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
,	,	O
the	DT	O
children	NNS	O
in	IN	O
the	DT	O
imitation	NN	O
group	NN	O
spent	VBD	O
less	JJR	O
time	NN	O
in	IN	O
gross	JJ	O
motor	NN	O
activity	NN	O
and	CC	O
more	JJR	O
time	NN	O
touching	VBG	O
the	DT	O
adult	NN	O
,	,	O
as	IN	O
if	IN	O
attempting	VBG	O
to	TO	O
initiate	VB	O
an	DT	O
interaction	NN	O
.	.	O

The	DT	O
contingency	NN	O
condition	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
way	NN	O
to	TO	O
facilitate	VB	O
a	DT	O
distal	JJ	O
social	JJ	O
behavior	NN	O
(	(	O
attention	NN	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
imitative	JJ	O
condition	NN	O
was	VBD	O
a	DT	O
more	RBR	O
effective	JJ	O
way	NN	O
to	TO	O
facilitate	VB	O
a	DT	O
proximal	JJ	O
social	JJ	O
behavior	NN	O
(	(	O
touching	VBG	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
long-term	JJ	O
vitamin	NN	O
E	NNP	O
supplementation	NN	O
on	IN	O
cardiovascular	JJ	C
events	NNS	C
and	CC	O
cancer	NN	C
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
Experimental	NNP	O
and	CC	O
epidemiological	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
vitamin	NN	O
E	NNP	O
supplementation	NN	O
may	MD	O
prevent	VB	O
cancer	NN	C
and	CC	O
cardiovascular	JJ	C
events	NNS	C
.	.	O

Clinical	JJ	O
trials	NNS	O
have	VBP	O
generally	RB	O
failed	VBN	O
to	TO	O
confirm	VB	O
benefits	NNS	O
,	,	O
possibly	RB	O
due	JJ	O
to	TO	O
their	PRP$	O
relatively	RB	O
short	JJ	O
duration	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
whether	IN	O
long-term	JJ	O
supplementation	NN	O
with	IN	O
vitamin	JJ	O
E	NN	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
cancer	NN	O
,	,	O
cancer	NN	O
death	NN	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
international	JJ	O
trial	NN	O
(	(	O
the	DT	O
initial	JJ	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
[	NNP	O
HOPE	NNP	O
]	NNP	O
trial	NN	O
conducted	VBD	O
between	IN	O
December	NNP	O
21	CD	O
,	,	O
1993	CD	O
,	,	O
and	CC	O
April	NNP	O
15	CD	O
,	,	O
1999	CD	O
)	)	O
of	IN	O
patients	NNS	O
at	IN	O
least	JJS	O
55	CD	A
years	NNS	O
old	JJ	O
with	IN	O
vascular	JJ	C
disease	NN	C
or	CC	O
diabetes	VBZ	C
mellitus	NN	C
was	VBD	O
extended	VBN	O
(	(	O
HOPE-The	NNP	O
Ongoing	NNP	O
Outcomes	NNP	O
[	NNP	O
HOPE-TOO	NNP	O
]	NNP	O
)	)	O
between	IN	O
April	NNP	O
16	CD	O
,	,	O
1999	CD	O
,	,	O
and	CC	O
May	NNP	O
26	CD	O
,	,	O
2003	CD	O
.	.	O

Of	IN	O
the	DT	O
initial	JJ	O
267	CD	O
HOPE	NNP	O
centers	NNS	O
that	WDT	O
had	VBD	O
enrolled	VBN	O
9541	CD	SS
patients	NNS	O
,	,	O
174	CD	O
centers	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
HOPE-TOO	NNP	O
trial	NN	O
.	.	O

Of	IN	O
7030	CD	SS
patients	NNS	O
enrolled	VBN	O
at	IN	O
these	DT	O
centers	NNS	O
,	,	O
916	CD	O
were	VBD	O
deceased	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
extension	NN	O
,	,	O
1382	CD	O
refused	VBD	O
participation	NN	O
,	,	O
3994	CD	O
continued	VBD	O
to	TO	O
take	VB	O
the	DT	O
study	NN	O
intervention	NN	O
,	,	O
and	CC	O
738	CD	O
agreed	VBD	O
to	TO	O
passive	VB	O
follow-up	NN	O
.	.	O

Median	JJ	O
duration	NN	O
of	IN	O
follow-up	NN	O
was	VBD	O
7.0	CD	O
years	NNS	O
.	.	O

INTERVENTION	NNP	O
Daily	NNP	O
dose	NN	O
of	IN	O
natural	JJ	O
source	NN	O
vitamin	NN	O
E	NNP	O
(	(	O
400	CD	O
IU	NNP	O
)	)	O
or	CC	O
matching	VBG	O
placebo	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
outcomes	NNS	O
included	VBD	O
cancer	NN	O
incidence	NN	O
,	,	O
cancer	NN	O
deaths	NNS	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
(	(	O
myocardial	JJ	O
infarction	NN	O
,	,	O
stroke	NN	O
,	,	O
and	CC	O
cardiovascular	JJ	O
death	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
heart	NN	O
failure	NN	O
,	,	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
revascularizations	NNS	O
.	.	O

RESULTS	NNP	O
Among	IN	O
all	DT	O
HOPE	NNP	O
patients	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
analysis	NN	O
:	:	O
for	IN	O
cancer	NN	O
incidence	NN	O
,	,	O
there	EX	O
were	VBD	O
552	CD	O
patients	NNS	O
(	(	O
11.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
group	NN	O
vs	VBD	O
586	CD	O
(	(	O
12.3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
0.94	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.84-1.06	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.30	NNP	O
)	)	O
;	:	O
for	IN	O
cancer	NN	O
deaths	NNS	O
,	,	O
156	CD	O
(	(	O
3.3	CD	O
%	NN	O
)	)	O
vs	NN	O
178	CD	O
(	(	O
3.7	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
RR	NNP	O
,	,	O
0.88	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.71-1.09	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.24	NNP	O
)	)	O
;	:	O
and	CC	O
for	IN	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
1022	CD	O
(	(	O
21.5	CD	O
%	NN	O
)	)	O
vs	NN	O
985	CD	O
(	(	O
20.6	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
RR	NNP	O
,	,	O
1.04	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.96-1.14	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.34	NNP	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
group	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
heart	NN	O
failure	NN	O
(	(	O
RR	NNP	O
,	,	O
1.13	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.26	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
and	CC	O
hospitalization	NN	O
for	IN	O
heart	NN	O
failure	NN	O
(	(	O
RR	NNP	O
,	,	O
1.21	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.00-1.47	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.045	NNP	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
among	IN	O
patients	NNS	O
enrolled	VBN	O
at	IN	O
the	DT	O
centers	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
HOPE-TOO	NNP	O
trial	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
cancer	NN	O
incidence	NN	O
,	,	O
cancer	NN	O
deaths	NNS	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
but	CC	O
higher	JJR	O
rates	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
and	CC	O
hospitalizations	NNS	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
diabetes	VBZ	O
mellitus	NNS	O
,	,	O
long-term	JJ	O
vitamin	NN	O
E	NNP	O
supplementation	NN	O
does	VBZ	O
not	RB	O
prevent	VB	O
cancer	NN	O
or	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
and	CC	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

Effect	NN	O
of	IN	O
motivational	JJ	O
music	NN	O
on	IN	O
lactate	NN	O
levels	NNS	O
during	IN	O
recovery	NN	O
from	IN	O
intense	JJ	O
exercise	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
music	NN	O
played	VBN	O
during	IN	O
an	DT	O
exercise	NN	O
task	NN	O
on	IN	O
athletic	JJ	O
performance	NN	O
have	VBP	O
been	VBN	O
previously	RB	O
studied	VBN	O
.	.	O

Yet	CC	O
,	,	O
these	DT	O
results	NNS	O
are	VBP	O
not	RB	O
applicable	JJ	O
for	IN	O
competitive	JJ	O
athletes	NNS	O
,	,	O
who	WP	O
can	MD	O
use	VB	O
music	NN	O
only	RB	O
during	IN	O
warm-up	NN	O
or	CC	O
recovery	NN	O
from	IN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
motivational	JJ	O
music	NN	O
(	(	O
music	NN	O
that	WDT	O
stimulates	VBZ	O
or	CC	O
inspires	VBZ	O
physical	JJ	O
activity	NN	O
)	)	O
during	IN	O
recovery	NN	O
from	IN	O
intense	JJ	O
exercise	NN	O
,	,	O
on	IN	O
activity	NN	O
pattern	NN	O
,	,	O
rate	NN	O
of	IN	O
perceived	VBN	O
exertion	NN	O
(	(	O
RPE	NNP	O
)	)	O
,	,	O
and	CC	O
blood	NN	O
lactate	NN	O
concentration	NN	O
.	.	O

Twenty	NNP	O
young	JJ	O
,	,	O
active	JJ	O
men	NNS	O
(	(	O
mean	JJ	O
age	NN	O
26.2	CD	O
?	.	O
2.1	CD	O
years	NNS	O
)	)	O
performed	VBD	O
a	DT	O
6-minute	JJ	O
run	NN	O
at	IN	O
peak	NN	O
oxygen	NN	O
consumption	NN	O
speed	NN	O
(	(	O
predetermined	VBN	O
from	IN	O
the	DT	O
VO	NNP	O
(	(	O
2	CD	O
)	)	O
max	FW	O
test	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
,	,	O
RPE	NNP	O
,	,	O
number	NN	O
of	IN	O
steps	NNS	O
(	(	O
determined	VBN	O
by	IN	O
step	NN	O
counter	NN	O
)	)	O
,	,	O
and	CC	O
blood	NN	O
lactate	NN	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
15	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
recovery	NN	O
from	IN	O
the	DT	O
exercise	NN	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
motivational	JJ	O
music	NN	O
(	(	O
2	CD	O
separate	JJ	O
sessions	NNS	O
,	,	O
at	IN	O
random	JJ	O
order	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	O
HR	NNP	O
during	IN	O
the	DT	O
recovery	NN	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
.	.	O

Listening	VBG	O
to	TO	O
motivational	JJ	O
music	NN	O
during	IN	O
the	DT	O
recovery	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
voluntary	JJ	O
activity	NN	O
of	IN	O
the	DT	O
participants	NNS	O
,	,	O
determined	VBN	O
by	IN	O
increased	JJ	O
number	NN	O
of	IN	O
steps	NNS	O
(	(	O
499.4	CD	O
?	.	O
220.1	CD	O
vs.	IN	O
413.2	CD	O
?	.	O
150.6	CD	O
steps	NNS	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increased	JJ	O
number	NN	O
of	IN	O
steps	NNS	O
during	IN	O
the	DT	O
recovery	NN	O
was	VBD	O
accompanied	VBN	O
by	IN	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
blood	NN	O
lactate	NN	O
concentration	NN	O
percentage	NN	O
(	(	O
28.1	CD	O
?	.	O
12.2	CD	O
vs.	IN	O
22.8	CD	O
?	.	O
10.9	CD	O
%	NN	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
,	,	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
decrease	NN	O
in	IN	O
RPE	NNP	O
(	(	O
77.7	CD	O
?	.	O
14.4	CD	O
vs.	IN	O
73.1	CD	O
?	.	O
14.7	CD	O
%	NN	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
listening	VBG	O
to	TO	O
motivational	JJ	O
music	NN	O
during	IN	O
nonstructured	JJ	O
recovery	NN	O
from	IN	O
intense	JJ	O
exercise	NN	O
leads	VBZ	O
to	TO	O
increased	VBN	O
activity	NN	O
,	,	O
faster	JJR	O
lactate	JJ	O
clearance	NN	O
,	,	O
and	CC	O
reduced	VBD	O
RPE	NNP	O
and	CC	O
therefore	RB	O
may	MD	O
be	VB	O
used	VBN	O
by	IN	O
athletes	NNS	O
in	IN	O
their	PRP$	O
effort	NN	O
to	TO	O
enhance	VB	O
recovery	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
physiotherapy	JJ	O
management	NN	O
of	IN	O
knee	NN	C
joint	JJ	C
osteoarthritis	NN	C
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
a	DT	O
multimodal	JJ	O
physiotherapy	NN	O
programme	NN	O
including	VBG	O
taping	VBG	O
,	,	O
exercises	NNS	O
,	,	O
and	CC	O
massage	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
knee	NN	C
osteoarthritis	NN	C
,	,	O
and	CC	O
if	IN	O
benefits	NNS	O
can	MD	O
be	VB	O
maintained	VBN	O
with	IN	O
self	JJ	O
management	NN	O
.	.	O

METHODS	NNP	O
Randomised	VBD	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
;	:	O
140	CD	SS
community	NN	O
volunteers	NNS	O
with	IN	O
knee	NN	C
osteoarthritis	NN	C
participated	VBD	O
and	CC	O
119	CD	SS
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Physiotherapy	NNP	O
and	CC	O
placebo	JJ	O
interventions	NNS	O
were	VBD	O
applied	VBN	O
by	IN	O
10	CD	O
physiotherapists	NNS	O
in	IN	O
private	JJ	O
practices	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Physiotherapy	NNP	O
included	VBD	O
exercise	NN	O
,	,	O
massage	NN	O
,	,	O
taping	VBG	O
,	,	O
and	CC	O
mobilisation	NN	O
,	,	O
followed	VBN	O
by	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
self	JJ	O
management	NN	O
.	.	O

Placebo	NNP	O
was	VBD	O
sham	VBN	O
ultrasound	JJ	O
and	CC	O
light	JJ	O
application	NN	O
of	IN	O
a	DT	O
non-therapeutic	JJ	O
gel	NN	O
,	,	O
followed	VBN	O
by	IN	O
no	DT	O
treatment	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
were	VBD	O
pain	RB	O
measured	VBN	O
by	IN	O
visual	JJ	O
analogue	NN	O
scale	NN	O
and	CC	O
patient	JJ	O
global	JJ	O
change	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
WOMAC	NNP	O
,	,	O
knee	NN	O
pain	NN	O
scale	NN	O
,	,	O
SF-36	NNP	O
,	,	O
assessment	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
index	NN	O
,	,	O
quadriceps	JJ	O
strength	NN	O
,	,	O
and	CC	O
balance	NN	O
test	NN	O
.	.	O

RESULTS	NNP	O
Using	VBG	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
,	,	O
physiotherapy	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
showed	VBD	O
similar	JJ	O
pain	NN	O
reductions	NNS	O
at	IN	O
12	CD	O
weeks	NNS	O
:	:	O
-2.2	NN	O
cm	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-2.6	NNP	O
to	TO	O
-1.7	VB	O
)	)	O
and	CC	O
-2.0	$	O
cm	NN	O
(	(	O
-2.5	UH	O
to	TO	O
-1.5	VB	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
24	CD	O
weeks	NNS	O
,	,	O
pain	NN	O
remained	VBD	O
reduced	VBN	O
from	IN	O
baseline	NN	O
in	IN	O
both	DT	O
groups	NNS	O
:	:	O
-2.1	NN	O
(	(	O
-2.6	UH	O
to	TO	O
-1.6	VB	O
)	)	O
and	CC	O
-1.6	NNP	O
(	(	O
-2.2	UH	O
to	TO	O
-1.0	VB	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Global	JJ	O
improvement	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
70	CD	O
%	NN	O
of	IN	O
physiotherapy	NN	O
participants	NNS	O
(	(	O
51/73	CD	O
)	)	O
at	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
by	IN	O
59	CD	O
%	NN	O
(	(	O
43/73	CD	O
)	)	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Similarly	RB	O
,	,	O
global	JJ	O
improvement	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
72	CD	O
%	NN	O
of	IN	O
placebo	NN	O
participants	NNS	O
(	(	O
48/67	CD	O
)	)	O
at	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
by	IN	O
49	CD	O
%	NN	O
(	(	O
33/67	CD	O
)	)	O
at	IN	O
24	CD	O
weeks	NNS	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
physiotherapy	NN	O
programme	NN	O
tested	VBN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
no	DT	O
more	RBR	O
effective	JJ	O
than	IN	O
regular	JJ	O
contact	NN	O
with	IN	O
a	DT	O
therapist	NN	O
at	IN	O
reducing	VBG	O
pain	NN	O
and	CC	O
disability	NN	O
.	.	O

Can	MD	O
a	DT	O
home-visit	JJ	O
invitation	NN	O
increase	NN	O
Pap	NNP	O
smear	JJ	O
screening	NN	O
in	IN	O
Samliem	NNP	O
,	,	O
Khon	NNP	O
Kaen	NNP	O
,	,	O
Thailand	NNP	O
?	.	O
Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
a	DT	O
home-visit	JJ	O
invitation	NN	O
aimed	VBN	O
to	TO	O
increase	VB	O
uptake	NN	O
of	IN	O
cervical	JJ	C
cancer	NN	C
screening	VBG	C
in	IN	O
women	NNS	SE
between	IN	O
35	CD	A
and	CC	A
60	CD	A
years	NNS	O
of	IN	O
age	NN	O
.	.	O

From	NN	O
May	NNP	O
,	,	O
2006	CD	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
quasi-randomized	JJ	O
trial	NN	O
to	TO	O
determine	VB	O
if	IN	O
an	DT	O
in-home	JJ	O
education	NN	O
and	CC	O
invitation	NN	O
intervention	NN	O
would	MD	O
increase	VB	O
uptake	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
.	.	O

We	PRP	O
randomly	RB	O
recruited	VBD	O
304	CD	SS
women	NNS	O
from	IN	O
the	DT	O
Samliem	NNP	O
inner-city	NN	O
community	NN	O
,	,	O
Khon	NNP	O
Kaen	NNP	O
,	,	O
Northeast	NNP	O
Thailand	NNP	O
,	,	O
and	CC	O
assigned	VBD	O
participants	NNS	O
to	TO	O
either	VB	O
the	DT	O
intervention	NN	O
or	CC	O
control	VB	O
zone	NN	O
.	.	O

Baseline	NNP	O
screening	VBG	O
coverage	NN	O
interviews	NNS	O
were	VBD	O
then	RB	O
performed	VBN	O
:	:	O
58	CD	O
of	IN	O
158	CD	SS
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
and	CC	O
46	CD	O
of	IN	O
146	CD	SS
in	IN	O
the	DT	O
control	NN	O
zone	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
having	VBG	O
had	VBD	O
a	DT	O
Pap	NNP	O
smear	NN	O
within	IN	O
5	CD	O
years	NNS	O
,	,	O
but	CC	O
these	DT	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
final	JJ	O
analysis	NN	O
.	.	O

First	NNP	O
,	,	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
were	VBD	O
visited	VBN	O
in	IN	O
their	PRP$	O
homes	NNS	O
by	IN	O
one	CD	O
of	IN	O
the	DT	O
researchers	NNS	O
,	,	O
who	WP	O
provided	VBD	O
culturally-sensitive	JJ	O
health	NN	O
education	NN	O
that	WDT	O
emphasized	VBD	O
the	DT	O
need	NN	O
for	IN	O
screening	VBG	O
.	.	O

Four	CD	O
months	NNS	O
later	RB	O
,	,	O
post-intervention	NN	O
,	,	O
screening-coverage	JJ	O
interviews	NNS	O
were	VBD	O
again	RB	O
performed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
same	JJ	O
health	NN	O
education	NN	O
for	IN	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
a	DT	O
comparison	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
baseline	NN	O
Pap	NNP	O
smear	JJ	O
screening-coverage	NN	O
rate	NN	O
in	IN	O
the	DT	O
intervention	NN	O
vs.	FW	O
control	NN	O
zones	NNS	O
(	(	O
36.7	CD	O
vs.	FW	O
31.5	CD	O
%	NN	O
,	,	O
p=0.339	NN	O
)	)	O
.	.	O

One	CD	O
hundred	JJ	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
completed	VBD	O
the	DT	O
intervention	NN	O
interviews	NNS	O
and	CC	O
after	IN	O
four	CD	O
months	NNS	O
,	,	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
100	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
also	RB	O
completed	VBD	O
the	DT	O
post-intervention	NN	O
interviews	NNS	O
.	.	O

The	DT	O
increased	JJ	O
screening-coverage	NN	O
rate	NN	O
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
zone	NN	O
(	(	O
43.6	CD	O
vs.	FW	O
34.9	CD	O
%	NN	O
,	,	O
p=0.119	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
borderline	NN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
36.7	CD	O
to	TO	O
43.6	CD	O
%	NN	O
,	,	O
p=0.070	NN	O
)	)	O
.	.	O

Therefore	NNP	O
,	,	O
home	NN	O
visit	NN	O
education	NN	O
and	CC	O
invitation	NN	O
intervention	NN	O
produced	VBD	O
only	RB	O
a	DT	O
nominal	JJ	O
effect	NN	O
on	IN	O
increasing	VBG	O
Pap	NNP	O
smear	JJ	O
coverage	NN	O
within	IN	O
a	DT	O
4-month	JJ	O
study	NN	O
period	NN	O
.	.	O

Niacin	NNP	O
revisited	VBD	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
of	IN	O
wax-matrix	JJ	O
sustained-release	JJ	O
niacin	NN	O
in	IN	O
hypercholesterolemia	NN	C
.	.	O

Two	CD	SS
hundred	VBD	SS
one	CD	SS
male	NN	SE
and	CC	SE
female	JJ	SE
subjects	NNS	O
,	,	O
aged	VBD	O
20	CD	A
to	TO	A
70	CD	A
years	NNS	O
,	,	O
with	IN	O
elevated	VBN	C
low-density	NN	C
lipoprotein	NN	C
cholesterol	NN	O
values	NNS	O
(	(	O
in	IN	O
the	DT	O
75th	CD	C
to	TO	C
95th	CD	C
percentiles	NNS	C
)	)	O
,	,	O
participated	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
,	,	O
double-blind	NN	O
study	NN	O
using	VBG	O
a	DT	O
new	JJ	O
form	NN	O
of	IN	O
niacin	NN	O
(	(	O
Enduracin	NNP	O
)	)	O
,	,	O
which	WDT	O
employs	VBZ	O
a	DT	O
wax-matrix	JJ	O
vehicle	NN	O
for	IN	O
sustained	JJ	O
release	NN	O
.	.	O

Four	CD	O
niacin	JJ	O
treatment	NN	O
groups	NNS	O
(	(	O
daily	JJ	O
doses	NNS	O
of	IN	O
2000	CD	O
,	,	O
1500	CD	O
,	,	O
1250	CD	O
,	,	O
and	CC	O
1000	CD	O
mg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
placebo-	JJ	O
and	CC	O
diet-treated	JJ	O
controls	NNS	O
to	TO	O
determine	VB	O
side-effect	JJ	O
profile	NN	O
and	CC	O
optimal	JJ	O
range	NN	O
of	IN	O
efficacy	NN	O
.	.	O

The	DT	O
groups	NNS	O
given	VBN	O
2000	CD	O
and	CC	O
1500	CD	O
mg	NN	O
demonstrated	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
values	NNS	O
of	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
-26	CD	O
%	NN	O
and	CC	O
-19.3	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
-18.4	CD	O
%	NN	O
and	CC	O
-13.3	NNP	O
%	NN	O
)	)	O
,	,	O
and	CC	O
total	JJ	O
cholesterol-high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
ratio	NN	O
(	(	O
-20.4	CD	O
%	NN	O
and	CC	O
-19.4	CD	O
%	NN	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
diet-	JJ	O
and	CC	O
placebo-treated	JJ	O
controls	NNS	O
.	.	O

Smaller	NN	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Blood	NNP	O
chemistry	NN	O
monitoring	NN	O
indicated	VBD	O
that	DT	O
reduction	NN	O
in	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
strongly	RB	O
correlated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
baseline	JJ	O
levels	NNS	O
of	IN	O
some	DT	O
enzymes	NNS	O
for	IN	O
niacin-treated	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
improved	JJ	O
side-effect	JJ	O
profile	NN	O
of	IN	O
the	DT	O
wax-matrix	JJ	O
form	NN	O
of	IN	O
niacin	NN	O
was	VBD	O
particularly	RB	O
notable	JJ	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
was	VBD	O
only	RB	O
3.4	CD	O
%	NN	O
and	CC	O
was	VBD	O
coupled	VBN	O
with	IN	O
good	JJ	O
medication	NN	O
compliance	NN	O
.	.	O

The	DT	O
problem	NN	O
of	IN	O
measurement	NN	O
error	NN	O
in	IN	O
multisite	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	O

The	DT	O
implementation	NN	O
of	IN	O
a	DT	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
clinical	JJ	O
psychopharmacologic	JJ	O
trial	NN	O
involves	VBZ	O
a	DT	O
substantial	JJ	O
investment	NN	O
of	IN	O
time	NN	O
and	CC	O
effort	NN	O
on	IN	O
the	DT	O
part	NN	O
of	IN	O
all	DT	O
participants	NNS	O
.	.	O

Because	IN	O
of	IN	O
their	PRP$	O
complexity	NN	O
,	,	O
such	JJ	O
clinical	JJ	O
trials	NNS	O
present	JJ	O
unique	JJ	O
methodological	JJ	O
and	CC	O
design	NN	O
challenges	NNS	O
.	.	O

Indeed	RB	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
uncommon	JJ	O
for	IN	O
such	JJ	O
studies	NNS	O
to	TO	O
conclude	VB	O
with	IN	O
uninterpretable	JJ	O
results	NNS	O
,	,	O
due	JJ	O
in	IN	O
part	NN	O
to	TO	O
such	JJ	O
methodological	JJ	O
pitfalls	NNS	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
clarification	NN	O
of	IN	O
such	JJ	O
methodologic	JJ	O
dilemmas	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
important	JJ	O
challenges	NNS	O
facing	VBG	O
the	DT	O
future	NN	O
of	IN	O
industry-sponsored	JJ	O
psychopharmacologic	JJ	O
drug	NN	O
development	NN	O
.	.	O

Among	IN	O
the	DT	O
many	JJ	O
factors	NNS	O
that	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
problematic	JJ	O
clinical	JJ	O
trial	NN	O
results	NNS	O
,	,	O
error	NN	O
in	IN	O
measuring	VBG	O
the	DT	O
phenomena	NN	O
being	VBG	O
studied	VBN	O
is	VBZ	O
of	IN	O
particular	JJ	O
concern	NN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
we	PRP	O
describe	VBP	O
the	DT	O
outcome	NN	O
of	IN	O
an	DT	O
intensive	JJ	O
series	NN	O
of	IN	O
interrater	JJ	O
reliability	NN	O
training	NN	O
sessions	NNS	O
for	IN	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
conducted	VBD	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
multisite	RB	O
clinical	JJ	O
drug	NN	O
trial	NN	O
.	.	O

The	DT	O
data	NN	O
underscore	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
error	NN	O
present	NN	O
in	IN	O
such	JJ	O
a	DT	O
test	NN	O
setting	NN	O
and	CC	O
provide	VB	O
preliminary	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
potential	JJ	O
effect	NN	O
of	IN	O
this	DT	O
problem	NN	O
on	IN	O
the	DT	O
detection	NN	O
of	IN	O
clinical	JJ	O
change	NN	O
.	.	O

Effect	NNP	O
of	IN	O
four	CD	O
intermediate	JJ	O
layer	NN	O
treatments	NNS	O
on	IN	O
microleakage	NN	C
of	IN	O
Class	NNP	C
II	NNP	C
composite	JJ	C
restorations	NNS	C
.	.	O

This	DT	O
in	IN	O
vitro	NN	O
study	NN	O
examines	VBZ	O
the	DT	O
marginal	JJ	O
sealing	NN	O
ability	NN	O
of	IN	O
four	CD	O
different	JJ	O
intermediate	JJ	O
materials	NNS	O
applied	VBN	O
before	IN	O
placement	NN	O
of	IN	O
a	DT	O
condensable	JJ	O
composite	NN	O
.	.	O

Class	NNP	C
II	NNP	C
preparations	NNS	C
were	VBD	O
made	VBN	O
with	IN	O
gingival	JJ	O
margins	NNS	O
placed	VBD	O
1.0	CD	O
mm	JJ	O
apical	JJ	O
to	TO	O
the	DT	O
cementoenamel	JJ	O
junction	NN	O
of	IN	O
60	CD	SS
extracted	JJ	C
teeth	NNS	C
,	,	O
randomly	RB	O
assigned	VBN	O
to	TO	O
five	CD	O
groups	NNS	O
of	IN	O
12	CD	SS
.	.	O

Following	VBG	O
restoration	NN	O
,	,	O
teeth	EX	O
were	VBD	O
thermocycled	VBN	O
,	,	O
soaked	VBN	O
in	IN	O
0.5	CD	O
%	NN	O
basic	JJ	O
fuchsin	NN	O
,	,	O
and	CC	O
sectioned	VBD	O
longitudinally	RB	O
.	.	O

The	DT	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
demonstrated	VBD	O
significantly	RB	O
less	JJR	O
microleakage	NN	O
than	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
dentin	NN	O
bonding	NN	O
agent	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
flowable	JJ	O
composite	JJ	O
,	,	O
flowable	JJ	O
compomer	NN	O
,	,	O
or	CC	O
autoploymerizing	VBG	O
composite	JJ	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
,	,	O
Dunn	NNP	O
's	POS	O
test	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
supports	VBZ	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
glass	NN	O
ionomer	NN	O
open	JJ	O
sandwich	NN	O
technique	NN	O
in	IN	O
deep	JJ	C
Class	NNP	C
II	NNP	C
direct	JJ	C
composite	JJ	C
restorations	NNS	C
.	.	O

Intranasal	NNP	O
nicotine	NN	O
for	IN	O
postoperative	JJ	C
pain	NN	C
treatment	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
pharmacological	JJ	O
treatment	NN	O
,	,	O
70-80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
report	NN	O
moderate	VBP	O
to	TO	O
severe	VB	O
pain	NN	O
after	IN	O
surgery	NN	O
.	.	O

Because	IN	O
nicotine	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
analgesic	JJ	O
properties	NNS	O
in	IN	O
animal	NN	O
and	CC	O
human	JJ	O
volunteer	NN	O
studies	NNS	O
,	,	O
the	DT	O
authors	NNS	O
assessed	VBD	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
single	JJ	O
3	CD	O
mg	NN	O
dose	NN	O
of	IN	O
nicotine	JJ	O
nasal	NN	O
spray	NN	O
administered	VBD	O
before	IN	O
emergence	NN	O
from	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
20	CD	SS
healthy	JJ	C
women	NNS	SE
(	(	O
mean	JJ	O
age	NN	O
45	CD	A
(	(	O
SD	NNP	O
8	CD	O
)	)	O
yr	NN	O
)	)	O
who	WP	O
were	VBD	O
to	TO	O
undergo	VB	O
uterine	JJ	C
surgery	NN	C
through	IN	O
a	DT	O
low	JJ	C
transverse	NN	C
incision	NN	C
.	.	O

After	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
surgery	NN	O
but	CC	O
before	IN	O
emergence	NN	O
from	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
the	DT	O
anesthesiologist	NN	O
administered	VBD	O
either	CC	O
nicotine	JJ	O
nasal	NN	O
spray	NN	O
or	CC	O
a	DT	O
placebo	NN	O
.	.	O

Numerical	JJ	O
analog	NN	O
pain	NN	O
score	NN	O
and	CC	O
morphine	JJ	O
utilization	NN	O
and	CC	O
hemodynamic	JJ	O
values	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
24	CD	O
h.	NN	O
RESULTS	NNP	O
The	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
nicotine	NN	O
reported	VBN	O
lower	JJR	O
pain	NN	O
scores	NNS	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
after	IN	O
surgery	NN	O
(	(	O
peak	JJ	O
numerical	JJ	O
analog	NN	O
score	NN	O
,	,	O
7.6	CD	O
(	(	O
SD	NNP	O
1.4	CD	O
)	)	O
versus	NN	O
5.3	CD	O
(	(	O
SD	NNP	O
1.6	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
used	VBN	O
half	PDT	O
the	DT	O
amount	NN	O
of	IN	O
morphine	NN	O
as	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
12	CD	O
(	(	O
SD	NNP	O
6	CD	O
)	)	O
versus	NN	O
6	CD	O
(	(	O
SD	NNP	O
5	CD	O
)	)	O
mg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Patients	NNPS	O
who	WP	O
received	VBD	O
nicotine	NN	O
still	RB	O
reported	VBD	O
less	RBR	O
pain	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
24	CD	O
h	NN	O
after	IN	O
surgery	NN	O
(	(	O
1.5	CD	O
(	(	O
SD	NNP	O
0.5	CD	O
)	)	O
versus	NN	O
4.9	CD	O
(	(	O
SD	NNP	O
1.4	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Systolic	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
nicotine	JJ	O
(	(	O
105	CD	O
(	(	O
SD	NNP	O
3	CD	O
)	)	O
versus	NN	O
122	CD	O
(	(	O
SD	NNP	O
3	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
or	CC	O
heart	NN	O
rate	NN	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
with	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
nicotine	JJ	O
immediately	RB	O
before	IN	O
emergence	NN	O
from	IN	O
anesthesia	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
lower	JJR	O
reported	VBD	O
pain	JJ	O
scores	NNS	O
during	IN	O
the	DT	O
first	JJ	O
day	NN	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
decreased	JJ	O
pain	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
morphine	JJ	O
utilization	NN	O
and	CC	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
nicotine	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
hypertension	NN	O
or	CC	O
tachycardia	NN	O
.	.	O

Sunbathing	VBG	O
and	CC	O
sunbed	VBN	O
use	NN	O
related	VBN	O
to	TO	O
self-image	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
Swedish	JJ	O
adolescents	NNS	A
.	.	O

In	IN	O
1996	CD	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
4,020	CD	SS
Swedish	JJ	O
adolescents	NNS	A
from	IN	O
three	CD	O
birth	NN	O
cohorts	NNS	O
were	VBD	O
sent	VBN	O
a	DT	O
questionnaire	NN	O
consisting	NN	O
of	IN	O
50	CD	O
items	NNS	O
concerning	VBG	O
habitual	JJ	O
sun-related	JJ	O
behaviours	NNS	O
and	CC	O
attitudes	NNS	O
,	,	O
knowledge	NN	O
about	IN	O
melanoma	NN	O
,	,	O
risk	NN	O
perception	NN	O
and	CC	O
self-image	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
2,615	CD	SS
questionnaires	NNS	O
were	VBD	O
returned	VBN	O
.	.	O

Girls	NNP	SE
sunbathed	VBD	O
and	CC	O
used	VBD	O
sunbeds	NNS	O
more	RBR	O
than	IN	O
boys	NNS	SE
at	IN	O
all	DT	O
ages	NNS	O
.	.	O

Sunbathing	VBG	O
and	CC	O
sunbed	VBN	O
use	NN	O
increased	VBN	O
with	IN	O
age	NN	O
.	.	O

Boys	NNS	O
who	WP	O
were	VBD	O
most	RBS	O
satisfied	JJ	O
and	CC	O
girls	NNS	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
sunbathed	VBD	O
most	JJS	O
.	.	O

Those	DT	O
who	WP	O
were	VBD	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
used	VBD	O
sunbeds	NNS	O
most	RBS	O
frequently	RB	O
.	.	O

Girls	NNP	O
reported	VBD	O
a	DT	O
higher	JJR	O
perceived	JJ	O
susceptibility	NN	O
to	TO	O
melanoma	VB	O
than	IN	O
did	VBD	O
boys	VB	O
.	.	O

The	DT	O
perception	NN	O
of	IN	O
susceptibility	NN	O
increased	VBN	O
with	IN	O
age	NN	O
.	.	O

Those	DT	O
who	WP	O
were	VBD	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
reported	VBD	O
feeling	VBG	O
most	RBS	O
susceptible	JJ	O
.	.	O

The	DT	O
overall	JJ	O
main	JJ	O
reason	NN	O
for	IN	O
sunbathing	NN	O
was	VBD	O
appearance	NN	O
,	,	O
both	DT	O
for	IN	O
own	JJ	O
sunbathing	NN	O
,	,	O
and	CC	O
to	TO	O
an	DT	O
even	RB	O
higher	JJR	O
degree	NN	O
,	,	O
as	IN	O
a	DT	O
supposed	JJ	O
reason	NN	O
for	IN	O
other	JJ	O
adolescents	NNS	O
'	POS	O
behaviour	NN	O
,	,	O
and	CC	O
was	VBD	O
reported	VBN	O
most	JJS	O
frequently	RB	O
by	IN	O
girls	NNS	O
and	CC	O
the	DT	O
older	JJR	O
age	NN	O
groups	NNS	O
.	.	O

The	DT	O
second	JJ	O
most	RBS	O
'important	JJ	O
'	POS	O
reason	NN	O
for	IN	O
sunbathing	NN	O
was	VBD	O
'feeling	VBG	O
warm	JJ	O
and	CC	O
comfortable	JJ	O
'	''	O
.	.	O

Preventive	JJ	O
programmes	NNS	O
aimed	VBN	O
at	IN	O
a	DT	O
change	NN	O
of	IN	O
sun	NN	O
related	VBN	O
behaviours	NNS	O
among	IN	O
Swedish	JJ	O
adolescents	NNS	O
have	VBP	O
to	TO	O
be	VB	O
tailored	VBN	O
to	TO	O
the	DT	O
climate	NN	O
and	CC	O
cultural	JJ	O
conditions	NNS	O
and	CC	O
must	MD	O
take	VB	O
into	IN	O
account	NN	O
that	IN	O
having	VBG	O
a	DT	O
tan	NN	O
,	,	O
and	CC	O
the	DT	O
warmth	NN	O
of	IN	O
the	DT	O
sun	NN	O
,	,	O
are	VBP	O
highly	RB	O
valued	VBN	O
by	IN	O
most	JJS	O
adolescents	NNS	O
.	.	O

Dose	NNP	O
response	NN	O
effect	NN	O
of	IN	O
cyclical	JJ	O
medroxyprogesterone	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
postmenopausal	JJ	C
women	NNS	SE
.	.	O

OBJECTIVE	VB	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
with	IN	O
placebo	PDT	O
the	DT	O
dose-response	JJ	O
effect	NN	O
of	IN	O
cyclical	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
C21	NNP	O
progestogen	NN	O
,	,	O
medroxyprogesterone	NN	O
acetate	NN	O
(	(	O
MPA	NNP	O
)	)	O
on	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
when	WRB	O
administered	VBN	O
to	TO	O
normotensive	JJ	C
postmenopausal	NN	C
women	NNS	SE
receiving	VBG	O
a	DT	O
fixed	JJ	O
mid-range	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
conjugated	JJ	O
equine	NN	O
oestrogen	NN	O
(	(	O
CEE	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Twenty	NNP	SS
normotensive	JJ	C
postmenopausal	NN	C
women	NNS	SE
(	(	O
median	JJ	O
age	NN	O
53	CD	A
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
which	WDT	O
used	VBD	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
randomised	VBN	O
treatment	NN	O
phases	NNS	O
,	,	O
each	DT	O
of	IN	O
4	CD	O
weeks	NNS	O
duration	NN	O
.	.	O

The	DT	O
four	CD	O
blinded	VBD	O
treatments	NNS	O
were	VBD	O
MPA	NNP	O
2.5	CD	O
mg	NN	O
,	,	O
MPA	NNP	O
5	CD	O
mg	NN	O
,	,	O
MPA	NNP	O
10	CD	O
mg	NN	O
and	CC	O
matching	VBG	O
placebo	NN	O
,	,	O
taken	VBN	O
for	IN	O
the	DT	O
last	JJ	O
14	CD	O
days	NNS	O
of	IN	O
each	DT	O
28	CD	O
day	NN	O
treatment	NN	O
cycle	NN	O
.	.	O

CEE	NNP	O
0.625	CD	O
mg	NN	O
was	VBD	O
also	RB	O
administered	VBN	O
once	RB	O
daily	JJ	O
as	IN	O
open	JJ	O
labelled	VBD	O
tablets	NNS	O
to	TO	O
all	DT	O
subjects	NNS	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Clinic	NNP	O
BP	NNP	O
was	VBD	O
measured	VBN	O
weekly	RB	O
with	IN	O
the	DT	O
mean	JJ	O
values	NNS	O
of	IN	O
weeks	NNS	O
3	CD	O
and	CC	O
4	CD	O
of	IN	O
each	DT	O
phase	NN	O
used	VBN	O
for	IN	O
analysis	NN	O
.	.	O

Ambulatory	NNP	O
BP	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
final	JJ	O
week	NN	O
of	IN	O
each	DT	O
phase	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
the	DT	O
placebo	NN	O
phase	NN	O
,	,	O
end	NN	O
of	IN	O
phase	NN	O
clinic	JJ	O
BP	NNP	O
was	VBD	O
unchanged	JJ	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
progestogen	NN	O
treatments	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
decrease	NN	O
in	IN	O
ambulatory	JJ	O
daytime	JJ	O
diastolic	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
BP	NNP	O
with	IN	O
the	DT	O
progestogen	NN	O
treatments	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
a	DT	O
regimen	NN	O
of	IN	O
postmenopausal	NN	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
with	IN	O
a	DT	O
fixed	JJ	O
mid-range	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
CEE	NNP	O
combined	VBD	O
with	IN	O
a	DT	O
cyclical	JJ	O
regimen	NN	O
of	IN	O
a	DT	O
C21	NNP	O
progestogen	NN	O
spanning	VBG	O
the	DT	O
current	JJ	O
clinical	JJ	O
dose	NN	O
range	NN	O
,	,	O
the	DT	O
progestogen	NN	O
has	VBZ	O
either	CC	O
no	DT	O
effect	NN	O
or	CC	O
a	DT	O
small	JJ	O
dose-dependent	JJ	O
reduction	NN	O
in	IN	O
clinic	NN	O
and	CC	O
ambulatory	JJ	O
BPs	NNP	O
over	IN	O
one	CD	O
treatment	NN	O
cycle	NN	O
.	.	O

Oral	NNP	O
health	NN	O
impacts	NNS	O
on	IN	O
daily	JJ	O
living	NN	O
related	VBN	O
to	TO	O
four	CD	O
different	JJ	O
treatment	NN	O
protocols	NNS	O
for	IN	O
chronic	JJ	C
periodontitis	NN	C
.	.	O

BACKGROUND	IN	O
The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
oral	JJ	O
health	NN	O
impacts	NNS	O
perceived	VBN	O
by	IN	O
patients	NNS	O
submitted	VBN	O
to	TO	O
different	JJ	O
treatments	NNS	O
of	IN	O
chronic	JJ	C
periodontitis	NN	C
and	CC	O
their	PRP$	O
association	NN	O
with	IN	O
clinical	JJ	O
parameters	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	SS
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
therapeutic	JJ	O
groups	NNS	O
:	:	O
control	NN	O
,	,	O
treated	VBN	O
with	IN	O
full-mouth	JJ	O
scaling	NN	O
and	CC	O
root	NN	O
planing	NN	O
(	(	O
SRP	NNP	O
)	)	O
;	:	O
test	$	O
1	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	O
and	CC	O
400	CD	O
mg	NNS	O
systemically	RB	O
administered	VBN	O
metronidazole	NN	O
(	(	O
MET	NNP	O
)	)	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
for	IN	O
10	CD	O
days	NNS	O
;	:	O
test	JJS	O
2	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	O
and	CC	O
professional	JJ	O
supragingival	NN	O
plaque	NN	O
removal	NN	O
(	(	O
PP	NNP	O
)	)	O
every	DT	O
week	NN	O
for	IN	O
3	CD	O
months	NNS	O
;	:	O
and	CC	O
test	VB	O
3	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	O
and	CC	O
MET	NNP	O
plus	CC	O
PP	NNP	O
.	.	O

Clinical	NNP	O
periodontal	JJ	O
measurements	NNS	O
and	CC	O
data	NNS	O
regarding	VBG	O
patients	NNS	O
'	POS	O
oral	JJ	O
health	NN	O
impacts	NNS	O
(	(	O
perceived	VBN	O
impacts	NNS	O
on	IN	O
bleeding	VBG	O
gums	NNS	O
,	,	O
gingival	JJ	O
recession	NN	O
,	,	O
sensitivity	NN	O
to	TO	O
cold	VB	O
,	,	O
packing	VBG	O
foods	NNS	O
,	,	O
aesthetics	NNS	O
,	,	O
bad	JJ	O
breath	NN	O
,	,	O
and	CC	O
tooth	DT	O
mobility	NN	O
)	)	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
presented	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
oral	JJ	O
health	NN	O
perceived	VBD	O
impacts	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
improvement	NN	O
of	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
among	IN	O
groups	NNS	O
subjected	VBN	O
to	TO	O
different	JJ	O
treatments	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
data	NNS	O
of	IN	O
percentage	NN	O
of	IN	O
deep	JJ	O
probing	VBG	O
depth	NN	O
,	,	O
deep	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
,	,	O
and	CC	O
bleeding	VBG	O
on	IN	O
probing	VBG	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
correlated	VBN	O
significantly	RB	O
with	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Periodontal	NNP	O
treatment	NN	O
leads	VBZ	O
to	TO	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
self-perceived	JJ	O
impacts	NNS	O
regardless	RB	O
of	IN	O
the	DT	O
non-surgical	JJ	O
treatment	NN	O
protocol	NN	O
employed	VBN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
clinical	JJ	O
data	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
.	.	O

Codeine/acetaminophen	NNP	O
and	CC	O
hydrocodone/acetaminophen	JJ	O
combination	NN	O
tablets	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
chronic	JJ	C
cancer	NN	C
pain	NN	C
in	IN	O
adults	NNS	A
:	:	O
a	DT	O
23-day	JJ	O
,	,	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Analgesics	NNPS	O
are	VBP	O
an	DT	O
essential	JJ	O
component	NN	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cancer-associated	JJ	O
pain	NN	O
.	.	O

Pharmacologic	NNP	O
treatment	NN	O
is	VBZ	O
usually	RB	O
begun	VBN	O
with	IN	O
nonopioid	JJ	O
analgesics	NNS	O
,	,	O
most	JJS	O
frequently	RB	O
acetaminophen	VBP	O
.	.	O

If	IN	O
pain	JJ	O
relief	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
,	,	O
the	DT	O
so-called	JJ	O
weak	JJ	O
opioids	NNS	O
,	,	O
such	JJ	O
as	IN	O
codeine	NN	O
and	CC	O
hydrocodone	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
acetaminophen	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
(	(	O
AEs	NNP	O
)	)	O
of	IN	O
the	DT	O
opioids	NNS	O
include	VBP	O
constipation	NN	O
,	,	O
somnolence	NN	O
,	,	O
nausea	NN	O
,	,	O
and	CC	O
vomiting	VBG	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
literature	NN	O
search	NN	O
,	,	O
data	NNS	O
comparing	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
opioids	NNS	O
are	VBP	O
lacking	VBG	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
codeine	NN	O
phosphate	NN	O
versus	IN	O
hydrocodone	NN	O
bitartrate	NN	O
in	IN	O
combination	NN	O
with	IN	O
acetaminophen	NN	O
in	IN	O
the	DT	O
relief	NN	O
of	IN	O
cancer-related	JJ	O
pain	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
23-day	JJ	O
,	,	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
3	CD	O
Colombian	JJ	O
centers	NNS	O
:	:	O
University	NNP	O
Libre	NNP	O
,	,	O
Social	NNP	O
Security	NNP	O
Institute	NNP	O
,	,	O
and	CC	O
General	NNP	O
Hospital	NNP	O
of	IN	O
Medell?n	NNP	O
,	,	O
Cali	NNP	O
,	,	O
Colombia	NNP	O
.	.	O

Outpatients	NNS	O
with	IN	O
cancer	NN	O
were	VBD	O
eligible	JJ	O
for	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
were	VBD	O
aged	VBN	O
>	JJ	O
-18	CD	O
years	NNS	O
and	CC	O
had	VBD	O
chronic	VBN	O
(	(	O
duration	NN	O
,	,	O
>	NNP	O
/=	VBZ	O
3	CD	O
months	NNS	O
)	)	O
moderate	VBP	O
to	TO	O
severe	VB	O
cancer-related	JJ	O
pain	NN	O
(	(	O
score	NN	O
on	IN	O
10-cm	JJ	O
visual	JJ	O
analog	NN	O
scale	NN	O
[	NNP	O
VAS	NNP	O
]	NNP	O
,	,	O
>	VBD	O
3	CD	O
cm	NN	O
[	NN	O
moderate	JJ	O
]	NN	O
;	:	O
score	NN	O
on	IN	O
a	DT	O
4-point	JJ	O
verbal	JJ	O
pain-intensity	NN	O
scale	NN	O
,	,	O
>	VBZ	O
1	CD	O
[	NN	O
moderate	JJ	O
]	NN	O
)	)	O
.	.	O

Eligible	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
1	CD	O
tablet	NN	O
of	IN	O
codeine/acetaminophen	NN	O
(	(	O
C/A	NNP	O
)	)	O
30/500	CD	O
mg	NN	O
or	CC	O
hydrocodone/acetaminophen	NN	O
(	(	O
H/A	NNP	O
)	)	O
5/500	CD	O
mg	NN	O
PO	NNP	O
q4h	NN	O
(	(	O
total	JJ	O
daily	JJ	O
doses	NNS	O
,	,	O
150/2500	CD	O
and	CC	O
25/2500	CD	O
mg	NN	O
,	,	O
respectively	RB	O
)	)	O
for	IN	O
23	CD	O
days	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
if	IN	O
pain	JJ	O
intensity	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
>	JJ	O
3	CD	O
on	IN	O
the	DT	O
VAS	NNP	O
at	IN	O
week	NN	O
1	CD	O
or	CC	O
2	CD	O
,	,	O
the	DT	O
dosage	NN	O
was	VBD	O
doubled	VBN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
pain	NN	O
relief	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
score	NN	O
of	IN	O
>	$	O
1	CD	O
on	IN	O
a	DT	O
5-point	JJ	O
verbal	NN	O
rating	NN	O
scale	NN	O
[	NNP	O
VRS	NNP	O
]	NNP	O
(	(	O
0	CD	O
=	NNP	O
none	NN	O
;	:	O
1	CD	O
=	IN	O
a	DT	O
little	JJ	O
;	:	O
2	CD	O
=	IN	O
some	DT	O
;	:	O
3	CD	O
=	IN	O
a	DT	O
lot	NN	O
;	:	O
and	CC	O
4	CD	O
=	NNP	O
complete	JJ	O
)	)	O
on	IN	O
study	NN	O
days	NNS	O
1	CD	O
and	CC	O
2	CD	O
and	CC	O
weeks	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
.	.	O

The	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
pain	NN	O
was	VBD	O
decreased	VBN	O
(	(	O
VAS	NNP	O
score	RB	O
,	,	O
<	NNP	O
-	:	O
3	CD	O
cm	NN	O
)	)	O
.	.	O

AEs	$	O
were	VBD	O
self-reported	VBN	O
on	IN	O
a	DT	O
4-point	JJ	O
VRS	NNP	O
(	(	O
0	CD	O
=	NNP	O
absent	NN	O
;	:	O
1	CD	O
=	NNP	O
mild	NN	O
;	:	O
2	CD	O
=	NN	O
moderate	NN	O
;	:	O
and	CC	O
3	CD	O
=	NNP	O
severe	RB	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
121	CD	O
patients	NNS	O
who	WP	O
participated	VBD	O
,	,	O
59	CD	O
received	VBD	O
C/A	NNP	O
and	CC	O
62	CD	O
received	VBD	O
H/A	NNP	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
cases	NNS	O
,	,	O
59	CD	O
%	NN	O
were	VBD	O
aged	VBN	O
60	CD	O
to	TO	O
89	CD	O
years	NNS	O
,	,	O
and	CC	O
55	CD	O
%	NN	O
were	VBD	O
men	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
88	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
described	VBD	O
their	PRP$	O
pain	NN	O
intensity	NN	O
as	IN	O
moderate	JJ	O
;	:	O
12	CD	O
%	NN	O
,	,	O
severe	JJ	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
C/A	NNP	O
,	,	O
58	CD	O
%	NN	O
responded	VBD	O
to	TO	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
150/2500	CD	O
mg/d	NN	O
,	,	O
and	CC	O
8	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
responded	VBD	O
to	TO	O
the	DT	O
double	JJ	O
dosage	NN	O
;	:	O
34	CD	O
%	NN	O
did	VBD	O
not	RB	O
experience	VB	O
pain	NN	O
relief	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
H/A	NNP	O
,	,	O
pain	NN	O
was	VBD	O
reported	VBN	O
as	IN	O
absent	NN	O
or	CC	O
mild	NN	O
in	IN	O
56	CD	O
%	NN	O
of	IN	O
patients	NNS	O
at	IN	O
the	DT	O
starting	VBG	O
dosage	NN	O
of	IN	O
25/2500	CD	O
mg/d	NN	O
;	:	O
an	DT	O
additional	JJ	O
15	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
responded	VBD	O
to	TO	O
the	DT	O
double	JJ	O
dosage	NN	O
;	:	O
the	DT	O
remaining	VBG	O
29	CD	O
%	NN	O
of	IN	O
patients	NNS	O
did	VBD	O
not	RB	O
experience	VB	O
any	DT	O
pain	NN	O
relief	NN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
between-group	JJ	O
differences	NNS	O
in	IN	O
response	NN	O
rates	NNS	O
were	VBD	O
significant	JJ	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
AEs	NNP	O
in	IN	O
the	DT	O
C/A	NNP	O
and	CC	O
H/A	NNP	O
groups	NNS	O
were	VBD	O
constipation	NN	O
(	(	O
36	CD	O
%	NN	O
and	CC	O
29	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
dizziness	NN	O
(	(	O
24	CD	O
%	NN	O
and	CC	O
19	CD	O
%	NN	O
)	)	O
,	,	O
vomiting	VBG	O
(	(	O
24	CD	O
%	NN	O
and	CC	O
16	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
dry	JJ	O
mouth	NN	O
(	(	O
15	CD	O
%	NN	O
and	CC	O
18	CD	O
%	NN	O
)	)	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
were	VBD	O
comparable	JJ	O
between	IN	O
C/A	NNP	O
and	CC	O
H/A	NNP	O
over	IN	O
23	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
in	IN	O
these	DT	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
,	,	O
chronic	JJ	O
,	,	O
cancer-related	JJ	O
pain	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
Dader	NNP	O
Method	NNP	O
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
total	JJ	O
cholesterol	NN	O
in	IN	O
outpatients	NNS	O
with	IN	O
cardiovascular	JJ	C
disease	NN	C
or	CC	O
cardiovascular	JJ	C
risk	NN	C
:	:	O
EMDADER-CV	JJ	O
randomized	NNS	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
some	DT	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
pharmacist	JJ	O
intervention	NN	O
can	MD	O
improve	VB	O
drug	NN	O
therapy	NN	O
among	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	C
disease	NN	C
(	(	O
CVD	NNP	C
)	)	O
,	,	O
more	JJR	O
evidence	NN	O
derived	VBN	O
from	IN	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
is	VBZ	O
needed	VBN	O
,	,	O
including	VBG	O
assessment	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
community	NN	O
pharmacist	NN	O
interventions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	C
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Dader	NNP	O
Method	NNP	O
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
achieving	VBG	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
,	,	O
and	CC	O
both	DT	O
BP	NNP	O
and	CC	O
TC	NNP	O
(	(	O
BP/TC	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	C
or	CC	C
intermediate	JJ	C
cardiovascular	NN	C
(	(	C
CV	NNP	C
)	)	C
risk	NN	C
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
aged	VBD	O
25	CD	A
to	TO	A
74	CD	A
years	NNS	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
with	IN	O
a	DT	O
prescription	NN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
drug	NN	O
indicated	VBN	O
for	IN	O
CVD	NNP	O
or	CC	O
CV	NNP	C
risk	NN	O
factors	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
an	DT	O
intervention	NN	O
group	NN	O
that	WDT	O
received	VBD	O
pharmaceutical	JJ	O
care	NN	O
,	,	O
which	WDT	O
was	VBD	O
provided	VBN	O
by	IN	O
specially	RB	O
trained	JJ	O
pharmacists	NNS	O
working	VBG	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
,	,	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
that	WDT	O
received	VBD	O
usual	JJ	O
care	NN	O
(	(	O
routine	JJ	O
dispensing	VBG	O
counseling	NN	O
)	)	O
and	CC	O
verbal	JJ	O
and	CC	O
written	VBN	O
counseling	VBG	O
regarding	VBG	O
CVD	NNP	O
prevention	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
December	NNP	O
2005	CD	O
to	TO	O
September	NNP	O
2006	CD	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
8	CD	O
months	NNS	O
.	.	O

Study	NNP	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
16	CD	O
and	CC	O
32	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
achieving	VBG	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
therapeutic	JJ	O
goals	NNS	O
(	(	O
BP	NNP	O
lower	JJR	O
than	IN	O
140/90	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
uncomplicated	JJ	O
hypertension	NN	O
and	CC	O
lower	JJR	O
than	IN	O
130/80	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
,	,	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
,	,	O
or	CC	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
stroke	NN	O
;	:	O
TC	NNP	O
lower	JJR	O
than	IN	O
200	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
without	IN	O
CVD	NNP	O
and	CC	O
lower	JJR	O
than	IN	O
175	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
BP	NNP	O
and	CC	O
TC	NNP	O
values	NNS	O
.	.	O

BP	NNP	O
was	VBD	O
assessed	VBN	O
manually	RB	O
by	IN	O
the	DT	O
pharmacist	NN	O
after	IN	O
a	DT	O
10-minute	JJ	O
rest	NN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

This	DT	O
measurement	NN	O
was	VBD	O
performed	VBN	O
twice	RB	O
for	IN	O
every	DT	O
participant	NN	O
,	,	O
and	CC	O
the	DT	O
average	NN	O
of	IN	O
the	DT	O
2	CD	O
measurements	NNS	O
was	VBD	O
calculated	VBN	O
.	.	O

TC	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
pharmacist	NN	O
during	IN	O
the	DT	O
study	NN	O
visit	NN	O
using	VBG	O
the	DT	O
enzymatic	JJ	O
dry	JJ	O
method	NN	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
2-tailed	JJ	O
McNemar	NNP	O
tests	NNS	O
,	,	O
Pearson	NNP	O
chi-square	NN	O
tests	NNS	O
,	,	O
and	CC	O
Student	NNP	O
's	POS	O
t-tests	NNS	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	VB	O
714	CD	SS
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
356	CD	O
intervention	NN	O
,	,	O
358	CD	O
control	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
was	VBD	O
62.8	CD	A
[	JJ	O
8.1	CD	O
]	JJ	O
years	NNS	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
clinical	JJ	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
including	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
at	IN	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
.	.	O

After	IN	O
8	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
there	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
favor	NN	O
of	IN	O
pharmaceutical	JJ	O
care	NN	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
(	(	O
52.5	CD	O
%	NN	O
vs.	FW	O
43.0	CD	O
%	NN	O
,	,	O
P=0.017	NNP	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
56.5	CD	O
%	NN	O
vs.	FW	O
44.1	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
and	CC	O
BP/TC	NNP	O
(	(	O
37.1	CD	O
%	NN	O
vs.	FW	O
21.8	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
usual	JJ	O
care	NN	O
plus	CC	O
written	VBN	O
education	NN	O
,	,	O
pharmaceutical	JJ	O
care	NN	O
focused	VBN	O
on	IN	O
patient	JJ	O
evaluation	NN	O
and	CC	O
follow-up	NN	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
improved	VBN	O
the	DT	O
achievement	NN	O
of	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
treatment	NN	O
goals	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
CV	NNP	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

Contingency	NNP	O
management	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antipsychotic-induced	JJ	O
weight	JJ	O
gain	NN	O
:	:	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Weight	NNP	O
gain	NN	O
is	VBZ	O
common	JJ	O
for	IN	O
individuals	NNS	O
with	IN	O
serious	JJ	C
mental	JJ	C
illness	NN	C
(	(	O
SMI	NNP	C
)	)	O
receiving	VBG	O
antipsychotic	JJ	O
drug	NN	O
therapy	NN	O
.	.	O

Contingency	NNP	O
management	NN	O
(	(	O
CM	NNP	O
)	)	O
is	VBZ	O
a	DT	O
behavioral	JJ	O
intervention	NN	O
that	IN	O
rewards	NNS	O
positive	JJ	O
performance	NN	O
and	CC	O
has	VBZ	O
demonstrated	VBN	O
effectiveness	NN	O
in	IN	O
reducing	VBG	O
drug	NN	O
use	NN	O
in	IN	O
SMI	NNP	O
populations	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
using	VBG	O
CM	NNP	O
to	TO	O
promote	VB	O
weight	JJ	O
loss	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
SMI	NNP	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

METHOD	NNP	O
30	CD	O
individuals	NNS	O
(	(	O
BMI	NNP	O
?	.	O
28	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
conditions	NNS	O
:	:	O
i	NN	O
)	)	O
The	DT	O
combination	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
lifestyle	NN	O
modification	NN	O
(	(	O
LM	NNP	O
)	)	O
program	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
SMI	NNP	O
and	CC	O
payment	NN	O
for	IN	O
group	NN	O
attendance	NN	O
(	(	O
CM	NNP	O
(	(	O
attendance	NN	O
)	)	O
)	)	O
,	,	O
ii	NN	O
)	)	O
The	DT	O
combination	NN	O
of	IN	O
LM	NNP	O
and	CC	O
payment	NN	O
for	IN	O
weight	JJ	O
loss	NN	O
(	(	O
CM	NNP	O
(	(	O
weight	NN	O
)	)	O
)	)	O
,	,	O
and	CC	O
iii	NN	O
)	)	O
waitlist	NN	O
control	NN	O
(	(	O
CON	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
waitlist	JJ	O
period	NN	O
,	,	O
those	DT	O
participants	NNS	O
joined	VBD	O
a	DT	O
LM	NNP	O
group	NN	O
and	CC	O
received	VBD	O
payment	NN	O
for	IN	O
behavioral	JJ	O
change	NN	O
(	(	O
CM	NNP	O
(	(	O
behavior	NN	O
)	)	O
)	)	O
.	.	O

RESULTS	JJ	O
Subjects	NNPS	O
in	IN	O
the	DT	O
CM	NNP	O
(	(	O
attendance	NN	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
CM	NNP	O
(	(	O
weight	NN	O
)	)	O
group	NN	O
lost	VBD	O
a	DT	O
mean	NN	O
of	IN	O
1.16	CD	O
kg	NNS	O
and	CC	O
1.23	CD	O
kg	NN	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
CON	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
0.68	CD	O
kg	NNS	O
.	.	O

Subjects	NNS	O
receiving	VBG	O
CM	NNP	O
(	(	O
behavior	NN	O
)	)	O
,	,	O
lost	VBD	O
a	DT	O
mean	NN	O
of	IN	O
2.54	CD	O
kg	NNS	O
,	,	O
which	WDT	O
was	VBD	O
a	DT	O
significant	JJ	O
weight	NN	O
loss	NN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
period	NN	O
.	.	O

CONCLUSION	NNP	O
LM	NNP	O
supplemented	VBD	O
with	IN	O
CM	NNP	O
may	MD	O
facilitate	VB	O
weight	NN	O
loss	NN	O
in	IN	O
patients	NNS	O
taking	VBG	O
antipsychotic	JJ	O
medications	NNS	O
;	:	O
financial	JJ	O
reimbursement	NN	O
for	IN	O
behavioral	JJ	O
change	NN	O
may	MD	O
be	VB	O
particularly	RB	O
effective	JJ	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Study	NN	O
of	IN	O
the	DT	O
vaginal	JJ	O
tolerance	NN	O
to	TO	O
Acidform	NNP	O
,	,	O
an	DT	O
acid-buffering	JJ	O
,	,	O
bioadhesive	JJ	O
gel	NN	O
.	.	O

Vaginal	JJ	O
tolerance	NN	O
tests	NNS	O
were	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
new	JJ	O
potential	JJ	O
microbicidal	NN	O
and	CC	O
spermicidal	JJ	O
product	NN	O
,	,	O
an	DT	O
acid-buffering	JJ	O
vaginal	JJ	O
gel	NN	O
(	(	O
Acidform	NNP	O
)	)	O
without	IN	O
or	CC	O
with	IN	O
nonoxynol-9	JJ	O
(	(	O
N-9	NNP	O
)	)	O
.	.	O

The	DT	O
potential	JJ	O
advantages	NNS	O
over	IN	O
other	JJ	O
vaginal	JJ	O
products	NNS	O
include	VBP	O
keeping	VBG	O
a	DT	O
low	JJ	O
pH	NN	O
,	,	O
decrease	NN	O
of	IN	O
the	DT	O
irritating	VBG	O
effect	NN	O
of	IN	O
N-9	NNP	O
on	IN	O
the	DT	O
cervix	NN	O
or	CC	O
vaginal	JJ	O
mucosa	NN	O
associated	VBN	O
with	IN	O
greater	JJR	O
retention	NN	O
of	IN	O
the	DT	O
product	NN	O
after	IN	O
application	NN	O
,	,	O
and	CC	O
decreasing	VBG	O
messiness	NN	O
as	IN	O
compared	VBN	O
to	TO	O
other	JJ	O
vaginal	JJ	O
products	NNS	O
.	.	O

Three	CD	O
groups	NNS	O
of	IN	O
six	CD	SS
women	NNS	SE
were	VBD	O
admitted	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
use	VB	O
Acidform	NNP	O
with	IN	O
0	CD	O
%	NN	O
,	,	O
2.5	CD	O
%	NN	O
,	,	O
and	CC	O
5	CD	O
%	NN	O
N-9	NNP	O
.	.	O

Colposcopic	NNP	O
evaluation	NN	O
for	IN	O
vulvar	NN	O
,	,	O
vaginal	JJ	O
,	,	O
and	CC	O
cervical	JJ	O
signs	NNS	O
of	IN	O
irritation	NN	O
was	VBD	O
performed	VBN	O
and	CC	O
photographs	NNS	O
were	VBD	O
taken	VBN	O
,	,	O
following	VBG	O
a	DT	O
specific	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
protocol	NN	O
,	,	O
at	IN	O
time	NN	O
0	CD	O
,	,	O
and	CC	O
after	IN	O
24	CD	O
h	NN	O
and	CC	O
6	CD	O
days	NNS	O
of	IN	O
application	NN	O
of	IN	O
the	DT	O
gel	NN	O
.	.	O

No	DT	O
irritation	NN	O
or	CC	O
symptom	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
users	NNS	O
of	IN	O
Acidform	NNP	O
without	IN	O
N-9	NNP	O
.	.	O

A	NNP	O
generalized	JJ	O
and	CC	O
intense	JJ	O
erythema	NN	O
in	IN	O
cervix	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
10	CD	O
of	IN	O
12	CD	O
Acidform/N-9	JJ	O
users	NNS	O
and	CC	O
abrasion	NN	O
occurred	VBD	O
in	IN	O
nine	CD	O
of	IN	O
them	PRP	O
.	.	O

Vulvar	NNP	O
irritation	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
seven	CD	O
of	IN	O
these	DT	O
10	CD	SS
volunteers	NNS	O
.	.	O

N-9	JJ	O
concentration	NN	O
in	IN	O
the	DT	O
gel	NN	O
(	(	O
2.5	CD	O
%	NN	O
or	CC	O
5.0	CD	O
%	NN	O
)	)	O
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
the	DT	O
findings	NNS	O
.	.	O

No	DT	O
ulcer	NN	O
,	,	O
exulceration	NN	O
,	,	O
or	CC	O
de-epithelialization	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Acidform	VB	O
without	IN	O
N-9	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
by	IN	O
volunteers	NNS	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
unable	JJ	O
to	TO	O
protect	VB	O
the	DT	O
cervix	NN	O
,	,	O
vagina	NN	O
,	,	O
and	CC	O
vulva	NN	O
from	IN	O
the	DT	O
N-9	JJ	O
effects	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
on	IN	O
adherence	NN	O
to	TO	O
a	DT	O
low-fat	JJ	O
dietary	JJ	O
pattern	NN	O
in	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
whether	IN	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
on	IN	O
adherance	NN	O
to	TO	O
a	DT	O
low-fat	JJ	O
(	(	O
20	CD	O
%	NN	O
energy	NN	O
)	)	O
dietary	JJ	O
pattern	NN	O
are	VBP	O
mediated	VBN	O
by	IN	O
participation	NN	O
in	IN	O
an	DT	O
intervention	NN	O
program	NN	O
(	(	O
attending	VBG	O
sessions	NNS	O
and	CC	O
self-monitoring	NN	O
)	)	O
.	.	O

DESIGN	VB	O
The	DT	O
Baron	NNP	O
and	CC	O
Kenny	NNP	O
mediator	NN	O
model	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
4	CD	O
regression	NN	O
analyses	NNS	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
whether	IN	O
:	:	O
a	DT	O
)	)	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
predicted	VBD	O
program	NN	O
participation	NN	O
,	,	O
b	NN	O
)	)	O
program	NN	O
participation	NN	O
predicted	VBD	O
dietary	JJ	O
adherence	NN	O
,	,	O
c	NN	O
)	)	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
factors	NNS	O
predicted	VBD	O
dietary	JJ	O
adherence	NN	O
,	,	O
and	CC	O
,	,	O
ultimately	RB	O
d	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
were	VBD	O
mediated	VBN	O
by	IN	O
program	NN	O
participation	NN	O
.	.	O

SUBJECTS/SETTING	NNP	O
Data	NNP	O
from	IN	O
13,277	CD	SS
postmenopausal	JJ	C
women	NNS	SE
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
low-fat	JJ	O
intervention	NN	O
arm	NN	O
of	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
Dietary	NNP	O
Modification	NNP	O
Trial	NNP	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
nutrition	NN	O
goals	NNS	O
for	IN	O
women	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
low-fat	JJ	O
intervention	NN	O
were	VBD	O
to	TO	O
reduce	VB	O
total	JJ	O
fat	JJ	O
intake	NN	O
to	TO	O
20	CD	O
%	NN	O
or	CC	O
less	JJR	O
of	IN	O
energy	NN	O
from	IN	O
fat	JJ	O
and	CC	O
to	TO	O
consume	VB	O
5	CD	O
or	CC	O
more	JJR	O
fruit/vegetable	JJ	O
servings	NNS	O
daily	RB	O
and	CC	O
6	CD	O
or	CC	O
more	JJR	O
grain	JJ	O
servings	NNS	O
daily	RB	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Year	NNP	O
1	CD	O
program	NN	O
participation	NN	O
(	(	O
degree	NN	O
of	IN	O
attending	VBG	O
group	NN	O
sessions	NNS	O
and	CC	O
submitting	VBG	O
fat	JJ	O
scores	NNS	O
)	)	O
and	CC	O
adherence	NN	O
to	TO	O
the	DT	O
low-fat	JJ	O
dietary	JJ	O
pattern	NN	O
(	(	O
percent	JJ	O
energy	NN	O
from	IN	O
fat	NN	O
)	)	O
as	IN	O
predicted	VBN	O
by	IN	O
baseline	JJ	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
(	(	O
eight	CD	O
SF-36	NNP	O
Health	NNP	O
Survey	NNP	O
subscales	VBZ	O
)	)	O
.	.	O

RESULTS	NNP	O
Participating	VBG	O
in	IN	O
the	DT	O
dietary	JJ	O
intervention	NN	O
program	NN	O
reduced	VBN	O
(	(	O
mediated	VBN	O
)	)	O
the	DT	O
negative	JJ	O
effect	NN	O
of	IN	O
poorer	JJR	O
mental	JJ	O
health	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
by	IN	O
15	CD	O
%	NN	O
.	.	O

Additional	JJ	O
findings	NNS	O
included	VBD	O
that	IN	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
physical	JJ	O
functioning	NN	O
increased	VBD	O
session	NN	O
attendance	NN	O
by	IN	O
0.4	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
mental	JJ	O
health	NN	O
predicted	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
percent	NN	O
energy	NN	O
from	IN	O
fat	NN	O
of	IN	O
0.3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Program	NNP	O
participation	NN	O
had	VBD	O
a	DT	O
marked	JJ	O
effect	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
:	:	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
session	NN	O
attendance	NN	O
predicted	VBD	O
a	DT	O
1.2	CD	O
%	NN	O
decrease	NN	O
in	IN	O
percent	NN	O
energy	NN	O
from	IN	O
fat	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

APPLICATIONS/CONCLUSIONS	NNP	O
Understanding	NNP	O
and	CC	O
using	VBG	O
instruments	NNS	O
to	TO	O
assess	VB	O
the	DT	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
of	IN	O
a	DT	O
target	NN	O
population	NN	O
will	MD	O
help	VB	O
dietetic	JJ	O
professionals	NNS	O
promote	VBP	O
healthful	JJ	O
dietary	JJ	O
change	NN	O
and	CC	O
maintenance	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
vs	NN	O
patient	JJ	O
education	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
hip	JJ	C
osteoarthritis	NN	C
:	:	O
a	DT	O
single	JJ	O
blind	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
with	IN	O
that	DT	O
of	IN	O
patient	JJ	O
education	NN	O
alone	RB	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hip	NN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	C
)	)	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blind	IN	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Recruitment	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
hospitals	NNS	O
,	,	O
primary	JJ	O
health	NN	O
care	NN	O
and	CC	O
advertisement	NN	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
109	CD	SS
patients	NNS	O
with	IN	O
radiographic	JJ	O
and	CC	O
symptomatic	JJ	O
hip	NN	O
OA	NNP	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Patient	NNP	O
education	NN	O
(	(	O
PE	NNP	O
)	)	O
.	.	O

Patient	JJ	O
education	NN	O
and	CC	O
supervised	VBN	O
exercise	NN	O
(	(	O
PE+SE	NNP	O
)	)	O
.	.	O

PRIMARY	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
pain	NN	O
subscale	NN	O
of	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
pain	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
over	IN	O
the	DT	O
16-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
(	(	O
P=0.011	NNP	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PE+SE	NNP	O
compared	VBN	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
PE	NNP	O
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
stiffness	NN	O
,	,	O
the	DT	O
SF-36	JJ	O
subscales	NNS	O
or	CC	O
the	DT	O
activity	NN	O
scale	NN	O
.	.	O

The	DT	O
effect	NN	O
sizes	VBZ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
were	VBD	O
-0.26	NNP	O
(	(	O
0.11	CD	O
,	,	O
-0.64	NN	O
)	)	O
,	,	O
-0.35	NNP	O
(	(	O
0.07	CD	O
,	,	O
-0.77	NN	O
)	)	O
,	,	O
and	CC	O
-0.30	NNP	O
(	(	O
0.15	CD	O
,	,	O
-0.75	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
-0.29	NNP	O
(	(	O
0.09	CD	O
,	,	O
-0.67	NN	O
)	)	O
,	,	O
-0.48	NNP	O
(	(	O
-0.06	NNP	O
,	,	O
-0.91	NNP	O
)	)	O
,	,	O
and	CC	O
-0.47	NNP	O
(	(	O
-0.02	NNP	O
,	,	O
-0.93	NNP	O
)	)	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
both	DT	O
PE	NNP	O
and	CC	O
SE	NNP	O
.	.	O

All	DT	O
patients	NNS	O
attended	VBD	O
the	DT	O
three-session	JJ	O
PE	NNP	O
program	NN	O
,	,	O
and	CC	O
75	CD	O
%	NN	O
performed	VBN	O
?16	JJ	O
sessions	NNS	O
of	IN	O
the	DT	O
12-week	JJ	O
SE	NNP	O
program	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
study	NN	O
could	MD	O
not	RB	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
reduction	NN	O
over	IN	O
time	NN	O
between	IN	O
PE+SE	NNP	O
vs	NNP	O
PE	NNP	O
alone	RB	O
.	.	O

Adding	VBG	O
SE	NNP	O
to	TO	O
PE	NNP	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
possible	JJ	O
benefit	NN	O
is	VBZ	O
unknown	JJ	O
as	IN	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
around	IN	O
the	DT	O
mean	JJ	O
difference	NN	O
were	VBD	O
wide	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinical	NNP	O
Trials	NNP	O
NCT00319423	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
alfuzosin	NN	O
10	CD	O
mg	NN	O
once	RB	O
daily	RB	O
on	IN	O
sexual	JJ	O
function	NN	O
in	IN	O
men	NNS	SE
treated	VBN	O
for	IN	O
symptomatic	JJ	C
benign	NN	C
prostatic	JJ	C
hyperplasia	NN	C
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
extended-release	JJ	O
alfuzosin	NN	O
HCl	NNP	O
10	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
(	(	O
q.d	JJ	O
.	.	O

)	)	O
on	IN	O
sexual	JJ	O
function	NN	O
in	IN	O
men	NNS	O
with	IN	O
lower	JJR	C
urinary	JJ	C
tract	NN	C
symptoms	NNS	C
associated	VBN	O
with	IN	O
benign	JJ	C
prostatic	JJ	C
hyperplasia	NN	C
(	(	O
BPH	NNP	C
)	)	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
men	NNS	O
aged	VBN	O
>	NN	A
or	CC	A
=	$	A
50	CD	A
years	NNS	O
,	,	O
after	IN	O
a	DT	O
28-day	JJ	O
placebo	NN	O
run-in	JJ	O
period	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
alfuzosin	NN	O
10	CD	O
mg	NN	O
q.d	NN	O
.	.	O

or	CC	O
matching	VBG	O
placebo	NN	O
for	IN	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
(	(	O
day	NN	O
1	CD	O
)	)	O
in	IN	O
sexual	JJ	O
function	NN	O
on	IN	O
day	NN	O
29	CD	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Danish	JJ	O
Prostate	NNP	O
Symptom	NNP	O
Score	NNP	O
Sex	NNP	O
(	(	O
DAN-PSSsex	NNP	O
)	)	O
questionnaire	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
372	CD	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
alfuzosin	NN	O
(	(	O
n=186	JJ	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=186	JJ	O
)	)	O
,	,	O
with	IN	O
355	CD	SS
completing	VBG	O
the	DT	O
study	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
64	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
reported	VBD	O
erectile	JJ	C
dysfunction	NN	C
(	(	O
ED	NNP	C
)	)	O
and	CC	O
63	CD	O
%	NN	O
reported	VBD	O
ejaculatory	JJ	C
dysfunction	NN	C
(	(	O
EjD	NNP	C
)	)	O
.	.	O

For	IN	O
the	DT	O
320	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
DAN-PSSsex	NNP	O
,	,	O
alfuzosin	NN	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
erectile	JJ	O
function	NN	O
on	IN	O
day	NN	O
29	CD	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
ejaculatory	JJ	O
function	NN	O
on	IN	O
day	NN	O
29	CD	O
.	.	O

For	IN	O
patients	NNS	O
with	IN	O
ED	NNP	O
at	IN	O
baseline	NN	O
,	,	O
a	DT	O
marginal	JJ	O
improvement	NN	O
in	IN	O
erectile	JJ	O
function	NN	O
was	VBD	O
demonstrated	VBN	O
with	IN	O
alfuzosin	NN	O
treatment	NN	O
(	(	O
P=0.09	NNP	O
vs	NNP	O
placebo	NN	O
)	)	O
.	.	O

For	IN	O
patients	NNS	O
with	IN	O
EjD	NNP	O
at	IN	O
baseline	NN	O
,	,	O
the	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
ejaculatory	JJ	O
function	NN	O
with	IN	O
alfuzosin	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
that	DT	O
with	IN	O
placebo	NN	O
.	.	O

Dizziness	NNP	O
was	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
with	IN	O
alfuzosin	NN	O
treatment	NN	O
(	(	O
5	CD	O
vs	RB	O
0	CD	O
%	NN	O
with	IN	O
placebo	NN	O
)	)	O
,	,	O
with	IN	O
other	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
with	IN	O
comparable	JJ	O
frequency	NN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

After	IN	O
1	CD	O
month	NN	O
of	IN	O
treatment	NN	O
,	,	O
alfuzosin	RB	O
10	CD	O
mg	NN	O
q.d	NN	O
.	.	O

significantly	RB	O
improved	VBN	O
erectile	JJ	O
function	NN	O
in	IN	O
men	NNS	O
with	IN	O
lower	JJR	O
urinary	JJ	O
tract	NN	O
symptoms/	NN	O
benign	JJ	O
prostatic	JJ	O
hypertrophy	NN	O
and	CC	O
had	VBD	O
no	DT	O
adverse	JJ	O
effect	NN	O
on	IN	O
ejaculatory	NN	O
function	NN	O
.	.	O

Induction	NNP	O
chemotherapy	NN	O
in	IN	O
head	NN	C
and	CC	C
neck	NN	C
cancer	NN	C
:	:	O
results	NNS	O
of	IN	O
a	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

Between	IN	O
December	NNP	O
1982	CD	O
and	CC	O
October	NNP	O
1986	CD	O
,	,	O
131	CD	SS
patients	NNS	O
with	IN	O
stage	JJ	C
II-III-IV	NNP	C
squamous	JJ	C
cell	NN	C
carcinoma	NN	C
of	IN	O
the	DT	O
oropharynx	NN	C
or	CC	O
oral	JJ	C
cavity	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
induction	VB	O
chemotherapy	NN	O
,	,	O
consisting	VBG	O
of	IN	O
bleomycin	NN	O
(	(	O
10	CD	O
mg/m2/day	NN	O
in	IN	O
continuous	JJ	O
infusion	NN	O
from	IN	O
day	NN	O
1	CD	O
to	TO	O
day	NN	O
5	CD	O
)	)	O
,	,	O
methotrexate	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
2	CD	O
)	)	O
followed	VBN	O
by	IN	O
folinic	JJ	O
acid	NN	O
,	,	O
5-fluorouracil	JJ	O
(	(	O
5	CD	O
FU	NNP	O
)	)	O
(	(	O
600	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
2	CD	O
)	)	O
,	,	O
and	CC	O
cisplatin	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
4	CD	O
)	)	O
every	DT	O
4	CD	O
weeks	NNS	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
three	CD	O
cycles	NNS	O
followed	VBN	O
by	IN	O
definitive	JJ	O
locoregional	JJ	O
treatment	NN	O
versus	IN	O
locoregional	JJ	O
treatment	NN	O
alone	RB	O
.	.	O

The	DT	O
modalities	NNS	O
of	IN	O
definitive	JJ	O
treatment	NN	O
(	(	O
radiotherapy	JJ	O
+/-	JJ	O
surgery	NN	O
)	)	O
were	VBD	O
chosen	VBN	O
prior	RB	O
to	TO	O
randomization	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
116	CD	SS
patients	NNS	O
were	VBD	O
evaluable	JJ	O
.	.	O

Of	IN	O
55	CD	O
patients	NNS	O
in	IN	O
the	DT	O
chemotherapy	NN	O
arm	NN	O
,	,	O
four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
and	CC	O
23	CD	O
(	(	O
42	CD	O
%	NN	O
)	)	O
a	DT	O
partial	JJ	O
response	NN	O
(	(	O
PR	NNP	O
)	)	O
following	VBG	O
the	DT	O
induction	NN	O
regimen	NNS	O
.	.	O

At	IN	O
the	DT	O
completion	NN	O
of	IN	O
locoregional	JJ	O
treatment	NN	O
,	,	O
76	CD	O
%	NN	O
(	(	O
42	CD	O
of	IN	O
55	CD	O
)	)	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
in	IN	O
CR	NNP	O
compared	VBN	O
to	TO	O
89	CD	O
%	NN	O
(	(	O
54	CD	O
of	IN	O
61	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
,	,	O
cause-specific	JJ	O
survival	NN	O
,	,	O
and	CC	O
pattern	NN	O
of	IN	O
relapse	NN	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
22	CD	O
months	NNS	O
in	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
and	CC	O
29	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Responders	NNS	O
to	TO	O
chemotherapy	VB	O
did	VBD	O
not	RB	O
fare	VB	O
better	JJR	O
than	IN	O
nonresponders	NNS	O
.	.	O

Chemotherapy-related	JJ	O
toxicities	NNS	O
were	VBD	O
few	JJ	O
and	CC	O
most	JJS	O
of	IN	O
them	PRP	O
related	VBN	O
to	TO	O
cisplatin	VB	O
which	WDT	O
was	VBD	O
reduced	VBN	O
to	TO	O
100	CD	O
mg/m2	NN	O
for	IN	O
35	CD	O
patients	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
treatment-related	JJ	O
deaths	NNS	O
and	CC	O
,	,	O
in	IN	O
the	DT	O
experimental	JJ	O
arm	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
no	DT	O
increased	VBN	O
morbidity	NN	O
from	IN	O
locoregional	JJ	O
treatment	NN	O
.	.	O

This	DT	O
induction	NN	O
regimen	NN	O
does	VBZ	O
not	RB	O
offer	VB	O
any	DT	O
advantages	NNS	O
over	IN	O
standard	JJ	O
treatment	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
a	DT	O
low-tilt	JJ	O
biphasic	JJ	O
waveform	NN	O
for	IN	O
transvenous	JJ	O
cardioversion	NN	O
of	IN	O
atrial	JJ	C
fibrillation	NN	C
:	:	O
improved	VBN	O
efficacy	NN	O
compared	VBN	O
with	IN	O
conventional	JJ	O
capacitor-based	JJ	O
waveforms	NNS	O
in	IN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
optimal	JJ	O
waveform	NN	O
tilt	NN	O
for	IN	O
defibrillation	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Most	JJS	O
modern	JJ	O
defibrillators	NNS	O
used	VBN	O
for	IN	O
the	DT	O
cardioversion	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
employ	VBD	O
high-tilt	JJ	O
,	,	O
capacitor-based	JJ	O
biphasic	JJ	O
waveforms	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
have	VBP	O
developed	VBN	O
a	DT	O
low-tilt	JJ	O
biphasic	JJ	O
waveform	NN	O
for	IN	O
defibrillation	NN	O
.	.	O

This	DT	O
low-tilt	JJ	O
waveform	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
conventional	JJ	O
waveform	NN	O
of	IN	O
equivalent	JJ	O
duration	NN	O
and	CC	O
voltage	NN	O
in	IN	O
patients	NNS	O
with	IN	O
AF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
persistent	JJ	C
AF	NNP	C
or	CC	O
AF	NNP	C
induced	VBD	C
during	IN	O
a	DT	O
routine	JJ	O
electrophysiology	NN	C
study	NN	C
(	(	O
EPS	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
the	DT	O
low-tilt	JJ	O
waveform	NN	O
or	CC	O
a	DT	O
conventional	JJ	O
waveform	NN	O
.	.	O

Defibrillation	NNP	O
electrodes	NNS	O
were	VBD	O
positioned	VBN	O
in	IN	O
the	DT	O
right	JJ	O
atrial	JJ	O
appendage	NN	O
and	CC	O
distal	JJ	O
coronary	JJ	O
sinus	NN	O
.	.	O

Phase	VB	O
1	CD	O
peak	JJ	O
voltage	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
a	DT	O
stepwise	NN	O
progression	NN	O
from	IN	O
50	CD	O
V	NNP	O
to	TO	O
300V	CD	O
.	.	O

Shock	NNP	O
success	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
return	NN	O
of	IN	O
sinus	NN	O
rhythm	NN	O
for	IN	O
>	NNP	O
/=30	NNP	O
seconds	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
low-tilt	JJ	O
waveform	NN	O
produced	VBN	O
successful	JJ	O
termination	NN	O
of	IN	O
persistent	JJ	O
AF	NNP	O
at	IN	O
a	DT	O
mean	JJ	O
voltage	NN	O
of	IN	O
223	CD	O
V	NNP	O
(	(	O
8.2	CD	O
J	NNP	O
)	)	O
versus	VBD	O
270	CD	O
V	NNP	O
(	(	O
6.7	CD	O
J	NNP	O
)	)	O
with	IN	O
the	DT	O
conventional	JJ	O
waveform	NN	O
(	(	O
P	NNP	O
=	VBZ	O
0.002	CD	O
for	IN	O
voltage	NN	O
,	,	O
P	NNP	O
=	NNP	O
ns	NN	O
for	IN	O
energy	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
induced	JJ	O
AF	NNP	O
the	DT	O
mean	JJ	O
voltage	NN	O
for	IN	O
the	DT	O
low-tilt	JJ	O
waveform	NN	O
was	VBD	O
91V	CD	O
(	(	O
1.6	CD	O
J	NNP	O
)	)	O
and	CC	O
for	IN	O
the	DT	O
conventional	JJ	O
waveform	NN	O
was	VBD	O
158	CD	O
V	NNP	O
(	(	O
2.0	CD	O
J	NNP	O
)	)	O
(	(	O
P	NNP	O
=	VBZ	O
0.005	CD	O
for	IN	O
voltage	NN	O
,	,	O
P	NNP	O
=	NNP	O
ns	NN	O
for	IN	O
energy	NN	O
)	)	O
.	.	O

The	DT	O
waveform	NN	O
was	VBD	O
much	RB	O
more	RBR	O
successful	JJ	O
at	IN	O
very	RB	O
low	JJ	O
voltages	NNS	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
100	CD	O
V	NNP	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
conventional	JJ	O
waveform	NN	O
(	(	O
Novel	NNP	O
:	:	O
82	CD	O
%	NN	O
vs	JJ	O
Conventional	NNP	O
22	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
low-tilt	JJ	O
biphasic	JJ	O
waveform	NN	O
was	VBD	O
more	RBR	O
successful	JJ	O
for	IN	O
the	DT	O
internal	JJ	O
cardioversion	NN	O
of	IN	O
both	DT	O
persistent	JJ	O
and	CC	O
induced	JJ	O
AF	NNP	O
in	IN	O
patients	NNS	O
(	(	O
in	IN	O
terms	NNS	O
of	IN	O
leading	VBG	O
edge	NN	O
voltage	NN	O
)	)	O
.	.	O

Intravenous	JJ	O
or	CC	O
intramuscular	JJ	O
teicoplanin	NN	O
once	RB	O
daily	JJ	O
for	IN	O
skin	NN	C
and	CC	C
soft-tissue	JJ	C
infections	NNS	C
.	.	O

Teicoplanin	NNP	O
is	VBZ	O
a	DT	O
new	JJ	O
glycopeptide	NN	O
antibiotic	JJ	O
with	IN	O
potent	JJ	O
activity	NN	O
against	IN	O
gram-positive	JJ	O
bacteria	NNS	O
and	CC	O
pharmacokinetics	NNS	O
that	WDT	O
allow	VBP	O
once	RB	O
daily	JJ	O
administration	NN	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
teicoplanin	NN	O
for	IN	O
skin	NN	O
and	CC	O
soft-tissue	NN	O
infections	NNS	O
,	,	O
75	CD	SS
patients	NNS	O
received	VBD	O
teicoplanin	JJ	O
intravenously	RB	O
(	(	O
38	CD	SS
)	)	O
or	CC	O
intramuscularly	RB	O
(	(	O
37	CD	SS
,	,	O
of	IN	O
which	WDT	O
16	CD	SS
were	VBD	O
outpatients	NNS	O
)	)	O
.	.	O

Of	IN	O
62	CD	SS
clinically	RB	O
evaluable	JJ	O
patients	NNS	O
,	,	O
97	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	O
iv	NN	O
and	CC	O
93	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	O
im	NN	O
patients	NNS	O
were	VBD	O
cured	VBN	O
or	CC	O
improved	VBN	O
.	.	O

All	DT	O
teicoplanin	JJ	O
iv	NN	O
patients	NNS	O
and	CC	O
64	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	O
im	NN	O
patients	NNS	O
were	VBD	O
cured	VBN	O
microbiologically	RB	O
at	IN	O
24-48	JJ	O
hours	NNS	O
posttherapy	NN	O
.	.	O

Persistence	NN	O
of	IN	O
organisms	NNS	O
frequently	RB	O
was	VBD	O
associated	VBN	O
with	IN	O
skin	JJ	O
ulcers	NNS	O
or	CC	O
abscess	JJ	O
cavities	NNS	O
and	CC	O
usually	RB	O
had	VBD	O
no	DT	O
bearing	NN	O
on	IN	O
clinical	JJ	O
outcome	NN	O
.	.	O

Possible	JJ	O
adverse	JJ	O
clinical	JJ	O
and	CC	O
laboratory	JJ	O
reactions	NNS	O
caused	VBN	O
by	IN	O
teicoplanin	NN	O
occurred	VBD	O
in	IN	O
4	CD	O
of	IN	O
38	CD	O
teicoplanin	JJ	O
iv	NN	O
patients	NNS	O
(	(	O
11	CD	O
percent	NN	O
)	)	O
and	CC	O
in	IN	O
8	CD	O
of	IN	O
37	CD	O
teicoplanin	JJ	O
im	NN	O
patients	NNS	O
(	(	O
22	CD	O
percent	NN	O
)	)	O
.	.	O

Reactions	NNPS	O
were	VBD	O
mild	JJ	O
and	CC	O
resolved	VBN	O
with	IN	O
discontinuation	NN	O
of	IN	O
teicoplanin	NN	O
in	IN	O
most	JJS	O
cases	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
teicoplanin	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
efficacious	JJ	O
,	,	O
and	CC	O
convenient	NN	O
for	IN	O
both	DT	O
hospital	JJ	O
staff	NN	O
and	CC	O
patients	NNS	O
,	,	O
and	CC	O
potentially	RB	O
cost-effective	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
skin	NN	O
and	CC	O
soft-tissue	JJ	O
infections	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
teicoplanin	JJ	O
appears	VBZ	O
to	TO	O
be	VB	O
appropriate	JJ	O
for	IN	O
outpatient	JJ	O
parenteral	JJ	O
therapy	NN	O
.	.	O

Predictors	NNS	O
of	IN	O
postdischarge	NN	O
outcomes	NNS	O
from	IN	O
information	NN	O
acquired	VBN	O
shortly	RB	O
after	IN	O
admission	NN	O
for	IN	O
acute	JJ	C
heart	NN	C
failure	NN	C
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Placebo-Controlled	NNP	O
Randomized	NNP	O
Study	NNP	O
of	IN	O
the	DT	O
Selective	NNP	O
A1	NNP	O
Adenosine	NNP	O
Receptor	NNP	O
Antagonist	NNP	O
Rolofylline	NNP	O
for	IN	O
Patients	NNP	O
Hospitalized	NNP	O
With	IN	O
Acute	NNP	C
Decompensated	NNP	C
Heart	NNP	C
Failure	NNP	C
and	CC	O
Volume	NN	C
Overload	NNP	C
to	TO	O
Assess	NNP	O
Treatment	NNP	O
Effect	NNP	O
on	IN	O
Congestion	NNP	O
and	CC	O
Renal	NNP	O
Function	NNP	O
(	(	O
PROTECT	NNP	O
)	)	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Acute	NNP	C
heart	NN	C
failure	NN	C
is	VBZ	O
a	DT	O
common	JJ	O
reason	NN	O
for	IN	O
admission	NN	O
,	,	O
and	CC	O
outcome	NN	O
is	VBZ	O
often	RB	O
poor	JJ	O
.	.	O

Improved	VBN	O
prognostic	JJ	O
risk	NN	O
stratification	NN	O
may	MD	O
assist	VB	O
in	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
and	CC	O
in	IN	O
patient	JJ	O
management	NN	O
.	.	O

Using	VBG	O
data	NNS	O
from	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
,	,	O
we	PRP	O
explored	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
clinical	JJ	O
variables	NNS	O
,	,	O
measured	VBN	O
at	IN	O
hospital	JJ	O
admission	NN	O
for	IN	O
acute	JJ	O
heart	NN	O
failure	NN	O
,	,	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
few	JJ	O
selected	VBN	O
variables	NNS	O
were	VBD	O
inferior	JJ	O
to	TO	O
an	DT	O
extended	VBN	O
data	NN	O
set	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
prognostic	JJ	O
model	NN	O
included	VBD	O
37	CD	O
clinical	JJ	O
characteristics	NNS	O
collected	VBN	O
at	IN	O
baseline	NN	O
in	IN	O
PROTECT	NNP	O
,	,	O
a	DT	O
study	NN	O
comparing	VBG	O
rolofylline	NN	O
and	CC	O
placebo	NN	O
in	IN	O
2033	CD	SS
patients	NNS	O
admitted	VBN	O
with	IN	O
acute	JJ	C
heart	NN	C
failure	NN	C
.	.	O

Prespecified	VBN	O
outcomes	NNS	O
at	IN	O
30	CD	O
days	NNS	O
were	VBD	O
death	NN	O
or	CC	O
rehospitalization	NN	O
for	IN	O
any	DT	O
reason	NN	O
;	:	O
death	NN	O
or	CC	O
rehospitalization	NN	O
for	IN	O
cardiovascular	NN	O
or	CC	O
renal	JJ	O
reasons	NNS	O
;	:	O
and	CC	O
,	,	O
at	IN	O
both	DT	O
30	CD	O
and	CC	O
180	CD	O
days	NNS	O
,	,	O
all-cause	JJ	O
mortality	NN	O
.	.	O

No	DT	O
variable	JJ	O
had	VBD	O
a	DT	O
c-index	NN	O
>	NN	O
0.70	CD	O
,	,	O
and	CC	O
few	JJ	O
had	VBD	O
values	NNS	O
>	$	O
0.60	CD	O
;	:	O
c-indices	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
composite	JJ	O
outcomes	NNS	O
than	IN	O
for	IN	O
mortality	NN	O
.	.	O

Blood	NNP	O
urea	NN	O
was	VBD	O
generally	RB	O
the	DT	O
strongest	JJS	O
single	JJ	O
predictor	NN	O
.	.	O

Eighteen	NNP	O
variables	NNS	O
contributed	VBD	O
independent	JJ	O
prognostic	JJ	O
information	NN	O
,	,	O
but	CC	O
a	DT	O
reduced	JJ	O
model	NN	O
using	VBG	O
only	RB	O
8	CD	O
items	NNS	O
(	(	O
age	NN	O
,	,	O
previous	JJ	O
heart	NN	O
failure	NN	O
hospitalization	NN	O
,	,	O
peripheral	JJ	O
edema	NN	O
,	,	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
serum	NN	O
sodium	NN	O
,	,	O
urea	JJ	O
,	,	O
creatinine	NN	O
,	,	O
and	CC	O
albumin	NN	O
)	)	O
performed	VBD	O
similarly	RB	O
.	.	O

For	IN	O
prediction	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
at	IN	O
180	CD	O
days	NNS	O
,	,	O
the	DT	O
model	NN	O
c-index	NN	O
using	VBG	O
all	DT	O
variables	NNS	O
was	VBD	O
0.72	CD	O
and	CC	O
for	IN	O
the	DT	O
simplified	JJ	O
model	NN	O
,	,	O
also	RB	O
0.72	CD	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
few	JJ	O
simple	JJ	O
clinical	JJ	O
variables	NNS	O
measured	VBN	O
on	IN	O
admission	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	C
heart	NN	C
failure	NN	C
predict	VBP	O
a	DT	O
variety	NN	O
of	IN	O
adverse	JJ	O
outcomes	NNS	O
with	IN	O
accuracy	NN	O
similar	JJ	O
to	TO	O
more	RBR	O
complex	JJ	O
models	NNS	O
.	.	O

However	RB	O
,	,	O
predictive	JJ	O
models	NNS	O
were	VBD	O
of	IN	O
only	RB	O
moderate	JJ	O
accuracy	NN	O
,	,	O
especially	RB	O
for	IN	O
outcomes	NNS	O
that	WDT	O
included	VBD	O
nonfatal	JJ	O
events	NNS	O
.	.	O

Better	NNP	O
methods	NNS	O
of	IN	O
risk	NN	O
stratification	NN	O
are	VBP	O
required	VBN	O
.	.	O

CLINICAL	JJ	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
.	.	O

Unique	JJ	O
identifiers	NNS	O
:	:	O
NCT00328692	NNP	O
and	CC	O
NCT00354458	NNP	O
.	.	O

Transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
following	VBG	O
appendicectomy	NN	C
:	:	O
the	DT	O
placebo	NN	O
effect	NN	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
(	(	O
TENS	NNP	O
)	)	O
with	IN	O
standard	JJ	O
intramuscular	JJ	O
opiate	NN	O
analgesia	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
following	VBG	O
appendicectomy	NN	C
.	.	O

Consecutive	JJ	O
patients	NNS	O
undergoing	VBG	O
emergency	NN	O
appendicectomy	NN	C
were	VBD	O
randomised	VBN	O
into	IN	O
control	NN	O
,	,	O
sham	NN	O
TENS	NNP	O
and	CC	O
active	JJ	O
TENS	NNP	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
pain	NN	O
severity	NN	O
and	CC	O
analgesic	JJ	O
intake	NN	O
in	IN	O
both	DT	O
active	JJ	O
and	CC	O
sham	JJ	O
TENS	NNP	O
groups	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
pain	NN	O
severity	NN	O
between	IN	O
active	JJ	O
and	CC	O
sham	JJ	O
TENS	NNP	O
groups	NNS	O
but	CC	O
the	DT	O
active	JJ	O
TENS	NNP	O
group	NN	O
required	VBD	O
slightly	RB	O
less	JJR	O
analgesia	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
major	JJ	O
benefit	NN	O
of	IN	O
TENS	NNP	O
in	IN	O
the	DT	O
postappendicectomy	NN	C
patient	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
its	PRP$	O
'placebo	JJ	O
effect	NN	O
'	POS	O
and	CC	O
its	PRP$	O
use	NN	O
in	IN	O
this	DT	O
situation	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

Nitrous	JJ	O
oxide	JJ	O
diffusion	NN	O
into	IN	O
tracheal	JJ	O
tube	JJ	O
cuffs	NNS	O
--	:	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
prototype	NN	O
cuff	NN	O
pressure	NN	O
release	NN	O
valve	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
a	DT	O
new	JJ	O
cuff	NN	O
pressure	NN	O
release	NN	O
valve	NN	O
(	(	O
CPRV	NNP	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
release	NN	O
pressure	NN	O
can	MD	O
be	VB	O
adjusted	VBN	O
from	IN	O
10	CD	O
to	TO	O
25	CD	O
cmH2O	NNS	O
,	,	O
particularly	RB	O
intended	VBN	O
to	TO	O
control	VB	O
pressure	NN	O
in	IN	O
paediatric	JJ	A
cuffed	NN	C
tracheal	NN	C
tubes	NNS	C
and	CC	O
to	TO	O
avoid	VB	O
cuff	NN	O
hyperinflation	NN	O
caused	VBN	O
by	IN	O
N2O	NNP	O
diffusion	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
vitro	NN	O
:	:	O
the	DT	O
PRV	NNP	O
was	VBD	O
set	VBN	O
to	TO	O
10	CD	O
,	,	O
15	CD	O
,	,	O
20	CD	O
or	CC	O
25	CD	O
cmH2O	JJ	O
release	NN	O
pressure	NN	O
and	CC	O
connected	VBN	O
to	TO	O
a	DT	O
cuffed	NN	O
tube	NN	O
placed	VBD	O
into	IN	O
a	DT	O
box	NN	O
flushed	VBN	O
with	IN	O
66	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
.	.	O

The	DT	O
cuff	NN	O
pressure	NN	O
was	VBD	O
monitored	VBN	O
with	IN	O
and	CC	O
without	IN	O
CPRV	NNP	O
for	IN	O
60	CD	O
min	NN	O
.	.	O

Experiments	NNS	O
were	VBD	O
performed	VBN	O
four	CD	O
times	NNS	O
using	VBG	O
two	CD	O
different	JJ	O
CPRVs	NNP	O
.	.	O

In	IN	O
vivo	NN	O
:	:	O
with	IN	O
Institutional	NNP	O
Review	NNP	O
Board	NNP	O
approval	NN	O
,	,	O
CPRV	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
50	CD	SS
children	NNS	A
undergoing	VBG	O
general	JJ	C
anaesthesia	NN	C
with	IN	C
tracheal	JJ	C
intubation	NN	C
and	CC	O
standardized	JJ	C
anaesthesia	NN	C
technique	NN	C
(	(	O
including	VBG	O
66	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
)	)	O
and	CC	O
ventilator	JJ	C
settings	NNS	C
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
CPRV	NNP	O
)	)	O
.	.	O

The	DT	O
cuff	JJ	O
pressure	NN	O
baseline	NN	O
was	VBD	O
20	CD	O
cmH2O	NN	O
and	CC	O
CPRV	NNP	O
was	VBD	O
set	VBN	O
to	TO	O
25	CD	O
cmH2O	NN	O
.	.	O

If	IN	O
the	DT	O
cuff	NN	O
pressure	NN	O
exceeded	VBD	O
25	CD	O
cmH2O	NN	O
,	,	O
it	PRP	O
was	VBD	O
manually	RB	O
released	VBN	O
to	TO	O
20	CD	O
cmH2O	NN	O
.	.	O

The	DT	O
numbers	NNS	O
of	IN	O
deflations	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
noted	VBN	O
and	CC	O
compared	VBN	O
by	IN	O
Mann-Whitney	NNP	O
U-test	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
vitro	NN	O
:	:	O
the	DT	O
cuff	NN	O
pressure	NN	O
exceeded	VBD	O
50	CD	O
cmH2O	NN	O
after	IN	O
60	CD	O
min	NN	O
without	IN	O
CPRV	NNP	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
settings	NNS	O
with	IN	O
CPRV	NNP	O
.	.	O

In	IN	O
vivo	NN	O
:	:	O
there	EX	O
was	VBD	O
no	DT	O
need	NN	O
to	TO	O
manually	RB	O
deflate	VB	O
the	DT	O
cuff	NN	O
in	IN	O
the	DT	O
CPRV	NNP	O
group	NN	O
but	CC	O
,	,	O
in	IN	O
every	DT	O
patient	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
three	CD	O
(	(	O
two	CD	O
to	TO	O
seven	CD	O
)	)	O
deflating	VBG	O
manoeuvres	NNS	O
were	VBD	O
required	VBN	O
within	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
anaesthesia	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
CPRV	NNP	O
allows	VBZ	O
reliable	JJ	O
cuff	NN	O
pressure	NN	O
release	NN	O
at	IN	O
various	JJ	O
pressure	NN	O
levels	NNS	O
and	CC	O
reliably	RB	O
prevents	NNS	O
cuff	JJ	O
pressure	NN	O
increases	NNS	O
caused	VBN	O
by	IN	O
N2O	NNP	O
.	.	O

Gefitinib	NNP	O
plus	CC	O
best	JJS	O
supportive	JJ	O
care	NN	O
in	IN	O
previously	RB	O
treated	VBN	O
patients	NNS	O
with	IN	O
refractory	JJ	C
advanced	JJ	C
non-small-cell	JJ	C
lung	NN	C
cancer	NN	C
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicentre	JJ	O
study	NN	O
(	(	O
Iressa	NNP	O
Survival	NNP	O
Evaluation	NNP	O
in	IN	O
Lung	NNP	O
Cancer	NNP	O
)	)	O
.	.	O

BACKGROUND	VB	O
This	DT	O
placebo-controlled	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
on	IN	O
survival	NN	O
of	IN	O
gefitinib	NN	O
as	IN	O
second-line	JJ	O
or	CC	O
third-line	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
locally	RB	C
advanced	JJ	C
or	CC	C
metastatic	JJ	C
non-small-cell	JJ	C
lung	NN	C
cancer	NN	C
.	.	O

METHODS	NNP	O
1692	CD	SS
patients	NNS	O
who	WP	O
were	VBD	O
refractory	JJ	C
to	TO	C
or	CC	C
intolerant	VB	C
of	IN	O
their	PRP$	O
latest	JJS	C
chemotherapy	NN	C
regimen	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
ratio	NN	O
of	IN	O
two	CD	O
to	TO	O
one	CD	O
either	DT	O
gefitinib	NN	O
(	(	O
250	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
plus	CC	O
best	JJS	O
supportive	JJ	O
care	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
survival	VBN	O
in	IN	O
the	DT	O
overall	JJ	O
population	NN	O
of	IN	O
patients	NNS	O
and	CC	O
those	DT	O
with	IN	O
adenocarcinoma	NN	O
.	.	O

The	DT	O
primary	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
population	NN	O
for	IN	O
survival	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
has	VBZ	O
been	VBN	O
submitted	VBN	O
for	IN	O
registration	NN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
1839IL/709	CD	O
.	.	O

FINDINGS	JJ	O
1129	CD	SS
patients	NNS	O
were	VBD	O
assigned	VBN	O
gefitinib	NNS	O
and	CC	O
563	CD	SS
placebo	NN	O
.	.	O

At	IN	O
median	JJ	O
follow-up	NN	O
of	IN	O
7.2	CD	O
months	NNS	O
,	,	O
median	JJ	O
survival	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
overall	JJ	O
population	NN	O
(	(	O
5.6	CD	O
months	NNS	O
for	IN	O
gefitinib	NN	O
and	CC	O
5.1	CD	O
months	NNS	O
for	IN	O
placebo	NN	O
;	:	O
hazard	CC	O
ratio	VB	O
0.89	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
0.77-1.02	CD	O
]	NNP	O
,	,	O
p=0.087	NN	O
)	)	O
or	CC	O
among	IN	O
the	DT	O
812	CD	SS
patients	NNS	O
with	IN	O
adenocarcinoma	NN	C
(	(	O
6.3	CD	O
months	NNS	O
vs	RB	O
5.4	CD	O
months	NNS	O
;	:	O
0.84	CD	O
[	IN	O
0.68-1.03	JJ	O
]	NN	O
,	,	O
p=0.089	NN	O
)	)	O
.	.	O

Preplanned	VBN	O
subgroup	NN	O
analyses	VBZ	O
showed	VBN	O
significantly	RB	O
longer	RBR	O
survival	NN	O
in	IN	O
the	DT	O
gefitinib	NN	O
group	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
never-smokers	NNS	O
(	(	O
n=375	NN	O
;	:	O
0.67	CD	O
[	IN	O
0.49-0.92	JJ	O
]	NN	O
,	,	O
p=0.012	NN	O
;	:	O
median	JJ	O
survival	NN	O
8.9	CD	O
vs	NN	O
6.1	CD	O
months	NNS	O
)	)	O
and	CC	O
patients	NNS	O
of	IN	O
Asian	JJ	O
origin	NN	O
(	(	O
n=342	JJ	O
;	:	O
0.66	CD	O
[	IN	O
0.48-0.91	JJ	O
]	NN	O
,	,	O
p=0.01	NN	O
;	:	O
median	JJ	O
survival	NN	O
9.5	CD	O
vs	NN	O
5.5	CD	O
months	NNS	O
)	)	O
.	.	O

Gefitinib	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
as	IN	O
in	IN	O
previous	JJ	O
studies	NNS	O
.	.	O

INTERPRETATION	NNP	O
Treatment	NNP	O
with	IN	O
gefitinib	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
in	IN	O
either	DT	O
coprimary	JJ	O
population	NN	O
.	.	O

There	EX	O
was	VBD	O
pronounced	JJ	O
heterogeneity	NN	O
in	IN	O
survival	JJ	O
outcomes	NNS	O
between	IN	O
groups	NNS	O
of	IN	O
patients	NNS	O
,	,	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
benefit	NN	O
among	IN	O
never-smokers	NNS	O
and	CC	O
patients	NNS	O
of	IN	O
Asian	JJ	O
origin	NN	O
.	.	O

Parent-mediated	JJ	O
communication-focused	JJ	O
treatment	NN	O
in	IN	O
children	NNS	A
with	IN	O
autism	NN	C
(	(	O
PACT	NNP	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Results	NNP	O
of	IN	O
small	JJ	O
trials	NNS	O
suggest	VBP	O
that	IN	O
early	JJ	O
interventions	NNS	O
for	IN	O
social	JJ	O
communication	NN	O
are	VBP	O
effective	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
in	IN	O
children	NNS	O
.	.	O

We	PRP	O
therefore	RB	O
investigated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
such	JJ	O
an	DT	O
intervention	NN	O
in	IN	O
a	DT	O
larger	JJR	O
trial	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
with	IN	O
core	NN	C
autism	NN	C
(	(	O
aged	VBN	O
2	CD	A
years	NNS	A
to	TO	A
4	CD	A
years	NNS	A
and	CC	A
11	CD	A
months	NNS	A
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
one-to-one	JJ	O
ratio	NN	O
to	TO	O
a	DT	O
parent-mediated	JJ	O
communication-focused	JJ	O
(	(	O
Preschool	NNP	O
Autism	NNP	O
Communication	NNP	O
Trial	NNP	O
[	NNP	O
PACT	NNP	O
]	NNP	O
)	)	O
intervention	NN	O
or	CC	O
treatment	NN	O
as	IN	O
usual	JJ	O
at	IN	O
three	CD	O
specialist	NN	O
centres	NNS	O
in	IN	O
the	DT	O
UK	NNP	O
.	.	O

Those	DT	O
assigned	VBN	O
to	TO	O
PACT	NNP	O
were	VBD	O
also	RB	O
given	VBN	O
treatment	NN	O
as	IN	O
usual	JJ	O
.	.	O

Randomisation	NN	O
was	VBD	O
by	IN	O
use	NN	O
of	IN	O
minimisation	NN	O
of	IN	O
probability	NN	O
in	IN	O
the	DT	O
marginal	JJ	O
distribution	NN	O
of	IN	O
treatment	NN	O
centre	NN	O
,	,	O
age	NN	O
(	(	O
<	JJ	O
/=42	NNP	O
months	NNS	O
or	CC	O
>	$	O
42	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
autism	NN	O
severity	NN	O
(	(	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule-Generic	NNP	O
[	NNP	O
ADOS-G	NNP	O
]	NNP	O
algorithm	VBZ	O
score	RB	O
12-17	JJ	O
or	CC	O
18-24	JJ	O
)	)	O
.	.	O

Primary	JJ	O
outcome	NN	O
was	VBD	O
severity	NN	O
of	IN	O
autism	NN	O
symptoms	NNS	O
(	(	O
a	DT	O
total	NN	O
score	NN	O
of	IN	O
social	JJ	O
communication	NN	O
algorithm	NNS	O
items	NNS	O
from	IN	O
ADOS-G	NNP	O
,	,	O
higher	JJR	O
score	NN	O
indicating	VBG	O
greater	JJR	O
severity	NN	O
)	)	O
at	IN	O
13	CD	O
months	NNS	O
.	.	O

Complementary	NNP	O
secondary	JJ	O
outcomes	NNS	O
were	VBD	O
measures	NNS	O
of	IN	O
parent-child	JJ	O
interaction	NN	O
,	,	O
child	JJ	O
language	NN	O
,	,	O
and	CC	O
adaptive	JJ	O
functioning	NN	O
in	IN	O
school	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
as	IN	O
an	DT	O
International	NNP	O
Standard	NNP	O
Randomised	VBD	O
Controlled	NNP	O
Trial	NNP	O
,	,	O
number	NN	O
ISRCTN58133827	NNP	O
.	.	O

RESULTS	NNP	O
152	CD	SS
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

77	CD	SS
were	VBD	O
assigned	VBN	O
to	TO	O
PACT	NNP	O
(	(	O
London	NNP	O
[	NNP	O
n=26	MD	O
]	VB	O
,	,	O
Manchester	NNP	O
[	NNP	O
n=26	MD	O
]	VB	O
,	,	O
and	CC	O
Newcastle	NNP	O
[	NNP	O
n=25	FW	O
]	NNP	O
)	)	O
;	:	O
and	CC	O
75	CD	SS
to	TO	O
treatment	NN	O
as	IN	O
usual	JJ	O
(	(	O
London	NNP	O
[	NNP	O
n=26	MD	O
]	VB	O
,	,	O
Manchester	NNP	O
[	NNP	O
n=26	MD	O
]	VB	O
,	,	O
and	CC	O
Newcastle	NNP	O
[	NNP	O
n=23	FW	O
]	NNP	O
)	)	O
.	.	O

At	IN	O
the	DT	O
13-month	JJ	O
endpoint	NN	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
symptoms	NNS	O
was	VBD	O
reduced	VBN	O
by	IN	O
3.9	CD	O
points	NNS	O
(	(	O
SD	NNP	O
4.7	CD	O
)	)	O
on	IN	O
the	DT	O
ADOS-G	NNP	O
algorithm	NN	O
in	IN	O
the	DT	O
group	NN	O
assigned	VBD	O
to	TO	O
PACT	NNP	O
,	,	O
and	CC	O
2.9	CD	O
(	(	O
3.9	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
assigned	VBD	O
to	TO	O
treatment	NN	O
as	IN	O
usual	JJ	O
,	,	O
representing	VBG	O
a	DT	O
between-group	JJ	O
effect	NN	O
size	NN	O
of	IN	O
-0.24	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-0.59	NNP	O
to	TO	O
0.11	CD	O
)	)	O
,	,	O
after	IN	O
adjustment	NN	O
for	IN	O
centre	NN	O
,	,	O
sex	NN	O
,	,	O
socioeconomic	JJ	O
status	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
verbal	JJ	O
and	CC	O
non-verbal	JJ	O
abilities	NNS	O
.	.	O

Treatment	NNP	O
effect	NN	O
was	VBD	O
positive	JJ	O
for	IN	O
parental	JJ	O
synchronous	JJ	O
response	NN	O
to	TO	O
child	VB	O
(	(	O
1.22	CD	O
,	,	O
0.85	CD	O
to	TO	O
1.59	CD	O
)	)	O
,	,	O
child	JJ	O
initiations	NNS	O
with	IN	O
parent	NN	O
(	(	O
0.41	CD	O
,	,	O
0.08	CD	O
to	TO	O
0.74	CD	O
)	)	O
,	,	O
and	CC	O
for	IN	O
parent-child	JJ	O
shared	VBN	O
attention	NN	O
(	(	O
0.33	CD	O
,	,	O
-0.02	NN	O
to	TO	O
0.68	CD	O
)	)	O
.	.	O

Effects	NNS	O
on	IN	O
directly	RB	O
assessed	VBN	O
language	NN	O
and	CC	O
adaptive	JJ	O
functioning	NN	O
in	IN	O
school	NN	O
were	VBD	O
small	JJ	O
.	.	O

INTERPRETATION	NN	O
On	IN	O
the	DT	O
basis	NN	O
of	IN	O
our	PRP$	O
findings	NNS	O
,	,	O
we	PRP	O
can	MD	O
not	RB	O
recommend	VB	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
PACT	NNP	O
intervention	NN	O
to	TO	O
treatment	NN	O
as	IN	O
usual	JJ	O
for	IN	O
the	DT	O
reduction	NN	O
of	IN	O
autism	NN	O
symptoms	NNS	O
;	:	O
however	RB	O
,	,	O
a	DT	O
clear	JJ	O
benefit	NN	O
was	VBD	O
noted	VBN	O
for	IN	O
parent-child	JJ	O
dyadic	JJ	O
social	JJ	O
communication	NN	O
.	.	O

FUNDING	NN	O
UK	NNP	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
,	,	O
and	CC	O
UK	NNP	O
Department	NNP	O
for	IN	O
Children	NNP	O
,	,	O
Schools	NNP	O
and	CC	O
Families	NNP	O
.	.	O

Shorter	NNP	O
treatment	NN	O
for	IN	O
vaginal	JJ	C
candidosis	NN	C
:	:	O
comparison	NN	O
between	IN	O
single-dose	JJ	O
oral	JJ	O
fluconazole	NN	O
and	CC	O
three-day	JJ	O
treatment	NN	O
with	IN	O
local	JJ	O
miconazole	NN	O
.	.	O

Fluconazole	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
,	,	O
simple	JJ	O
and	CC	O
safe	JJ	O
,	,	O
although	IN	O
slightly	RB	O
expensive	JJ	O
,	,	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	C
candidosis	NN	C
.	.	O

Single-dose	JJ	O
fluconazole	NN	O
(	(	O
150	CD	O
mg	NN	O
)	)	O
administered	VBD	O
orally	RB	O
in	IN	O
capsule	NN	O
form	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
three-day	JJ	O
local	JJ	O
treatment	NN	O
with	IN	O
miconazole	JJ	O
pessaries	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	C
candidosis	NN	C
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
in	IN	O
Finland	NNP	O
.	.	O

Cure	NN	O
rates	NNS	O
were	VBD	O
good	JJ	O
(	(	O
>	JJ	O
80	CD	O
%	NN	O
)	)	O
in	IN	O
randomized	VBN	O
patient	NN	O
groups	NNS	O
assessed	VBD	O
both	DT	O
clinically	RB	O
and	CC	O
by	IN	O
the	DT	O
results	NNS	O
of	IN	O
yeast	JJ	O
cultures	NNS	O
.	.	O

Oral	JJ	O
administration	NN	O
was	VBD	O
preferred	VBN	O
to	TO	O
local	JJ	O
therapy	NN	O
by	IN	O
patients	NNS	O
in	IN	O
both	DT	O
the	DT	O
miconazole	NN	O
and	CC	O
fluconazole	JJ	O
groups	NNS	O
.	.	O

For	IN	O
the	DT	O
time	NN	O
being	VBG	O
,	,	O
fluconazole	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
during	IN	O
pregnancy	NN	O
or	CC	O
lactation	NN	O
.	.	O

Cytokine	NN	O
levels	NNS	O
and	CC	O
systemic	JJ	O
toxicity	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
isolated	JJ	C
limb	NN	C
perfusion	NN	C
with	IN	O
high-dose	JJ	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
,	,	O
interferon	NN	O
gamma	NN	O
,	,	O
and	CC	O
melphalan	NN	O
.	.	O

PURPOSE	NNP	O
Isolated	NNP	O
limb	NN	O
perfusion	NN	O
(	(	O
ILP	NNP	O
)	)	O
with	IN	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF	NNP	O
)	)	O
,	,	O
interferon	JJ	O
gamma	NN	O
,	,	O
and	CC	O
melphalan	NN	O
(	(	O
M	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
result	VB	O
in	IN	O
high	JJ	O
response	NN	O
rates	NNS	O
for	IN	O
extremity	NN	O
melanoma	NN	O
and	CC	O
sarcoma	NN	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
the	DT	O
relationship	NN	O
of	IN	O
systemic	JJ	O
TNF	NNP	O
exposure	NN	O
to	TO	O
induction	NN	O
of	IN	O
several	JJ	O
secondary	JJ	O
mediators	NNS	O
and	CC	O
incidence	NN	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Nineteen	NNP	SS
patients	NNS	O
with	IN	O
extremity	NN	C
melanoma	NN	C
(	(	O
n	JJ	O
=	NNP	O
16	CD	SS
)	)	O
or	CC	O
sarcoma	NN	C
(	(	O
n	JJ	O
=	NNP	O
3	CD	SS
)	)	O
,	,	O
underwent	JJ	O
90-minute	JJ	O
ILP	NNP	O
with	IN	O
TNF-alpha	NNP	O
,	,	O
interferon	NN	O
gamma	NN	O
(	(	O
0.2	CD	O
mg	NN	O
)	)	O
,	,	O
and	CC	O
M	NNP	O
(	(	O
10	CD	O
to	TO	O
13	CD	O
mg/L	NN	O
of	IN	O
limb	NN	O
volume	NN	O
)	)	O
(	(	O
TNF/IFN/M	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
,	,	O
or	CC	O
M	NNP	O
alone	RB	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
.	.	O

Continuous	JJ	O
intraoperative	JJ	O
monitoring	NN	O
(	(	O
CIM	NNP	O
)	)	O
for	IN	O
systemic	JJ	O
leak	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
radioactive	JJ	O
iodine-131	JJ	O
albumin	NN	O
.	.	O

Cytokine	NN	O
levels	NNS	O
in	IN	O
the	DT	O
perfusate	NN	O
and	CC	O
systemic	JJ	O
circulation	NN	O
during	IN	O
and	CC	O
after	IN	O
ILP	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
.	.	O

RESULTS	NNP	O
Systemic	NNP	O
leaks	VBZ	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
occurred	VBD	O
in	IN	O
six	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
TNF/IFN/M	NNP	O
and	CC	O
in	IN	O
four	CD	O
who	WP	O
received	VBD	O
M	NNP	O
alone	RB	O
.	.	O

Hypotension	NNP	O
that	IN	O
required	VBD	O
vasopressor	NN	O
support	NN	O
occurred	VBD	O
in	IN	O
six	CD	O
of	IN	O
six	CD	O
patients	NNS	O
with	IN	O
evidence	NN	O
of	IN	O
a	DT	O
leak	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
)	)	O
and	CC	O
zero	CD	O
of	IN	O
six	CD	O
patients	NNS	O
without	IN	O
a	DT	O
leak	NN	O
(	(	O
<	JJ	O
1	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
six	CD	O
patients	NNS	O
had	VBD	O
significantly	RB	O
higher	JJR	O
peak	JJ	O
systemic	JJ	O
TNF	NNP	O
levels	NNS	O
during	IN	O
and	CC	O
after	IN	O
perfusion	NN	O
than	IN	O
patients	NNS	O
without	IN	O
a	DT	O
leak	NN	O
(	(	O
2.8	CD	O
and	CC	O
8.2	CD	O
ng/mL	JJ	O
v	NN	O
0.7	CD	O
and	CC	O
2.0	CD	O
ng/mL	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	PDT	O
patients	NNS	O
who	WP	O
received	VBD	O
TNF/IFN/M	NNP	O
had	VBD	O
significantly	RB	O
greater	JJR	O
increases	NNS	O
in	IN	O
systemic	JJ	O
interleukin-6	JJ	O
(	(	O
IL-6	NNP	O
)	)	O
levels	NNS	O
than	IN	O
in	IN	O
patients	NNS	O
with	IN	O
M	NNP	O
alone	RB	O
(	(	O
12,395	CD	O
+/-	JJ	O
10,374	CD	O
pg/mL	NN	O
v	NN	O
79.4	CD	O
+/-	JJ	O
7.2	CD	O
pg/mL	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Intracellular	JJ	O
adhesion	NN	O
molecule	NN	O
(	(	O
ICAM	NNP	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
TNF-R	JJ	O
levels	NNS	O
were	VBD	O
also	RB	O
increased	VBN	O
after	IN	O
ILP	NNP	O
with	IN	O
TNF/IFN/M	NNP	O
.	.	O

CONCLUSION	NNP	O
ILP	NNP	O
with	IN	O
TNF/IFN/M	NNP	O
can	MD	O
be	VB	O
safely	RB	O
performed	VBN	O
,	,	O
as	IN	O
I131	NNP	O
albumin	VBP	O
provides	VBZ	O
a	DT	O
sensitive	JJ	O
measure	NN	O
of	IN	O
systemic	JJ	O
leakage	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
measured	JJ	O
leak	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
develop	NN	O
mild	NN	O
and	CC	O
transient	JJ	O
postoperative	JJ	O
hypotension	NN	O
with	IN	O
significantly	RB	O
higher	JJR	O
systemic	JJ	O
TNF	NNP	O
levels	NNS	O
and	CC	O
lower	JJR	O
perfusate	NN	O
TNF	NNP	O
levels	NNS	O
than	IN	O
in	IN	O
patients	NNS	O
without	IN	O
leaks	NNS	O
.	.	O

[	JJ	O
Dose-reduced	NNP	O
antihypertensive	JJ	O
agents	NNS	O
--	:	O
use	NN	O
in	IN	O
complex	JJ	O
nonmedicamentous	JJ	O
therapy	NN	O
of	IN	O
hypertension	NN	O
]	NNP	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
estimate	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
non-medicamentous	JJ	O
therapy	NN	O
(	(	O
CNT	NNP	O
)	)	O
on	IN	O
the	DT	O
consumption	NN	O
of	IN	O
medicaments	NNS	O
and	CC	O
coronary	JJ	O
risk	NN	O
in	IN	O
high	JJ	O
blood	NN	O
pressure	NN	O
73	CD	SS
hypertensives	NNS	C
of	IN	O
a	DT	O
medicamentously	RB	O
stabilized	VBN	O
CNT-group	NNP	O
were	VBD	O
examined	VBN	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
the	DT	O
same	JJ	O
size	NN	O
of	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	C
who	WP	O
were	VBD	O
managed	VBN	O
exclusively	RB	O
medicamentously	RB	O
for	IN	O
behaviour	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
,	,	O
need	NN	O
of	IN	O
antihypertensive	JJ	O
drugs	NNS	O
and	CC	O
changes	NNS	O
of	IN	O
hypertension-associated	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

After	IN	O
an	DT	O
exactly	RB	O
controlled	VBN	O
6-month	JJ	O
treatment	NN	O
hypertensives	NNS	C
with	IN	O
additionally	RB	O
recommended	VBN	O
far-reaching	NN	O
CNT	NNP	O
showed	VBD	O
an	DT	O
economization	NN	O
of	IN	O
medicaments	NNS	O
by	IN	O
scarcely	RB	O
the	DT	O
half	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
reference	NN	O
group	NN	O
.	.	O

By	IN	O
means	NNS	O
of	IN	O
suitable	JJ	O
control	NN	O
methods	VBZ	O
a	DT	O
causal	JJ	O
non-medicamentously	RB	O
conditioned	JJ	O
decrease	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
could	MD	O
be	VB	O
excluded	VBN	O
.	.	O

A	DT	O
different	JJ	O
need	NN	O
of	IN	O
antihypertensive	JJ	O
drugs	NNS	O
was	VBD	O
simulated	VBN	O
by	IN	O
the	DT	O
exacter	JJ	O
intake	NN	O
of	IN	O
medicaments	NNS	O
in	IN	O
the	DT	O
index-patients	NNS	O
.	.	O

Notwithstanding	VBG	O
the	DT	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
additional	JJ	O
therapy	NN	O
have	VBP	O
induced	VBN	O
a	DT	O
positive	JJ	O
change	NN	O
of	IN	O
atherogenic	JJ	O
lipids	NNS	O
.	.	O

The	DT	O
examinations	NNS	O
indicate	VBP	O
in	IN	O
general	JJ	O
the	DT	O
difficulty	NN	O
of	IN	O
the	DT	O
judgement	NN	O
of	IN	O
efficacy	NN	O
of	IN	O
non-medicamentous	JJ	O
therapeutic	JJ	O
measures	NNS	O
in	IN	O
connection	NN	O
with	IN	O
a	DT	O
rational	JJ	O
dose-reduced	JJ	O
long-term	JJ	O
therapy	NN	O
with	IN	O
antihypertensive	JJ	O
drugs	NNS	O
.	.	O

Psychoeducational	NNP	O
group	NN	O
intervention	NN	O
for	IN	O
wives	NNS	SE
of	IN	O
men	NNS	SE
with	IN	O
prostate	NN	C
cancer	NN	C
.	.	O

OBJECTIVE	CC	O
The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
6-week	JJ	O
psychoeducational	JJ	O
group	NN	O
intervention	NN	O
on	IN	O
the	DT	O
distress	NN	O
,	,	O
coping	NN	O
,	,	O
personal	JJ	O
growth	NN	O
,	,	O
and	CC	O
marital	JJ	O
communication	NN	O
of	IN	O
wives	NNS	SE
of	IN	O
men	NNS	SE
diagnosed	VBN	O
with	IN	O
prostate	JJ	C
cancer	NN	C
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	SS
wives	NNS	SE
completed	VBD	O
measures	NNS	O
prior	RB	O
to	TO	O
random	VB	O
assignment	NN	O
to	TO	O
either	VB	O
the	DT	O
psychoeducational	JJ	O
group	NN	O
intervention	NN	O
or	CC	O
a	DT	O
no-treatment	JJ	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
completion	NN	O
of	IN	O
the	DT	O
group	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
with	IN	O
regard	NN	O
to	TO	O
wives	NNS	O
'	POS	O
general	JJ	O
distress	NN	O
or	CC	O
cancer-specific	JJ	O
distress	NN	O
were	VBD	O
noted	VBN	O
.	.	O

In	IN	O
comparison	NN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
participants	NNS	O
receiving	VBG	O
the	DT	O
intervention	NN	O
perceived	VBD	O
that	IN	O
having	VBG	O
a	DT	O
spouse	NN	O
with	IN	O
prostate	NN	O
cancer	NN	O
had	VBD	O
made	VBN	O
positive	JJ	O
contributions	NNS	O
to	TO	O
their	PRP$	O
lives	NNS	O
,	,	O
reported	VBD	O
gains	NNS	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
positive	JJ	O
reappraisal	NN	O
coping	VBG	O
and	CC	O
reductions	NNS	O
in	IN	O
denial	JJ	O
coping	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
the	DT	O
psychoeducational	JJ	O
intervention	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
changes	NNS	O
in	IN	O
psychological	JJ	O
distress	NN	O
,	,	O
improvements	NNS	O
in	IN	O
adaptive	JJ	O
coping	NN	O
and	CC	O
indicators	NNS	O
of	IN	O
psychological	JJ	O
growth	NN	O
were	VBD	O
found	VBN	O
.	.	O

The	DT	O
utility	NN	O
of	IN	O
group	NN	O
interventions	NNS	O
for	IN	O
spouses	NNS	SE
of	IN	O
men	NNS	SE
with	IN	O
prostate	NN	C
cancer	NN	C
is	VBZ	O
discussed	VBN	O
.	.	O

Psychological	JJ	O
well-being	NN	O
correlates	NNS	O
with	IN	O
free	JJ	O
thyroxine	NN	O
but	CC	O
not	RB	O
free	JJ	O
3,5,3'-triiodothyronine	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
on	IN	O
thyroid	JJ	C
hormone	NN	C
replacement	NN	C
.	.	O

CONTEXT	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
An	DT	O
association	NN	O
between	IN	O
mood	NN	O
disorders	NNS	O
and	CC	O
overt	JJ	O
thyroid	JJ	O
dysfunction	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
on	IN	O
the	DT	O
potential	NN	O
for	IN	O
thyroid	JJ	O
hormone	NN	O
levels	NNS	O
closer	RBR	O
to	TO	O
the	DT	O
reference	NN	O
range	NN	O
to	TO	O
correlate	VB	O
with	IN	O
psychological	JJ	O
well-being	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
analyzed	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
psychological	JJ	O
well-being	NN	O
and	CC	O
free	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
(	(	O
fT4	NN	O
)	)	O
,	,	O
free	JJ	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
(	(	O
fT3	NN	O
)	)	O
,	,	O
TSH	NNP	O
,	,	O
and	CC	O
total	JJ	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
in	IN	O
697	CD	SS
patients	NNS	O
on	IN	O
thyroid	JJ	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
at	IN	O
entry	NN	O
to	TO	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
combined	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
replacement	NN	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
on	IN	O
100	CD	O
mug	NN	O
or	CC	O
more	JJR	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
AND	CC	O
MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Psychological	NNP	O
well-being	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
General	NNP	O
Health	NNP	O
Questionnaire-12	NNP	O
(	(	O
GHQ-12	NNP	O
)	)	O
,	,	O
Thyroid	NNP	O
Symptom	NNP	O
Questionnaire	NNP	O
,	,	O
and	CC	O
Hospital	NNP	O
Anxiety	NNP	O
and	CC	O
Depression	NNP	O
Scale	NNP	O
.	.	O

RESULTS	NNP	O
fT	NN	O
(	(	O
4	CD	O
)	)	O
and	CC	O
TSH	NNP	O
showed	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
with	IN	O
GHQ-12	NNP	O
scores	NNS	O
(	(	O
fT4	SYM	O
-	:	O
b	NN	O
:	:	O
-0.16	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
;	:	O
TSH	NNP	O
-	:	O
b	NN	O
:	:	O
0.663	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

No	UH	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
GHQ	NNP	O
scores	NNS	O
and	CC	O
fT3	NN	O
(	(	O
b	NN	O
:	:	O
0.318	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.275	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
(	(	O
b	NN	O
:	:	O
0.095	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.95	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
to	TO	O
fT4	VB	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
71.83	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.09	CD	O
)	)	O
or	CC	O
fT3	VBN	O
to	TO	O
rT	VB	O
(	(	O
3	CD	O
)	)	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
0.05	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.32	CD	O
)	)	O
.	.	O

The	DT	O
correlations	NNS	O
remained	VBD	O
when	WRB	O
the	DT	O
data	NN	O
set	NN	O
was	VBD	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
TSH	NNP	O
in	IN	O
the	DT	O
range	NN	O
0.3-4.0	JJ	O
mIU/liter	NN	O
.	.	O

Similar	JJ	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
with	IN	O
the	DT	O
Thyroid	NNP	O
Symptom	NNP	O
Questionnaire	NNP	O
,	,	O
although	IN	O
not	RB	O
with	IN	O
the	DT	O
Hospital	NNP	O
Anxiety	NNP	O
and	CC	O
Depression	NNP	O
Scale	NNP	O
scores	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Differences	NNPS	O
in	IN	O
fT4	NN	O
and	CC	O
TSH	NNP	O
concentration	NN	O
,	,	O
even	RB	O
within	IN	O
the	DT	O
reference	NN	O
range	NN	O
,	,	O
may	MD	O
be	VB	O
a	DT	O
determinant	NN	O
of	IN	O
psychological	JJ	O
well-being	NN	O
in	IN	O
treated	JJ	O
hypothyroid	NN	C
patients	NNS	O
although	IN	O
not	RB	O
necessarily	RB	O
with	IN	O
symptoms	NNS	O
typical	JJ	O
of	IN	O
anxiety	NN	O
or	CC	O
depression	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
amantadine	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
hepatitis	NN	C
C	NNP	C
treated	VBD	O
with	IN	O
interferon-alpha	JJ	O
and	CC	O
ribavirin	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

AIM	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
amantadine	JJ	O
reduces	NNS	O
deterioration	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
during	IN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
interferon-alpha	JJ	O
(	(	O
IFN-alpha	NNP	O
)	)	O
and	CC	O
ribavirin	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
,	,	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	C
hepatitis	NN	C
C	NNP	C
were	VBD	O
treated	VBN	O
with	IN	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
[	NN	O
17	CD	O
]	NN	O
and	CC	O
randomized	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
amantadine	NN	O
(	(	O
200	CD	O
mg/day	NN	O
,	,	O
orally	RB	O
,	,	O
n=136	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=131	JJ	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
'Profile	NN	O
of	IN	O
Mood	NNP	O
States	NNPS	O
'	POS	O
scale	NN	O
and	CC	O
the	DT	O
'Everyday	JJ	O
Life	NNP	O
'	POS	O
questionnaire	NN	O
at	IN	O
baseline	NN	O
,	,	O
treatment	NN	O
week	NN	O
(	(	O
TW	NNP	O
)	)	O
8	CD	O
,	,	O
TW24	NNP	O
,	,	O
TW48	NNP	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
Early	JJ	O
during	IN	O
treatment	NN	O
at	IN	O
TW8	NNP	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
amantadine	NN	O
group	NN	O
.	.	O

At	IN	O
TW24	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
amantadine	NN	O
group	NN	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
modalities	NNS	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Especially	RB	O
,	,	O
nonresponders	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
lower	JJR	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
anger	NN	O
,	,	O
mind	NN	O
function	NN	O
,	,	O
everyday	JJ	O
life	NN	O
,	,	O
and	CC	O
zest	JJS	O
for	IN	O
life	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
amantadine	NN	O
disappeared	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
addition	NN	O
of	IN	O
amantadine	NN	O
to	TO	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
combination	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
during	IN	O
treatment	NN	O
but	CC	O
does	VBZ	O
not	RB	O
affect	JJ	O
quality	NN	O
of	IN	O
life	NN	O
after	IN	O
treatment	NN	O
.	.	O

Laser	NNP	O
conization	NN	O
versus	NN	O
cold	JJ	O
knife	NN	O
conization	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
compares	VBZ	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
measured	VBN	O
blood	NN	O
loss	NN	O
at	IN	O
conization	NN	O
and	CC	O
within	IN	O
24	CD	O
hours	NNS	O
after	IN	O
using	VBG	O
either	CC	O
the	DT	O
cold	JJ	O
knife	NN	O
technique	NN	O
or	CC	O
the	DT	O
carbon	NN	O
dioxide	NN	O
laser	NN	O
scalpel	NN	O
.	.	O

One	CD	SS
hundred	CD	SS
and	CC	SS
ten	VB	SS
consecutive	JJ	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

The	DT	O
median	JJ	O
blood	NN	O
loss	NN	O
in	IN	O
the	DT	O
laser	NN	O
group	NN	O
of	IN	O
55	CD	O
patients	NNS	O
was	VBD	O
4.6	CD	O
milliliters	NNS	O
at	IN	O
,	,	O
and	CC	O
within	IN	O
,	,	O
24	CD	O
hours	NNS	O
after	IN	O
operation	NN	O
compared	VBN	O
with	IN	O
30.1	CD	O
milliliters	NNS	O
in	IN	O
the	DT	O
cold	JJ	O
knife	NN	O
group	NN	O
of	IN	O
55	CD	O
patients	NNS	O
.	.	O

More	RBR	O
important	JJ	O
,	,	O
however	RB	O
,	,	O
is	VBZ	O
that	IN	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
for	IN	O
the	DT	O
range	NN	O
of	IN	O
bleeding	VBG	O
were	VBD	O
0.4	CD	O
to	TO	O
155.4	CD	O
milliliters	NNS	O
and	CC	O
5.6	CD	O
to	TO	O
1,570.9	CD	O
milliliters	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
incidence	NN	O
rate	NN	O
for	IN	O
bleeding	VBG	O
complications	NNS	O
requiring	VBG	O
surgical	JJ	O
intervention	NN	O
was	VBD	O
1.8	CD	O
per	IN	O
cet	NN	O
for	IN	O
the	DT	O
laser	NN	O
group	NN	O
and	CC	O
14.6	CD	O
per	IN	O
cent	NN	O
for	IN	O
the	DT	O
cold	JJ	O
knife	NN	O
group	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.015	CD	O
--	:	O
Fischer	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

Conization	NN	O
for	IN	O
treatment	NN	O
of	IN	O
premalignant	JJ	C
changes	NNS	C
of	IN	C
the	DT	C
cervix	NN	C
uteri	NN	C
will	MD	O
probably	RB	O
remain	VB	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
some	DT	O
time	NN	O
to	TO	O
come	VB	O
.	.	O

It	PRP	O
is	VBZ	O
our	PRP$	O
opinion	NN	O
that	IN	O
,	,	O
in	IN	O
the	DT	O
future	NN	O
,	,	O
laser	JJR	O
conization	NN	O
will	MD	O
replace	VB	O
cold	JJ	O
knife	NN	O
conization	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
methyldopa	NN	O
and	CC	O
labetalol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	C
.	.	O

1	CD	O
Twenty	CD	SS
patients	NNS	O
with	IN	O
essential	JJ	C
hypertension	NN	C
completed	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
dose-tritrated	JJ	O
,	,	O
cross-over	JJ	O
comparison	NN	O
of	IN	O
methyldopa	NN	O
and	CC	O
labetalol	NN	O
.	.	O

2	CD	O
Average	JJ	O
lying	VBG	O
BPs	NNP	O
(	(	O
systolic/diastolic	JJ	O
)	)	O
were	VBD	O
reduced	VBN	O
by	IN	O
28/15	CD	O
mmHg	NNS	O
with	IN	O
methyldopa	NN	O
and	CC	O
by	IN	O
23/15	CD	O
mmHg	NNS	O
with	IN	O
labetalol	NN	O
.	.	O

3	CD	O
Average	JJ	O
standing	VBG	O
BPs	NNP	O
(	(	O
systolic/diastolic	JJ	O
)	)	O
were	VBD	O
reduced	VBN	O
by	IN	O
29/14	CD	O
mmHg	NNS	O
with	IN	O
methyldopa	NN	O
and	CC	O
by	IN	O
29/15	CD	O
mmHg	NNS	O
with	IN	O
labetalol	NN	O
.	.	O

4	CD	O
Both	DT	O
lying	NN	O
and	CC	O
standing	VBG	O
heart	NN	O
rates	NNS	O
were	VBD	O
reduced	VBN	O
with	IN	O
labetalol	NN	O
.	.	O

5	CD	O
It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
antihypertensive	JJ	O
properties	NNS	O
of	IN	O
labetalol	NN	O
and	CC	O
methyldopa	NN	O
are	VBP	O
similar	JJ	O
but	CC	O
that	IN	O
larger	JJR	O
patient	NN	O
populations	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
study	VB	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
subjective	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

The	DT	O
evaluation	NN	O
of	IN	O
pulmonary	JJ	O
hypertension	NN	O
using	VBG	O
right	JJ	O
ventricular	JJ	O
myocardial	JJ	O
isovolumic	JJ	O
relaxation	NN	O
time	NN	O
.	.	O

Right	JJ	O
ventricular	NN	O
(	(	O
RV	NNP	O
)	)	O
blood	VBD	O
pool-derived	JJ	O
isovolumic	JJ	O
relaxation	NN	O
time	NN	O
(	(	O
IVRT	NNP	O
)	)	O
correlates	VBZ	O
well	RB	O
with	IN	O
systolic	JJ	O
pulmonary	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
PAP	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
because	IN	O
of	IN	O
complex	JJ	O
parameter	NN	O
derivation	NN	O
,	,	O
the	DT	O
method	NN	O
is	VBZ	O
rarely	RB	O
used	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
validate	VB	O
the	DT	O
measurement	NN	O
of	IN	O
myocardial	JJ	O
velocity	NN	O
imaging-derived	JJ	O
RV	NNP	O
IVRT	NNP	O
(	(	O
IVRT	NNP	O
'	POS	O
)	)	O
against	IN	O
invasively	RB	O
measured	VBN	O
PAP	NNP	O
.	.	O

Transthoracic	NNP	O
echocardiography	NN	O
with	IN	O
myocardial	JJ	O
velocity	NN	O
imaging	NN	O
and	CC	O
right	JJ	O
heart	NN	O
catheterization	NN	O
were	VBD	O
performed	VBN	O
in	IN	O
33	CD	SS
patients	NNS	O
with	IN	O
pulmonary	JJ	C
hypertension	NN	C
.	.	O

Blood	NNP	O
pool	NN	O
IVRT	NNP	O
and	CC	O
myocardial	JJ	O
IVRTs	NNP	O
for	IN	O
the	DT	O
tricuspid	JJ	O
valve	NN	O
annulus	NN	O
ring	NN	O
,	,	O
basal	NN	O
and	CC	O
apical	JJ	O
RV	NNP	O
free	JJ	O
wall	NN	O
segments	NNS	O
were	VBD	O
measured	VBN	O
and	CC	O
compared	VBN	O
with	IN	O
data	NNS	O
from	IN	O
33	CD	SS
age-	JJ	O
and	CC	O
sex-matched	JJ	O
control	NN	O
subjects	NNS	O
.	.	O

Measured	VBN	O
IVRTs	NNP	O
were	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
than	IN	O
in	IN	O
control	NN	O
subjects	NNS	O
.	.	O

The	DT	O
strongest	JJS	O
correlation	NN	O
(	(	O
R	NNP	O
=	NNP	O
0.74	CD	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
systolic	JJ	O
PAP	NNP	O
and	CC	O
the	DT	O
heart	NN	O
rate-corrected	JJ	O
IVRT	NNP	O
'	POS	O
derived	VBN	O
from	IN	O
the	DT	O
basal	NN	O
RV	NNP	O
free	JJ	O
wall	NN	O
segment	NN	O
.	.	O

The	DT	O
basal	NN	O
segment	NN	O
IVRT	NNP	O
'	POS	O
corrected	VBN	O
for	IN	O
heart	NN	O
rate	NN	O
correlates	NNS	O
well	RB	O
with	IN	O
the	DT	O
invasive	JJ	O
PAP	NNP	O
measurement	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
systolic	JJ	O
PAP	NNP	O
.	.	O

It	PRP	O
can	MD	O
even	RB	O
be	VB	O
considered	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
tricuspid	VB	O
regurgitation-derived	JJ	O
PAP	NNP	O
systolic	NN	O
when	WRB	O
tricuspid	JJ	O
regurgitation	NN	O
is	VBZ	O
nonrecordable	JJ	O
.	.	O

A	DT	O
proposed	VBN	O
method	NN	O
to	TO	O
derive	VB	O
systolic	JJ	O
PAP	NNP	O
should	MD	O
be	VB	O
used	VBN	O
while	IN	O
screening	VBG	O
the	DT	O
patients	NNS	O
at	IN	O
risk	NN	O
for	IN	O
pulmonary	JJ	O
hypertension	NN	O
,	,	O
monitoring	VBG	O
the	DT	O
disease	NN	O
progression	NN	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
.	.	O

Take	VB	O
a	DT	O
walk	NN	O
in	IN	O
the	DT	O
park	NN	O
?	.	O
A	DT	O
cross-over	NN	O
pilot	NN	O
trial	NN	O
comparing	VBG	O
brisk	JJ	O
walking	VBG	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
:	:	O
park	NN	O
and	CC	O
urban	JJ	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
whether	IN	O
differences	NNS	O
exist	VBP	O
between	IN	O
a	DT	O
30	CD	O
minute	NN	O
brisk	NN	O
walk	VBP	O
taken	VBN	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
which	WDT	O
environment	NN	O
best	JJS	O
facilitates	NNS	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
:	:	O
park	NN	O
or	CC	O
urban	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomised	JJ	O
cross-over	NN	O
pilot	NN	O
study	NN	O
,	,	O
participants	NNS	O
performed	VBD	O
a	DT	O
self-timed	JJ	O
30	CD	O
minute	NN	O
brisk	NN	C
walk	VBP	C
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
,	,	O
park	NN	O
and	CC	O
urban	JJ	O
,	,	O
in	IN	O
Glasgow	NNP	O
,	,	O
Scotland	NNP	O
(	(	O
October	NNP	O
2009	CD	O
to	TO	O
January	NNP	O
2010	CD	O
)	)	O
.	.	O

Cadence	NN	O
,	,	O
recorded	VBD	O
using	VBG	O
the	DT	O
activPAL?	NN	O
activity	NN	O
monitor	NN	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
intensity	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
:	:	O
mean	JJ	O
cadence	NN	O
;	:	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
time	NN	O
accumulated	VBN	O
in	IN	O
bouts	NNS	O
lasting	VBG	O
?	.	O
10	CD	O
min	NN	O
;	:	O
number	NN	O
of	IN	O
walking	VBG	O
breaks	NNS	O
;	:	O
and	CC	O
duration	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
convenience	NN	O
sample	NN	O
of	IN	O
40	CD	O
healthy	JJ	O
adults	NNS	O
was	VBD	O
recruited	VBN	O
:	:	O
16	CD	O
males	NNS	O
,	,	O
24	CD	O
females	NNS	O
,	,	O
mean	JJ	O
age	NN	O
22.9	CD	O
(	(	O
5.5	CD	O
)	)	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
cadence	NN	O
for	IN	O
the	DT	O
whole	JJ	O
walk	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
park	NN	O
:	:	O
119.3	CD	O
(	(	O
8.3	CD	O
)	)	O
vs.	FW	O
110.9	CD	O
(	(	O
8.9	CD	O
)	)	O
steps/min	NN	O
.	.	O

Participants	NNS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
?	.	O
10	CD	O
minute	NN	O
bouts	NNS	O
during	IN	O
park	JJ	O
walks	NNS	O
:	:	O
25.5	CD	O
(	(	O
9.6	CD	O
)	)	O
[	NN	O
median	JJ	O
(	(	O
interquartile	JJ	O
range	NN	O
)	)	O
]	VBZ	O
vs.	FW	O
14.0	CD	O
(	(	O
20.3	CD	O
)	)	O
min	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
self-timed	JJ	O
duration	NN	O
between	IN	O
locations	NNS	O
.	.	O

CONCLUSION	NNP	O
Participants	NNPS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
bouts	NNS	O
?	.	O
10	CD	O
min	NN	O
in	IN	O
duration	NN	O
on	IN	O
park	NN	O
walks	NNS	O
due	JJ	O
to	TO	O
the	DT	O
lack	NN	O
of	IN	O
interruptions	NNS	O
in	IN	O
walking	VBG	O
.	.	O

Hence	NNP	O
the	DT	O
park	NN	O
environment	NN	O
better	RBR	O
facilitated	VBD	O
the	DT	O
achievement	NN	O
of	IN	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
.	.	O

Further	JJ	O
research	NN	O
involving	VBG	O
a	DT	O
larger	JJR	O
,	,	O
more	RBR	O
heterogeneous	JJ	O
sample	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Effect	NN	O
of	IN	O
aliskiren	NN	O
on	IN	O
proteinuria	NNS	O
in	IN	O
non-diabetic	JJ	C
chronic	JJ	C
kidney	NN	C
disease	NN	C
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
proteinuria-lowering	JJ	O
effect	NN	O
of	IN	O
a	DT	O
renin	NN	O
inhibitor	NN	O
(	(	O
aliskiren	NN	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
placebo	VB	O
and	CC	O
to	TO	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
(	(	O
perindopril	NN	O
)	)	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
non-diabetic	JJ	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
A	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
14	CD	O
patients	NNS	O
with	IN	O
nondiabetic	JJ	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
with	IN	O
24-h	JJ	O
mean	JJ	O
proteinuria	NN	O
of	IN	O
2.01	CD	O
g	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.36?2.66	CD	O
)	)	O
and	CC	O
estimated	VBN	O
creatinine	JJ	O
clearance	NN	O
of	IN	O
93?6.8	CD	O
ml/min	NN	O
.	.	O

The	DT	O
study	NN	O
consisted	VBD	O
of	IN	O
five	CD	O
treatment	NN	O
periods	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
aliskiren	NNS	O
(	(	O
150	CD	O
mg	NN	O
)	)	O
,	,	O
aliskiren	RB	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
,	,	O
perindopril	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
,	,	O
perindopril	NN	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	NNP	O
Aliskiren	NNP	O
and	CC	O
perindopril	NN	O
reduced	VBN	O
proteinuria	NN	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
dose-dependent	JJ	O
.	.	O

Furthermore	CD	O
,	,	O
24-h	JJ	O
proteinuria	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
23	CD	O
%	NN	O
(	(	O
mean	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
;	:	O
2?44	CD	O
)	)	O
by	IN	O
treatment	NN	O
with	IN	O
aliskiren	NNS	O
(	(	O
150	CD	O
mg	NN	O
)	)	O
,	,	O
by	IN	O
36	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
17?55	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
aliskiren	NN	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
,	,	O
by	IN	O
7.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
11?26	CD	O
)	)	O
with	IN	O
perindopril	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
and	CC	O
by	IN	O
25	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
11?39	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
perindopril	NN	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
aliskiren	NNS	O
and	CC	O
perindopril	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aliskiren	NNP	O
significantly	RB	O
reduced	VBD	O
proteinuria	NNS	O
.	.	O

The	DT	O
antiproteinuric	JJ	O
effect	NN	O
is	VBZ	O
probably	RB	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
perindopril	NN	O
,	,	O
for	IN	O
equivalent	JJ	O
hypotensive	JJ	O
dosages	NNS	O
.	.	O

The	DT	O
renin	JJ	O
inhibitor	NN	O
provides	VBZ	O
a	DT	O
promising	JJ	O
alternative	JJ	O
approach	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
proteinuric	JJ	O
non-diabetic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

Iron	NNP	O
in	IN	O
relation	NN	O
to	TO	O
gastric	JJ	C
cancer	NN	C
in	IN	O
the	DT	O
Alpha-tocopherol	NNP	O
,	,	O
Beta-carotene	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Iron	NNP	O
is	VBZ	O
an	DT	O
essential	JJ	O
micronutrient	NN	O
that	WDT	O
can	MD	O
have	VB	O
carcinogenic	JJ	O
effects	NNS	O
when	WRB	O
at	IN	O
high	JJ	O
or	CC	O
low	JJ	O
concentrations	NNS	O
.	.	O

Previous	JJ	O
studies	NNS	O
of	IN	O
iron	NN	O
in	IN	O
relation	NN	O
to	TO	O
gastric	JJ	O
cancer	NN	O
have	VBP	O
not	RB	O
assessed	VBN	O
subtype-specific	JJ	O
relationships	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
prospective	JJ	O
Alpha-Tocopherol	NNP	O
,	,	O
Beta-Carotene	NNP	O
(	(	O
ATBC	NNP	O
)	)	O
Cancer	NNP	O
Prevention	NNP	O
Study	NNP	O
to	TO	O
assess	VB	O
whether	IN	O
iron	NN	O
metrics	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
gastric	JJ	C
cardia	NN	C
cancer	NN	C
(	(	O
GCC	NNP	C
)	)	O
and	CC	O
gastric	JJ	C
noncardia	NN	C
cancer	NN	C
(	(	O
GNCC	NNP	C
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
selected	VBD	O
341	CD	SS
incident	JJ	O
gastric	JJ	O
cancer	NN	O
cases	NNS	O
(	(	O
86	CD	O
cardia	NN	O
,	,	O
172	CD	O
noncardia	NN	O
,	,	O
and	CC	O
83	CD	O
nonspecified	VBN	O
)	)	O
,	,	O
accrued	VBN	O
during	IN	O
22	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
and	CC	O
341	CD	SS
individually	RB	O
matched	VBN	O
controls	NNS	O
.	.	O

We	PRP	O
measured	VBD	O
prediagnostic	JJ	O
serum	NN	O
iron	NN	O
,	,	O
ferritin	NN	O
,	,	O
unsaturated	JJ	O
iron	NN	O
binding	NN	O
capacity	NN	O
,	,	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
.	.	O

Total	JJ	O
iron-binding	JJ	O
capacity	NN	O
(	(	O
TIBC	NNP	O
)	)	O
and	CC	O
transferrin	JJ	O
saturation	NN	O
were	VBD	O
estimated	VBN	O
from	IN	O
these	DT	O
metrics	NNS	O
.	.	O

Dietary	NNP	O
iron	NN	O
exposures	NNS	O
were	VBD	O
estimated	VBN	O
from	IN	O
a	DT	O
food	NN	O
frequency	NN	O
questionnaire	NN	O
.	.	O

Multivariable	JJ	O
logistic	JJ	O
regression	NN	O
was	VBD	O
used	VBN	O
for	IN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Serum	NNP	O
iron	NN	O
metrics	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
GCC	NNP	O
,	,	O
except	IN	O
for	IN	O
a	DT	O
potential	JJ	O
n	NN	O
-shaped	VBD	O
relationship	NN	O
with	IN	O
TIBC	NNP	O
(	(	O
global	JJ	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
.	.	O

GNCC	NNP	O
was	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
serum	NN	O
ferritin	NN	O
(	(	O
global	JJ	O
P	NNP	O
=	NNP	O
0.024	CD	O
)	)	O
,	,	O
serum	JJ	O
iron	NN	O
(	(	O
global	JJ	O
P	NNP	O
=	NNP	O
0.060	CD	O
)	)	O
and	CC	O
,	,	O
possibly	RB	O
,	,	O
transferrin	JJ	O
saturation	NN	O
.	.	O

TIBC	NNP	O
appeared	VBD	O
to	TO	O
share	NN	O
a	DT	O
u	NN	O
-shaped	VBD	O
relationship	NN	O
with	IN	O
GNCC	NNP	O
(	(	O
global	JJ	O
P	NNP	O
=	NNP	O
0.033	CD	O
)	)	O
.	.	O

Dietary	NNP	O
iron	NN	O
exposures	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
either	DT	O
subsite	NN	O
.	.	O

Adjustment	NN	O
for	IN	O
Helicobacter	NNP	O
pylori	NN	O
and	CC	O
gastric	JJ	O
atrophy	NN	O
had	VBD	O
little	JJ	O
effect	NN	O
on	IN	O
observed	JJ	O
associations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
little	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
involvement	NN	O
of	IN	O
iron	NN	O
exposure	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
GCC	NNP	O
.	.	O

GNCC	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
iron	NN	O
profile	NN	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
iron	NN	O
deficiency	NN	O
.	.	O

IMPACT	NNP	O
Our	PRP$	O
findings	NNS	O
indicate	VBP	O
that	IN	O
inverse	JJ	O
associations	NNS	O
between	IN	O
iron	NN	O
metrics	NNS	O
and	CC	O
gastric	JJ	O
cancer	NN	O
are	VBP	O
driven	VBN	O
by	IN	O
associations	NNS	O
with	IN	O
GNCC	NNP	O
.	.	O

Further	NNP	O
elucidation	NN	O
of	IN	O
potential	JJ	O
mechanisms	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Validity	NNP	O
and	CC	O
reliability	NN	O
assessment	NN	O
of	IN	O
the	DT	O
Siriraj	NNP	O
Asthma	NNP	C
Control	NNP	O
Questionnaire	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
present	JJ	O
study	NN	O
assessed	VBD	O
the	DT	O
validity	NN	O
and	CC	O
reliability	NN	O
of	IN	O
the	DT	O
Siriraj	NNP	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
in	IN	O
Asthma	NNP	O
Clinic	NNP	O
,	,	O
Siriraj	NNP	O
Hospital	NNP	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
The	DT	O
data	NN	O
of	IN	O
the	DT	O
questionnaire	NN	O
responses	NNS	O
and	CC	O
spirometric	JJ	O
results	NNS	O
from	IN	O
20	CD	SS
randomized	JJ	O
asthmatic	JJ	C
patients	NNS	O
in	IN	O
the	DT	O
clinic	NN	O
including	VBG	O
the	DT	O
record	NN	O
of	IN	O
3	CD	O
visits	NNS	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

The	DT	O
validation	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
Kruskal-Wallis	NNP	O
test	NN	O
comparing	VBG	O
the	DT	O
scores	NNS	O
with	IN	O
the	DT	O
level	NN	O
of	IN	O
asthma	NNS	O
control	NN	O
determined	VBN	O
by	IN	O
physicians	NNS	O
according	VBG	O
to	TO	O
GINA	NNP	O
guideline	NN	O
.	.	O

Internal	NNP	O
consistency	NN	O
reliability	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
questionnaires	VBZ	O
from	IN	O
20	CD	O
patients	NNS	O
with	IN	O
age	NN	O
29-73	CD	A
years	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

There	EX	O
were	VBD	O
40	CD	O
controlled	VBN	O
,	,	O
7	CD	O
partly	RB	O
controlled	VBN	O
and	CC	O
13	CD	O
uncontrolled	JJ	O
visits	NNS	O
.	.	O

The	DT	O
scores	NNS	O
from	IN	O
5-items	JJ	O
questionnaires	NNS	O
and	CC	O
6-items	JJ	O
clinical	JJ	O
score	NN	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
the	DT	O
physician-diagnosed	JJ	O
groups	NNS	O
(	(	O
i.e.	FW	O
,	,	O
controlled	VBD	O
,	,	O
partly	RB	O
controlled	VBN	O
and	CC	O
uncontrolled	JJ	O
groups	NNS	O
)	)	O
.	.	O

Median	JJ	O
scores	NNS	O
(	(	O
min	NN	O
,	,	O
max	NN	O
)	)	O
were	VBD	O
0	CD	O
(	(	O
0	CD	O
,	,	O
5	CD	O
)	)	O
,	,	O
2	CD	O
(	(	O
0	CD	O
,	,	O
6	CD	O
)	)	O
,	,	O
4	CD	O
(	(	O
0	CD	O
,	,	O
12	CD	O
)	)	O
respectively	RB	O
,	,	O
(	(	O
5-items	CD	O
,	,	O
p	VBZ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
2	CD	O
(	(	O
0	CD	O
,	,	O
7	CD	O
)	)	O
,	,	O
3	CD	O
(	(	O
1	CD	O
,	,	O
7	CD	O
)	)	O
,	,	O
6	CD	O
(	(	O
2,15	CD	O
)	)	O
respectively	RB	O
,	,	O
(	(	O
6-items	CD	O
,	,	O
p	VBZ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Internal	NNP	O
consistency	NN	O
reliability	NN	O
of	IN	O
both	DT	O
5-items	JJ	O
questionnaire	NN	O
and	CC	O
6-items	JJ	O
clinical	JJ	O
score	NN	O
were	VBD	O
within	IN	O
the	DT	O
acceptable	JJ	O
range	NN	O
(	(	O
0.829	CD	O
and	CC	O
0.708	CD	O
respectively	RB	O
)	)	O
.	.	O

5-items	JJ	O
questionnaire	NN	O
is	VBZ	O
more	RBR	O
associated	JJ	O
with	IN	O
the	DT	O
physician	NN	O
diagnosed	VBN	O
group	NN	O
and	CC	O
more	JJR	O
consistent	JJ	O
than	IN	O
6-items	JJ	O
clinical	JJ	O
score	NN	O
.	.	O

Further	JJ	O
analysis	NN	O
revealed	VBD	O
cutoff	NN	O
point	NN	O
at	IN	O
2.5	CD	O
to	TO	O
separate	VB	O
uncontrolled	JJ	O
from	IN	O
controlled	VBN	O
or	CC	O
partly	RB	O
controlled	VBN	O
patient	NN	O
with	IN	O
sensitivity	NN	O
76.9	CD	O
%	NN	O
and	CC	O
specificity	NN	O
89.4	CD	O
%	NN	O
and	CC	O
cutoff	NN	O
point	NN	O
at	IN	O
1.5	CD	O
to	TO	O
separate	VB	O
uncontrolled	JJ	O
or	CC	O
partly	RB	O
controlled	VBN	O
from	IN	O
controlled	VBN	O
patient	NN	O
with	IN	O
sensitivity	NN	O
70.0	CD	O
%	NN	O
and	CC	O
specificity	NN	O
85.0	CD	O
%	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
validity	NN	O
and	CC	O
reliability	NN	O
of	IN	O
Siriraj	NNP	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
is	VBZ	O
acceptable	JJ	O
and	CC	O
might	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
practice	NN	O
and	CC	O
research	NN	O
in	IN	O
Thai	NNP	O
asthmatic	JJ	C
patients	NNS	O
.	.	O

Social	JJ	O
support	NN	O
and	CC	O
abstinence	NN	O
from	IN	O
opiates	NNS	O
and	CC	O
cocaine	NN	O
during	IN	O
opioid	JJ	C
maintenance	NN	C
treatment	NN	C
.	.	O

Social	NNP	O
support	NN	O
may	MD	O
play	VB	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
helping	VBG	O
drug	NN	C
users	NNS	C
achieve	VBP	O
abstinence	NN	O
;	:	O
however	RB	O
these	DT	O
benefits	NNS	O
may	MD	O
depend	VB	O
on	IN	O
the	DT	O
type	NN	O
of	IN	O
support	NN	O
experienced	VBN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
observational	NN	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
general	JJ	O
and	CC	O
abstinence-specific	JJ	O
support	NN	O
,	,	O
both	DT	O
structural	JJ	O
and	CC	O
functional	JJ	O
,	,	O
predicted	JJ	O
opiate	NN	O
and	CC	O
cocaine	NN	O
abstinence	NN	O
in	IN	O
128	CD	SS
opioid	JJ	C
maintenance	NN	C
patients	NNS	C
receiving	VBG	O
either	CC	O
methadone	NN	O
or	CC	O
LAAM	NNP	O
.	.	O

A	DT	O
new	JJ	O
multidimensional	JJ	O
self-report	NN	O
instrument	NN	O
assessing	VBG	O
abstinence-specific	JJ	O
functional	JJ	O
support	NN	O
was	VBD	O
developed	VBN	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Previously	RB	O
validated	VBN	O
measures	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
remaining	VBG	O
types	NNS	O
of	IN	O
support	NN	O
.	.	O

With	IN	O
baseline	JJ	O
abstinence	NN	O
and	CC	O
other	JJ	O
statistically	RB	O
important	JJ	O
covariates	NNS	O
adjusted	VBN	O
,	,	O
hierarchical	JJ	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
demonstrated	VBD	O
that	IN	O
the	DT	O
associations	NNS	O
between	IN	O
social	JJ	O
support	NN	O
at	IN	O
study	NN	O
baseline	NN	O
and	CC	O
biochemically	RB	O
confirmed	VBN	O
abstinence	NN	O
3	CD	O
months	NNS	O
later	RB	O
varied	VBN	O
by	IN	O
type	NN	O
of	IN	O
support	NN	O
and	CC	O
by	IN	O
drug	NN	O
.	.	O

Greater	NNP	O
abstinence-specific	JJ	O
structural	JJ	O
support	NN	O
(	(	O
operationalized	VBN	O
as	IN	O
fewer	JJR	O
drug	NN	O
users	NNS	O
in	IN	O
the	DT	O
social	JJ	O
network	NN	O
)	)	O
and	CC	O
decreases	VBZ	O
in	IN	O
three	CD	O
types	NNS	O
of	IN	O
negative	JJ	O
abstinence-specific	JJ	O
functional	JJ	O
support	NN	O
(	(	O
Complaints	NNS	O
about	IN	O
Drug	NNP	O
Use	NNP	O
,	,	O
Drug	NNP	O
Exposure	NNP	O
,	,	O
and	CC	O
Demoralization	NNP	O
)	)	O
predicted	VBD	O
cocaine	NN	O
,	,	O
but	CC	O
not	RB	O
opiate	JJ	O
abstinence	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
effects	NNS	O
for	IN	O
general	JJ	O
support	NN	O
,	,	O
whether	IN	O
structural	JJ	O
or	CC	O
functional	JJ	O
,	,	O
on	IN	O
abstinence	NN	O
from	IN	O
either	DT	O
drug	NN	O
.	.	O

Interventions	NNS	O
that	WDT	O
focus	VBP	O
on	IN	O
modifying	VBG	O
patients	NNS	O
'	POS	O
abstinence-specific	JJ	O
support	NN	O
may	MD	O
be	VB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
high	JJ	O
rates	NNS	O
of	IN	O
cocaine	NN	C
use	NN	C
disorders	NNS	C
in	IN	O
this	DT	O
population	NN	O
.	.	O

In-hospital	JJ	O
costs	NNS	O
of	IN	O
self-expanding	JJ	O
nitinol	JJ	O
stent	NN	O
implantation	NN	O
versus	NN	O
balloon	NN	O
angioplasty	NN	O
in	IN	O
the	DT	O
femoropopliteal	JJ	O
artery	NN	O
(	(	O
the	DT	O
VascuCoil	NNP	O
Trial	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Although	IN	O
several	JJ	O
prospective	JJ	O
studies	NNS	O
have	VBP	O
examined	VBN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
stent	JJ	O
placement	NN	O
for	IN	O
femoropopliteal	JJ	C
arterial	JJ	C
disease	NN	C
,	,	O
the	DT	O
current	JJ	O
cost	NN	O
of	IN	O
these	DT	O
procedures	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
estimate	VB	O
and	CC	O
compare	VB	O
hospital	NN	O
costs	NNS	O
associated	VBN	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
(	(	O
percutaneous	JJ	O
transluminal	NN	O
angioplasty	NN	O
[	NNP	O
PTA	NNP	O
]	NNP	O
)	)	O
and	CC	O
stent	JJ	O
placement	NN	O
for	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
,	,	O
the	DT	O
authors	NNS	O
performed	VBD	O
a	DT	O
prospective	JJ	O
economic	JJ	O
evaluation	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Intracoil	NNP	O
Femoropopliteal	NNP	O
Stent	NNP	O
Trial	NNP	O
(	(	O
VascuCoil	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
May	NNP	O
1997	CD	O
and	CC	O
December	NNP	O
1999	CD	O
,	,	O
266	CD	SS
patients	NNS	O
with	IN	O
stenotic	JJ	C
or	CC	C
occluded	VBN	C
superficial	JJ	C
femoral	JJ	C
or	CC	C
popliteal	JJ	C
arteries	NNS	C
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
the	DT	O
IntraCoil	NNP	O
stent	NN	O
or	CC	O
PTA	NNP	O
.	.	O

Detailed	NNP	O
resource	NN	O
use	NN	O
and	CC	O
cost	NN	O
data	NNS	O
for	IN	O
each	DT	O
patient	NN	O
's	POS	O
initial	JJ	O
revascularization	NN	O
procedure	NN	O
and	CC	O
ensuing	VBG	O
hospitalization	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
analyzed	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
,	,	O
stent	JJ	O
placement	NN	O
did	VBD	O
not	RB	O
improve	VB	O
clinical	JJ	O
outcomes	NNS	O
but	CC	O
increased	JJ	O
procedure	NN	O
duration	NN	O
,	,	O
equipment	NN	O
costs	NNS	O
,	,	O
and	CC	O
physician	JJ	O
services	NNS	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
initial	JJ	O
hospital	NN	O
costs	NNS	O
were	VBD	O
approximately	RB	O
3,500	CD	O
dollars	NNS	O
higher	JJR	O
for	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
IntraCoil	NNP	O
stent	NN	O
,	,	O
compared	VBN	O
with	IN	O
PTA	NNP	O
(	(	O
8,435	CD	O
dollars	NNS	O
vs	RB	O
4,980	CD	O
dollars	NNS	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
As	IN	O
performed	VBN	O
in	IN	O
the	DT	O
VascuCoil	NNP	O
trial	NN	O
,	,	O
primary	JJ	O
stent	NN	O
placement	NN	O
for	IN	O
femoropopliteal	JJ	O
disease	NN	O
did	VBD	O
not	RB	O
improve	VB	O
clinical	JJ	O
outcomes	NNS	O
but	CC	O
increased	VBD	O
initial	JJ	O
treatment	NN	O
costs	NNS	O
by	IN	O
more	JJR	O
than	IN	O
3,000	CD	O
dollars	NNS	O
.	.	O

Because	IN	O
there	EX	O
were	VBD	O
no	DT	O
substantial	JJ	O
differences	NNS	O
in	IN	O
subsequent	JJ	O
clinical	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
that	IN	O
these	DT	O
increased	VBN	O
initial	JJ	O
costs	NNS	O
would	MD	O
be	VB	O
offset	VBN	O
by	IN	O
savings	NNS	O
in	IN	O
follow-up	JJ	O
costs	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
strategy	NN	O
of	IN	O
routine	JJ	O
stent	NN	O
implantation	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
femoropopliteal	JJ	C
PTA	NNP	C
is	VBZ	O
not	RB	O
optimal	JJ	O
on	IN	O
economic	JJ	O
grounds	NNS	O
and	CC	O
that	DT	O
PTA	NNP	O
with	IN	O
provisional	JJ	O
stent	JJ	O
implantation	NN	O
is	VBZ	O
preferred	VBN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
transient	JJ	O
ulnar	JJ	O
artery	NN	O
compression	NN	O
to	TO	O
recanalize	VB	O
acute	JJ	O
radial	JJ	O
artery	NN	O
occlusion	NN	O
after	IN	O
transradial	JJ	O
catheterization	NN	O
.	.	O

Radial	JJ	O
artery	NN	O
occlusion	NN	O
(	(	O
RAO	NNP	O
)	)	O
can	MD	O
result	VB	O
from	IN	O
transradial	JJ	O
catheterization	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
RAO	NNP	O
with	IN	O
2	CD	O
heparin	JJ	O
dosage	NN	O
regimens	NNS	O
after	IN	O
transradial	JJ	O
coronary	JJ	O
angiography	NN	O
,	,	O
and	CC	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
transient	JJ	O
homolateral	JJ	O
ulnar	JJ	O
artery	NN	O
compression	NN	O
to	TO	O
achieve	VB	O
acute	JJ	O
radial	JJ	O
artery	NN	O
recanalization	NN	O
.	.	O

Patients	NNS	O
referred	VBD	O
for	IN	O
coronary	JJ	C
angiography	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
very-low-dose	JJ	O
heparin	NN	O
(	(	O
2,000	CD	O
IU	NNP	O
)	)	O
or	CC	O
low-dose	JJ	O
heparin	NN	O
(	(	O
5,000	CD	O
IU	NNP	O
)	)	O
.	.	O

On	IN	O
sheath	NN	O
removal	NN	O
,	,	O
hemostasis	NN	O
was	VBD	O
obtained	VBN	O
using	VBG	O
the	DT	O
TR	NNP	O
band	NN	O
with	IN	O
a	DT	O
plethysmography-guided	JJ	O
patent	NN	O
hemostasis	NN	O
technique	NN	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
RAO	NNP	O
as	IN	O
assessed	VBN	O
by	IN	O
duplex	JJ	O
ultrasonography	NN	O
3	CD	O
to	TO	O
4	CD	O
hours	NNS	O
after	IN	O
hemostasis	NN	O
,	,	O
immediate	JJ	O
1-hour	JJ	O
ulnar	JJ	O
artery	NN	O
compression	NN	O
was	VBD	O
applied	VBN	O
.	.	O

Hematomas	NNP	O
>	VBD	O
15	CD	O
cm	NN	O
(	(	O
2	CD	O
)	)	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

We	PRP	O
randomized	VBD	O
465	CD	SS
patients	NNS	O
,	,	O
222	CD	O
in	IN	O
the	DT	O
2,000-IU	JJ	O
group	NN	O
and	CC	O
243	CD	O
in	IN	O
the	DT	O
5,000-IU	JJ	O
group	NN	O
.	.	O

The	DT	O
baseline	NN	O
and	CC	O
procedural	JJ	O
characteristics	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
initial	JJ	O
RAO	NNP	O
was	VBD	O
5.9	CD	O
%	NN	O
in	IN	O
the	DT	O
2,000-IU	JJ	O
group	NN	O
and	CC	O
2.9	CD	O
%	NN	O
in	IN	O
the	DT	O
5,000-IU	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.17	CD	O
)	)	O
,	,	O
with	IN	O
a	DT	O
compression	NN	O
time	NN	O
of	IN	O
2.10	CD	O
?	.	O
0.78	CD	O
hours	NNS	O
and	CC	O
2.25	CD	O
?	.	O
0.82	CD	O
hours	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.051	CD	O
)	)	O
.	.	O

After	IN	O
ulnar	JJ	O
artery	NN	O
compression	NN	O
,	,	O
the	DT	O
final	JJ	O
incidence	NN	O
of	IN	O
RAO	NNP	O
was	VBD	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
2,000-IU	JJ	O
group	NN	O
and	CC	O
0.8	CD	O
%	NN	O
in	IN	O
the	DT	O
5,000-IU	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
local	JJ	O
hematoma	NN	O
was	VBD	O
2.3	CD	O
%	NN	O
and	CC	O
3.7	CD	O
%	NN	O
in	IN	O
the	DT	O
2,000-	JJ	O
and	CC	O
5,000-IU	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.42	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
acute	JJ	O
RAO	NNP	O
after	IN	O
transradial	JJ	O
catheterization	NN	O
can	MD	O
be	VB	O
recanalized	VBN	O
by	IN	O
early	JJ	O
1-hour	JJ	O
homolateral	JJ	O
ulnar	JJ	O
artery	NN	O
compression	NN	O
.	.	O

This	DT	O
simple	JJ	O
nonpharmacologic	JJ	O
method	NN	O
was	VBD	O
effective	JJ	O
and	CC	O
safe	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
very-low-	JJ	O
and	CC	O
low-dose	JJ	O
heparin	NN	O
.	.	O

Nevertheless	NNP	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
final	JJ	O
RAO	NNP	O
remained	VBD	O
significantly	RB	O
lower	JJR	O
after	IN	O
a	DT	O
higher	JJR	O
anticoagulation	NN	O
level	NN	O
.	.	O

Norfloxacin	NNP	O
modulates	VBZ	O
the	DT	O
inflammatory	JJ	O
response	NN	O
and	CC	O
directly	RB	O
affects	VBZ	O
neutrophils	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
decompensated	JJ	C
cirrhosis	NN	C
.	.	O

BACKGROUND	NNP	O
&	CC	O
AIMS	NNP	O
Patients	NNPS	O
with	IN	O
cirrhosis	NN	C
undergoing	VBG	O
selective	JJ	O
intestinal	JJ	O
decontamination	NN	O
with	IN	O
norfloxacin	JJ	O
show	NN	O
a	DT	O
reduction	NN	O
in	IN	O
serum	JJ	O
cytokine	NN	O
levels	NNS	O
,	,	O
probably	RB	O
because	IN	O
of	IN	O
a	DT	O
combined	JJ	O
effect	NN	O
of	IN	O
norfloxacin	NN	O
on	IN	O
bowel	NN	O
flora	NNS	O
and	CC	O
neutrophils	NNS	O
.	.	O

METHODS	NNP	O
Thirty-one	CD	SS
patients	NNS	O
with	IN	O
cirrhosis	NN	O
receiving	VBG	O
norfloxacin	NN	O
(	(	O
400	CD	O
mg/day	NN	O
)	)	O
were	VBD	O
included	VBN	O
.	.	O

Blood	NNP	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
0.5-4	JJ	O
hours	NNS	O
(	(	O
peak	JJ	O
samples	NNS	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
47	CD	O
)	)	O
and	CC	O
at	IN	O
22-24	JJ	O
hours	NNS	O
(	(	O
trough	IN	O
samples	NNS	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
84	CD	O
)	)	O
after	IN	O
dose	NN	O
.	.	O

Fifty-nine	JJ	O
ascitic	JJ	O
fluid	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

Single	NNP	O
doses	NNS	O
of	IN	O
norfloxacin	NN	O
and	CC	O
trimethoprim/sulfamethoxazole	NN	O
were	VBD	O
administered	VBN	O
to	TO	O
13	CD	O
and	CC	O
5	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
(	(	O
temporal	JJ	O
profile	NN	O
group	NN	O
)	)	O
and	CC	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
0	CD	O
,	,	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
1.5	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

Norfloxacin	NNP	O
,	,	O
trimethoprim/sulfamethoxazole	NN	O
,	,	O
cytokines	NNS	O
,	,	O
nitric	JJ	O
oxide	NN	O
,	,	O
expression	NN	O
levels	NNS	O
of	IN	O
nuclear	JJ	O
factor	NN	O
(	(	O
NF	NNP	O
)	)	O
-kappaB	NN	O
and	CC	O
inhibitor	NN	O
of	IN	O
NF-kappaB	NNP	O
(	(	O
IkB-alpha	NNP	O
)	)	O
,	,	O
neutrophil	JJ	O
oxidative	JJ	O
burst	NN	O
,	,	O
and	CC	O
rate	NN	O
of	IN	O
apoptotic	JJ	O
events	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
samples	NNS	O
were	VBD	O
bacterial	JJ	O
DNA	NNP	O
negative	NN	O
and	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
levels	NNS	O
of	IN	O
lipopolysaccharide	NN	O
.	.	O

Serum	NNP	O
and	CC	O
ascitic	JJ	O
levels	NNS	O
of	IN	O
tumor	NN	O
necrosis	NN	O
factor-alpha	JJ	O
,	,	O
interferon-gamma	JJ	O
,	,	O
interleukin-12	JJ	O
,	,	O
and	CC	O
nitric	JJ	O
oxide	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
peak	NN	O
than	IN	O
in	IN	O
trough	JJ	O
samples	NNS	O
.	.	O

A	DT	O
correlation	NN	O
was	VBD	O
present	JJ	O
between	IN	O
serum	NN	O
norfloxacins	NNS	O
concentrations	NNS	O
and	CC	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.68	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
interferon-gamma	JJ	O
(	(	O
r	JJ	O
=	NNP	O
-0.66	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
interleukin-12	JJ	O
(	(	O
r	JJ	O
=	NNP	O
-0.66	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
nitric	JJ	O
oxide	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.68	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Serum	NNP	O
norfloxacin	NN	O
's	POS	O
highest	JJS	O
concentrations	NNS	O
(	(	O
1	CD	O
+/-	JJ	O
0.5	CD	O
microg/mL	NN	O
)	)	O
were	VBD	O
achieved	VBN	O
at	IN	O
1-2	JJ	O
hours	NNS	O
and	CC	O
concurred	VBN	O
in	IN	O
time	NN	O
with	IN	O
the	DT	O
lower	JJR	O
levels	NNS	O
of	IN	O
cytokines	NNS	O
and	CC	O
nitric	JJ	O
oxide	NN	O
.	.	O

Intracellular	NNP	O
norfloxacin	NN	O
's	POS	O
highest	JJS	O
levels	NNS	O
(	(	O
2	CD	O
+/-	JJ	O
1	CD	O
microg/mL/10	NN	O
(	(	O
7	CD	O
)	)	O
cells	NNS	O
)	)	O
were	VBD	O
observed	VBN	O
at	IN	O
2	CD	O
hours	NNS	O
and	CC	O
concurred	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
NF-kappaB	JJ	O
expression	NN	O
,	,	O
a	DT	O
reduced	JJ	O
anion	NN	O
superoxide	NN	O
generation	NN	O
,	,	O
and	CC	O
apoptotic	JJ	O
rate	NN	O
in	IN	O
response	NN	O
to	TO	O
phorbol	VB	O
myristate	JJ	O
acetate	NN	O
.	.	O

Trimethoprim/sulfamethoxazole	NNP	O
did	VBD	O
not	RB	O
significantly	RB	O
modulate	VB	O
cytokine	JJ	O
expression	NN	O
.	.	O

CONCLUSIONS	NNP	O
Norfloxacin	NNP	O
but	CC	O
not	RB	O
trimethoprim/sulfamethoxazole	JJ	O
modulates	NNS	O
inflammatory	JJ	O
response	NN	O
and	CC	O
directly	RB	O
affects	VBZ	O
neutrophils	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
cirrhosis	NN	C
.	.	O

Randomized	NNP	O
comparison	NN	O
of	IN	O
interferon	NN	O
alpha	NN	O
and	CC	O
hydroxyurea	NN	O
with	IN	O
hydroxyurea	JJ	O
monotherapy	NN	O
in	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
CML-study	NNP	O
II	NNP	O
)	)	O
:	:	O
prolongation	NN	O
of	IN	O
survival	NN	O
by	IN	O
the	DT	O
combination	NN	O
of	IN	O
interferon	NN	O
alpha	NN	O
and	CC	O
hydroxyurea	NN	O
.	.	O

The	DT	O
optimum	JJ	O
treatment	NN	O
conditions	NNS	O
of	IN	O
interferon	NN	O
(	(	O
IFN	NNP	O
)	)	O
alpha	VBP	O
therapy	NN	O
in	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
CML	NNP	O
)	)	O
are	VBP	O
still	RB	O
controversial	JJ	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
role	NN	O
of	IN	O
hydroxyurea	NN	O
(	(	O
HU	NNP	O
)	)	O
for	IN	O
the	DT	O
outcome	NN	O
of	IN	O
IFN	NNP	O
therapy	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
combination	NN	O
of	IN	O
IFN	NNP	O
and	CC	O
HU	NNP	O
vs	VBP	O
HU	NNP	O
monotherapy	NN	O
(	(	O
CML-study	NNP	O
II	NNP	O
)	)	O
.	.	O

From	IN	O
February	NNP	O
1991	CD	O
to	TO	O
December	NNP	O
1994	CD	O
,	,	O
376	CD	SS
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
CML	NNP	C
in	IN	O
chronic	JJ	C
phase	NN	C
were	VBD	O
randomized	VBN	O
.	.	O

In	IN	O
all	DT	O
,	,	O
340	CD	SS
patients	NNS	O
were	VBD	O
Ph/BCR-ABL	NNP	C
positive	JJ	O
and	CC	O
evaluable	JJ	O
.	.	O

Randomization	NN	O
was	VBD	O
unbalanced	JJ	O
1:2	CD	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
,	,	O
since	IN	O
study	NN	O
conditions	NNS	O
were	VBD	O
identical	JJ	O
to	TO	O
the	DT	O
previous	JJ	O
CML-study	NNP	O
I	PRP	O
and	CC	O
it	PRP	O
had	VBD	O
been	VBN	O
planned	VBN	O
in	IN	O
advance	NN	O
to	TO	O
add	VB	O
the	DT	O
HU	NNP	O
patients	NNS	O
of	IN	O
study	NN	O
I	PRP	O
(	(	O
n=194	RB	O
)	)	O
to	TO	O
the	DT	O
HU	NNP	O
control	NN	O
group	NN	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
534	CD	SS
patients	NNS	O
were	VBD	O
evaluable	JJ	O
(	(	O
226	CD	SS
patients	NNS	O
with	IN	O
IFN/HU	NNP	O
and	CC	O
308	CD	SS
patients	NNS	O
with	IN	O
HU	NNP	O
)	)	O
.	.	O

Analyses	NNS	O
were	VBD	O
according	VBG	O
to	TO	O
intention-to-treat	NN	O
.	.	O

Median	JJ	O
observation	NN	O
time	NN	O
of	IN	O
nontransplanted	JJ	O
living	NN	O
patients	NNS	O
was	VBD	O
7.6	CD	O
years	NNS	O
(	(	O
7.9	CD	O
years	NNS	O
for	IN	O
IFN/HU	NNP	O
and	CC	O
7.3	CD	O
years	NNS	O
for	IN	O
HU	NNP	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
profile	NN	O
(	(	O
new	JJ	O
CML	NNP	O
score	NN	O
)	)	O
was	VBD	O
available	JJ	O
for	IN	O
532	CD	O
patients	NNS	O
:	:	O
200	CD	O
patients	NNS	O
(	(	O
38	CD	O
%	NN	O
)	)	O
were	VBD	O
low	JJ	O
,	,	O
239	CD	O
patients	NNS	O
(	(	O
45	CD	O
%	NN	O
)	)	O
intermediate	NN	O
,	,	O
and	CC	O
93	CD	O
patients	NNS	O
(	(	O
17	CD	O
%	NN	O
)	)	O
high	JJ	O
risk	NN	O
.	.	O

Complete	NNP	O
hematologic	JJ	O
response	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
IFN/HU-treated	JJ	O
patients	NNS	O
(	(	O
59	CD	O
vs	RB	O
32	CD	O
%	NN	O
)	)	O
.	.	O

Of	IN	O
169	CD	O
evaluable	JJ	O
IFN/HU-treated	JJ	O
patients	NNS	O
(	(	O
75	CD	O
%	NN	O
)	)	O
,	,	O
104	CD	O
patients	NNS	O
(	(	O
62	CD	O
%	NN	O
)	)	O
achieved	VBD	O
a	DT	O
cytogenetic	JJ	O
response	NN	O
that	WDT	O
was	VBD	O
complete	JJ	O
in	IN	O
12	CD	O
%	NN	O
(	(	O
n=21	JJ	O
)	)	O
,	,	O
major	JJ	O
in	IN	O
14	CD	O
%	NN	O
(	(	O
n=24	JJ	O
)	)	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
minimal	JJ	O
in	IN	O
35	CD	O
%	NN	O
(	(	O
n=59	JJ	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
534	CD	SS
patients	NNS	O
,	,	O
105	CD	O
(	(	O
20	CD	O
%	NN	O
)	)	O
underwent	NN	O
allogeneic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
in	IN	O
first	JJ	O
chronic	JJ	O
phase	NN	O
.	.	O

In	IN	O
the	DT	O
low-risk	JJ	O
group	NN	O
,	,	O
65	CD	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
transplanted	VBN	O
(	(	O
33	CD	O
%	NN	O
)	)	O
,	,	O
30	CD	O
(	(	O
13	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
intermediate-risk	JJ	O
group	NN	O
,	,	O
and	CC	O
nine	CD	O
(	(	O
10	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
high-risk	JJ	O
group	NN	O
.	.	O

Duration	NN	O
of	IN	O
chronic	JJ	O
phase	NN	O
was	VBD	O
55	CD	O
months	NNS	O
for	IN	O
IFN/HU	NNP	O
and	CC	O
41	CD	O
months	NNS	O
for	IN	O
HU	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Median	JJ	O
survival	NN	O
was	VBD	O
64	CD	O
months	NNS	O
for	IN	O
IFN/HU	NNP	O
and	CC	O
53	CD	O
months	NNS	O
for	IN	O
HU-treated	JJ	O
patients	NNS	O
(	(	O
P=0.0063	NNP	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
IFN	NNP	O
in	IN	O
combination	NN	O
with	IN	O
HU	NNP	O
achieves	VBZ	O
a	DT	O
significant	JJ	O
long-term	JJ	O
survival	NN	O
advantage	NN	O
over	IN	O
HU	NNP	O
monotherapy	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
data	NNS	O
of	IN	O
CML-study	NNP	O
I	PRP	O
,	,	O
these	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
IFN/HU	NNP	O
is	VBZ	O
also	RB	O
superior	JJ	O
to	TO	O
IFN	NNP	O
alone	RB	O
.	.	O

HU	NNP	O
should	MD	O
be	VB	O
combined	VBN	O
with	IN	O
IFN	NNP	O
in	IN	O
IFN-based	JJ	O
therapies	NNS	O
and	CC	O
for	IN	O
comparisons	NNS	O
with	IN	O
new	JJ	O
therapies	NNS	O
.	.	O

Smoking	VBG	O
cessation	NN	O
with	IN	O
smokeless	JJ	O
tobacco	NN	O
and	CC	O
group	NN	O
therapy	NN	O
:	:	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

Smokeless	NNP	O
tobacco	NN	O
might	MD	O
be	VB	O
effective	JJ	O
as	IN	O
an	DT	O
adjunct	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
smokeless	NN	O
tobacco	NN	O
and	CC	O
group	NN	O
support	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
in	IN	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
that	WDT	O
compared	VBN	O
smokeless	NN	O
tobacco	NN	O
plus	CC	O
group	NN	O
support	NN	O
versus	NN	O
group	NN	O
support	NN	O
only	RB	O
.	.	O

The	DT	O
study	NN	O
enrolled	VBD	O
263	CD	SS
healthy	JJ	C
smokers	NNS	C
(	(	O
M	NNP	O
(	(	O
age	NN	O
)	)	O
=	VBZ	O
49	CD	A
years	NNS	A
)	)	O
who	WP	O
smoked	VBD	C
a	DT	O
mean	NN	O
of	IN	O
24	CD	C
cigarettes/day	NN	C
,	,	O
with	IN	O
a	DT	O
mean	NN	O
of	IN	O
31	CD	C
pack-years	NNS	C
.	.	O

Smokeless	NNP	O
tobacco	NN	O
was	VBD	O
provided	VBN	O
for	IN	O
7	CD	O
weeks	NNS	O
(	(	O
or	CC	O
up	RB	O
to	TO	O
12	CD	O
)	)	O
,	,	O
combined	VBN	O
with	IN	O
eight	CD	O
group	NN	O
support	NN	O
visits	NNS	O
provided	VBN	O
by	IN	O
nurses	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
group	NN	O
support	NN	O
only	RB	O
.	.	O

Smoking	VBG	O
cessation	NN	O
rates	NNS	O
were	VBD	O
statistically	RB	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
smokeless	NN	O
tobacco	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
during	IN	O
the	DT	O
first	JJ	O
7	CD	O
weeks	NNS	O
.	.	O

Point-prevalence	NN	O
abstinence	NN	O
rates	NNS	O
at	IN	O
7	CD	O
weeks	NNS	O
were	VBD	O
36.4	CD	O
%	NN	O
versus	IN	O
20.8	CD	O
%	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
2.52	CD	O
,	,	O
p	NN	O
=	NNP	O
.001	NNP	O
)	)	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
continuous	JJ	O
abstinence	NN	O
rates	NNS	O
from	IN	O
weeks	NNS	O
4	CD	O
to	TO	O
7	CD	O
were	VBD	O
31.5	CD	O
%	NN	O
versus	IN	O
19.2	CD	O
%	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
1.94	CD	O
,	,	O
p	NN	O
=	NNP	O
.023	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
(	(	O
i.e.	JJ	O
,	,	O
6-month	JJ	O
point	NN	O
prevalence	NN	O
)	)	O
were	VBD	O
23.1	CD	O
%	NN	O
versus	IN	O
20.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
OR	NNP	O
=	VBZ	O
1.31	CD	O
,	,	O
ns	NN	O
)	)	O
.	.	O

Smokeless	NNP	O
tobacco	NN	O
was	VBD	O
relatively	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
although	IN	O
15	CD	O
subjects	NNS	O
(	(	O
11.2	CD	O
%	NN	O
)	)	O
stopped	VBD	O
use	NN	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
25	CD	O
subjects	NNS	O
(	(	O
17.5	CD	O
%	NN	O
)	)	O
were	VBD	O
still	RB	O
using	VBG	O
smokeless	JJ	O
tobacco	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

This	DT	O
trial	NN	O
demonstrated	VBD	O
short-term	JJ	O
efficacy	NN	O
of	IN	O
smokeless	JJ	O
tobacco	NN	O
in	IN	O
combination	NN	O
with	IN	O
group	NN	O
support	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
but	CC	O
no	DT	O
long-term	JJ	O
efficacy	NN	O
.	.	O

Computer-navigated	JJ	O
versus	NN	O
conventional	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
literature	NN	O
lacks	VBZ	O
studies	NNS	O
that	IN	O
confirm	VBP	O
whether	IN	O
the	DT	O
improved	JJ	O
radiographic	JJ	O
alignment	NN	O
that	WDT	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
computer-navigated	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
improves	VBZ	O
patients?	JJ	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
or	CC	O
the	DT	O
durability	NN	O
of	IN	O
total	JJ	O
knee	NN	O
prostheses	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
computer-navigated	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
improves	VBZ	O
the	DT	O
clinical	JJ	O
function	NN	O
,	,	O
alignment	NN	O
,	,	O
and	CC	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
compared	VBN	O
the	DT	O
results	NNS	O
of	IN	O
520	CD	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
who	WP	O
underwent	VBD	O
computer-navigated	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
for	IN	O
one	CD	O
knee	NN	O
and	CC	O
conventional	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
for	IN	O
the	DT	O
other	JJ	O
.	.	O

The	DT	O
assignment	NN	O
of	IN	O
the	DT	O
knee	NN	O
to	TO	O
navigation	NN	O
or	CC	O
not	RB	O
was	VBD	O
done	VBN	O
randomly	RB	O
.	.	O

There	EX	O
were	VBD	O
452	CD	O
women	NNS	O
(	(	O
904	CD	O
knees	NNS	O
)	)	O
and	CC	O
sixty-eight	JJ	O
men	NNS	O
(	(	O
136	CD	O
knees	NNS	O
)	)	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
sixty-eight	JJ	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
forty-nine	JJ	O
to	TO	O
eighty-eight	JJ	O
years	NNS	O
)	)	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
index	NN	O
arthroplasty	NN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
10.8	CD	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
ten	VB	O
to	TO	O
twelve	VB	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
clinically	RB	O
and	CC	O
radiographically	RB	O
with	IN	O
the	DT	O
rating	NN	O
system	NN	O
of	IN	O
the	DT	O
Knee	NNP	O
Society	NNP	O
and	CC	O
with	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
score	NN	O
at	IN	O
three	CD	O
months	NNS	O
,	,	O
one	CD	O
year	NN	O
,	,	O
and	CC	O
annually	RB	O
thereafter	RB	O
.	.	O

RESULTS	NNP	O
Total	JJ	O
knee	NN	O
scores	NNS	O
,	,	O
knee	NN	O
function	NN	O
scores	NNS	O
,	,	O
pain	NN	O
scores	NNS	O
,	,	O
WOMAC	NNP	O
scores	VBZ	O
,	,	O
knee	VB	O
motion	NN	O
,	,	O
and	CC	O
activity	NN	O
scores	NNS	O
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
preoperatively	RB	O
or	CC	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
final	JJ	O
follow-up	NN	O
.	.	O

Alignment	NNP	O
and	CC	O
the	DT	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
Kaplan-Meier	NNP	O
survivorship	NN	O
with	IN	O
revision	NN	O
as	IN	O
the	DT	O
end	NN	O
point	NN	O
at	IN	O
10.8	CD	O
years	NNS	O
was	VBD	O
98.8	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.96	CD	O
to	TO	O
1.00	CD	O
)	)	O
in	IN	O
the	DT	O
computernavigated	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
group	NN	O
and	CC	O
99.2	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.96	CD	O
to	TO	O
1.00	CD	O
)	)	O
in	IN	O
the	DT	O
conventional	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
data	NNS	O
demonstrated	VBD	O
no	DT	O
difference	NN	O
in	IN	O
clinical	JJ	O
function	NN	O
or	CC	O
alignment	NN	O
and	CC	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
between	IN	O
the	DT	O
knees	NNS	O
that	WDT	O
underwent	VBD	O
computer-navigated	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
and	CC	O
those	DT	O
that	WDT	O
underwent	JJ	O
conventional	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

Glibenclamide	NNP	O
vs	NN	O
gliclazide	NN	O
in	IN	O
reducing	VBG	O
oxidative	JJ	O
stress	NN	O
in	IN	O
patients	NNS	O
of	IN	O
noninsulin	JJ	C
dependent	JJ	C
diabetes	VBZ	C
mellitus	NN	C
--	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomized	VBN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Parameters	NNPS	O
of	IN	O
oxidative	JJ	O
stress	NN	O
were	VBD	O
quantitated	VBN	O
in	IN	O
50	CD	SS
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
mellitus	VBP	C
in	IN	C
uncontrolled	JJ	C
state	NN	C
and	CC	O
after	IN	O
control	NN	O
using	VBG	O
oral	JJ	O
glibenclamide	NN	O
or	CC	O
gliclazide	NN	O
.	.	O

The	DT	O
estimates	NNS	O
were	VBD	O
further	RB	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
irrespective	JJ	O
of	IN	O
drug	NN	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
difference	NN	O
,	,	O
if	IN	O
any	DT	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
uncontrolled	JJ	O
,	,	O
noncrossover	RB	O
and	CC	O
randomized	JJ	O
trial	NN	O
.	.	O

Fifty	JJ	SS
patients	NNS	O
of	IN	O
uncontrolled	JJ	C
type	NN	C
2	CD	C
diabetes	NNS	C
were	VBD	O
divided	VBN	O
in	IN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
received	VBD	O
capsule	NN	O
A	NNP	O
(	(	O
glibenclamide	NN	O
)	)	O
while	IN	O
Group	NNP	O
II	NNP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
received	VBD	O
capsule	NN	O
B	NNP	O
(	(	O
gliclazide	NN	O
)	)	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBN	O
were	VBD	O
Superoxide	NNP	O
dismutase	NN	O
(	(	O
SOD	NNP	O
)	)	O
,	,	O
malonyl-dialdehyde	JJ	O
(	(	O
MDA	NNP	O
)	)	O
and	CC	O
reduced	VBN	O
glutathione	NN	O
(	(	O
GSH	NNP	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
done	VBN	O
at	IN	O
(	(	O
a	DT	O
)	)	O
uncontrolled	JJ	O
stage	NN	O
(	(	O
FBS	NNP	O
--	:	O
165	CD	O
+/-	JJ	O
16.7	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
240	CD	O
+/-	JJ	O
30.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
10.5	CD	O
+/-	JJ	O
0.9	CD	O
%	NN	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
FBS	NNP	O
--	:	O
150	CD	O
+/-	JJ	O
15.8	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
246	CD	O
+/-	JJ	O
29.1	CD	O
mg/dl	NN	O
HbA1	NNP	O
10.6	CD	O
+/-	JJ	O
0.8	CD	O
%	NN	O
in	IN	O
group	NN	O
II	NNP	O
)	)	O
and	CC	O
during	IN	O
controlled	VBN	O
stage	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
(	(	O
FBS	NNP	O
--	:	O
120	CD	O
+/-	JJ	O
18.5	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
180	CD	O
+/-	JJ	O
19.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
8.4	CD	O
+/-	JJ	O
0.29	CD	O
%	NN	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
FBS	NNP	O
--	:	O
118	CD	O
+/-	JJ	O
17.6	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
176	CD	O
+/-	JJ	O
20.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
8.5	CD	O
+/-	JJ	O
0.39	CD	O
%	NN	O
in	IN	O
group	NN	O
II	NNP	O
patients	NNS	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
significantly	RB	O
raised	VBN	O
levels	NNS	O
of	IN	O
MDA	NNP	O
and	CC	O
SOD	NNP	O
,	,	O
and	CC	O
decreased	JJ	O
levels	NNS	O
of	IN	O
reduced	VBN	O
glutathione	NN	O
(	(	O
GSH	NNP	O
)	)	O
during	IN	O
uncontrolled	JJ	O
stage	NN	O
of	IN	O
diabetes	NNS	O
indicated	VBD	O
free	JJ	O
radical	JJ	O
stress	NN	O
induced	VBD	O
lipid	JJ	O
peroxidation	NN	O
.	.	O

The	DT	O
significant	JJ	O
fall	NN	O
of	IN	O
MDA	NNP	O
and	CC	O
SOD	NNP	O
and	CC	O
increased	VBD	O
levels	NNS	O
of	IN	O
GSH	NNP	O
in	IN	O
blood	NN	O
in	IN	O
both	DT	O
groups	NNS	O
after	IN	O
control	NN	O
revealed	VBD	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
glycemic	JJ	O
control	NN	O
on	IN	O
oxidative	JJ	O
stress	NN	O
.	.	O

The	DT	O
levels	NNS	O
were	VBD	O
not	RB	O
normalized	VBN	O
and	CC	O
stayed	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
in	IN	O
controls	NNS	O
.	.	O

On	IN	O
intergroup	JJ	O
comparison	NN	O
;	:	O
the	DT	O
control	NN	O
of	IN	O
diabetes	NNS	O
with	IN	O
gliclazide	NN	O
(	(	O
group	NN	O
II	NNP	O
)	)	O
showed	VBD	O
improvement	NN	O
in	IN	O
oxidative	JJ	O
stress	NN	O
(	(	O
MDA	NNP	O
,	,	O
GSH	NNP	O
)	)	O
better	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
than	IN	O
glibenclamide	NN	O
(	(	O
group	NN	O
I	PRP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Oxidative	NNP	O
stress	NN	O
in	IN	O
uncontrolled	JJ	O
diabetes	NNS	O
is	VBZ	O
decreased	VBN	O
with	IN	O
glycemic	JJ	O
control	NN	O
.	.	O

The	DT	O
control	NN	O
of	IN	O
diabetes	NNS	O
with	IN	O
gliclazide	NN	O
reduced	VBN	O
oxidative	JJ	O
stress	NN	O
more	JJR	O
than	IN	O
glibenclamide	NN	O
,	,	O
indicating	VBG	O
higher	JJR	O
antioxidant	JJ	O
properties	NNS	O
of	IN	O
gliclazide	NN	O
.	.	O

Normalization	NN	O
of	IN	O
oxidative	JJ	O
stress	NN	O
was	VBD	O
not	RB	O
achieved	VBN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
see	VB	O
long-term	JJ	O
effect	NN	O
of	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
combating	VBG	O
oxidative	JJ	O
stress	NN	O
after	IN	O
achieving	VBG	O
acceptable	JJ	O
control	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
on	IN	O
subjective	JJ	O
and	CC	O
autonomic	JJ	O
responses	NNS	O
to	TO	O
needle	VB	O
insertion	NN	O
.	.	O

BACKGROUND	NNP	O
Premedication	NNP	O
with	IN	O
sedatives	NNS	O
can	MD	O
decrease	VB	O
the	DT	O
discomfort	NN	O
associated	VBN	O
with	IN	O
invasive	JJ	O
anesthetic	JJ	O
procedures	NNS	O
.	.	O

Some	DT	O
researchers	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
acupressure	NN	O
on	IN	O
the	DT	O
acupuncture	NN	O
extra	JJ	O
1	CD	O
point	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
sedation	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
acupressure	NN	O
on	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
could	MD	O
alleviate	VB	O
the	DT	O
pain	NN	O
of	IN	O
needle	JJ	O
insertion	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
or	CC	O
a	DT	O
sham	JJ	O
point	NN	O
on	IN	O
needle	JJ	O
insertion	NN	O
using	VBG	O
verbal	JJ	O
rating	NN	O
scale	NN	O
(	(	O
VRS	NNP	O
)	)	O
pain	NN	O
scores	NNS	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
.	.	O

Twenty-two	NNP	SS
healthy	JJ	C
female	NN	SE
volunteers	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
:	:	O
the	DT	O
extra	JJ	O
1	CD	O
group	NN	O
received	VBD	O
acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
,	,	O
and	CC	O
the	DT	O
sham	NN	O
group	NN	O
received	VBD	O
acupressure	NN	O
at	IN	O
a	DT	O
sham	JJ	O
point	NN	O
.	.	O

After	IN	O
starting	VBG	O
the	DT	O
electrocardiogram	NN	O
record	NN	O
,	,	O
a	DT	O
27-gauge	JJ	O
needle	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
skin	NN	O
of	IN	O
a	DT	O
forearm	NN	O
.	.	O

Thereafter	NNP	O
,	,	O
another	DT	O
needle	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
skin	NN	O
of	IN	O
the	DT	O
other	JJ	O
forearm	NN	O
during	IN	O
acupressure	NN	O
.	.	O

RESULTS	JJ	O
Acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
VRS	NNP	O
,	,	O
but	CC	O
acupressure	NN	O
at	IN	O
the	DT	O
sham	NN	O
increased	VBD	O
the	DT	O
VRS	NNP	O
.	.	O

Acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
significantly	RB	O
reduced	VBD	O
the	DT	O
low	JJ	O
frequency/high	JJ	O
frequency	NN	O
ratio	NN	O
of	IN	O
HRV	NNP	O
responding	VBG	O
to	TO	O
needle	DT	O
insertion	NN	O
.	.	O

CONCLUSIONS	JJ	O
Acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
needle	JJ	O
insertion	NN	O
pain	NN	O
compared	VBN	O
with	IN	O
acupressure	NN	O
at	IN	O
the	DT	O
sham	NN	O
point	NN	O
.	.	O

Also	RB	O
,	,	O
acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
low	JJ	O
frequency/high	JJ	O
frequency	NN	O
ratio	NN	O
of	IN	O
HRV	NNP	O
responding	VBG	O
to	TO	O
needle	VB	O
insertion	NN	O
,	,	O
which	WDT	O
implies	VBZ	O
a	DT	O
reduction	NN	O
in	IN	O
sympathetic	JJ	O
nervous	JJ	O
system	NN	O
activity	NN	O
.	.	O

Influence	NN	O
of	IN	O
occlusal	JJ	O
access	NN	O
on	IN	O
demineralized	JJ	O
dentin	NN	O
removal	NN	O
in	IN	O
the	DT	O
atraumatic	JJ	O
restorative	JJ	O
treatment	NN	O
(	(	O
ART	NNP	O
)	)	O
approach	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
verify	VB	O
the	DT	O
influence	NN	O
of	IN	O
cavity	NN	O
access	NN	O
diameter	NN	O
on	IN	O
demineralized	JJ	O
dentin	NN	O
removal	NN	O
in	IN	O
the	DT	O
ART	NNP	O
approach	NN	O
.	.	O

METHODS	$	O
40	CD	SS
non-carious	JJ	C
human	JJ	C
premolars	NNS	C
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
.	.	O

The	DT	O
occlusal	JJ	O
surface	NN	O
was	VBD	O
ground	NN	O
flat	JJ	O
and	CC	O
the	DT	O
teeth	NNS	O
were	VBD	O
sectioned	VBN	O
mesio-distally	RB	O
.	.	O

The	DT	O
hemi-sections	NNS	O
were	VBD	O
reassembled	VBN	O
and	CC	O
occlusal	JJ	O
access	NN	O
preparations	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
ball-shaped	JJ	O
diamonds	NNS	O
.	.	O

The	DT	O
resulting	VBG	O
size	NN	O
of	IN	O
the	DT	O
occlusal	NN	O
opening	NN	O
was	VBD	O
1.0	CD	O
mm	NN	O
,	,	O
1.4	CD	O
mm	NN	O
,	,	O
1.6	CD	O
mm	NN	O
and	CC	O
1.8	CD	O
mm	NN	O
for	IN	O
Groups	NNP	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
and	CC	O
D	NNP	O
,	,	O
respectively	RB	O
.	.	O

Standardized	VBN	O
artificial	JJ	O
carious	JJ	O
lesions	NNS	O
were	VBD	O
created	VBN	O
and	CC	O
demineralized	VBN	O
dentin	NN	O
was	VBD	O
excavated	VBN	O
.	.	O

After	IN	O
excavation	NN	O
,	,	O
the	DT	O
cavities	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
:	:	O
(	(	O
a	DT	O
)	)	O
the	DT	O
tactile	NN	O
method	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
caries-detection	NN	O
dye	NN	O
to	TO	O
stain	VB	O
demineralized	JJ	O
dentin	NN	O
,	,	O
as	IN	O
proposed	VBN	O
by	IN	O
Smales	NNP	O
&	CC	O
Fang	NNP	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
Demineralized	NNP	O
Tissue	NNP	O
Removal	NNP	O
index	NN	O
,	,	O
as	IN	O
proposed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
Fisher	NNP	O
,	,	O
Spearman	NNP	O
correlation	NN	O
coefficient	NN	O
,	,	O
kappa	NN	O
,	,	O
Kruskal-Wallis	NNP	O
and	CC	O
Miller	NNP	O
tests	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
three	CD	O
methods	NNS	O
of	IN	O
evaluation	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
Groups	NNP	O
A	NNP	O
vs.	NN	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
vs.	FW	O
D	NNP	O
,	,	O
while	IN	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
Groups	NNP	O
A	NNP	O
vs.	FW	O
C	NNP	O
,	,	O
A	NNP	O
vs.	NN	O
D	NNP	O
,	,	O
B	NNP	O
vs.	FW	O
C	NNP	O
and	CC	O
B	NNP	O
vs.	FW	O
D.	NNP	O
Based	VBD	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
the	DT	O
size	NN	O
of	IN	O
occlusal	JJ	O
access	NN	O
significantly	RB	O
affected	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
demineralized	JJ	O
tissue	NN	O
removal	NN	O
.	.	O

Are	NNP	O
tyrosine	JJ	O
kinase	NN	O
inhibitors	NNS	O
still	RB	O
active	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	C
renal	NN	C
cell	NN	C
carcinoma	VBZ	C
previously	RB	O
treated	VBN	O
with	IN	O
a	DT	O
tyrosine	JJ	O
kinase	NN	O
inhibitor	NN	O
and	CC	O
everolimus	VB	O
?	.	O
Experience	NNP	O
of	IN	O
36	CD	SS
patients	NNS	O
treated	VBN	O
in	IN	O
France	NNP	O
in	IN	O
the	DT	O
RECORD-1	JJ	O
Trial	NNP	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
the	DT	O
response	NN	O
to	TO	O
treatment	NN	O
is	VBZ	O
limited	JJ	O
,	,	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
carcinoma	NN	O
(	(	O
mRCC	NN	C
)	)	O
typically	RB	O
receive	JJ	O
multiple	NN	O
treatments	NNS	O
.	.	O

Guidelines	NNS	O
recommend	VBP	O
everolimus	NN	O
for	IN	O
patients	NNS	O
previously	RB	O
treated	VBN	O
with	IN	O
tyrosine	JJ	O
kinase	NN	O
inhibitors	NNS	O
(	(	O
TKI	NNP	O
)	)	O
sunitinib	NN	O
or	CC	O
sorafenib	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
TKI	NNP	O
re-treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
disease	JJ	O
progression	NN	O
after	IN	O
a	DT	O
TKI-everolimus	JJ	O
sequence	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Data	NNP	O
were	VBD	O
reviewed	VBN	O
for	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
RECORD-1	NNP	O
(	(	O
Renal	NNP	C
Cell	NNP	C
Cancer	NNP	C
Treatment	NNP	O
With	IN	O
Oral	NNP	O
RAD001	NNP	O
Given	NNP	O
Daily	NNP	O
)	)	O
at	IN	O
French	JJ	O
sites	NNS	O
.	.	O

Response	NNP	O
,	,	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
a	DT	O
TKI-everolimus-TKI	JJ	O
sequence	NN	O
.	.	O

RESULTS	NNP	O
Thirty-six	JJ	O
patients	NNS	O
received	VBD	O
a	DT	O
TKI	NNP	O
after	IN	O
everolimus	NN	O
:	:	O
sunitinib	NN	O
in	IN	O
17	CD	O
patients	NNS	O
,	,	O
sorafenib	NN	O
in	IN	O
15	CD	O
,	,	O
and	CC	O
dovitinib	NN	O
(	(	O
TKI258	NNP	O
)	)	O
in	IN	O
4	CD	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
with	IN	O
TKI	NNP	O
re-treatment	NN	O
was	VBD	O
8	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
disease-control	JJ	O
rate	NN	O
(	(	O
response	NN	O
plus	CC	O
stable	JJ	O
disease	NN	O
)	)	O
was	VBD	O
75	CD	O
%	NN	O
.	.	O

The	DT	O
median	JJ	O
PFS	NNP	O
with	IN	O
each	DT	O
component	NN	O
of	IN	O
the	DT	O
TKI-everolimus-TKI	NNP	O
sequence	NN	O
was	VBD	O
10.7	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.8-28.5	JJ	O
months	NNS	O
)	)	O
,	,	O
8.9	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.7-34.6	JJ	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
8.2	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
5.2-11.9	JJ	O
months	NNS	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
from	IN	O
the	DT	O
start	NN	O
of	IN	O
everolimus	NN	O
was	VBD	O
29.1	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
21.1	CD	O
to	TO	O
not	RB	O
reached	VB	O
months	NNS	O
)	)	O
,	,	O
which	WDT	O
suggests	VBZ	O
a	DT	O
benefit	NN	O
in	IN	O
using	VBG	O
TKI	NNP	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
a	DT	O
TKI-everolimus-TKI	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
clinical	JJ	O
benefit	NN	O
and	CC	O
should	MD	O
be	VB	O
prospectively	RB	O
investigated	VBN	O
.	.	O

Treatment	NN	O
with	IN	O
metformin	NN	O
of	IN	O
non-diabetic	JJ	C
men	NNS	SE
with	IN	O
hypertension	NN	C
,	,	O
hypertriglyceridaemia	NN	C
and	CC	O
central	JJ	C
fat	JJ	C
distribution	NN	C
:	:	O
the	DT	O
BIGPRO	NNP	O
1.2	CD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
trial	NN	O
,	,	O
one	CD	O
year	NN	O
of	IN	O
treatment	NN	O
with	IN	O
metformin	NN	O
in	IN	O
non-diabetic	JJ	C
obese	JJ	C
subjects	NNS	O
with	IN	O
a	DT	O
central	JJ	C
fat	JJ	C
distribution	NN	C
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
fasting	VBG	O
plasma	JJ	O
triglyceride	JJ	O
concentration	NN	O
or	CC	O
on	IN	O
blood	NN	O
pressure	NN	O
despite	IN	O
a	DT	O
decrease	NN	O
in	IN	O
weight	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
insulin	NN	O
and	CC	O
glucose	JJ	O
concentrations	NNS	O
.	.	O

To	TO	O
re-evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
metformin	NN	O
on	IN	O
fasting	VBG	O
triglyceride	JJ	O
concentration	NN	O
and	CC	O
on	IN	O
blood	NN	O
pressure	NN	O
,	,	O
the	DT	O
BIGPRO	NNP	O
1.2	CD	O
trial	NN	O
included	VBD	O
non-diabetic	JJ	C
men	NNS	SE
(	(	O
n=168	NN	SS
)	)	O
with	IN	O
a	DT	O
fasting	VBG	O
plasma	NN	O
triglyceride	JJ	O
concentration	NN	O
>	NN	C
or	CC	C
=1.7	NN	C
and	CC	C
<	NN	C
or	CC	C
=6.5	NN	C
mmol/l	NN	C
,	,	O
high	JJ	C
blood	NN	C
pressure	NN	C
(	(	O
systolic	JJ	O
>	NN	O
or	CC	O
=140	NN	O
and	CC	O
<	NN	O
or	CC	O
=180	VB	O
and/or	JJ	O
diastolic	JJ	O
>	NN	O
or	CC	O
=90	NN	O
and	CC	O
<	NN	O
or	CC	O
=105	NN	O
mmHg	NN	O
,	,	O
or	CC	O
treatment	NN	O
for	IN	O
hypertension	NN	C
)	)	O
and	CC	O
a	DT	O
waist-to-hip	JJ	C
ratio	NN	C
>	NN	C
or	CC	C
=0.95	NN	C
.	.	C

METHODS	NNP	O
A	DT	O
randomised	JJ	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
metformin	NN	O
treatment	NN	O
(	(	O
850	CD	O
mg	RB	O
bid	NN	O
)	)	O
with	IN	O
placebo	NN	O
.	.	O

RESULTS	NNP	O
Metformin	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
either	DT	O
on	IN	O
blood	NN	O
pressure	NN	O
or	CC	O
plasma	NN	O
triglyceride	JJ	O
concentration	NN	O
.	.	O

In	IN	O
comparison	NN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
insulin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.04	CD	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
Apo	NNP	O
B	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.008	CD	O
)	)	O
concentrations	NNS	O
decreased	VBD	O
more	RBR	O
in	IN	O
the	DT	O
metformin	NN	O
group	NN	O
in	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
.	.	O

2	CD	O
trial	NN	O
,	,	O
confirming	VBG	O
most	JJS	O
of	IN	O
the	DT	O
previous	JJ	O
results	NNS	O
of	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
trial	NN	O
.	.	O

Tissue	NNP	O
plasminogen	NN	O
activator	NN	O
antigen	NN	O
concentration	NN	O
decreased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
only	RB	O
in	IN	O
the	DT	O
metformin	NN	O
group	NN	O
,	,	O
but	CC	O
this	DT	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.12	CD	O
)	)	O
;	:	O
further	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
1	CD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
consistency	NN	O
of	IN	O
the	DT	O
two	CD	O
BIGPRO	NNP	O
trials	NNS	O
supports	VBZ	O
the	DT	O
conclusion	NN	O
that	IN	O
metformin	VBZ	O
affects	NNS	O
several	JJ	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
favourably	RB	O
in	IN	O
non-diabetic	JJ	C
subjects	NNS	O
with	IN	O
a	DT	O
central	JJ	C
fat	JJ	C
distribution	NN	C
.	.	O

Outcomes	NNS	O
in	IN	O
a	DT	O
nursing	NN	O
home	NN	O
transition	NN	O
case-management	JJ	O
program	NN	O
targeting	VBG	O
new	JJ	O
admissions	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
Providing	VBG	O
Assistance	NNP	O
to	TO	O
Caregivers	NNPS	O
in	IN	O
Transition	NNP	O
(	(	O
PACT	NNP	O
)	)	O
program	NN	O
offers	NNS	O
nursing	VBG	O
home	NN	O
discharge	NN	O
planning	NN	O
and	CC	O
case	NN	O
management	NN	O
for	IN	O
individuals	NNS	O
in	IN	O
the	DT	O
transitional	JJ	O
period	NN	O
following	VBG	O
a	DT	O
return	NN	O
to	TO	O
the	DT	O
community	NN	O
.	.	O

The	DT	O
PACT	NNP	O
program	NN	O
targeted	VBN	O
individuals	NNS	O
newly	RB	O
admitted	VBN	O
to	TO	O
nursing	VBG	C
homes	NNS	C
and	CC	O
worked	VBD	O
with	IN	O
a	DT	O
family	NN	O
caregiver	NN	O
to	TO	O
develop	VB	O
and	CC	O
implement	VB	O
a	DT	O
nursing	NN	O
home	NN	O
discharge	NN	O
plan	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Reported	NNP	O
are	VBP	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
control	NN	O
design	NN	O
evaluating	VBG	O
the	DT	O
program	NN	O
's	POS	O
effectiveness	NN	O
.	.	O

Those	DT	O
individuals	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	SS
)	)	O
received	VBN	O
PACT	NNP	O
case	NN	O
management	NN	O
in	IN	O
addition	NN	O
to	TO	O
their	PRP$	O
usual	JJ	O
medical	JJ	O
and	CC	O
nursing	NN	O
home	NN	O
care	NN	O
.	.	O

The	DT	O
individuals	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
29	CD	SS
)	)	O
continued	VBD	O
their	PRP$	O
usual	JJ	O
care	NN	O
.	.	O

RESULT	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
discharge	NN	O
rate	NN	O
(	(	O
84	CD	O
%	NN	O
treatment	NN	O
vs	RB	O
76	CD	O
%	NN	O
controls	NNS	O
)	)	O
or	CC	O
in	IN	O
the	DT	O
median	JJ	O
length	NN	O
of	IN	O
stay	NN	O
(	(	O
42	CD	O
days	NNS	O
vs	RB	O
55	CD	O
days	NNS	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
individuals	NNS	O
.	.	O

IMPLICATIONS	NNP	O
Replications	NNPS	O
or	CC	O
extensions	NNS	O
of	IN	O
a	DT	O
PACT-type	JJ	O
intervention	NN	O
might	MD	O
consider	VB	O
a	DT	O
broader	JJR	O
mix	NN	O
of	IN	O
nursing	NN	O
homes	NNS	O
,	,	O
working	VBG	O
directly	RB	O
with	IN	O
the	DT	O
nursing	NN	O
home	NN	O
's	POS	O
admission	NN	O
Minimum	NNP	O
Data	NNP	O
Set	NNP	O
coordinator	NN	O
in	IN	O
patient	JJ	O
selection	NN	O
,	,	O
or	CC	O
working	VBG	O
with	IN	O
Medicare	NNP	O
or	CC	O
Medicaid	NNP	O
HMO	NNP	O
plans	VBZ	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
leisure	NN	O
programme	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
stress	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
ASD	NNP	C
.	.	O

BACKGROUND	NNP	O
Even	RB	O
though	IN	O
there	EX	O
is	VBZ	O
research	NN	O
demonstrating	VBG	O
a	DT	O
positive	JJ	O
relationship	NN	O
between	IN	O
leisure	NN	O
participation	NN	O
and	CC	O
the	DT	O
two	CD	O
constructs	NNS	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
stress	NN	O
reduction	NN	O
,	,	O
current	JJ	O
conceptualisation	NN	O
of	IN	O
leisure	NN	O
as	IN	O
a	DT	O
contributor	NN	O
to	TO	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
improvements	NNS	O
in	IN	O
accurate	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
(	(	O
ASD	NNP	O
)	)	O
at	IN	O
increasingly	RB	O
earlier	JJR	O
ages	NNS	O
and	CC	O
proliferation	NN	O
of	IN	O
interventions	NNS	O
,	,	O
research	NN	O
associated	VBN	O
with	IN	O
leisure	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
people	NNS	O
with	IN	O
ASD	NNP	O
is	VBZ	O
lacking	VBG	O
.	.	O

METHODS	NNP	O
Therefore	NNP	O
,	,	O
a	DT	O
study	NN	O
using	VBG	O
a	DT	O
repeated	JJ	O
measures	NNS	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
effects	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
group	NN	O
leisure	NN	O
programme	NN	O
intended	VBN	O
to	TO	O
facilitate	VB	O
interaction	NN	O
with	IN	O
media	NNS	O
,	,	O
engagement	NN	O
in	IN	O
exercise	NN	O
,	,	O
playing	VBG	O
games	NNS	O
and	CC	O
doing	VBG	O
crafts	NNS	O
,	,	O
attending	VBG	O
events	NNS	O
,	,	O
and	CC	O
participating	VBG	O
in	IN	O
other	JJ	O
recreation	NN	O
activities	NNS	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
stress	NN	O
of	IN	O
37	CD	SS
participants	NNS	O
(	(	O
22	CD	SS
male	NN	SE
,	,	O
15	CD	SS
female	NN	SE
)	)	O
,	,	O
ages	VBZ	O
17-39	JJ	A
(	(	O
M	NNP	O
=	NNP	O
31.49	CD	A
)	)	O
years	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
programme	NN	O
)	)	O
diagnosed	VBD	O
with	IN	O
an	DT	O
ASD	NNP	O
and	CC	O
a	DT	O
group	NN	O
of	IN	O
34	CD	SS
adults	NNS	O
with	IN	O
ASD	NNP	O
as	IN	O
control	NN	O
group	NN	O
(	(	O
waiting	VBG	O
list	NN	O
)	)	O
(	(	O
19	CD	SS
male	NN	SE
,	,	O
15	CD	SS
female	NN	SE
)	)	O
,	,	O
ages	VBZ	O
24-38	JJ	A
(	(	O
M	NNP	O
=	VBZ	O
30	CD	A
at	IN	O
programme	JJ	O
initiation	NN	O
)	)	O
years	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
overall	JJ	O
scores	NNS	O
of	IN	O
stress	NN	O
levels	NNS	O
for	IN	O
participants	NNS	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
four	CD	O
factors	NNS	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
that	WDT	O
were	VBD	O
measured	VBN	O
(	(	O
satisfaction	NN	O
,	,	O
independence	NN	O
,	,	O
competence	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
total	JJ	O
score	NN	O
for	IN	O
quality	NN	O
of	IN	O
life	NN	O
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
demonstrated	VBD	O
no	DT	O
significant	JJ	O
improvements	NNS	O
related	VBN	O
to	TO	O
stress	VB	O
or	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
to	TO	O
leisure	VB	O
services	NNS	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
discussed	VBN	O
.	.	O

CONCLUSION	NNP	O
Findings	NNP	O
support	NN	O
the	DT	O
contention	NN	O
that	WDT	O
participation	NN	O
in	IN	O
recreation	NN	O
activities	NNS	O
positively	RB	O
influenced	VBD	O
the	DT	O
stress	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
adults	NNS	A
with	IN	O
ASD	NNP	O
.	.	O

Warfarin	NNP	O
for	IN	O
atrial	JJ	C
fibrillation	NN	C
.	.	O

The	DT	O
patient	NN	O
's	POS	O
perspective	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
minimal	JJ	O
clinically	RB	O
important	JJ	O
difference	NN	O
(	(	O
MCID	NNP	O
)	)	O
of	IN	O
warfarin	NN	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nonvalvular	JJ	C
atrial	JJ	C
fibrillation	NN	C
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
patients	NNS	O
using	VBG	O
2	CD	O
different	JJ	O
elicitation	NN	O
methods	NNS	O
.	.	O

DESIGN	NNP	O
All	DT	O
patients	NNS	O
completed	VBD	O
2	CD	O
face-to-face	JJ	O
interviews	NNS	O
,	,	O
which	WDT	O
were	VBD	O
2	CD	O
weeks	NNS	O
apart	RB	O
.	.	O

For	IN	O
each	DT	O
interview	NN	O
,	,	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
2	CD	O
elicitation	NN	O
methods	NNS	O
:	:	O
ping-ponging	NN	O
or	CC	O
starting	VBG	O
at	IN	O
the	DT	O
known	JJ	O
efficacy	NN	O
.	.	O

SETTING	CC	O
The	DT	O
practices	NNS	O
of	IN	O
2	CD	O
university-affiliated	JJ	O
family	NN	O
medicine	NN	O
centers	NNS	O
(	(	O
8	CD	O
physicians	NNS	O
each	DT	O
)	)	O
,	,	O
14	CD	O
community-based	JJ	O
family	NN	O
physicians	NNS	O
,	,	O
and	CC	O
2	CD	O
cardiologists	NNS	O
.	.	O

PATIENTS	VB	O
Sixty-four	JJ	SS
patients	NNS	O
with	IN	O
nonvalvular	JJ	C
atrial	JJ	C
fibrillation	NN	C
who	WP	O
were	VBD	O
initiated	VBN	O
with	IN	O
warfarin	JJ	O
therapy	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
before	IN	O
the	DT	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
During	IN	O
each	DT	O
interview	NN	O
,	,	O
the	DT	O
patients	NNS	O
'	POS	O
MCIDs	NNP	O
were	VBD	O
determined	VBN	O
by	IN	O
using	VBG	O
(	(	O
1	CD	O
)	)	O
a	DT	O
pictorial	JJ	O
flip	NN	O
chart	NN	O
to	TO	O
describe	VB	O
atrial	JJ	O
fibrillation	NN	O
;	:	O
the	DT	O
consequences	NNS	O
of	IN	O
a	DT	O
minor	JJ	O
stroke	NN	O
,	,	O
a	DT	O
major	JJ	O
stroke	NN	O
,	,	O
and	CC	O
a	DT	O
major	JJ	O
bleeding	NN	O
episode	NN	O
;	:	O
the	DT	O
chance	NN	O
of	IN	O
stroke	NN	O
if	IN	O
not	RB	O
taking	VBG	O
warfarin	NN	O
;	:	O
the	DT	O
chance	NN	O
of	IN	O
a	DT	O
major	JJ	O
bleeding	NN	O
episode	NN	O
if	IN	O
taking	VBG	O
warfarin	NN	O
;	:	O
examples	NNS	O
of	IN	O
the	DT	O
inconvenience	NN	O
,	,	O
minor	JJ	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
costs	NNS	O
of	IN	O
warfarin	JJ	O
therapy	NN	O
;	:	O
and	CC	O
then	RB	O
(	(	O
2	CD	O
)	)	O
1	CD	O
of	IN	O
the	DT	O
2	CD	O
elicitation	NN	O
methods	NNS	O
to	TO	O
determine	VB	O
their	PRP$	O
MCIDs	NNP	O
(	(	O
the	DT	O
smallest	JJS	O
reduction	NN	O
in	IN	O
stroke	NN	O
risk	NN	O
at	IN	O
which	WDT	O
the	DT	O
patients	NNS	O
were	VBD	O
willing	JJ	O
to	TO	O
take	VB	O
warfarin	NN	O
)	)	O
.	.	O

Patients	NNS	O
'	POS	O
knowledge	NN	O
of	IN	O
their	PRP$	O
stroke	NN	O
risk	NN	O
,	,	O
acceptability	NN	O
of	IN	O
the	DT	O
interview	NN	O
process	NN	O
,	,	O
and	CC	O
factors	NNS	O
determining	VBG	O
their	PRP$	O
preferences	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Given	NNP	O
a	DT	O
baseline	NN	O
risk	NN	O
of	IN	O
having	VBG	O
a	DT	O
stroke	NN	O
in	IN	O
the	DT	O
next	JJ	O
2	CD	O
years	NNS	O
,	,	O
if	IN	O
not	RB	O
taking	VBG	O
warfarin	NN	O
,	,	O
of	IN	O
10	CD	O
of	IN	O
100	CD	O
,	,	O
the	DT	O
mean	JJ	O
MCID	NNP	O
was	VBD	O
2.01	CD	O
of	IN	O
100	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.60-2.42	JJ	O
)	)	O
.	.	O

Fifty-two	JJ	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
would	MD	O
take	VB	O
warfarin	NN	O
for	IN	O
an	DT	O
absolute	JJ	O
decrease	NN	O
in	IN	O
stroke	NN	O
risk	NN	O
of	IN	O
1	CD	O
%	NN	O
over	IN	O
2	CD	O
years	NNS	O
.	.	O

Before	IN	O
eliciting	VBG	O
their	PRP$	O
MCIDs	NNP	O
,	,	O
patients	NNS	O
showed	VBD	O
poor	JJ	O
knowledge	NN	O
of	IN	O
their	PRP$	O
stroke	NN	O
risk	NN	O
,	,	O
which	WDT	O
improved	VBD	O
afterward	RB	O
.	.	O

The	DT	O
interview	NN	O
process	NN	O
was	VBD	O
well	RB	O
accepted	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
MCID	NNP	O
using	VBG	O
the	DT	O
ping-ponging	JJ	O
elicitation	NN	O
method	NN	O
was	VBD	O
1.015	CD	O
of	IN	O
100	CD	O
smaller	JJR	O
compared	VBN	O
with	IN	O
use	NN	O
of	IN	O
the	DT	O
starting	NN	O
at	IN	O
the	DT	O
known	JJ	O
efficacy	NN	O
method	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NN	O
We	PRP	O
were	VBD	O
able	JJ	O
to	TO	O
determine	VB	O
the	DT	O
MCID	NNP	O
of	IN	O
warfarin	NN	O
therapy	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
stroke	NN	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
patients	NNS	O
with	IN	O
nonvalvular	JJ	C
atrial	JJ	C
fibrillation	NN	C
.	.	O

Their	PRP$	O
MCIDs	NNPS	O
were	VBD	O
much	RB	O
smaller	JJR	O
than	IN	O
those	DT	O
that	WDT	O
have	VBP	O
been	VBN	O
implied	VBN	O
by	IN	O
some	DT	O
experts	NNS	O
and	CC	O
clinicians	NNS	O
.	.	O

The	DT	O
interview	NN	O
process	NN	O
,	,	O
using	VBG	O
the	DT	O
flip	JJ	O
chart	NN	O
approach	NN	O
,	,	O
appeared	VBD	O
to	TO	O
improve	VB	O
the	DT	O
patients	NNS	O
'	POS	O
knowledge	NN	O
of	IN	O
their	PRP$	O
disease	NN	O
and	CC	O
its	PRP$	O
consequences	NNS	O
and	CC	O
treatment	NN	O
.	.	O

The	DT	O
method	NN	O
used	VBN	O
to	TO	O
elicit	VB	O
the	DT	O
patients	NNS	O
'	POS	O
MCIDs	NNP	O
can	MD	O
have	VB	O
a	DT	O
clinically	RB	O
important	JJ	O
effect	NN	O
on	IN	O
patient	NN	O
responses	NNS	O
.	.	O

The	DT	O
method	NN	O
used	VBN	O
in	IN	O
our	PRP$	O
study	NN	O
can	MD	O
be	VB	O
generalized	VBN	O
to	TO	O
other	JJ	O
conditions	NNS	O
and	CC	O
,	,	O
thus	RB	O
,	,	O
could	MD	O
be	VB	O
helpful	JJ	O
in	IN	O
3	CD	O
ways	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
from	IN	O
a	DT	O
clinical	JJ	O
decision-making	NN	O
perspective	NN	O
,	,	O
it	PRP	O
could	MD	O
facilitate	VB	O
patient-physician	JJ	O
communication	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
it	PRP	O
could	MD	O
clarify	VB	O
the	DT	O
patient	NN	O
perspective	NN	O
when	WRB	O
interpreting	VBG	O
the	DT	O
results	NNS	O
of	IN	O
previously	RB	O
completed	VBN	O
trials	NNS	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
it	PRP	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
derive	VB	O
more	RBR	O
clinically	RB	O
relevant	JJ	O
sample	NN	O
sizes	NNS	O
for	IN	O
randomized	JJ	O
treatment	NN	O
trials	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
improve	VB	O
colon	NN	O
cancer	NN	O
screening	VBG	O
in	IN	O
rural	JJ	C
family	NN	C
medicine	NN	O
:	:	O
an	DT	O
Iowa	NNP	O
Research	NNP	O
Network	NNP	O
(	(	O
IRENE	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Many	JJ	O
adults	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
screened	VBN	O
for	IN	O
colon	NN	O
cancer	NN	O
,	,	O
a	DT	O
potentially	RB	O
preventable	JJ	O
cause	NN	O
of	IN	O
death	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
conducted	VBN	O
between	IN	O
December	NNP	O
2008	CD	O
and	CC	O
April	NNP	O
2011	CD	O
to	TO	O
improve	VB	O
CRC	NNP	O
screening	VBG	O
in	IN	O
16	CD	O
rural	JJ	O
family	NN	O
physician	NN	O
offices	NNS	O
.	.	O

Subjects	NNS	C
due	JJ	O
for	IN	O
CRC	NNP	C
screening	VBG	C
were	VBD	O
randomized	VBN	O
within	IN	O
each	DT	O
practice	NN	O
to	TO	O
1	CD	O
of	IN	O
4	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
usual	JJ	O
care	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
physician	JJ	O
chart	NN	O
reminder	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
physician	JJ	O
chart	NN	O
reminder	NN	O
,	,	O
mailed	VBN	O
education	NN	O
,	,	O
CRC	NNP	O
reminder	NN	O
magnet	NN	O
,	,	O
and	CC	O
fecal	JJ	O
immunochemical	JJ	O
test	NN	O
(	(	O
FIT	NNP	O
)	)	O
(	(	O
mailed	JJ	O
education/FIT	NN	O
)	)	O
;	:	O
or	CC	O
(	(	O
4	CD	O
)	)	O
all	PDT	O
the	DT	O
preceding	VBG	O
plus	CC	O
a	DT	O
structured	JJ	O
telephone	NN	O
call	NN	O
to	TO	O
the	DT	O
patient	NN	O
from	IN	O
project	JJ	O
staff	NN	O
to	TO	O
provide	VB	O
education	NN	O
,	,	O
assess	JJ	O
interest	NN	O
in	IN	O
screening	VBG	O
,	,	O
explain	VB	O
the	DT	O
screening	NN	O
tests	NNS	O
,	,	O
and	CC	O
address	JJ	O
barriers	NNS	O
(	(	O
mailed	VBN	O
education/FIT	RB	O
plus	CC	O
phone	NN	O
call	NN	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
completion	NN	O
of	IN	O
any	DT	O
CRC	NNP	O
screening	NN	O
.	.	O

RESULTS	VB	O
This	DT	O
study	NN	O
enrolled	VBD	O
743	CD	SS
patients	NNS	O
.	.	O

CRC	NNP	O
screening	NN	O
was	VBD	O
completed	VBN	O
by	IN	O
17.8	CD	O
%	NN	O
in	IN	O
the	DT	O
usual	JJ	O
care	NN	O
group	NN	O
,	,	O
20.5	CD	O
%	NN	O
in	IN	O
the	DT	O
chart	NN	O
reminder	NN	O
group	NN	O
,	,	O
56.5	CD	O
%	NN	O
in	IN	O
the	DT	O
mailed	JJ	O
education/FIT	NN	O
group	NN	O
,	,	O
and	CC	O
57.2	CD	O
%	NN	O
in	IN	O
the	DT	O
mailed	JJ	O
education/FIT	NN	O
plus	CC	O
phone	NN	O
call	NN	O
group	NN	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
effect	NN	O
from	IN	O
the	DT	O
chart	NN	O
reminder	NN	O
compared	VBN	O
with	IN	O
usual	JJ	O
care	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
,	,	O
1.2	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.7-2.0	NNP	O
)	)	O
;	:	O
and	CC	O
a	DT	O
beneficial	JJ	O
effect	NN	O
from	IN	O
the	DT	O
mailed	VBN	O
education/FIT	NN	O
(	(	O
OR	NNP	O
,	,	O
6.0	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
3.7-9.6	JJ	O
)	)	O
and	CC	O
the	DT	O
mailed	JJ	O
education/FIT	NN	O
plus	CC	O
phone	NN	O
call	NN	O
(	(	O
OR	NNP	O
,	,	O
6.2	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
3.8-9.9	JJ	O
)	)	O
.	.	O

Both	DT	O
FIT	NNP	O
and	CC	O
colonoscopy	JJ	O
rates	NNS	O
increased	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
mailed	JJ	O
education	NN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
CRC	NNP	O
screening	VBG	O
rates	NNS	O
increased	VBD	O
significantly	RB	O
among	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
overdue	JJ	O
for	IN	O
screening	VBG	O
after	IN	O
they	PRP	O
received	VBD	O
mailed	VBD	O
educational	JJ	O
materials	NNS	O
and	CC	O
a	DT	O
FIT	NNP	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
a	DT	O
phone	NN	O
call	NN	O
did	VBD	O
not	RB	O
further	JJ	O
increase	NN	O
screening	VBG	O
rates	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
parent-implemented	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
spontaneous	JJ	O
imitation	NN	O
skills	NNS	O
in	IN	O
young	JJ	A
children	NNS	A
with	IN	O
autism	NN	C
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
exhibit	NN	O
significant	JJ	O
deficits	NNS	O
in	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
spontaneously	RB	O
imitate	VB	O
the	DT	O
play	NN	O
actions	NNS	O
and	CC	O
descriptive	JJ	O
gestures	NNS	O
of	IN	O
others	NNS	O
.	.	O

Reciprocal	JJ	O
imitation	NN	O
training	NN	O
(	(	O
RIT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
naturalistic	JJ	O
imitation	NN	O
intervention	NN	O
designed	VBN	O
to	TO	O
teach	VB	O
spontaneous	JJ	O
imitation	NN	O
skills	NNS	O
during	IN	O
play	NN	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
parent-implemented	JJ	O
RIT	NNP	O
using	VBG	O
a	DT	O
multiple-baseline	JJ	O
design	NN	O
across	IN	O
three	CD	SS
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
their	PRP$	O
mothers	NNS	O
.	.	O

After	IN	O
an	DT	O
initial	JJ	O
baseline	NN	O
,	,	O
mothers	NNS	O
were	VBD	O
taught	VBN	O
to	TO	O
implement	VB	O
RIT	NNP	O
techniques	NNS	O
with	IN	O
their	PRP$	O
child	NN	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
10	CD	O
weeks	NNS	O
in	IN	O
a	DT	O
clinic	JJ	O
setting	NN	O
.	.	O

Two	CD	O
mothers	NNS	O
were	VBD	O
taught	VBN	O
to	TO	O
use	VB	O
RIT	NNP	O
to	TO	O
teach	VB	O
object	JJ	O
imitation	NN	O
.	.	O

The	DT	O
third	JJ	O
mother	NN	O
was	VBD	O
taught	VBN	O
to	TO	O
use	VB	O
RIT	NNP	O
to	TO	O
target	VB	O
both	DT	O
object	JJ	O
and	CC	O
gesture	JJ	O
imitation	NN	O
in	IN	O
a	DT	O
multiple-baseline	JJ	O
design	NN	O
across	IN	O
behaviors	NNS	O
.	.	O

Generalization	NNP	O
was	VBD	O
assessed	VBN	O
in	IN	O
the	DT	O
families	NNS	O
'	POS	O
homes	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
and	CC	O
a	DT	O
1-month	JJ	O
follow-up	NN	O
.	.	O

Parents	NNS	O
learned	VBD	O
to	TO	O
use	VB	O
the	DT	O
intervention	NN	O
strategies	NNS	O
and	CC	O
their	PRP$	O
children	NNS	O
exhibited	VBN	O
increases	NNS	O
in	IN	O
spontaneous	JJ	O
imitation	NN	O
.	.	O

These	DT	O
findings	NNS	O
replicate	VBP	O
the	DT	O
results	NNS	O
from	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
RIT	NNP	O
is	VBZ	O
effective	JJ	O
for	IN	O
teaching	VBG	O
imitation	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
in	IN	O
a	DT	O
naturalistic	JJ	O
setting	NN	O
and	CC	O
extend	VB	O
the	DT	O
findings	NNS	O
to	TO	O
parents	NNS	O
.	.	O

Similar	JJ	O
effects	NNS	O
of	IN	O
rofecoxib	NN	O
and	CC	O
indomethacin	NN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
after	IN	O
hip	NN	C
arthroplasty	NN	C
.	.	O

BACKGROUND	NNP	O
Although	IN	O
indomethacin	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
preventing	VBG	O
heterotopic	NN	O
ossification	NN	O
(	(	O
HO	NNP	O
)	)	O
after	IN	O
primary	JJ	C
total	JJ	C
hip	NN	C
arthroplasty	NN	C
,	,	O
side	NN	O
effects	NNS	O
are	VBP	O
frequently	RB	O
observed	VBN	O
.	.	O

In	IN	O
the	DT	O
last	JJ	O
decade	NN	O
a	DT	O
new	JJ	O
class	NN	O
of	IN	O
drugs	NNS	O
--	:	O
the	DT	O
COX-2	NNP	O
selective	JJ	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
--	:	O
has	VBZ	O
been	VBN	O
developed	VBN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
these	DT	O
COX-2	NNP	O
selective	NN	O
NSAIDs	NNP	O
on	IN	O
heterotopic	NN	O
ossification	NN	O
(	(	O
HO	NNP	O
)	)	O
after	IN	O
primary	JJ	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
(	(	O
THA	NNP	O
)	)	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
using	VBG	O
either	CC	O
indomethacin	NN	O
or	CC	O
rofecoxib	NN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

METHODS	NNP	O
186	CD	SS
patients	NNS	O
received	VBD	O
either	RB	O
indomethacin	JJ	O
3	CD	O
times	NNS	O
daily	RB	O
,	,	O
or	CC	O
rofecoxib	VB	O
twice	RB	O
,	,	O
and	CC	O
1	CD	O
placebo	NN	O
,	,	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

HO	NNP	O
was	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
1-year	JJ	O
postoperative	NN	O
radiographs	NN	O
according	VBG	O
to	TO	O
the	DT	O
Brooker	NNP	O
classification	NN	O
.	.	O

RESULTS	NNP	O
12	CD	O
of	IN	O
the	DT	O
186	CD	O
patients	NNS	O
included	VBD	O
discontinued	VBN	O
their	PRP$	O
medication	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

The	DT	O
remaining	VBG	O
174	CD	SS
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
.	.	O

In	IN	O
the	DT	O
indomethacin	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
89	CD	SS
)	)	O
,	,	O
77	CD	O
patients	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
showed	VBD	O
no	DT	O
HO	NNP	O
,	,	O
9	CD	O
showed	VBD	O
HO	NNP	O
of	IN	O
grade	NN	O
1	CD	O
and	CC	O
3	CD	O
showed	VBD	O
HO	NNP	O
of	IN	O
grade	NN	O
2	CD	O
according	VBG	O
to	TO	O
the	DT	O
Brooker	NNP	O
classification	NN	O
.	.	O

In	IN	O
the	DT	O
rofecoxib	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
85	CD	SS
)	)	O
73	CD	O
patients	NNS	O
(	(	O
86	CD	O
%	NN	O
)	)	O
showed	VBD	O
no	DT	O
ossification	NN	O
,	,	O
9	CD	O
showed	VBD	O
grade	NN	O
1	CD	O
,	,	O
and	CC	O
3	CD	O
showed	VBD	O
grade	JJ	O
2	CD	O
.	.	O

INTERPRETATION	VB	O
The	DT	O
prophylactic	JJ	O
effect	NN	O
of	IN	O
rofecoxib	NN	O
for	IN	O
7	CD	O
days	NNS	O
in	IN	O
preventing	VBG	O
heterotopic	NN	O
ossification	NN	O
after	IN	O
primary	JJ	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
is	VBZ	O
comparable	JJ	O
to	TO	O
the	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	O
given	VBN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
development	NN	O
of	IN	O
HO	NNP	O
follows	VBZ	O
a	DT	O
COX-2	JJ	O
pathway	NN	O
.	.	O

Late	JJ	O
patient-reported	JJ	O
toxicity	NN	O
after	IN	O
preoperative	JJ	O
radiotherapy	NN	O
or	CC	O
chemoradiotherapy	NN	O
in	IN	O
nonresectable	JJ	C
rectal	JJ	C
cancer	NN	C
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
Phase	NNP	O
III	NNP	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Preoperative	NNP	O
chemoradiotherapy	NN	O
(	(	O
CRT	NNP	O
)	)	O
is	VBZ	O
superior	JJ	O
to	TO	O
radiotherapy	VB	O
(	(	O
RT	NNP	O
)	)	O
in	IN	O
locally	RB	C
advanced	JJ	C
rectal	JJ	C
cancer	NN	C
,	,	O
but	CC	O
the	DT	O
survival	JJ	O
gain	NN	O
is	VBZ	O
limited	JJ	O
.	.	O

Late	JJ	O
toxicity	NN	O
is	VBZ	O
,	,	O
therefore	RB	O
,	,	O
important	JJ	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
late	JJ	O
bowel	NN	O
,	,	O
urinary	JJ	O
,	,	O
and	CC	O
sexual	JJ	O
functions	NNS	O
after	IN	O
CRT	NNP	O
or	CC	O
RT	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Patients	NNP	O
(	(	O
N	NNP	O
=	NNP	O
207	CD	O
)	)	O
with	IN	O
nonresectable	JJ	O
rectal	JJ	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
preoperative	VB	O
CRT	NNP	O
or	CC	O
RT	NNP	O
(	(	O
2	CD	O
Gy	NNP	O
?	.	O
25	CD	O
?	.	O
5-fluorouracil/leucovorin	JJ	O
)	)	O
.	.	O

Extended	VBN	O
surgery	NN	O
was	VBD	O
often	RB	O
required	VBN	O
.	.	O

Self-reported	JJ	O
late	JJ	O
toxicity	NN	O
was	VBD	O
scored	VBN	O
according	VBG	O
to	TO	O
the	DT	O
LENT	NNP	O
SOMA	NNP	O
criteria	NNS	O
in	IN	O
a	DT	O
structured	JJ	O
telephone	NN	O
interview	NN	O
and	CC	O
with	IN	O
questionnaires	NNS	O
European	JJ	O
Organisation	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
(	(	O
EORTC	NNP	O
)	)	O
Quality	NN	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
QLQ-C30	NNP	O
)	)	O
,	,	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function	NNP	O
(	(	O
IIEF	NNP	O
)	)	O
,	,	O
and	CC	O
sexual	JJ	O
function-vaginal	JJ	O
changes	NNS	O
questionnaire	VBP	O
(	(	O
SVQ	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
105	CD	O
patients	NNS	O
alive	JJ	O
in	IN	O
Norway	NNP	O
and	CC	O
Sweden	NNP	O
after	IN	O
4	CD	O
to	TO	O
12	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
78	CD	O
(	(	O
74	CD	O
%	NN	O
)	)	O
responded	VBD	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
CRT	NNP	O
group	NN	O
had	VBD	O
received	VBN	O
a	DT	O
stoma	NN	O
(	(	O
73	CD	O
%	NN	O
vs.	FW	O
52	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.09	CD	O
)	)	O
.	.	O

Most	JJS	O
patients	NNS	O
without	IN	O
a	DT	O
stoma	NN	O
(	(	O
7	CD	O
of	IN	O
12	CD	O
in	IN	O
CRT	NNP	O
group	NN	O
and	CC	O
9	CD	O
of	IN	O
16	CD	O
in	IN	O
RT	NNP	O
group	NN	O
)	)	O
had	VBD	O
incontinence	NN	O
for	IN	O
liquid	NN	O
stools	NNS	O
or	CC	O
gas	NN	O
.	.	O

No	DT	O
stoma	NN	O
and	CC	O
good	JJ	O
anal	JJ	O
function	NN	O
were	VBD	O
seen	VBN	O
in	IN	O
5	CD	O
patients	NNS	O
(	(	O
11	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
CRT	NNP	O
group	NN	O
and	CC	O
in	IN	O
11	CD	O
(	(	O
30	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
RT	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.046	CD	O
)	)	O
.	.	O

Of	IN	O
44	CD	O
patients	NNS	O
in	IN	O
the	DT	O
CRT	NNP	O
group	NN	O
,	,	O
12	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
had	VBD	O
had	VBN	O
bowel	VBN	O
obstruction	NN	O
compared	VBN	O
with	IN	O
5	CD	O
of	IN	O
33	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
RT	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.27	CD	O
)	)	O
.	.	O

One-quarter	NN	O
of	IN	O
the	DT	O
patients	NNS	O
reported	VBD	O
urinary	JJ	O
incontinence	NN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
men	NNS	O
had	VBD	O
severe	JJ	O
erectile	JJ	O
dysfunction	NN	O
.	.	O

Few	JJ	O
women	NNS	O
reported	VBD	O
sexual	JJ	O
activity	NN	O
during	IN	O
the	DT	O
previous	JJ	O
month	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
majority	NN	O
did	VBD	O
not	RB	O
have	VB	O
concerns	NNS	O
about	IN	O
their	PRP$	O
sex	NN	O
life	NN	O
.	.	O

CONCLUSIONS	NNP	O
Fecal	NNP	O
incontinence	NN	O
and	CC	O
erectile	JJ	O
dysfunction	NN	O
are	VBP	O
frequent	JJ	O
after	IN	O
combined	JJ	O
treatment	NN	O
for	IN	O
locally	RB	O
advanced	JJ	O
rectal	JJ	O
cancer	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
clear	JJ	O
tendency	NN	O
for	IN	O
the	DT	O
problems	NNS	O
to	TO	O
be	VB	O
more	JJR	O
common	JJ	O
after	IN	O
CRT	NNP	O
than	IN	O
after	IN	O
RT	NNP	O
.	.	O

Docosahexaenoic	NNP	O
acid-rich	JJ	O
fish	JJ	O
oil	NN	O
modulates	VBZ	O
the	DT	O
cerebral	JJ	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
cognitive	JJ	O
tasks	NNS	O
in	IN	O
healthy	JJ	C
young	JJ	A
adults	NNS	A
.	.	O

A	DT	O
number	NN	O
of	IN	O
recent	JJ	O
studies	NNS	O
have	VBP	O
assessed	VBN	O
the	DT	O
impact	NN	O
of	IN	O
dietary	JJ	O
omega-3	JJ	O
polyunsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
(	(	O
n-3	JJ	O
PUFAs	NNP	O
)	)	O
on	IN	O
behavioral	JJ	O
outcomes	NNS	O
;	:	O
however	RB	O
,	,	O
very	RB	O
little	JJ	O
attention	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
to	TO	O
their	PRP$	O
impact	NN	O
upon	IN	O
brain	NN	O
function	NN	O
in	IN	O
physiological	JJ	O
terms	NNS	O
.	.	O

Sixty-five	JJ	SS
healthy	JJ	C
adults	NNS	A
aged	VBD	O
18-29yrs	JJ	A
took	VBD	O
part	NN	O
in	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
assessing	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
12	CD	O
weeks	NNS	O
daily	RB	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
docosahexaenoic	JJ	O
acid-rich	JJ	O
fish	JJ	O
oil	NN	O
(	(	O
1g	CD	O
,	,	O
2g	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
olive	JJ	O
oil	NN	O
)	)	O
.	.	O

Relative	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
concentration	NN	O
of	IN	O
oxyhemoglobin	NN	O
and	CC	O
deoxyhemoglobin	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
the	DT	O
prefrontal	JJ	O
cortex	NN	O
using	VBG	O
near-infrared	JJ	O
spectroscopy	NN	O
during	IN	O
performance	NN	O
of	IN	O
nine	CD	O
computerized	JJ	O
cognitive	JJ	O
tasks	NNS	O
.	.	O

Supplementation	NN	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
fish	JJ	O
oil	NN	O
,	,	O
in	IN	O
comparison	NN	O
with	IN	O
placebo	NN	O
,	,	O
resulted	VBD	O
in	IN	O
significantly	RB	O
increased	JJ	O
concentrations	NNS	O
of	IN	O
oxyhemoglobin	NN	O
and	CC	O
total	JJ	O
levels	NNS	O
of	IN	O
hemoglobin	NN	O
,	,	O
indicative	JJ	O
of	IN	O
increased	JJ	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
,	,	O
during	IN	O
the	DT	O
cognitive	JJ	O
tasks	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
tasks	NNS	O
were	VBD	O
not	RB	O
accompanied	VBN	O
by	IN	O
consistent	JJ	O
changes	NNS	O
in	IN	O
cognitive	JJ	O
performance	NN	O
.	.	O

Family	RB	O
education	NN	O
for	IN	O
people	NNS	O
with	IN	O
schizophrenia	NN	C
in	IN	O
Beijing	NNP	O
,	,	O
China	NNP	O
:	:	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Much	NNP	O
of	IN	O
China	NNP	O
lacks	VBZ	O
well-developed	JJ	O
services	NNS	O
for	IN	O
people	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
their	PRP$	O
families	NNS	O
,	,	O
and	CC	O
most	JJS	O
of	IN	O
the	DT	O
existing	VBG	O
services	NNS	O
focus	NN	O
on	IN	O
hospitals	NNS	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
need	NN	O
for	IN	O
culturally	RB	O
sensitive	JJ	O
family	NN	O
treatments	NNS	O
offered	VBN	O
by	IN	O
nurses	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
conduct	VB	O
a	DT	O
longitudinal	JJ	O
experimental	NN	O
study	NN	O
examining	VBG	O
the	DT	O
effect	NN	O
of	IN	O
patient	NN	O
and	CC	O
family	NN	O
education	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
Chinese	JJ	O
people	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
a	DT	O
large	JJ	O
hospital	NN	O
with	IN	O
a	DT	O
was	VBD	O
conducted	VBN	O
in	IN	O
a	DT	O
large	JJ	O
hospital	NN	O
with	IN	O
a	DT	O
sample	NN	O
of	IN	O
101	CD	SS
patients	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
then	RB	O
at	IN	O
3	CD	O
and	CC	O
9	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
family	NN	O
education	NN	O
,	,	O
and	CC	O
data	NNS	O
on	IN	O
their	PRP$	O
knowledge	NN	O
about	IN	O
schizophrenia	NN	O
,	,	O
symptoms	NNS	O
,	,	O
functioning	VBG	O
,	,	O
psychosocial	JJ	O
behaviour	NN	O
,	,	O
relapse	NN	O
and	CC	O
medication	NN	O
adherence	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
knowledge	NN	O
about	IN	O
schizophrenia	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
and	CC	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
symptom	JJ	O
scores	NNS	O
and	CC	O
functioning	VBG	O
at	IN	O
9	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

Patients	NNS	O
who	WP	O
were	VBD	O
nonadherent	JJ	O
to	TO	O
medication	NN	O
regimens	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
relapse	VB	O
.	.	O

CONCLUSIONS	NNP	O
Family	NNP	O
education	NN	O
on	IN	O
schizophrenia	NN	O
by	IN	O
nurses	NNS	O
in	IN	O
China	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
improving	VBG	O
knowledge	NN	O
and	CC	O
promoting	VBG	O
improvement	NN	O
in	IN	O
patients	NNS	O
'	POS	O
symptoms	NNS	O
.	.	O

Once-daily	RB	O
MMX	NNP	O
(	(	O
?	.	O
)	)	O
mesalamine	NN	O
for	IN	O
endoscopic	JJ	O
maintenance	NN	O
of	IN	O
remission	NN	O
of	IN	O
ulcerative	JJ	O
colitis	NN	O
.	.	O

OBJECTIVES	NNP	O
Treatment	NNP	O
with	IN	O
mesalamine	NN	O
to	TO	O
maintain	VB	O
endoscopic	JJ	O
remission	NN	O
(	(	O
mucosal	JJ	O
healing	VBG	O
)	)	O
of	IN	O
ulcerative	JJ	O
colitis	NN	O
(	(	O
UC	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
relapse	NN	O
and	CC	O
is	VBZ	O
the	DT	O
recommended	JJ	O
first-line	JJ	O
maintenance	NN	O
therapy	NN	O
.	.	O

To	TO	O
improve	VB	O
treatment	NN	O
adherence	NN	O
,	,	O
a	DT	O
mesalamine	NN	O
formulation	NN	O
that	WDT	O
can	MD	O
be	VB	O
administered	VBN	O
once-daily	RB	O
,	,	O
MMX	NNP	O
(	(	O
?	.	O
)	)	O
mesalamine	NN	O
(	(	O
Lialda	NNP	O
;	:	O
Shire	NNP	O
Pharmaceuticals	NNP	O
LLC	NNP	O
,	,	O
Wayne	NNP	O
,	,	O
PA	NNP	O
)	)	O
,	,	O
was	VBD	O
developed	VBN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
once-daily	JJ	O
MMX	NNP	O
mesalamine	NN	O
compared	VBN	O
with	IN	O
twice-daily	JJ	O
delayed-release	JJ	O
mesalamine	NN	O
(	(	O
Asacol	NNP	O
;	:	O
Warner	NNP	O
Chilcott	NNP	O
,	,	O
Dublin	NNP	O
,	,	O
Ireland	NNP	O
)	)	O
for	IN	O
maintaining	VBG	O
endoscopic	JJ	O
remission	NN	O
in	IN	O
patients	NNS	O
with	IN	O
UC	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
6-month	JJ	O
,	,	O
active-control	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
non-inferiority	NN	O
of	IN	O
once-daily	JJ	O
MMX	NNP	O
mesalamine	NN	O
2.4	CD	O
g/day	NN	O
compared	VBN	O
with	IN	O
twice-daily	JJ	O
delayed-release	JJ	O
mesalamine	NN	O
at	IN	O
a	DT	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
1.6	CD	O
g/day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
UC	NNP	O
in	IN	O
endoscopic	JJ	O
remission	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
maintenance	NN	O
of	IN	O
endoscopic	JJ	O
remission	NN	O
at	IN	O
month	NN	O
6	CD	O
in	IN	O
the	DT	O
per-protocol	NN	O
(	(	O
PP	NNP	O
)	)	O
population	NN	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
826	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
and	CC	O
dosed	VBN	O
.	.	O

The	DT	O
primary	JJ	O
objective	JJ	O
(	(	O
non-inferiority	NN	O
)	)	O
was	VBD	O
met	VBN	O
.	.	O

At	IN	O
month	NN	O
6	CD	O
,	,	O
83.7	CD	O
and	CC	O
77.8	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
MMX	NNP	O
mesalamine	NN	O
in	IN	O
the	DT	O
PP	NNP	O
and	CC	O
intent-to-treat	NN	O
(	(	O
ITT	NNP	O
)	)	O
populations	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
maintained	VBN	O
endoscopic	JJ	O
remission	NN	O
compared	VBN	O
with	IN	O
81.5	CD	O
%	NN	O
(	(	O
PP	NNP	O
)	)	O
and	CC	O
76.9	CD	O
%	NN	O
(	(	O
ITT	NNP	O
)	)	O
of	IN	O
patients	NNS	O
receiving	VBG	O
delayed-release	JJ	O
mesalamine	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
difference	NN	O
:	:	O
-3.9	CD	O
%	NN	O
,	,	O
8.1	CD	O
%	NN	O
(	(	O
PP	NNP	O
)	)	O
;	:	O
-5.0	CD	O
%	NN	O
,	,	O
6.9	CD	O
%	NN	O
(	(	O
ITT	NNP	O
)	)	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
relapse	VB	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
log-rank	JJ	O
test	NN	O
,	,	O
P=0.5116	NNP	O
(	(	O
PP	NNP	O
)	)	O
;	:	O
P=0.5455	NNP	O
(	(	O
ITT	NNP	O
)	)	O
)	)	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
37.1	CD	O
and	CC	O
36.0	CD	O
%	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
MMX	NNP	O
mesalamine	NN	O
and	CC	O
delayed-release	JJ	O
mesalamine	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Once-daily	JJ	O
dosing	NN	O
of	IN	O
MMX	NNP	O
mesalamine	NN	O
2.4	CD	O
g/day	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
well	RB	O
tolerated	VBN	O
and	CC	O
non-inferior	JJ	O
to	TO	O
twice-daily	JJ	O
dosing	VBG	O
with	IN	O
delayed-release	JJ	O
mesalamine	NN	O
1.6	CD	O
g/day	NN	O
for	IN	O
maintenance	NN	O
of	IN	O
endoscopic	JJ	O
remission	NN	O
in	IN	O
patients	NNS	O
with	IN	O
UC	NNP	O
.	.	O

Arthroscopic	NNP	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
and	CC	O
without	IN	O
acromioplasty	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
full-thickness	JJ	C
rotator	NN	C
cuff	NN	C
tears	NNS	C
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
to	TO	O
compare	VB	O
functional	JJ	O
and	CC	O
quality-of-life	JJ	O
indices	NNS	O
and	CC	O
rates	NNS	O
of	IN	O
revision	NN	O
surgery	NN	O
in	IN	O
arthroscopic	NN	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
and	CC	O
without	IN	O
acromioplasty	JJ	O
.	.	O

METHODS	NNP	O
Eighty-six	JJ	SS
patients	NNS	O
consented	VBN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
intraoperatively	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
,	,	O
and	CC	O
sixty-eight	NN	SS
of	IN	O
them	PRP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
Western	JJ	O
Ontario	NNP	O
Rotator	NNP	O
Cuff	NNP	O
(	(	O
WORC	NNP	O
)	)	O
index	NN	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
the	DT	O
American	JJ	O
Shoulder	NNP	O
and	CC	O
Elbow	NNP	O
Surgeons	NNP	O
(	(	O
ASES	NNP	O
)	)	O
shoulder	NN	O
assessment	JJ	O
form	NN	O
and	CC	O
a	DT	O
count	NN	O
of	IN	O
revisions	NNS	O
required	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
were	VBD	O
completed	VBN	O
preoperatively	RB	O
and	CC	O
at	IN	O
three	CD	O
,	,	O
six	CD	O
,	,	O
twelve	NN	O
,	,	O
eighteen	NN	O
,	,	O
and	CC	O
twenty-four	JJ	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
WORC	NNP	O
and	CC	O
ASES	NNP	O
scores	VBZ	O
improved	VBN	O
significantly	RB	O
in	IN	O
each	DT	O
group	NN	O
over	IN	O
time	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
WORC	NNP	O
or	CC	O
ASES	NNP	O
scores	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
with	IN	O
or	CC	O
without	IN	O
acromioplasty	JJ	O
at	IN	O
any	DT	O
time	NN	O
point	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
scores	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
acromion	NN	O
type	NN	O
,	,	O
nor	CC	O
were	VBD	O
any	DT	O
interaction	NN	O
effects	NNS	O
identified	VBN	O
between	IN	O
group	NN	O
and	CC	O
acromion	NN	O
type	NN	O
.	.	O

Four	CD	O
participants	NNS	O
(	(	O
9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
alone	RB	O
,	,	O
one	CD	O
with	IN	O
a	DT	O
Type-2	JJ	O
and	CC	O
three	CD	O
with	IN	O
a	DT	O
Type-3	JJ	O
acromion	NN	O
,	,	O
required	VBN	O
additional	JJ	O
surgery	NN	O
by	IN	O
the	DT	O
twenty-four-month	JJ	O
time	NN	O
point	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
required	VBD	O
additional	JJ	O
surgery	NN	O
was	VBD	O
greater	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
alone	RB	O
than	IN	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
and	CC	O
acromioplasty	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
previous	JJ	O
research	NN	O
reports	NNS	O
in	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
functional	JJ	O
and	CC	O
quality-of-life	JJ	O
indices	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
or	CC	O
without	IN	O
acromioplasty	JJ	O
.	.	O

The	DT	O
higher	JJR	O
reoperation	NN	O
rate	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
group	NN	O
without	IN	O
acromioplasty	NN	O
.	.	O

Further	CC	O
study	NN	O
that	WDT	O
includes	VBZ	O
follow-up	JJ	O
imaging	NN	O
and	CC	O
patient-reported	JJ	O
outcomes	NNS	O
over	IN	O
a	DT	O
greater	JJR	O
follow-up	JJ	O
period	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Acute	JJ	O
effects	NNS	O
of	IN	O
decaffeinated	JJ	O
coffee	NN	O
and	CC	O
the	DT	O
major	JJ	O
coffee	NN	O
components	NNS	O
chlorogenic	JJ	O
acid	NN	O
and	CC	O
trigonelline	NN	O
on	IN	O
glucose	JJ	C
tolerance	NN	C
.	.	O

OBJECTIVE	NNP	O
Coffee	NNP	O
consumption	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
lower	JJR	O
risk	NN	O
of	IN	O
type	NN	C
2	CD	C
diabetes	NNS	C
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
decaffeinated	JJ	O
coffee	NN	O
and	CC	O
the	DT	O
major	JJ	O
coffee	NN	O
components	NNS	O
chlorogenic	JJ	O
acid	NN	O
and	CC	O
trigonelline	NN	O
on	IN	O
glucose	JJ	O
tolerance	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
crossover	NN	O
trial	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
12	CD	O
g	NN	O
decaffeinated	VBD	O
coffee	NN	O
,	,	O
1	CD	O
g	NN	O
chlorogenic	JJ	O
acid	NN	O
,	,	O
500	CD	O
mg	NN	O
trigonelline	NN	O
,	,	O
and	CC	O
placebo	NN	O
(	(	O
1	CD	O
g	NN	O
mannitol	NN	O
)	)	O
on	IN	O
glucose	NN	O
and	CC	O
insulin	NN	O
concentrations	NNS	O
during	IN	O
a	DT	O
2-h	JJ	O
oral	JJ	O
glucose	NN	O
tolerance	NN	O
test	NN	O
(	(	O
OGTT	NNP	O
)	)	O
in	IN	O
15	CD	SS
overweight	JJ	C
men	NNS	SE
.	.	O

RESULTS	NNP	O
Chlorogenic	NNP	O
acid	NN	O
and	CC	O
trigonelline	NN	O
ingestion	NN	O
significantly	RB	O
reduced	VBN	O
glucose	NN	O
(	(	O
-0.7	JJ	O
mmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
,	,	O
and	CC	O
-0.5	NNP	O
mmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.024	CD	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
insulin	NN	O
(	(	O
-73	JJ	O
pmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.038	CD	O
,	,	O
and	CC	O
-117	NNP	O
pmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
concentrations	NNS	O
15	CD	O
min	NN	O
following	VBG	O
an	DT	O
OGTT	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
treatments	NNS	O
affected	VBD	O
insulin	NN	O
or	CC	O
glucose	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
values	NNS	O
during	IN	O
the	DT	O
OGTT	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Chlorogenic	NNP	O
acid	NN	O
and	CC	O
trigonelline	NN	O
reduced	VBD	O
early	JJ	O
glucose	NN	O
and	CC	O
insulin	NN	O
responses	NNS	O
during	IN	O
an	DT	O
OGTT	NNP	O
.	.	O

Perioperative	JJ	O
myocardial	JJ	O
infarctions	NNS	O
are	VBP	O
common	JJ	O
and	CC	O
often	RB	O
unrecognized	JJ	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
hip	JJ	C
fracture	NN	C
surgery	NN	C
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
incidence	NN	O
and	CC	O
characteristics	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
surgery	NN	C
for	IN	O
acute	JJ	C
hip	NN	C
fracture	NN	C
.	.	O

METHODS	NNP	O
A	NNP	O
consecutive	JJ	O
cohort	NN	O
of	IN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NN	O
200	CD	SS
,	,	O
68	CD	SS
men	NNS	SE
)	)	O
referred	VBD	O
to	TO	O
acute	VB	C
surgical	JJ	C
correction	NN	O
of	IN	O
hip	NN	C
fracture	NN	C
was	VBD	O
studied	VBN	O
.	.	O

Troponin	NNP	O
T	NNP	O
(	(	O
TnT	NNP	O
)	)	O
measurements	NNS	O
and	CC	O
electrocardiographic	JJ	O
(	(	O
ECG	NNP	O
)	)	O
recordings	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
admission	NN	O
,	,	O
before	IN	O
operation	NN	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
first	JJ	O
and	CC	O
2nd	CD	O
postoperative	JJ	O
days	NNS	O
,	,	O
which	WDT	O
were	VBD	O
used	VBN	O
for	IN	O
diagnosis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
ranged	VBD	O
from	IN	O
32	CD	A
to	TO	A
98	CD	A
years	NNS	O
(	(	O
mean	NN	O
,	,	O
80.8	CD	A
years	NNS	A
)	)	O
,	,	O
and	CC	O
65	CD	SS
patients	NNS	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	C
artery	NN	C
disease	NN	C
.	.	O

A	DT	O
significant	JJ	O
rise	NN	O
in	IN	O
TnT	NNP	O
as	IN	O
a	DT	O
sign	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
71	CD	O
patients	NNS	O
(	(	O
35.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
25	CD	O
of	IN	O
them	PRP	O
had	VBD	O
a	DT	O
TnT	NNP	O
elevation	NN	O
exceeding	VBG	O
five	CD	O
times	NNS	O
the	DT	O
upper	JJ	O
normal	JJ	O
limit	NN	O
.	.	O

TnT	NNP	O
elevation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
36	CD	O
patients	NNS	O
(	(	O
51	CD	O
%	NN	O
)	)	O
already	RB	O
before	RB	O
surgery	NN	O
.	.	O

Seven	CD	O
patients	NNS	O
(	(	O
10	CD	O
%	NN	O
)	)	O
had	VBD	O
ST	NNP	O
elevation	NN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
23	CD	O
patients	NNS	O
(	(	O
32	CD	O
%	NN	O
)	)	O
had	VBD	O
new	JJ	O
ST	NNP	O
depressions	NNS	O
,	,	O
and	CC	O
21	CD	O
patients	NNS	O
(	(	O
30	CD	O
%	NN	O
)	)	O
had	VBD	O
no	DT	O
new	JJ	O
ST	NNP	O
segment	NN	O
changes	NNS	O
in	IN	O
the	DT	O
serial	JJ	O
electrocardiographic	JJ	O
recordings	NNS	O
.	.	O

In	IN	O
40	CD	O
patients	NNS	O
(	(	O
56	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
perioperative	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
the	DT	O
first	JJ	O
manifestation	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Multivariate	NNP	O
logistic	JJ	O
regression	NN	O
revealed	VBD	O
that	IN	O
old	JJ	O
age	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
,	,	O
1.06	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.02-1.10	JJ	O
;	:	O
p	VB	O
=	$	O
0.002	CD	O
)	)	O
,	,	O
earlier	JJR	O
revascularization	NN	O
(	(	O
OR	NNP	O
,	,	O
3.29	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.12-9.73	CD	O
;	:	O
p	CC	O
=	VB	O
0.03	CD	O
)	)	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
(	(	O
OR	NNP	O
,	,	O
2.42	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.04-5.61	CD	O
;	:	O
p	CC	O
=	VB	O
0.04	CD	O
)	)	O
were	VBD	O
independent	JJ	O
predictors	NNS	O
of	IN	O
TnT	NNP	O
elevation	NN	O
.	.	O

Majority	NNP	O
of	IN	O
myocardial	JJ	O
infarctions	NNS	O
were	VBD	O
asymptomatic	JJ	O
or	CC	O
unrecognized	JJ	O
.	.	O

Evidence-based	JJ	O
medications	NNS	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
seldom	RB	O
started	VBN	O
and	CC	O
cardiologist	NN	O
was	VBD	O
consulted	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
(	(	O
16.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	JJ	O
Patients	NNS	O
with	IN	O
hip	JJ	O
fracture	NN	O
often	RB	O
develop	VBZ	O
asymptomatic	JJ	O
and	CC	O
clinically	RB	O
unrecognized	JJ	O
perioperative	JJ	O
myocardial	JJ	O
infarctions	NNS	O
.	.	O

Earlier	JJR	O
diagnosis	NN	O
and	CC	O
appropriate	JJ	O
treatment	NN	O
of	IN	O
cardiac	JJ	O
infarction	NN	O
may	MD	O
improve	VB	O
survival	NN	O
of	IN	O
hip	NN	O
fracture	NN	O
patients	NNS	O
.	.	O

LEVEL	NNP	O
OF	IN	O
EVIDENCE	NNP	O
Epidemiologic	NNP	O
study	NN	O
,	,	O
level	NN	O
III	NNP	O
.	.	O

Short-term	JJ	O
studies	NNS	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
glycerol	NN	O
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
continuous	JJ	C
ambulatory	JJ	C
peritoneal	JJ	C
dialysis	NN	C
(	(	O
CAPD	NNP	C
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
glycerol	NN	O
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
two	CD	O
different	JJ	O
concentrations	NNS	O
(	(	O
92	CD	O
mmol/l	NN	O
and	CC	O
272	CD	O
mmol/l	NN	O
)	)	O
in	IN	O
peritoneal	JJ	O
dialysis	NN	O
fluid	NN	O
was	VBD	O
investigated	VBN	O
over	IN	O
3	CD	O
days	NNS	O
in	IN	O
six	CD	SS
patients	NNS	O
on	IN	O
continuous	JJ	C
ambulatory	JJ	C
peritoneal	JJ	C
dialysis	NN	C
and	CC	O
compared	VBN	O
with	IN	O
two	CD	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
(	(	O
76	CD	O
mmol/l	NN	O
and	CC	O
215	CD	O
mmol/l	NN	O
)	)	O
in	IN	O
the	DT	O
same	JJ	O
patients	NNS	O
.	.	O

The	DT	O
calorific	JJ	O
value	NN	O
of	IN	O
the	DT	O
absorbed	JJ	O
osmotic	JJ	O
agent	NN	O
was	VBD	O
lower	JJR	O
,	,	O
by	IN	O
19	CD	O
%	NN	O
with	IN	O
isotonic	JJ	O
and	CC	O
22	CD	O
%	NN	O
with	IN	O
hypertonic	JJ	O
solutions	NNS	O
,	,	O
when	WRB	O
glycerol	NN	O
was	VBD	O
used	VBN	O
in	IN	O
place	NN	O
of	IN	O
glucose	NN	O
.	.	O

However	RB	O
,	,	O
glycerol	NN	O
provided	VBD	O
significantly	RB	O
lower	JJR	O
total	JJ	O
ultrafiltration	NN	O
than	IN	O
glucose	NN	O
at	IN	O
each	DT	O
concentration	NN	O
,	,	O
despite	IN	O
a	DT	O
higher	JJR	O
initial	JJ	O
osmotic	JJ	O
pressure	NN	O
of	IN	O
the	DT	O
glycerol-based	JJ	O
solutions	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
higher	JJR	O
concentration	NN	O
of	IN	O
glycerol	NN	O
required	VBN	O
to	TO	O
provide	VB	O
equal	JJ	O
ultrafiltration	NN	O
may	MD	O
offset	VB	O
any	DT	O
calorific	JJ	O
advantage	NN	O
.	.	O

Equilibration	NN	O
of	IN	O
creatinine	NN	O
and	CC	O
urea	NN	O
was	VBD	O
slower	JJR	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
lower	RBR	O
with	IN	O
glycerol	NN	O
.	.	O

Solutions	NNS	O
containing	VBG	O
glycerol	NN	O
were	VBD	O
initially	RB	O
less	JJR	O
acid	JJ	O
(	(	O
pH	JJ	O
6.5	CD	O
)	)	O
than	IN	O
those	DT	O
containing	VBG	O
glucose	NN	O
(	(	O
pH	JJ	O
5.1	CD	O
)	)	O
.	.	O

Blood	NNP	O
glycerol	NN	O
levels	NNS	O
,	,	O
which	WDT	O
were	VBD	O
in	IN	O
the	DT	O
physiological	JJ	O
range	NN	O
with	IN	O
glucose	NN	O
as	IN	O
the	DT	O
osmotic	JJ	O
agent	NN	O
,	,	O
reached	VBD	O
a	DT	O
peak	JJ	O
80-fold	JJ	O
greater	JJR	O
at	IN	O
4.3	CD	O
+/-	JJ	O
0.8	CD	O
mmol/l	NN	O
during	IN	O
dialysis	NN	O
with	IN	O
fluid	NN	O
containing	VBG	O
glycerol	NN	O
at	IN	O
272	CD	O
mmol/l	NN	O
and	CC	O
eightfold	VB	O
higher	JJR	O
at	IN	O
0.42	CD	O
+/-	JJ	O
0.09	CD	O
mmol/l	NN	O
with	IN	O
glycerol	NN	O
at	IN	O
92	CD	O
mmol/l	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
haemolysis	NN	O
or	CC	O
other	JJ	O
toxic	JJ	O
effect	NN	O
despite	IN	O
these	DT	O
levels	NNS	O
.	.	O

The	DT	O
rise	NN	O
in	IN	O
blood	NN	O
glucose	NN	O
and	CC	O
insulin	NN	O
noted	VBD	O
during	IN	O
the	DT	O
use	NN	O
of	IN	O
glucose-based	JJ	O
solutions	NNS	O
was	VBD	O
not	RB	O
found	VBN	O
with	IN	O
glycerol	NN	O
.	.	O

Circulating	NNP	O
levels	NNS	O
of	IN	O
lactate	NN	O
,	,	O
pyruvate	NN	O
,	,	O
alanine	NN	O
,	,	O
non-esterified	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
the	DT	O
ketone	NN	O
bodies	NNS	O
were	VBD	O
similar	JJ	O
with	IN	O
the	DT	O
two	CD	O
agents	NNS	O
.	.	O

Although	IN	O
these	DT	O
short-term	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
no	DT	O
conclusive	JJ	O
advantage	NN	O
of	IN	O
glycerol	NN	O
over	IN	O
glucose	JJ	O
,	,	O
long-term	JJ	O
effects	NNS	O
of	IN	O
glycerol	NN	O
,	,	O
particularly	RB	O
on	IN	O
circulating	VBG	O
lipid	JJ	O
levels	NNS	O
,	,	O
will	MD	O
determine	VB	O
its	PRP$	O
future	JJ	O
role	NN	O
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
continuous	JJ	O
ambulatory	JJ	C
peritoneal	JJ	C
dialysis	NN	C
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
imiquimod	JJ	O
5	CD	O
%	NN	O
cream	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
to	TO	O
curettage	VB	O
and	CC	O
electrodesiccation	NN	O
for	IN	O
nodular	JJ	C
basal	NN	C
cell	NN	C
carcinoma	NN	C
.	.	O

BACKGROUND	NNP	O
Curettage	NNP	O
and	CC	O
electrodesiccation	NN	O
(	(	O
C	NNP	O
&	CC	O
D	NNP	O
)	)	O
is	VBZ	O
a	DT	O
widely	RB	O
used	VBN	O
method	NN	O
to	TO	O
treat	VB	O
nodular	JJ	C
basal	NN	C
cell	NN	C
carcinoma	NN	C
(	(	O
BCC	NNP	C
)	)	O
.	.	O

However	RB	O
,	,	O
residual	JJ	O
tumor	NN	O
is	VBZ	O
present	JJ	O
immediately	RB	O
after	IN	O
the	DT	O
procedure	NN	O
in	IN	O
approximately	RB	O
20	CD	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
cases	NNS	O
.	.	O

Imiquimod	NNP	O
,	,	O
a	DT	O
topical	JJ	O
immune	NN	O
response	NN	O
modifier	NN	O
that	WDT	O
targets	VBZ	O
Toll-like	NNP	O
receptor	NN	O
7	CD	O
,	,	O
is	VBZ	O
currently	RB	O
approved	VBN	O
for	IN	O
superficial	JJ	O
BCC	NNP	O
.	.	O

OBJECTIVE	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
,	,	O
the	DT	O
administration	NN	O
of	IN	O
imiquimod	NN	O
after	IN	O
C	NNP	O
&	CC	O
D	NNP	O
was	VBD	O
investigated	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
combination	NN	O
regimen	NNS	O
would	MD	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
residual	JJ	O
tumor	NN	O
compared	VBN	O
with	IN	O
C	NNP	O
&	CC	O
D	NNP	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
nodular	JJ	C
BCC	NNP	C
.	.	O

METHODS	NNP	O
Twenty	NNP	SS
patients	NNS	O
received	VBD	O
three	CD	O
cycles	NNS	O
of	IN	O
C	NNP	O
&	CC	O
D	NNP	O
followed	VBN	O
by	IN	O
imiquimod	JJ	O
5	CD	O
%	NN	O
or	CC	O
vehicle	NN	O
cream	NN	O
once	RB	O
daily	JJ	O
for	IN	O
1	CD	O
month	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
residual	JJ	O
tumor	NN	O
.	.	O

The	DT	O
secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
the	DT	O
time	NN	O
to	TO	O
heal	VB	O
and	CC	O
cosmetic	JJ	O
appearance	NN	O
.	.	O

RESULTS	NNP	O
Twenty	NNP	SS
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
imiquimod	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	SS
)	)	O
or	CC	O
vehicle	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	SS
)	)	O
treatment	NN	O
group	NN	O
.	.	O

At	IN	O
8	CD	O
weeks	NNS	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
residual	JJ	O
tumor	NN	O
was	VBD	O
substantially	RB	O
decreased	VBN	O
with	IN	O
imiquimod	JJ	O
therapy	NN	O
(	(	O
10	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
vehicle	NN	O
(	(	O
40	CD	O
%	NN	O
)	)	O
.	.	O

Wounds	VBZ	O
in	IN	O
the	DT	O
vehicle	NN	O
group	NN	O
healed	VBD	O
more	RBR	O
quickly	RB	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
imiquimod	NN	O
group	NN	O
,	,	O
although	IN	O
by	IN	O
8	CD	O
weeks	NNS	O
,	,	O
all	DT	O
excision	NN	O
sites	NNS	O
were	VBD	O
healed	VBN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
scars	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
atrophic	JJ	O
and	CC	O
hypopigmented	VBD	O
,	,	O
whereas	IN	O
most	JJS	O
scars	NNS	O
in	IN	O
the	DT	O
imiquimod	NN	O
group	NN	O
were	VBD	O
flat	JJ	O
and	CC	O
slightly	RB	O
pink	VBP	O
.	.	O

CONCLUSION	NNP	O
Imiquimod	NNP	O
5	CD	O
%	NN	O
cream	NN	O
once	RB	O
daily	JJ	O
for	IN	O
1	CD	O
month	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
after	IN	O
C	NNP	O
&	CC	O
D	NNP	O
substantially	RB	O
reduced	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
residual	JJ	O
tumor	NN	O
and	CC	O
improved	VBD	O
the	DT	O
cosmetic	JJ	O
appearance	NN	O
compared	VBN	O
with	IN	O
C	NNP	O
&	CC	O
D	NNP	O
alone	RB	O
.	.	O

These	DT	O
preliminary	JJ	O
results	NNS	O
suggest	VBP	O
that	IN	O
further	JJ	O
studies	NNS	O
to	TO	O
investigate	VB	O
imiquimod	JJ	O
adjunctive	JJ	O
therapy	NN	O
are	VBP	O
warranted	VBN	O
.	.	O

Differential	JJ	O
effects	NNS	O
of	IN	O
amino	NN	O
acid	NN	O
and	CC	O
ketoacid	VB	O
on	IN	O
protein	NN	O
metabolism	NN	O
in	IN	O
humans	NNS	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
,	,	O
amino	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
,	,	O
and	CC	O
branched-chain	JJ	O
ketoacid	NN	O
(	(	O
KA	NNP	O
)	)	O
availability	NN	O
on	IN	O
leucine	JJ	O
kinetics	NNS	O
in	IN	O
eight	CD	SS
healthy	JJ	C
volunteers	NNS	O
(	(	O
age	NN	O
=	VBZ	O
22	CD	A
+/-	JJ	A
2	CD	A
y	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
=	VBD	O
24	CD	C
+/-	JJ	C
1	CD	C
kg	NN	C
)	)	O
by	IN	O
using	VBG	O
the	DT	O
euglycemic	JJ	O
insulin	NN	O
clamp	NN	O
and	CC	O
[	JJ	O
1-14C	JJ	O
]	NNP	O
leucine	NN	O
turnover	NN	O
techniques	NNS	O
.	.	O

Four	CD	O
experimental	JJ	O
conditions	NNS	O
were	VBD	O
studied	VBN	O
:	:	O
study	NN	O
I	PRP	O
,	,	O
hyperinsulinemia	NN	O
;	:	O
study	NN	O
II	NNP	O
,	,	O
hyperinsulinemia	NN	O
with	IN	O
maintenance	NN	O
of	IN	O
basal	NN	O
plasma	NN	O
AA	NNP	O
and	CC	O
branched-chain	JJ	O
KA	NNP	O
concentrations	NNS	O
;	:	O
study	NN	O
III	NNP	O
,	,	O
hyperinsulinemia	NN	O
with	IN	O
hyperaminoacidemia	NN	O
and	CC	O
basal	NN	O
plasma	VBP	O
branched-chain	NN	O
KA	NNP	O
concentrations	NNS	O
;	:	O
and	CC	O
study	VB	O
IV	NNP	O
,	,	O
hyperinsulinemia	NN	O
plus	CC	O
basal	NN	O
plasma	VBP	O
AA	NNP	O
concentrations	NNS	O
and	CC	O
elevated	VBD	O
branched-chain	NN	O
KA	NNP	O
levels	NNS	O
.	.	O

Basal	NNP	O
endogenous	JJ	O
leucine	NN	O
flux	NN	O
(	(	O
ELF	NNP	O
)	)	O
averaged	VBD	O
1.20	CD	O
+/-	JJ	O
0.05	CD	O
(	(	O
mumol.kg-1.min-1	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
)	)	O
;	:	O
basal	CC	O
leucine	JJ	O
oxidation	NN	O
(	(	O
LOX	NNP	O
)	)	O
was	VBD	O
0.25	CD	O
+/-	JJ	O
0.01	CD	O
;	:	O
and	CC	O
basal	VB	O
non-oxidative	JJ	O
leucine	NN	O
disposal	NN	O
(	(	O
NOLD	NNP	O
)	)	O
was	VBD	O
0.95	CD	O
+/-	JJ	O
0.04	CD	O
.	.	O

ELF	NNP	O
significantly	RB	O
decreased	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.77	CD	O
+/-	JJ	O
0.06	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
.	.	O

When	WRB	O
plasma	NN	O
AA	NNP	O
and	CC	O
branched-chain	JJ	O
KA	NNP	O
were	VBD	O
either	RB	O
maintained	VBN	O
at	IN	O
their	PRP$	O
basal	NN	O
levels	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
or	CC	O
increased	VBN	O
above	IN	O
baseline	NN	O
values	NNS	O
(	(	O
studies	NNS	O
III	NNP	O
and	CC	O
IV	NNP	O
)	)	O
,	,	O
ELF	NNP	O
declined	VBD	O
further	RBR	O
(	(	O
0.64	CD	O
+/-	JJ	O
0.05	CD	O
,	,	O
0.66	CD	O
+/-	JJ	O
0.02	CD	O
,	,	O
and	CC	O
0.66	CD	O
+/-	JJ	O
0.03	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
respectively	RB	O
;	:	O
all	DT	O
Ps	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
basal	NN	O
and	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
study	NN	O
I	PRP	O
)	)	O
.	.	O

LOX	NNP	O
declined	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.12	CD	O
+/-	JJ	O
0.02	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
but	CC	O
increased	VBD	O
significantly	RB	O
in	IN	O
studies	NNS	O
II	NNP	O
,	,	O
III	NNP	O
,	,	O
and	CC	O
IV	NNP	O
(	(	O
0.31	CD	O
+/-	JJ	O
0.04	CD	O
,	,	O
0.37	CD	O
+/-	JJ	O
0.03	CD	O
,	,	O
and	CC	O
0.40	CD	O
+/-	JJ	O
0.03	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
respectively	RB	O
,	,	O
all	DT	O
Ps	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
basal	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
study	NN	O
IV	NNP	O
versus	NN	O
study	NN	O
II	NNP	O
,	,	O
and	CC	O
P	NNP	O
<	NNP	O
0.05	CD	O
study	NN	O
III	NNP	O
versus	NN	O
study	NN	O
II	NNP	O
)	)	O
.	.	O

NOLD	NNP	O
declined	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.65	CD	O
+/-	JJ	O
0.05	CD	O
mumol/kg.min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
,	,	O
whereas	IN	O
neither	CC	O
the	DT	O
maintenance	NN	O
of	IN	O
basal	NN	O
plasma	IN	O
AA/branched-chain	NNP	O
KA	NNP	O
levels	NNS	O
(	(	O
study	NN	O
II	NNP	O
;	:	O
0.89	CD	O
+/-	JJ	O
0.2	CD	O
mumol.kg-1.min-1	NN	O
)	)	O
nor	CC	O
the	DT	O
elevation	NN	O
of	IN	O
plasma	JJ	O
branched-chain	JJ	O
KA	NNP	O
concentration	NN	O
(	(	O
study	JJ	O
IV	NNP	O
;	:	O
0.96	CD	O
+/-	JJ	O
0.1	CD	O
mumol.kg-1.min-1	NN	O
)	)	O
increased	VBD	O
NOLD	NNP	O
above	IN	O
baseline	NN	O
level	NN	O
.	.	O

A	DT	O
stimulation	NN	O
of	IN	O
NOLD	NNP	O
was	VBD	O
observed	VBN	O
only	RB	O
when	WRB	O
plasma	JJ	O
AA	NNP	O
levels	NNS	O
were	VBD	O
increased	VBN	O
(	(	O
study	NN	O
III	NNP	O
;	:	O
1.23	CD	O
+/-	JJ	O
0.03	CD	O
mumol/kg.min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
present	JJ	O
data	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
concept	NN	O
of	IN	O
a	DT	O
direct	JJ	O
anabolic	JJ	O
action	NN	O
of	IN	O
ketoanalogs	NNS	O
but	CC	O
do	VBP	O
provide	VB	O
additional	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
pivotal	JJ	O
role	NN	O
of	IN	O
AA	NNP	O
availability	NN	O
in	IN	O
the	DT	O
stimulation	NN	O
of	IN	O
whole-body	NN	O
protein	NN	O
synthesis	NN	O
.	.	O

Somatostatin	NNP	O
and	CC	O
ranitidine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
non-variceal	JJ	C
upper	JJ	C
gastrointestinal	JJ	C
bleeding	NN	C
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	NN	O
,	,	O
controlled	VBN	O
study	NN	O
.	.	O

BACKGROUND/AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
somatostatin	NN	O
vs.	FW	O
ranitidine	NN	O
in	IN	O
controlling	VBG	O
acute	JJ	C
non-variceal	JJ	C
gastrointestinal	JJ	C
bleeding	NN	C
.	.	O

METHODOLOGY	NNP	O
A	NNP	O
total	NN	O
of	IN	O
48	CD	SS
patients	NNS	O
with	IN	O
acute	JJ	C
upper	JJ	C
gastrointestinal	NN	C
bleeding	NN	C
due	JJ	O
to	TO	O
duodenal	JJ	C
or	CC	C
gastric	JJ	C
ulcer	NN	C
were	VBD	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
consisted	VBD	O
of	IN	O
15	CD	SS
patients	NNS	O
with	IN	O
Forrest	NNP	O
IB	NNP	O
and	CC	O
Group	NNP	O
II	NNP	O
consisted	VBD	O
of	IN	O
30	CD	SS
patients	NNS	O
with	IN	O
Forrest	NNP	O
II	NNP	O
.	.	O

Two	CD	O
regimens	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
all	DT	O
patients	NNS	O
within	IN	O
half	PDT	O
an	DT	O
hour	NN	O
after	IN	O
the	DT	O
endoscopic	JJ	O
procedure	NN	O
:	:	O
1	CD	O
)	)	O
somatostatin-UCB	NN	O
250	CD	O
mcg	NN	O
i.v	NN	O
.	.	O

bolus	CC	O
followed	VBN	O
by	IN	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
6	CD	O
mg/d	NN	O
for	IN	O
72	CD	O
h	NN	O
,	,	O
or	CC	O
2	CD	O
)	)	O
ranitidine	NN	O
300	CD	O
mg/d	NN	O
by	IN	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
for	IN	O
72	CD	O
h.	JJ	O
RESULTS	NNP	O
In	IN	O
Group	NNP	O
I	PRP	O
,	,	O
although	IN	O
mean	JJ	O
blood	NN	O
transfusion	NN	O
requirements	NNS	O
(	(	O
no	DT	O
.	.	O

of	IN	O
units	NNS	O
)	)	O
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
somatostatin	NN	O
than	IN	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
ranitidine	NN	O
,	,	O
this	DT	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
2.56	CD	O
+/-	JJ	O
3.05	CD	O
vs.	FW	O
5.17	CD	O
+/-	JJ	O
4.96	CD	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
;	:	O
the	DT	O
time	NN	O
of	IN	O
bleeding	VBG	O
stop	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
somatostatin	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
ranitidine	NN	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
3.24	CD	O
+/-	JJ	O
2.45	CD	O
vs.	FW	O
11.25	CD	O
+/-	JJ	O
11.63	CD	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.0383	CD	O
)	)	O
.	.	O

The	DT	O
rebleeding	NN	O
and	CC	O
the	DT	O
mortality	NN	O
rates	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
both	DT	O
Group	NNP	O
I	PRP	O
and	CC	O
Group	NNP	O
II	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Somatostatin	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
ranitidine	NN	O
in	IN	O
controlling	VBG	O
acute	JJ	O
non-variceal	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Forrest	NNP	O
IB	NNP	O
bleeding	NN	O
activity	NN	O
.	.	O

Somatostatin	NNP	O
has	VBZ	O
no	DT	O
additional	JJ	O
benefit	NN	O
in	IN	O
those	DT	O
with	IN	O
Forrest	NNP	O
II	NNP	O
bleeding	NN	O
activity	NN	O
.	.	O

Phytase	NNP	O
and	CC	O
1alpha-hydroxycholecalciferol	JJ	O
supplementation	NN	O
of	IN	O
broiler	NN	C
chickens	NNS	C
during	IN	O
the	DT	O
starting	NN	O
and	CC	O
growing/finishing	NN	O
phases	NNS	O
.	.	O

Supplemental	JJ	O
1alpha-hydroxycholecalciferol	JJ	O
(	(	O
1alpha-OHD3	JJ	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
qualitatively	RB	O
similar	JJ	O
and	CC	O
quantitatively	RB	O
additive	JJ	O
effects	NNS	O
to	TO	O
exogenous	JJ	O
phytase	NN	O
.	.	O

Two	CD	O
experiments	NNS	O
were	VBD	O
conducted	VBN	O
from	IN	O
0	CD	O
to	TO	O
35	CD	O
d	NN	O
in	IN	O
floor	NN	O
pens	NNS	O
to	TO	O
determine	VB	O
the	DT	O
additive	JJ	O
effect	NN	O
of	IN	O
phytase	NN	O
and	CC	O
1alpha-OHD3	JJ	O
when	WRB	O
supplemented	VBN	O
to	TO	O
Ca-	NNP	O
and	CC	O
P-deficient	NNP	O
diets	NNS	O
.	.	O

In	IN	O
both	DT	O
experiments	NNS	O
,	,	O
at	IN	O
least	JJS	O
4	CD	O
replicates	NNS	O
per	IN	O
treatment	NN	O
(	(	O
50	CD	SS
chicks	NNS	O
per	IN	O
replicate	NN	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O

Corn-soybean-meal-and	JJ	O
soybean-oil-based	JJ	O
diets	NNS	O
were	VBD	O
fed	VBN	O
and	CC	O
birds	NNS	O
were	VBD	O
raised	VBN	O
in	IN	O
a	DT	O
house	NN	O
impervious	JJ	O
to	TO	O
ultraviolet	VB	O
light	NN	O
.	.	O

During	IN	O
the	DT	O
starter	JJ	O
phase	NN	O
(	(	O
ST	NNP	O
)	)	O
,	,	O
from	IN	O
0	CD	O
to	TO	O
18	CD	O
d	NN	O
,	,	O
chicks	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
23	CD	O
%	NN	O
CP	NNP	O
diet	JJ	O
containing	VBG	O
0.60	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.47	CD	O
%	NN	O
total	JJ	O
P	NNP	O
(	(	O
tP	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
grower/finisher	NN	O
phase	NN	O
(	(	O
GF	NNP	O
)	)	O
,	,	O
from	IN	O
19	CD	O
to	TO	O
35	CD	O
d	NN	O
,	,	O
birds	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
19	CD	O
%	NN	O
CP	NNP	O
diet	JJ	O
containing	VBG	O
0.30	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.37	CD	O
%	NN	O
tP	NN	O
.	.	O

A	DT	O
combination	NN	O
of	IN	O
1,000	CD	O
phytase	NN	O
units/kg	NN	O
of	IN	O
Natuphos	NNP	O
phytase	NN	O
and	CC	O
5	CD	O
microg/kg	NN	O
of	IN	O
1alpha-OHD3	JJ	O
(	(	O
P+1A	NNP	O
)	)	O
was	VBD	O
supplemented	VBN	O
to	TO	O
some	DT	O
of	IN	O
the	DT	O
feed	NN	O
during	IN	O
the	DT	O
ST	NNP	O
and	CC	O
GF	NNP	O
.	.	O

Diets	NNS	O
containing	VBG	O
adequate	NN	O
Ca	NNP	O
and	CC	O
P	NNP	O
were	VBD	O
also	RB	O
fed	VBN	O
during	IN	O
the	DT	O
ST	NNP	O
(	(	O
0.90	CD	O
%	NN	O
Ca	NNP	O
,	,	O
0.68	CD	O
%	NN	O
tP	NN	O
)	)	O
and	CC	O
GF	NNP	O
(	(	O
0.80	CD	O
%	NN	O
Ca	NNP	O
,	,	O
0.67	CD	O
%	NN	O
tP	NN	O
)	)	O
.	.	O

Performance	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
rickets	NNS	O
and	CC	O
tibial	JJ	O
dyschondroplasia	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
18	CD	O
and	CC	O
35	CD	O
d.	NN	O
In	IN	O
experiment	JJ	O
1	CD	O
,	,	O
unsupplemented	JJ	O
chicks	NNS	O
performed	VBN	O
well	RB	O
but	CC	O
had	VBD	O
considerable	JJ	O
leg	JJ	O
problems	NNS	O
.	.	O

Chicks	NNP	O
fed	VBD	O
P+1A	NNP	O
during	IN	O
the	DT	O
ST	NNP	O
or	CC	O
GF	NNP	O
did	VBD	O
not	RB	O
perform	VB	O
as	RB	O
well	RB	O
as	IN	O
birds	NNS	O
fed	VBN	O
P+1A	NNP	O
throughout	IN	O
.	.	O

Birds	NNS	O
fed	VBD	O
P+1A	NNP	O
throughout	IN	O
performed	VBN	O
as	IN	O
well	RB	O
birds	NNS	O
fed	VBD	O
the	DT	O
adequate	JJ	O
diets	NNS	O
without	IN	O
any	DT	O
indication	NN	O
of	IN	O
leg	NN	O
problems	NNS	O
.	.	O

In	IN	O
experiment	JJ	O
2	CD	O
,	,	O
unsupplemented	JJ	O
birds	NNS	O
performed	VBD	O
similarly	RB	O
to	TO	O
unsupplemented	JJ	O
birds	NNS	O
in	IN	O
experiment	JJ	O
1	CD	O
.	.	O

However	RB	O
,	,	O
chicks	NNS	O
fed	VBP	O
the	DT	O
supplements	NNS	O
or	CC	O
the	DT	O
control	JJ	O
diets	NNS	O
did	VBD	O
not	RB	O
perform	VB	O
as	RB	O
well	RB	O
or	CC	O
accumulate	VB	O
as	IN	O
much	JJ	O
bone	NN	O
ash	NN	O
as	IN	O
birds	NNS	O
in	IN	O
experiment	JJ	O
1	CD	O
,	,	O
although	IN	O
the	DT	O
diets	NNS	O
were	VBD	O
formulated	VBN	O
identically	RB	O
in	IN	O
both	DT	O
experiments	NNS	O
.	.	O

Diets	NNS	O
with	IN	O
as	RB	O
little	JJ	O
as	IN	O
0.30	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.37	CD	O
%	NN	O
tP	NN	O
appear	VBP	O
to	TO	O
be	VB	O
adequate	JJ	O
for	IN	O
broilers	NNS	O
older	JJR	O
than	IN	O
18	CD	O
d	NN	O
if	IN	O
supplemented	VBN	O
with	IN	O
the	DT	O
correct	JJ	O
amounts	NNS	O
of	IN	O
phytase	NN	O
and	CC	O
1alpha-OHD3	JJ	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
unknown	JJ	O
variables	NNS	O
that	WDT	O
may	MD	O
limit	VB	O
the	DT	O
potential	NN	O
of	IN	O
broilers	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
bone	NN	O
mineralization	NN	O
and	CC	O
bone	NN	O
pathology	NN	O
,	,	O
even	RB	O
when	WRB	O
adequate	JJ	O
diets	NNS	O
are	VBP	O
fed	VBN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
routine	JJ	O
blood	NN	O
pressure	NN	O
lowering	VBG	O
in	IN	O
older	JJR	O
patients	NNS	O
with	IN	O
diabetes	NNS	C
:	:	O
results	NNS	O
from	IN	O
the	DT	O
ADVANCE	NNP	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
lowering	VBG	O
in	IN	O
elderly	JJ	A
patients	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
sufficiently	RB	O
investigated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	C
.	.	O

Using	VBG	O
data	NNS	O
from	IN	O
the	DT	O
Action	NNP	O
in	IN	O
Diabetes	NNP	O
and	CC	O
Vascular	NNP	O
disease	NN	O
:	:	O
preterAx	NN	O
and	CC	O
diamicroN-MR	NN	O
Controlled	NNP	O
Evaluation	NNP	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
routine	JJ	O
blood	NN	O
pressure	NN	O
lowering	VBG	O
to	TO	O
prevent	VB	O
major	JJ	O
clinical	JJ	O
outcomes	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
.	.	O

METHODS	NNP	O
Eleven	NNP	SS
thousand	VBP	SS
one	CD	SS
hundred	CD	SS
and	CC	SS
forty	JJ	SS
patients	NNS	O
aged	VBN	O
at	IN	O
least	JJS	O
55	CD	A
years	NNS	O
with	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
(	(	O
mean	JJ	O
66+/-6	CD	A
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
perindopril-indapamide	JJ	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
a	DT	O
composite	NN	O
of	IN	O
major	JJ	O
macrovascular	NN	O
and	CC	O
microvascular	JJ	O
disease	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
active	JJ	O
treatment	NN	O
on	IN	O
outcomes	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
subgroups	NNS	O
according	VBG	O
to	TO	O
age	NN	O
:	:	O
below	IN	A
65	CD	A
,	,	O
65-74	JJ	A
and	CC	O
at	IN	A
least	JJS	A
75	CD	A
years	NNS	A
.	.	O

RESULTS	NNP	O
During	IN	O
a	DT	O
mean	JJ	O
4.3-year	JJ	O
follow-up	NN	O
,	,	O
1799	CD	O
(	(	O
16.1	CD	O
%	NN	O
)	)	O
patients	NNS	O
experienced	VBD	O
a	DT	O
major	JJ	O
event	NN	O
.	.	O

Active	JJ	O
treatment	NN	O
produced	VBD	O
similar	JJ	O
relative	JJ	O
risk	NN	O
reductions	NNS	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
,	,	O
major	JJ	O
macrovascular	JJ	O
disease	NN	O
,	,	O
death	NN	O
and	CC	O
renal	JJ	O
events	NNS	O
across	IN	O
age	NN	O
groups	NNS	O
(	(	O
all	DT	O
P	NNP	O
heterogeneity	NN	O
>	NNP	O
0.3	CD	O
)	)	O
.	.	O

Over	IN	O
5	CD	O
years	NNS	O
,	,	O
active	JJ	O
treatment	NN	O
was	VBD	O
estimated	VBN	O
to	TO	O
prevent	VB	O
one	CD	O
primary	JJ	O
outcome	NN	O
in	IN	O
every	DT	O
21	CD	O
,	,	O
71	CD	O
and	CC	O
118	CD	O
patients	NNS	O
of	IN	O
at	IN	O
least	JJS	O
75	CD	O
,	,	O
65-74	JJ	O
and	CC	O
below	IN	O
65	CD	O
years	NNS	O
,	,	O
respectively	RB	O
.	.	O

Similar	JJ	O
patterns	NNS	O
of	IN	O
benefits	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
tolerability	NN	O
between	IN	O
randomized	VBN	O
allocations	NNS	O
across	IN	O
age	NN	O
groups	NNS	O
(	(	O
all	DT	O
P	NNP	O
heterogeneity	NN	O
>	NNP	O
0.6	CD	O
)	)	O
CONCLUSION	NNP	O
Routine	NNP	O
administration	NN	O
of	IN	O
perindopril-indapamide	JJ	O
lowers	NNS	O
blood	NN	O
pressure	NN	O
safely	RB	O
and	CC	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
major	JJ	O
clinical	JJ	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
of	IN	O
at	IN	O
least	JJS	O
75	CD	O
years	NNS	O
with	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

The	DT	O
greater	JJR	O
absolute	JJ	O
benefits	NNS	O
in	IN	O
older	JJR	O
patients	NNS	O
in	IN	O
this	DT	O
age	NN	O
group	NN	O
were	VBD	O
not	RB	O
offset	VBN	O
by	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

[	JJ	O
Observation	NNP	O
of	IN	O
curative	JJ	O
effect	NN	O
on	IN	O
fixed-point	NN	O
spin	NN	O
reduction	NN	O
of	IN	O
spinal	JJ	O
manipulation	NN	O
therapy	NN	O
for	IN	O
cervical	JJ	C
vertigo	NN	C
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
the	DT	O
role	NN	O
of	IN	O
fixed-point	JJ	O
spin	JJ	O
reduction	NN	O
of	IN	O
spinal	JJ	O
manipulation	NN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cervical	JJ	C
vertigo	NN	C
and	CC	O
its	PRP$	O
effect	NN	O
on	IN	O
cervical	JJ	O
artery	NN	O
spasm	NN	O
index	NN	O
(	(	O
RI	NNP	O
)	)	O
and	CC	O
atlantoaxial	JJ	O
displacement	NN	O
index	NN	O
(	(	O
ADI	NNP	O
)	)	O
.	.	O

METHODS	NN	O
From	IN	O
January	NNP	O
2002	CD	O
to	TO	O
May	NNP	O
2008	CD	O
,	,	O
168	CD	SS
patients	NNS	O
with	IN	O
cervical	JJ	O
vertigo	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
treatment	NN	O
group	NN	O
(	(	O
84	CD	SS
cases	NNS	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
84	CD	SS
cases	NNS	O
)	)	O
,	,	O
22	CD	SS
males	NNS	SE
and	CC	O
62	CD	SS
females	NNS	SE
in	IN	O
treatment	NN	O
group	NN	O
;	:	O
24	CD	SS
males	NNS	SE
and	CC	O
60	CD	SS
females	NNS	SE
in	IN	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
patients	NNS	O
of	IN	O
treatment	NN	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
were	VBD	O
respectively	RB	O
treated	VBN	O
with	IN	O
fixed-point	JJ	O
spin	NN	O
reduction	NN	O
of	IN	O
spinal	JJ	O
manipulation	NN	O
therapy	NN	O
and	CC	O
dialectical	JJ	O
prescription	NN	O
.	.	O

The	DT	O
score	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
,	,	O
RI	NNP	O
,	,	O
ADI	NNP	O
were	VBD	O
observed	VBN	O
and	CC	O
compared	VBN	O
between	IN	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
score	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
markedly	RB	O
decreased	VBD	O
after	IN	O
treatment	NN	O
,	,	O
in	IN	O
treatment	NN	O
group	NN	O
:	:	O
vertigo	NN	O
had	VBD	O
(	(	O
2.75	CD	O
+/-	JJ	O
1.01	CD	O
)	)	O
scores	NNS	O
,	,	O
neck-shoulder	JJ	O
pain	NN	O
(	(	O
1.58	CD	O
+/-	JJ	O
0.36	CD	O
)	)	O
,	,	O
headache	NN	O
(	(	O
0.39	CD	O
+/-	JJ	O
0.09	CD	O
)	)	O
,	,	O
nausea-vomiting	JJ	O
(	(	O
1.58	CD	O
+/-	JJ	O
1.30	CD	O
)	)	O
,	,	O
ear	JJ	O
noises	NNS	O
(	(	O
0.48	CD	O
+/-	JJ	O
0.32	CD	O
)	)	O
,	,	O
positive	JJ	O
neck	NN	O
rotation	NN	O
test	NN	O
(	(	O
0.59	CD	O
+/-	JJ	O
0.21	CD	O
)	)	O
;	:	O
and	CC	O
in	IN	O
control	NN	O
group	NN	O
:	:	O
vertigo	NN	O
had	VBD	O
(	(	O
5.68	CD	O
+/-	JJ	O
2.02	CD	O
)	)	O
scores	NNS	O
,	,	O
neck-shoulder	JJ	O
pain	NN	O
(	(	O
3.12	CD	O
+/-	JJ	O
1.82	CD	O
)	)	O
,	,	O
headache	NN	O
(	(	O
1.86	CD	O
+/-	JJ	O
0.65	CD	O
)	)	O
,	,	O
nausea-vomiting	JJ	O
(	(	O
3.25	CD	O
+/-	JJ	O
0.69	CD	O
)	)	O
,	,	O
ear	JJ	O
noises	NNS	O
(	(	O
1.64	CD	O
+/-	JJ	O
0.61	CD	O
)	)	O
,	,	O
positive	JJ	O
neck	NN	O
rotation	NN	O
test	NN	O
(	(	O
1.79	CD	O
+/-	JJ	O
0.67	CD	O
)	)	O
.	.	O

Cervical	JJ	O
artery	NN	O
spasm	NN	O
index	NN	O
and	CC	O
atlantoaxial	JJ	O
displacement	NN	O
index	NN	O
had	VBD	O
been	VBN	O
significantly	RB	O
improved	VBN	O
,	,	O
cervical	JJ	O
artery	NN	O
spasm	NN	O
index	NN	O
was	VBD	O
respectively	RB	O
0.54	CD	O
+/-	JJ	O
0.07	CD	O
and	CC	O
0.52	CD	O
+/-	JJ	O
0.13	CD	O
,	,	O
atlantoaxial	JJ	O
displacement	NN	O
index	NN	O
was	VBD	O
respectively	RB	O
2.92	CD	O
+/-	JJ	O
0.82	CD	O
and	CC	O
4.50	CD	O
+/-	JJ	O
1.32	CD	O
between	IN	O
treatment	NN	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Fixed-point	NNP	O
spin	NN	O
reduction	NN	O
of	IN	O
spinal	JJ	O
manipulation	NN	O
therapy	NN	O
for	IN	O
cervical	JJ	O
vertigo	NN	O
can	MD	O
accurately	RB	O
correct	VB	O
single	JJ	O
or	CC	O
multiple	JJ	O
vertebral	JJ	C
body	NN	C
displacement	NN	C
,	,	O
restore	VB	O
normal	JJ	O
spinal	JJ	O
position	NN	O
,	,	O
reduce	VB	O
the	DT	O
oppression	NN	O
and	CC	O
stimulus	NN	O
of	IN	O
the	DT	O
vertebral	JJ	O
artery	NN	O
,	,	O
release	NN	O
ischemia	NN	O
of	IN	O
vestibular	JJ	O
labyrinth	NN	O
,	,	O
eliminate	VB	O
symptoms	NNS	O
of	IN	O
vertigo	NN	O
.	.	O

Hip	NNP	O
protectors	NNS	O
improve	VBP	O
falls	VBZ	O
self-efficacy	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
use	NN	O
of	IN	O
external	JJ	O
hip	NN	O
protectors	NNS	O
on	IN	O
subjects	NNS	O
'	POS	O
fear	NN	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
self-efficacy	NN	O
(	(	O
belief	NN	O
in	IN	O
their	PRP$	O
own	JJ	O
ability	NN	O
to	TO	O
avoid	VB	O
falling	VBG	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	CC	O
Aged-care	JJ	A
health	NN	O
services	NNS	O
in	IN	O
Sydney	NNP	O
,	,	O
Australia	NNP	O
.	.	O

PARTICIPANTS	NNP	O
131	CD	SS
women	NNS	SE
aged	VBN	O
75	CD	A
years	NNS	A
or	CC	A
older	JJR	A
,	,	O
who	WP	O
had	VBD	O
two	CD	O
or	CC	O
more	JJR	O
falls	NNS	C
or	CC	O
one	CD	O
fall	NN	C
requiring	VBG	C
hospital	JJ	C
admission	NN	C
in	IN	O
the	DT	O
previous	JJ	O
year	NN	O
and	CC	O
who	WP	O
live	VBP	O
at	IN	O
home	NN	O
.	.	O

Sixty-one	JJ	SS
subjects	NNS	O
were	VBD	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
70	CD	SS
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

INTERVENTION	NNP	O
Use	NNP	O
of	IN	O
external	JJ	O
hip	NN	O
protectors	NNS	O
and	CC	O
encouragement	NN	O
to	TO	O
use	VB	O
the	DT	O
protectors	NNS	O
by	IN	O
an	DT	O
adherence	NN	O
nurse	NN	O
.	.	O

MEASUREMENTS	CC	O
At	IN	O
the	DT	O
time	NN	O
of	IN	O
enrolment	NN	O
into	IN	O
a	DT	O
wider	NN	O
study	NN	O
examining	VBG	O
the	DT	O
effect	NN	O
of	IN	O
hip	NN	O
protectors	NNS	O
on	IN	O
hip	NN	O
fractures	NNS	O
,	,	O
participants	NNS	O
recruited	VBD	O
at	IN	O
home	NN	O
completed	VBD	O
an	DT	O
assessment	NN	O
of	IN	O
fear	NN	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
efficacy	NN	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
.	.	O

At	IN	O
4-month	JJ	O
follow-up	NN	O
,	,	O
these	DT	O
scales	NNS	O
were	VBD	O
readministered	VBN	O
by	IN	O
an	DT	O
observer	NN	O
who	WP	O
was	VBD	O
not	RB	O
aware	JJ	O
of	IN	O
the	DT	O
allocation	NN	O
of	IN	O
the	DT	O
participant	NN	O
to	TO	O
intervention	NN	O
or	CC	O
control	NN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Fear	NNP	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
self-efficacy	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
and	CC	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scales	NNP	O
,	,	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Fear	NN	O
of	IN	O
falling	VBG	O
was	VBD	O
present	JJ	O
at	IN	O
follow-up	NN	O
in	IN	O
43	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
using	VBG	O
hip	NN	O
protectors	NNS	O
and	CC	O
57	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
chi2	JJ	O
=	NN	O
2.58	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
.	.	O

Hip	NNP	O
protector	NN	O
users	NNS	O
had	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
falls	VBZ	O
self-efficacy	NN	O
at	IN	O
follow-up	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
(	(	O
t	JJ	O
=	NN	O
2.44	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.016	CD	O
)	)	O
and	CC	O
the	DT	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
(	(	O
t	JJ	O
=	NN	O
2.08	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Hip	NNP	O
protectors	NNS	O
improve	VBP	O
falls	VBZ	O
self-efficacy	NN	O
.	.	O

As	IN	O
users	NNS	O
of	IN	O
hip	NN	O
protectors	NNS	O
feel	VBP	O
more	RBR	O
confident	JJ	O
that	IN	O
they	PRP	O
can	MD	O
complete	VB	O
tasks	NNS	O
safely	RB	O
,	,	O
they	PRP	O
may	MD	O
become	VB	O
more	RBR	O
physically	RB	O
active	JJ	O
and	CC	O
require	VB	O
less	JJR	O
assistance	NN	O
with	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
long-term	JJ	O
tolerability	NN	O
of	IN	O
sublingual	JJ	O
fentanyl	NN	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Breakthrough	NNP	O
cancer	NN	O
pain	NN	O
(	(	O
BTcP	NNP	O
)	)	O
represents	VBZ	O
an	DT	O
important	JJ	O
clinical	JJ	O
challenge	NN	O
in	IN	O
the	DT	O
care	NN	O
of	IN	O
patients	NNS	O
with	IN	O
cancer	NN	C
.	.	O

This	DT	O
trial	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
long-term	JJ	O
tolerability	NN	O
of	IN	O
a	DT	O
sublingual	JJ	O
formulation	NN	O
of	IN	O
the	DT	O
fast-acting	JJ	O
opioid	NN	O
fentanyl	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
BTcP	NNP	O
in	IN	O
opioid-tolerant	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multi-center	JJ	O
,	,	O
phase	JJ	O
III	NNP	O
trial	NN	O
,	,	O
conducted	VBN	O
in	IN	O
opioid-tolerant	JJ	O
male	NN	SE
and	CC	SE
female	JJ	SE
patients	NNS	O
(	(	O
aged	VBN	O
>	NN	A
or	CC	A
=17	CD	A
years	NNS	O
)	)	O
with	IN	O
BTcP	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
36	CD	O
centers	NNS	O
across	IN	O
the	DT	O
USA	NNP	O
.	.	O

The	DT	O
study	NN	O
comprised	VBD	O
a	DT	O
2-week	JJ	O
open-label	JJ	O
titration	NN	O
phase	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
double-blind	JJ	O
efficacy	NN	O
phase	NN	O
,	,	O
during	IN	O
which	WDT	O
patients	NNS	O
received	VBD	O
sublingual	JJ	O
fentanyl	NN	O
citrate	NN	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
(	(	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
in	IN	O
a	DT	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
sum	NN	O
of	IN	O
pain	NN	O
intensity	NN	O
difference	NN	O
(	(	O
SPID	NNP	O
)	)	O
over	IN	O
30	CD	O
min	JJ	O
post-administration	NN	O
.	.	O

Secondary	JJ	O
efficacy	NN	O
endpoints	NNS	O
included	VBD	O
pain	NN	O
intensity	NN	O
difference	NN	O
(	(	O
PID	NNP	O
)	)	O
and	CC	O
pain	NN	O
relief	NN	O
(	(	O
PR	NNP	O
)	)	O
throughout	IN	O
the	DT	O
60-min	JJ	O
post-dose	JJ	O
assessment	NN	O
period	NN	O
.	.	O

Following	VBG	O
efficacy	NN	O
evaluation	NN	O
,	,	O
patients	NNS	O
entered	VBD	O
a	DT	O
long-term	JJ	O
safety	NN	O
phase	NN	O
of	IN	O
up	IN	O
to	TO	O
12	CD	O
months	NNS	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

[	VB	O
CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
NCT00262678	NNP	O
]	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
131	CD	SS
patients	NNS	O
entered	VBD	O
the	DT	O
titration	NN	O
phase	NN	O
,	,	O
of	IN	O
whom	WP	O
61	CD	SS
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
SPID	NNP	O
relative	VBP	O
to	TO	O
placebo	VB	O
at	IN	O
30	CD	O
min	NN	O
(	(	O
49.5	CD	O
vs.	FW	O
36.6	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0004	CD	O
)	)	O
and	CC	O
60	CD	O
min	NNS	O
post-administration	NN	O
(	(	O
143.0	CD	O
vs.	FW	O
104.5	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0002	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
PID	NNP	O
and	CC	O
PR	NNP	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
from	IN	O
10	CD	O
min	NNS	O
post-dose	JJ	O
(	(	O
p	JJ	O
=	NN	O
0.0055	CD	O
and	CC	O
p	VB	O
=	$	O
0.049	CD	O
for	IN	O
PID	NNP	O
and	CC	O
PR	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Patient	JJ	O
recruitment	NN	O
was	VBD	O
stopped	VBN	O
early	RB	O
,	,	O
due	JJ	O
to	TO	O
positive	JJ	O
interim	JJ	O
analysis	NN	O
results	NNS	O
(	(	O
significant	JJ	O
at	IN	O
prespecified	JJ	O
level	NN	O
,	,	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.0414	CD	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
well-tolerated	JJ	O
both	DT	O
systemically	RB	O
and	CC	O
sublingually	RB	O
,	,	O
with	IN	O
41	CD	O
patients	NNS	O
experiencing	VBG	O
>	NN	O
or	CC	O
=1	NN	O
study	NN	O
drug-related	JJ	O
adverse	JJ	O
event	NN	O
(	(	O
AE	NNP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
AEs	NNP	O
included	VBD	O
nausea	NN	O
(	(	O
12.2	CD	O
%	NN	O
)	)	O
,	,	O
vomiting	VBG	O
(	(	O
5.3	CD	O
%	NN	O
)	)	O
and	CC	O
somnolence	NN	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
.	.	O

One	CD	O
serious	JJ	O
AE	NNP	O
(	(	O
mild	JJ	O
affect	VBP	O
lability	NN	O
)	)	O
was	VBD	O
considered	VBN	O
possibly	RB	O
related	VBN	O
to	TO	O
study	VB	O
medication	NN	O
.	.	O

The	DT	O
observed	JJ	O
pattern	NN	O
of	IN	O
AEs	NNP	O
was	VBD	O
consistent	JJ	O
with	IN	O
that	DT	O
previously	RB	O
observed	VBN	O
with	IN	O
fentanyl	NN	O
.	.	O

CONCLUSIONS	NNP	O
Sublingual	NNP	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
efficacious	JJ	O
and	CC	O
well-tolerated	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
BTcP	NNP	O
in	IN	O
opioid-tolerant	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
pain	NN	O
intensity	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
from	IN	O
10	CD	O
min	JJ	O
post-administration	NN	O
and	CC	O
throughout	IN	O
the	DT	O
60-min	JJ	O
post-dose	JJ	O
assessment	NN	O
period	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
over	IN	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Cognitive-behavioural	JJ	O
stress	NN	O
management	NN	O
with	IN	O
HIV-positive	JJ	C
homosexual	JJ	O
men	NNS	SE
:	:	O
mechanisms	NNS	O
of	IN	O
sustained	JJ	O
reductions	NNS	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
examined	VBD	O
the	DT	O
sustained	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
group-based	JJ	O
cognitive-behavioural	JJ	O
stress	NN	O
management	NN	O
(	(	O
CBSM	NNP	O
)	)	O
intervention	NN	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
modified	VBN	O
wait-list	NN	O
control	NN	O
condition	NN	O
on	IN	O
measures	NNS	O
of	IN	O
mood	NN	O
,	,	O
coping	VBG	O
and	CC	O
social	JJ	O
support	NN	O
in	IN	O
mildly	RB	O
symptomatic	JJ	O
HIV-positive	JJ	C
homosexual	JJ	C
and	CC	O
bisexual	JJ	C
men	NNS	SE
.	.	O

Participants	NNS	O
were	VBD	O
recruited	VBN	O
largely	RB	O
during	IN	O
the	DT	O
era	NN	O
prior	RB	O
to	TO	O
highly	RB	O
active	JJ	O
antiretroviral	JJ	O
therapy	NN	O
(	(	O
HAART	NNP	O
;	:	O
1992-1997	JJ	O
)	)	O
.	.	O

METHODS	NNP	O
Men	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	VB	O
a	DT	O
10-week	JJ	O
,	,	O
group-based	JJ	O
CBSM	NNP	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
83	CD	O
)	)	O
or	CC	O
a	DT	O
psychoeducational	JJ	O
seminar	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	SS
)	)	O
.	.	O

All	DT	O
participants	NNS	O
completed	VBD	O
a	DT	O
battery	NN	O
of	IN	O
psychosocial	JJ	O
questionnaires	NNS	O
administered	VBN	O
by	IN	O
a	DT	O
research	NN	O
assistant	NN	O
at	IN	O
baseline	NN	O
,	,	O
immediately	RB	O
following	VBG	O
the	DT	O
10-week	JJ	O
CBSM	NNP	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
6-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Men	NNP	O
in	IN	O
the	DT	O
CBSM	NNP	O
group	NN	O
maintained	VBD	O
previously	RB	O
observed	VBN	O
effects	NNS	O
on	IN	O
depressive	NN	O
symptoms	NNS	O
and	CC	O
perceived	VBD	O
social	JJ	O
support	NN	O
.	.	O

These	DT	O
sustained	JJ	O
effects	NNS	O
of	IN	O
CBSM	NNP	O
on	IN	O
depressive	JJ	O
symptoms	NNS	O
were	VBD	O
mediated	VBN	O
by	IN	O
10-week	JJ	O
increases	NNS	O
in	IN	O
cognitive	JJ	O
coping	NN	O
(	(	O
i.e	JJ	O
.	.	O

positive	JJ	O
reframing	NN	O
)	)	O
.	.	O

DISCUSSION	NNP	O
CBSM	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
potentially	RB	O
efficacious	JJ	O
treatment	NN	O
that	WDT	O
reduces	VBZ	O
and	CC	O
maintains	NNS	O
lower	JJR	O
levels	NNS	O
of	IN	O
depressive	NN	O
symptoms	NNS	O
and	CC	O
enhances	VBZ	O
social	JJ	O
support	NN	O
in	IN	O
HIV-positive	JJ	O
homosexual	JJ	O
and	CC	O
bisexual	JJ	O
men	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
changes	NNS	O
in	IN	O
positive	JJ	O
reframing	NN	O
during	IN	O
the	DT	O
10-week	JJ	O
intervention	NN	O
period	NN	O
remain	VBP	O
a	DT	O
crucial	JJ	O
factor	NN	O
contributing	VBG	O
to	TO	O
sustained	VBN	O
reductions	NNS	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
chemical	JJ	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	C
interphalangeal	NN	C
joint	NN	C
in	IN	O
the	DT	O
horse	NN	O
by	IN	O
using	VBG	O
monoiodoacetate	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
monoiodoacetate	NN	O
(	(	O
MIA	NNP	O
)	)	O
for	IN	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	O
interphalangeal	NN	O
joint	NN	O
(	(	O
PIJ	NNP	O
)	)	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
on	IN	O
the	DT	O
degree	NN	O
of	IN	O
fusion	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Eight	JJ	SS
horses	NNS	O
received	VBD	O
3	CD	O
injections	NNS	O
(	(	O
Weeks	NNP	O
0	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
)	)	O
of	IN	O
MIA	NNP	O
(	(	O
2	CD	O
mL	NN	O
;	:	O
60	CD	O
mg/mL	NN	O
)	)	O
into	IN	O
the	DT	O
right	NN	O
or	CC	O
left	VBD	O
front	JJ	O
PIJ	NNP	O
.	.	O

Peri-operatively	RB	O
,	,	O
the	DT	O
horses	NNS	O
received	VBD	O
phenylbutazone	NN	O
,	,	O
butorphanol	NN	O
,	,	O
and	CC	O
abaxial	JJ	O
sesamoidean	NN	O
nerve	NN	O
blocks	NNS	O
to	TO	O
relieve	VB	O
pain	NN	O
.	.	O

During	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
horses	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
general	JJ	O
health	NN	O
,	,	O
lameness	NN	O
,	,	O
and	CC	O
swelling	VBG	O
around	IN	O
the	DT	O
injection	NN	O
area	NN	O
.	.	O

Radiographs	NNP	O
were	VBD	O
taken	VBN	O
biweekly	RB	O
to	TO	O
evaluate	VB	O
bony	NN	O
fusion	NN	O
.	.	O

Horses	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
non-exercised	JJ	O
and	CC	O
exercised	JJ	O
groups	NNS	O
.	.	O

Exercise	NNP	O
consisted	VBD	O
of	IN	O
20	CD	O
minutes	NNS	O
of	IN	O
trotting	VBG	O
on	IN	O
a	DT	O
treadmill	NN	O
(	(	O
4	CD	O
m/s	NN	O
)	)	O
,	,	O
3	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
weeks	NNS	O
.	.	O

The	DT	O
horses	NNS	O
were	VBD	O
euthanized	VBN	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Slab	NNP	O
sections	NNS	O
of	IN	O
the	DT	O
PIJ	NNP	O
were	VBD	O
evaluated	VBN	O
grossly	RB	O
and	CC	O
radiographically	RB	O
for	IN	O
bony	NN	O
fusion	NN	O
.	.	O

Histologic	JJ	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
articular	JJ	O
cartilage	NN	O
.	.	O

Three	CD	O
horses	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
after	IN	O
developing	VBG	O
soft	JJ	O
tissue	NN	O
necrosis	NN	O
around	IN	O
the	DT	O
injection	NN	O
site	NN	O
,	,	O
septic	JJ	O
arthritis	NN	O
,	,	O
and	CC	O
necrotic	JJ	O
tendinitis	NN	O
.	.	O

The	DT	O
remaining	VBG	O
horses	NNS	O
remained	VBD	O
healthy	JJ	O
,	,	O
developed	VBD	O
a	DT	O
grade	NN	O
1	CD	O
to	TO	O
4	CD	O
lameness	NN	O
with	IN	O
minimal	JJ	O
to	TO	O
severe	VB	O
swelling	VBG	O
in	IN	O
the	DT	O
PIJ	NNP	O
region	NN	O
.	.	O

All	DT	O
5	CD	O
horses	NNS	O
showed	VBD	O
radiographic	JJ	O
evidence	NN	O
of	IN	O
bony	NN	O
fusion	NN	O
,	,	O
however	RB	O
,	,	O
no	DT	O
fusion	NN	O
was	VBD	O
present	JJ	O
when	WRB	O
injected	JJ	O
joints	NNS	O
were	VBD	O
examined	VBN	O
on	IN	O
postmortem	NN	O
examination	NN	O
.	.	O

Histologic	NNP	O
examination	NN	O
revealed	VBD	O
thinning	NN	O
of	IN	O
the	DT	O
cartilage	NN	O
,	,	O
diffuse	VBP	O
necrosis	NN	O
of	IN	O
chondrocytes	NNS	O
,	,	O
with	IN	O
the	DT	O
calcified	JJ	O
zone	NN	O
intact	JJ	O
.	.	O

Subjectively	RB	O
,	,	O
exercise	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
degree	NN	O
of	IN	O
cartilage	NN	O
destruction	NN	O
.	.	O

Based	VBN	O
on	IN	O
this	DT	O
study	NN	O
,	,	O
chemical	JJ	O
arthrodesis	NN	O
can	MD	O
not	RB	O
be	VB	O
advocated	VBN	O
in	IN	O
clinical	JJ	O
cases	NNS	O
because	IN	O
of	IN	O
the	DT	O
high	JJ	O
complication	NN	O
rate	NN	O
and	CC	O
lack	NN	O
of	IN	O
bony	NN	O
fusion	NN	O
.	.	O

Cyclosporin	NNP	O
versus	NN	O
cyclophosphamide	NN	O
for	IN	O
patients	NNS	O
with	IN	O
steroid-dependent	JJ	C
and	CC	O
frequently	RB	C
relapsing	VBG	C
idiopathic	JJ	C
nephrotic	JJ	C
syndrome	NN	C
:	:	O
a	DT	O
multicentre	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
(	(	O
maintenance	NN	O
of	IN	O
remission	NN	O
)	)	O
,	,	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
cyclosporin	NN	O
(	(	O
CsA	NNP	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
cyclophosphamide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
steroid-dependent	JJ	C
or	CC	O
frequently	RB	C
relapsing	VBG	C
nephrotic	JJ	C
syndrome	NN	C
(	(	O
NS	NNP	C
)	)	O
.	.	O

DESIGN	NNP	O
Open	NNP	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
,	,	O
controlled	VBD	O
study	NN	O
for	IN	O
parallel	JJ	O
groups	NNS	O
,	,	O
stratified	VBN	O
for	IN	O
adults	NNS	A
and	CC	O
children	NNS	A
.	.	O

The	DT	O
setting	NN	O
was	VBD	O
in	IN	O
nephrological	JJ	O
departments	NNS	O
in	IN	O
Italy	NNP	O
.	.	O

SUBJECTS	NNP	O
AND	CC	O
INTERVENTIONS	NNP	O
Seventy-three	JJ	SS
patients	NNS	O
with	IN	O
steroid-sensitive	JJ	C
idiopathic	JJ	C
NS	NNP	C
admitted	VBD	O
to	TO	O
the	DT	O
study	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
cyclophosphamide	VB	O
(	(	O
2.5	CD	O
mg/kg/day	NN	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
or	CC	O
CsA	NNP	O
(	(	O
5	CD	O
mg/kg/day	NN	O
in	IN	O
adults	NNS	O
,	,	O
6	CD	O
mg/kg/day	NN	O
in	IN	O
children	NNS	O
)	)	O
for	IN	O
9	CD	O
months	NNS	O
,	,	O
tapered	VBD	O
off	RP	O
by	IN	O
25	CD	O
%	NN	O
every	DT	O
month	NN	O
until	IN	O
complete	JJ	O
discontinuation	NN	O
at	IN	O
month	NN	O
12	CD	O
.	.	O

Seven	CD	O
patients	NNS	O
lost	VBN	O
to	TO	O
follow	VB	O
up	RP	O
were	VBD	O
not	RB	O
considered	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
.	.	O

The	DT	O
remaining	VBG	O
66	CD	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
3-24	JJ	O
months	NNS	O
after	IN	O
randomization	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Relapse-free	NNP	O
survival	NN	O
;	:	O
number	NN	O
of	IN	O
N.S	NNP	O
.	.	O

relapses/patient/year	NN	O
;	:	O
cumulative	JJ	O
dose	NN	O
of	IN	O
prednisone/patient	NN	O
;	:	O
laboratory	JJ	O
investigations	NNS	O
(	(	O
kidney	NN	O
and	CC	O
liver	NN	O
functions	NNS	O
,	,	O
haematological	JJ	O
parameters	NNS	O
)	)	O
;	:	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
month	NN	O
9	CD	O
,	,	O
26	CD	O
of	IN	O
35	CD	O
CsA-treated	JJ	O
patients	NNS	O
were	VBD	O
still	RB	O
in	IN	O
complete	JJ	O
remission	NN	O
and	CC	O
a	DT	O
further	JJ	O
five	CD	O
patients	NNS	O
were	VBD	O
in	IN	O
partial	JJ	O
remission	NN	O
;	:	O
18	CD	O
of	IN	O
28	CD	O
cyclophosphamide-treated	JJ	O
patients	NNS	O
were	VBD	O
in	IN	O
complete	JJ	O
remission	NN	O
,	,	O
and	CC	O
one	CD	O
in	IN	O
partial	JJ	O
remission	NN	O
(	(	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
between	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
was	VBD	O
seen	VBN	O
with	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
relapse	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
frequent	JJ	O
relapsers	NNS	O
(	(	O
19	CD	O
of	IN	O
22	CD	O
)	)	O
and	CC	O
steroid-dependent	JJ	O
patients	NNS	O
(	(	O
8	CD	O
of	IN	O
14	CD	O
)	)	O
given	VBN	O
CsA	NNP	O
,	,	O
and	CC	O
those	DT	O
given	VBN	O
cyclophosphamide	NN	O
(	(	O
5	CD	O
of	IN	O
15	CD	O
and	CC	O
6	CD	O
of	IN	O
15	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
relapses	NNS	O
per	IN	O
year	NN	O
and	CC	O
the	DT	O
mean	NN	O
dose	NN	O
of	IN	O
prednisone	NN	O
per	IN	O
year	NN	O
were	VBD	O
significantly	RB	O
less	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
both	DT	O
groups	NNS	O
for	IN	O
the	DT	O
experimental	JJ	O
year	NN	O
than	IN	O
for	IN	O
the	DT	O
year	NN	O
before	IN	O
randomization	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
,	,	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
given	VBN	O
CsA	NNP	O
(	(	O
50	CD	O
%	NN	O
adults	NNS	O
and	CC	O
20	CD	O
%	NN	O
children	NNS	O
)	)	O
and	CC	O
63	CD	O
%	NN	O
of	IN	O
those	DT	O
given	VBN	O
cyclophosphamide	NN	O
(	(	O
40	CD	O
%	NN	O
adults	NNS	O
and	CC	O
68	CD	O
%	NN	O
children	NNS	O
)	)	O
had	VBD	O
not	RB	O
had	VBN	O
any	DT	O
relapse	NN	O
of	IN	O
NS	NNP	O
.	.	O

Tolerance	NN	O
to	TO	O
the	DT	O
two	CD	O
drugs	NNS	O
was	VBD	O
generally	RB	O
good	JJ	O
.	.	O

The	DT	O
CsA-related	JJ	O
side-effects	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
disappeared	VBD	O
after	IN	O
drug	NN	O
discontinuation	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
both	DT	O
treatments	NNS	O
are	VBP	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBD	O
;	:	O
more	RBR	O
patients	NNS	O
given	VBN	O
cyclophosphamide	JJ	O
had	VBD	O
stable	JJ	O
remissions	NNS	O
.	.	O

Diode	NNP	O
laser	NN	O
photocoagulation	NN	O
for	IN	O
threshold	JJ	O
retinopathy	NN	C
of	IN	C
prematurity	NN	C
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
peripheral	JJ	O
cryotherapy	NN	O
decreases	VBZ	O
the	DT	O
incidence	NN	O
of	IN	O
unfavorable	JJ	O
anatomic	JJ	O
outcomes	NNS	O
in	IN	O
threshold	JJ	O
retinopathy	NN	C
of	IN	C
prematurity	NN	C
(	(	O
ROP	NNP	C
)	)	O
,	,	O
apnea	RB	O
,	,	O
bradycardia	NN	O
,	,	O
and	CC	O
lid	JJ	O
edema	NN	O
can	MD	O
occur	VB	O
.	.	O

Argon	NNP	O
laser	NN	O
indirect	JJ	O
ophthalmoscope	NN	O
photocoagulation	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
cryotherapy	VB	O
,	,	O
with	IN	O
fewer	JJR	O
adverse	JJ	O
effects	NNS	O
.	.	O

Retinal	JJ	O
lesions	NNS	O
placed	VBN	O
with	IN	O
diode	NN	O
lasers	NNS	O
are	VBP	O
deeper	JJR	O
than	IN	O
similar	JJ	O
argon	NN	O
laser	NN	O
lesions	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
difference	NN	O
could	MD	O
influence	VB	O
the	DT	O
response	NN	O
to	TO	O
ablative	JJ	O
therapy	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
enrolled	VBN	O
under	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
protocol	NN	O
.	.	O

One	CD	O
eye	NN	O
of	IN	O
each	DT	O
patient	NN	O
with	IN	O
symmetric	JJ	O
,	,	O
threshold	JJ	O
ROP	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
an	DT	O
814/815	CD	O
nm	JJ	O
diode	NN	O
laser	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
eye	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
cryotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
asymmetric	JJ	O
diseases	NNS	O
also	RB	O
were	VBD	O
randomized	VBN	O
for	IN	O
treatment	NN	O
in	IN	O
the	DT	O
threshold	NN	O
eye	NN	O
.	.	O

RESULTS	NNP	O
Nineteen	JJ	SS
infants	NNS	O
(	(	O
33	CD	SS
eyes	NNS	O
)	)	O
were	VBD	O
treated	VBN	O
,	,	O
ranging	VBG	O
from	IN	O
485	CD	O
to	TO	O
863	CD	O
g	NNS	O
birth	JJ	O
weight	NN	O
(	(	O
23	CD	O
to	TO	O
27	CD	O
weeks	NNS	O
gestational	JJ	O
age	NN	O
)	)	O
;	:	O
18	CD	SS
patients	NNS	O
(	(	O
32	CD	SS
eyes	NNS	O
)	)	O
were	VBD	O
followed	VBN	O
for	IN	O
3	CD	O
months	NNS	O
or	CC	O
longer	JJR	O
.	.	O

Four	CD	SS
patients	NNS	O
(	(	O
8	CD	SS
eyes	NNS	O
)	)	O
had	VBD	O
bilateral	JJ	O
zone	CD	O
1	CD	O
disease	NN	O
.	.	O

Postconceptional	JJ	O
age	NN	O
was	VBD	O
36	CD	A
to	TO	A
45	CD	A
weeks	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
diode	NN	O
laser	NN	O
treatment	NN	O
was	VBD	O
better	RBR	O
tolerated	VBN	O
than	IN	O
cryotherapy	NN	O
,	,	O
and	CC	O
the	DT	O
treatment	NN	O
apparatus	NN	O
was	VBD	O
more	RBR	O
easily	RB	O
transported	VBN	O
.	.	O

Apneic	NNP	O
episodes	VBZ	O
requiring	VBG	O
intubation	NN	O
resulted	VBD	O
from	IN	O
two	CD	O
cryotherapy	NN	O
sessions	NNS	O
but	CC	O
no	DT	O
diode	NN	O
laser	NN	O
sessions	NNS	O
.	.	O

Five	CD	O
cryotherapy-treated	JJ	O
eyes	NNS	O
required	VBN	O
retreatment	NN	O
because	IN	O
of	IN	O
persistent	JJ	O
disease	NN	O
with	IN	O
adjacent	JJ	O
skip	NN	O
areas	NNS	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
followed	VBD	O
for	IN	O
3	CD	O
to	TO	O
15	CD	O
months	NNS	O
,	,	O
1	CD	O
cryotherapy-treated	JJ	O
eye	NN	O
and	CC	O
1	CD	O
diode	NN	O
laser-treated	JJ	O
eye	NN	O
progressed	VBD	O
to	TO	O
stage	VB	O
5	CD	O
retinal	JJ	O
detachment	NN	O
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
cryotherapy	NN	O
,	,	O
the	DT	O
diode	NN	O
laser	NN	O
was	VBD	O
more	RBR	O
convenient	JJ	O
,	,	O
technically	RB	O
easier	JJR	O
to	TO	O
administer	VB	O
,	,	O
and	CC	O
better	RB	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

Although	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
was	VBD	O
too	RB	O
small	JJ	O
for	IN	O
meaningful	JJ	O
statistical	JJ	O
analysis	NN	O
of	IN	O
outcome	NN	O
,	,	O
diode	VB	O
laser	RBR	O
peripheral	JJ	O
retinal	JJ	O
ablation	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
cryotherapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
threshold	JJ	O
ROP	NNP	O
.	.	O

Relationship	NN	O
between	IN	O
baseline	NN	O
blood	NN	O
pressure	NN	O
parameters	NNS	O
(	(	O
including	VBG	O
mean	JJ	O
pressure	NN	O
,	,	O
pulse	JJ	O
pressure	NN	O
,	,	O
and	CC	O
variability	NN	O
)	)	O
and	CC	O
early	JJ	O
outcome	NN	O
after	IN	O
stroke	NN	C
:	:	O
data	NN	O
from	IN	O
the	DT	O
Tinzaparin	NNP	O
in	IN	O
Acute	NNP	C
Ischaemic	NNP	C
Stroke	NNP	C
Trial	NNP	O
(	(	O
TAIST	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
PURPOSE	NNP	O
High	NNP	C
blood	NN	C
pressure	NN	C
(	(	O
BP	NNP	O
)	)	O
in	IN	O
acute	JJ	C
stroke	NN	C
is	VBZ	O
associated	VBN	O
independently	RB	O
with	IN	O
a	DT	O
poor	JJ	O
outcome	NN	O
.	.	O

Recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
other	JJ	O
hemodynamic	JJ	O
parameters	NNS	O
may	MD	O
also	RB	O
be	VB	O
associated	VBN	O
with	IN	O
outcomes	NNS	O
following	VBG	O
stroke	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
baseline	NN	O
BP	NNP	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
other	JJ	O
hemodynamic	JJ	O
parameters	NNS	O
,	,	O
and	CC	O
early	RB	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
TAIST	NNP	O
trial	NN	O
.	.	O

RESULTS	NNP	O
Death	NNP	O
or	CC	O
neurological	JJ	O
deterioration	NN	O
at	IN	O
day	NN	O
10	CD	O
was	VBD	O
associated	VBN	O
,	,	O
both	DT	O
in	IN	O
unadjusted	JJ	O
and	CC	O
adjusted	JJ	O
analyses	NNS	O
,	,	O
with	IN	O
systolic	JJ	O
BP	NNP	O
(	(	O
adjusted	VBN	O
OR	NNP	O
,	,	O
1.02	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.03	JJ	O
)	)	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
OR	NNP	O
,	,	O
1.02	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.04	JJ	O
)	)	O
,	,	O
pulse	JJ	O
pressure	NN	O
(	(	O
OR	NNP	O
,	,	O
1.02	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.03	JJ	O
)	)	O
,	,	O
and	CC	O
BP	NNP	O
variability	NN	O
(	(	O
OR	NNP	O
,	,	O
1.03	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.05	JJ	O
)	)	O
.	.	O

Similar	JJ	O
relationships	NNS	O
were	VBD	O
noted	VBN	O
for	IN	O
deterioration	NN	O
alone	RB	O
,	,	O
and	CC	O
recurrent	JJ	O
stroke	NN	O
.	.	O

CONCLUSIONS	NNP	O
Early	JJ	O
death	NN	O
or	CC	O
neurologic	JJ	O
deterioration	NN	O
,	,	O
deterioration	NN	O
,	,	O
and	CC	O
recurrent	JJ	O
stroke	NN	O
are	VBP	O
associated	VBN	O
independently	RB	O
with	IN	O
high	JJ	O
systolic	JJ	O
BP	NNP	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
pulse	JJ	O
pressure	NN	O
,	,	O
and	CC	O
BP	NNP	O
variability	NN	O
.	.	O

These	DT	O
measures	NNS	O
offer	VBP	O
potential	JJ	O
therapeutic	JJ	O
targets	NNS	O
for	IN	O
improving	VBG	O
early	JJ	O
outcome	NN	O
after	IN	O
acute	JJ	C
ischemic	JJ	C
stroke	NN	C
.	.	O

Immunogenicity	NN	O
and	CC	O
safety	NN	O
of	IN	O
a	DT	O
plasma-derived	JJ	O
heat-inactivated	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
(	(	O
CLB	NNP	O
)	)	O
.	.	O

Studies	NNPS	O
in	IN	O
volunteers	NNS	O
at	IN	O
a	DT	O
low	JJ	C
risk	NN	C
of	IN	O
infection	NN	O
with	IN	O
hepatitis	NN	C
B	NNP	C
virus	NN	C
.	.	O

The	DT	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
a	DT	O
plasma-derived	JJ	O
heat-inactivated	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
(	(	O
CLB	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
471	CD	SS
healthy	JJ	C
human	JJ	O
volunteers	NNS	O
,	,	O
who	WP	O
,	,	O
both	DT	O
in	IN	O
their	PRP$	O
occupations	NNS	O
and	CC	O
in	IN	O
their	PRP$	O
private	JJ	O
lives	NNS	O
,	,	O
had	VBD	O
been	VBN	O
at	IN	O
minimal	JJ	C
risk	NN	C
of	IN	O
being	VBG	O
infected	VBN	O
with	IN	O
hepatitis	NN	C
B	NNP	C
virus	NN	C
.	.	O

The	DT	O
first	JJ	O
202	JJ	O
individuals	NNS	O
received	VBD	O
three	CD	O
3-micrograms	JJ	O
doses	NNS	O
of	IN	O
heat-inactivated	JJ	O
hepatitis	NN	O
B	NNP	O
surface	NN	O
antigen	NN	O
(	(	O
HBsAg	NNP	O
)	)	O
at	IN	O
one-month	JJ	O
intervals	NNS	O
(	(	O
trial	NN	O
A	DT	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
42	CD	O
%	NN	O
one	CD	O
month	NN	O
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
,	,	O
84	CD	O
%	NN	O
after	IN	O
two	CD	O
months	NNS	O
,	,	O
and	CC	O
93	CD	O
%	NN	O
after	IN	O
five	CD	O
months	NNS	O
had	VBD	O
become	VBN	O
anti-HBs	JJ	O
(	(	O
antibody	NN	O
to	TO	O
hepatitis	VB	O
B	NNP	O
surface	NN	O
antigen	NN	O
)	)	O
positive	JJ	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
randomized	VBN	O
study	NN	O
(	(	O
trial	NN	O
B	NNP	O
)	)	O
,	,	O
the	DT	O
immunogenicity	NN	O
of	IN	O
five	CD	O
different	JJ	O
dosages	NNS	O
of	IN	O
the	DT	O
vaccine	NN	O
was	VBD	O
compared	VBN	O
in	IN	O
269	CD	O
volunteers	NNS	O
.	.	O

When	WRB	O
the	DT	O
dose	NN	O
of	IN	O
HBsAg	NNP	O
was	VBD	O
diminished	VBN	O
from	IN	O
3	CD	O
micrograms	NNS	O
to	TO	O
1.5	CD	O
,	,	O
0.6	CD	O
,	,	O
and	CC	O
0.25	CD	O
microgram	NN	O
,	,	O
no	DT	O
decrease	NN	O
of	IN	O
the	DT	O
anti-HBs	JJ	O
response	NN	O
was	VBD	O
observed	VBN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
the	DT	O
dose	NN	O
was	VBD	O
diminished	VBN	O
to	TO	O
0.1	CD	O
microgram	NN	O
of	IN	O
HBsAg	NNP	O
,	,	O
the	DT	O
anti-HBs	JJ	O
response	NN	O
dropped	VBD	O
significantly	RB	O
to	TO	O
63	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
recipients	NNS	O
of	IN	O
all	DT	O
five	CD	O
vaccine	NN	O
dosages	NNS	O
,	,	O
no	DT	O
influence	NN	O
of	IN	O
sex	NN	O
and	CC	O
age	NN	O
was	VBD	O
found	VBN	O
on	IN	O
the	DT	O
anti-HBs	JJ	O
conversion	NN	O
rates	NNS	O
.	.	O

During	IN	O
the	DT	O
eight-month	JJ	O
observation	NN	O
period	NN	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
vaccinees	NNS	O
became	VBD	O
HBsAg	NNP	O
and/or	IN	O
anti-HBc	JJ	O
(	(	O
antibody	NN	O
to	TO	O
hepatitis	VB	O
B	NNP	O
core	NN	O
antigen	NN	O
)	)	O
positive	JJ	O
,	,	O
and	CC	O
none	NN	O
developed	VBD	O
antibodies	NNS	O
associated	VBN	O
with	IN	O
autoimmune	JJ	O
liver	NN	O
disease	NN	O
.	.	O

No	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
magnesium	NN	O
added	VBN	O
to	TO	O
levobupivacaine	VB	O
for	IN	O
femoral	JJ	O
nerve	NN	O
block	NN	O
on	IN	O
postoperative	JJ	O
analgesia	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
ACL	NNP	C
reconstruction	NN	C
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
randomised	VBD	O
double-blind	NN	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
magnesium	NN	O
added	VBN	O
to	TO	O
local	JJ	O
anaesthetics	NNS	O
on	IN	O
postoperative	JJ	O
VAS	NNP	O
scores	NNS	O
,	,	O
total	JJ	O
opioid	JJ	O
consumption	NN	O
,	,	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
,	,	O
patient	JJ	O
satisfaction	NN	O
and	CC	O
rescue	NN	O
analgesic	JJ	O
requirements	NNS	O
in	IN	O
arthroscopic	JJ	O
ACL	NNP	O
reconstruction	NN	O
surgery	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
107	CD	SS
American	JJ	O
Society	NNP	O
of	IN	O
Anaesthesiologists	NNP	O
physical	JJ	O
status	NN	O
grade	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
between	IN	O
18	CD	A
and	CC	A
65	CD	A
years	NNS	O
of	IN	O
age	NN	O
who	WP	O
were	VBD	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
elective	JJ	C
anterior	JJ	C
crucial	JJ	C
ligament	NN	C
(	(	C
ACL	NNP	C
)	)	C
reconstruction	NN	C
with	IN	O
hamstring	VBG	O
autografts	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
Groups	NNP	O
L	NNP	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
and	CC	O
LM	NNP	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
using	VBG	O
the	DT	O
closed-envelope	NN	O
method	NN	O
.	.	O

Group	NNP	O
LM	NNP	O
was	VBD	O
administered	VBN	O
19	CD	O
ml	NN	O
of	IN	O
0.25	CD	O
%	NN	O
levobupivacaine	NN	O
and	CC	O
1	CD	O
ml	NN	O
of	IN	O
15	CD	O
%	NN	O
magnesium	NN	O
sulphate	NN	O
,	,	O
while	IN	O
Group	NNP	O
L	NNP	O
was	VBD	O
administered	VBN	O
20	CD	O
ml	NN	O
of	IN	O
0.25	CD	O
%	NN	O
levobupivacaine	NN	O
for	IN	O
femoral	JJ	O
blockade	NN	O
.	.	O

General	NNP	O
anaesthesia	NN	O
was	VBD	O
administered	VBN	O
using	VBG	O
laryngeal	JJ	O
airway	RB	O
masks	NNS	O
following	VBG	O
neural	JJ	O
blockade	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
heart	NN	O
rate	NN	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
,	,	O
oxygen	NN	O
saturation	NN	O
,	,	O
visual	JJ	O
analogue	NN	O
score	NN	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
verbal	JJ	O
rating	NN	O
scale	NN	O
(	(	O
VRS	NNP	O
)	)	O
,	,	O
rescue	NN	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
total	JJ	O
opioid	JJ	O
consumption	NN	O
,	,	O
side	NN	O
effects	NNS	O
and	CC	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
at	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
4th	CD	O
,	,	O
6th	CD	O
,	,	O
12th	CD	O
and	CC	O
24th	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
demographic	JJ	O
data	NNS	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
or	CC	O
oxygen	NN	O
saturation	NN	O
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
VAS	NNP	O
and	CC	O
VRS	NNP	O
scores	NNS	O
were	VBD	O
lower	JJR	O
at	IN	O
4	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
h	NN	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.001	CD	O
,	,	O
p	NN	O
=	VBD	O
0.016	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
rescue	NN	O
analgesic	JJ	O
requirement	NN	O
and	CC	O
the	DT	O
total	JJ	O
opioid	JJ	O
consumption	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.015	CD	O
,	,	O
p	NN	O
=	VBD	O
0.019	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
and	CC	O
the	DT	O
Likert	NNP	O
score	NN	O
(	(	O
completely	RB	O
comfortable	JJ	O
;	:	O
quite	RB	O
comfortable	JJ	O
;	:	O
slight	JJ	O
discomfort	NN	O
;	:	O
painful	JJ	O
;	:	O
very	RB	O
painful	JJ	O
)	)	O
were	VBD	O
higher	JJR	O
,	,	O
and	CC	O
the	DT	O
block	NN	O
onset	VBD	O
time	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.014	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.012	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
magnesium	NN	O
to	TO	O
levobupivacaine	VB	O
prolongs	NNS	O
the	DT	O
sensory	NN	O
and	CC	O
motor	NN	O
block	NN	O
duration	NN	O
without	IN	O
increasing	VBG	O
side	NN	O
effects	NNS	O
,	,	O
enhances	VBZ	O
the	DT	O
quality	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
and	CC	O
increases	VBZ	O
patient	JJ	O
satisfaction	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
magnesium	NN	O
delays	VBZ	O
the	DT	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
and	CC	O
decreases	VBZ	O
rescue	NN	O
analgesic	JJ	O
requirements	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
adults	NNS	A
with	IN	O
acute	JJ	C
lymphoblastic	JJ	C
leukemia	NN	C
:	:	O
do	VB	O
the	DT	O
specifics	NNS	O
of	IN	O
the	DT	O
regimen	NNS	O
matter	NN	O
?	.	O
:	:	O
Results	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Induction	NNP	O
therapy	NN	O
for	IN	O
adults	NNS	A
with	IN	O
acute	JJ	C
lymphoblastic	JJ	C
leukemia	NN	C
(	(	O
ALL	DT	C
)	)	O
is	VBZ	O
similar	JJ	O
across	IN	O
essentially	RB	O
all	DT	O
regimens	NNS	O
,	,	O
comprised	VBN	O
of	IN	O
vincristine	NN	O
,	,	O
corticosteroids	NNS	O
,	,	O
and	CC	O
anthracyclines	NNS	O
intensified	VBN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
asparaginase	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

Given	VBN	O
the	DT	O
lack	NN	O
of	IN	O
randomized	VBN	O
data	NNS	O
,	,	O
to	TO	O
date	NN	O
,	,	O
no	DT	O
regimen	NN	O
has	VBZ	O
emerged	VBN	O
as	IN	O
standard	NN	O
.	.	O

The	DT	O
authors	NNS	O
previously	RB	O
evaluated	VBD	O
cytarabine	JJ	O
3	CD	O
g/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
with	IN	O
mitoxantrone	NN	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
)	)	O
as	IN	O
a	DT	O
novel	JJ	O
induction	NN	O
regimen	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
historic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
ALL-2	NNP	O
regimen	NN	O
was	VBD	O
superior	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
incidence	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
,	,	O
failure	NN	O
with	IN	O
resistant	JJ	O
disease	NN	O
,	,	O
and	CC	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Philadelphia	NNP	C
chromosome	NN	C
(	(	C
Ph	NNP	C
)	)	C
-positive	VBP	C
ALL	NNP	O
.	.	O

METHODS	NNP	O
The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
standard	JJ	O
4-drug	JJ	O
induction	NN	O
(	(	O
the	DT	O
L-20	NNP	O
regimen	NNS	O
)	)	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
consolidation	NN	O
,	,	O
maintenance	NN	O
therapy	NN	O
,	,	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
.	.	O

The	DT	O
trial	NN	O
accrued	VBD	O
patients	NNS	O
from	IN	O
August	NNP	O
1996	CD	O
to	TO	O
October	NNP	O
2004	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
follow-up	NN	O
for	IN	O
survivors	NNS	O
was	VBD	O
7	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
patient	NN	O
age	NN	O
was	VBD	O
43	CD	A
years	NNS	O
.	.	O

Responses	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
164	CD	SS
patients	NNS	O
.	.	O

The	DT	O
treatment	NN	O
arms	NNS	O
were	VBD	O
balanced	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
pretreatment	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
for	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
versus	IN	O
the	DT	O
L-20	JJ	O
regimen	NN	O
was	VBD	O
83	CD	O
%	NN	O
versus	IN	O
71	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.06	NNP	O
)	)	O
.	.	O

More	JJR	O
patients	NNS	O
on	IN	O
the	DT	O
L-20	NNP	O
arm	NN	O
failed	VBD	O
with	IN	O
resistant	JJ	O
disease	NN	O
(	(	O
21	CD	O
%	NN	O
vs	JJ	O
8	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

Induction	NNP	O
deaths	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
9	CD	O
%	NN	O
(	(	O
ALL-2	NNP	O
)	)	O
versus	VBD	O
7	CD	O
%	NN	O
(	(	O
L-20	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
similar	JJ	O
;	:	O
and	CC	O
,	,	O
at	IN	O
5	CD	O
years	NNS	O
,	,	O
the	DT	O
survival	NN	O
rate	NN	O
was	VBD	O
33	CD	O
%	NN	O
alive	JJ	O
on	IN	O
the	DT	O
ALL-2	NNP	O
arm	NN	O
versus	NN	O
27	CD	O
%	NN	O
on	IN	O
the	DT	O
L-20	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
superior	JJ	O
results	NNS	O
of	IN	O
induction	NN	O
therapy	NN	O
with	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
,	,	O
this	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
improve	VB	O
long-term	JJ	O
outcomes	NNS	O
.	.	O

When	WRB	O
coupled	VBN	O
to	TO	O
the	DT	O
reported	VBN	O
experience	NN	O
of	IN	O
other	JJ	O
studies	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
ALL	NNP	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
randomized	VBN	O
trial	NN	O
raise	NN	O
the	DT	O
possibility	NN	O
that	WDT	O
ultimate	JJ	O
outcomes	NNS	O
in	IN	O
adult	NN	O
ALL	NNP	O
may	MD	O
be	VB	O
independent	JJ	O
of	IN	O
the	DT	O
specific	JJ	O
regimen	NNS	O
chosen	VBN	O
.	.	O

Cancer	NN	O
2013	CD	O
.	.	O

?	.	O
2012	CD	O
American	JJ	O
Cancer	NNP	O
Society	NNP	O
.	.	O

The	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
fluid	JJ	O
intake	NN	O
on	IN	O
urine	JJ	O
specific	JJ	O
gravity	NN	O
and	CC	O
fluid	JJ	O
retention	NN	O
in	IN	O
a	DT	O
mildly	RB	C
dehydrated	JJ	C
state	NN	C
.	.	O

Many	JJ	O
athletes	NNS	O
arrive	VBP	O
at	IN	O
training	NN	O
sessions	NNS	O
and	CC	O
competitions	NNS	O
in	IN	O
a	DT	O
mildly	RB	O
hypohydrated	VBN	O
(	(	O
HYPO	NNP	C
)	)	O
state	NN	O
and	CC	O
are	VBP	O
instructed	VBN	O
to	TO	O
drink	VB	O
fluids	NNS	O
before	IN	O
exercise	NN	O
to	TO	O
reach	VB	O
a	DT	O
euhydrated	JJ	O
(	(	O
HYD	NNP	O
)	)	O
state	NN	O
.	.	O

Ten	CD	O
recreational	JJ	O
athletes	NNS	O
(	(	O
6	CD	O
women	NNS	O
,	,	O
4	CD	O
men	NNS	O
;	:	O
71.9	CD	O
?	.	O
4.6	CD	O
kg	NN	O
,	,	O
25.2	CD	O
?	.	O
0.9	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
the	DT	O
studies	NNS	O
to	TO	O
examine	VB	O
(	(	O
a	DT	O
)	)	O
the	DT	O
day-to-day	JJ	O
variability	NN	O
of	IN	O
morning	NN	O
urine	NN	O
specific	JJ	O
gravity	NN	O
(	(	O
USG	NNP	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
consuming	VBG	O
600	CD	O
ml	NN	O
of	IN	O
water	NN	O
on	IN	O
the	DT	O
hydration	NN	O
status	NN	O
of	IN	O
HYD	NNP	O
and	CC	O
HYPO	NNP	O
(	(	O
USG	NNP	O
>	NNP	O
1.020	CD	O
)	)	O
subjects	NNS	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
consuming	VBG	O
water	NN	O
(	(	O
W	NNP	O
)	)	O
,	,	O
salt-water	JJ	O
(	(	O
SW	NNP	O
,	,	O
40	CD	O
mM	NN	O
Na	NNP	O
)	)	O
,	,	O
a	DT	O
carbohydrate-electrolyte	JJ	O
solution	NN	O
with	IN	O
3	CD	O
%	NN	O
or	CC	O
light	JJ	O
carbohydrate	NN	O
(	(	O
CES-L	NNP	O
,	,	O
20	CD	O
mM	NN	O
Na	NNP	O
)	)	O
or	CC	O
a	DT	O
CES	NN	O
with	IN	O
6	CD	O
%	NN	O
carbohydrate	NN	O
(	(	O
CES	NNP	O
,	,	O
20	CD	O
mM	NN	O
Na	NNP	O
)	)	O
on	IN	O
the	DT	O
hydration	NN	O
status	NN	O
of	IN	O
HYPO	NNP	O
subjects	NNS	O
.	.	O

The	DT	O
hydration	NN	O
status	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
USG	NNP	O
and	CC	O
body	NN	O
mass	NN	O
measures	NNS	O
and	CC	O
urine	JJ	O
volume	NN	O
collections	NNS	O
.	.	O

The	DT	O
day-to-day	JJ	O
variability	NN	O
in	IN	O
morning	NN	O
USG	NNP	O
(	(	O
coefficient	NN	O
of	IN	O
variation	NN	O
=	FW	O
0.2	CD	O
?	.	O
0.1	CD	O
%	NN	O
)	)	O
was	VBD	O
low	JJ	O
and	CC	O
the	DT	O
responses	NNS	O
to	TO	O
600	CD	O
ml	NN	O
of	IN	O
W	NNP	O
ingestion	NN	O
were	VBD	O
repeatable	JJ	O
.	.	O

Pretrial	JJ	O
USG	NNP	O
was	VBD	O
1.022	CD	O
?	.	O
0.001	CD	O
in	IN	O
the	DT	O
HYPO	NNP	O
trial	NN	O
and	CC	O
decreased	VBD	O
<	NNS	O
1.020	CD	O
by	IN	O
45	CD	O
minutes	NNS	O
(	(	O
1.013	CD	O
?	.	O
0.003	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
CES	NNP	O
study	NN	O
,	,	O
HYPO	NNP	O
subjects	VBZ	O
reached	VBN	O
HYD	NNP	O
status	NN	O
at	IN	O
45	CD	O
minutes	NNS	O
in	IN	O
all	DT	O
conditions	NNS	O
(	(	O
W	NNP	O
1.013	CD	O
?	.	O
0.003	CD	O
,	,	O
SW	NNP	O
1.013	CD	O
?	.	O
0.003	CD	O
,	,	O
CES-L	NNP	O
1.011	CD	O
?	.	O
0.003	CD	O
,	,	O
CES	NNP	O
1.017	CD	O
?	.	O
0.004	CD	O
)	)	O
because	IN	O
salt	NN	O
or	CC	O
CES	NNP	O
ingestion	NN	O
did	VBD	O
not	RB	O
affect	VB	O
fluid	NN	O
retention	NN	O
(	(	O
W	NNP	O
68	CD	O
%	NN	O
,	,	O
SW	NNP	O
72	CD	O
%	NN	O
,	,	O
CES-L	JJ	O
68	CD	O
%	NN	O
,	,	O
CES	NNP	O
76	CD	O
%	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
mildly	RB	O
HYPO	NNP	O
subjects	NNS	O
could	MD	O
reach	VB	O
euhydration	NN	O
within	IN	O
45	CD	O
minutes	NNS	O
of	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
600	CD	O
ml	NN	O
of	IN	O
W	NNP	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
salt	NN	O
and	CC	O
CES	NNP	O
solutions	NNS	O
.	.	O

Following	VBG	O
this	DT	O
practice	NN	O
will	MD	O
minimize	VB	O
the	DT	O
incidence	NN	O
of	IN	O
starting	VBG	O
a	DT	O
practice	NN	O
or	CC	O
competition	NN	O
hypohydrated	VBN	O
.	.	O

International	NNP	O
Czech	NNP	O
and	CC	O
Slovak	NNP	O
cooperation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	C
thyroid	NN	C
cancer	NN	C
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
paper	NN	O
is	VBZ	O
to	TO	O
present	VB	O
our	PRP$	O
experience	NN	O
concerning	VBG	O
cooperation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Slovak	NNP	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
in	IN	O
Slovak	NNP	O
and	CC	O
Czech	NNP	O
hospitals	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
demonstrate	VB	O
the	DT	O
means	NNS	O
of	IN	O
this	DT	O
cooperation	NN	O
and	CC	O
the	DT	O
results	NNS	O
of	IN	O
therapy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
September	NNP	O
1991	CD	O
to	TO	O
October	NNP	O
2005	CD	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
357	CD	SS
patients	NNS	O
from	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
with	IN	O
differentiated	VBN	C
thyroid	NN	C
cancers	NNS	C
(	(	O
follicular	JJ	C
and	CC	C
papillary	JJ	C
)	)	O
underwent	NN	O
complex	JJ	O
therapy	NN	O
.	.	O

They	PRP	O
were	VBD	O
diagnosed	VBN	O
and	CC	O
operated	VBN	O
due	JJ	O
to	TO	O
the	DT	O
cancer	NN	O
(	(	O
near-total	JJ	C
thyroidectomy	NN	C
and	CC	O
removal	NN	C
of	IN	C
lymph	JJ	C
node	JJ	C
metastases	NNS	C
)	)	O
in	IN	O
Slovak	NNP	O
hospitals	NNS	O
.	.	O

Then	RB	O
they	PRP	O
were	VBD	O
sent	VBN	O
to	TO	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
in	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

In	IN	O
this	DT	O
department	NN	O
a	DT	O
radioiodine	JJ	O
ablation	NN	O
of	IN	O
thyroid	JJ	O
remnants	NNS	O
,	,	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
amount	NN	O
of	IN	O
radioiodine	NN	O
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
3.7	CD	O
GBq	NNP	O
,	,	O
was	VBD	O
performed	VBN	O
,	,	O
and	CC	O
then	RB	O
a	DT	O
suppression	NN	O
and	CC	O
substitution	NN	O
therapy	NN	O
of	IN	O
thyroid	JJ	O
hormones	NNS	O
was	VBD	O
started	VBN	O
.	.	O

After	IN	O
3-6	JJ	O
months	NNS	O
some	DT	O
patients	NNS	O
were	VBD	O
examined	VBN	O
by	IN	O
means	NNS	O
of	IN	O
diagnostic	JJ	O
whole	JJ	O
body	NN	O
scintigraphy	NN	O
after	IN	O
application	NN	O
of	IN	O
300	CD	O
MBq	NNP	O
131I	CD	O
.	.	O

Some	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
7.4	CD	O
GBq	NNP	O
131I	CD	O
and	CC	O
after	IN	O
5	CD	O
days	NNS	O
whole	JJ	O
body	NN	O
scintigraphy	NN	O
(	(	O
WBS	NNP	O
)	)	O
was	VBD	O
performed	VBN	O
.	.	O

In	IN	O
both	DT	O
of	IN	O
these	DT	O
groups	NNS	O
of	IN	O
patients	NNS	O
the	DT	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
radioiodine	NN	O
application	NN	O
was	VBD	O
done	VBN	O
after	IN	O
withdrawal	NN	O
of	IN	O
thyroid	JJ	O
hormone	NN	O
treatment	NN	O
.	.	O

If	IN	O
thyroglobulin	JJ	O
levels	NNS	O
were	VBD	O
low	JJ	O
and	CC	O
WBSs	NNP	O
were	VBD	O
negative	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
radioiodine	NN	O
accumulated	VBN	O
metastases	NNS	O
were	VBD	O
again	RB	O
treated	VBN	O
with	IN	O
radioiodine	NN	O
in	IN	O
Ostrava	NNP	O
.	.	O

If	IN	O
indicated	VBN	O
,	,	O
external	JJ	O
radiation	NN	O
therapy	NN	O
targeted	VBN	O
on	IN	O
the	DT	O
neck	NN	O
and	CC	O
upper	JJ	O
mediastinum	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
,	,	O
in	IN	O
the	DT	O
University	NNP	O
Hospital	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Newly	RB	O
formed	VBN	O
lymph	JJ	O
node	NN	O
metastases	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
Slovakia	NNP	O
,	,	O
too	RB	O
.	.	O

Generally	RB	O
we	PRP	O
have	VBP	O
very	RB	O
good	JJ	O
treatment	NN	O
results	NNS	O
.	.	O

Also	RB	O
,	,	O
economically	RB	O
our	PRP$	O
partnership	NN	O
is	VBZ	O
cost	VBN	O
effective	JJ	O
.	.	O

Our	PRP$	O
collaboration	NN	O
also	RB	O
successfully	RB	O
continues	VBZ	O
after	IN	O
entrance	NN	O
of	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
and	CC	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
to	TO	O
the	DT	O
European	NNP	O
Union	NNP	O
in	IN	O
2004	CD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
multi-centre	JJ	O
study	NN	O
show	NN	O
that	IN	O
international	JJ	O
Czech	NNP	O
and	CC	O
Slovak	NNP	O
cooperation	NN	O
in	IN	O
the	DT	O
complex	JJ	O
therapy	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancers	NNS	O
is	VBZ	O
successful	JJ	O
,	,	O
with	IN	O
high	JJ	O
efficacy	NN	O
.	.	O

The	DT	O
treatment	NN	O
results	NNS	O
were	VBD	O
very	RB	O
similar	JJ	O
to	TO	O
therapeutic	JJ	O
results	NNS	O
in	IN	O
our	PRP$	O
patients	NNS	O
from	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

Pegfilgrastim	NN	O
for	IN	O
peripheral	JJ	O
CD34+	NNP	O
mobilization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
solid	JJ	C
tumours	NNS	C
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
pegfilgrastim+/-chemotherapy	NN	O
for	IN	O
mobilizing	VBG	O
stem	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
solid	JJ	C
tumours	NN	C
was	VBD	O
assessed	VBN	O
.	.	O

In	IN	O
cycle	NN	O
0	CD	O
,	,	O
a	DT	O
14-day	JJ	O
prechemotherapy	NN	O
cycle	NN	O
,	,	O
patients	NNS	O
(	(	O
N=61	NNP	SS
)	)	O
were	VBD	O
randomized	VBN	O
open-label	NN	O
to	TO	O
single	JJ	O
doses	NNS	O
of	IN	O
pegfilgrastim	NN	O
(	(	O
6	CD	O
,	,	O
12	CD	O
or	CC	O
18	CD	O
mg	NN	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
or	CC	O
daily	RB	O
filgrastim	NNS	O
(	(	O
10	CD	O
microg/kg	NN	O
)	)	O
for	IN	O
<	NN	O
or	CC	O
=7	JJ	O
days	NNS	O
.	.	O

Mean	JJ	O
peak	JJ	O
peripheral	JJ	O
CD34+	NNP	O
cell	NN	O
counts	NNS	O
increased	VBD	O
with	IN	O
pegfilgrastim	NN	O
dose	NN	O
,	,	O
but	CC	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
filgrastim	JJR	O
only	RB	O
at	IN	O
the	DT	O
18	CD	O
mg	NN	O
dose	NN	O
(	(	O
10.17	CD	O
vs	RB	O
4.96	CD	O
x	JJ	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
;	:	O
P=0.014	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
clinically	NN	O
relevant	JJ	O
period	NN	O
of	IN	O
days	NNS	O
3-7	CD	O
,	,	O
both	DT	O
12	CD	O
and	CC	O
18	CD	O
mg	NN	O
pegfilgrastim	NN	O
doses	NNS	O
produced	VBD	O
significantly	RB	O
higher	JJR	O
peak	NN	O
CD34+	NNP	O
counts	VBZ	O
(	(	O
8.18	CD	O
and	CC	O
9.96	CD	O
vs	NN	O
4.51	CD	O
x	NN	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
for	IN	O
filgrastim	NN	O
;	:	O
P=0.034	NNP	O
and	CC	O
0.006	CD	O
)	)	O
.	.	O

In	IN	O
cycle	NN	O
1	CD	O
,	,	O
patients	NNS	O
received	VBD	O
carboplatin/paclitaxel	NNS	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
followed	VBD	O
from	IN	O
day	NN	O
2	CD	O
by	IN	O
pegfilgrastim	JJ	O
6-18	JJ	O
mg	NN	O
or	CC	O
daily	JJ	O
filgrastim	NN	O
(	(	O
5	CD	O
microg/kg/day	NN	O
for	IN	O
<	NN	O
or	CC	O
=14	NNP	O
days	NNS	O
)	)	O
as	IN	O
per	IN	O
randomization	NN	O
in	IN	O
cycle	NN	O
0	CD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mean	JJ	O
peak	NN	O
CD34+	NNP	O
count	NN	O
between	IN	O
pegfilgrastim	NN	O
and	CC	O
filgrastim	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
an	DT	O
advantage	NN	O
for	IN	O
pegfilgrastim	NN	O
18	CD	O
mg	NN	O
in	IN	O
the	DT	O
relevant	JJ	O
period	NN	O
of	IN	O
days	NNS	O
7-12	NNP	O
(	(	O
3.14	CD	O
vs	RB	O
1.19	CD	O
x	JJ	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
;	:	O
P=0.043	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
pegfilgrastim	NN	O
dose	NN	O
(	(	O
>	CD	O
or	CC	O
=6	VB	O
mg	NN	O
)	)	O
could	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
daily	JJ	O
filgrastim	NN	O
in	IN	O
cytokine-only	JJ	O
peripheral	JJ	O
CD34+	NNP	O
cell	NN	O
mobilization	NN	O
.	.	O

The	DT	O
dipeptidyl	JJ	O
peptidase-4	JJ	O
inhibitor	NN	O
PHX1149	NNP	O
improves	VBZ	O
blood	NN	O
glucose	NN	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
mellitus	RB	C
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
PHX1149	NNP	O
,	,	O
a	DT	O
novel	JJ	O
dipeptidyl	NN	O
peptidase-4	NN	O
(	(	O
DPP4	NNP	O
)	)	O
inhibitor	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	C
2	CD	C
diabetes	NNS	C
.	.	O

METHODS	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
multicentre	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
4-week	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
with	IN	O
suboptimal	JJ	O
metabolic	JJ	O
control	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
baseline	NN	O
haemoglobin	NN	O
A	NNP	O
(	(	O
1c	CD	O
)	)	O
(	(	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
)	)	O
of	IN	O
7.3	CD	O
to	TO	O
11.0	CD	O
%	NN	O
were	VBD	O
randomized	VBN	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
to	TO	O
receive	VB	O
once-daily	JJ	O
oral	JJ	O
therapy	NN	O
with	IN	O
either	DT	O
PHX1149	NNP	O
(	(	O
100	CD	O
,	,	O
200	CD	O
or	CC	O
400	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
;	:	O
patients	NNS	O
were	VBD	O
on	IN	O
a	DT	O
constant	JJ	O
background	NN	O
therapy	NN	O
of	IN	O
either	DT	O
metformin	NN	O
alone	RB	O
or	CC	O
metformin	JJ	O
plus	CC	O
a	DT	O
glitazone	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
100	CD	O
,	,	O
200	CD	O
or	CC	O
400	CD	O
mg	NN	O
of	IN	O
PHX1149	NNP	O
significantly	RB	O
decreased	VBD	O
postprandial	JJ	O
glucose	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
AUC	NNP	O
(	(	O
0-2	JJ	O
h	NN	O
)	)	O
by	IN	O
approximately	RB	O
20	CD	O
%	NN	O
(	(	O
+0.11	JJ	O
+/-	JJ	O
0.50	CD	O
,	,	O
-2.08	VBD	O
+/-	JJ	O
0.51	CD	O
,	,	O
-1.73	VBD	O
+/-	JJ	O
0.49	CD	O
and	CC	O
-1.88	VB	O
+/-	JJ	O
0.48	CD	O
mmol/l	NN	O
x	NN	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
(	(	O
p	JJ	O
=	NN	O
0.002	CD	O
,	,	O
0.008	CD	O
and	CC	O
0.004	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Postprandial	JJ	O
AUC	NNP	O
(	(	O
0-2	JJ	O
h	NN	O
)	)	O
of	IN	O
intact	JJ	O
glucagon-like	JJ	O
peptide-1	NN	O
,	,	O
the	DT	O
principal	JJ	O
mediator	NN	O
of	IN	O
the	DT	O
biological	JJ	O
effects	NNS	O
of	IN	O
DPP4	NNP	O
inhibitors	NNS	O
,	,	O
was	VBD	O
increased	VBN	O
by	IN	O
3.90	CD	O
+/-	JJ	O
2.83	CD	O
,	,	O
11.63	CD	O
+/-	JJ	O
2.86	CD	O
,	,	O
16.42	CD	O
+/-	JJ	O
2.72	CD	O
and	CC	O
15.75	CD	O
+/-	JJ	O
2.71	CD	O
pmol/l	NN	O
x	NN	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
(	(	O
p	JJ	O
=	NN	O
0.053	CD	O
,	,	O
0.001	CD	O
and	CC	O
0.002	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Mean	JJ	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
was	VBD	O
lower	JJR	O
in	IN	O
all	DT	O
dose	JJ	O
groups	NNS	O
;	:	O
the	DT	O
placebo-corrected	JJ	O
change	NN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
400	CD	O
mg	JJ	O
PHX1149	NNP	O
was	VBD	O
-0.28	VBN	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

DPP4	NNP	O
inhibition	NN	O
on	IN	O
day	NN	O
28	CD	O
was	VBD	O
53	CD	O
,	,	O
73	CD	O
and	CC	O
78	CD	O
%	NN	O
at	IN	O
24	CD	O
h	NN	O
postdose	NN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
PHX1149	NNP	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	O
events	NNS	O
between	IN	O
PHX1149-treated	NNP	O
and	CC	O
placebo	JJ	O
subjects	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Addition	NNP	O
of	IN	O
the	DT	O
DPP4	NNP	O
inhibitor	NN	O
PHX1149	NNP	O
to	TO	O
a	DT	O
stable	JJ	O
regimen	NN	O
of	IN	O
metformin	NN	O
or	CC	O
metformin	NN	O
plus	CC	O
a	DT	O
glitazone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
improved	VBN	O
blood	NN	O
glucose	NN	O
control	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
intermittent	JJ	O
vaginal	JJ	O
administration	NN	O
of	IN	O
misoprostol	NN	O
with	IN	O
continuous	JJ	O
dinoprostone	NN	O
for	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
labor	NN	O
induction	NN	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
vaginal	JJ	O
administration	NN	O
of	IN	O
misoprostol	NN	O
(	(	O
Cytotec	NNP	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
dinoprostone	NN	O
(	(	O
Cervidil	NNP	O
)	)	O
on	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
labor	NN	O
induction	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Two	CD	SS
hundred	VBD	SS
patients	NNS	O
with	IN	O
indications	NNS	O
for	IN	O
induction	NN	C
of	IN	C
labor	NN	C
and	CC	O
unfavorable	JJ	C
cervical	JJ	C
examinations	NNS	C
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
vaginally	RB	O
administered	VBN	O
misoprostol	NN	O
(	(	O
prostaglandin	JJ	O
E1	NNP	O
)	)	O
or	CC	O
the	DT	O
dinoprostone	NN	O
(	(	O
prostaglandin	JJ	O
E2	NNP	O
)	)	O
vaginal	NN	O
insert	NN	O
.	.	O

Twenty-five	JJ	O
microgram	JJ	O
tablets	NNS	O
of	IN	O
misoprostol	NN	O
were	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
posterior	JJ	O
vaginal	JJ	O
fornix	NN	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
six	CD	O
doses	NNS	O
.	.	O

Additional	NNP	O
misoprostol	NN	O
was	VBD	O
not	RB	O
given	VBN	O
after	IN	O
either	DT	O
spontaneous	JJ	O
rupture	NN	O
of	IN	O
membranes	NNS	O
,	,	O
adequate	JJ	O
cervical	JJ	O
ripening	NN	O
(	(	O
Bishop	NNP	O
score	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
8	CD	O
or	CC	O
cervical	JJ	O
dilatation	NN	O
of	IN	O
>	NN	O
or	CC	O
=	$	O
3	CD	O
cm	NN	O
)	)	O
,	,	O
or	CC	O
beginning	NN	O
of	IN	O
active	JJ	O
labor	NN	O
.	.	O

The	DT	O
vaginal	JJ	O
insert	NN	O
,	,	O
Cervidil	NNP	O
,	,	O
containing	VBG	O
10	CD	O
mg	NN	O
of	IN	O
dinoprostone	NN	O
in	IN	O
a	DT	O
timed-release	JJ	O
preparation	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
posterior	JJ	O
vaginal	JJ	O
formix	NN	O
for	IN	O
a	DT	O
maximum	JJ	O
period	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
vaginal	JJ	O
insert	NN	O
was	VBD	O
removed	VBN	O
for	IN	O
spontaneous	JJ	O
rupture	NN	O
of	IN	O
membranes	NNS	O
,	,	O
entry	NN	O
into	IN	O
active	JJ	O
labor	NN	O
,	,	O
adequate	JJ	O
cervical	JJ	O
ripening	NN	O
,	,	O
or	CC	O
abnormality	NN	O
of	IN	O
uterine	JJ	O
contractile	NN	O
pattern	NN	O
or	CC	O
fetal	JJ	O
cardiac	JJ	O
activity	NN	O
.	.	O

RESULTS	NN	O
Of	IN	O
the	DT	O
200	CD	SS
patients	NNS	O
enrolled	VBD	O
,	,	O
99	CD	SS
were	VBD	O
randomized	VBN	O
to	TO	O
misoprostol	VB	O
and	CC	O
101	CD	SS
to	TO	O
dinoprostone	VB	O
.	.	O

The	DT	O
average	JJ	O
interval	NN	O
from	IN	O
start	NN	O
of	IN	O
induction	NN	O
to	TO	O
vaginal	JJ	O
delivery	NN	O
was	VBD	O
1	CD	O
hour	NN	O
shorter	NN	O
in	IN	O
the	DT	O
misoprostol	NN	O
group	NN	O
(	(	O
1296.7	CD	O
+/-	JJ	O
722.1	CD	O
minutes	NNS	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
dinoprostone	NN	O
group	NN	O
(	(	O
1360.0	CD	O
+/-	JJ	O
792.0	CD	O
minutes	NNS	O
)	)	O
,	,	O
but	CC	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

Oxytocin	NNP	O
augmentation	NN	O
of	IN	O
labor	NN	O
was	VBD	O
used	VBN	O
in	IN	O
50	CD	O
(	(	O
50.5	CD	O
%	NN	O
)	)	O
misoprostol-treated	JJ	O
patients	NNS	O
and	CC	O
43	CD	O
(	(	O
43.5	CD	O
%	NN	O
)	)	O
dinoprostone-treated	JJ	O
patients	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
1.14	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.86	CD	O
to	TO	O
1.51	CD	O
,	,	O
p	NN	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
routes	NNS	O
of	IN	O
delivery	NN	O
with	IN	O
misoprostol	NN	O
or	CC	O
dinoprostone	NN	O
.	.	O

Overall	NNP	O
,	,	O
38	CD	SS
patients	NNS	O
(	(	O
19.3	CD	O
%	NN	O
)	)	O
had	VBD	O
cesarean	JJ	O
deliveries	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
prevalence	NN	O
of	IN	O
tachysystole	NN	O
(	(	O
six	CD	O
or	CC	O
more	JJR	O
uterine	JJ	O
contractions	NNS	O
in	IN	O
a	DT	O
10-minute	JJ	O
window	NN	O
for	IN	O
two	CD	O
consecutive	JJ	O
10-minute	JJ	O
periods	NNS	O
)	)	O
in	IN	O
the	DT	O
misoprostol	NN	O
group	NN	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
dinoprostone	NN	O
group	NN	O
(	(	O
18.4	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk	NN	O
0.52	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.31	CD	O
to	TO	O
0.89	CD	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
frequency	NN	O
of	IN	O
uterine	JJ	O
hyperstimulation	NN	O
or	CC	O
hypertonus	NN	O
.	.	O

Abnormal	NNP	O
fetal	JJ	O
heart	NN	O
rate	NN	O
tracings	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
23	CD	O
(	(	O
23.2	CD	O
%	NN	O
)	)	O
of	IN	O
misoprostol-treated	JJ	O
patients	NNS	O
and	CC	O
35	CD	O
(	(	O
35.7	CD	O
%	NN	O
)	)	O
of	IN	O
dinoprostone-treated	JJ	O
patients	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
0.73	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.52	CD	O
to	TO	O
1.01	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0546	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
meconium	NN	O
passage	NN	O
,	,	O
1-	JJ	O
or	CC	O
5-minute	JJ	O
Apgar	NNP	O
scores	NNS	O
<	VBP	O
7	CD	O
,	,	O
neonatal	JJ	O
resuscitations	NNS	O
,	,	O
or	CC	O
admissions	NNS	O
to	TO	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Vaginally	NNP	O
administered	VBD	O
misoprostol	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
dinoprostone	NN	O
for	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
the	DT	O
induction	NN	O
of	IN	O
labor	NN	O
.	.	O

Mean	JJ	O
time	NN	O
intervals	NNS	O
to	TO	O
delivery	NN	O
,	,	O
need	NN	O
for	IN	O
oxytocin	JJ	O
augmentation	NN	O
,	,	O
and	CC	O
routes	NNS	O
of	IN	O
delivery	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Incidence	NN	O
of	IN	O
uterine	JJ	O
tachysystole	NN	O
with	IN	O
misoprostol	NN	O
every	DT	O
4	CD	O
hours	NNS	O
was	VBD	O
significantly	RB	O
less	JJR	O
than	IN	O
with	IN	O
dinoprostone	NN	O
.	.	O

Effect	NN	O
of	IN	O
entacapone	NN	O
,	,	O
a	DT	O
peripherally	RB	O
acting	VBG	O
catechol-O-methyltransferase	NN	O
inhibitor	NN	O
,	,	O
on	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
acute	VB	O
treatment	NN	O
with	IN	O
levodopa	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
.	.	O

Catechol-O-methyltransferase	NNP	O
(	(	O
COMT	NNP	O
)	)	O
inhibitors	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
by	IN	O
improving	VBG	O
the	DT	O
bioavailability	NN	O
of	IN	O
levodopa	NN	O
and	CC	O
by	IN	O
prolonging	VBG	O
its	PRP$	O
effects	NNS	O
.	.	O

Entacapone	NNP	O
(	(	O
OR-611	NNP	O
)	)	O
,	,	O
a	DT	O
novel	JJ	O
COMT	NNP	O
inhibitor	NN	O
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
cross	VB	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
in	IN	O
12	CD	SS
patients	NNS	O
with	IN	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
and	CC	O
motor	NN	C
fluctuations	NNS	C
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
,	,	O
single	JJ	O
dose	NN	O
study	NN	O
.	.	O

The	DT	O
magnitude	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
response	NN	O
to	TO	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
levodopa/50	JJ	O
mg	FW	O
carbidopa	NN	O
was	VBD	O
evaluated	VBN	O
after	IN	O
concomitant	JJ	O
placebo	NN	O
,	,	O
or	CC	O
200	CD	O
or	CC	O
800	CD	O
mg	NN	O
entacapone	NN	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
levodopa	NN	O
was	VBD	O
seen	VBN	O
when	WRB	O
200	CD	O
mg	NN	O
entacapone	NN	O
was	VBD	O
given	VBN	O
with	IN	O
levodopa/carbidopa	NN	O
.	.	O

Plasma	NNP	O
levodopa	JJ	O
concentrations	NNS	O
were	VBD	O
increased	VBN	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
the	DT	O
COMT	NNP	O
inhibitor	NN	O
.	.	O

The	DT	O
latency	NN	O
to	TO	O
onset	VB	O
of	IN	O
motor	NN	O
response	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
active	JJ	O
drug	NN	O
and	CC	O
placebo	NN	O
.	.	O

Entacapone	NN	O
may	MD	O
prove	VB	O
useful	JJ	O
in	IN	O
prolonging	VBG	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
benefit	NN	O
obtained	VBN	O
from	IN	O
individual	JJ	O
doses	NNS	O
of	IN	O
levodopa	NN	O
.	.	O

Measurement	NN	O
of	IN	O
transfer	NN	O
factor	NN	O
during	IN	O
constant	JJ	O
exhalation	NN	O
.	.	O

BACKGROUND	NNP	O
Transfer	NNP	O
factor	NN	O
of	IN	O
the	DT	O
lung	NN	O
for	IN	O
carbon	NN	O
monoxide	NN	O
(	(	O
TLCO	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
new	JJ	O
method	NN	O
based	VBN	O
on	IN	O
analysis	NN	O
of	IN	O
the	DT	O
ratio	NN	O
of	IN	O
the	DT	O
concentrations	NNS	O
of	IN	O
carbon	NN	O
monoxide	NN	O
to	TO	O
an	DT	O
inert	NN	O
gas	NN	O
(	(	O
methane	NN	O
)	)	O
relative	NN	O
to	TO	O
lung	NN	O
volume	NN	O
during	IN	O
a	DT	O
constant	JJ	O
exhalation	NN	O
.	.	O

Since	IN	O
this	DT	O
new	JJ	O
technique	NN	O
is	VBZ	O
based	VBN	O
solely	RB	O
upon	JJ	O
exhalation	NN	O
,	,	O
anomalies	NNS	O
associated	VBN	O
with	IN	O
inspiration	NN	O
and	CC	O
breath	NN	O
holding	VBG	O
do	VBP	O
not	RB	O
affect	VB	O
results	NNS	O
.	.	O

Additionally	RB	O
,	,	O
because	IN	O
prolonged	JJ	O
breath	NN	O
holding	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
,	,	O
measurements	NNS	O
can	MD	O
readily	RB	O
be	VB	O
made	VBN	O
in	IN	O
dyspnoeic	JJ	C
patients	NNS	O
.	.	O

METHODS	NNP	O
Exhalation	NNP	O
TLCO	NNP	O
(	(	O
TLCO	NNP	O
,	,	O
ex	NN	O
)	)	O
was	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
standard	NN	O
(	(	O
Jones	NNP	O
and	CC	O
Meade	NNP	O
)	)	O
10	CD	O
second	JJ	O
breath	NN	O
holding	VBG	O
TLCO	NNP	O
(	(	O
TLCO	NNP	O
,	,	O
bh	NN	O
)	)	O
in	IN	O
100	CD	SS
consecutive	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
did	VBD	O
not	RB	O
practise	VB	O
the	DT	O
exhalation	NN	O
manoeuvre	NN	O
prior	RB	O
to	TO	O
testing	VBG	O
.	.	O

RESULTS	VB	O
The	DT	O
comparative	JJ	O
results	NNS	O
were	VBD	O
very	RB	O
close	RB	O
;	:	O
mean	JJ	O
difference	NN	O
(	(	O
bias	JJ	O
)	)	O
+/-	JJ	O
standard	JJ	O
deviation	NN	O
(	(	O
precision	NN	O
)	)	O
was	VBD	O
0.05	CD	O
(	(	O
0.84	CD	O
)	)	O
mmol/min/kPa	NN	O
.	.	O

The	DT	O
relation	NN	O
was	VBD	O
equally	RB	O
strong	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	C
pulmonary	JJ	C
disease	NN	C
;	:	O
for	IN	O
patients	NNS	O
with	IN	O
FEV1	NNP	O
<	$	O
1.51	CD	O
the	DT	O
mean	NN	O
difference	NN	O
was	VBD	O
0.21	CD	O
(	(	O
0.80	CD	O
)	)	O
mmol/min/kPa	NN	O
.	.	O

CONCLUSIONS	NNP	O
Since	IN	O
the	DT	O
results	NNS	O
were	VBD	O
essentially	RB	O
identical	JJ	O
between	IN	O
the	DT	O
techniques	NNS	O
,	,	O
it	PRP	O
seems	VBZ	O
that	IN	O
comparable	JJ	O
pathophysiological	JJ	O
factors	NNS	O
affect	VBP	O
TLCO	NNP	O
during	IN	O
breath	NN	O
holding	NN	O
and	CC	O
constant	JJ	O
exhalation	NN	O
.	.	O

Constant	JJ	O
exhalation	NN	O
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
useful	JJ	O
alternative	NN	O
to	TO	O
the	DT	O
breath	NN	O
holding	NN	O
technique	NN	O
for	IN	O
clinical	JJ	O
measurement	NN	O
of	IN	O
TLCO	NNP	O
.	.	O

Paricalcitol	NNP	O
capsule	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
secondary	JJ	C
hyperparathyroidism	NN	C
in	IN	O
stages	NNS	C
3	CD	C
and	CC	C
4	CD	C
CKD	NNP	C
.	.	O

BACKGROUND	NNP	O
The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
paricalcitol	NN	O
injection	NN	O
have	VBP	O
been	VBN	O
well	RB	O
established	VBN	O
for	IN	O
the	DT	O
prevention	NN	O
and	CC	O
treatment	NN	O
of	IN	O
secondary	JJ	O
hyperparathyroidism	NN	O
(	(	O
SHPT	NNP	C
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	C
kidney	NN	C
disease	NN	C
(	(	O
CKD	NNP	C
)	)	O
stage	NN	C
5	CD	C
.	.	O

The	DT	O
capsule	JJ	O
form	NN	O
of	IN	O
paricalcitol	NN	O
was	VBD	O
developed	VBN	O
to	TO	O
provide	VB	O
a	DT	O
convenient	JJ	O
dosage	NN	O
form	NN	O
for	IN	O
patients	NNS	O
with	IN	O
stages	NNS	O
3	CD	O
and	CC	O
4	CD	O
CKD	NNP	O
.	.	O

METHODS	NNP	O
Three	NNP	O
randomized	VBD	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase-3	JJ	O
trials	NNS	O
were	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
stages	NNS	O
3	CD	O
and	CC	O
4	CD	O
CKD	NNP	O
with	IN	O
SHPT	NNP	O
.	.	O

Enrollment	NNP	O
criteria	NNS	O
included	VBD	O
an	DT	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
between	IN	O
15	CD	O
and	CC	O
60	CD	O
mL/min/1.73	NN	O
m2	NN	O
(	(	O
0.25	CD	O
and	CC	O
1.00	CD	O
mL/s/1.73	NNS	O
m2	NN	O
)	)	O
,	,	O
an	DT	O
average	NN	O
of	IN	O
2	CD	O
consecutive	JJ	O
intact	JJ	O
parathyroid	NN	O
hormone	NN	O
(	(	O
iPTH	NN	O
)	)	O
levels	NNS	O
greater	JJR	O
than	IN	O
150	CD	O
pg/mL	NN	O
(	(	O
ng/L	JJ	O
)	)	O
,	,	O
2	CD	O
consecutive	JJ	O
serum	NN	O
calcium	NN	O
levels	NNS	O
between	IN	O
8.0	CD	O
and	CC	O
10.0	CD	O
mg/dL	NN	O
(	(	O
2.00	CD	O
and	CC	O
2.50	CD	O
mmol/L	NN	O
)	)	O
,	,	O
and	CC	O
2	CD	O
consecutive	JJ	O
serum	NN	O
phosphorus	NN	O
levels	NNS	O
of	IN	O
5.2	CD	O
mg/dL	NN	O
or	CC	O
less	JJR	O
(	(	O
<	NN	O
or	CC	O
=	$	O
1.68	CD	O
mmol/L	NN	O
)	)	O
.	.	O

Two	CD	O
studies	NNS	O
used	VBD	O
a	DT	O
thrice-weekly	JJ	O
dosing	NN	O
regimen	NNS	O
and	CC	O
1	CD	O
study	NN	O
used	VBD	O
a	DT	O
once-daily	JJ	O
dosing	NN	O
regimen	NNS	O
for	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Dosing	NNP	O
was	VBD	O
based	VBN	O
on	IN	O
serum	NN	O
iPTH	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
phosphorus	NN	O
levels	NNS	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	JJ	O
end	NN	O
point	NN	O
is	VBZ	O
2	CD	O
consecutive	JJ	O
decreases	NNS	O
in	IN	O
iPTH	NN	O
levels	NNS	O
greater	JJR	O
than	IN	O
30	CD	O
%	NN	O
from	IN	O
baseline	NN	O
.	.	O

RESULTS	NNP	O
Two	CD	SS
hundred	VBD	SS
twenty	NN	SS
patients	NNS	O
participated	VBD	O
(	(	O
n	JJ	O
=	NN	O
107	CD	SS
,	,	O
paricalcitol	NN	O
;	:	O
n	CC	O
=	$	O
113	CD	SS
,	,	O
placebo	NN	O
)	)	O
.	.	O

At	IN	O
least	JJS	O
2	CD	O
consecutive	JJ	O
decreases	NNS	O
in	IN	O
iPTH	JJ	O
levels	NNS	O
of	IN	O
30	CD	O
%	NN	O
or	CC	O
greater	JJR	O
from	IN	O
baseline	NN	O
occurred	VBN	O
in	IN	O
91	CD	O
%	NN	O
of	IN	O
paricalcitol	JJ	O
versus	FW	O
13	CD	O
%	NN	O
of	IN	O
placebo	NN	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Incidences	NNS	O
of	IN	O
hypercalcemia	NN	O
,	,	O
hyperphosphatemia	NN	O
,	,	O
and	CC	O
elevated	VBD	O
calcium-phosphorus	JJ	O
product	NN	O
levels	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Similarly	RB	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
urinary	JJ	O
calcium	NN	O
and	CC	O
phosphorus	JJ	O
excretion	NN	O
or	CC	O
deterioration	NN	O
in	IN	O
kidney	NN	O
function	NN	O
were	VBD	O
detected	VBN	O
in	IN	O
patients	NNS	O
administered	VBN	O
paricalcitol	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
Paricalcitol	NNP	O
capsule	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
effectively	RB	O
decreased	VBN	O
iPTH	NN	O
levels	NNS	O
with	IN	O
minimal	JJ	O
or	CC	O
no	DT	O
impact	NN	O
on	IN	O
calcium	NN	O
levels	NNS	O
,	,	O
phosphorus	NN	O
balance	NN	O
,	,	O
and	CC	O
kidney	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stages	NNS	O
3	CD	O
and	CC	O
4	CD	O
CKD	NNP	O
.	.	O

Timing	VBG	O
for	IN	O
delivering	VBG	O
individualized	JJ	O
patient	JJ	O
education	NN	O
intervention	NN	O
to	TO	O
Coronary	NNP	C
Artery	NNP	C
Bypass	NNP	C
Graft	NNP	C
patients	NNS	O
:	:	O
An	DT	O
RCT	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
primary	JJ	O
focus	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
on	IN	O
the	DT	O
timing	NN	O
of	IN	O
the	DT	O
delivery	NN	O
of	IN	O
education	NN	O
to	TO	O
patients	NNS	O
who	WP	O
had	VBD	O
CABG	NNP	C
surgery	NN	C
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
individualized	JJ	O
telephone	NN	O
patient	JJ	O
education	NN	O
intervention	NN	O
,	,	O
delivered	VBN	O
at	IN	O
two	CD	O
different	JJ	O
points	NNS	O
in	IN	O
time	NN	O
(	(	O
1-2	JJ	O
days	NNS	O
pre-discharge	JJ	O
versus	JJ	O
1-2	JJ	O
days	NNS	O
post-discharge	NN	O
)	)	O
in	IN	O
enhancing	VBG	O
the	DT	O
CABG	NNP	C
patient	NN	O
's	POS	O
knowledge	NN	O
of	IN	O
self-care	JJ	O
behaviours	NNS	O
,	,	O
performance	NN	O
of	IN	O
self-care	JJ	O
behaviours	NNS	O
,	,	O
and	CC	O
symptom	JJ	O
frequency	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
that	WDT	O
included	VBD	O
a	DT	O
convenience	NN	O
sample	NN	O
of	IN	O
first	JJ	O
time	NN	O
CABG	NNP	C
patients	NNS	O
.	.	O

Individuals	NNS	O
who	WP	O
received	VBD	O
education	NN	O
pre-discharge	NN	O
were	VBD	O
compared	VBN	O
to	TO	O
individuals	NNS	O
who	WP	O
received	VBD	O
education	NN	O
post-discharge	NN	O
on	IN	O
the	DT	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
indicated	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

As	NNP	O
well	RB	O
,	,	O
anxiety	NN	O
levels	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
pre-discharge	NN	O
group	NN	O
than	IN	O
the	DT	O
post-discharge	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
individualized	JJ	O
nature	NN	O
of	IN	O
the	DT	O
educational	JJ	O
intervention	NN	O
may	MD	O
have	VB	O
accounted	VBN	O
for	IN	O
non-significant	JJ	O
findings	NNS	O
reported	VBN	O
in	IN	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

PRACTICE	NNP	O
IMPLICATIONS	NNP	O
Nurses	NNP	O
may	MD	O
consider	VB	O
assessing	VBG	O
anxiety	NN	O
levels	NNS	O
prior	RB	O
to	TO	O
delivery	NN	O
of	IN	O
educational	JJ	O
interventions	NNS	O
,	,	O
implement	JJ	O
interventions	NNS	O
aimed	VBN	O
at	IN	O
reducing	VBG	O
anxiety	NN	O
levels	NNS	O
,	,	O
and	CC	O
provide	VB	O
individualized	JJ	O
teaching	NN	O
.	.	O

Genotyping	VBG	O
of	IN	O
CYP21	NNP	O
,	,	O
linked	VBD	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
,	,	O
and	CC	O
a	DT	O
sex-specific	JJ	O
gene	NN	O
in	IN	O
neonatal	JJ	A
screening	NN	O
for	IN	O
congenital	JJ	C
adrenal	JJ	C
hyperplasia	NN	C
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
and	CC	O
diagnostic	JJ	O
utility	NN	O
of	IN	O
genotyping	VBG	O
9	CD	O
CYP21	NNP	O
mutations	NNS	O
,	,	O
linked	VBD	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
,	,	O
and	CC	O
a	DT	O
dimorphic	JJ	O
X-Y	JJ	O
marker	NN	O
from	IN	O
neonatal	JJ	A
screening	NN	O
samples	NNS	O
.	.	O

Blood-impregnated	JJ	O
filter	NN	O
papers	NNS	O
(	(	O
Guthrie	NNP	O
cards	NNS	O
)	)	O
from	IN	O
603	CD	SS
randomly	RB	O
chosen	VBN	O
New	NNP	O
Zealand	NNP	O
neonates	NNS	A
were	VBD	O
genotyped	VBN	O
blind	IN	O
to	TO	O
17-hydroxyprogesterone	CD	O
(	(	O
17-OHP	CD	O
)	)	O
levels	NNS	O
.	.	O

Another	DT	O
50	CD	SS
samples	NNS	O
from	IN	O
Swiss	NNP	O
and	CC	O
North	NNP	O
American	JJ	O
infants	NNS	O
with	IN	O
correlative	JJ	O
hormonal	JJ	O
data	NNS	O
were	VBD	O
also	RB	O
genotyped	VBN	O
.	.	O

DNA	NN	O
was	VBD	O
extracted	VBN	O
,	,	O
and	CC	O
gene-specific	JJ	O
PCR	NNP	O
was	VBD	O
performed	VBN	O
.	.	O

CYP21	NNP	O
PCR	NNP	O
products	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
ligase	VB	O
detection	NN	O
reaction	NN	O
,	,	O
simultaneously	RB	O
analyzing	VBG	O
9	CD	O
CYP21	NNP	O
mutations	NNS	O
;	:	O
PCR	NNP	O
products	NNS	O
of	IN	O
other	JJ	O
genes	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
direct	VB	O
gel	JJ	O
analysis	NN	O
.	.	O

CYP21	NNP	O
genotyping	VBG	O
indicated	VBD	O
a	DT	O
heterozygote	NN	O
rate	NN	O
of	IN	O
2.8	CD	O
%	NN	O
for	IN	O
classic	JJ	O
mutations	NNS	O
(	(	O
excluding	VBG	O
CYP21	NNP	O
deletions	NNS	O
)	)	O
,	,	O
and	CC	O
2.0	CD	O
%	NN	O
for	IN	O
nonclassic	JJ	O
mutations	NNS	O
in	IN	O
New	NNP	O
Zealanders	NNP	O
.	.	O

Ten	CD	O
full-term	JJ	O
affected	JJ	O
neonates	NNS	O
showed	VBD	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
17-OHP	JJ	O
levels	NNS	O
(	(	O
15-1400	JJ	O
nmol/L	NN	O
)	)	O
.	.	O

Sick	NNP	O
or	CC	O
preterm	JJ	O
infants	NNS	O
or	CC	O
infants	NNS	O
screened	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
life	NN	O
with	IN	O
high	JJ	O
17-OHP	JJ	O
proved	VBN	O
genetically	RB	O
unaffected	JJ	O
.	.	O

Genetic	JJ	O
linkage	NN	O
disequilibrium	NN	O
was	VBD	O
found	VBN	O
between	IN	O
two	CD	O
CYP21	NNP	O
mutations	NNS	O
and	CC	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
.	.	O

Guthrie	NNP	O
cards	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
accurately	RB	O
genotype	VB	O
CYP21	NNP	O
and	CC	O
other	JJ	O
relevant	JJ	O
markers	NNS	O
,	,	O
potentially	RB	O
enhancing	VBG	O
the	DT	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
of	IN	O
congenital	JJ	O
adrenal	JJ	O
hyperplasia	NN	O
screening	NN	O
.	.	O

CYP21	NNP	O
heterozygote	JJ	O
frequency	NN	O
for	IN	O
classic	JJ	O
mutations	NNS	O
is	VBZ	O
higher	JJR	O
than	IN	O
expected	VBN	O
based	VBN	O
on	IN	O
genotype	NN	O
compared	VBN	O
with	IN	O
that	DT	O
predicted	VBN	O
by	IN	O
hormonal	JJ	O
newborn	JJ	A
screening	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
rectal	JJ	O
midazolam	NN	O
and	CC	O
diazepam	NN	O
for	IN	O
premedication	NN	O
in	IN	O
pediatric	JJ	A
dental	JJ	C
patients	NNS	C
.	.	O

Rectally	RB	O
administered	VBN	O
midazolam	NN	O
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
diazepam	NN	O
(	(	O
0.70	CD	O
mg/kg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
each	DT	O
other	JJ	O
and	CC	O
with	IN	O
placebo	NN	O
for	IN	O
preanesthetic	JJ	O
medication	NN	O
in	IN	O
children	NNS	A
undergoing	VBG	O
dental	JJ	C
extractions	NNS	C
.	.	O

All	DT	O
rectal	JJ	O
medications	NNS	O
were	VBD	O
very	RB	O
well	RB	O
accepted	VBN	O
,	,	O
but	CC	O
mask	JJ	O
acceptance	NN	O
,	,	O
improvement	NN	O
in	IN	O
anxiety	NN	O
,	,	O
and	CC	O
sedation	NN	O
were	VBD	O
best	RBS	O
in	IN	O
the	DT	O
midazolam	NN	O
group	NN	O
.	.	O

Improvement	NNP	O
in	IN	O
anxiety	NN	O
and	CC	O
sedation	NN	O
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
two	CD	O
drug	NN	O
groups	NNS	O
than	IN	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
placebo	NN	O
.	.	O

Thirty	NNP	O
minutes	NNS	O
after	IN	O
rectal	JJ	O
administration	NN	O
of	IN	O
midazolam	NNS	O
,	,	O
patients	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
.	.	O

Although	IN	O
these	DT	O
decreases	NNS	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
premedication	NN	O
values	NNS	O
,	,	O
they	PRP	O
were	VBD	O
probably	RB	O
of	IN	O
little	JJ	O
clinical	JJ	O
importance	NN	O
.	.	O

Only	RB	O
minor	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Overall	NNP	O
rectally	RB	O
administered	VBD	O
midazolam	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
somewhat	RB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
diazepam	NN	O
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
Panax	NNP	O
quinquefolius	NN	O
(	(	O
American	NNP	O
ginseng	NN	O
)	)	O
to	TO	O
improve	VB	O
cancer-related	JJ	C
fatigue	NN	C
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
dose-finding	JJ	O
evaluation	NN	O
:	:	O
NCCTG	NNP	O
trial	NN	O
N03CA	NNP	O
.	.	O

PURPOSE	NNP	O
This	DT	O
pilot	NN	O
trial	NN	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
any	DT	O
of	IN	O
three	CD	O
doses	NNS	O
of	IN	O
American	JJ	O
ginseng	NN	O
(	(	O
Panax	NNP	O
quinquefolius	RB	O
)	)	O
might	MD	O
help	VB	O
cancer-related	JJ	C
fatigue	NN	C
.	.	O

A	DT	O
secondary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
toxicity	NN	O
.	.	O

METHODS	NNP	O
Eligible	JJ	O
adults	NNS	A
with	IN	O
cancer	NN	C
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
manner	NN	O
,	,	O
to	TO	O
receive	VB	O
American	JJ	O
ginseng	NN	O
in	IN	O
doses	NNS	O
of	IN	O
750	CD	O
,	,	O
1,000	CD	O
,	,	O
or	CC	O
2,000	CD	O
mg/day	NN	O
or	CC	O
placebo	VB	O
given	VBN	O
in	IN	O
twice	JJ	O
daily	JJ	O
dosing	NN	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Brief	NNP	O
Fatigue	NNP	O
Inventory	NNP	O
,	,	O
vitality	NN	O
subscale	NN	O
of	IN	O
the	DT	O
Medical	NNP	O
Outcome	NNP	O
Scale	NNP	O
Short	NNP	O
Form-36	NNP	O
(	(	O
SF-36	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Global	NNP	O
Impression	NNP	O
of	IN	O
Benefit	NNP	O
Scale	NNP	O
at	IN	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Two	CD	SS
hundred	VBD	SS
ninety	NN	SS
patients	NNS	O
were	VBD	O
accrued	VBN	O
to	TO	O
this	DT	O
trial	NN	O
.	.	O

Nonsignificant	JJ	O
trends	NNS	O
for	IN	O
all	DT	O
outcomes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
doses	NNS	O
of	IN	O
American	JJ	O
ginseng	NN	O
.	.	O

Area	NNP	O
under	IN	O
the	DT	O
curve	NN	O
analysis	NN	O
of	IN	O
activity	NN	O
interference	NN	O
from	IN	O
the	DT	O
Brief	NNP	O
Fatigue	NNP	O
Inventory	NNP	O
was	VBD	O
460-467	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
750	CD	O
mg/day	NN	O
group	NN	O
versus	VBD	O
480-551	CD	O
in	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
vitality	NN	O
subscale	NN	O
of	IN	O
the	DT	O
SF-36	NNP	O
was	VBD	O
7.3-7.8	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
and	CC	O
the	DT	O
750-mg/day	JJ	O
arm	NN	O
,	,	O
versus	NN	O
10.5-14.6	JJ	O
in	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
arms	NNS	O
.	.	O

Over	NNP	O
twice	RB	O
as	RB	O
many	JJ	O
patients	NNS	O
on	IN	O
ginseng	NN	O
perceived	VBD	O
a	DT	O
benefit	NN	O
and	CC	O
were	VBD	O
satisfied	VBN	O
with	IN	O
treatment	NN	O
over	IN	O
those	DT	O
on	IN	O
placebo	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
measured	JJ	O
toxicities	NNS	O
between	IN	O
any	DT	O
of	IN	O
the	DT	O
arms	NNS	O
.	.	O

CONCLUSION	NN	O
There	EX	O
appears	VBZ	O
to	TO	O
be	VB	O
some	DT	O
activity	NN	O
and	CC	O
tolerable	JJ	O
toxicity	NN	O
at	IN	O
1,000-2,000	CD	O
mg/day	JJ	O
doses	NNS	O
of	IN	O
American	JJ	O
ginseng	NN	O
with	IN	O
regard	NN	O
to	TO	O
cancer-related	JJ	O
fatigue	NN	O
.	.	O

Thus	NNP	O
,	,	O
further	JJ	O
study	NN	O
of	IN	O
American	NNP	O
ginseng	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Mechanisms	NNP	O
underlying	VBG	O
the	DT	O
lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
implantable	JJ	O
cardioverter-defibrillator	JJ	O
therapy	NN	O
on	IN	O
mortality	NN	O
in	IN	O
high-risk	JJ	O
patients	NNS	O
with	IN	O
recent	JJ	O
myocardial	JJ	C
infarction	NN	C
:	:	O
insights	NNS	O
from	IN	O
the	DT	O
Defibrillation	NNP	O
in	IN	O
Acute	NNP	O
Myocardial	NNP	O
Infarction	NNP	O
Trial	NNP	O
(	(	O
DINAMIT	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
although	IN	O
implantable	JJ	O
cardioverter-defibrillators	NNS	O
(	(	O
ICDs	NNP	O
)	)	O
lower	JJR	O
mortality	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
low	JJ	C
ejection	NN	C
fraction	NN	C
late	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
randomized	VBN	O
trials	NNS	O
of	IN	O
ICD	NNP	O
versus	FW	O
control	NN	O
subjects	NNS	O
implanted	VBD	O
early	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
do	VBP	O
not	RB	O
show	VB	O
mortality	NN	O
benefit	NN	O
.	.	O

Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
possible	JJ	O
mechanisms	NNS	O
underlying	VBG	O
the	DT	O
lack	NN	O
of	IN	O
mortality	NN	O
benefit	NN	O
in	IN	O
the	DT	O
Defibrillation	NNP	O
in	IN	O
Acute	NNP	O
Myocardial	NNP	O
Infarction	NNP	O
Trial	NNP	O
(	(	O
DINAMIT	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
this	DT	O
is	VBZ	O
a	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Outpatients	NNS	O
with	IN	O
recent	JJ	O
(	(	O
6	CD	O
to	TO	O
40	CD	O
days	NNS	O
)	)	O
acute	VBP	C
myocardial	JJ	C
infarction	NN	C
,	,	O
left	VBD	C
ventricular	JJ	C
dysfunction	NN	C
(	(	C
ejection	JJ	C
fraction	NN	C
<	VBD	C
35	CD	C
%	NN	C
)	)	O
,	,	O
and	CC	O
low	JJ	C
heart	NN	C
rate	NN	C
variability	NN	C
were	VBD	O
randomized	VBN	O
to	TO	O
ICD	NNP	O
(	(	O
n=311	NN	O
)	)	O
or	CC	O
to	TO	O
standard	VB	O
medical	JJ	O
therapy	NN	O
(	(	O
n=342	JJ	O
)	)	O
.	.	O

In	IN	O
a	DT	O
competing-risks	JJ	O
analysis	NN	O
,	,	O
those	DT	O
factors	NNS	O
that	WDT	O
increased	VBD	O
the	DT	O
risk	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
also	RB	O
increased	VBD	O
the	DT	O
risk	NN	O
of	IN	O
nonarrhythmic	JJ	O
deaths	NNS	O
.	.	O

After	IN	O
adjustment	NN	O
for	IN	O
these	DT	O
factors	NNS	O
,	,	O
receiving	VBG	O
an	DT	O
ICD	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
risk	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.15	CD	O
to	TO	O
0.71	CD	O
)	)	O
but	CC	O
an	DT	O
increase	NN	O
in	IN	O
nonarrhythmic	JJ	O
death	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
1.70	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.00	CD	O
to	TO	O
2.80	CD	O
)	)	O
.	.	O

In	IN	O
an	DT	O
adjusted	JJ	O
time-dependent	JJ	O
analysis	NN	O
,	,	O
patients	NNS	O
receiving	VBG	O
an	DT	O
ICD	NNP	O
and	CC	O
having	VBG	O
appropriate	JJ	O
ICD	NNP	O
therapy	NN	O
had	VBD	O
a	DT	O
15.1	CD	O
%	NN	O
yearly	RB	O
hazard	NN	O
of	IN	O
mortality	NN	O
compared	VBN	O
with	IN	O
5.2	CD	O
%	NN	O
in	IN	O
ICD	NNP	C
patients	NNS	O
with	IN	O
no	DT	O
appropriate	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
sudden	JJ	O
death	NN	O
in	IN	O
ICD	NNP	C
patients	NNS	O
was	VBD	O
completely	RB	O
offset	VBN	O
by	IN	O
increased	JJ	O
nonarrhythmic	JJ	O
deaths	NNS	O
,	,	O
which	WDT	O
were	VBD	O
greatest	JJS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ICD	NNP	O
shock	NN	O
therapy	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
6.0	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
2.8	CD	O
to	TO	O
12.7	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ICDs	NNP	C
early	RB	O
after	IN	O
myocardial	JJ	C
infarction	NN	C
,	,	O
those	DT	O
factors	NNS	O
that	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
arrhythmia	NN	O
requiring	VBG	O
ICD	NNP	O
therapy	NN	O
are	VBP	O
also	RB	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
nonsudden	JJ	O
death	NN	O
,	,	O
negating	VBG	O
the	DT	O
benefit	NN	O
of	IN	O
ICDs	NNP	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Attenuation	NN	O
of	IN	O
hemodynamic	JJ	O
responses	NNS	O
to	TO	O
laryngoscopy	VB	O
and	CC	O
tracheal	VB	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
:	:	O
remifentanil	NN	O
vs.	FW	O
lidocaine	NN	O
with	IN	O
esmolol	NN	O
.	.	O

AIM	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
remifentanil	NN	O
vs.	FW	O
a	DT	O
lidocaine-esmolol	JJ	O
combination	NN	O
in	IN	O
blunting	VBG	O
the	DT	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
laryngoscopy	VB	O
and	CC	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
using	VBG	O
thiopental	JJ	O
and	CC	O
rocuronium	NN	O
in	IN	O
normotensive	JJ	C
patients	NNS	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	SS
patients	NNS	O
with	IN	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	C
ASA	NNP	C
)	)	C
physical	JJ	C
status	NN	C
class	NN	C
I	PRP	C
who	WP	O
required	VBD	O
tracheal	JJ	C
intubation	NN	C
for	IN	O
elective	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
R	NNP	O
received	VBD	O
0.9	CD	O
%	NN	O
saline	NN	O
10	CD	O
ml	NN	O
and	CC	O
remifentanil	VB	O
1	CD	O
microg/kg	NN	O
.	.	O

Group	NNP	O
LE	NNP	O
received	VBD	O
lidocaine	JJ	O
1.5	CD	O
mg/kg	NN	O
and	CC	O
esmolol	$	O
1.0	CD	O
mg/kg	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
sodium	NN	O
5	CD	O
mg/kg	NN	O
,	,	O
followed	VBN	O
by	IN	O
rocuronium	NN	O
1.0	CD	O
mg/kg	NN	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
induction	NN	O
,	,	O
immediately	RB	O
after	IN	O
intubation	NN	O
and	CC	O
every	DT	O
minute	NN	O
for	IN	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

RESULTS	NNP	O
Changes	NNP	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
over	IN	O
time	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximum	JJ	O
pressor	NN	O
response	NN	O
was	VBD	O
observed	VBN	O
immediately	RB	O
after	IN	O
intubation	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
the	DT	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
group	NN	O
LE	NNP	O
(	(	O
29.7	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
116.1	CD	O
,	,	O
121.9	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
R	NNP	O
(	(	O
4.4	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
92.9	CD	O
,	,	O
98.5	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
R	NNP	O
and	CC	O
15	CD	O
patients	NNS	O
in	IN	O
group	NN	O
LE	NNP	O
developed	VBD	O
hypertension	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NN	O
:	:	O
0.064	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
over	IN	O
time	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P=0.465	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
remifentanil	VBZ	O
1	CD	O
mg/kg	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
combination	NN	O
of	IN	O
lidocaine	JJ	O
1.5	CD	O
mg/kg	NN	O
and	CC	O
esmolol	$	O
1	CD	O
mg/kg	NN	O
for	IN	O
attenuating	VBG	O
the	DT	O
hemodynamic	JJ	O
responses	NNS	O
to	TO	O
rapid	JJ	O
sequence	NN	O
intubation	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
release	NN	O
of	IN	O
digoxin	NN	O
from	IN	O
four	CD	O
different	JJ	O
soft	JJ	O
gelatin	NN	O
capsule	NN	O
formulations	NNS	O
.	.	O

A	DT	O
blinded	JJ	O
,	,	O
four-treatment	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
16	CD	SS
normal	JJ	O
adult	NN	A
male	NN	SE
volunteers	NNS	O
compared	VBN	O
plasma	JJ	O
concentrations	NNS	O
and	CC	O
urinary	JJ	O
excretion	NN	O
of	IN	O
digoxin	NN	O
,	,	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
,	,	O
after	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
soft	JJ	O
gelatin	NN	O
capsule	NN	O
formulations	NNS	O
of	IN	O
digoxin	NN	O
.	.	O

Four	CD	O
0.4-mg	JJ	O
formulations	NNS	O
with	IN	O
different	JJ	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
and	CC	O
dissolution	NN	O
rates	NNS	O
were	VBD	O
administered	VBN	O
,	,	O
with	IN	O
2-week	JJ	O
intervals	NNS	O
between	IN	O
treatments	NNS	O
.	.	O

The	DT	O
two	CD	O
capsules	NNS	O
with	IN	O
lowest	JJS	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
(	(	O
2.9	CD	O
and	CC	O
16	CD	O
min	NN	O
)	)	O
gave	VBD	O
comparable	JJ	O
in	IN	O
vivo	JJ	O
results	NNS	O
.	.	O

The	DT	O
other	JJ	O
two	CD	O
capsules	NNS	O
,	,	O
with	IN	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
of	IN	O
62	CD	O
and	CC	O
229	CD	O
min	NN	O
,	,	O
produced	VBD	O
significant	JJ	O
delays	NNS	O
in	IN	O
digoxin	NN	O
absorption	NN	O
.	.	O

In	IN	O
vitro-in	JJ	O
vivo	NN	O
correlations	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
comparing	VBG	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
burst	NN	O
time	NN	O
with	IN	O
time	NN	O
to	TO	O
peak	VB	O
plasma	JJ	O
level	NN	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
the	DT	O
first	JJ	O
measurable	JJ	O
plasma	NN	O
level	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
0	CD	O
.	.	O

05	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
mean	JJ	O
time	NN	O
to	TO	O
peak	VB	O
plasma	JJ	O
level	NN	O
correlated	VBN	O
with	IN	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
release	VB	O
either	RB	O
50	CD	O
%	NN	O
or	CC	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
digoxin	NN	O
in	IN	O
vitro	NN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
digoxin	NN	O
absorbed	VBN	O
from	IN	O
each	DT	O
capsule	NN	O
as	IN	O
determined	VBN	O
by	IN	O
urinary	JJ	O
excretion	NN	O
or	CC	O
AUC0-infinity	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
early	JJ	O
and	CC	O
mid-term	JJ	O
results	NNS	O
of	IN	O
stapled	JJ	O
versus	NN	O
open	JJ	O
hemorrhoidectomy	NN	C
.	.	O

BACKGROUND	VB	O
The	DT	O
new	JJ	O
technique	NN	O
of	IN	O
circular	JJ	O
stapler	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hemorrhoids	NNS	C
has	VBZ	O
shown	VBN	O
early	JJ	O
promise	NN	O
in	IN	O
terms	NNS	O
of	IN	O
minimal	NN	O
or	CC	O
no	DT	O
postoperative	JJ	O
pain	NN	O
,	,	O
early	JJ	O
discharge	NN	O
from	IN	O
hospital	NN	O
,	,	O
and	CC	O
quick	JJ	O
return	NN	O
to	TO	O
work	VB	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
stapled	VBN	O
technique	NN	O
with	IN	O
the	DT	O
well-accepted	JJ	O
conventional	JJ	O
Milligan	NNP	O
Morgan	NNP	O
hemorrhoidectomy	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
fulfilling	VBG	O
the	DT	O
selection	NN	O
criteria	NNS	O
,	,	O
84	CD	SS
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
stapled	VBN	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	SS
)	)	O
or	CC	O
open	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	SS
)	)	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
under	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

The	DT	O
2	CD	O
techniques	NNS	O
were	VBD	O
evaluated	VBN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
operative	JJ	O
time	NN	O
,	,	O
pain	NN	O
scores	NNS	O
,	,	O
complications	NNS	O
,	,	O
day	NN	O
of	IN	O
discharge	NN	O
,	,	O
return	NN	O
to	TO	O
work	VB	O
,	,	O
and	CC	O
level	NN	O
of	IN	O
satisfaction	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
age	NN	O
of	IN	O
patients	NNS	O
was	VBD	O
46.02	CD	A
years	NNS	O
(	(	O
SD	NNP	O
,	,	O
12.33	CD	O
)	)	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
and	CC	O
48.64	CD	A
years	NNS	O
(	(	O
14.57	CD	O
)	)	O
in	IN	O
the	DT	O
open	JJ	O
group	NN	O
.	.	O

Grade	NNP	C
III	NNP	C
or	CC	C
IV	NNP	C
hemorrhoids	NNS	C
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
men	NNS	O
(	(	O
ie	NN	O
,	,	O
80.9	CD	O
%	NN	O
and	CC	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
stapled	JJ	O
and	CC	O
open	JJ	O
group	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
operative	JJ	O
time	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
24.28	CD	O
minutes	NNS	O
(	(	O
4.25	CD	O
)	)	O
versus	NN	O
45.21	CD	O
minutes	NNS	O
(	(	O
5.36	CD	O
)	)	O
in	IN	O
the	DT	O
Milligan-Morgan	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
blood	NN	O
loss	NN	O
,	,	O
pain	NN	O
scores	NNS	O
and	CC	O
requirement	NN	O
of	IN	O
analgesics	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
.	.	O

Mean	NNP	O
hospital	NN	O
stay	NN	O
was	VBD	O
1.24	CD	O
days	NNS	O
(	(	O
0.62	CD	O
)	)	O
and	CC	O
2.76	CD	O
days	NNS	O
(	(	O
1.01	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
stapled	JJ	O
and	CC	O
open	JJ	O
group	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
returned	VBD	O
to	TO	O
work	VB	O
or	CC	O
routine	VB	O
activities	NNS	O
earlier	RBR	O
(	(	O
ie	NN	O
,	,	O
within	IN	O
8.12	CD	O
days	NNS	O
[	RB	O
2.48	CD	O
]	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
17.62	CD	O
(	(	O
5.59	CD	O
)	)	O
in	IN	O
the	DT	O
open	JJ	O
group	NN	O
.	.	O

Only	RB	O
88.1	CD	O
%	NN	O
of	IN	O
patients	NNS	O
were	VBD	O
satisfied	VBN	O
by	IN	O
the	DT	O
open	JJ	O
method	NN	O
compared	VBN	O
with	IN	O
97.6	CD	O
%	NN	O
after	IN	O
the	DT	O
stapled	JJ	O
technique	NN	O
.	.	O

The	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
11	CD	O
months	NNS	O
with	IN	O
a	DT	O
maximum	JJ	O
follow-up	NN	O
of	IN	O
19	CD	O
months	NNS	O
(	(	O
range	VB	O
2-19	JJ	O
months	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Stapled	NNP	O
hemorrhoidectomy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
day-care	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
grade	NN	C
III	NNP	C
and	CC	C
grade	VBD	C
IV	NNP	C
hemorrhoids	NNS	C
.	.	O

It	PRP	O
ensures	VBZ	O
lesser	RBR	O
postoperative	JJ	O
pain	NN	O
,	,	O
early	JJ	O
discharge	NN	O
,	,	O
less	JJR	O
time	NN	O
off	IN	O
work	NN	O
,	,	O
complications	NNS	O
similar	JJ	O
to	TO	O
the	DT	O
open	JJ	O
technique	NN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
end	NN	O
a	DT	O
more	RBR	O
satisfied	JJ	O
patient	NN	O
with	IN	O
no	DT	O
perianal	JJ	O
wound	NN	O
.	.	O

However	RB	O
,	,	O
more	RBR	O
such	JJ	O
randomized	JJ	O
trials	NNS	O
are	VBP	O
essential	JJ	O
to	TO	O
deny	VB	O
any	DT	O
long-term	JJ	O
complication	NN	O
.	.	O

Does	VBZ	O
the	DT	O
result	NN	O
of	IN	O
completion	NN	O
axillary	JJ	O
lymph	NN	O
node	NN	O
dissection	NN	O
influence	NN	O
the	DT	O
recommendation	NN	O
for	IN	O
adjuvant	JJ	O
treatment	NN	O
in	IN	O
sentinel	JJ	C
lymph	JJ	C
node-positive	JJ	C
patients	NNS	O
?	.	O
OBJECTIVE	IN	O
The	DT	O
Hungarian	NNP	O
National	NNP	O
Institute	NNP	O
of	IN	O
Oncology	NNP	O
has	VBZ	O
just	RB	O
closed	VBN	O
a	DT	O
single-center	JJ	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

The	DT	O
Optimal	NNP	O
Treatment	NNP	O
of	IN	O
the	DT	O
Axilla-Surgery	NNP	O
or	CC	O
Radiotherapy	NNP	O
(	(	O
OTOASOR	NNP	O
)	)	O
trial	NN	O
compares	VBZ	O
completion	NN	O
axillary	JJ	O
lymph	NN	O
node	NN	O
dissection	NN	O
(	(	O
cALND	NN	O
)	)	O
with	IN	O
regional	JJ	O
nodal	JJ	O
irradiation	NN	O
(	(	O
RNI	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
sentinel	JJ	C
lymph	JJ	C
node-positive	JJ	C
(	(	C
SLN+	NNP	C
)	)	C
primary	VBP	C
invasive	JJ	C
breast	NN	C
cancer	NN	C
.	.	O

In	IN	O
the	DT	O
investigational	JJ	O
treatment	NN	O
arm	NN	O
,	,	O
patients	NNS	O
received	VBD	O
50	CD	O
Gy	NNP	O
RNI	NNP	O
instead	RB	O
of	IN	O
cALND	NN	O
.	.	O

In	IN	O
these	DT	O
patients	NNS	O
we	PRP	O
had	VBD	O
information	NN	O
only	RB	O
about	IN	O
the	DT	O
sentinel	NN	O
lymph	NN	O
node	NN	O
(	(	O
SLN	NNP	O
)	)	O
status	NN	O
,	,	O
but	CC	O
the	DT	O
further	JJ	O
axillary	JJ	O
nodal	JJ	O
involvement	NN	O
remained	VBD	O
unknown	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
result	NN	O
of	IN	O
cALND	NN	O
influenced	VBD	O
the	DT	O
recommendation	NN	O
for	IN	O
adjuvant	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SLN+	NNP	C
breast	NN	C
cancer	NN	C
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
SLN+	NNP	C
primary	JJ	C
breast	NN	C
cancer	NN	C
were	VBD	O
randomized	VBN	O
for	IN	O
cALND	NN	O
(	(	O
arm	NN	O
A	NNP	O
,	,	O
standard	JJ	O
treatment	NN	O
)	)	O
or	CC	O
RNI	NNP	O
(	(	O
arm	NN	O
B	NNP	O
,	,	O
investigational	JJ	O
treatment	NN	O
)	)	O
.	.	O

Adjuvant	JJ	O
systemic	JJ	O
treatments	NNS	O
were	VBD	O
given	VBN	O
according	VBG	O
to	TO	O
the	DT	O
standard	JJ	O
institutional	JJ	O
protocol	NN	O
,	,	O
and	CC	O
patients	NNS	O
were	VBD	O
followed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
actual	JJ	O
institutional	JJ	O
guidelines	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
August	NNP	O
2002	CD	O
and	CC	O
June	NNP	O
2009	CD	O
,	,	O
474	CD	SS
SLN+	NN	C
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
cALND	VB	O
(	(	O
arm	NN	O
A	NNP	O
,	,	O
standard	JJ	O
treatment	NN	O
=	JJ	O
244	CD	O
patients	NNS	O
)	)	O
or	CC	O
RNI	NNP	O
(	(	O
arm	NN	O
B	NNP	O
,	,	O
investigational	JJ	O
treatment	NN	O
=	VBD	O
230	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
2	CD	O
arms	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
according	VBG	O
to	TO	O
the	DT	O
majority	NN	O
of	IN	O
main	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

However	RB	O
,	,	O
more	JJR	O
patients	NNS	O
were	VBD	O
premenopausal	JJ	C
(	(	O
34	CD	O
%	NN	O
vs.	FW	O
27	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.095	NNP	O
)	)	O
and	CC	O
had	VBD	O
pT2-3	NN	O
tumors	NNS	O
(	(	O
57	CD	O
%	NN	O
vs.	FW	O
40	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
in	IN	O
the	DT	O
completion	NN	O
axillary	JJ	O
lymph	NN	O
node	NN	O
dissection	NN	O
(	(	O
ALND	NNP	O
)	)	O
arm	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
there	EX	O
were	VBD	O
more	JJR	O
patients	NNS	O
with	IN	O
known	JJ	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
type	VBD	O
2	CD	O
positive	JJ	O
tumor	NN	O
(	(	O
12	CD	O
%	NN	O
vs.	FW	O
17	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.066	NNP	O
)	)	O
in	IN	O
the	DT	O
RNI	NNP	O
arm	NN	O
.	.	O

In	IN	O
the	DT	O
ALND	NNP	O
and	CC	O
RNI	NNP	O
arms	NNS	O
,	,	O
78	CD	O
%	NN	O
(	(	O
190/244	CD	O
)	)	O
and	CC	O
69	CD	O
%	NN	O
(	(	O
159/230	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
received	VBD	O
chemotherapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
.020	NNP	O
)	)	O
.	.	O

Endocrine	NNP	O
therapy	NN	O
was	VBD	O
administered	VBN	O
in	IN	O
87	CD	O
%	NN	O
(	(	O
213/244	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
ALND	NNP	O
arm	NN	O
and	CC	O
89	CD	O
%	NN	O
(	(	O
204/230	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
RNI	NNP	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
.372	NNP	O
)	)	O
.	.	O

Six	CD	O
patients	NNS	O
(	(	O
2.5	CD	O
%	NN	O
)	)	O
on	IN	O
arm	NN	O
A	NN	O
and	CC	O
13	CD	O
patients	NNS	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
on	IN	O
arm	NN	O
B	NNP	O
received	VBD	O
adjuvant	JJ	O
trastuzumab	NN	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Subgroup	NNP	O
analyses	VBZ	O
explored	VBD	O
that	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
in	IN	O
arm	NN	O
A	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
higher	JJR	O
percentage	NN	O
of	IN	O
premenopausal	NN	O
patients	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
larger	JJR	O
(	(	C
pT2-3	NN	C
)	)	C
tumors	NNS	C
.	.	O

CONCLUSIONS	VB	O
The	DT	O
result	NN	O
of	IN	O
cALND	NN	O
after	IN	O
positive	JJ	O
SLN	NNP	O
biopsy	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
no	DT	O
major	JJ	O
impact	NN	O
on	IN	O
the	DT	O
administration	NN	O
of	IN	O
adjuvant	JJ	O
systemic	JJ	O
therapy	NN	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
administration	NN	O
of	IN	O
nicorandil	JJ	O
before	IN	O
reperfusion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ST-segment-elevation	NNP	C
myocardial	JJ	C
infarction	NN	C
.	.	O

BACKGROUND	NNP	O
Intravenous	NNP	O
nicorandil	NN	O
,	,	O
a	DT	O
hybrid	JJ	O
compound	NN	O
of	IN	O
ATP-sensitive	JJ	O
potassium	NN	O
channel	NN	O
opener	NN	O
and	CC	O
nitric	JJ	O
oxide	NN	O
donor	NN	O
,	,	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
ameliorate	VB	O
early	JJ	O
functional	NN	O
and	CC	O
clinical	JJ	O
problems	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
late	JJ	O
phase	NN	O
remain	VBP	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
This	DT	O
follow-up	JJ	O
study	NN	O
to	TO	O
5	CD	O
years	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
368	CD	SS
patients	NNS	O
with	IN	O
first	JJ	O
ST-segment-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
undergoing	VBG	O
percutaneous	JJ	C
coronary	JJ	C
intervention	NN	C
(	(	O
PCI	NNP	C
)	)	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
12	CD	O
mg	NN	O
of	IN	O
nicorandil	NN	O
or	CC	O
a	DT	O
placebo	NN	O
intravenously	RB	O
just	RB	O
before	IN	O
reperfusion	NN	O
.	.	O

We	PRP	O
analyzed	VBD	O
incidence	NN	O
of	IN	O
cardiovascular	JJ	O
death	NN	O
or	CC	O
rehospitalization	NN	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
after	IN	O
PCI	NNP	O
as	RB	O
well	RB	O
as	IN	O
various	JJ	O
aspects	NNS	O
of	IN	O
epicardial	JJ	O
flow	NN	O
and	CC	O
microvascular	JJ	O
function	NN	O
.	.	O

Mean	JJ	O
follow-up	NN	O
was	VBD	O
2.4	CD	O
years	NNS	O
(	(	O
SD	NNP	O
,	,	O
1.4	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
12	CD	O
(	(	O
6.5	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
nicorandil	JJ	O
and	CC	O
30	CD	O
(	(	O
16.4	CD	O
%	NN	O
)	)	O
receiving	NN	O
placebo	NN	O
had	VBD	O
cardiovascular	JJ	O
death	NN	O
or	CC	O
hospital	NN	O
admission	NN	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.20	CD	O
to	TO	O
0.76	CD	O
;	:	O
P=0.0058	NNP	O
)	)	O
.	.	O

Postprocedural	NNP	O
TIMI	NNP	O
3	CD	O
flow	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
89.7	CD	O
%	NN	O
of	IN	O
the	DT	O
nicorandil	JJ	O
group	NN	O
and	CC	O
in	IN	O
81.4	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
1.99	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.09	CD	O
to	TO	O
3.65	CD	O
;	:	O
P=0.025	NNP	O
)	)	O
.	.	O

Corrected	VBN	O
TIMI	NNP	O
frame	NN	O
count	NN	O
was	VBD	O
furthermore	RB	O
lower	JJR	O
in	IN	O
the	DT	O
nicorandil	NN	O
group	NN	O
(	(	O
21.0+/-9.1	JJ	O
versus	NN	O
25.1+/-14.1	CD	O
;	:	O
P=0.0009	NNP	O
)	)	O
.	.	O

ST-segment	JJ	O
resolution	NN	O
>	VBD	O
50	CD	O
%	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
79.5	CD	O
%	NN	O
and	CC	O
61.2	CD	O
%	NN	O
of	IN	O
the	DT	O
nicorandil	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
2.45	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.54	CD	O
to	TO	O
3.90	CD	O
;	:	O
P=0.0002	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
intravenous	JJ	O
nicorandil	NNS	O
to	TO	O
PCI	NNP	O
leads	VBZ	O
to	TO	O
beneficial	JJ	O
clinical	JJ	O
outcomes	NNS	O
and	CC	O
prevents	NNS	O
cardiovascular	JJ	O
events	NNS	O
of	IN	O
long	JJ	O
duration	NN	O
and	CC	O
death	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ST-segment-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
.	.	O

The	DT	O
development	NN	O
of	IN	O
a	DT	O
web-	JJ	O
and	CC	O
a	DT	O
print-based	JJ	O
decision	NN	O
aid	NN	O
for	IN	O
prostate	NN	C
cancer	NN	C
screening	VBG	O
.	.	O

BACKGROUND	NNP	O
Whether	NNP	O
early	JJ	O
detection	NN	O
and	CC	O
treatment	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
(	(	O
PCa	NNP	O
)	)	O
will	MD	O
reduce	VB	O
disease-related	JJ	O
mortality	NN	O
remains	VBZ	O
uncertain	JJ	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
tools	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
facilitate	VB	O
informed	JJ	O
decision	NN	O
making	NN	O
.	.	O

While	IN	O
there	EX	O
have	VBP	O
been	VBN	O
several	JJ	O
decision	NN	O
aids	NNS	O
(	(	O
DAs	NNP	O
)	)	O
developed	VBD	O
and	CC	O
tested	VBD	O
,	,	O
very	RB	O
few	JJ	O
have	VBP	O
included	VBN	O
an	DT	O
exercise	NN	O
to	TO	O
help	VB	O
men	NNS	O
clarify	VB	O
their	PRP$	O
values	NNS	O
and	CC	O
preferences	NNS	O
about	IN	O
PCa	NNP	O
screening	NN	O
.	.	O

Further	NNP	O
,	,	O
only	RB	O
one	CD	O
DA	NNP	O
has	VBZ	O
utilized	VBN	O
an	DT	O
interactive	JJ	O
web-based	JJ	O
format	NN	O
,	,	O
which	WDT	O
allows	VBZ	O
for	IN	O
an	DT	O
expansion	NN	O
and	CC	O
customization	NN	O
of	IN	O
the	DT	O
material	NN	O
.	.	O

We	PRP	O
describe	VBP	O
the	DT	O
development	NN	O
of	IN	O
two	CD	O
DAs	NNP	O
,	,	O
a	DT	O
booklet	NN	O
and	CC	O
an	DT	O
interactive	JJ	O
website	NN	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
values	NNS	O
clarification	NN	O
component	NN	O
and	CC	O
designed	VBN	O
for	IN	O
use	NN	O
in	IN	O
diverse	JJ	O
settings	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
two	CD	O
feasibility	NN	O
studies	NNS	O
to	TO	O
assess	VB	O
men	NNS	SE
's	POS	SE
(	(	O
45-70	CD	A
years	NNS	O
)	)	O
Internet	NNP	O
access	NN	O
and	CC	O
their	PRP$	O
willingness	NN	O
to	TO	O
use	VB	O
a	DT	O
web-	JJ	O
vs.	FW	O
a	DT	O
print-based	JJ	O
tool	NN	O
.	.	O

The	DT	O
booklet	NN	O
was	VBD	O
adapted	VBN	O
from	IN	O
two	CD	O
previous	JJ	O
versions	NNS	O
evaluated	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
and	CC	O
the	DT	O
website	NN	O
was	VBD	O
created	VBN	O
to	TO	O
closely	RB	O
match	VB	O
the	DT	O
content	NN	O
of	IN	O
the	DT	O
revised	JJ	O
booklet	NN	O
.	.	O

Usability	NNP	O
testing	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
obtain	VB	O
feedback	NN	O
regarding	VBG	O
draft	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
materials	NNS	O
.	.	O

The	DT	O
tools	NNS	O
were	VBD	O
also	RB	O
reviewed	VBN	O
by	IN	O
a	DT	O
plain	NN	O
language	NN	O
expert	NN	O
and	CC	O
the	DT	O
interdisciplinary	JJ	O
research	NN	O
team	NN	O
.	.	O

Feedback	NN	O
on	IN	O
the	DT	O
content	NN	O
and	CC	O
presentation	NN	O
led	VBD	O
to	TO	O
iterative	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
tools	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
feasibility	NN	O
studies	NNS	O
confirmed	VBD	O
that	IN	O
the	DT	O
Internet	NNP	O
was	VBD	O
a	DT	O
viable	JJ	O
medium	NN	O
,	,	O
as	IN	O
the	DT	O
majority	NN	O
of	IN	O
men	NNS	O
used	VBN	O
a	DT	O
computer	NN	O
,	,	O
had	VBD	O
access	NN	O
to	TO	O
the	DT	O
Internet	NNP	O
,	,	O
and	CC	O
Internet	NNP	O
use	NN	O
increased	VBD	O
over	IN	O
time	NN	O
.	.	O

Feedback	NN	O
from	IN	O
the	DT	O
usability	NN	O
testing	VBG	O
on	IN	O
the	DT	O
length	NN	O
,	,	O
presentation	NN	O
,	,	O
and	CC	O
content	NN	O
of	IN	O
the	DT	O
materials	NNS	O
was	VBD	O
incorporated	VBN	O
into	IN	O
the	DT	O
final	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
booklet	NN	O
and	CC	O
website	NN	O
.	.	O

Both	CC	O
the	DT	O
feasibility	NN	O
studies	NNS	O
and	CC	O
the	DT	O
usability	NN	O
testing	VBG	O
highlighted	VBD	O
the	DT	O
need	NN	O
to	TO	O
address	VB	O
men	NNS	O
's	POS	O
informed	VBN	O
decision	NN	O
making	VBG	O
regarding	VBG	O
screening	NN	O
.	.	O

CONCLUSIONS	NNP	O
Informed	NNP	O
decision	NN	O
making	VBG	O
for	IN	O
PCa	NNP	O
screening	NN	O
is	VBZ	O
crucial	JJ	O
at	IN	O
present	JJ	O
and	CC	O
may	MD	O
be	VB	O
important	JJ	O
for	IN	O
some	DT	O
time	NN	O
,	,	O
particularly	RB	O
if	IN	O
a	DT	O
definitive	JJ	O
recommendation	NN	O
either	DT	O
for	IN	O
or	CC	O
against	IN	O
screening	VBG	O
does	VBZ	O
not	RB	O
emerge	VB	O
from	IN	O
ongoing	VBG	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
trials	NNS	O
.	.	O

We	PRP	O
have	VBP	O
detailed	VBN	O
our	PRP$	O
efforts	NNS	O
at	IN	O
developing	VBG	O
print-	JJ	O
and	CC	O
web-based	JJ	O
DAs	NNP	O
to	TO	O
assist	VB	O
men	NNS	O
in	IN	O
determining	VBG	O
how	WRB	O
to	TO	O
best	VB	O
meet	VB	O
their	PRP$	O
PCa	NNP	O
screening	NN	O
preferences	NNS	O
.	.	O

Following	VBG	O
completion	NN	O
of	IN	O
our	PRP$	O
ongoing	JJ	O
RCT	NNP	O
designed	VBN	O
to	TO	O
test	VB	O
these	DT	O
materials	NNS	O
,	,	O
our	PRP$	O
goal	NN	O
will	MD	O
be	VB	O
to	TO	O
develop	VB	O
a	DT	O
dissemination	NN	O
project	NN	O
for	IN	O
the	DT	O
more	RBR	O
effective	JJ	O
tool	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NCT00623090	NNP	O
.	.	O

Midazolam	NNP	O
vs	NN	O
ondansetron	NN	O
for	IN	O
preventing	VBG	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
prophylactic	JJ	O
anti-emetic	JJ	O
efficacy	NN	O
of	IN	O
midazolam	NN	O
and	CC	O
ondansetron	NN	O
in	IN	O
90	CD	SS
patients	NNS	O
scheduled	VBN	O
for	IN	O
minor	JJ	C
gynaecological	JJ	C
(	(	O
hysteroscopy	NN	C
)	)	O
or	CC	O
urological	JJ	C
(	(	O
ureteroscopy	JJ	C
)	)	O
procedures	NNS	O
planned	VBN	O
to	TO	O
last	JJ	O
1-2	JJ	O
h	NN	O
under	IN	O
sevoflurane	NN	O
anaesthesia	NN	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
of	IN	O
the	DT	O
lungs	NNS	O
via	IN	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
.	.	O

Midazolam	NNP	O
2	CD	O
mg	NN	O
or	CC	O
ondansetron	$	O
4	CD	O
mg	NN	O
were	VBD	O
administered	VBN	O
intravenously	RB	O
30	CD	O
min	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
postoperative	JJ	C
nausea	NN	C
and	CC	O
vomiting	NN	C
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
h	NN	O
(	(	O
30	CD	O
%	NN	O
and	CC	O
27	CD	O
%	NN	O
for	IN	O
the	DT	O
midazolam	NN	O
and	CC	O
ondansetron	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
was	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
both	DT	O
groups	NNS	O
than	IN	O
predicted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
underlying	JJ	O
risks	NNS	O
(	(	O
midazolam	JJ	O
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.018	CD	O
;	:	O
ondansetron	VBN	O
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.017	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
average	JJ	O
sedation	NN	O
scores	NNS	O
or	CC	O
pain	NN	O
scores	NNS	O
.	.	O

Treatment	NNP	O
using	VBG	O
ondansetron	NN	O
for	IN	O
anti-emetic	JJ	O
prophylaxis	NN	O
did	VBD	O
not	RB	O
provide	VB	O
a	DT	O
superior	JJ	O
benefit	NN	O
compared	VBN	O
to	TO	O
midazolam	VB	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

Pre-bent	JJ	O
instruments	NNS	O
used	VBN	O
in	IN	O
single-port	JJ	O
laparoscopic	NN	O
surgery	NN	O
versus	IN	O
conventional	JJ	O
laparoscopic	NN	O
surgery	NN	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
performance	NN	O
in	IN	O
a	DT	O
dry	JJ	O
lab	NN	O
.	.	O

BACKGROUND	NNP	O
Different	NNP	O
types	NNS	O
of	IN	O
single-incision	NN	O
laparoscopic	NN	O
surgery	NN	O
(	(	O
SILS	NNP	O
)	)	O
have	VBP	O
become	VBN	O
increasingly	RB	O
popular	JJ	O
.	.	O

Although	IN	O
SILS	NNP	O
is	VBZ	O
technically	RB	O
even	RB	O
more	RBR	O
challenging	JJ	O
than	IN	O
conventional	JJ	O
laparoscopy	NN	O
,	,	O
published	VBN	O
data	NNS	O
of	IN	O
first	JJ	O
clinical	JJ	O
series	NN	O
seem	VBP	O
to	TO	O
demonstrate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
these	DT	O
approaches	NNS	O
.	.	O

Various	JJ	O
attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
overcome	VB	O
restrictions	NNS	O
due	JJ	O
to	TO	O
loss	NN	O
of	IN	O
triangulation	NN	O
in	IN	O
SILS	NNP	O
by	IN	O
specially	RB	O
designed	VBN	O
SILS-specific	JJ	O
instruments	NNS	O
.	.	O

This	DT	O
study	NN	O
involving	VBG	O
novices	NNS	O
in	IN	O
a	DT	O
dry	JJ	O
lab	NN	O
compared	VBN	O
task	NN	O
performances	NNS	O
between	IN	O
conventional	JJ	O
laparoscopic	NN	O
surgery	NN	O
(	(	O
CLS	NNP	O
)	)	O
and	CC	O
single-port	JJ	O
laparoscopic	NN	O
surgery	NN	O
(	(	O
SPLS	NNP	O
)	)	O
using	VBG	O
newly	RB	O
designed	VBN	O
pre-bent	JJ	O
instruments	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
90	CD	SS
medical	JJ	C
students	NNS	O
without	IN	O
previous	JJ	O
experience	NN	O
in	IN	O
laparoscopic	NN	O
techniques	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
one	CD	O
of	IN	O
three	CD	O
procedures	NNS	O
:	:	O
CLS	NNP	O
,	,	O
SPLS	NNP	O
using	VBG	O
two	CD	O
pre-bent	JJ	O
instruments	NNS	O
(	(	O
SPLS-pp	NNP	O
)	)	O
,	,	O
or	CC	O
SPLS	NNP	O
using	VBG	O
one	CD	O
pre-bent	NN	O
and	CC	O
one	CD	O
straight	NN	O
laparoscopic	NN	O
instrument	NN	O
(	(	O
SPLS-ps	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
dry	JJ	O
lab	NN	O
,	,	O
the	DT	O
participants	NNS	O
performed	VBD	O
four	CD	O
typical	JJ	O
laparoscopic	NN	O
tasks	NNS	O
of	IN	O
increasing	VBG	O
difficulty	NN	O
.	.	O

Evaluation	NNP	O
included	VBD	O
performance	NN	O
times	NNS	O
or	CC	O
number	NN	O
of	IN	O
completed	VBN	O
tasks	NNS	O
within	IN	O
a	DT	O
given	VBN	O
time	NN	O
frame	NN	O
.	.	O

All	DT	O
performances	NNS	O
were	VBD	O
videotaped	VBN	O
and	CC	O
evaluated	VBN	O
for	IN	O
unsuccessful	JJ	O
attempts	NNS	O
and	CC	O
unwanted	JJ	O
interactions	NNS	O
of	IN	O
instruments	NNS	O
.	.	O

Using	VBG	O
subjective	JJ	O
questionnaires	NNS	O
,	,	O
the	DT	O
participants	NNS	O
rated	VBN	O
difficulties	NNS	O
with	IN	O
two-dimensional	JJ	O
vision	NN	O
and	CC	O
coordination	NN	O
of	IN	O
instruments	NNS	O
.	.	O

RESULTS	NNP	O
Task	NNP	O
performances	NNS	O
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
CLS	NNP	O
group	NN	O
than	IN	O
in	IN	O
either	DT	O
SPLS	NNP	O
group	NN	O
.	.	O

The	DT	O
SPLS-ps	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
tendency	NN	O
toward	IN	O
better	JJR	O
performances	NNS	O
than	IN	O
the	DT	O
SPLS-pp	NNP	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

Video	NNP	O
sequences	NNS	O
and	CC	O
participants`	NN	O
questionnaires	NNS	O
showed	VBD	O
instrument	JJ	O
interaction	NN	O
as	IN	O
the	DT	O
major	JJ	O
problem	NN	O
in	IN	O
the	DT	O
single-incision	NN	O
surgery	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
SILS	NNP	O
is	VBZ	O
feasible	JJ	O
,	,	O
as	IN	O
shown	VBN	O
in	IN	O
clinical	JJ	O
series	NN	O
published	VBN	O
by	IN	O
laparoscopically	RB	O
experienced	JJ	O
experts	NNS	O
,	,	O
SILS	NNP	O
techniques	NNS	O
are	VBP	O
demanding	VBG	O
due	JJ	O
to	TO	O
restrictions	NNS	O
that	IN	O
come	VBP	O
with	IN	O
the	DT	O
loss	NN	O
of	IN	O
triangulation	NN	O
.	.	O

These	DT	O
can	MD	O
be	VB	O
compensated	VBN	O
only	RB	O
partially	RB	O
by	IN	O
currently	RB	O
available	JJ	O
SILS-designed	JJ	O
instruments	NNS	O
.	.	O

The	DT	O
future	NN	O
of	IN	O
SILS	NNP	O
depends	VBZ	O
on	IN	O
further	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
available	JJ	O
equipment	NN	O
or	CC	O
the	DT	O
development	NN	O
of	IN	O
new	JJ	O
approaches	NNS	O
such	JJ	O
as	IN	O
needlescopically	RB	O
assisted	VBN	O
or	CC	O
robotically	RB	O
assisted	JJ	O
procedures	NNS	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
twice	JJ	O
daily	JJ	O
fluticasone	NN	O
propionate	NN	O
powder	NN	O
versus	NN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	C
asthma	NN	C
.	.	O

BACKGROUND	NNP	O
Fluticasone	NNP	O
propionate	NN	O
,	,	O
an	DT	O
inhaled	JJ	O
corticosteroid	NN	O
with	IN	O
negligible	JJ	O
systemic	JJ	O
bioavailability	NN	O
via	IN	O
the	DT	O
oral	JJ	O
route	NN	O
,	,	O
is	VBZ	O
efficacious	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
asthma	NN	C
when	WRB	O
administered	VBN	O
via	IN	O
metered-dose	JJ	O
inhaler	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
inhaled	JJ	O
fluticasone	NN	O
propionate	NN	O
powder	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	C
asthma	NNS	C
previously	RB	O
treated	VBN	O
with	IN	O
an	DT	O
inhaled	JJ	O
corticosteroid	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
of	IN	O
342	CD	SS
adolescent	NN	A
and	CC	O
adult	NN	A
patients	NNS	O
with	IN	O
moderate	JJ	C
asthma	NNS	C
[	RB	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
(	(	O
FEV1	NNP	O
)	)	O
between	IN	O
50	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
predicted	JJ	O
]	NNP	O
treated	VBD	O
previously	RB	O
by	IN	O
beclomethasone	NN	O
dipropionate	NN	O
or	CC	O
triamcinolone	NN	O
acetonide	RB	O
.	.	O

Patients	NNS	O
received	VBD	O
fluticasone	JJ	O
propionate	NN	O
powder	NN	O
50	CD	O
micrograms	NNS	O
,	,	O
100	CD	O
micrograms	NNS	O
,	,	O
250	CD	O
micrograms	NNS	O
,	,	O
or	CC	O
placebo	NN	O
via	IN	O
a	DT	O
breath-actuated	JJ	O
inhalation	NN	O
device	NN	O
,	,	O
the	DT	O
Diskhaler	NNP	O
,	,	O
twice	RB	O
daily	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
in	IN	O
the	DT	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
experienced	VBD	O
a	DT	O
mean	JJ	O
increase	NN	O
from	IN	O
baseline	NN	O
to	TO	O
endpoint	VB	O
in	IN	O
FEV1	NNP	O
ranging	VBG	O
from	IN	O
0.43	CD	O
L	NNP	O
to	TO	O
0.47	CD	O
L.	NNP	O
Patients	NNPS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
experienced	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
from	IN	O
baseline	NN	O
of	IN	O
0.22	CD	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
probability	NN	O
of	IN	O
patients	NNS	O
remaining	VBG	O
in	IN	O
the	DT	O
study	NN	O
over	IN	O
time	NN	O
without	IN	O
developing	VBG	O
signs	NNS	O
of	IN	O
exacerbating	VBG	O
asthma	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Asthma	NNP	O
symptom	NN	O
scores	NNS	O
,	,	O
supplemental	JJ	O
rescue	NN	O
albuterol	NN	O
use	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
nighttime	JJ	O
awakenings	NNS	O
due	JJ	O
to	TO	O
asthma	VB	O
requiring	VBG	O
treatment	NN	O
also	RB	O
improved	VBN	O
significantly	RB	O
with	IN	O
all	DT	O
fluticasone	NN	O
propionate	NN	O
treatment	NN	O
regimens	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
at	IN	O
endpoint	NN	O
among	IN	O
the	DT	O
three	CD	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
.	.	O

No	DT	O
serious	JJ	O
drug-related	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
.	.	O

CONCLUSIONS	NNP	O
Fluticasone	NNP	O
propionate	NN	O
powder	NN	O
(	(	O
50	CD	O
,	,	O
100	CD	O
,	,	O
and	CC	O
250	CD	O
micrograms	NNS	O
)	)	O
was	VBD	O
well-tolerated	JJ	O
and	CC	O
significantly	RB	O
improved	VBN	O
lung	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	C
asthma	NNS	C
.	.	O

Utility	NN	O
of	IN	O
the	DT	O
bladder	NN	O
flap	NN	O
at	IN	O
cesarean	JJ	C
delivery	NN	C
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
omission	NN	O
of	IN	O
the	DT	O
bladder	NN	O
flap	NN	O
in	IN	O
primary	JJ	C
and	CC	O
repeat	JJ	C
cesarean	JJ	C
deliveries	NNS	C
shortens	VBZ	O
operating	VBG	O
time	NN	O
without	IN	O
increasing	VBG	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomized	VBD	O
258	CD	SS
women	NNS	SE
undergoing	VBG	O
primary	JJ	O
and	CC	O
repeat	JJ	O
cesarean	JJ	O
deliveries	NNS	O
at	IN	O
32	CD	O
weeks	NNS	O
of	IN	O
gestation	NN	O
or	CC	O
more	JJR	O
to	TO	O
creation	NN	O
(	(	O
n=131	JJ	SS
)	)	O
or	CC	O
omission	NN	O
(	(	O
n=127	JJ	SS
)	)	O
of	IN	O
the	DT	O
bladder	NN	O
flap	NN	O
.	.	O

Emergency	NNP	O
cesarean	JJ	O
deliveries	NNS	O
,	,	O
planned	VBD	O
vertical	JJ	O
uterine	NN	O
incisions	NNS	O
,	,	O
and	CC	O
previous	JJ	O
abdominal	JJ	O
surgeries	NNS	O
besides	IN	O
cesarean	JJ	O
deliveries	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
total	JJ	O
operating	NN	O
time	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
bladder	JJ	O
injury	NN	O
,	,	O
incision-to-delivery	JJ	O
time	NN	O
,	,	O
incision-to-fascial	JJ	O
closure	NN	O
time	NN	O
,	,	O
estimated	VBN	O
blood	NN	O
loss	NN	O
,	,	O
postoperative	JJ	O
microhematuria	NN	O
,	,	O
postoperative	JJ	O
pain	NN	O
,	,	O
hospital	NN	O
days	NNS	O
,	,	O
endometritis	NN	O
,	,	O
and	CC	O
urinary	JJ	O
tract	NN	O
infection	NN	O
.	.	O

Analysis	NN	O
followed	VBD	O
the	DT	O
intention-to-treat	JJ	O
principle	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
skin	NN	O
incision	NN	O
to	TO	O
delivery	NN	O
interval	NN	O
was	VBD	O
shorter	JJR	O
with	IN	O
omission	NN	O
of	IN	O
the	DT	O
bladder	NN	O
flap	NN	O
(	(	O
9	CD	O
[	NN	O
range	NN	O
1-43	JJ	O
]	NNS	O
compared	VBN	O
with	IN	O
10	CD	O
[	JJ	O
range	NN	O
2-70	JJ	O
]	NNP	O
minutes	NNS	O
;	:	O
P=.04	NNP	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
total	JJ	O
operating	NN	O
time	NN	O
(	(	O
51	CD	O
[	NN	O
range	NN	O
18-124	JJ	O
]	NNP	O
minutes	NNS	O
compared	VBN	O
with	IN	O
51	CD	O
[	JJ	O
range	NN	O
16-178	JJ	O
]	NN	O
;	:	O
P=.10	NNP	O
)	)	O
.	.	O

No	DT	O
bladder	NN	O
injuries	NNS	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
estimated	VBN	O
blood	NN	O
loss	NN	O
,	,	O
change	NN	O
in	IN	O
hemoglobin	JJ	O
level	NN	O
,	,	O
postoperative	JJ	O
microhematuria	NN	O
,	,	O
postoperative	JJ	O
pain	NN	O
,	,	O
hospital	NN	O
days	NNS	O
,	,	O
endometritis	NN	O
,	,	O
or	CC	O
urinary	JJ	O
tract	NN	O
infection	NN	O
.	.	O

CONCLUSION	NNP	O
Omission	NNP	O
of	IN	O
the	DT	O
bladder	NN	O
flap	NN	O
at	IN	O
primary	JJ	O
and	CC	O
repeat	JJ	O
cesarean	JJ	O
deliveries	NNS	O
does	VBZ	O
not	RB	O
increase	VB	O
intraoperative	JJ	O
or	CC	O
postoperative	JJ	O
complications	NNS	O
.	.	O

Incision-to-delivery	JJ	O
time	NN	O
is	VBZ	O
shortened	VBN	O
but	CC	O
total	JJ	O
operating	NN	O
time	NN	O
appears	VBZ	O
unchanged	JJ	O
.	.	O

CLINICAL	JJ	O
TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
,	,	O
www.ClinicalTrials.gov	NN	O
,	,	O
NCT00918996	NNP	O
.	.	O

LEVEL	NNP	O
OF	IN	O
EVIDENCE	NNP	O
I	PRP	O
.	.	O

B-domain	NNP	O
deleted	VBD	O
recombinant	JJ	O
factor	NN	O
VIII	NNP	O
preparations	NNS	O
are	VBP	O
bioequivalent	JJ	O
to	TO	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
purified	VBD	O
plasma-derived	JJ	O
factor	NN	O
VIII	NNP	O
concentrate	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
three-way	JJ	O
crossover	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Deletion	NNP	O
of	IN	O
the	DT	O
B-domain	NNP	O
of	IN	O
recombinant	JJ	O
blood	NN	O
coagulation	NN	O
factor	NN	O
VIII	NNP	O
(	(	O
BDDrFVIII	NNP	O
)	)	O
increases	VBZ	O
the	DT	O
manufacturing	VBG	O
yield	NN	O
of	IN	O
the	DT	O
product	NN	O
but	CC	O
does	VBZ	O
not	RB	O
impair	VB	O
in	IN	O
vitro	NN	O
or	CC	O
in	IN	O
vivo	JJ	O
functionality	NN	O
.	.	O

BDDrFVIII	NNP	O
(	(	O
ReFacto	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
developed	VBN	O
with	IN	O
the	DT	O
additional	JJ	O
benefit	NN	O
of	IN	O
being	VBG	O
formulated	VBN	O
without	IN	O
human	JJ	O
albumin	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
three-way	JJ	O
crossover-design	NN	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetic	JJ	O
(	(	O
PK	NNP	O
)	)	O
parameters	NNS	O
of	IN	O
two	CD	O
BDDrFVIII	NNP	O
formulations	NNS	O
(	(	O
one	CD	O
reconstituted	VBN	O
with	IN	O
5	CD	O
mL	NNS	O
of	IN	O
sterile	JJ	O
water	NN	O
,	,	O
the	DT	O
other	JJ	O
reconstituted	VBD	O
with	IN	O
4	CD	O
mL	NNS	O
sodium	JJ	O
chloride	RB	O
0.9	CD	O
%	NN	O
USP	NNP	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
a	DT	O
plasma-derived	JJ	O
,	,	O
full-length	JJ	O
FVIII	NNP	O
preparation	NN	O
(	(	O
Hemofil	NNP	O
M	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
haemophilia	PDT	C
A	DT	C
to	TO	O
determine	VB	O
bioequivalence	NN	O
.	.	O

METHODS	VB	O
A	NNP	O
series	NN	O
of	IN	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
48	CD	O
h	NN	O
after	IN	O
i.v	NN	O
.	.	O

administration	NN	O
of	IN	O
each	DT	O
of	IN	O
the	DT	O
FVIII	NNP	O
preparations	NNS	O
.	.	O

Plasma	NNP	O
FVIII	NNP	O
activity	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
chromogenic	JJ	O
substrate	NN	O
assay	NN	O
.	.	O

Plasma	NNP	O
FVIII	NNP	O
activity	NN	O
vs.	FW	O
time	NN	O
curves	NNS	O
was	VBD	O
characterized	VBN	O
for	IN	O
a	DT	O
standard	JJ	O
set	NN	O
of	IN	O
PK	NNP	O
parameter	NN	O
estimates	NNS	O
.	.	O

Two	CD	O
parameter	NN	O
estimates	NNS	O
,	,	O
the	DT	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
and	CC	O
the	DT	O
area	NN	O
under	IN	O
plasma	JJ	O
concentration	NN	O
vs.	FW	O
time	NN	O
curves	NNS	O
(	(	O
AUCs	NNP	O
)	)	O
,	,	O
were	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
bioequivalence	NN	O
.	.	O

The	DT	O
two	CD	O
preparations	NNS	O
were	VBD	O
considered	VBN	O
bioequivalent	NN	O
if	IN	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
ratio	NN	O
of	IN	O
geometric	JJ	O
means	NNS	O
for	IN	O
Cmax	NNP	O
and	CC	O
AUCs	NNP	O
fell	VBD	O
within	IN	O
the	DT	O
bioequivalence	NN	O
window	NN	O
of	IN	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
.	.	O

RESULTS/CONCLUSION	NNP	O
Results	NNP	O
show	VBP	O
that	IN	O
each	DT	O
BDDrFVIII	NNP	O
formulation	NN	O
is	VBZ	O
bioequivalent	JJ	O
to	TO	O
Hemofil	NNP	O
M	NNP	O
and	CC	O
the	DT	O
two	CD	O
formulations	NNS	O
of	IN	O
BDDrFVIII	NNP	O
are	VBP	O
bioequivalent	JJ	O
to	TO	O
each	DT	O
other	JJ	O
.	.	O

Short-	JJ	O
and	CC	O
long-term	JJ	O
effects	NNS	O
of	IN	O
tactile	JJ	O
massage	NN	O
on	IN	O
salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
in	IN	O
Parkinson	NNP	C
's	POS	C
disease	NN	C
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
is	VBZ	O
a	DT	O
chronic	JJ	O
neurodegenerative	JJ	O
disorder	NN	O
with	IN	O
limited	JJ	O
knowledge	NN	O
about	IN	O
the	DT	O
normal	JJ	O
function	NN	O
and	CC	O
effects	NNS	O
of	IN	O
non-pharmacological	JJ	O
therapies	NNS	O
on	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
basal	NN	O
diurnal	JJ	O
and	CC	O
total	JJ	O
secretion	NN	O
of	IN	O
salivary	JJ	O
cortisol	NN	O
in	IN	O
short-	JJ	O
and	CC	O
long-term	JJ	O
aspects	NNS	O
of	IN	O
tactile	JJ	O
massage	NN	O
(	(	O
TM	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
,	,	O
Controlled	NNP	O
and	CC	O
Randomised	VBD	O
Multicentre	NNP	O
Trial	NNP	O
.	.	O

SETTING	NN	O
AND	JJ	O
INTERVENTIONS	NNP	O
Forty-five	NNP	SS
women	NNS	SE
and	CC	SE
men	NNS	SE
,	,	O
aged	VBN	O
50-79	CD	A
years	NNS	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

Twenty-nine	NN	SS
of	IN	O
them	PRP	O
were	VBD	O
blindly	RB	O
randomised	VBN	O
to	TO	O
tactile	VB	O
massage	NN	O
(	(	O
TM	NNP	O
)	)	O
and	CC	O
16	CD	SS
of	IN	O
them	PRP	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
rest	NN	O
to	TO	O
music	NN	O
(	(	O
RTM	NNP	O
)	)	O
.	.	O

Ten	CD	O
interventions	NNS	O
were	VBD	O
given	VBN	O
during	IN	O
8	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
26	CD	O
weeks	NNS	O
of	IN	O
follow	JJ	O
up	RB	O
.	.	O

Salivary	JJ	O
cortisol	NN	O
was	VBD	O
collected	VBN	O
at	IN	O
8	CD	O
am	VBP	O
,	,	O
1	CD	O
pm	NN	O
,	,	O
8	CD	O
pm	NN	O
,	,	O
and	CC	O
8	CD	O
am	VBP	O
the	DT	O
next	JJ	O
day	NN	O
,	,	O
on	IN	O
five	CD	O
occasions	NNS	O
.	.	O

With	IN	O
the	DT	O
first	JJ	O
and	CC	O
eighth	JJ	O
interventions	NNS	O
,	,	O
it	PRP	O
was	VBD	O
collected	VBN	O
immediately	RB	O
before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
and	CC	O
compare	VB	O
cortisol	JJ	O
concentrations	NNS	O
before	IN	O
and	CC	O
immediately	RB	O
after	IN	O
intervention	NN	O
and	CC	O
also	RB	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
secondary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
PD	NNP	O
,	,	O
effects	NNS	O
of	IN	O
interventional	JJ	O
time-point	NN	O
of	IN	O
the	DT	O
day	NN	O
,	,	O
and	CC	O
levodopa	JJ	O
doses	NNS	O
on	IN	O
cortisol	JJ	O
concentration	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
cortisol	NN	O
concentrations	NNS	O
for	IN	O
all	DT	O
participants	NNS	O
were	VBD	O
16.0	CD	O
,	,	O
5.8	CD	O
,	,	O
2.8	CD	O
,	,	O
and	CC	O
14.0	CD	O
nmol/L	NN	O
at	IN	O
baseline	NN	O
,	,	O
later	RB	O
reproduced	VBD	O
four	CD	O
times	NNS	O
without	IN	O
significant	JJ	O
differences	NNS	O
.	.	O

Cortisol	NNP	O
concentrations	NNS	O
decreased	VBD	O
significantly	RB	O
after	IN	O
TM	NNP	O
intervention	NN	O
but	CC	O
no	DT	O
change	NN	O
in	IN	O
diurnal	JJ	O
salivary	JJ	O
cortisol	NN	O
pattern	NN	O
was	VBD	O
found	VBN	O
.	.	O

The	DT	O
findings	NNS	O
of	IN	O
reduced	JJ	O
salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
immediately	RB	O
after	IN	O
the	DT	O
interventions	NNS	O
are	VBP	O
in	IN	O
agreement	NN	O
with	IN	O
previous	JJ	O
studies	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
TM	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
correlations	NNS	O
between	IN	O
cortisol	JJ	O
concentrations	NNS	O
and	CC	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
BMI	NNP	O
,	,	O
time-point	NN	O
for	IN	O
intervention	NN	O
,	,	O
time	NN	O
interval	NN	O
between	IN	O
anti-parkinson	JJ	O
pharmacy	NN	O
intake	NN	O
and	CC	O
sampling	NN	O
,	,	O
levodopa	NN	O
doses	NNS	O
,	,	O
duration	NN	O
,	,	O
or	CC	O
severity	NN	O
of	IN	O
PD	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Diurnal	NNP	O
salivary	JJ	O
cortisol	NN	O
rhythm	NN	O
was	VBD	O
normal	JJ	O
.	.	O

Salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
the	DT	O
TM	NNP	O
intervention	NN	O
and	CC	O
after	IN	O
RTM	NNP	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
and	CC	O
no	DT	O
sustained	JJ	O
long-term	JJ	O
effect	NN	O
.	.	O

No	CC	O
associations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
salivary	JJ	O
cortisol	NN	O
concentration	NN	O
and	CC	O
clinical	JJ	O
and/or	NN	O
pharmacological	JJ	O
characteristics	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrial.gov	NNP	O
,	,	O
NCT01734876	NNP	O
and	CC	O
FoU	NNP	O
Sweden	NNP	O
108881	CD	O
.	.	O

Longitudinal	JJ	O
follow-up	NN	O
of	IN	O
children	NNS	A
with	IN	O
autism	NN	C
receiving	VBG	O
targeted	VBN	O
interventions	NNS	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
cognitive	NN	O
and	CC	O
language	NN	O
outcomes	NNS	O
of	IN	O
children	NNS	O
with	IN	O
an	DT	O
autism	NN	C
spectrum	NN	C
disorder	NN	C
(	(	O
ASD	NNP	C
)	)	O
over	IN	O
a	DT	O
5-year	JJ	O
period	NN	O
after	IN	O
receiving	VBG	O
targeted	VBD	O
early	JJ	O
interventions	NNS	O
that	WDT	O
focused	VBD	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
skills	NNS	O
.	.	O

METHOD	NNP	O
Forty	NNP	SS
children	NNS	O
from	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
n	JJ	O
=	NNP	O
58	CD	SS
)	)	O
had	VBD	O
complete	JJ	O
data	NNS	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
all	DT	O
,	,	O
80	CD	O
%	NN	O
of	IN	O
children	NNS	O
had	VBD	O
achieved	VBN	O
functional	JJ	O
use	NN	O
of	IN	O
spoken	JJ	O
language	NN	O
with	IN	O
baseline	JJ	O
play	NN	O
level	NN	O
predicting	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

Of	IN	O
children	NNS	O
who	WP	O
were	VBD	O
using	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
,	,	O
several	JJ	O
baseline	NN	O
behaviors	NNS	O
predicted	VBD	O
their	PRP$	O
later	JJ	O
ability	NN	O
,	,	O
including	VBG	O
earlier	JJR	O
age	NN	O
of	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
skill	NN	O
,	,	O
play	VB	O
level	NN	O
,	,	O
and	CC	O
assignment	NN	O
to	TO	O
either	VB	O
the	DT	O
joint	JJ	O
attention	NN	O
or	CC	O
symbolic	JJ	O
play	NN	O
intervention	NN	O
group	NN	O
.	.	O

Only	RB	O
baseline	JJ	O
play	NN	O
diversity	NN	O
predicted	VBD	O
cognitive	JJ	O
scores	NNS	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
only	JJ	O
long-term	JJ	O
follow-up	JJ	O
studies	NNS	O
of	IN	O
children	NNS	A
who	WP	O
participated	VBD	O
in	IN	O
preschool	NN	O
early	JJ	O
interventions	NNS	O
aimed	VBN	O
at	IN	O
targeting	VBG	O
core	NN	C
developmental	NN	C
difficulties	NNS	C
.	.	O

The	DT	O
study	NN	O
findings	NNS	O
suggest	VBP	O
that	IN	O
focusing	VBG	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
skills	NNS	O
in	IN	O
comprehensive	JJ	O
treatment	NN	O
models	NNS	O
is	VBZ	O
important	JJ	O
for	IN	O
long-term	JJ	O
spoken	JJ	O
language	NN	O
outcomes	NNS	O
.	.	O

Ten-year	JJ	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
prognosis	NN	O
after	IN	O
infarction	NN	O
.	.	O

Department	NNP	O
of	IN	O
Veterans	NNP	O
Affairs	NNP	O
Cooperative	NNP	O
Study	NNP	O
of	IN	O
Coronary	NNP	O
Artery	NNP	O
Bypass	NNP	O
Surgery	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
10-year	JJ	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
(	(	O
fatal	JJ	O
and	CC	O
nonfatal	JJ	O
)	)	O
and	CC	O
the	DT	O
prognosis	NN	O
after	IN	O
infarction	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
686	CD	SS
patients	NNS	O
with	IN	O
stable	JJ	C
angina	NNS	C
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
medical	JJ	O
or	CC	O
surgical	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
Veterans	NNPS	O
Administration	NNP	O
Cooperative	NNP	O
Study	NNP	O
of	IN	O
Coronary	NNP	O
Artery	NNP	O
Bypass	NNP	O
Surgery	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Myocardial	NNP	O
infarction	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
either	DT	O
new	JJ	O
Q	NNP	O
wave	VBP	O
findings	NNS	O
or	CC	O
clinical	JJ	O
symptoms	NNS	O
compatible	JJ	O
with	IN	O
myocardial	JJ	C
infarction	NN	C
accompanied	VBN	O
by	IN	O
serum	NN	O
enzyme	NN	O
elevations	NNS	O
with	IN	O
or	CC	O
without	IN	O
electrocardiographic	JJ	O
findings	NNS	O
.	.	O

Treatment	JJ	O
comparisons	NNS	O
were	VBD	O
made	VBN	O
according	VBG	O
to	TO	O
original	JJ	O
treatment	NN	O
assignment	NN	O
;	:	O
35	CD	O
%	NN	O
of	IN	O
the	DT	O
medical	JJ	O
cohort	NN	O
had	VBD	O
bypass	NN	O
surgery	NN	O
during	IN	O
the	DT	O
10-year	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
overall	JJ	O
cumulative	JJ	O
infarction	NN	O
rate	NN	O
was	VBD	O
somewhat	RB	O
higher	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
surgery	VB	O
(	(	O
36	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
medical	JJ	O
patients	NNS	O
(	(	O
31	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.13	CD	O
)	)	O
due	JJ	O
to	TO	O
perioperative	JJ	O
infarctions	NNS	O
(	(	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
an	DT	O
accelerated	JJ	O
infarction	NN	O
rate	NN	O
after	IN	O
the	DT	O
fifth	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
(	(	O
average	JJ	O
,	,	O
2.4	CD	O
%	NN	O
/yr	NN	O
in	IN	O
the	DT	O
surgical	JJ	O
group	NN	O
versus	VBD	O
1.4	CD	O
%	NN	O
/yr	NN	O
in	IN	O
the	DT	O
medical	JJ	O
group	NN	O
)	)	O
.	.	O

The	DT	O
10-year	JJ	O
cumulative	JJ	O
incidence	NN	O
of	IN	O
death	NN	O
or	CC	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
surgical	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
medical	JJ	O
(	(	O
49	CD	O
%	NN	O
)	)	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.20	CD	O
)	)	O
.	.	O

According	VBG	O
to	TO	O
the	DT	O
Cox	NNP	O
model	NN	O
,	,	O
the	DT	O
estimated	VBN	O
risk	NN	O
of	IN	O
death	NN	O
after	IN	O
infarction	NN	O
was	VBD	O
59	CD	O
%	NN	O
lower	JJR	O
in	IN	O
surgical	JJ	O
than	IN	O
in	IN	O
medical	JJ	O
patients	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
postinfarction	NN	O
mortality	NN	O
with	IN	O
surgery	NN	O
was	VBD	O
most	RBS	O
striking	JJ	O
in	IN	O
the	DT	O
first	JJ	O
month	NN	O
after	IN	O
the	DT	O
event	NN	O
:	:	O
99	CD	O
%	NN	O
in	IN	O
the	DT	O
first	JJ	O
month	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
49	CD	O
%	NN	O
subsequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
estimated	VBN	O
risk	NN	O
of	IN	O
death	NN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
infarction	NN	O
was	VBD	O
nearly	RB	O
identical	JJ	O
regardless	NN	O
of	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.75	CD	O
)	)	O
.	.	O

Exclusion	NN	O
of	IN	O
perioperative	JJ	O
infarctions	NNS	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
findings	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
surgery	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
overall	RB	O
,	,	O
it	PRP	O
does	VBZ	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
mortality	NN	O
after	IN	O
infarction	NN	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
first	JJ	O
30	CD	O
days	NNS	O
after	IN	O
the	DT	O
event	NN	O
(	(	O
fatal	JJ	O
infarctions	NNS	O
)	)	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
steady	JJ	O
state	NN	O
pharmacokinetics	NNS	O
of	IN	O
BMS-181101	NNP	O
,	,	O
an	DT	O
antidepressant	NN	O
,	,	O
in	IN	O
healthy	JJ	C
subjects	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
BMS-181101	NNP	O
,	,	O
a	DT	O
new	JJ	O
anti-depressant	JJ	O
under	IN	O
development	NN	O
,	,	O
was	VBD	O
investigated	VBN	O
in	IN	O
12	CD	SS
healthy	JJ	C
male	NN	SE
volunteers	NNS	O
at	IN	O
steady	JJ	O
state	NN	O
.	.	O

Each	DT	O
subject	NN	O
received	VBD	O
a	DT	O
15	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
BMS-181101	NNP	O
twice	NN	O
a	DT	O
day	NN	O
(	(	O
q	JJ	O
12	CD	O
h	NN	O
)	)	O
for	IN	O
11	CD	O
days	NNS	O
and	CC	O
a	DT	O
morning	NN	O
dose	NN	O
of	IN	O
BMS-181101	NNP	O
on	IN	O
day	NN	O
12	CD	O
.	.	O

Six	CD	SS
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
BMS-181101	NNP	O
under	IN	O
fasted	VBN	O
conditions	NNS	O
from	IN	O
days	NNS	O
1	CD	O
to	TO	O
6	CD	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
fed	VB	O
conditions	NNS	O
from	IN	O
days	NNS	O
7	CD	O
to	TO	O
12	CD	O
.	.	O

The	DT	O
other	JJ	O
six	CD	SS
subjects	NNS	O
received	VBD	O
the	DT	O
reverse	NN	O
conditions	NNS	O
,	,	O
fed	VBN	O
for	IN	O
days	NNS	O
1-6	CD	O
and	CC	O
fasted	VBN	O
for	IN	O
days	NNS	O
7-12	CD	O
.	.	O

Serial	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
up	RB	O
to	TO	O
12	CD	O
h	NNS	O
on	IN	O
days	NNS	O
6	CD	O
and	CC	O
12	CD	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
morning	NN	O
dose	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
trough	IN	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
4	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
11	CD	O
prior	RB	O
to	TO	O
the	DT	O
morning	NN	O
dose	NN	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
intact	JJ	O
BMS-181101	NNP	O
using	VBG	O
a	DT	O
validated	JJ	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
method	NN	O
with	IN	O
an	DT	O
electrochemical	JJ	O
detector	NN	O
.	.	O

BMS-181101	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
both	DT	O
with	IN	O
and	CC	O
without	IN	O
ingestion	NN	O
of	IN	O
food	NN	O
.	.	O

The	DT	O
statistical	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
Cmin	NNP	O
values	NNS	O
indicated	VBD	O
that	IN	O
steady	JJ	O
state	NN	O
of	IN	O
BMS-181101	NNP	O
was	VBD	O
achieved	VBN	O
by	IN	O
the	DT	O
fourth	JJ	O
day	NN	O
of	IN	O
dosing	VBG	O
regardless	NN	O
of	IN	O
whether	IN	O
the	DT	O
subject	NN	O
was	VBD	O
fasted	VBN	O
or	CC	O
fed	VBN	O
.	.	O

When	WRB	O
BMS-181101	NNP	O
was	VBD	O
administered	VBN	O
with	IN	O
food	NN	O
,	,	O
Cmax	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
about	IN	O
25	CD	O
%	NN	O
and	CC	O
tmax	NN	O
was	VBD	O
prolonged	VBN	O
by	IN	O
1	CD	O
h.	NN	O
However	RB	O
,	,	O
AUCtau	NNP	O
,	,	O
t1/2	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
attain	VB	O
steady	JJ	O
state	NN	O
of	IN	O
BMS-181101	NNP	O
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
ingestion	NN	O
of	IN	O
food	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
BMS-181101	NNP	O
can	MD	O
be	VB	O
given	VBN	O
with	IN	O
food	NN	O
without	IN	O
adversely	RB	O
impacting	VBG	O
the	DT	O
safety	NN	O
or	CC	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

